ASSI,DOI,ASST,ASSCT,TISI,Ti,Descr,ASTI,CONFISC,CEI,ASORG,SI,ASSTAI,RELAT,CUB,ASSST,SRASI,CHEI,BFOR,VAI
1,11087,B,,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL615117,BAO_0000019,
2,684,F,,,22226,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,0,,,1,,U,Autocuration,,,CHEMBL615118,BAO_0000219,
3,15453,B,,,22226,,,0,,,1,,U,Autocuration,,,CHEMBL615119,BAO_0000019,
4,17841,B,,,104729,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,4,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL615120,BAO_0000249,
5,17430,F,143B,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,1,163.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615121,BAO_0000219,
6,17430,F,143B,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,1,163.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615122,BAO_0000219,
7,13799,F,143B,,80001,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,1,163.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615123,BAO_0000219,
8,17774,F,143B,,80001,In vitro cell cytotoxicity was determined against 143B cell line,,1,163.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615124,BAO_0000219,
9,3801,F,143B,,80001,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,1,163.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615125,BAO_0000219,
10,17430,F,143B,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,1,163.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615126,BAO_0000219,
11,17430,F,143B,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,1,163.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615127,BAO_0000219,
12,17774,F,143B,,80001,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,1,163.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615128,BAO_0000219,
13,11324,F,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1,,Staphylococcus aureus,1,1280.0,N,Intermediate,,,CHEMBL857900,BAO_0000218,
14,11324,F,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1,,Staphylococcus aureus,1,1280.0,N,Intermediate,,,CHEMBL615129,BAO_0000218,
15,11324,F,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1,,Staphylococcus aureus,1,1280.0,N,Intermediate,,,CHEMBL615130,BAO_0000218,
16,11324,F,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1,,Staphylococcus aureus,1,1280.0,N,Intermediate,,,CHEMBL615131,BAO_0000218,
17,11347,A,,,100122,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL884521,BAO_0000357,
18,16474,B,,,12054,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615132,BAO_0000357,
19,10091,B,,,12054,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,8,,,1,,H,Autocuration,,,CHEMBL615133,BAO_0000019,
20,16474,B,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615134,BAO_0000357,
21,16474,B,,,12054,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615135,BAO_0000357,
22,16474,B,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615136,BAO_0000357,
23,16474,B,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,8,,,1,,H,Autocuration,,,CHEMBL615137,BAO_0000357,
24,16474,B,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,8,,,1,,H,Autocuration,,,CHEMBL615138,BAO_0000357,
25,14352,B,,,22226,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,0,,,1,,U,Autocuration,,,CHEMBL836324,BAO_0000219,
26,5646,B,,,12054,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL615139,BAO_0000357,
27,5646,B,,,12054,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL615140,BAO_0000357,
28,10997,B,,,12426,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,8,,,1,,H,Autocuration,,,CHEMBL615141,BAO_0000219,
29,6309,B,,,12054,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,8,,soya bean,1,3847.0,H,Autocuration,,,CHEMBL615142,BAO_0000357,
30,167,B,,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL615143,BAO_0000357,
31,167,B,,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL615144,BAO_0000357,
32,11087,B,,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL872867,BAO_0000357,
33,11087,B,,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL615145,BAO_0000357,
34,13622,B,,,12054,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL615146,BAO_0000357,
35,13622,B,,,12054,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL615147,BAO_0000357,
36,11347,A,,,22226,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615148,BAO_0000019,
37,5926,B,,,22226,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,0,,Escherichia coli,1,562.0,U,Autocuration,,,CHEMBL615149,BAO_0000019,
38,4567,B,,,22226,Dissociation constant with dimeric 16S rRNA RNA construct B,,0,,,1,,U,Autocuration,,,CHEMBL615150,BAO_0000019,
39,3782,B,,,22222,Dissociation constant towards 16S rRNA construct A,,3,,,1,,M,Intermediate,,,CHEMBL615151,BAO_0000225,
40,3782,B,,,22222,Dissociation constant towards 16S rRNA construct B,,3,,,1,,M,Intermediate,,,CHEMBL615152,BAO_0000225,
41,4466,B,,,100263,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,3,,Escherichia coli,1,562.0,M,Expert,,,CHEMBL615153,BAO_0000225,
42,6592,B,,,100263,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,3,,Escherichia coli,1,562.0,M,Expert,,,CHEMBL615154,BAO_0000225,
43,898,B,,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,1,,H,Autocuration,,,CHEMBL615155,BAO_0000019,
44,898,B,,,13053,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,1,,H,Autocuration,,,CHEMBL615156,BAO_0000019,
45,13163,B,,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,8,,Homo sapiens,1,9606.0,H,Autocuration,,,CHEMBL615157,BAO_0000019,
46,13163,B,,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,8,,Homo sapiens,1,9606.0,H,Autocuration,,,CHEMBL615158,BAO_0000019,
47,10691,B,,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615159,BAO_0000019,
48,10691,B,,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615172,BAO_0000019,
49,10691,B,,,12971,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615173,BAO_0000019,
50,10691,B,,,12971,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615174,BAO_0000019,
51,898,B,,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,1,,H,Autocuration,,,CHEMBL884518,BAO_0000019,
52,912,B,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,8,,,1,,H,Autocuration,,,CHEMBL615175,BAO_0000357,
53,912,B,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL615176,BAO_0000357,
54,912,B,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL615177,BAO_0000357,
55,15103,B,,,104740,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615178,BAO_0000249,
56,5116,F,1A9,,80002,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615179,BAO_0000219,
57,14578,F,Oocytes,,104835,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615180,BAO_0000219,
58,14578,F,Oocytes,,104821,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615181,BAO_0000219,
59,14578,F,Oocytes,,104848,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615182,BAO_0000219,
60,4787,F,1A9,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,1,506.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615183,BAO_0000219,
61,4787,F,1A9,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615184,BAO_0000219,
62,3547,F,1A9,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615185,BAO_0000219,
63,3547,F,1A9,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615186,BAO_0000219,
64,6726,F,1A9,,80002,Effective dose of compound against replication of 1A9 cell line was evaluated,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615187,BAO_0000219,
65,3455,F,1A9,,80002,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,1,506.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL885343,BAO_0000219,
66,5726,F,1A9,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615188,BAO_0000219,
67,5726,F,1A9,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615189,BAO_0000219,
68,5726,F,1A9,,80002,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615190,BAO_0000219,
69,3395,F,1A9,,80002,Inhibitory activity against Taxol resistant 1A9 cell lines,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615191,BAO_0000219,
70,3415,F,1A9,,80002,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,1,506.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615192,BAO_0000219,
71,3415,F,1A9,,80002,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,1,506.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL827083,BAO_0000219,
72,17099,F,1A9,,80002,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,1,506.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615193,BAO_0000219,
73,17099,F,1A9,,80002,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615194,BAO_0000219,
74,17099,F,1A9,,80002,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615195,BAO_0000219,
75,17099,F,1A9,,80002,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,1,506.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615196,BAO_0000219,
76,17721,F,Jurkat,,81072,Inhibitory concentration against Jurkat cells,,1,503.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615197,BAO_0000219,
77,1229,F,,,22226,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL615198,BAO_0000019,
78,11347,A,,,100121,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615199,BAO_0000357,
79,17117,B,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,8,,,1,,H,Expert,,,CHEMBL615200,BAO_0000357,
80,17117,B,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,8,,,1,,H,Expert,,,CHEMBL615201,BAO_0000357,
81,17117,B,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,8,,,1,,H,Expert,,,CHEMBL615202,BAO_0000357,
82,11375,B,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,8,,Candida albicans,1,5476.0,H,Autocuration,,,CHEMBL615203,BAO_0000251,
83,11375,B,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,8,,Candida albicans,1,5476.0,H,Autocuration,,,CHEMBL615204,BAO_0000251,
84,11375,B,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,8,,Saccharomyces cerevisiae,1,4932.0,H,Autocuration,,,CHEMBL615205,BAO_0000251,
85,11375,B,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,8,,Saccharomyces cerevisiae,1,4932.0,H,Autocuration,,,CHEMBL615206,BAO_0000251,
86,11375,B,,2107.0,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Liver,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615207,BAO_0000251,
87,791,B,,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,8,,Rattus norvegicus,1,10116.0,H,Autocuration,,,CHEMBL827084,BAO_0000019,
88,791,B,,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,8,,Rattus norvegicus,1,10116.0,H,Autocuration,,,CHEMBL615208,BAO_0000019,
89,791,B,,,11231,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,8,,Rattus norvegicus,1,10116.0,H,Autocuration,,,CHEMBL615209,BAO_0000019,
90,11375,B,,2107.0,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615210,BAO_0000251,
91,11375,B,,2107.0,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615211,BAO_0000251,
92,153,B,,2107.0,12083,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615212,BAO_0000251,
93,8269,B,,,11377,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,8,,,1,,H,Expert,,,CHEMBL615213,BAO_0000357,
94,8269,B,,,11377,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,8,,,1,,H,Expert,,,CHEMBL615273,BAO_0000357,
95,17653,F,HepG2,,81020,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615274,BAO_0000219,
96,14277,F,HepG2,,81020,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615275,BAO_0000219,
97,1717,F,HepG2,,81020,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615276,BAO_0000219,
98,14091,F,HepG2,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615277,BAO_0000219,
99,14091,F,HepG2,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615326,BAO_0000219,
100,17653,F,,,50606,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,1,,Hepatitis B virus,1,10407.0,N,Expert,,,CHEMBL883130,BAO_0000218,
101,13105,F,HepG2,,81020,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884519,BAO_0000219,
102,1717,F,HepG2,,81020,Concentration required to inhibit 50% of 2.2.15 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615327,BAO_0000219,
103,13105,A,HepG2,,81020,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615328,BAO_0000219,
104,13600,F,2.2.15,,50587,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615329,BAO_0000218,
105,13467,F,2.2.15,,50587,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615330,BAO_0000218,
106,17477,F,2.2.15,,50606,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,1,,Hepatitis B virus,1,10407.0,N,Expert,,,CHEMBL615331,BAO_0000218,
107,1593,F,2.2.15,,50587,In vitro anti-HBV activity in 2.2.15 cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615332,BAO_0000218,
108,1593,F,2.2.15,,50587,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615333,BAO_0000218,
109,15089,F,2.2.15,,50587,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615334,BAO_0000218,
110,15089,F,2.2.15,,50587,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615335,BAO_0000218,
111,1593,F,2.2.15,,50587,Cytotoxicity in 2.2.15 cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615336,BAO_0000218,
112,1593,F,2.2.15,,50587,Cytotoxicity in 2.2.15 cells; Not determined,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615337,BAO_0000218,
113,13600,F,2.2.15,,50587,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615338,BAO_0000218,
114,13467,F,2.2.15,,50587,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615339,BAO_0000218,
115,13467,F,2.2.15,,50587,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615340,BAO_0000218,
116,14764,F,HepG2,,81020,Antiviral activity against HBV was determined in 2.215 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615341,BAO_0000219,
117,6531,B,,,22226,Inhibition of 20-HETE synthesis in human renal microsomes,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615342,BAO_0000251,
118,17322,B,,,22226,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,0,,,1,,U,Autocuration,,,CHEMBL615343,BAO_0000019,
119,17072,F,2008,,80612,Inhibitory concentration against 2008 (ovarian) cells,,1,388.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615344,BAO_0000219,
120,16936,F,2008,,80612,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,1,388.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615345,BAO_0000219,
121,16936,F,2008,,80612,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,1,388.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615346,BAO_0000219,
122,17146,F,2008,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,1,388.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615347,BAO_0000219,
123,17146,F,2008,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,1,388.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615348,BAO_0000219,
124,10797,F,2008/R,,80613,In vitro inhibition of 2008/R ovarian cancer cell line,,1,561.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL827085,BAO_0000219,
125,10797,F,2008/R,,80613,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,1,561.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615349,BAO_0000219,
126,10797,F,2008/S,,80614,In vitro inhibition of 2008/S ovarian cancer cell line,,1,389.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615350,BAO_0000219,
127,10797,F,2008/S,,80614,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,1,389.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615351,BAO_0000219,
128,4823,B,,,100256,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,2,,Homo sapiens,1,9606.0,S,Expert,,,CHEMBL615352,BAO_0000220,
129,12912,B,,,100256,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,2,,Homo sapiens,1,9606.0,S,Intermediate,,,CHEMBL615353,BAO_0000220,
130,2957,B,,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome,,2,,,1,,S,Expert,,,CHEMBL615354,BAO_0000220,
131,2957,B,,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,2,,,1,,S,Expert,,,CHEMBL615355,BAO_0000220,
132,3260,B,,,100256,Inhibitory activity against 20S proteosome,,2,,,1,,S,Intermediate,,,CHEMBL615356,BAO_0000220,
133,3451,B,,,22226,Compound was tested for inhibitory activity against tryptase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615357,BAO_0000019,
134,13885,F,HepG2,,81020,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615358,BAO_0000219,
135,13885,F,HepG2,,81020,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,1,726.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL827086,BAO_0000219,
136,3676,B,,,22226,Compound was tested for the inhibition of Alpha-glucosidase,,0,,,1,,U,Autocuration,,,CHEMBL615359,BAO_0000019,
137,6043,B,,,235,Inhibitory concentration against human neutrophil elastase (HNE),,8,,,1,,H,Autocuration,,,CHEMBL615360,BAO_0000357,
138,11140,F,,948.0,22226,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Heart,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615361,BAO_0000218,
139,10543,F,,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,1,,H,Autocuration,,,CHEMBL615362,BAO_0000019,
140,10543,F,,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,1,,H,Expert,,,CHEMBL615363,BAO_0000019,
141,10543,B,,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,1,,H,Autocuration,,,CHEMBL615364,BAO_0000357,
142,10543,F,,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,1,,H,Expert,,,CHEMBL615365,BAO_0000019,
143,11365,F,P338,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,1,524.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615366,BAO_0000219,
144,11365,F,P338,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,1,524.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615367,BAO_0000219,
145,11803,F,PBL,,80384,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,1,554.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615368,BAO_0000219,
146,11803,F,,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL615369,BAO_0000019,
147,11803,F,,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL615370,BAO_0000019,
148,12278,B,,,191,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,8,,,1,,H,Autocuration,,,CHEMBL615673,BAO_0000357,
149,8249,F,,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615674,BAO_0000019,
150,8249,F,,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615675,BAO_0000019,
151,8249,F,CCRF-CEM,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,0,635.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615676,BAO_0000219,
152,8249,F,CCRF-CEM,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,0,635.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615677,BAO_0000219,
153,8249,F,CCRF-CEM,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,0,635.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615678,BAO_0000219,
154,8249,F,CCRF-CEM,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,0,635.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615679,BAO_0000219,
155,8249,F,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615680,BAO_0000019,
156,8249,F,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615681,BAO_0000019,
157,16992,B,,,104290,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,6,,,1,,H,Autocuration,,,CHEMBL857972,BAO_0000249,
158,10543,F,,,50264,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,1,,Streptococcus pyogenes,1,1314.0,N,Intermediate,,,CHEMBL857899,BAO_0000218,
159,17833,F,,,50527,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,1,,Human herpesvirus 3,1,10335.0,N,Intermediate,,,CHEMBL615371,BAO_0000218,
160,17290,F,HEL,,50527,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,1,468.0,vericilla zoster virus,1,10335.0,N,Expert,,,CHEMBL615372,BAO_0000218,
161,17290,F,,,50527,Antiviral activity against 07/1 strain of VZV; ND: No data,,1,,vericilla zoster virus,1,10335.0,N,Intermediate,,,CHEMBL615373,BAO_0000218,
162,17290,F,,,50527,Antiviral activity against 07/1 strain of VZV; ND=No data,,1,,vericilla zoster virus,1,10335.0,N,Intermediate,,,CHEMBL615374,BAO_0000218,
163,10932,F,,,50145,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,1,,escherichia cloac,1,561.0,N,Intermediate,,,CHEMBL615375,BAO_0000218,
164,9707,B,,,22226,Ratio of Ki at A2 to Ki at A1 receptors,,0,,,1,,U,Autocuration,,,CHEMBL615376,BAO_0000019,
165,2346,B,,,11143,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,8,,Candida albicans,1,5476.0,H,Expert,,,CHEMBL615377,BAO_0000249,
166,2205,B,,,18077,"Inhibition of 1,3-beta-glucan synthase",,8,,Candida glabrata CBS 138,1,284593.0,H,Expert,,,CHEMBL615378,BAO_0000357,
167,11900,F,1-87 tumor cell line,,80609,Inhibition of growth of 1-87 human tumor cell line,,1,832.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615379,BAO_0000219,
168,14864,B,,,12166,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615380,BAO_0000219,
169,16474,B,,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO),,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615381,BAO_0000357,
170,16474,B,,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615382,BAO_0000357,
171,16474,B,,,100171,% inhibition against soybean 1-lipoxygenase (SLO),,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615383,BAO_0000357,
172,16474,B,,,100171,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615384,BAO_0000357,
173,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615385,BAO_0000357,
174,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615386,BAO_0000357,
175,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615387,BAO_0000357,
176,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615388,BAO_0000357,
177,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615214,BAO_0000357,
178,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL827087,BAO_0000357,
179,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615215,BAO_0000357,
180,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615216,BAO_0000357,
181,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615217,BAO_0000357,
182,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615218,BAO_0000357,
183,3094,B,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,9,,Glycine max,1,3847.0,D,Autocuration,,,CHEMBL615219,BAO_0000357,
184,10413,B,,,22226,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL615220,BAO_0000019,
185,16929,F,C3H 10T1/2,,80049,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,1,294.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615221,BAO_0000219,
186,1229,F,,,22226,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL615222,BAO_0000019,
187,16587,B,,,11489,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,8,,,1,,H,Autocuration,,,CHEMBL615223,BAO_0000357,
188,16587,B,,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,8,,,1,,H,Autocuration,,,CHEMBL615224,BAO_0000357,
189,16587,B,,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,8,,,1,,H,Autocuration,,,CHEMBL615225,BAO_0000357,
190,16587,B,,,11489,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,8,,,1,,H,Autocuration,,,CHEMBL615226,BAO_0000357,
191,16587,B,,,11862,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,8,,,1,,H,Autocuration,,,CHEMBL615227,BAO_0000357,
192,8058,F,,,12347,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,9,,Bos taurus,1,9913.0,D,Expert,,,CHEMBL615228,BAO_0000019,
193,9065,B,,,100120,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615229,BAO_0000357,
194,8865,B,,2369.0,100120,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Adrenal gland,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615230,BAO_0000357,
195,9066,B,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615231,BAO_0000357,
196,8394,B,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL884520,BAO_0000357,
197,8394,B,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615232,BAO_0000357,
198,6431,B,,,10328,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,8,,,1,,H,Autocuration,,,CHEMBL615233,BAO_0000019,
199,6431,B,,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,8,,,1,,H,Autocuration,,,CHEMBL827088,BAO_0000357,
200,6431,B,,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,8,,,1,,H,Autocuration,,,CHEMBL615234,BAO_0000357,
201,9295,F,,,11134,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL615235,BAO_0000019,
202,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL615236,BAO_0000019,
203,13622,B,,,11134,Compound was tested in vitro for inhibition of 12-LO human platelet,,8,,,1,,H,Autocuration,,,CHEMBL615237,BAO_0000019,
204,12079,F,,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL615238,BAO_0000019,
205,13622,B,,,11134,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,8,,,1,,H,Autocuration,,,CHEMBL615239,BAO_0000019,
206,12079,F,,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,,9,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL615240,BAO_0000019,
207,13500,B,,,11835,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,8,,,1,,H,Expert,,,CHEMBL615241,BAO_0000019,
208,13723,B,,,11601,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL615242,BAO_0000357,
209,16474,B,,,11134,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615243,BAO_0000019,
210,1630,B,,,11134,Inhibitory activity against human platelet 12-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL615244,BAO_0000019,
211,167,B,,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,8,,,1,,H,Autocuration,,,CHEMBL615245,BAO_0000019,
212,16474,B,,,11134,% inhibition against human platelet 12-lipoxygenase (12-HLO),,8,,,1,,H,Autocuration,,,CHEMBL615246,BAO_0000019,
213,167,B,,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,8,,,1,,H,Autocuration,,,CHEMBL615247,BAO_0000019,
214,16474,B,,,11134,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,8,,,1,,H,Autocuration,,,CHEMBL615248,BAO_0000019,
215,10091,B,,,11601,Inhibitory activity towards porcine 12-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL615249,BAO_0000357,
216,11966,B,,,11601,Tested for inhibition against porcine 12-LO,,8,,,1,,H,Autocuration,,,CHEMBL615250,BAO_0000357,
217,951,B,,,12052,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,8,,,1,,H,Autocuration,,,CHEMBL615251,BAO_0000019,
218,10997,B,,,12052,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,8,,,1,,H,Autocuration,,,CHEMBL615252,BAO_0000019,
219,10193,B,,,12052,In vitro inhibition of rat platelet 12-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL828340,BAO_0000019,
220,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL615253,BAO_0000019,
221,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,8,,,1,,H,Autocuration,,,CHEMBL615254,BAO_0000019,
222,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL615255,BAO_0000019,
223,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL615256,BAO_0000019,
224,10193,B,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL615257,BAO_0000019,
225,11087,B,,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,8,,,1,,H,Autocuration,,,CHEMBL615258,BAO_0000019,
226,15569,F,41M,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,1,621.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615259,BAO_0000219,
227,12989,F,41M,,80007,In vitro antitumor activity against 41M cell line.,,1,621.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615260,BAO_0000219,
228,16745,F,41M,,80007,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,1,621.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615261,BAO_0000219,
229,15569,F,41M,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,1,621.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615262,BAO_0000219,
230,12989,F,41M,,80007,In vitro antitumor activity against 41McisR cell line.,,1,621.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL615263,BAO_0000219,
231,12989,F,41M,,80007,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,1,621.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL838393,BAO_0000219,
232,16745,F,41M,,80007,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,1,621.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615264,BAO_0000219,
233,6210,B,,,84,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615265,BAO_0000357,
234,6210,B,,,68,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615266,BAO_0000357,
235,6226,B,,,68,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,8,,,1,,H,Expert,,,CHEMBL615267,BAO_0000357,
236,17855,B,,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,8,,,1,,H,Expert,,,CHEMBL615268,BAO_0000357,
237,17855,B,,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,8,,,1,,H,Expert,,,CHEMBL615269,BAO_0000357,
238,17855,B,,,10201,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,8,,,1,,H,Expert,,,CHEMBL615270,BAO_0000357,
239,10413,B,,,12220,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,8,,,1,,H,Autocuration,,,CHEMBL615271,BAO_0000357,
240,10413,B,,,11303,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615272,BAO_0000357,
241,10413,B,,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615103,BAO_0000357,
242,10413,B,,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615104,BAO_0000357,
243,10413,B,,,12220,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,8,,,1,,H,Autocuration,,,CHEMBL615105,BAO_0000357,
244,10413,B,,,12220,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,8,,,1,,H,Autocuration,,,CHEMBL872866,BAO_0000357,
245,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615106,BAO_0000357,
246,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615107,BAO_0000019,
247,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615108,BAO_0000357,
248,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615109,BAO_0000357,
249,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615110,BAO_0000357,
250,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL840105,BAO_0000019,
251,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615111,BAO_0000019,
252,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615112,BAO_0000019,
253,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615113,BAO_0000019,
254,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615114,BAO_0000019,
255,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615115,BAO_0000357,
256,7587,B,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL615116,BAO_0000019,
257,7323,B,,,11303,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,8,,,1,,H,Autocuration,,,CHEMBL615698,BAO_0000357,
258,7587,B,,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL615699,BAO_0000019,
259,7587,B,,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL615700,BAO_0000019,
260,13750,B,,,100249,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,8,,Saccharomyces cerevisiae,1,4932.0,H,Expert,,,CHEMBL615701,BAO_0000357,
261,7662,B,,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615702,BAO_0000019,
262,7662,B,,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615703,BAO_0000019,
263,7662,B,,,22226,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615704,BAO_0000019,
264,12211,F,,,104698,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,6,,,1,,H,Autocuration,,,CHEMBL615705,BAO_0000019,
265,12211,F,,,104698,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,6,,,1,,H,Autocuration,,,CHEMBL615706,BAO_0000019,
266,12211,F,,2116.0,20033,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL615707,BAO_0000221,
267,12211,F,,,10623,Stimulatory activity of intragastric pressure was tested in the rat,,8,,,1,,H,Expert,,,CHEMBL615708,BAO_0000019,
268,15453,B,,,121,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL615709,BAO_0000357,
269,11884,F,,,22226,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615710,BAO_0000218,
270,7185,F,,,12688,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,8,,,1,,H,Autocuration,,,CHEMBL615711,BAO_0000019,
271,6876,B,,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615712,BAO_0000357,
272,6876,B,,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL836325,BAO_0000357,
273,11863,F,,,12198,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL615713,BAO_0000019,
274,11863,B,,,12198,Inhibition constant of high-affinity 5-HT uptake,,8,,,1,,H,Autocuration,,,CHEMBL615714,BAO_0000357,
275,11863,F,,,12198,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,8,,,1,,H,Autocuration,,,CHEMBL615715,BAO_0000019,
276,11863,F,,,12198,Maximum rate was determined for high affinity transport of 5-HT,,8,,,1,,H,Autocuration,,,CHEMBL615716,BAO_0000019,
277,4639,F,,,104714,Compound was tested for agonistic activity against 5-HT uptake,,4,,,1,,H,Autocuration,,,CHEMBL615717,BAO_0000019,
278,15796,B,,,10577,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,8,,,1,,H,Expert,,,CHEMBL881818,BAO_0000019,
279,15796,B,,,105,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL884540,BAO_0000357,
280,12801,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615718,BAO_0000224,
281,12801,B,,,104744,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL615719,BAO_0000224,
282,12120,B,,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,4,,,1,,H,Autocuration,,,CHEMBL615720,BAO_0000249,
283,12120,B,,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,4,,,1,,H,Autocuration,,,CHEMBL615721,BAO_0000249,
284,11963,B,,,104744,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL615722,BAO_0000019,
285,11701,F,,,51,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,8,,,1,,H,Autocuration,,,CHEMBL615723,BAO_0000019,
286,9995,B,,10000000.0,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615724,BAO_0000221,
287,9995,B,,10000000.0,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615725,BAO_0000221,
288,9995,B,,10000000.0,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615726,BAO_0000221,
289,16394,F,,,10576,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,8,,,1,,H,Autocuration,,,CHEMBL615727,BAO_0000218,
290,11574,F,,,105570,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL615728,BAO_0000019,
291,15779,B,CHO,,279,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL857971,BAO_0000219,
292,15363,B,,,107,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615729,BAO_0000357,
293,15363,F,,,12687,Efficacy against 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615730,BAO_0000019,
294,15329,F,,,12687,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,8,,,1,,H,Expert,,,CHEMBL615731,BAO_0000019,
295,15329,F,,,12687,Relative potency towards 5-HT2A receptor of rat tail artery,,8,,,1,,H,Expert,,,CHEMBL615732,BAO_0000019,
296,15329,F,,,12687,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,8,,,1,,H,Expert,,,CHEMBL615733,BAO_0000019,
297,15329,F,,,12687,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,8,,,1,,H,Expert,,,CHEMBL615734,BAO_0000019,
298,15329,F,,,12687,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,8,,,1,,H,Autocuration,,,CHEMBL615735,BAO_0000019,
299,15329,F,,,12687,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,8,,,1,,H,Expert,,,CHEMBL615736,BAO_0000019,
300,273,F,,2116.0,20033,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL615737,BAO_0000221,
301,273,F,,2116.0,20033,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL615738,BAO_0000221,
302,273,F,,2116.0,20033,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL615739,BAO_0000221,
303,12092,B,,,10623,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL615278,BAO_0000357,
304,1317,F,,,10623,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615279,BAO_0000019,
305,12409,B,,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Expert,,,CHEMBL615280,BAO_0000357,
306,11126,B,,,22226,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,0,,Gallus gallus,1,9031.0,U,Autocuration,,,CHEMBL615281,BAO_0000019,
307,11126,F,,,22226,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615282,BAO_0000019,
308,11126,F,,,22226,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615283,BAO_0000019,
309,11126,B,HL-60,,80156,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,1,649.0,Homo sapiens,1,9606.0,N,Autocuration,,,CHEMBL615284,BAO_0000219,
310,11126,B,,,22226,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615285,BAO_0000019,
311,11126,B,,,22226,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615286,BAO_0000019,
312,17807,B,Oocytes,,104703,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,7,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL615287,BAO_0000219,
313,16575,F,,,100256,Chymotryptic inhibitory activity against 26S proteasome,,2,,,1,,S,Intermediate,,,CHEMBL615288,BAO_0000220,
314,15407,B,,,100256,Inhibitory activity against 26S proteasome degradation of IkB,,2,,,1,,S,Intermediate,,,CHEMBL615289,BAO_0000220,
315,10797,F,A2780,,81034,In vitro inhibition of 2780/DOX ovarian cancer cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615290,BAO_0000219,
316,10797,F,A2780,,81034,In vitro inhibition of 2780/S ovarian cancer cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884522,BAO_0000219,
317,3469,F,,,22226,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615291,BAO_0000019,
318,16037,B,,,22222,Association constant for binding to AATT 28-mer AATT hairpin,,3,,,1,,M,Intermediate,,,CHEMBL615292,BAO_0000225,
319,16037,B,,,22222,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,3,,,1,,M,Intermediate,,,CHEMBL615293,BAO_0000225,
320,16037,B,,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,,3,,,1,,M,Intermediate,,,CHEMBL615294,BAO_0000225,
321,16037,B,,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,,3,,,1,,M,Intermediate,,,CHEMBL615295,BAO_0000225,
322,16524,F,,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL825021,BAO_0000019,
323,16524,F,,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615296,BAO_0000019,
324,16524,F,,,22226,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615297,BAO_0000019,
325,16758,F,,,22226,Cytotoxicity against cell line 2SC/20 determined by MTT test,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL615298,BAO_0000019,
326,16758,F,,,22226,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL615299,BAO_0000019,
327,16758,F,,,22226,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL615300,BAO_0000019,
328,14360,B,,,241,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,8,,,1,,H,Autocuration,,,CHEMBL615301,BAO_0000357,
329,14360,B,,,241,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615302,BAO_0000357,
330,9964,B,,,22226,Selectivity ratio of ID50 in liver and heart,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615303,BAO_0000019,
331,9964,B,,,12132,"Selectivity, ratio of relative ID50 in liver and heart",,8,,,1,,H,Autocuration,,,CHEMBL615304,BAO_0000019,
332,9964,B,,,12132,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,8,,,1,,H,Autocuration,,,CHEMBL615305,BAO_0000019,
333,9964,B,,,12132,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615306,BAO_0000218,
334,9964,B,,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615307,BAO_0000218,
335,9964,B,,,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615308,BAO_0000218,
336,9964,F,,,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615309,BAO_0000218,
337,9964,B,,,22226,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,0,,,1,,U,Autocuration,,,CHEMBL615310,BAO_0000019,
338,9964,B,,,12132,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,8,,,1,,H,Autocuration,,,CHEMBL615311,BAO_0000019,
339,9964,B,,,22226,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615312,BAO_0000019,
340,9964,B,,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,8,,,1,,H,Autocuration,,,CHEMBL615313,BAO_0000019,
341,9964,F,,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,8,,,1,,H,Autocuration,,,CHEMBL615314,BAO_0000019,
342,9964,B,,,12132,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615315,BAO_0000019,
343,9964,B,,,22226,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615316,BAO_0000218,
344,9964,B,,,12132,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,8,,,1,,H,Autocuration,,,CHEMBL615317,BAO_0000218,
345,9964,B,,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615318,BAO_0000218,
346,9964,B,,,22226,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615319,BAO_0000218,
347,9964,B,,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615320,BAO_0000019,
348,9964,F,,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,8,,,1,,H,Autocuration,,,CHEMBL615321,BAO_0000019,
349,3796,B,,,22226,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615322,BAO_0000019,
350,4251,B,,,19690,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615323,BAO_0000357,
351,4251,B,,,19690,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615407,BAO_0000357,
352,4251,B,,,19690,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL857267,BAO_0000357,
353,4251,B,,,19690,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,8,,Escherichia coli,1,562.0,H,Autocuration,,,CHEMBL615408,BAO_0000357,
354,166,B,,,19690,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,8,,,1,,H,Autocuration,,,CHEMBL615409,BAO_0000357,
355,17861,B,,,19690,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,8,,,1,,H,Autocuration,,,CHEMBL615410,BAO_0000357,
356,166,B,,,19690,Inhibition constant against 3-dehydroquinate synthase,,8,,,1,,H,Autocuration,,,CHEMBL615411,BAO_0000357,
357,166,B,,,19690,Association rate constant against 3-dehydroquinate synthase,,8,,,1,,H,Autocuration,,,CHEMBL615412,BAO_0000357,
358,166,B,,,19690,Rate constant against 3-dehydroquinate synthase,,8,,,1,,H,Autocuration,,,CHEMBL615413,BAO_0000357,
359,3548,B,,,22226,Inhibitory activity against fuc-TVII,,0,,,1,,U,Autocuration,,,CHEMBL615414,BAO_0000019,
360,9877,B,,2107.0,12236,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615415,BAO_0000251,
361,9877,B,,2107.0,12236,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615416,BAO_0000251,
362,9877,B,,2107.0,12236,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615417,BAO_0000251,
363,9877,B,,2107.0,12236,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615418,BAO_0000251,
364,9877,B,,2107.0,12236,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615419,BAO_0000251,
365,9877,B,,2107.0,12236,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615420,BAO_0000251,
366,9877,B,,2107.0,12236,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615421,BAO_0000251,
367,9877,B,,2107.0,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615422,BAO_0000251,
368,9877,B,,2107.0,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615423,BAO_0000251,
369,9877,B,,2107.0,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL872868,BAO_0000251,
370,9877,B,,2107.0,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Liver,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615424,BAO_0000251,
371,3003,B,,,104832,Inhibitory activity against 3-phosphoglycerate kinase.,,4,,,1,,H,Autocuration,,,CHEMBL825022,BAO_0000224,
372,3003,B,,,104832,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,4,,,1,,H,Autocuration,,,CHEMBL615425,BAO_0000224,
373,3003,B,,,104832,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,4,,,1,,H,Autocuration,,,CHEMBL615426,BAO_0000224,
374,17185,B,,,10612,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615427,BAO_0000357,
375,6072,F,3677 melanoma cell line,,80616,Cytotoxicity on 3677 melanoma cells,,1,844.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615428,BAO_0000219,
376,6072,F,3677 melanoma cell line,,80616,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,1,844.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615429,BAO_0000219,
377,5018,F,MC-38,,80617,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,1,700.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615430,BAO_0000219,
378,2852,F,,,22226,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,0,,Homo sapiens,1,9606.0,U,Intermediate,,,CHEMBL615431,BAO_0000019,
379,8663,F,B16,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,0,798.0,,1,,U,Autocuration,,,CHEMBL615432,BAO_0000218,
380,8663,F,B16,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,0,798.0,,1,,U,Autocuration,,,CHEMBL615433,BAO_0000218,
381,3245,F,,,12464,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,9,,Human rhinovirus 14,1,12131.0,D,Expert,,,CHEMBL615434,BAO_0000019,
382,3245,F,,,50085,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,1,,Human rhinovirus sp.,1,169066.0,N,Intermediate,,,CHEMBL615435,BAO_0000218,
383,3877,F,,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,1,,human rhinovirus type 14,1,169066.0,N,Intermediate,,,CHEMBL615436,BAO_0000218,
384,3877,F,,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,1,,human rhinovirus type 14,1,169066.0,N,Intermediate,,,CHEMBL615437,BAO_0000218,
385,5861,F,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,9,,Human rhinovirus 14,1,12131.0,D,Expert,,,CHEMBL615438,BAO_0000019,
386,5861,F,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,9,,Human rhinovirus 14,1,12131.0,D,Expert,,,CHEMBL615439,BAO_0000019,
387,5861,F,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,9,,Human rhinovirus 14,1,12131.0,D,Expert,,,CHEMBL615440,BAO_0000019,
388,5861,F,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,9,,Human rhinovirus 14,1,12131.0,D,Expert,,,CHEMBL615441,BAO_0000019,
389,13748,F,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,1,,Enterovirus,1,12059.0,N,Intermediate,,,CHEMBL615641,BAO_0000218,
390,13748,F,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,1,,Enterovirus,1,12059.0,N,Intermediate,,,CHEMBL872065,BAO_0000218,
391,13748,F,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,1,,Enterovirus,1,12059.0,N,Intermediate,,,CHEMBL825023,BAO_0000218,
392,13748,F,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,1,,Enterovirus,1,12059.0,N,Intermediate,,,CHEMBL615642,BAO_0000218,
393,13748,B,,,12464,Inhibition of human rhinovirus 3C protease,,8,,Human rhinovirus B,1,147712.0,H,Expert,,,CHEMBL615643,BAO_0000357,
394,17699,B,,,22226,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL615644,BAO_0000019,
395,7145,F,3EM 37,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615645,BAO_0000218,
396,7145,F,3EM 37,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615646,BAO_0000218,
397,7145,F,3EM 37,,80619,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615647,BAO_0000218,
398,7145,F,3EM 37,,80619,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615648,BAO_0000218,
399,7145,F,3EM 37,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615649,BAO_0000218,
400,7145,F,3EM 37,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,1,833.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615650,BAO_0000218,
401,5325,F,3LL cell line,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615651,BAO_0000218,
402,5325,F,3LL cell line,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615652,BAO_0000218,
403,5325,F,3LL cell line,,80620,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,1,847.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615653,BAO_0000218,
404,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615654,BAO_0000219,
405,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615655,BAO_0000219,
406,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL825024,BAO_0000219,
407,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615656,BAO_0000219,
408,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615657,BAO_0000219,
409,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615658,BAO_0000219,
410,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615659,BAO_0000219,
411,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615660,BAO_0000219,
412,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615661,BAO_0000219,
413,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615662,BAO_0000219,
414,16169,F,3LL cell line,,80620,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615663,BAO_0000219,
415,16169,F,3LL cell line,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615664,BAO_0000219,
416,16169,F,3LL cell line,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615665,BAO_0000219,
417,16169,F,3LL cell line,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615666,BAO_0000219,
418,16169,F,3LL cell line,,80620,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615667,BAO_0000219,
419,16169,F,3LL cell line,,80620,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615668,BAO_0000219,
420,16169,F,3LL cell line,,80620,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615669,BAO_0000219,
421,16169,F,3LL cell line,,80620,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615670,BAO_0000219,
422,16169,F,3LL cell line,,80620,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL836739,BAO_0000219,
423,16169,F,3LL cell line,,80620,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615671,BAO_0000219,
424,16169,F,3LL cell line,,80620,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615672,BAO_0000219,
425,16169,F,3LL cell line,,80620,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615791,BAO_0000219,
426,16169,F,3LL cell line,,80620,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615792,BAO_0000219,
427,16169,F,3LL cell line,,80620,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615793,BAO_0000219,
428,16169,F,3LL cell line,,80620,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615794,BAO_0000219,
429,16169,F,3LL cell line,,80620,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,1,847.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615795,BAO_0000219,
430,15547,F,3LLD122,,80621,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,1,971.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL615590,BAO_0000219,
431,8663,F,,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,0,,,1,,U,Autocuration,,,CHEMBL615591,BAO_0000218,
432,8663,F,,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,0,,,1,,U,Autocuration,,,CHEMBL615592,BAO_0000218,
433,8663,F,,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,0,,,1,,U,Autocuration,,,CHEMBL615593,BAO_0000218,
434,8663,F,,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,0,,,1,,U,Autocuration,,,CHEMBL615594,BAO_0000218,
435,4504,F,NIH3T3,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615595,BAO_0000219,
436,4504,F,NIH3T3,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615596,BAO_0000219,
437,12695,F,NIH3T3,,11169,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,8,723.0,,1,,H,Expert,,,CHEMBL615597,BAO_0000219,
438,12695,F,NIH3T3,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615598,BAO_0000219,
439,12695,F,NIH3T3,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615599,BAO_0000219,
440,17642,F,NIH3T3,,80951,Effective dose against murine 3T3 fibroblasts cells,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615600,BAO_0000219,
441,17642,F,NIH3T3,,80951,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615601,BAO_0000219,
442,12340,F,NIH3T3,,80951,Cytotoxic effect on 3T3 cells,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615602,BAO_0000219,
443,12340,F,NIH3T3,,80951,Cytotoxic effect on 3T3 cells,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615603,BAO_0000219,
444,12716,F,NIH3T3,,80951,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615604,BAO_0000219,
445,6277,F,NIH3T3,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615605,BAO_0000219,
446,6277,F,NIH3T3,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615606,BAO_0000219,
447,6277,F,NIH3T3,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL884526,BAO_0000219,
448,6277,F,NIH3T3,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615607,BAO_0000219,
449,6277,F,NIH3T3,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615608,BAO_0000219,
450,6277,F,NIH3T3,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615609,BAO_0000219,
451,6277,F,NIH3T3,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615682,BAO_0000219,
452,6277,F,NIH3T3,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615683,BAO_0000219,
453,17780,F,NIH3T3,,80951,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615684,BAO_0000218,
454,12751,F,,,104860,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,7,,Mus musculus,1,10090.0,D,Autocuration,,,CHEMBL615685,BAO_0000219,
455,12380,F,NIH3T3,,80951,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615686,BAO_0000219,
456,14892,F,NIH3T3,,80951,Inhibitory activity against 3T3 cell line,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615687,BAO_0000219,
457,12695,F,NIH3T3,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL884523,BAO_0000219,
458,12695,F,,,11169,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,8,,,1,,H,Expert,,,CHEMBL615688,BAO_0000019,
459,12695,F,NIH3T3,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615689,BAO_0000219,
460,12695,F,NIH3T3,,80951,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615690,BAO_0000219,
461,12695,F,,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,8,,,1,,H,Expert,,,CHEMBL615691,BAO_0000019,
462,12695,F,,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,8,,,1,,H,Expert,,,CHEMBL615692,BAO_0000019,
463,6277,F,NIH3T3,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615693,BAO_0000219,
464,6277,F,NIH3T3,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615324,BAO_0000219,
465,4959,F,NIH3T3,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,9,723.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615325,BAO_0000219,
466,4959,F,NIH3T3,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,9,723.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615490,BAO_0000219,
467,4959,F,NIH3T3,,188,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,9,723.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615491,BAO_0000219,
468,4959,F,NIH3T3,,188,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,9,723.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615492,BAO_0000219,
469,12082,F,NIH3T3,,80951,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615493,BAO_0000219,
470,12082,F,NIH3T3,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615494,BAO_0000219,
471,12082,F,NIH3T3,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615495,BAO_0000219,
472,12082,F,NIH3T3,,80951,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615496,BAO_0000219,
473,2643,F,NIH3T3,,80951,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615497,BAO_0000219,
474,11926,F,NIH3T3,,80951,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615498,BAO_0000219,
475,15204,A,NIH3T3,,80951,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615499,BAO_0000219,
476,15992,F,NIH3T3,,80951,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL835522,BAO_0000219,
477,16279,F,NIH3T3,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615500,BAO_0000219,
478,16279,F,NIH3T3,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615501,BAO_0000219,
479,16279,F,NIH3T3,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615502,BAO_0000219,
480,16279,F,NIH3T3,,80951,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615503,BAO_0000219,
481,16279,F,NIH3T3,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615504,BAO_0000219,
482,16279,F,NIH3T3,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615505,BAO_0000219,
483,12831,F,NIH3T3,,80951,Inhibition of swiss 3T3 mouse fibroblast proliferation,,1,723.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615506,BAO_0000219,
484,13497,F,NIH3T3,,80951,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,1,723.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615507,BAO_0000219,
485,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615508,BAO_0000218,
486,13618,F,3T3-L1,,80006,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615509,BAO_0000219,
487,11902,F,3T3-L1,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615510,BAO_0000219,
488,11902,F,3T3-L1,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615511,BAO_0000219,
489,11902,F,3T3-L1,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615512,BAO_0000219,
490,14840,F,3T3-L1,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615513,BAO_0000218,
491,14840,F,3T3-L1,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615514,BAO_0000218,
492,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,1,620.0,,1,,N,Intermediate,,,CHEMBL615515,BAO_0000219,
493,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615516,BAO_0000219,
494,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615517,BAO_0000219,
495,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615518,BAO_0000219,
496,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615519,BAO_0000219,
497,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615520,BAO_0000218,
498,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615521,BAO_0000218,
499,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615522,BAO_0000218,
500,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615523,BAO_0000218,
501,13715,F,3T3-L1,,80006,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,1,620.0,,1,,N,Expert,,,CHEMBL615524,BAO_0000218,
502,13715,F,3T3-L1,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,620.0,,1,,N,Expert,,,CHEMBL615525,BAO_0000218,
503,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615526,BAO_0000218,
504,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615527,BAO_0000218,
505,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615528,BAO_0000218,
506,13715,F,3T3-L1,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,620.0,,1,,N,Expert,,,CHEMBL615529,BAO_0000218,
507,13715,F,3T3-L1,,80006,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,620.0,,1,,N,Expert,,,CHEMBL615530,BAO_0000218,
508,13715,F,3T3-L1,,80006,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,1,620.0,,1,,N,Expert,,,CHEMBL615531,BAO_0000218,
509,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615532,BAO_0000219,
510,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615533,BAO_0000219,
511,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,1,620.0,,1,,N,Intermediate,,,CHEMBL615534,BAO_0000219,
512,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615535,BAO_0000218,
513,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615536,BAO_0000218,
514,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615537,BAO_0000218,
515,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL615538,BAO_0000218,
516,13715,F,3T3-L1,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,1,620.0,,1,,N,Intermediate,,,CHEMBL836166,BAO_0000218,
517,6411,F,3T3-L1,,11214,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,8,620.0,,1,,H,Expert,,,CHEMBL615539,BAO_0000219,
518,6411,F,3T3-L1,,80006,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615540,BAO_0000219,
519,6411,F,3T3-L1,,11214,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,8,620.0,,1,,H,Expert,,,CHEMBL615541,BAO_0000219,
520,3966,F,3T3-L1,,80006,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615542,BAO_0000219,
521,3966,F,3T3-L1,,80006,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,1,620.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL615543,BAO_0000219,
522,15556,F,3T3-L1,,80006,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615544,BAO_0000219,
523,5845,F,3T3-L1,,80006,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615545,BAO_0000219,
524,14422,F,3T3-L1,,80006,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615546,BAO_0000219,
525,5845,F,3T3-L1,,80006,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615547,BAO_0000219,
526,14508,F,3T3-L1,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615548,BAO_0000219,
527,14508,F,3T3-L1,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615549,BAO_0000219,
528,14508,F,3T3-L1,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,1,620.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL615550,BAO_0000219,
529,6349,F,3Y1 cell line,,80622,Inhibitory activity against rat fibroblast (3Y1) cell line,,1,1118.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL615551,BAO_0000219,
530,15899,F,3Y1 cell line,,80622,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,1,1118.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL615552,BAO_0000219,
531,15899,F,3Y1 cell line,,80622,Cytotoxicity in 3Y1 cells.,,1,1118.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL615553,BAO_0000219,
532,15899,F,3Y1 cell line,,80622,Cytostatic effect in 3Y1 cells.,,1,1118.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL615554,BAO_0000219,
533,15899,F,3Y1 cell line,,80622,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,1,1118.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL615555,BAO_0000219,
534,17038,F,3Y1 cell line,,80622,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,1,1118.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL615556,BAO_0000219,
535,12421,B,,,22226,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,0,,,1,,U,Autocuration,,,CHEMBL615557,BAO_0000019,
536,12947,B,,,22226,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,0,,,1,,U,Autocuration,,,CHEMBL615558,BAO_0000019,
537,12947,B,,,22226,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,0,,,1,,U,Autocuration,,,CHEMBL872066,BAO_0000019,
538,4896,B,,,11607,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,9,,Sus scrofa,1,9823.0,D,Expert,,,CHEMBL615559,BAO_0000019,
539,6148,B,,,11607,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,8,,,1,,H,Autocuration,,,CHEMBL615560,BAO_0000019,
540,16432,B,,,11607,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,8,,,1,,H,Autocuration,,,CHEMBL615561,BAO_0000019,
541,4978,B,,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,8,,,1,,H,Expert,,,CHEMBL857062,BAO_0000019,
542,4978,B,,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,8,,,1,,H,Expert,,,CHEMBL615562,BAO_0000019,
543,3723,B,,,11607,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,8,,,1,,H,Autocuration,,,CHEMBL615563,BAO_0000019,
544,3518,B,,,11607,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,8,,,1,,H,Autocuration,,,CHEMBL615564,BAO_0000357,
545,4164,B,,,11607,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,8,,,1,,H,Autocuration,,,CHEMBL615565,BAO_0000019,
546,3518,B,,,11607,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,8,,,1,,H,Autocuration,,,CHEMBL615566,BAO_0000019,
547,4164,B,,,11607,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,9,,Sus scrofa,1,9823.0,D,Expert,,,CHEMBL615567,BAO_0000019,
548,3518,B,,,11607,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,8,,,1,,H,Autocuration,,,CHEMBL615568,BAO_0000019,
549,3518,B,,,11607,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,8,,,1,,H,Autocuration,,,CHEMBL615569,BAO_0000357,
550,4978,B,,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,8,,,1,,H,Autocuration,,,CHEMBL615570,BAO_0000019,
551,4978,B,,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,8,,,1,,H,Autocuration,,,CHEMBL615571,BAO_0000019,
552,6455,B,,,104733,Binding affinity against melatonin (MT1) receptor (pC1),,4,,,1,,H,Autocuration,,,CHEMBL615572,BAO_0000224,
553,2222,B,,,22226,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,0,,,1,,U,Autocuration,,,CHEMBL615573,BAO_0000019,
554,13020,B,,,22226,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,0,,,1,,U,Autocuration,,,CHEMBL615574,BAO_0000019,
555,13021,B,,,22226,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,0,,,1,,U,Autocuration,,,CHEMBL615575,BAO_0000019,
556,14532,B,,,10619,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,8,,,1,,H,Autocuration,,,CHEMBL615576,BAO_0000357,
557,14118,B,,,10619,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615577,BAO_0000357,
558,11884,B,,10000000.0,51,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615578,BAO_0000221,
559,13969,B,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615579,BAO_0000357,
560,13392,B,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL615580,BAO_0000357,
561,14430,B,,,51,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,8,,,1,,H,Expert,,,CHEMBL615581,BAO_0000019,
562,12248,B,,10000000.0,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615582,BAO_0000221,
563,12249,B,,10000000.0,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615583,BAO_0000221,
564,9995,B,,10000000.0,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615584,BAO_0000221,
565,9995,B,,10000000.0,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL833691,BAO_0000221,
566,9995,B,,10000000.0,51,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615585,BAO_0000221,
567,9995,B,,10000000.0,51,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615586,BAO_0000221,
568,9995,B,,10000000.0,51,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL884524,BAO_0000221,
569,12249,B,,10000000.0,51,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615587,BAO_0000221,
570,11799,B,,10000000.0,51,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615588,BAO_0000221,
571,14331,B,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615589,BAO_0000249,
572,11884,B,,10000000.0,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Hippocampus,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL615442,BAO_0000221,
573,14331,B,,10000000.0,51,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615443,BAO_0000221,
574,11701,B,,10000000.0,51,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615444,BAO_0000221,
575,11701,B,,10000000.0,51,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615445,BAO_0000221,
576,12248,B,,10000000.0,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615446,BAO_0000221,
577,12248,B,CHO,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615447,BAO_0000219,
578,12248,B,,10000000.0,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615448,BAO_0000221,
579,12249,B,,10000000.0,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615449,BAO_0000221,
580,12248,B,CHO,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615450,BAO_0000219,
581,11799,B,,10000000.0,51,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,8,,,1,,H,Expert,,,CHEMBL615451,BAO_0000221,
582,634,B,,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615452,BAO_0000357,
583,9995,B,,10000000.0,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615453,BAO_0000221,
584,9995,B,,10000000.0,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615454,BAO_0000221,
585,9995,B,,10000000.0,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615455,BAO_0000221,
586,9995,B,,10000000.0,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615456,BAO_0000221,
587,9995,B,,10000000.0,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615457,BAO_0000221,
588,12210,B,,10000000.0,51,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615458,BAO_0000218,
589,13311,B,,10000000.0,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615459,BAO_0000221,
590,2331,B,CHO,,51,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615460,BAO_0000219,
591,1375,F,,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615461,BAO_0000019,
592,1375,F,,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615462,BAO_0000019,
593,11574,F,,10000000.0,51,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Hippocampus,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615463,BAO_0000221,
594,12867,B,,2116.0,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615464,BAO_0000221,
595,12867,B,,2116.0,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615465,BAO_0000221,
596,12867,B,,2116.0,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615466,BAO_0000221,
597,12867,B,,2116.0,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615467,BAO_0000221,
598,12867,B,,2116.0,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615468,BAO_0000221,
599,12867,B,,2116.0,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Ileum,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615469,BAO_0000221,
600,11574,B,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615470,BAO_0000357,
601,13114,B,,,51,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615471,BAO_0000357,
602,13181,B,,,51,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615472,BAO_0000357,
603,10639,B,,10000000.0,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL883242,BAO_0000221,
604,10639,F,,10000000.0,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615473,BAO_0000221,
605,11883,B,CHO,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,8,449.0,Cricetulus griseus,1,10029.0,H,Autocuration,,,CHEMBL615474,BAO_0000218,
606,17785,B,,,51,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615475,BAO_0000357,
607,1558,F,HeLa,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,8,308.0,,1,,H,Autocuration,,,CHEMBL615476,BAO_0000219,
608,1558,F,HeLa,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,8,308.0,,1,,H,Autocuration,,,CHEMBL615477,BAO_0000219,
609,15740,F,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615478,BAO_0000019,
610,17624,F,CHO,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL615160,BAO_0000219,
611,17624,F,CHO,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Expert,,,CHEMBL615161,BAO_0000219,
612,17624,F,CHO,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615162,BAO_0000219,
613,17624,F,CHO,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615163,BAO_0000219,
614,17624,B,CHO,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL615164,BAO_0000219,
615,17624,B,CHO,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL615165,BAO_0000219,
616,17624,B,CHO,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615166,BAO_0000219,
617,14256,F,,,51,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,8,,,1,,H,Autocuration,,,CHEMBL615167,BAO_0000219,
618,3445,B,HeLa,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615168,BAO_0000219,
619,3445,B,HeLa,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615169,BAO_0000219,
620,17200,B,CHO,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615170,BAO_0000219,
621,17200,B,CHO,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615171,BAO_0000219,
622,15180,F,,,51,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615694,BAO_0000019,
623,15180,F,,,51,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615695,BAO_0000019,
624,16026,F,,,51,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL615696,BAO_0000019,
625,2759,F,CHO,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL615697,BAO_0000219,
626,2759,F,CHO,,51,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL859410,BAO_0000219,
627,2759,F,CHO,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,8,449.0,,1,,H,Autocuration,,,CHEMBL615841,BAO_0000219,
628,2759,F,CHO,,51,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615842,BAO_0000219,
629,2759,F,CHO,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL835003,BAO_0000219,
630,2759,F,CHO,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,8,449.0,,1,,H,Autocuration,,,CHEMBL615843,BAO_0000219,
631,2759,F,CHO,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615979,BAO_0000219,
632,2759,F,CHO,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,8,449.0,,1,,H,Autocuration,,,CHEMBL615980,BAO_0000219,
633,2759,F,CHO,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615981,BAO_0000219,
634,3445,F,,,51,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615982,BAO_0000019,
635,5272,F,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615983,BAO_0000019,
636,5272,F,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615984,BAO_0000019,
637,5272,F,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615985,BAO_0000019,
638,17624,F,CHO,,51,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615986,BAO_0000219,
639,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615987,BAO_0000219,
640,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615988,BAO_0000219,
641,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL615989,BAO_0000219,
642,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615990,BAO_0000219,
643,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615991,BAO_0000219,
644,17624,F,CHO,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL615992,BAO_0000219,
645,17624,F,CHO,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615993,BAO_0000219,
646,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,449.0,,1,,H,Expert,,,CHEMBL615994,BAO_0000219,
647,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615995,BAO_0000219,
648,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL615996,BAO_0000219,
649,17624,F,CHO,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615997,BAO_0000219,
650,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,1,,H,Autocuration,,,CHEMBL615998,BAO_0000019,
651,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,1,,H,Autocuration,,,CHEMBL615999,BAO_0000019,
652,6563,F,,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,8,,,1,,H,Autocuration,,,CHEMBL616000,BAO_0000019,
653,17296,F,HEK293,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,722.0,,1,,H,Autocuration,,,CHEMBL616001,BAO_0000219,
654,6876,F,,,51,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616002,BAO_0000019,
655,6876,F,,,51,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,8,,,1,,H,Expert,,,CHEMBL616003,BAO_0000019,
656,5272,F,,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616004,BAO_0000019,
657,5272,F,,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616005,BAO_0000019,
658,5548,F,,,51,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,1,,H,Autocuration,,,CHEMBL616006,BAO_0000019,
659,5548,F,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,8,,,1,,H,Expert,,,CHEMBL616007,BAO_0000019,
660,5548,F,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,1,,H,Autocuration,,,CHEMBL616008,BAO_0000019,
661,5548,F,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,1,,H,Autocuration,,,CHEMBL616009,BAO_0000019,
662,5929,F,,,51,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,8,,,1,,H,Expert,,,CHEMBL616010,BAO_0000019,
663,5929,F,,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616011,BAO_0000019,
664,5929,F,,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615740,BAO_0000019,
665,16245,F,,,51,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL615741,BAO_0000019,
666,5640,F,,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,8,,,1,,H,Expert,,,CHEMBL615742,BAO_0000019,
667,5640,F,,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,8,,,1,,H,Autocuration,,,CHEMBL615743,BAO_0000019,
668,14509,F,CHO,,51,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,8,449.0,,1,,H,Autocuration,,,CHEMBL615744,BAO_0000219,
669,14509,F,CHO,,51,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,8,449.0,,1,,H,Expert,,,CHEMBL615745,BAO_0000219,
670,15331,B,,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL615746,BAO_0000357,
671,15331,B,,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL615747,BAO_0000357,
672,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,1,,H,Autocuration,,,CHEMBL615748,BAO_0000019,
673,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,8,,,1,,H,Autocuration,,,CHEMBL615749,BAO_0000019,
674,6563,F,,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,8,,,1,,H,Autocuration,,,CHEMBL615750,BAO_0000019,
675,6563,F,,,51,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616259,BAO_0000019,
676,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,1,,H,Autocuration,,,CHEMBL616260,BAO_0000019,
677,5272,F,,,51,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616261,BAO_0000019,
678,5272,F,,,51,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616262,BAO_0000019,
679,5272,F,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616263,BAO_0000019,
680,5272,F,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616264,BAO_0000019,
681,5272,F,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616265,BAO_0000019,
682,5272,F,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616266,BAO_0000019,
683,5272,F,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616267,BAO_0000019,
684,5272,F,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616268,BAO_0000019,
685,16146,B,,,51,Inhibition of human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616269,BAO_0000357,
686,17624,B,CHO,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL884528,BAO_0000219,
687,13706,B,HEK293,,105,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,9,722.0,,1,,D,Expert,,,CHEMBL616270,BAO_0000219,
688,15250,B,CHO,,51,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616271,BAO_0000219,
689,17624,F,CHO,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL616272,BAO_0000219,
690,6861,B,,,51,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,8,,,1,,H,Expert,,,CHEMBL616273,BAO_0000357,
691,17200,B,,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616274,BAO_0000357,
692,17624,B,CHO,,51,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616275,BAO_0000219,
693,17624,B,CHO,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616276,BAO_0000219,
694,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616277,BAO_0000218,
695,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616278,BAO_0000218,
696,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616279,BAO_0000218,
697,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616280,BAO_0000218,
698,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616281,BAO_0000218,
699,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616282,BAO_0000218,
700,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616283,BAO_0000218,
701,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616284,BAO_0000218,
702,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616285,BAO_0000218,
703,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616286,BAO_0000218,
704,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616287,BAO_0000218,
705,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616288,BAO_0000218,
706,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL616289,BAO_0000218,
707,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615610,BAO_0000218,
708,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615611,BAO_0000218,
709,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615612,BAO_0000218,
710,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615613,BAO_0000218,
711,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615614,BAO_0000218,
712,12058,F,,,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615615,BAO_0000218,
713,11440,B,,,105093,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,4,,,1,,H,Autocuration,,,CHEMBL615616,BAO_0000019,
714,6238,B,,1898.0,11923,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Hypothalamus,8,,,1,,H,Autocuration,,,CHEMBL615617,BAO_0000249,
715,10046,B,,,10577,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,8,,,1,,H,Autocuration,,,CHEMBL615618,BAO_0000019,
716,10046,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,8,,,1,,H,Autocuration,,,CHEMBL615619,BAO_0000019,
717,10046,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,8,,,1,,H,Expert,,,CHEMBL615620,BAO_0000019,
718,167,B,,,55,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,8,,,1,,H,Autocuration,,,CHEMBL615621,BAO_0000357,
719,167,B,,,55,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,8,,,1,,H,Autocuration,,,CHEMBL615622,BAO_0000357,
720,11520,F,,,12166,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,8,,,1,,H,Autocuration,,,CHEMBL615623,BAO_0000019,
721,11520,F,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,1,,H,Autocuration,,,CHEMBL615624,BAO_0000019,
722,11520,F,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,1,,H,Autocuration,,,CHEMBL615625,BAO_0000019,
723,11520,F,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,1,,H,Autocuration,,,CHEMBL767045,BAO_0000019,
724,135,F,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615626,BAO_0000019,
725,135,F,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615627,BAO_0000019,
726,11311,B,,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615628,BAO_0000019,
727,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL615629,BAO_0000357,
728,12281,B,,,55,Inhibitory concentration against 5-lipoxygenase from human whole blood,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615630,BAO_0000357,
729,11311,B,,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL615631,BAO_0000219,
730,12576,F,,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,8,,,1,,H,Autocuration,,,CHEMBL615632,BAO_0000218,
731,12281,B,,,17087,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,8,,,1,,H,Autocuration,,,CHEMBL615633,BAO_0000357,
732,12576,F,,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,8,,,1,,H,Autocuration,,,CHEMBL615634,BAO_0000218,
733,11089,B,,,55,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL615635,BAO_0000019,
734,11006,B,,,12166,In vitro inhibition of rat 5-Lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL615636,BAO_0000357,
735,11481,B,,,12166,Inhibitory activity against 5-Lipoxygenase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615637,BAO_0000357,
736,10864,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,8,702.0,,1,,H,Expert,,,CHEMBL615638,BAO_0000219,
737,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,702.0,,1,,H,Autocuration,,,CHEMBL615639,BAO_0000219,
738,11311,B,RBL-1,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,8,702.0,,1,,H,Autocuration,,,CHEMBL615640,BAO_0000219,
739,11311,B,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,8,,,1,,H,Autocuration,,,CHEMBL615796,BAO_0000019,
740,11311,B,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL615845,BAO_0000219,
741,11006,B,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL615846,BAO_0000357,
742,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL615847,BAO_0000219,
743,11311,B,,,12166,The compound was tested for inhibition of isolated 5-Lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL615848,BAO_0000357,
744,11481,B,,,22226,Ratio of IC50 against 5-LO and COX,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615849,BAO_0000019,
745,11006,B,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL615850,BAO_0000357,
746,11006,B,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,8,,,1,,H,Autocuration,,,CHEMBL615851,BAO_0000357,
747,11311,B,,,12166,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL615852,BAO_0000219,
748,11006,F,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,8,,,1,,H,Autocuration,,,CHEMBL615853,BAO_0000019,
749,4288,B,,2367.0,120,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Prostate gland,8,,,1,,H,Autocuration,,,CHEMBL884527,BAO_0000357,
750,7587,B,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,0,,Columba livia,1,8932.0,U,Autocuration,,,CHEMBL872871,BAO_0000019,
751,7587,B,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,0,,Columba livia,1,8932.0,U,Autocuration,,,CHEMBL615854,BAO_0000019,
752,7587,B,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,0,,Columba livia,1,8932.0,U,Autocuration,,,CHEMBL767046,BAO_0000019,
753,11249,B,,,10732,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,8,,,1,,H,Autocuration,,,CHEMBL615855,BAO_0000357,
754,8003,F,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615856,BAO_0000019,
755,8003,F,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615857,BAO_0000019,
756,8003,F,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615858,BAO_0000019,
757,12416,B,,10000000.0,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615859,BAO_0000221,
758,16293,B,,,51,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,8,,,1,,H,Autocuration,,,CHEMBL615860,BAO_0000357,
759,13047,B,,,22226,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL615861,BAO_0000019,
760,13047,B,,,22226,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL615862,BAO_0000019,
761,13047,B,,,22226,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL615863,BAO_0000019,
762,13047,B,,,22226,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL615864,BAO_0000019,
763,10085,B,,10000000.0,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL615865,BAO_0000221,
764,10085,B,,10000000.0,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL615866,BAO_0000221,
765,10085,B,,10000000.0,104744,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL615867,BAO_0000221,
766,9841,B,,,104744,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,4,,,1,,H,Autocuration,,,CHEMBL615868,BAO_0000249,
767,8822,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615869,BAO_0000249,
768,9806,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615870,BAO_0000019,
769,9806,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615871,BAO_0000019,
770,8868,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,4,,,1,,H,Autocuration,,,CHEMBL615872,BAO_0000224,
771,9036,B,,10000000.0,104744,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL833492,BAO_0000221,
772,11374,B,,10000000.0,104744,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL615873,BAO_0000221,
773,10881,B,,,104744,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,4,,,1,,H,Autocuration,,,CHEMBL615479,BAO_0000224,
774,8822,B,,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,4,,,1,,H,Autocuration,,,CHEMBL615480,BAO_0000019,
775,9806,B,,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615481,BAO_0000249,
776,15463,B,,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL872869,BAO_0000019,
777,15463,B,,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL615482,BAO_0000019,
778,14542,B,,955.0,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,4,,,1,,H,Autocuration,,,CHEMBL615483,BAO_0000221,
779,14542,B,,955.0,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,4,,,1,,H,Autocuration,,,CHEMBL615484,BAO_0000221,
780,8569,B,,,104744,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,4,,,1,,H,Autocuration,,,CHEMBL615485,BAO_0000019,
781,10062,B,,,104744,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615486,BAO_0000224,
782,4771,B,,,104744,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,4,,,1,,H,Autocuration,,,CHEMBL615487,BAO_0000224,
783,10062,B,,,104744,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,1,,H,Autocuration,,,CHEMBL615488,BAO_0000224,
784,10062,B,,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,1,,H,Autocuration,,,CHEMBL615489,BAO_0000224,
785,10062,B,,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,1,,H,Autocuration,,,CHEMBL615389,BAO_0000224,
786,15463,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL615390,BAO_0000019,
787,15463,B,,,104744,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL615391,BAO_0000019,
788,9098,B,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL615392,BAO_0000224,
789,3070,B,,,22226,Affinity for 5-hydroxytryptamine 1 receptor,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615393,BAO_0000019,
790,14542,B,,955.0,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Brain,4,,,1,,H,Autocuration,,,CHEMBL615394,BAO_0000221,
791,14542,B,,955.0,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,4,,,1,,H,Autocuration,,,CHEMBL615395,BAO_0000221,
792,6398,B,,,104744,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,4,,,1,,H,Autocuration,,,CHEMBL615396,BAO_0000224,
793,1344,B,,955.0,104744,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Brain,4,,,1,,H,Autocuration,,,CHEMBL615397,BAO_0000221,
794,11963,B,,,104744,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL615398,BAO_0000019,
795,8908,B,,,22226,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615399,BAO_0000019,
796,9098,B,,,104744,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL615400,BAO_0000019,
797,8841,B,,,104744,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL615401,BAO_0000019,
798,8814,B,,,22226,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL615402,BAO_0000019,
799,11752,B,,,104744,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,4,,,1,,H,Autocuration,,,CHEMBL615403,BAO_0000019,
800,11642,B,,955.0,104744,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Brain,4,,,1,,H,Autocuration,,,CHEMBL615404,BAO_0000221,
801,11642,B,,,104744,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL615781,BAO_0000019,
802,9231,B,,955.0,104744,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Brain,4,,,1,,H,Autocuration,,,CHEMBL615782,BAO_0000220,
803,11351,B,,955.0,104744,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Brain,4,,,1,,H,Autocuration,,,CHEMBL615783,BAO_0000221,
804,4639,B,,,22226,Compound was tested for binding affinity against 5-HT1 receptor,,0,,,1,,U,Autocuration,,,CHEMBL873481,BAO_0000019,
805,1205,B,,,22226,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,0,,,1,,U,Autocuration,,,CHEMBL615784,BAO_0000019,
806,10025,B,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,8,,,1,,H,Expert,,,CHEMBL615785,BAO_0000357,
807,13241,F,,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL615786,BAO_0000249,
808,16245,F,,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,8,,,1,,H,Autocuration,,,CHEMBL615787,BAO_0000218,
809,16245,F,,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,8,,,1,,H,Autocuration,,,CHEMBL615788,BAO_0000218,
810,12438,F,,,10576,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL767044,BAO_0000019,
811,16245,F,,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,8,,,1,,H,Autocuration,,,CHEMBL615789,BAO_0000218,
812,16245,F,,,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,8,,,1,,H,Autocuration,,,CHEMBL615790,BAO_0000218,
813,15740,F,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,8,,,1,,H,Autocuration,,,CHEMBL615813,BAO_0000019,
814,15535,F,,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL615814,BAO_0000219,
815,15535,F,,,51,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,8,,,1,,H,Expert,,,CHEMBL615815,BAO_0000219,
816,15535,F,,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,8,,,1,,H,Autocuration,,,CHEMBL615816,BAO_0000219,
817,9888,B,,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,8,,,1,,H,Expert,,,CHEMBL615817,BAO_0000249,
818,10085,B,,10000000.0,10576,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615818,BAO_0000221,
819,10085,B,,10000000.0,10576,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615819,BAO_0000221,
820,17331,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,8,,,1,,H,Expert,,,CHEMBL615820,BAO_0000249,
821,10845,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615821,BAO_0000221,
822,10845,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615822,BAO_0000221,
823,10845,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615823,BAO_0000221,
824,10845,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615824,BAO_0000221,
825,10845,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615825,BAO_0000221,
826,13730,B,,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615826,BAO_0000357,
827,13508,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615827,BAO_0000249,
828,13508,B,,10000000.0,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615828,BAO_0000249,
829,12073,B,,10000000.0,10576,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615829,BAO_0000221,
830,4671,B,,10000000.0,10576,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615830,BAO_0000221,
831,13631,B,,10000000.0,10576,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615831,BAO_0000221,
832,12438,B,,,10576,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615832,BAO_0000357,
833,10483,B,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615833,BAO_0000019,
834,10483,B,,10000000.0,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615834,BAO_0000221,
835,12352,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,8,,,1,,H,Intermediate,,,CHEMBL615835,BAO_0000249,
836,14732,B,,10000000.0,10576,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615836,BAO_0000249,
837,11049,B,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615837,BAO_0000019,
838,11049,B,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615838,BAO_0000019,
839,13657,B,,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,8,,,1,,H,Expert,,,CHEMBL615839,BAO_0000249,
840,11473,B,,,10576,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL884525,BAO_0000019,
841,2014,B,,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,8,,,1,,H,Autocuration,,,CHEMBL615840,BAO_0000249,
842,3086,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615405,BAO_0000221,
843,15854,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,1,,H,Expert,,,CHEMBL615406,BAO_0000019,
844,10922,B,,10000000.0,10576,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615900,BAO_0000221,
845,13346,B,,10000000.0,10576,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615901,BAO_0000221,
846,15311,B,,,10576,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,8,,,1,,H,Expert,,,CHEMBL615902,BAO_0000357,
847,10922,B,,10000000.0,10576,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615903,BAO_0000221,
848,10025,B,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL615904,BAO_0000357,
849,10025,B,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,8,,,1,,H,Expert,,,CHEMBL615905,BAO_0000357,
850,9742,B,,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,1,,H,Autocuration,,,CHEMBL615906,BAO_0000019,
851,9742,F,,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,1,,H,Autocuration,,,CHEMBL615907,BAO_0000019,
852,12304,B,,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,1,,H,Expert,,,CHEMBL615908,BAO_0000019,
853,15789,B,,10000000.0,10576,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615909,BAO_0000221,
854,9912,B,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,8,,,1,,H,Autocuration,,,CHEMBL615910,BAO_0000019,
855,9912,B,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,8,,,1,,H,Autocuration,,,CHEMBL615911,BAO_0000019,
856,9912,B,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,8,,,1,,H,Autocuration,,,CHEMBL615912,BAO_0000019,
857,16693,B,,,10576,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615913,BAO_0000019,
858,13276,B,,,10576,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL615914,BAO_0000357,
859,12678,B,,10000000.0,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615915,BAO_0000221,
860,11825,B,,,10576,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,8,,,1,,H,Autocuration,,,CHEMBL615916,BAO_0000357,
861,12443,B,,,10576,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,8,,,1,,H,Expert,,,CHEMBL615917,BAO_0000357,
862,13830,B,,,10576,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL615918,BAO_0000357,
863,14286,B,,10000000.0,10576,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615919,BAO_0000249,
864,14356,B,,10000000.0,10576,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615920,BAO_0000221,
865,15306,B,,,10576,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615921,BAO_0000357,
866,15306,B,,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,8,,,1,,H,Expert,,,CHEMBL615922,BAO_0000357,
867,16616,F,,,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL881290,BAO_0000249,
868,3651,B,,10000000.0,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615923,BAO_0000221,
869,14331,F,,10000000.0,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615924,BAO_0000221,
870,14331,F,,10000000.0,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615925,BAO_0000221,
871,14178,B,,,10576,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615926,BAO_0000357,
872,10639,B,,,10576,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615927,BAO_0000019,
873,12306,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615928,BAO_0000221,
874,1348,B,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615929,BAO_0000357,
875,13605,B,,10000000.0,10576,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615930,BAO_0000221,
876,17624,B,CHO,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615931,BAO_0000219,
877,17624,F,CHO,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL615932,BAO_0000219,
878,17624,F,CHO,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL615933,BAO_0000219,
879,15267,B,,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615934,BAO_0000357,
880,16532,B,,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL615935,BAO_0000357,
881,6563,F,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,1,,H,Autocuration,,,CHEMBL615936,BAO_0000019,
882,4751,B,CHO,,51,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,8,449.0,,1,,H,Autocuration,,,CHEMBL615937,BAO_0000219,
883,15463,B,,,51,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615938,BAO_0000357,
884,3805,B,,,51,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL615797,BAO_0000357,
885,5640,B,,,51,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615798,BAO_0000357,
886,6563,B,,,51,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,8,,,1,,H,Autocuration,,,CHEMBL872870,BAO_0000357,
887,5548,B,,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL615799,BAO_0000357,
888,6347,B,,,51,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615800,BAO_0000357,
889,17296,F,HEK293,,51,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,722.0,,1,,H,Autocuration,,,CHEMBL615801,BAO_0000219,
890,13047,B,,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,8,,,1,,H,Autocuration,,,CHEMBL615802,BAO_0000019,
891,15740,B,,,51,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,8,,,1,,H,Autocuration,,,CHEMBL615803,BAO_0000357,
892,5640,F,,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,8,,,1,,H,Expert,,,CHEMBL835002,BAO_0000019,
893,5640,F,,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,8,,,1,,H,Autocuration,,,CHEMBL615804,BAO_0000019,
894,17211,B,HeLa,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,8,308.0,,1,,H,Expert,,,CHEMBL615805,BAO_0000219,
895,4751,B,CHO,,51,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL615806,BAO_0000219,
896,6491,B,,,51,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615807,BAO_0000357,
897,4707,B,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615808,BAO_0000357,
898,13910,B,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615809,BAO_0000357,
899,16190,B,HeLa,,51,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,8,308.0,,1,,H,Autocuration,,,CHEMBL615810,BAO_0000219,
900,16633,B,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615811,BAO_0000357,
901,11898,B,CHO,,51,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615812,BAO_0000219,
902,11898,B,CHO,,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL615751,BAO_0000219,
903,14331,B,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615752,BAO_0000357,
904,17624,B,CHO,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,8,449.0,,1,,H,Expert,,,CHEMBL615753,BAO_0000219,
905,17624,B,CHO,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL615754,BAO_0000219,
906,3307,B,,,51,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615755,BAO_0000357,
907,6563,B,CHO,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615756,BAO_0000219,
908,14165,B,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615757,BAO_0000019,
909,5732,B,,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL615758,BAO_0000357,
910,13366,B,,,51,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL615759,BAO_0000357,
911,17626,B,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615760,BAO_0000357,
912,6588,B,HeLa,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,8,308.0,,1,,H,Expert,,,CHEMBL615761,BAO_0000219,
913,16209,B,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872104,BAO_0000357,
914,15463,B,,,51,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615762,BAO_0000357,
915,15463,B,,,51,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615763,BAO_0000357,
916,14770,B,,,51,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL615764,BAO_0000357,
917,16245,B,Cell line,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,8,1167.0,,1,,H,Autocuration,,,CHEMBL615765,BAO_0000219,
918,16245,B,,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,8,,,1,,H,Autocuration,,,CHEMBL615766,BAO_0000019,
919,5548,B,,,51,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615767,BAO_0000357,
920,5548,B,,,51,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615768,BAO_0000357,
921,5548,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615769,BAO_0000357,
922,6876,B,,,51,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,8,,,1,,H,Expert,,,CHEMBL615770,BAO_0000357,
923,2598,B,,,51,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615771,BAO_0000357,
924,17785,B,,,51,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,8,,,1,,H,Expert,,,CHEMBL615772,BAO_0000357,
925,6013,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL615773,BAO_0000357,
926,5929,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615774,BAO_0000357,
927,16633,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615775,BAO_0000357,
928,1558,B,,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL615776,BAO_0000357,
929,16026,B,,,51,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL615777,BAO_0000357,
930,12469,B,,,51,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL615778,BAO_0000219,
931,15874,B,,,51,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615779,BAO_0000357,
932,15874,B,,,51,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL615780,BAO_0000357,
933,3935,B,,,51,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616298,BAO_0000357,
934,15818,B,,,51,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616299,BAO_0000357,
935,13706,B,CHO-K1,,51,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL616300,BAO_0000219,
936,13729,F,CHO-K1,,51,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,8,485.0,,1,,H,Expert,,,CHEMBL616301,BAO_0000219,
937,15413,B,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616302,BAO_0000019,
938,15413,B,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,8,,,1,,H,Autocuration,,,CHEMBL616117,BAO_0000019,
939,15413,B,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,8,,,1,,H,Autocuration,,,CHEMBL616118,BAO_0000019,
940,15413,B,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,8,,,1,,H,Autocuration,,,CHEMBL616119,BAO_0000019,
941,3445,B,HeLa,,51,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616120,BAO_0000219,
942,15740,B,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616121,BAO_0000357,
943,15740,B,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,8,,,1,,H,Autocuration,,,CHEMBL616122,BAO_0000357,
944,17626,B,,,51,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616123,BAO_0000357,
945,4234,B,,,51,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616124,BAO_0000357,
946,5640,B,,,51,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL616125,BAO_0000357,
947,5272,B,,,51,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,8,,Rattus norvegicus,1,10116.0,H,Expert,,,CHEMBL616126,BAO_0000357,
948,4622,B,CHO,,51,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616127,BAO_0000219,
949,17085,B,,,51,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616128,BAO_0000019,
950,3025,B,,,51,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616129,BAO_0000357,
951,15315,B,,,51,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616130,BAO_0000357,
952,15267,B,,,51,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,8,,,1,,H,Autocuration,,,CHEMBL616131,BAO_0000357,
953,17158,B,HeLa,,51,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,8,308.0,,1,,H,Autocuration,,,CHEMBL616132,BAO_0000219,
954,14214,B,HeLa,,51,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616133,BAO_0000219,
955,17133,B,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616134,BAO_0000357,
956,16532,B,,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,8,,,1,,H,Autocuration,,,CHEMBL616135,BAO_0000357,
957,2391,B,,,51,Affinity for 5-hydroxytryptamine 1A receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616136,BAO_0000357,
958,14447,B,,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,8,,,1,,H,Autocuration,,,CHEMBL616137,BAO_0000019,
959,14447,B,,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,8,,,1,,H,Autocuration,,,CHEMBL872105,BAO_0000019,
960,15086,B,,,51,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,8,,,1,,H,Autocuration,,,CHEMBL616138,BAO_0000357,
961,13051,B,,,51,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616139,BAO_0000357,
962,16026,F,,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,8,,,1,,H,Autocuration,,,CHEMBL616140,BAO_0000019,
963,17085,B,,,51,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,8,,,1,,H,Expert,,,CHEMBL616141,BAO_0000019,
964,17133,B,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616142,BAO_0000357,
965,17133,B,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616143,BAO_0000357,
966,17211,B,HeLa,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616144,BAO_0000219,
967,17211,B,HeLa,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616145,BAO_0000219,
968,17211,B,HeLa,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616012,BAO_0000219,
969,17211,B,HeLa,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616013,BAO_0000219,
970,16394,F,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,1,,H,Autocuration,,,CHEMBL616014,BAO_0000019,
971,16394,F,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,1,,H,Autocuration,,,CHEMBL616015,BAO_0000019,
972,16394,F,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,1,,H,Autocuration,,,CHEMBL616016,BAO_0000019,
973,16394,F,,,51,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,8,,,1,,H,Autocuration,,,CHEMBL616017,BAO_0000218,
974,16394,B,,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,8,,,1,,H,Autocuration,,,CHEMBL616018,BAO_0000019,
975,15740,F,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL616019,BAO_0000019,
976,15740,F,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL616020,BAO_0000019,
977,15740,B,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL858018,BAO_0000357,
978,17296,F,HEK293,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,722.0,,1,,H,Autocuration,,,CHEMBL616021,BAO_0000219,
979,5640,F,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,8,,,1,,H,Expert,,,CHEMBL616022,BAO_0000019,
980,5640,F,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,8,,,1,,H,Autocuration,,,CHEMBL616023,BAO_0000019,
981,5640,F,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,8,,,1,,H,Autocuration,,,CHEMBL616024,BAO_0000019,
982,5640,F,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,8,,,1,,H,Autocuration,,,CHEMBL616025,BAO_0000019,
983,2759,F,CHO,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL616026,BAO_0000219,
984,16394,F,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,8,,,1,,H,Autocuration,,,CHEMBL616027,BAO_0000019,
985,16394,F,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616028,BAO_0000019,
986,3445,F,,,51,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616029,BAO_0000019,
987,4316,B,CHO,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,8,449.0,,1,,H,Expert,,,CHEMBL616030,BAO_0000219,
988,4316,B,,,51,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,8,,,1,,H,Expert,,,CHEMBL616031,BAO_0000019,
989,15180,F,,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616032,BAO_0000019,
990,15180,F,,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616033,BAO_0000019,
991,15042,F,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,1,,H,Autocuration,,,CHEMBL616034,BAO_0000019,
992,15042,F,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,1,,H,Autocuration,,,CHEMBL616035,BAO_0000019,
993,15042,F,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616036,BAO_0000019,
994,15042,F,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,1,,H,Autocuration,,,CHEMBL616037,BAO_0000019,
995,15042,F,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,1,,H,Autocuration,,,CHEMBL616038,BAO_0000019,
996,15042,F,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,1,,H,Autocuration,,,CHEMBL616039,BAO_0000019,
997,15042,F,,,51,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616040,BAO_0000019,
998,15180,F,HeLa,,51,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616041,BAO_0000219,
999,15180,F,HeLa,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616042,BAO_0000219,
1000,15180,F,HeLa,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616043,BAO_0000219,
1001,16245,F,,,51,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL616044,BAO_0000019,
1002,16026,F,,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL616045,BAO_0000019,
1003,17296,F,HEK293,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,722.0,,1,,H,Autocuration,,,CHEMBL616046,BAO_0000219,
1004,2759,F,CHO,,51,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,8,449.0,,1,,H,Autocuration,,,CHEMBL616047,BAO_0000219,
1005,2759,F,CHO,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616048,BAO_0000219,
1006,2759,F,CHO,,51,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616049,BAO_0000219,
1007,2759,F,CHO,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,8,449.0,,1,,H,Autocuration,,,CHEMBL616050,BAO_0000219,
1008,15419,F,,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,8,,,1,,H,Expert,,,CHEMBL616051,BAO_0000219,
1009,15419,F,,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL616212,BAO_0000219,
1010,16026,F,,,51,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL616213,BAO_0000019,
1011,1414,B,,,51,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,8,,,1,,H,Expert,,,CHEMBL616214,BAO_0000219,
1012,1414,B,,,51,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,8,,,1,,H,Expert,,,CHEMBL616215,BAO_0000219,
1013,12861,B,,,51,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616216,BAO_0000357,
1014,12861,B,,,51,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616217,BAO_0000019,
1015,5104,B,,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616218,BAO_0000357,
1016,5105,B,,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616219,BAO_0000357,
1017,16312,B,,,51,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616220,BAO_0000357,
1018,15180,B,,,51,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL833493,BAO_0000357,
1019,5033,B,,,51,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616221,BAO_0000357,
1020,16909,B,CHO,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616222,BAO_0000219,
1021,2590,F,,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616223,BAO_0000019,
1022,2590,F,,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616224,BAO_0000019,
1023,16394,B,,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,8,,,1,,H,Expert,,,CHEMBL616225,BAO_0000019,
1024,4540,B,HEK293,,51,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616226,BAO_0000219,
1025,17296,B,HEK293,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,8,722.0,,1,,H,Autocuration,,,CHEMBL616227,BAO_0000219,
1026,17296,B,HEK293,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616228,BAO_0000219,
1027,15779,B,HEK293,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,8,722.0,,1,,H,Autocuration,,,CHEMBL616229,BAO_0000219,
1028,15779,B,HEK293,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,8,722.0,,1,,H,Autocuration,,,CHEMBL616230,BAO_0000219,
1029,15779,B,HEK293,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,8,722.0,,1,,H,Autocuration,,,CHEMBL616231,BAO_0000219,
1030,6166,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616232,BAO_0000357,
1031,15779,B,HEK293,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,8,722.0,,1,,H,Autocuration,,,CHEMBL616233,BAO_0000219,
1032,4199,B,HEK293,,51,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL857973,BAO_0000219,
1033,15316,B,,,51,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,8,,,1,,H,Autocuration,,,CHEMBL616234,BAO_0000219,
1034,14875,B,,,51,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616235,BAO_0000357,
1035,14727,B,HeLa,,51,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,8,308.0,,1,,H,Expert,,,CHEMBL616236,BAO_0000219,
1036,14727,B,,,51,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,8,,,1,,H,Expert,,,CHEMBL616237,BAO_0000019,
1037,15146,B,HEK293,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,8,722.0,,1,,H,Autocuration,,,CHEMBL616238,BAO_0000219,
1038,5213,B,HEK293,,51,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616239,BAO_0000219,
1039,16429,B,,,51,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616240,BAO_0000219,
1040,15042,B,HeLa,,51,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616241,BAO_0000219,
1041,14818,B,HEK293,,51,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,8,722.0,,1,,H,Autocuration,,,CHEMBL616242,BAO_0000219,
1042,4829,B,HEK293,,51,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL616243,BAO_0000219,
1043,17200,B,,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,9,,,1,,D,Expert,,,CHEMBL616244,BAO_0000357,
1044,13051,B,,,51,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,9,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL616245,BAO_0000357,
1045,5486,B,,,106,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,8,,,1,,H,Autocuration,,,CHEMBL616246,BAO_0000357,
1046,5254,B,,,105,Binding affinity against 5-HT1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616247,BAO_0000357,
1047,5254,B,,,105,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616248,BAO_0000357,
1048,15331,B,,,107,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL616249,BAO_0000357,
1049,13506,B,,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,8,,Homo sapiens,1,9606.0,H,Autocuration,,,CHEMBL616250,BAO_0000357,
1050,15267,B,,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616251,BAO_0000357,
1051,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,8,,,1,,H,Autocuration,,,CHEMBL616252,BAO_0000218,
1052,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,8,,,1,,H,Autocuration,,,CHEMBL616253,BAO_0000218,
1053,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,8,,,1,,H,Autocuration,,,CHEMBL616254,BAO_0000218,
1054,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616255,BAO_0000218,
1055,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL832872,BAO_0000218,
1056,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616256,BAO_0000218,
1057,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616257,BAO_0000218,
1058,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616258,BAO_0000218,
1059,16616,F,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616384,BAO_0000218,
1060,10297,B,,10000000.0,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616385,BAO_0000221,
1061,13704,B,,,11863,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,8,,,1,,H,Expert,,,CHEMBL616386,BAO_0000357,
1062,10297,B,,10000000.0,11863,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616387,BAO_0000221,
1063,10297,B,,10000000.0,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616388,BAO_0000221,
1064,10297,B,,10000000.0,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616389,BAO_0000221,
1065,10297,B,,10000000.0,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616390,BAO_0000221,
1066,217,B,,,11863,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616391,BAO_0000357,
1067,10297,B,,10000000.0,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616392,BAO_0000221,
1068,4921,B,,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616393,BAO_0000357,
1069,4921,B,,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616394,BAO_0000357,
1070,4996,B,,,51,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616395,BAO_0000019,
1071,12918,B,,,51,Compound was evaluated for the binding affinity at 5- HT1A receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616396,BAO_0000357,
1072,5333,B,,,51,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL872907,BAO_0000019,
1073,4437,B,,,51,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616397,BAO_0000019,
1074,1742,B,,,51,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616398,BAO_0000019,
1075,16688,B,,,51,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616399,BAO_0000357,
1076,12861,B,,,51,Binding activity radioligand.,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL857065,BAO_0000357,
1077,12861,B,,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616400,BAO_0000019,
1078,12861,B,,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616401,BAO_0000019,
1079,12490,B,,,10624,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,8,,,1,,H,Expert,,,CHEMBL616402,BAO_0000019,
1080,11828,B,,,51,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616403,BAO_0000019,
1081,11866,B,,10000000.0,51,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Hippocampus,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616404,BAO_0000221,
1082,12827,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616405,BAO_0000249,
1083,12918,B,,,51,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616406,BAO_0000019,
1084,12919,F,,,51,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616407,BAO_0000019,
1085,13047,B,,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616408,BAO_0000019,
1086,15796,B,,,10576,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616409,BAO_0000249,
1087,3651,B,,10000000.0,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616410,BAO_0000221,
1088,188,B,,,10576,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,8,,,1,,H,Autocuration,,,CHEMBL616411,BAO_0000357,
1089,16616,F,,,10576,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616412,BAO_0000249,
1090,16616,F,,10000000.0,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616413,BAO_0000249,
1091,12306,B,,10000000.0,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616414,BAO_0000221,
1092,17167,B,,10000000.0,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616415,BAO_0000221,
1093,14776,B,,,10576,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,8,,,1,,H,Autocuration,,,CHEMBL616416,BAO_0000019,
1094,12158,B,,,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL616417,BAO_0000357,
1095,13481,B,,,10576,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616418,BAO_0000357,
1096,13427,B,,,10576,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,8,,,1,,H,Autocuration,,,CHEMBL616419,BAO_0000219,
1097,10210,B,,,10576,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616420,BAO_0000357,
1098,10205,B,,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,8,,,1,,H,Autocuration,,,CHEMBL616421,BAO_0000249,
1099,10205,B,,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,8,,,1,,H,Autocuration,,,CHEMBL616422,BAO_0000249,
1100,10205,B,,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL616423,BAO_0000249,
1101,12280,B,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616424,BAO_0000357,
1102,17386,B,,,10576,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616425,BAO_0000357,
1103,13654,B,,,10576,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,8,,,1,,H,Expert,,,CHEMBL616426,BAO_0000357,
1104,14423,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616427,BAO_0000221,
1105,15412,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616428,BAO_0000221,
1106,12073,B,,10000000.0,10576,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616290,BAO_0000221,
1107,4101,B,,,10576,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616052,BAO_0000357,
1108,10062,B,,,10576,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616053,BAO_0000357,
1109,6238,B,,,10576,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616054,BAO_0000249,
1110,16273,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616055,BAO_0000357,
1111,11139,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616056,BAO_0000357,
1112,16796,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,8,,,1,,H,Expert,,,CHEMBL616057,BAO_0000019,
1113,9548,B,,955.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616058,BAO_0000221,
1114,10381,B,,955.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,8,,,1,,H,Autocuration,,,CHEMBL616059,BAO_0000221,
1115,13408,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616060,BAO_0000249,
1116,13825,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616061,BAO_0000221,
1117,11147,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616062,BAO_0000221,
1118,10552,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616063,BAO_0000249,
1119,10552,B,,2435.0,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,8,,,1,,H,Autocuration,,,CHEMBL616064,BAO_0000249,
1120,17136,B,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616065,BAO_0000249,
1121,5778,B,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616066,BAO_0000249,
1122,13481,B,,10000000.0,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616067,BAO_0000221,
1123,13481,B,,10000000.0,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616068,BAO_0000221,
1124,13630,B,,10000000.0,10576,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Intermediate,,,CHEMBL616069,BAO_0000221,
1125,16245,B,,,10576,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,1,,H,Expert,,,CHEMBL616070,BAO_0000249,
1126,14509,B,,10000000.0,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616071,BAO_0000221,
1127,14509,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616072,BAO_0000221,
1128,14509,B,,10000000.0,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616073,BAO_0000221,
1129,14509,B,,10000000.0,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616074,BAO_0000221,
1130,14256,B,,,10576,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,8,,,1,,H,Expert,,,CHEMBL616075,BAO_0000019,
1131,11139,B,,,10576,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616076,BAO_0000357,
1132,11047,B,,,10576,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616077,BAO_0000019,
1133,11047,B,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616078,BAO_0000019,
1134,11047,B,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616079,BAO_0000019,
1135,2395,B,CHO-K1,,10576,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,9,485.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616080,BAO_0000219,
1136,9699,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616081,BAO_0000357,
1137,12028,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616082,BAO_0000221,
1138,12028,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616083,BAO_0000221,
1139,5815,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,1,,H,Autocuration,,,CHEMBL616084,BAO_0000019,
1140,16616,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,8,,,1,,H,Expert,,,CHEMBL616085,BAO_0000019,
1141,5815,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616086,BAO_0000019,
1142,2761,B,,10000000.0,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616087,BAO_0000221,
1143,13133,B,,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,8,,,1,,H,Expert,,,CHEMBL616088,BAO_0000357,
1144,10444,B,,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,8,,,1,,H,Autocuration,,,CHEMBL616089,BAO_0000019,
1145,13278,B,,,10576,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616090,BAO_0000357,
1146,15874,B,,,10576,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616091,BAO_0000357,
1147,10552,B,,2435.0,10576,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,8,,,1,,H,Autocuration,,,CHEMBL616092,BAO_0000249,
1148,11130,B,,,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,8,,,1,,H,Autocuration,,,CHEMBL616093,BAO_0000357,
1149,11130,B,,,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,8,,,1,,H,Autocuration,,,CHEMBL616094,BAO_0000218,
1150,14542,B,,955.0,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Brain,8,,,1,,H,Autocuration,,,CHEMBL616095,BAO_0000221,
1151,13670,B,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616096,BAO_0000357,
1152,9888,B,,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,8,,,1,,H,Expert,,,CHEMBL616097,BAO_0000249,
1153,3678,B,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616098,BAO_0000249,
1154,11332,B,,10000000.0,10576,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616099,BAO_0000221,
1155,11332,B,,10000000.0,10576,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616100,BAO_0000221,
1156,1185,B,,,10576,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616101,BAO_0000357,
1157,2014,B,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL616102,BAO_0000249,
1158,1185,B,,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616103,BAO_0000357,
1159,14429,B,,,10576,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,8,,,1,,H,Expert,,,CHEMBL616104,BAO_0000019,
1160,16288,B,,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,8,,,1,,H,Expert,,,CHEMBL616105,BAO_0000019,
1161,5432,B,,,10576,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616106,BAO_0000019,
1162,14429,B,,,10576,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,8,,,1,,H,Autocuration,,,CHEMBL616107,BAO_0000019,
1163,13672,B,,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,8,,,1,,H,Expert,,,CHEMBL616108,BAO_0000357,
1164,11296,B,,10000000.0,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616109,BAO_0000221,
1165,11296,B,,,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,8,,,1,,H,Autocuration,,,CHEMBL616110,BAO_0000357,
1166,14749,B,CHO,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,8,449.0,,1,,H,Expert,,,CHEMBL616111,BAO_0000219,
1167,15086,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL616112,BAO_0000019,
1168,13462,B,,10000000.0,10576,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616113,BAO_0000221,
1169,15363,B,,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616114,BAO_0000019,
1170,15363,B,,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616115,BAO_0000019,
1171,10796,B,,,10576,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616116,BAO_0000357,
1172,12816,B,,955.0,10576,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Brain,8,,,1,,H,Expert,,,CHEMBL615844,BAO_0000221,
1173,13542,B,,10000000.0,10576,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615939,BAO_0000221,
1174,13308,B,,,10576,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,8,,,1,,H,Expert,,,CHEMBL615940,BAO_0000019,
1175,13541,B,,10000000.0,10576,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL615941,BAO_0000221,
1176,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615942,BAO_0000221,
1177,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615943,BAO_0000221,
1178,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615944,BAO_0000221,
1179,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615945,BAO_0000221,
1180,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615946,BAO_0000221,
1181,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615947,BAO_0000221,
1182,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615948,BAO_0000221,
1183,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615949,BAO_0000221,
1184,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615950,BAO_0000221,
1185,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615951,BAO_0000221,
1186,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615952,BAO_0000221,
1187,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615953,BAO_0000221,
1188,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615954,BAO_0000221,
1189,10058,B,,10000000.0,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615955,BAO_0000221,
1190,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615956,BAO_0000221,
1191,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL615957,BAO_0000221,
1192,12879,B,,,10576,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,8,,,1,,H,Expert,,,CHEMBL615958,BAO_0000019,
1193,11964,B,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,8,,,1,,H,Expert,,,CHEMBL615959,BAO_0000019,
1194,11964,B,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,8,,,1,,H,Autocuration,,,CHEMBL615960,BAO_0000019,
1195,11964,B,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,8,,,1,,H,Autocuration,,,CHEMBL615961,BAO_0000019,
1196,9548,B,,955.0,10576,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,8,,,1,,H,Expert,,,CHEMBL615962,BAO_0000221,
1197,9098,B,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,8,,,1,,H,Expert,,,CHEMBL615963,BAO_0000019,
1198,9098,B,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,8,,,1,,H,Autocuration,,,CHEMBL615964,BAO_0000019,
1199,9098,B,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,8,,,1,,H,Autocuration,,,CHEMBL615965,BAO_0000019,
1200,13248,B,CHO,,10576,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL615966,BAO_0000219,
1201,3147,B,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,8,,,1,,H,Expert,,,CHEMBL615967,BAO_0000249,
1202,13949,B,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL615968,BAO_0000019,
1203,11883,B,CHO,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,8,449.0,,1,,H,Autocuration,,,CHEMBL615969,BAO_0000218,
1204,11883,B,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,8,,,1,,H,Autocuration,,,CHEMBL615970,BAO_0000218,
1205,11883,B,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615971,BAO_0000357,
1206,15535,B,,,10576,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,1,,H,Expert,,,CHEMBL615972,BAO_0000249,
1207,15535,B,,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,8,,,1,,H,Autocuration,,,CHEMBL615973,BAO_0000249,
1208,15535,B,,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,8,,,1,,H,Autocuration,,,CHEMBL615974,BAO_0000249,
1209,16372,B,CHO,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL615975,BAO_0000219,
1210,14608,B,,,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,8,,,1,,H,Expert,,,CHEMBL615976,BAO_0000249,
1211,4795,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL872106,BAO_0000221,
1212,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615977,BAO_0000357,
1213,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,8,,,1,,H,Autocuration,,,CHEMBL615978,BAO_0000357,
1214,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,8,,,1,,H,Autocuration,,,CHEMBL616166,BAO_0000357,
1215,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,8,,,1,,H,Autocuration,,,CHEMBL616167,BAO_0000357,
1216,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,8,,,1,,H,Autocuration,,,CHEMBL616168,BAO_0000357,
1217,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,8,,,1,,H,Autocuration,,,CHEMBL616169,BAO_0000357,
1218,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,8,,,1,,H,Autocuration,,,CHEMBL616170,BAO_0000357,
1219,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,8,,,1,,H,Autocuration,,,CHEMBL616171,BAO_0000357,
1220,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,8,,,1,,H,Autocuration,,,CHEMBL616172,BAO_0000357,
1221,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,8,,,1,,H,Autocuration,,,CHEMBL616173,BAO_0000357,
1222,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,8,,,1,,H,Autocuration,,,CHEMBL616174,BAO_0000357,
1223,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,8,,,1,,H,Autocuration,,,CHEMBL616175,BAO_0000357,
1224,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,8,,,1,,H,Autocuration,,,CHEMBL616176,BAO_0000357,
1225,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,8,,,1,,H,Autocuration,,,CHEMBL616177,BAO_0000357,
1226,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,8,,,1,,H,Autocuration,,,CHEMBL616178,BAO_0000357,
1227,9742,B,,,10576,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,1,,H,Autocuration,,,CHEMBL616179,BAO_0000019,
1228,12073,B,,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616180,BAO_0000357,
1229,4101,B,,,10576,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616181,BAO_0000357,
1230,15360,B,,,10576,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,8,,,1,,H,Autocuration,,,CHEMBL616182,BAO_0000019,
1231,11576,B,,10000000.0,10576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616183,BAO_0000221,
1232,5834,B,,,10576,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,8,,,1,,H,Expert,,,CHEMBL615874,BAO_0000019,
1233,2395,B,CHO-K1,,10576,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,9,485.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615875,BAO_0000219,
1234,1375,B,,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL615876,BAO_0000019,
1235,1375,B,,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,8,,,1,,H,Autocuration,,,CHEMBL615877,BAO_0000019,
1236,3967,B,,,10576,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,8,,,1,,H,Autocuration,,,CHEMBL615878,BAO_0000357,
1237,12884,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,8,,,1,,H,Expert,,,CHEMBL615879,BAO_0000357,
1238,2343,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,8,,,1,,H,Expert,,,CHEMBL615880,BAO_0000357,
1239,11511,B,,,10576,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,8,,,1,,H,Autocuration,,,CHEMBL615881,BAO_0000019,
1240,11511,B,,,10576,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615882,BAO_0000019,
1241,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,8,,,1,,H,Autocuration,,,CHEMBL615883,BAO_0000218,
1242,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,8,,,1,,H,Autocuration,,,CHEMBL615884,BAO_0000218,
1243,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,8,,,1,,H,Autocuration,,,CHEMBL615885,BAO_0000218,
1244,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,8,,,1,,H,Autocuration,,,CHEMBL615886,BAO_0000218,
1245,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,8,,,1,,H,Autocuration,,,CHEMBL615887,BAO_0000218,
1246,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,8,,,1,,H,Autocuration,,,CHEMBL615888,BAO_0000218,
1247,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,8,,,1,,H,Autocuration,,,CHEMBL615889,BAO_0000218,
1248,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,8,,,1,,H,Autocuration,,,CHEMBL615890,BAO_0000218,
1249,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,8,,,1,,H,Autocuration,,,CHEMBL615891,BAO_0000218,
1250,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,8,,,1,,H,Autocuration,,,CHEMBL615892,BAO_0000218,
1251,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,8,,,1,,H,Autocuration,,,CHEMBL615893,BAO_0000218,
1252,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,8,,,1,,H,Autocuration,,,CHEMBL615894,BAO_0000218,
1253,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,8,,,1,,H,Autocuration,,,CHEMBL615895,BAO_0000218,
1254,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,8,,,1,,H,Autocuration,,,CHEMBL615896,BAO_0000218,
1255,16394,F,,,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,8,,,1,,H,Autocuration,,,CHEMBL615897,BAO_0000218,
1256,16616,F,,,10576,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL615898,BAO_0000249,
1257,16796,B,,,10576,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,8,,,1,,H,Autocuration,,,CHEMBL615899,BAO_0000019,
1258,16796,B,,,10576,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,8,,,1,,H,Autocuration,,,CHEMBL616291,BAO_0000019,
1259,15629,B,,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,8,,,1,,H,Autocuration,,,CHEMBL616292,BAO_0000357,
1260,13241,F,,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,8,,,1,,H,Autocuration,,,CHEMBL616293,BAO_0000249,
1261,12073,B,,10000000.0,10576,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616294,BAO_0000221,
1262,14286,B,,10000000.0,10576,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616295,BAO_0000249,
1263,14542,B,,955.0,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Brain,8,,,1,,H,Autocuration,,,CHEMBL616296,BAO_0000221,
1264,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616297,BAO_0000019,
1265,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616605,BAO_0000019,
1266,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616606,BAO_0000019,
1267,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,8,,,1,,H,Autocuration,,,CHEMBL616607,BAO_0000019,
1268,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,8,,,1,,H,Expert,,,CHEMBL616608,BAO_0000019,
1269,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616609,BAO_0000019,
1270,13630,F,,,10576,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616610,BAO_0000019,
1271,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616611,BAO_0000019,
1272,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,8,,,1,,H,Expert,,,CHEMBL616612,BAO_0000019,
1273,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616613,BAO_0000019,
1274,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,8,,,1,,H,Expert,,,CHEMBL616614,BAO_0000019,
1275,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616615,BAO_0000019,
1276,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,8,,,1,,H,Expert,,,CHEMBL616616,BAO_0000019,
1277,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616617,BAO_0000019,
1278,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616618,BAO_0000019,
1279,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616619,BAO_0000019,
1280,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,8,,,1,,H,Expert,,,CHEMBL616620,BAO_0000019,
1281,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,8,,,1,,H,Expert,,,CHEMBL616621,BAO_0000019,
1282,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL616622,BAO_0000019,
1283,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,8,,,1,,H,Expert,,,CHEMBL616146,BAO_0000019,
1284,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL832873,BAO_0000019,
1285,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,8,,,1,,H,Autocuration,,,CHEMBL616147,BAO_0000019,
1286,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL872872,BAO_0000019,
1287,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL616148,BAO_0000019,
1288,9783,B,,10000000.0,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616149,BAO_0000221,
1289,9783,B,,10000000.0,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616150,BAO_0000221,
1290,14331,B,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616151,BAO_0000249,
1291,15260,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Hippocampus,8,,,1,,H,Expert,,,CHEMBL872873,BAO_0000221,
1292,15260,B,,10000000.0,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616670,BAO_0000221,
1293,15260,B,,10000000.0,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616671,BAO_0000221,
1294,16616,F,,,10576,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL884861,BAO_0000249,
1295,15629,B,,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616672,BAO_0000357,
1296,15086,B,,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,8,,,1,,H,Autocuration,,,CHEMBL616673,BAO_0000019,
1297,5717,F,,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL616674,BAO_0000019,
1298,12652,B,,,10576,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616675,BAO_0000357,
1299,14608,B,,10000000.0,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616676,BAO_0000221,
1300,12306,B,,10000000.0,10576,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616677,BAO_0000221,
1301,12306,B,,10000000.0,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616678,BAO_0000221,
1302,15247,B,,,10576,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616679,BAO_0000357,
1303,17529,B,,10000000.0,10576,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616680,BAO_0000221,
1304,14826,B,,10000000.0,10576,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616681,BAO_0000221,
1305,14826,B,,10000000.0,10576,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616682,BAO_0000221,
1306,13241,B,,10000000.0,10576,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616683,BAO_0000221,
1307,14093,B,,10000000.0,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616684,BAO_0000221,
1308,14093,B,,10000000.0,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616685,BAO_0000221,
1309,14442,B,,955.0,10576,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Brain,8,,,1,,H,Autocuration,,,CHEMBL616686,BAO_0000221,
1310,9919,B,,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,,8,,,1,,H,Autocuration,,,CHEMBL616687,BAO_0000357,
1311,9919,B,,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,,8,,,1,,H,Autocuration,,,CHEMBL616688,BAO_0000357,
1312,11440,B,,10000000.0,10576,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616689,BAO_0000221,
1313,11257,B,,,10576,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616690,BAO_0000357,
1314,10330,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL616691,BAO_0000357,
1315,17331,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616692,BAO_0000221,
1316,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,8,,,1,,H,Expert,,,CHEMBL616693,BAO_0000249,
1317,12058,B,,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616694,BAO_0000019,
1318,9699,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616695,BAO_0000221,
1319,9547,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616696,BAO_0000357,
1320,10330,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616697,BAO_0000357,
1321,14331,B,,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616698,BAO_0000357,
1322,14060,B,,,10576,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616949,BAO_0000019,
1323,14744,B,,10000000.0,10576,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616950,BAO_0000221,
1324,13506,B,,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,8,,,1,,H,Autocuration,,,CHEMBL832875,BAO_0000357,
1325,10862,B,,955.0,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,8,,,1,,H,Expert,,,CHEMBL616951,BAO_0000221,
1326,10862,B,,955.0,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,8,,,1,,H,Expert,,,CHEMBL616952,BAO_0000221,
1327,10062,B,,,10576,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,8,,,1,,H,Expert,,,CHEMBL616953,BAO_0000357,
1328,12073,B,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,8,,,1,,H,Autocuration,,,CHEMBL616954,BAO_0000357,
1329,14875,B,,,106,GTPgammaS radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616955,BAO_0000357,
1330,2391,B,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616956,BAO_0000357,
1331,2391,F,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,8,,,1,,H,Autocuration,,,CHEMBL616957,BAO_0000019,
1332,2391,F,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,8,,,1,,H,Autocuration,,,CHEMBL616958,BAO_0000019,
1333,2391,B,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616959,BAO_0000357,
1334,2391,B,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616960,BAO_0000357,
1335,2391,F,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,8,,,1,,H,Autocuration,,,CHEMBL616961,BAO_0000019,
1336,17211,B,HeLa,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,8,308.0,,1,,H,Expert,,,CHEMBL616962,BAO_0000219,
1337,17211,B,HeLa,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,8,308.0,,1,,H,Autocuration,,,CHEMBL616963,BAO_0000219,
1338,6491,B,,,106,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616524,BAO_0000357,
1339,16190,B,CHO,,106,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616525,BAO_0000219,
1340,14165,B,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872908,BAO_0000019,
1341,14165,B,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616526,BAO_0000019,
1342,4234,B,,,106,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616527,BAO_0000357,
1343,6328,B,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,8,,,1,,H,Expert,,,CHEMBL616528,BAO_0000219,
1344,14770,B,,,106,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616529,BAO_0000357,
1345,2598,B,,,106,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616530,BAO_0000357,
1346,6897,B,,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616531,BAO_0000357,
1347,6897,B,,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616532,BAO_0000357,
1348,6013,B,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616533,BAO_0000357,
1349,5843,B,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616534,BAO_0000357,
1350,14454,B,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,8,,,1,,H,Expert,,,CHEMBL616535,BAO_0000357,
1351,16209,B,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616536,BAO_0000357,
1352,3935,B,,,106,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616537,BAO_0000357,
1353,13729,F,CHO-K1,,106,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,8,485.0,,1,,H,Expert,,,CHEMBL616538,BAO_0000219,
1354,14251,F,,,106,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616539,BAO_0000019,
1355,17085,B,,,106,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616540,BAO_0000019,
1356,3025,B,,,106,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616429,BAO_0000357,
1357,15315,B,,,106,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616430,BAO_0000357,
1358,14214,B,,,106,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616431,BAO_0000219,
1359,3804,B,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616432,BAO_0000357,
1360,2391,B,,,106,Affinity for 5-hydroxytryptamine 1B receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616433,BAO_0000357,
1361,4175,B,,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616434,BAO_0000357,
1362,17296,B,CHO,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL616435,BAO_0000219,
1363,17085,B,,,106,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,8,,,1,,H,Expert,,,CHEMBL616436,BAO_0000019,
1364,17211,B,HeLa,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616437,BAO_0000219,
1365,17211,B,HeLa,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616438,BAO_0000219,
1366,17211,B,HeLa,,106,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,8,308.0,,1,,H,Autocuration,,,CHEMBL616439,BAO_0000219,
1367,15926,B,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616440,BAO_0000357,
1368,16312,B,CHO-K1,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,8,485.0,,1,,H,Autocuration,,,CHEMBL616441,BAO_0000219,
1369,5843,B,,,106,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,8,,,1,,H,Expert,,,CHEMBL616442,BAO_0000357,
1370,5843,B,,,106,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616443,BAO_0000357,
1371,16312,B,CHO-K1,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,8,485.0,,1,,H,Expert,,,CHEMBL616444,BAO_0000219,
1372,15926,B,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616445,BAO_0000357,
1373,15926,B,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616446,BAO_0000357,
1374,4540,B,CHO,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616447,BAO_0000219,
1375,6166,B,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616448,BAO_0000357,
1376,17296,B,CHO,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616449,BAO_0000219,
1377,17296,B,CHO,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616450,BAO_0000219,
1378,17296,B,CHO,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL857974,BAO_0000219,
1379,15779,B,CHO,,106,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616451,BAO_0000219,
1380,15779,B,CHO,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616452,BAO_0000219,
1381,15779,B,CHO,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616453,BAO_0000219,
1382,4199,B,CHO,,106,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616454,BAO_0000219,
1383,14875,B,,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616455,BAO_0000357,
1384,15146,B,CHO,,106,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL616456,BAO_0000219,
1385,5213,B,,,106,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616457,BAO_0000357,
1386,14818,B,CHO,,106,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL616458,BAO_0000219,
1387,4829,B,CHO,,106,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL616459,BAO_0000219,
1388,14454,F,,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,8,,,1,,H,Expert,,,CHEMBL616460,BAO_0000019,
1389,14454,F,,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,8,,,1,,H,Expert,,,CHEMBL616461,BAO_0000019,
1390,14875,F,CHO,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,8,449.0,,1,,H,Autocuration,,,CHEMBL616462,BAO_0000219,
1391,14875,F,CHO,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,8,449.0,,1,,H,Autocuration,,,CHEMBL616463,BAO_0000219,
1392,15250,F,,,105,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,8,,,1,,H,Autocuration,,,CHEMBL616464,BAO_0000019,
1393,15250,B,CHO,,105,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616465,BAO_0000219,
1394,15086,B,,,17105,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL832874,BAO_0000357,
1395,3025,F,,,106,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616184,BAO_0000019,
1396,14998,B,,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616185,BAO_0000019,
1397,14998,B,,,106,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,8,,Oryctolagus cuniculus,1,9986.0,H,Intermediate,,,CHEMBL616186,BAO_0000019,
1398,14998,B,,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616187,BAO_0000019,
1399,13969,B,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,8,,,1,,H,Expert,,,CHEMBL616188,BAO_0000357,
1400,13392,B,,,10577,Binding affinity for 5-hydroxytryptamine 1B receptor,,9,,,1,,D,Intermediate,,,CHEMBL873475,BAO_0000357,
1401,3651,B,,2435.0,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Striatum,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616189,BAO_0000019,
1402,10025,B,,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,8,,,1,,H,Expert,,,CHEMBL616190,BAO_0000357,
1403,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,8,,,1,,H,Autocuration,,,CHEMBL616191,BAO_0000357,
1404,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,8,,,1,,H,Autocuration,,,CHEMBL616192,BAO_0000357,
1405,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,8,,,1,,H,Autocuration,,,CHEMBL616193,BAO_0000357,
1406,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,8,,,1,,H,Autocuration,,,CHEMBL616194,BAO_0000357,
1407,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,8,,,1,,H,Autocuration,,,CHEMBL616195,BAO_0000357,
1408,13863,B,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,8,,,1,,H,Autocuration,,,CHEMBL616196,BAO_0000357,
1409,4622,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616197,BAO_0000249,
1410,14911,B,,,10576,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Intermediate,,,CHEMBL616198,BAO_0000019,
1411,12678,B,,10000000.0,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616199,BAO_0000221,
1412,12678,B,,10000000.0,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616200,BAO_0000221,
1413,14235,B,,10000000.0,10576,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616201,BAO_0000221,
1414,14949,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616202,BAO_0000221,
1415,14949,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616203,BAO_0000221,
1416,14949,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616204,BAO_0000221,
1417,14949,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616205,BAO_0000221,
1418,14949,B,,10000000.0,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616206,BAO_0000221,
1419,16118,B,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,8,,,1,,H,Expert,,,CHEMBL616207,BAO_0000249,
1420,3268,B,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,8,,,1,,H,Autocuration,,,CHEMBL616208,BAO_0000249,
1421,3268,B,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,8,,,1,,H,Autocuration,,,CHEMBL616209,BAO_0000249,
1422,16117,B,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,8,,,1,,H,Expert,,,CHEMBL616210,BAO_0000357,
1423,9783,B,,10000000.0,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616211,BAO_0000221,
1424,9783,B,,10000000.0,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616504,BAO_0000221,
1425,14356,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616505,BAO_0000221,
1426,15740,F,,,10576,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616506,BAO_0000019,
1427,12306,B,,10000000.0,10576,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL872107,BAO_0000221,
1428,13348,B,,10000000.0,10576,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616507,BAO_0000221,
1429,10394,B,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616303,BAO_0000249,
1430,15260,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616304,BAO_0000221,
1431,10046,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616305,BAO_0000221,
1432,15260,F,,10000000.0,10576,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Hippocampus,8,,,1,,H,Intermediate,,,CHEMBL616306,BAO_0000221,
1433,12851,B,,,10576,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616307,BAO_0000357,
1434,2148,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL881829,BAO_0000221,
1435,13134,B,,,10576,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,8,,,1,,H,Expert,,,CHEMBL616308,BAO_0000357,
1436,12462,B,,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,8,,,1,,H,Autocuration,,,CHEMBL616309,BAO_0000019,
1437,12462,B,,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,8,,,1,,H,Expert,,,CHEMBL616310,BAO_0000019,
1438,12462,B,CHO,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616311,BAO_0000219,
1439,11933,B,,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL616312,BAO_0000357,
1440,11933,B,,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,8,,,1,,H,Autocuration,,,CHEMBL616313,BAO_0000357,
1441,403,B,,10000000.0,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616314,BAO_0000221,
1442,15538,B,,10000000.0,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616315,BAO_0000221,
1443,15538,B,,10000000.0,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616567,BAO_0000221,
1444,15538,B,,10000000.0,10576,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616568,BAO_0000221,
1445,12464,B,,,10576,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,8,,,1,,H,Intermediate,,,CHEMBL616569,BAO_0000019,
1446,1455,B,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,8,,,1,,H,Expert,,,CHEMBL616570,BAO_0000357,
1447,12652,B,,,10576,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,8,,,1,,H,Autocuration,,,CHEMBL616571,BAO_0000357,
1448,12639,B,,10000000.0,10576,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616572,BAO_0000221,
1449,13949,B,,,10576,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,8,,,1,,H,Expert,,,CHEMBL616573,BAO_0000249,
1450,12463,B,,,10576,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616574,BAO_0000357,
1451,14829,B,,10000000.0,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616575,BAO_0000221,
1452,14829,B,,10000000.0,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL872108,BAO_0000221,
1453,12092,B,,,10576,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616576,BAO_0000357,
1454,403,B,,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,8,,,1,,H,Autocuration,,,CHEMBL616577,BAO_0000249,
1455,403,B,,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,8,,,1,,H,Autocuration,,,CHEMBL616578,BAO_0000249,
1456,3967,B,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL616579,BAO_0000357,
1457,12771,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616580,BAO_0000019,
1458,15086,B,,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,8,,,1,,H,Autocuration,,,CHEMBL616581,BAO_0000019,
1459,14909,B,,10000000.0,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616582,BAO_0000221,
1460,14949,B,,10000000.0,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616583,BAO_0000221,
1461,2309,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616584,BAO_0000221,
1462,4170,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616585,BAO_0000357,
1463,11642,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616586,BAO_0000221,
1464,11642,B,,10000000.0,10576,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616587,BAO_0000221,
1465,12953,B,,10000000.0,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616588,BAO_0000221,
1466,12953,B,,10000000.0,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616589,BAO_0000221,
1467,12953,B,,10000000.0,10576,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616590,BAO_0000221,
1468,12903,B,CHO,,10576,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,8,449.0,,1,,H,Expert,,,CHEMBL616591,BAO_0000219,
1469,12536,B,,,10576,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616592,BAO_0000357,
1470,10058,B,,,10576,The inhibition activity of 5-HT1A at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL616593,BAO_0000357,
1471,12902,B,CHO-K1,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,8,485.0,,1,,H,Expert,,,CHEMBL616594,BAO_0000219,
1472,14057,B,,,10576,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,8,,,1,,H,Expert,,,CHEMBL616595,BAO_0000249,
1473,11296,B,,,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,8,,,1,,H,Autocuration,,,CHEMBL616596,BAO_0000357,
1474,11296,B,,10000000.0,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616597,BAO_0000221,
1475,11296,B,,10000000.0,10576,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,8,,,1,,H,Expert,,,CHEMBL616598,BAO_0000221,
1476,16616,F,,,10576,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616599,BAO_0000249,
1477,16616,F,,10000000.0,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616600,BAO_0000249,
1478,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,8,,,1,,H,Autocuration,,,CHEMBL616601,BAO_0000019,
1479,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,8,,,1,,H,Autocuration,,,CHEMBL616602,BAO_0000019,
1480,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,8,,,1,,H,Autocuration,,,CHEMBL616603,BAO_0000019,
1481,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,8,,,1,,H,Autocuration,,,CHEMBL616604,BAO_0000019,
1482,17136,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,8,,,1,,H,Autocuration,,,CHEMBL616316,BAO_0000249,
1483,17136,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616317,BAO_0000249,
1484,16616,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616318,BAO_0000019,
1485,17331,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616319,BAO_0000221,
1486,17331,B,,10000000.0,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616320,BAO_0000221,
1487,17167,B,,10000000.0,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616321,BAO_0000221,
1488,15740,F,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL616322,BAO_0000019,
1489,15740,F,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,8,,,1,,H,Autocuration,,,CHEMBL616323,BAO_0000019,
1490,4671,B,,,10576,Ratio of binding affinity to 5-HT 1A and D2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL616324,BAO_0000357,
1491,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616325,BAO_0000221,
1492,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616326,BAO_0000221,
1493,10058,B,,10000000.0,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616327,BAO_0000221,
1494,12073,B,,,10576,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616328,BAO_0000357,
1495,2759,B,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,8,,,1,,H,Autocuration,,,CHEMBL858110,BAO_0000249,
1496,2759,F,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,8,,,1,,H,Autocuration,,,CHEMBL616329,BAO_0000249,
1497,2759,B,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,8,,,1,,H,Autocuration,,,CHEMBL616330,BAO_0000249,
1498,2759,F,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,8,,,1,,H,Autocuration,,,CHEMBL616331,BAO_0000249,
1499,2759,F,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,8,,,1,,H,Autocuration,,,CHEMBL616332,BAO_0000249,
1500,9737,B,,955.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,8,,,1,,H,Autocuration,,,CHEMBL857063,BAO_0000249,
1501,9737,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616333,BAO_0000019,
1502,5717,F,,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL616334,BAO_0000019,
1503,12253,B,,10000000.0,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616335,BAO_0000221,
1504,14025,B,,,10576,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,8,,,1,,H,Autocuration,,,CHEMBL616336,BAO_0000019,
1505,10425,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL616337,BAO_0000249,
1506,14998,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,8,,,1,,H,Autocuration,,,CHEMBL616338,BAO_0000019,
1507,13694,B,,10000000.0,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616339,BAO_0000221,
1508,13694,B,,10000000.0,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616340,BAO_0000221,
1509,4342,B,,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616341,BAO_0000357,
1510,12936,B,,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616342,BAO_0000357,
1511,13144,B,,,10576,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616343,BAO_0000019,
1512,13343,B,,,10576,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,8,,,1,,H,Expert,,,CHEMBL616344,BAO_0000019,
1513,12132,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,1,,H,Expert,,,CHEMBL616345,BAO_0000357,
1514,15419,B,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,8,,,1,,H,Expert,,,CHEMBL616346,BAO_0000019,
1515,1479,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616347,BAO_0000221,
1516,14287,B,,,10576,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,8,,,1,,H,Expert,,,CHEMBL616348,BAO_0000019,
1517,13116,B,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616349,BAO_0000357,
1518,2759,B,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616152,BAO_0000249,
1519,2759,B,,,10576,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,8,,,1,,H,Autocuration,,,CHEMBL616153,BAO_0000249,
1520,14748,B,,,10576,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,8,,,1,,H,Expert,,,CHEMBL616154,BAO_0000019,
1521,12304,B,,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,1,,H,Autocuration,,,CHEMBL616155,BAO_0000019,
1522,12409,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616156,BAO_0000221,
1523,12409,B,,10000000.0,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616157,BAO_0000221,
1524,13267,B,,10000000.0,10576,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616158,BAO_0000221,
1525,15194,B,,,10576,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616159,BAO_0000357,
1526,14256,B,,,10576,pKi value against rat 5-hydroxytryptamine 1A receptor.,,8,,,1,,H,Expert,,,CHEMBL616160,BAO_0000357,
1527,16567,B,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,8,,,1,,H,Autocuration,,,CHEMBL616161,BAO_0000019,
1528,15740,F,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL616162,BAO_0000019,
1529,13278,B,,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616163,BAO_0000357,
1530,1970,B,,,10626,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,1,,H,Expert,,,CHEMBL616164,BAO_0000249,
1531,10034,B,,955.0,10576,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Brain,8,,,1,,H,Autocuration,,,CHEMBL616165,BAO_0000221,
1532,13348,B,,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,8,,Rattus norvegicus,1,10116.0,H,Autocuration,,,CHEMBL616355,BAO_0000019,
1533,13630,F,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,8,,,1,,H,Autocuration,,,CHEMBL616356,BAO_0000019,
1534,10862,B,,955.0,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,8,,,1,,H,Autocuration,,,CHEMBL616357,BAO_0000221,
1535,12058,B,,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,8,,,1,,H,Autocuration,,,CHEMBL616358,BAO_0000019,
1536,4639,B,,,51,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616359,BAO_0000357,
1537,15453,B,,,51,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,8,,,1,,H,Expert,,,CHEMBL616360,BAO_0000357,
1538,4820,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL616361,BAO_0000357,
1539,1089,B,,,51,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616362,BAO_0000357,
1540,386,B,,,51,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,8,,,1,,H,Autocuration,,,CHEMBL616363,BAO_0000249,
1541,6011,B,,,51,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL616364,BAO_0000357,
1542,5014,B,,,51,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616365,BAO_0000357,
1543,4402,B,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Expert,,,CHEMBL616366,BAO_0000357,
1544,17066,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Expert,,,CHEMBL872906,BAO_0000357,
1545,17515,B,,,51,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL616367,BAO_0000357,
1546,2474,B,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616368,BAO_0000357,
1547,4775,B,,,51,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616369,BAO_0000357,
1548,14294,B,,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616370,BAO_0000357,
1549,14294,B,,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616371,BAO_0000357,
1550,12249,B,CHO,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616372,BAO_0000219,
1551,11376,B,,,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,8,,,1,,H,Expert,,,CHEMBL616373,BAO_0000219,
1552,2474,B,,,51,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616374,BAO_0000218,
1553,13311,B,,10000000.0,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL616375,BAO_0000221,
1554,4373,B,,,51,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616376,BAO_0000357,
1555,1633,B,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,8,,,1,,H,Expert,,,CHEMBL857064,BAO_0000357,
1556,11866,B,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616377,BAO_0000357,
1557,4373,B,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616378,BAO_0000357,
1558,4687,B,,,51,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616379,BAO_0000357,
1559,16946,B,,,11863,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616380,BAO_0000357,
1560,13291,B,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616381,BAO_0000357,
1561,14159,B,,,11863,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616382,BAO_0000357,
1562,10812,B,,,11863,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616383,BAO_0000357,
1563,3032,B,CHO,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,9,449.0,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616350,BAO_0000219,
1564,16655,B,,,11863,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616351,BAO_0000357,
1565,14532,B,,,11863,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,8,,,1,,H,Autocuration,,,CHEMBL616352,BAO_0000357,
1566,13944,B,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616353,BAO_0000357,
1567,13033,B,,,11863,Binding affinity against serotonergic 5-HT1a receptor,,8,,,1,,H,Autocuration,,,CHEMBL616354,BAO_0000357,
1568,10321,B,,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616508,BAO_0000357,
1569,2968,B,,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616559,BAO_0000357,
1570,13964,B,,,11863,Binding affinity at 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616560,BAO_0000357,
1571,15527,B,,,11863,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,8,,,1,,H,Autocuration,,,CHEMBL616561,BAO_0000357,
1572,12248,B,CHO,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616562,BAO_0000219,
1573,12249,B,CHO,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616563,BAO_0000219,
1574,15120,B,,,11863,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616564,BAO_0000357,
1575,13313,B,,,11863,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616565,BAO_0000357,
1576,2613,B,,,11863,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616566,BAO_0000218,
1577,16700,B,,,11863,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL616989,BAO_0000357,
1578,2201,B,,,11863,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL857975,BAO_0000357,
1579,1274,B,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL616990,BAO_0000357,
1580,1317,B,,,11863,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616991,BAO_0000357,
1581,12146,B,,,11863,Tested against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616992,BAO_0000357,
1582,14059,B,,,11863,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616993,BAO_0000357,
1583,14025,B,,,106,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL616994,BAO_0000019,
1584,14025,B,,,106,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616995,BAO_0000019,
1585,14447,B,HEK293,,105571,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,9,722.0,Gorilla gorilla,1,9593.0,D,Intermediate,,,CHEMBL616996,BAO_0000219,
1586,3025,F,,,106,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL616997,BAO_0000218,
1587,3025,F,,,106,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL616998,BAO_0000218,
1588,15329,F,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL616999,BAO_0000019,
1589,15329,F,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617000,BAO_0000019,
1590,15847,F,,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617001,BAO_0000019,
1591,15847,F,,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL858111,BAO_0000019,
1592,14165,F,,,106,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,8,,,1,,H,Autocuration,,,CHEMBL617002,BAO_0000019,
1593,14214,F,,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,8,,,1,,H,Autocuration,,,CHEMBL617003,BAO_0000019,
1594,14214,F,,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,8,,,1,,H,Autocuration,,,CHEMBL617004,BAO_0000019,
1595,14214,F,,,106,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617005,BAO_0000019,
1596,13729,F,CHO-K1,,106,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,9,485.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616623,BAO_0000219,
1597,3025,F,CHO,,106,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,8,449.0,,1,,H,Autocuration,,,CHEMBL616624,BAO_0000219,
1598,2391,B,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL883243,BAO_0000357,
1599,2391,F,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,8,,,1,,H,Autocuration,,,CHEMBL616625,BAO_0000019,
1600,14956,F,CHO,,106,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,8,449.0,,1,,H,Expert,,,CHEMBL616626,BAO_0000219,
1601,2598,F,CHO,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,8,449.0,,1,,H,Autocuration,,,CHEMBL616627,BAO_0000219,
1602,2598,F,CHO,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,8,449.0,,1,,H,Autocuration,,,CHEMBL616628,BAO_0000219,
1603,2598,F,CHO,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,8,449.0,,1,,H,Autocuration,,,CHEMBL616629,BAO_0000219,
1604,2598,F,CHO,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,8,449.0,,1,,H,Autocuration,,,CHEMBL616630,BAO_0000219,
1605,14956,F,,,106,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,8,,,1,,H,Expert,,,CHEMBL616631,BAO_0000019,
1606,14956,F,,,106,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,8,,,1,,H,Autocuration,,,CHEMBL616632,BAO_0000019,
1607,14214,B,,,106,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616633,BAO_0000357,
1608,3463,B,CHO,,106,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,8,449.0,,1,,H,Expert,,,CHEMBL616634,BAO_0000219,
1609,15331,B,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL616635,BAO_0000357,
1610,16146,B,,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL885358,BAO_0000357,
1611,14159,B,CHO,,106,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616636,BAO_0000219,
1612,14158,B,CHO,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,8,449.0,,1,,H,Expert,,,CHEMBL616637,BAO_0000219,
1613,14159,B,,,106,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616638,BAO_0000357,
1614,15250,B,CHO,,106,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616639,BAO_0000219,
1615,15250,B,CHO,,106,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,8,449.0,,1,,H,Expert,,,CHEMBL616640,BAO_0000219,
1616,15331,B,CHO,,106,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616641,BAO_0000219,
1617,15332,B,CHO,,106,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,8,449.0,,1,,H,Expert,,,CHEMBL616642,BAO_0000219,
1618,14956,B,CHO,,106,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616643,BAO_0000219,
1619,3805,B,,,106,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL616644,BAO_0000357,
1620,14875,B,,,106,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,8,,,1,,H,Autocuration,,,CHEMBL616645,BAO_0000357,
1621,14454,F,,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616646,BAO_0000019,
1622,14454,F,,,105,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL616647,BAO_0000019,
1623,16288,B,,,105,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,8,,,1,,H,Autocuration,,,CHEMBL616509,BAO_0000357,
1624,16288,B,,,105,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,8,,,1,,H,Autocuration,,,CHEMBL616510,BAO_0000357,
1625,16312,B,,,105,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616511,BAO_0000357,
1626,1348,B,,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616512,BAO_0000357,
1627,5834,B,,,105,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616513,BAO_0000357,
1628,13366,B,,2435.0,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616514,BAO_0000019,
1629,1414,B,,,105,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616515,BAO_0000357,
1630,14998,B,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616516,BAO_0000019,
1631,11473,B,,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616517,BAO_0000357,
1632,11473,B,,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616518,BAO_0000357,
1633,10639,B,,,105,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616519,BAO_0000357,
1634,10639,B,,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616520,BAO_0000357,
1635,1375,B,,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616521,BAO_0000357,
1636,1375,B,,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616522,BAO_0000357,
1637,16532,B,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL884531,BAO_0000357,
1638,11147,B,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616523,BAO_0000357,
1639,13366,B,,2435.0,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616731,BAO_0000019,
1640,10444,B,,,105,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616732,BAO_0000019,
1641,16532,B,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616733,BAO_0000357,
1642,16532,B,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616734,BAO_0000357,
1643,12827,B,,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616735,BAO_0000249,
1644,12827,B,,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616736,BAO_0000249,
1645,12919,F,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616737,BAO_0000019,
1646,14025,B,,,105,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616738,BAO_0000019,
1647,12919,F,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616739,BAO_0000019,
1648,12919,F,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616740,BAO_0000019,
1649,12919,F,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL616741,BAO_0000019,
1650,14447,B,HEK293,,105,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,8,722.0,Gorilla gorilla,1,9593.0,H,Autocuration,,,CHEMBL616742,BAO_0000219,
1651,1375,B,,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616743,BAO_0000019,
1652,1375,B,,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616744,BAO_0000019,
1653,12409,F,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616745,BAO_0000019,
1654,12409,F,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616746,BAO_0000019,
1655,12409,F,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616747,BAO_0000019,
1656,12409,F,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616748,BAO_0000019,
1657,12409,F,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616648,BAO_0000019,
1658,11574,B,,,105570,Binding affinity against 5-hydroxytryptamine 1D receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616649,BAO_0000357,
1659,1558,B,,,105570,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616650,BAO_0000357,
1660,12409,F,,,105570,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616651,BAO_0000218,
1661,12409,F,,,105570,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616652,BAO_0000218,
1662,12409,F,,,105570,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616653,BAO_0000218,
1663,12409,F,,,105570,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616654,BAO_0000218,
1664,12253,B,,,105570,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616655,BAO_0000019,
1665,12936,B,,,105570,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616656,BAO_0000357,
1666,13181,B,,,105,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL616657,BAO_0000019,
1667,12409,B,,2435.0,105570,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616658,BAO_0000357,
1668,10639,B,,,105570,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL616659,BAO_0000357,
1669,5254,B,,,51,Binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616660,BAO_0000357,
1670,13051,B,,,106,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,8,,,1,,H,Autocuration,,,CHEMBL616661,BAO_0000357,
1671,3463,F,,,105,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Expert,,,CHEMBL616662,BAO_0000019,
1672,15315,F,,,105,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616663,BAO_0000019,
1673,6011,F,,,105,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616664,BAO_0000019,
1674,14159,F,CHO,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL881820,BAO_0000219,
1675,14159,F,CHO,,105,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,8,449.0,,1,,H,Autocuration,,,CHEMBL616665,BAO_0000219,
1676,15250,B,CHO,,105,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,8,449.0,,1,,H,Expert,,,CHEMBL616666,BAO_0000219,
1677,15250,B,CHO,,105,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL616667,BAO_0000219,
1678,15331,F,CHO,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,8,449.0,,1,,H,Expert,,,CHEMBL616668,BAO_0000219,
1679,15332,F,CHO,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616669,BAO_0000219,
1680,15332,F,CHO,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,8,449.0,,1,,H,Expert,,,CHEMBL617040,BAO_0000219,
1681,3294,F,CHO,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,8,449.0,,1,,H,Autocuration,,,CHEMBL617041,BAO_0000219,
1682,14158,F,CHO,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,8,449.0,,1,,H,Expert,,,CHEMBL617042,BAO_0000219,
1683,14956,F,CHO,,105,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,8,449.0,,1,,H,Expert,,,CHEMBL617043,BAO_0000219,
1684,12469,F,,,105,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617044,BAO_0000019,
1685,3463,F,CHO,,105,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,8,449.0,,1,,H,Expert,,,CHEMBL617045,BAO_0000219,
1686,15250,F,CHO,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617046,BAO_0000219,
1687,15250,F,CHO,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617047,BAO_0000219,
1688,14956,F,,,105,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,8,,,1,,H,Expert,,,CHEMBL617048,BAO_0000019,
1689,14159,F,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,8,,,1,,H,Autocuration,,,CHEMBL616897,BAO_0000019,
1690,14159,F,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616898,BAO_0000019,
1691,14499,F,CHO,,105,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL858201,BAO_0000219,
1692,15315,F,,,105,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616899,BAO_0000019,
1693,3294,B,,,105,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,8,,,1,,H,Autocuration,,,CHEMBL616900,BAO_0000219,
1694,3463,B,CHO,,105,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,8,449.0,,1,,H,Expert,,,CHEMBL616901,BAO_0000219,
1695,15331,B,,,105,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL616902,BAO_0000357,
1696,14159,B,CHO,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616903,BAO_0000219,
1697,14158,B,CHO,,105,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,8,449.0,,1,,H,Expert,,,CHEMBL616904,BAO_0000219,
1698,14159,B,,,105,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616905,BAO_0000357,
1699,15250,B,CHO,,105,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,8,449.0,,1,,H,Expert,,,CHEMBL616906,BAO_0000219,
1700,15250,B,CHO,,105,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616907,BAO_0000219,
1701,15331,B,CHO,,105,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616908,BAO_0000219,
1702,15332,B,CHO,,105,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616909,BAO_0000219,
1703,14499,B,CHO,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616910,BAO_0000219,
1704,15332,B,CHO,,105,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616911,BAO_0000219,
1705,14956,B,CHO,,105,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL616912,BAO_0000219,
1706,3805,B,,,105,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL616913,BAO_0000357,
1707,6011,B,CHO,,105,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616914,BAO_0000219,
1708,16190,B,CHO,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616915,BAO_0000219,
1709,14165,B,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616916,BAO_0000019,
1710,4234,B,,,105,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616917,BAO_0000357,
1711,15527,B,,,105,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,8,,,1,,H,Autocuration,,,CHEMBL616918,BAO_0000357,
1712,6328,B,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,8,,,1,,H,Expert,,,CHEMBL616919,BAO_0000219,
1713,16209,B,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616920,BAO_0000357,
1714,14770,B,,,105,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL872914,BAO_0000357,
1715,2598,B,,,105,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616921,BAO_0000357,
1716,6897,B,,,105,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Expert,,,CHEMBL616922,BAO_0000357,
1717,6013,B,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616923,BAO_0000357,
1718,5843,B,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Expert,,,CHEMBL616924,BAO_0000357,
1719,14454,B,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,8,,,1,,H,Expert,,,CHEMBL875909,BAO_0000357,
1720,14454,B,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL616925,BAO_0000357,
1721,14454,B,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,8,,,1,,H,Autocuration,,,CHEMBL616926,BAO_0000357,
1722,15818,B,,,105,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616927,BAO_0000357,
1723,13729,F,CHO-K1,,105,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,8,485.0,,1,,H,Expert,,,CHEMBL616928,BAO_0000219,
1724,6011,B,,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616929,BAO_0000219,
1725,4234,B,,,105,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616930,BAO_0000357,
1726,17085,B,,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Expert,,,CHEMBL616931,BAO_0000019,
1727,3025,B,,,105,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616932,BAO_0000357,
1728,15315,B,,,105,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Expert,,,CHEMBL616933,BAO_0000357,
1729,14214,B,,,105,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616934,BAO_0000219,
1730,3804,B,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616935,BAO_0000357,
1731,16700,B,,,105,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL616936,BAO_0000357,
1732,2391,B,,,105,Affinity for 5-hydroxytryptamine 1D receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616937,BAO_0000357,
1733,4175,B,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616938,BAO_0000357,
1734,17085,B,,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616939,BAO_0000019,
1735,17085,B,,,105,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,8,,,1,,H,Expert,,,CHEMBL616940,BAO_0000019,
1736,15926,B,,,105,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616941,BAO_0000357,
1737,16312,B,CHO-K1,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,8,485.0,,1,,H,Autocuration,,,CHEMBL616942,BAO_0000219,
1738,16312,B,CHO-K1,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,8,485.0,,1,,H,Autocuration,,,CHEMBL616943,BAO_0000219,
1739,14956,B,CHO,,104802,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,4,449.0,,1,,H,Autocuration,,,CHEMBL616944,BAO_0000219,
1740,3294,F,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,8,,,1,,H,Autocuration,,,CHEMBL616945,BAO_0000019,
1741,12861,B,,,105,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616946,BAO_0000357,
1742,12861,B,,,105,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616947,BAO_0000019,
1743,16312,B,CHO-K1,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,8,485.0,,1,,H,Expert,,,CHEMBL616948,BAO_0000219,
1744,5104,B,,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616851,BAO_0000357,
1745,5105,B,,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616852,BAO_0000357,
1746,14499,B,,,105,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616853,BAO_0000357,
1747,15926,B,,,105,Binding activity against human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616854,BAO_0000357,
1748,4540,B,CHO,,105,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616855,BAO_0000219,
1749,15779,B,CHO,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616856,BAO_0000219,
1750,15779,B,CHO,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616857,BAO_0000219,
1751,6166,B,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616858,BAO_0000357,
1752,15779,B,CHO,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616859,BAO_0000219,
1753,15779,B,CHO,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616860,BAO_0000219,
1754,17451,B,HEK293,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616861,BAO_0000219,
1755,17451,B,HEK293,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616541,BAO_0000219,
1756,17451,B,HEK293,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,8,722.0,,1,,H,Autocuration,,,CHEMBL616542,BAO_0000219,
1757,4199,B,CHO,,105,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616543,BAO_0000219,
1758,14875,B,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616544,BAO_0000357,
1759,15146,B,CHO,,105,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL616545,BAO_0000219,
1760,5213,B,,,105,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616546,BAO_0000357,
1761,14818,B,CHO,,105,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616547,BAO_0000219,
1762,4829,B,CHO,,105,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL616548,BAO_0000219,
1763,14454,F,,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,8,,,1,,H,Expert,,,CHEMBL616549,BAO_0000019,
1764,14454,F,,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,8,,,1,,H,Expert,,,CHEMBL616550,BAO_0000019,
1765,5254,B,,,108,Binding affinity against 5-HT2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL857066,BAO_0000357,
1766,5254,B,,,108,Binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616551,BAO_0000357,
1767,10639,B,,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,8,,,1,,H,Autocuration,,,CHEMBL616552,BAO_0000357,
1768,10639,F,,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,8,,,1,,H,Autocuration,,,CHEMBL832876,BAO_0000019,
1769,12352,B,,,10577,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,8,,,1,,H,Expert,,,CHEMBL616553,BAO_0000019,
1770,9098,B,,,10577,Binding affinity towards 5-HT1B was determined,,8,,,1,,H,Autocuration,,,CHEMBL616554,BAO_0000357,
1771,14430,B,,,10577,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,8,,,1,,H,Expert,,,CHEMBL616555,BAO_0000019,
1772,13657,B,,,10577,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,8,,,1,,H,Expert,,,CHEMBL616556,BAO_0000019,
1773,13657,B,,,10577,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,8,,,1,,H,Autocuration,,,CHEMBL616557,BAO_0000019,
1774,15854,B,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,1,,H,Expert,,,CHEMBL616558,BAO_0000019,
1775,10639,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616749,BAO_0000019,
1776,10025,B,,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL616750,BAO_0000357,
1777,10025,B,,,10577,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,8,,,1,,H,Autocuration,,,CHEMBL616751,BAO_0000357,
1778,14286,B,,,10577,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,8,,,1,,H,Autocuration,,,CHEMBL616752,BAO_0000249,
1779,3651,B,,2435.0,10577,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616753,BAO_0000019,
1780,14178,B,,,10577,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616754,BAO_0000357,
1781,10639,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616755,BAO_0000019,
1782,13605,B,,2435.0,10577,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616756,BAO_0000019,
1783,5834,B,,2435.0,10577,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616757,BAO_0000019,
1784,10922,B,,2435.0,10577,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616758,BAO_0000357,
1785,14286,B,,,10577,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,8,,,1,,H,Autocuration,,,CHEMBL616759,BAO_0000249,
1786,11825,B,,,10577,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,8,,,1,,H,Autocuration,,,CHEMBL616760,BAO_0000357,
1787,14826,B,,2435.0,10577,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616761,BAO_0000019,
1788,9699,B,,2435.0,10577,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616762,BAO_0000019,
1789,14423,B,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,8,,,1,,H,Autocuration,,,CHEMBL616763,BAO_0000019,
1790,10062,B,,,10577,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,8,,,1,,H,Expert,,,CHEMBL872909,BAO_0000357,
1791,10062,B,,,10577,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616764,BAO_0000357,
1792,12280,B,,,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616765,BAO_0000357,
1793,15412,B,,2435.0,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616766,BAO_0000357,
1794,15412,B,,2435.0,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616767,BAO_0000357,
1795,10062,B,,,10577,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616768,BAO_0000357,
1796,11147,B,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616769,BAO_0000357,
1797,9547,B,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,8,,,1,,H,Autocuration,,,CHEMBL616770,BAO_0000019,
1798,10444,B,,,10577,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,8,,,1,,H,Autocuration,,,CHEMBL616771,BAO_0000019,
1799,12469,B,,2435.0,10577,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Striatum,8,,,1,,H,Autocuration,,,CHEMBL616772,BAO_0000019,
1800,9098,B,,,10577,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,8,,,1,,H,Expert,,,CHEMBL616773,BAO_0000019,
1801,9098,B,,,10577,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,8,,,1,,H,Autocuration,,,CHEMBL616774,BAO_0000019,
1802,9699,B,,,10577,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616775,BAO_0000357,
1803,10394,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616776,BAO_0000249,
1804,12092,B,,,10577,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616777,BAO_0000357,
1805,16700,B,,,10577,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL616778,BAO_0000357,
1806,403,B,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616779,BAO_0000249,
1807,12771,B,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616780,BAO_0000357,
1808,11642,B,,,10577,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,8,,,1,,H,Autocuration,,,CHEMBL616781,BAO_0000019,
1809,12953,B,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616782,BAO_0000357,
1810,12953,B,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616783,BAO_0000357,
1811,12953,B,,2435.0,10577,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Striatum,8,,,1,,H,Expert,,,CHEMBL616784,BAO_0000019,
1812,12953,B,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL616785,BAO_0000357,
1813,9737,B,,955.0,10577,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,8,,,1,,H,Autocuration,,,CHEMBL857067,BAO_0000249,
1814,9737,B,,,10577,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616786,BAO_0000019,
1815,9737,B,,955.0,10577,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,8,,,1,,H,Autocuration,,,CHEMBL616787,BAO_0000249,
1816,12827,B,,,10577,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,8,,,1,,H,Autocuration,,,CHEMBL616788,BAO_0000357,
1817,5033,B,,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616789,BAO_0000357,
1818,9786,B,,,10577,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616790,BAO_0000019,
1819,13116,B,,,10577,Binding affinity at 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Expert,,,CHEMBL616791,BAO_0000357,
1820,16429,B,,,10577,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616792,BAO_0000019,
1821,12409,B,,,10577,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616793,BAO_0000249,
1822,15194,B,,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616794,BAO_0000357,
1823,15194,B,,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616795,BAO_0000357,
1824,5486,B,,,104686,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL616796,BAO_0000019,
1825,4639,B,,,106,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616797,BAO_0000357,
1826,386,B,,,106,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,8,,,1,,H,Autocuration,,,CHEMBL616798,BAO_0000249,
1827,2474,B,,,106,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616799,BAO_0000357,
1828,6011,B,,,106,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL616800,BAO_0000357,
1829,5014,B,,,106,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616801,BAO_0000357,
1830,17515,B,,,106,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL616802,BAO_0000357,
1831,4373,B,,,106,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616803,BAO_0000357,
1832,1633,B,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,8,,,1,,H,Expert,,,CHEMBL857068,BAO_0000357,
1833,1633,B,,,106,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,8,,,1,,H,Autocuration,,,CHEMBL616804,BAO_0000357,
1834,4373,B,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616805,BAO_0000357,
1835,4687,B,,,106,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616806,BAO_0000357,
1836,11574,B,,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL616807,BAO_0000357,
1837,10321,B,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616808,BAO_0000357,
1838,15527,B,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL616809,BAO_0000357,
1839,17200,B,,,106,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616810,BAO_0000357,
1840,14423,B,,,104802,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616811,BAO_0000224,
1841,5834,B,,,108,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL616812,BAO_0000357,
1842,11473,B,,,108,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616813,BAO_0000357,
1843,11473,B,,,108,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616814,BAO_0000357,
1844,10639,B,,,108,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616815,BAO_0000357,
1845,10639,B,,,108,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616816,BAO_0000357,
1846,14331,B,,,108,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616817,BAO_0000357,
1847,10796,B,,,108,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616818,BAO_0000357,
1848,9098,B,,,108,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616819,BAO_0000357,
1849,14331,B,,,108,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616820,BAO_0000357,
1850,11828,B,,,108,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL616821,BAO_0000019,
1851,11866,B,,,108,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL616822,BAO_0000357,
1852,13047,B,,,108,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616823,BAO_0000019,
1853,188,B,,,12689,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616824,BAO_0000357,
1854,11825,B,,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616825,BAO_0000357,
1855,11825,B,,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616826,BAO_0000357,
1856,11624,B,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616827,BAO_0000019,
1857,11139,B,,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616828,BAO_0000357,
1858,11147,B,,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616829,BAO_0000357,
1859,10444,B,,,12689,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616830,BAO_0000019,
1860,11624,B,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616831,BAO_0000357,
1861,11662,B,,,12689,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616832,BAO_0000019,
1862,11662,B,,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616833,BAO_0000019,
1863,11662,B,,,12689,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL616834,BAO_0000019,
1864,11662,B,,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL829595,BAO_0000019,
1865,9098,B,,,12689,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616835,BAO_0000357,
1866,10394,B,,,12689,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL872910,BAO_0000249,
1867,11933,B,,,12689,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,8,,,1,,H,Expert,,,CHEMBL616836,BAO_0000357,
1868,12092,B,,,12689,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616837,BAO_0000357,
1869,12253,B,,,12689,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616466,BAO_0000019,
1870,12253,B,HEK293,,12689,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,9,722.0,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616467,BAO_0000219,
1871,1558,B,,,108,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,8,,,1,,H,Autocuration,,,CHEMBL616468,BAO_0000357,
1872,2474,B,,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616469,BAO_0000357,
1873,2474,B,,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616470,BAO_0000357,
1874,11574,B,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,8,,,1,,H,Autocuration,,,CHEMBL616471,BAO_0000357,
1875,1558,B,,,12689,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,8,,,1,,H,Autocuration,,,CHEMBL616472,BAO_0000357,
1876,13944,B,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,8,,,1,,H,Autocuration,,,CHEMBL616473,BAO_0000357,
1877,13033,B,,,12689,Binding affinity against serotonergic 5-HT1c receptor,,8,,,1,,H,Autocuration,,,CHEMBL616474,BAO_0000357,
1878,10321,B,,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616475,BAO_0000357,
1879,11866,B,,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616476,BAO_0000357,
1880,14454,B,,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616477,BAO_0000019,
1881,11574,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616478,BAO_0000224,
1882,11574,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616479,BAO_0000224,
1883,13631,B,,,104686,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,4,,,1,,H,Autocuration,,,CHEMBL616480,BAO_0000019,
1884,9630,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616481,BAO_0000019,
1885,8822,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616482,BAO_0000249,
1886,9064,B,,955.0,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Brain,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL884713,BAO_0000221,
1887,8868,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,4,,,1,,H,Autocuration,,,CHEMBL616483,BAO_0000224,
1888,9064,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,4,,,1,,H,Autocuration,,,CHEMBL616484,BAO_0000224,
1889,9806,B,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,4,,,1,,H,Autocuration,,,CHEMBL616485,BAO_0000019,
1890,9098,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL616486,BAO_0000224,
1891,8868,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,4,,,1,,H,Autocuration,,,CHEMBL616487,BAO_0000224,
1892,12765,B,,,104686,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,4,,,1,,H,Autocuration,,,CHEMBL616488,BAO_0000224,
1893,11049,B,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616489,BAO_0000019,
1894,11049,B,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616490,BAO_0000019,
1895,11049,B,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,4,,,1,,H,Autocuration,,,CHEMBL616491,BAO_0000019,
1896,11049,B,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,4,,,1,,H,Autocuration,,,CHEMBL616492,BAO_0000019,
1897,11049,B,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616493,BAO_0000019,
1898,11473,B,,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL616494,BAO_0000019,
1899,11473,B,,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL616495,BAO_0000019,
1900,3086,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL616496,BAO_0000019,
1901,11049,B,,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616497,BAO_0000019,
1902,11049,B,,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616498,BAO_0000019,
1903,10639,B,,,104686,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,4,,,1,,H,Autocuration,,,CHEMBL616499,BAO_0000019,
1904,10922,B,,,104686,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,4,,,1,,H,Autocuration,,,CHEMBL616500,BAO_0000019,
1905,9064,B,,955.0,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616501,BAO_0000221,
1906,10748,B,,955.0,104686,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Brain,4,,,1,,H,Autocuration,,,CHEMBL616502,BAO_0000221,
1907,11614,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,4,,,1,,H,Autocuration,,,CHEMBL884529,BAO_0000249,
1908,11615,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,4,,,1,,H,Autocuration,,,CHEMBL616503,BAO_0000249,
1909,11615,B,,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL616964,BAO_0000224,
1910,11614,B,,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,4,,,1,,H,Autocuration,,,CHEMBL616965,BAO_0000249,
1911,11702,B,,,104686,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,4,,,1,,H,Autocuration,,,CHEMBL616966,BAO_0000224,
1912,11702,B,,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,1,,H,Autocuration,,,CHEMBL616967,BAO_0000224,
1913,11702,B,,,104686,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616968,BAO_0000224,
1914,11702,B,,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,1,,H,Autocuration,,,CHEMBL616969,BAO_0000224,
1915,13346,B,,,104686,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,4,,,1,,H,Autocuration,,,CHEMBL884530,BAO_0000019,
1916,10025,B,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL616970,BAO_0000224,
1917,10025,B,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,4,,,1,,H,Autocuration,,,CHEMBL616971,BAO_0000224,
1918,10025,B,,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,4,,,1,,H,Autocuration,,,CHEMBL616972,BAO_0000224,
1919,9036,B,,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,4,,,1,,H,Autocuration,,,CHEMBL616973,BAO_0000224,
1920,9036,B,,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,4,,,1,,H,Autocuration,,,CHEMBL616974,BAO_0000224,
1921,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,4,,,1,,H,Autocuration,,,CHEMBL616975,BAO_0000019,
1922,12304,B,,,104686,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL616976,BAO_0000019,
1923,13276,B,,,104686,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL616977,BAO_0000224,
1924,11825,B,,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,4,,,1,,H,Autocuration,,,CHEMBL616978,BAO_0000224,
1925,12443,B,,,104686,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL616979,BAO_0000224,
1926,13830,B,,,104686,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL616980,BAO_0000224,
1927,9592,B,,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,4,,,1,,H,Autocuration,,,CHEMBL616981,BAO_0000249,
1928,9592,B,,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,4,,,1,,H,Autocuration,,,CHEMBL616982,BAO_0000249,
1929,10881,B,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,4,,,1,,H,Autocuration,,,CHEMBL616983,BAO_0000224,
1930,13605,B,,,104686,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,4,,,1,,H,Autocuration,,,CHEMBL616984,BAO_0000019,
1931,11624,B,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL616985,BAO_0000224,
1932,4101,B,,,104686,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL616986,BAO_0000224,
1933,4101,B,,,104686,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL616987,BAO_0000224,
1934,15360,B,,,104686,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,4,,,1,,H,Autocuration,,,CHEMBL616988,BAO_0000019,
1935,11576,B,,,104686,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,1,,H,Autocuration,,,CHEMBL617243,BAO_0000019,
1936,5834,B,,,104686,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,4,,,1,,H,Autocuration,,,CHEMBL617244,BAO_0000019,
1937,2395,B,CHO-K1,,104686,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,5,485.0,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617245,BAO_0000219,
1938,11965,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,4,,,1,,H,Autocuration,,,CHEMBL617246,BAO_0000249,
1939,3967,B,,,104686,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,4,,,1,,H,Autocuration,,,CHEMBL617546,BAO_0000224,
1940,11130,B,,,104686,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,4,,,1,,H,Autocuration,,,CHEMBL617547,BAO_0000249,
1941,13427,B,,,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,4,,,1,,H,Autocuration,,,CHEMBL617548,BAO_0000219,
1942,9443,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617549,BAO_0000224,
1943,9443,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,4,,,1,,H,Autocuration,,,CHEMBL617550,BAO_0000224,
1944,11825,B,,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,4,,,1,,H,Autocuration,,,CHEMBL617551,BAO_0000224,
1945,12120,B,,,104686,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,4,,,1,,H,Autocuration,,,CHEMBL617552,BAO_0000249,
1946,12120,B,,,104686,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,4,,,1,,H,Autocuration,,,CHEMBL617553,BAO_0000249,
1947,11963,F,,1515.0,104686,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Thoracic aorta,4,,,1,,H,Autocuration,,,CHEMBL617554,BAO_0000019,
1948,9069,B,,,104686,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617555,BAO_0000019,
1949,8868,B,,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,4,,,1,,H,Autocuration,,,CHEMBL617556,BAO_0000224,
1950,17200,B,,,10624,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617557,BAO_0000357,
1951,17200,B,,,10624,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617558,BAO_0000357,
1952,13969,B,,,17106,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,8,,,1,,H,Expert,,,CHEMBL617559,BAO_0000357,
1953,13392,B,,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor,,9,,,1,,D,Expert,,,CHEMBL617560,BAO_0000357,
1954,1742,B,,,17106,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,1,,H,Autocuration,,,CHEMBL617561,BAO_0000249,
1955,1742,B,,,17106,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,1,,H,Autocuration,,,CHEMBL617562,BAO_0000249,
1956,14331,B,,2435.0,17106,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Striatum,8,,,1,,H,Autocuration,,,CHEMBL617563,BAO_0000357,
1957,12861,F,,,17106,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617564,BAO_0000019,
1958,12861,B,,,17106,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,8,,,1,,H,Expert,,,CHEMBL617565,BAO_0000019,
1959,12861,B,,,17106,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL856076,BAO_0000357,
1960,12861,B,,,17106,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617566,BAO_0000019,
1961,12861,B,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,1,,H,Expert,,,CHEMBL875911,BAO_0000019,
1962,12861,B,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,8,,,1,,H,Autocuration,,,CHEMBL617567,BAO_0000019,
1963,675,B,,,17106,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,1,,H,Autocuration,,,CHEMBL617568,BAO_0000249,
1964,12490,B,,,17106,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,8,,,1,,H,Expert,,,CHEMBL617569,BAO_0000019,
1965,11828,B,,,17106,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,8,,,1,,H,Expert,,,CHEMBL617570,BAO_0000249,
1966,11866,B,,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,8,,,1,,H,Autocuration,,,CHEMBL617571,BAO_0000357,
1967,773,B,,,105,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617572,BAO_0000357,
1968,13047,B,,,105,The compound was tested for intrinsic activity against 5-HT1D receptor,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL617573,BAO_0000357,
1969,13047,B,,,105,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617574,BAO_0000019,
1970,13047,B,,,105,The compound was tested for binding affinity against 5-HT1D receptor,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL617575,BAO_0000357,
1971,188,B,,,10578,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,8,,,1,,H,Autocuration,,,CHEMBL617576,BAO_0000357,
1972,10639,F,,,10578,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,8,,,1,,H,Autocuration,,,CHEMBL617577,BAO_0000019,
1973,12438,F,,,10578,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617578,BAO_0000019,
1974,12438,B,,,10578,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617579,BAO_0000357,
1975,15854,B,,,10578,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,1,,H,Expert,,,CHEMBL617580,BAO_0000019,
1976,10394,B,,,10578,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617581,BAO_0000249,
1977,12092,B,,,10578,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617582,BAO_0000357,
1978,3389,B,,,10578,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,8,,,1,,H,Expert,,,CHEMBL617583,BAO_0000019,
1979,6011,B,,,105,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL617584,BAO_0000357,
1980,4639,B,,,105,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617585,BAO_0000357,
1981,2474,B,,,105,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL875912,BAO_0000357,
1982,5014,B,,,105,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617586,BAO_0000357,
1983,17515,B,,,105,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617587,BAO_0000357,
1984,11866,B,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617588,BAO_0000357,
1985,4687,B,,,105,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL857980,BAO_0000357,
1986,12146,B,,,105,Tested against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL617589,BAO_0000357,
1987,10321,B,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617590,BAO_0000357,
1988,13267,B,HEK293,,105,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617591,BAO_0000219,
1989,1274,B,,,105,Binding affinity against 5-Hydroxytryptamine 1D receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617592,BAO_0000357,
1990,15250,B,,,105,,,8,,,1,,H,Autocuration,,,CHEMBL617593,BAO_0000357,
1991,13706,B,CHO-K1,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL617594,BAO_0000219,
1992,13706,B,CHO-K1,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL617595,BAO_0000219,
1993,13706,B,HEK293,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617596,BAO_0000219,
1994,13706,B,HEK293,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,8,722.0,,1,,H,Autocuration,,,CHEMBL617597,BAO_0000219,
1995,13047,B,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,8,,,1,,H,Autocuration,,,CHEMBL617598,BAO_0000019,
1996,13366,B,,,105,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,8,,,1,,H,Autocuration,,,CHEMBL872916,BAO_0000357,
1997,13366,B,,,105,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,8,,,1,,H,Expert,,,CHEMBL617599,BAO_0000357,
1998,1558,B,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,8,,,1,,H,Autocuration,,,CHEMBL617091,BAO_0000357,
1999,12902,B,CHO-K1,,105,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,8,485.0,,1,,H,Expert,,,CHEMBL617092,BAO_0000219,
2000,13706,B,CHO-K1,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL617093,BAO_0000219,
2001,13706,F,,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,8,,,1,,H,Autocuration,,,CHEMBL617094,BAO_0000019,
2002,13706,F,,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,1,,H,Autocuration,,,CHEMBL617095,BAO_0000019,
2003,14251,F,,,105,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,1,,H,Autocuration,,,CHEMBL617096,BAO_0000019,
2004,14251,F,,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,1,,H,Autocuration,,,CHEMBL617097,BAO_0000019,
2005,14251,F,,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,1,,H,Autocuration,,,CHEMBL617098,BAO_0000019,
2006,13313,B,,,105,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617301,BAO_0000357,
2007,13313,B,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617302,BAO_0000357,
2008,13366,B,,,105,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Autocuration,,,CHEMBL617303,BAO_0000357,
2009,13051,B,,,105,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Expert,,,CHEMBL617304,BAO_0000357,
2010,12903,B,CHO,,105,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,8,449.0,,1,,H,Expert,,,CHEMBL617305,BAO_0000219,
2011,12469,B,,,105,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,9,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617306,BAO_0000219,
2012,5619,B,,,17106,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL617307,BAO_0000357,
2013,13047,B,,,105,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617308,BAO_0000019,
2014,16633,B,,,105,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Autocuration,,,CHEMBL617309,BAO_0000357,
2015,16633,B,,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Autocuration,,,CHEMBL617310,BAO_0000357,
2016,16633,B,,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Autocuration,,,CHEMBL617311,BAO_0000357,
2017,16633,B,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617312,BAO_0000357,
2018,3269,B,,,105,Affinity against 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Autocuration,,,CHEMBL617313,BAO_0000357,
2019,12409,B,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,8,,,1,,H,Expert,,,CHEMBL617314,BAO_0000357,
2020,13706,F,,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,1,,H,Autocuration,,,CHEMBL617315,BAO_0000019,
2021,13706,B,HEK293,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617316,BAO_0000219,
2022,13706,B,HEK293,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,8,722.0,,1,,H,Autocuration,,,CHEMBL617317,BAO_0000219,
2023,12903,B,CHO,,106,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL617318,BAO_0000219,
2024,13047,B,,,106,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,8,,,1,,H,Autocuration,,,CHEMBL617319,BAO_0000019,
2025,13366,B,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,1,,D,Expert,,,CHEMBL617320,BAO_0000357,
2026,13366,B,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,1,,D,Expert,,,CHEMBL617321,BAO_0000357,
2027,13366,B,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,1,,D,Expert,,,CHEMBL617322,BAO_0000357,
2028,13366,B,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616862,BAO_0000357,
2029,13366,B,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616863,BAO_0000357,
2030,12469,B,CHO,,106,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL616864,BAO_0000219,
2031,13706,B,CHO-K1,,106,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL616865,BAO_0000219,
2032,13706,B,CHO-K1,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL616866,BAO_0000219,
2033,13706,F,,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,1,,H,Autocuration,,,CHEMBL616867,BAO_0000019,
2034,12902,B,CHO-K1,,106,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,8,485.0,,1,,H,Expert,,,CHEMBL616868,BAO_0000219,
2035,13051,B,,,105,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,8,,,1,,H,Expert,,,CHEMBL616869,BAO_0000357,
2036,12903,B,CHO,,106,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,8,449.0,,1,,H,Expert,,,CHEMBL616870,BAO_0000219,
2037,1558,F,CHO-K1,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,8,485.0,,1,,H,Autocuration,,,CHEMBL616871,BAO_0000219,
2038,1558,F,CHO-K1,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,8,485.0,,1,,H,Autocuration,,,CHEMBL616872,BAO_0000219,
2039,1558,F,CHO-K1,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,8,485.0,,1,,H,Autocuration,,,CHEMBL616873,BAO_0000219,
2040,1558,F,CHO-K1,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,8,485.0,,1,,H,Autocuration,,,CHEMBL616838,BAO_0000219,
2041,1558,B,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,8,,,1,,H,Autocuration,,,CHEMBL616839,BAO_0000357,
2042,13047,B,,,106,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL616840,BAO_0000019,
2043,13313,B,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616841,BAO_0000357,
2044,13313,B,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616842,BAO_0000357,
2045,12409,B,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,8,,,1,,H,Expert,,,CHEMBL857976,BAO_0000357,
2046,15250,B,CHO,,10618,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616843,BAO_0000219,
2047,1348,B,,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616844,BAO_0000357,
2048,1348,B,,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,8,,,1,,H,Autocuration,,,CHEMBL616845,BAO_0000357,
2049,4234,B,,,10618,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616846,BAO_0000357,
2050,16209,B,,,10618,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616847,BAO_0000357,
2051,10444,B,,,10618,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,8,,,1,,H,Autocuration,,,CHEMBL616848,BAO_0000019,
2052,3935,B,,,10618,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL616849,BAO_0000357,
2053,15818,B,,,10618,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL872911,BAO_0000357,
2054,17085,B,,,10618,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL616850,BAO_0000019,
2055,12936,B,CHO,,10618,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616699,BAO_0000219,
2056,6166,B,,,10618,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616700,BAO_0000357,
2057,15779,B,CHO,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616701,BAO_0000219,
2058,15779,B,CHO,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616702,BAO_0000219,
2059,15779,B,CHO,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616703,BAO_0000219,
2060,13181,B,,,10618,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,8,,,1,,H,Autocuration,,,CHEMBL616704,BAO_0000357,
2061,4199,B,CHO,,10618,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616705,BAO_0000219,
2062,14875,B,,,10618,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL616706,BAO_0000357,
2063,15146,B,CHO,,10618,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL616707,BAO_0000219,
2064,5213,B,,,10618,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616708,BAO_0000357,
2065,12146,B,,,10618,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616709,BAO_0000357,
2066,13267,B,CHO,,10618,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616710,BAO_0000219,
2067,14818,B,CHO,,10618,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL616711,BAO_0000219,
2068,4829,B,CHO,,10618,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL616712,BAO_0000219,
2069,4373,B,,,10618,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616713,BAO_0000357,
2070,4373,B,,,10618,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616714,BAO_0000357,
2071,14159,B,,,10618,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL616715,BAO_0000357,
2072,16633,B,,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor,,8,,,1,,H,Autocuration,,,CHEMBL616716,BAO_0000357,
2073,17085,F,,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,8,,,1,,H,Autocuration,,,CHEMBL616717,BAO_0000019,
2074,17085,F,,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,8,,,1,,H,Expert,,,CHEMBL616718,BAO_0000019,
2075,16209,F,,,279,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL875905,BAO_0000019,
2076,16209,F,,,279,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL616719,BAO_0000019,
2077,17085,F,,,279,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,8,,,1,,H,Expert,,,CHEMBL616720,BAO_0000019,
2078,14159,B,,,279,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL616721,BAO_0000357,
2079,15250,B,CHO,,279,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL616722,BAO_0000219,
2080,3805,B,,,279,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL616723,BAO_0000357,
2081,16190,B,CHO,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL616724,BAO_0000219,
2082,16190,B,,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616725,BAO_0000357,
2083,16209,B,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL616726,BAO_0000357,
2084,16209,B,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL616727,BAO_0000357,
2085,16209,B,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL616728,BAO_0000357,
2086,6866,B,,,279,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL616729,BAO_0000357,
2087,17085,B,,,279,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Expert,,,CHEMBL616730,BAO_0000019,
2088,16312,B,,,279,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL617125,BAO_0000357,
2089,6166,B,,,279,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL857977,BAO_0000357,
2090,15779,B,CHO,,279,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,449.0,,1,,H,Autocuration,,,CHEMBL617126,BAO_0000219,
2091,4199,B,CHO,,279,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL617127,BAO_0000219,
2092,14875,B,,,279,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL617128,BAO_0000357,
2093,15146,B,CHO,,279,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL617129,BAO_0000219,
2094,5213,B,,,279,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617130,BAO_0000357,
2095,14818,B,CHO,,279,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL617131,BAO_0000219,
2096,4829,B,CHO,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL617132,BAO_0000219,
2097,4829,B,CHO,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,8,449.0,,1,,H,Autocuration,,,CHEMBL617133,BAO_0000219,
2098,4373,B,,,279,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617134,BAO_0000357,
2099,4373,B,,,279,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617135,BAO_0000357,
2100,5014,B,,,279,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,8,,,1,,H,Autocuration,,,CHEMBL617136,BAO_0000357,
2101,11662,B,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,4,,,1,,H,Autocuration,,,CHEMBL617137,BAO_0000019,
2102,11662,B,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,4,,,1,,H,Autocuration,,,CHEMBL617138,BAO_0000019,
2103,11662,B,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,1,,H,Autocuration,,,CHEMBL617139,BAO_0000019,
2104,14093,B,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617140,BAO_0000019,
2105,11200,F,,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,4,,,1,,H,Autocuration,,,CHEMBL617141,BAO_0000218,
2106,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL858112,BAO_0000019,
2107,12352,B,,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,8,,,1,,H,Intermediate,,,CHEMBL617142,BAO_0000019,
2108,13657,B,,,22226,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL617143,BAO_0000019,
2109,14331,B,,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL617144,BAO_0000019,
2110,14331,B,,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL617145,BAO_0000019,
2111,14331,B,,,22226,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,0,,,1,,U,Autocuration,,,CHEMBL617146,BAO_0000019,
2112,12685,B,,,104784,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617147,BAO_0000019,
2113,14389,B,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617148,BAO_0000019,
2114,14386,B,,,104784,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617149,BAO_0000019,
2115,5732,B,,,104784,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL617150,BAO_0000224,
2116,16293,B,,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL617151,BAO_0000224,
2117,2078,B,,,104784,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617201,BAO_0000224,
2118,5486,B,,,10209,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,8,,,1,,H,Autocuration,,,CHEMBL617202,BAO_0000357,
2119,11820,B,,,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617203,BAO_0000218,
2120,10297,B,,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL617204,BAO_0000019,
2121,13704,B,,,104826,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,4,,,1,,H,Autocuration,,,CHEMBL617205,BAO_0000224,
2122,10297,B,,,104826,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,5,,Mus musculus,1,10090.0,D,Autocuration,,,CHEMBL617206,BAO_0000019,
2123,11820,B,,,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617207,BAO_0000218,
2124,10297,B,,,104826,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,5,,Mus musculus,1,10090.0,D,Autocuration,,,CHEMBL617208,BAO_0000019,
2125,11555,B,,,104826,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617209,BAO_0000224,
2126,11555,B,,,104826,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,4,,,1,,H,Autocuration,,,CHEMBL617210,BAO_0000224,
2127,11555,B,,,104826,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,4,,,1,,H,Autocuration,,,CHEMBL617211,BAO_0000224,
2128,10297,B,,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,5,,Mus musculus,1,10090.0,D,Autocuration,,,CHEMBL617212,BAO_0000019,
2129,16688,B,,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,4,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617213,BAO_0000224,
2130,16688,B,,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,4,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617214,BAO_0000224,
2131,5333,B,,,22226,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,0,,,1,,U,Autocuration,,,CHEMBL617215,BAO_0000221,
2132,4437,B,,,22226,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,0,,,1,,U,Autocuration,,,CHEMBL617216,BAO_0000221,
2133,5033,B,,,17005,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617217,BAO_0000357,
2134,15267,B,,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617218,BAO_0000019,
2135,15267,B,,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL872913,BAO_0000019,
2136,11820,B,,,104826,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,4,,,1,,H,Autocuration,,,CHEMBL617219,BAO_0000019,
2137,9069,B,,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL873482,BAO_0000224,
2138,9162,B,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617220,BAO_0000019,
2139,9162,B,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,4,,,1,,H,Autocuration,,,CHEMBL617221,BAO_0000019,
2140,9162,B,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,4,,,1,,H,Autocuration,,,CHEMBL617222,BAO_0000019,
2141,10428,F,,,104686,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,4,,,1,,H,Autocuration,,,CHEMBL875906,BAO_0000019,
2142,9628,B,,,104686,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,4,,,1,,H,Autocuration,,,CHEMBL617223,BAO_0000019,
2143,12704,B,,,104686,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617224,BAO_0000224,
2144,15453,B,,,104686,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617225,BAO_0000224,
2145,188,B,,,104686,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,4,,,1,,H,Autocuration,,,CHEMBL617226,BAO_0000224,
2146,10349,B,,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617227,BAO_0000224,
2147,10349,B,,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617228,BAO_0000224,
2148,8868,B,,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,4,,,1,,H,Autocuration,,,CHEMBL617229,BAO_0000224,
2149,10025,B,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,4,,,1,,H,Autocuration,,,CHEMBL617230,BAO_0000224,
2150,10025,B,,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,4,,,1,,H,Autocuration,,,CHEMBL617231,BAO_0000224,
2151,11702,B,,,104686,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617232,BAO_0000224,
2152,11702,B,,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617233,BAO_0000224,
2153,11702,B,,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,1,,H,Autocuration,,,CHEMBL617234,BAO_0000224,
2154,11702,F,,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats,,4,,,1,,H,Autocuration,,,CHEMBL617235,BAO_0000019,
2155,11702,F,,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,4,,,1,,H,Autocuration,,,CHEMBL617236,BAO_0000019,
2156,10085,B,,10000000.0,104686,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL617237,BAO_0000221,
2157,10085,B,,10000000.0,104686,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Hippocampus,4,,,1,,H,Autocuration,,,CHEMBL617238,BAO_0000221,
2158,9630,B,,955.0,104686,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Brain,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617239,BAO_0000221,
2159,11070,B,,,104686,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,1,,H,Autocuration,,,CHEMBL617240,BAO_0000019,
2160,9841,B,,,104686,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,4,,,1,,H,Autocuration,,,CHEMBL617241,BAO_0000249,
2161,9841,B,,,104686,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,4,,,1,,H,Autocuration,,,CHEMBL875907,BAO_0000249,
2162,13291,B,,,104686,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,4,,,1,,H,Autocuration,,,CHEMBL617242,BAO_0000019,
2163,10590,F,,,104686,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,4,,,1,,H,Autocuration,,,CHEMBL617152,BAO_0000019,
2164,9064,B,,955.0,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617153,BAO_0000221,
2165,12268,B,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617154,BAO_0000249,
2166,13508,B,,955.0,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Brain,4,,,1,,H,Autocuration,,,CHEMBL617155,BAO_0000221,
2167,11279,F,,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,4,,,1,,H,Autocuration,,,CHEMBL617156,BAO_0000019,
2168,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL617157,BAO_0000019,
2169,11200,F,,,104686,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL617158,BAO_0000019,
2170,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,4,,,1,,H,Autocuration,,,CHEMBL617159,BAO_0000019,
2171,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,4,,,1,,H,Autocuration,,,CHEMBL617160,BAO_0000019,
2172,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL858113,BAO_0000019,
2173,9231,B,,955.0,104686,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Brain,4,,,1,,H,Autocuration,,,CHEMBL617247,BAO_0000220,
2174,9737,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617248,BAO_0000019,
2175,9737,B,,955.0,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,4,,,1,,H,Autocuration,,,CHEMBL617249,BAO_0000249,
2176,9737,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617250,BAO_0000019,
2177,9737,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617251,BAO_0000019,
2178,11828,B,,,104686,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617252,BAO_0000019,
2179,12253,B,,,104686,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617006,BAO_0000019,
2180,12253,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617007,BAO_0000019,
2181,11279,F,,,104686,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,4,,,1,,H,Autocuration,,,CHEMBL617008,BAO_0000019,
2182,11866,B,,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617009,BAO_0000019,
2183,14424,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617010,BAO_0000224,
2184,15180,B,,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL857978,BAO_0000019,
2185,15180,B,,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617011,BAO_0000019,
2186,9786,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617012,BAO_0000019,
2187,12132,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617013,BAO_0000224,
2188,5486,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,4,,,1,,H,Autocuration,,,CHEMBL617014,BAO_0000249,
2189,15316,B,,,104686,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617015,BAO_0000019,
2190,16429,B,,,104686,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617016,BAO_0000019,
2191,14617,B,,,104686,pKi value for 5-hydroxytryptamine 2 receptor binding site,,4,,,1,,H,Autocuration,,,CHEMBL617017,BAO_0000224,
2192,11351,B,,955.0,104686,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Brain,4,,,1,,H,Autocuration,,,CHEMBL617018,BAO_0000221,
2193,11279,F,,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,4,,,1,,H,Autocuration,,,CHEMBL617019,BAO_0000019,
2194,9523,B,,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617020,BAO_0000019,
2195,9523,B,,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617021,BAO_0000019,
2196,9523,B,,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617022,BAO_0000019,
2197,9523,B,,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617023,BAO_0000019,
2198,9523,B,,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617024,BAO_0000019,
2199,9523,B,,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617025,BAO_0000019,
2200,9523,B,,,105075,Hill coefficient of compound was determined,,4,,,1,,H,Autocuration,,,CHEMBL617026,BAO_0000224,
2201,4771,B,,,22226,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,0,,,1,,U,Autocuration,,,CHEMBL617027,BAO_0000019,
2202,5033,B,,,104686,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617028,BAO_0000019,
2203,10845,B,,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,8,,,1,,H,Expert,,,CHEMBL617029,BAO_0000019,
2204,10845,B,,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,8,,,1,,H,Expert,,,CHEMBL875908,BAO_0000019,
2205,16288,B,,,12687,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,8,,,1,,H,Autocuration,,,CHEMBL617030,BAO_0000357,
2206,16288,B,,,12687,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,8,,,1,,H,Autocuration,,,CHEMBL617031,BAO_0000019,
2207,16190,B,,,12687,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617032,BAO_0000019,
2208,12463,B,,,104686,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617033,BAO_0000224,
2209,9699,B,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,4,,,1,,H,Autocuration,,,CHEMBL617034,BAO_0000224,
2210,9699,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617035,BAO_0000224,
2211,11662,B,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,1,,H,Autocuration,,,CHEMBL617036,BAO_0000019,
2212,1205,B,,,104784,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617037,BAO_0000224,
2213,11376,B,,,22226,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,0,,,1,,U,Autocuration,,,CHEMBL617038,BAO_0000219,
2214,11376,B,,,104784,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,4,,,1,,H,Autocuration,,,CHEMBL617039,BAO_0000219,
2215,4639,B,,,104784,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617161,BAO_0000224,
2216,2222,B,,,104784,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617162,BAO_0000224,
2217,1558,B,,,104784,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617163,BAO_0000224,
2218,1089,B,,,104784,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617164,BAO_0000224,
2219,386,B,,,104784,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,4,,,1,,H,Autocuration,,,CHEMBL617165,BAO_0000249,
2220,2474,B,,,104784,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617166,BAO_0000224,
2221,17066,B,,,104784,Binding affinity towards 5-HT2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617167,BAO_0000224,
2222,959,B,,,104784,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL872912,BAO_0000224,
2223,6398,B,,,104784,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,4,,,1,,H,Autocuration,,,CHEMBL617168,BAO_0000224,
2224,11889,B,,,104686,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,4,,,1,,H,Autocuration,,,CHEMBL617169,BAO_0000224,
2225,4221,B,,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617170,BAO_0000224,
2226,11026,B,,,104784,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617171,BAO_0000224,
2227,11866,B,,,104784,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL617172,BAO_0000224,
2228,4221,B,,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617173,BAO_0000224,
2229,13950,B,,,22226,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,0,,,1,,U,Autocuration,,,CHEMBL617174,BAO_0000019,
2230,1263,B,,,104784,5-hydroxytryptamine 2 receptor binding affinity,,4,,,1,,H,Autocuration,,,CHEMBL617175,BAO_0000224,
2231,13291,B,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617176,BAO_0000357,
2232,10812,B,,,17005,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617177,BAO_0000357,
2233,13020,B,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,4,,,1,,H,Autocuration,,,CHEMBL617178,BAO_0000224,
2234,13021,B,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,4,,,1,,H,Autocuration,,,CHEMBL617179,BAO_0000224,
2235,13020,B,,,104784,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,4,,,1,,H,Autocuration,,,CHEMBL617180,BAO_0000224,
2236,14532,B,,,17005,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,8,,,1,,H,Autocuration,,,CHEMBL617181,BAO_0000357,
2237,13944,B,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617182,BAO_0000357,
2238,14331,B,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617183,BAO_0000357,
2239,14118,B,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617184,BAO_0000357,
2240,13033,B,,,17005,Binding affinity against serotonergic 5-HT2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617185,BAO_0000357,
2241,10321,B,,,17005,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617186,BAO_0000357,
2242,12918,B,,,17005,Compound was evaluated for the binding affinity at 5- HT2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617187,BAO_0000357,
2243,15120,B,,,17005,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617188,BAO_0000357,
2244,2613,B,,,17005,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617189,BAO_0000218,
2245,13378,B,,,104784,Inhibitory activity against cloned human 5-HT2 receptor,,5,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617190,BAO_0000224,
2246,2331,B,CHO,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,5,449.0,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617191,BAO_0000219,
2247,2331,B,CHO,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,5,449.0,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617192,BAO_0000219,
2248,2331,B,CHO,,104784,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,5,449.0,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617193,BAO_0000219,
2249,2331,B,CHO,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,5,449.0,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL617194,BAO_0000219,
2250,4170,B,,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617195,BAO_0000224,
2251,15453,B,,,104784,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL881830,BAO_0000224,
2252,1479,B,,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor,,8,,,1,,H,Autocuration,,,CHEMBL617196,BAO_0000357,
2253,11139,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,4,,,1,,H,Autocuration,,,CHEMBL617197,BAO_0000224,
2254,13969,B,,,17005,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL617198,BAO_0000357,
2255,13392,B,,,17005,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL873476,BAO_0000357,
2256,14430,B,,,17005,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,8,,,1,,H,Expert,,,CHEMBL617199,BAO_0000019,
2257,13181,B,,,107,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617200,BAO_0000357,
2258,17200,B,,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617484,BAO_0000357,
2259,17200,B,,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617485,BAO_0000357,
2260,17200,B,,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617486,BAO_0000357,
2261,13463,B,,,107,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL858022,BAO_0000357,
2262,6347,B,CHO,,107,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL617049,BAO_0000219,
2263,6857,F,CHO,,107,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617050,BAO_0000219,
2264,4176,F,,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,8,,,1,,H,Autocuration,,,CHEMBL617051,BAO_0000219,
2265,4176,F,,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,8,,,1,,H,Autocuration,,,CHEMBL617052,BAO_0000219,
2266,4176,F,,,107,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,8,,,1,,H,Autocuration,,,CHEMBL617053,BAO_0000219,
2267,6347,B,CHO,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,8,449.0,,1,,H,Autocuration,,,CHEMBL617054,BAO_0000219,
2268,6347,B,CHO,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,8,449.0,,1,,H,Autocuration,,,CHEMBL617055,BAO_0000219,
2269,15331,B,,,107,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,8,,,1,,H,Autocuration,,,CHEMBL882924,BAO_0000357,
2270,16146,B,,,107,Inhibition of human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617056,BAO_0000357,
2271,15250,B,CHO,,107,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL617057,BAO_0000219,
2272,13631,B,,,107,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,8,,,1,,H,Expert,,,CHEMBL617058,BAO_0000219,
2273,3805,B,,,107,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL617059,BAO_0000357,
2274,4011,B,CHO,,107,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL617060,BAO_0000219,
2275,4012,B,CHO,,107,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,8,449.0,,1,,H,Expert,,,CHEMBL617061,BAO_0000219,
2276,6366,B,L929,,107,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,8,307.0,,1,,H,Expert,,,CHEMBL617062,BAO_0000219,
2277,15949,B,CHO,,107,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL617063,BAO_0000219,
2278,14093,F,,,107,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617064,BAO_0000019,
2279,13481,F,,,107,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617065,BAO_0000019,
2280,6347,B,CHO,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL617066,BAO_0000219,
2281,6347,B,CHO,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,8,449.0,,1,,H,Autocuration,,,CHEMBL617067,BAO_0000219,
2282,14093,F,,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617068,BAO_0000019,
2283,14093,F,,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617069,BAO_0000019,
2284,13481,F,,,107,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617070,BAO_0000019,
2285,14442,B,,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617071,BAO_0000357,
2286,14442,B,,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872915,BAO_0000357,
2287,14755,B,,,107,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617072,BAO_0000357,
2288,16441,B,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,8,,,1,,H,Autocuration,,,CHEMBL617073,BAO_0000357,
2289,14744,B,,,107,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617074,BAO_0000357,
2290,16659,B,CHO,,107,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL617075,BAO_0000219,
2291,3307,B,,,107,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617076,BAO_0000357,
2292,6857,B,,,107,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617077,BAO_0000019,
2293,5635,B,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,8,,,1,,H,Expert,,,CHEMBL617078,BAO_0000357,
2294,4234,B,,,107,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617079,BAO_0000357,
2295,15527,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617080,BAO_0000357,
2296,6588,B,CHO,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL617081,BAO_0000219,
2297,13631,B,,,107,Binding affinity towards human 5-HT2A receptor in BEK cells,,8,,,1,,H,Expert,,,CHEMBL617082,BAO_0000219,
2298,17723,B,,,107,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617083,BAO_0000357,
2299,14770,B,,,107,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617084,BAO_0000357,
2300,16293,B,,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617085,BAO_0000357,
2301,16209,B,,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617086,BAO_0000357,
2302,12469,B,,,107,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,8,,,1,,H,Autocuration,,,CHEMBL617087,BAO_0000219,
2303,15363,B,,,107,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617088,BAO_0000357,
2304,15363,B,,,107,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617089,BAO_0000357,
2305,16441,B,,,107,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,8,,,1,,H,Expert,,,CHEMBL617090,BAO_0000019,
2306,8,B,,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617513,BAO_0000357,
2307,4176,B,HEK293,,107,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617514,BAO_0000219,
2308,17085,B,,,107,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617515,BAO_0000019,
2309,17200,B,,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617516,BAO_0000357,
2310,17200,B,,,107,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617517,BAO_0000357,
2311,4013,B,CHO,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617518,BAO_0000219,
2312,5088,B,,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617519,BAO_0000357,
2313,5088,B,,,107,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617520,BAO_0000357,
2314,5088,B,,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,8,,,1,,H,Autocuration,,,CHEMBL617521,BAO_0000357,
2315,5088,B,,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617522,BAO_0000357,
2316,5088,B,,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617523,BAO_0000357,
2317,5088,B,,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617524,BAO_0000357,
2318,9786,B,,,104686,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,4,,,1,,H,Autocuration,,,CHEMBL617525,BAO_0000019,
2319,9205,B,,,104686,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617526,BAO_0000019,
2320,11257,B,,,104686,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,4,,,1,,H,Autocuration,,,CHEMBL617527,BAO_0000224,
2321,9362,B,,,104686,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,4,,,1,,H,Autocuration,,,CHEMBL617528,BAO_0000019,
2322,9362,B,,,104686,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,4,,,1,,H,Autocuration,,,CHEMBL617529,BAO_0000019,
2323,10590,B,,,104686,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,4,,,1,,H,Autocuration,,,CHEMBL617530,BAO_0000224,
2324,10468,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617531,BAO_0000019,
2325,13050,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617532,BAO_0000019,
2326,11624,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617533,BAO_0000019,
2327,10468,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617534,BAO_0000019,
2328,10330,B,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617535,BAO_0000224,
2329,10062,B,,,104686,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,4,,,1,,H,Autocuration,,,CHEMBL617536,BAO_0000224,
2330,11642,B,,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617537,BAO_0000224,
2331,10062,B,,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617538,BAO_0000224,
2332,13427,B,,,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,4,,,1,,H,Autocuration,,,CHEMBL617539,BAO_0000219,
2333,12280,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617540,BAO_0000224,
2334,4101,B,,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617541,BAO_0000224,
2335,10062,B,,,104686,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617542,BAO_0000224,
2336,11147,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,4,,,1,,H,Autocuration,,,CHEMBL617543,BAO_0000224,
2337,2395,B,CHO-K1,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,5,485.0,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617544,BAO_0000219,
2338,2395,B,CHO-K1,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,5,485.0,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617545,BAO_0000219,
2339,9098,B,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617413,BAO_0000019,
2340,9098,B,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617414,BAO_0000019,
2341,9098,B,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617415,BAO_0000019,
2342,9443,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617416,BAO_0000224,
2343,9443,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,4,,,1,,H,Autocuration,,,CHEMBL617417,BAO_0000224,
2344,9699,B,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,4,,,1,,H,Autocuration,,,CHEMBL617418,BAO_0000019,
2345,9699,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,4,,,1,,H,Autocuration,,,CHEMBL617419,BAO_0000019,
2346,9098,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL617420,BAO_0000224,
2347,3070,B,,,104686,Affinity for 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617421,BAO_0000224,
2348,9547,B,,,104686,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,4,,,1,,H,Autocuration,,,CHEMBL617422,BAO_0000224,
2349,10444,B,,,104686,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,4,,,1,,H,Autocuration,,,CHEMBL617423,BAO_0000019,
2350,14617,B,,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,4,,,1,,H,Autocuration,,,CHEMBL617424,BAO_0000019,
2351,14617,B,,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,4,,,1,,H,Autocuration,,,CHEMBL617425,BAO_0000019,
2352,11130,B,,,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,4,,,1,,H,Autocuration,,,CHEMBL617426,BAO_0000224,
2353,11130,B,,,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,4,,,1,,H,Autocuration,,,CHEMBL617427,BAO_0000218,
2354,14542,B,,955.0,104686,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Brain,4,,,1,,H,Autocuration,,,CHEMBL617428,BAO_0000221,
2355,2797,B,,,104686,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,4,,,1,,H,Autocuration,,,CHEMBL617429,BAO_0000224,
2356,11332,B,,,104686,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617430,BAO_0000019,
2357,11332,B,,,104686,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617431,BAO_0000019,
2358,10752,B,,1870.0,104686,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Frontal cortex,4,,,1,,H,Autocuration,,,CHEMBL617432,BAO_0000019,
2359,1185,B,,,104686,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617433,BAO_0000224,
2360,1185,B,,,104686,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617434,BAO_0000224,
2361,11624,B,,,104686,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617435,BAO_0000224,
2362,1344,B,,,104686,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,4,,,1,,H,Autocuration,,,CHEMBL617436,BAO_0000019,
2363,15453,B,,2435.0,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Striatum,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617437,BAO_0000019,
2364,11662,B,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,4,,,1,,H,Autocuration,,,CHEMBL617438,BAO_0000019,
2365,11662,B,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,1,,H,Autocuration,,,CHEMBL617439,BAO_0000019,
2366,10796,B,,,104686,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617440,BAO_0000224,
2367,9069,B,,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617441,BAO_0000224,
2368,8814,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL872918,BAO_0000019,
2369,8908,B,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617442,BAO_0000019,
2370,9098,B,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,4,,,1,,H,Autocuration,,,CHEMBL617443,BAO_0000019,
2371,9098,B,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617444,BAO_0000019,
2372,9098,B,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,4,,,1,,H,Autocuration,,,CHEMBL617445,BAO_0000019,
2373,9098,B,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617446,BAO_0000019,
2374,9098,B,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,4,,,1,,H,Autocuration,,,CHEMBL617447,BAO_0000249,
2375,9098,B,,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,4,,,1,,H,Autocuration,,,CHEMBL617448,BAO_0000019,
2376,9098,B,,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,4,,,1,,H,Autocuration,,,CHEMBL617449,BAO_0000019,
2377,9161,B,,,104686,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,4,,,1,,H,Autocuration,,,CHEMBL617450,BAO_0000019,
2378,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,4,,,1,,H,Autocuration,,,CHEMBL617451,BAO_0000019,
2379,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,4,,,1,,H,Autocuration,,,CHEMBL617452,BAO_0000019,
2380,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,4,,,1,,H,Autocuration,,,CHEMBL617453,BAO_0000019,
2381,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,4,,,1,,H,Autocuration,,,CHEMBL617660,BAO_0000019,
2382,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,4,,,1,,H,Autocuration,,,CHEMBL617661,BAO_0000019,
2383,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,4,,,1,,H,Autocuration,,,CHEMBL617662,BAO_0000019,
2384,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,4,,,1,,H,Autocuration,,,CHEMBL872919,BAO_0000019,
2385,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,4,,,1,,H,Autocuration,,,CHEMBL617663,BAO_0000019,
2386,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,4,,,1,,H,Autocuration,,,CHEMBL617664,BAO_0000019,
2387,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,4,,,1,,H,Autocuration,,,CHEMBL617665,BAO_0000019,
2388,9161,B,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,4,,,1,,H,Autocuration,,,CHEMBL617666,BAO_0000019,
2389,12094,B,,,104686,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,4,,,1,,H,Autocuration,,,CHEMBL617667,BAO_0000019,
2390,12018,B,,,104686,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,4,,,1,,H,Autocuration,,,CHEMBL617668,BAO_0000249,
2391,10394,B,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617669,BAO_0000249,
2392,15260,B,,,104686,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617670,BAO_0000224,
2393,11624,B,,,104686,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617671,BAO_0000224,
2394,13654,B,,,104686,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617672,BAO_0000224,
2395,9541,B,,,104686,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,4,,,1,,H,Autocuration,,,CHEMBL617673,BAO_0000019,
2396,11933,B,,,104686,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617674,BAO_0000224,
2397,15538,B,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,1,,H,Autocuration,,,CHEMBL617675,BAO_0000019,
2398,15538,B,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,4,,,1,,H,Autocuration,,,CHEMBL617676,BAO_0000019,
2399,15538,B,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,4,,,1,,H,Autocuration,,,CHEMBL617677,BAO_0000019,
2400,8841,B,,,104686,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,5,,,1,,D,Autocuration,,,CHEMBL617678,BAO_0000019,
2401,1455,B,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,4,,,1,,H,Autocuration,,,CHEMBL617679,BAO_0000224,
2402,1455,B,,,104686,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,4,,,1,,H,Autocuration,,,CHEMBL617680,BAO_0000224,
2403,11752,B,,,104686,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,4,,,1,,H,Autocuration,,,CHEMBL617681,BAO_0000019,
2404,11642,B,,955.0,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Brain,4,,,1,,H,Autocuration,,,CHEMBL617682,BAO_0000221,
2405,12092,B,,,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617683,BAO_0000224,
2406,3967,B,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,4,,,1,,H,Autocuration,,,CHEMBL617684,BAO_0000224,
2407,12771,B,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617685,BAO_0000224,
2408,11642,B,,,104686,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,4,,,1,,H,Autocuration,,,CHEMBL617686,BAO_0000019,
2409,11628,B,,,104686,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617687,BAO_0000224,
2410,13654,B,,,104686,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617688,BAO_0000224,
2411,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL617689,BAO_0000019,
2412,11200,F,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,1,,H,Autocuration,,,CHEMBL617690,BAO_0000019,
2413,11200,F,,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,4,,,1,,H,Autocuration,,,CHEMBL617691,BAO_0000218,
2414,11200,F,,,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,4,,,1,,H,Autocuration,,,CHEMBL617692,BAO_0000218,
2415,11200,F,,,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,4,,,1,,H,Autocuration,,,CHEMBL617693,BAO_0000218,
2416,11200,F,,,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,4,,,1,,H,Autocuration,,,CHEMBL617694,BAO_0000218,
2417,15436,B,,955.0,12687,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Brain,8,,,1,,H,Expert,,,CHEMBL857985,BAO_0000221,
2418,15436,B,,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617695,BAO_0000019,
2419,14025,B,,,12687,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,8,,,1,,H,Autocuration,,,CHEMBL617696,BAO_0000019,
2420,4342,B,,,12687,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617697,BAO_0000357,
2421,13735,B,,,12687,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617257,BAO_0000019,
2422,5816,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617258,BAO_0000357,
2423,14287,B,,,12687,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,8,,,1,,H,Expert,,,CHEMBL617259,BAO_0000019,
2424,15738,B,,,12687,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,8,,,1,,H,Autocuration,,,CHEMBL617260,BAO_0000357,
2425,15738,B,,,12687,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617261,BAO_0000357,
2426,15026,B,,,12687,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617262,BAO_0000019,
2427,16647,B,,,12687,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,8,,,1,,H,Expert,,,CHEMBL617263,BAO_0000019,
2428,16647,B,,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,8,,,1,,H,Autocuration,,,CHEMBL617264,BAO_0000019,
2429,13345,B,,,12687,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617265,BAO_0000019,
2430,1543,B,,,12687,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617266,BAO_0000249,
2431,12444,B,,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,8,,,1,,H,Autocuration,,,CHEMBL617267,BAO_0000019,
2432,16404,B,,,12687,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,8,,,1,,H,Expert,,,CHEMBL617268,BAO_0000019,
2433,16404,B,CHO,,12687,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL617269,BAO_0000219,
2434,15577,B,,,12687,Kinetic inhibition constant evaluated by measuring serotonergic activity,,8,,,1,,H,Expert,,,CHEMBL617323,BAO_0000357,
2435,15577,B,,,12687,Serotonergic activity of the compound.,,8,,,1,,H,Autocuration,,,CHEMBL617324,BAO_0000357,
2436,2495,B,,,12687,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,8,,,1,,H,Autocuration,,,CHEMBL617325,BAO_0000249,
2437,15042,B,,,12687,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617326,BAO_0000019,
2438,15026,B,,,12687,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,8,,,1,,H,Expert,,,CHEMBL617327,BAO_0000249,
2439,12919,F,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617328,BAO_0000019,
2440,12919,F,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617329,BAO_0000019,
2441,12919,F,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617330,BAO_0000019,
2442,15194,B,,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617331,BAO_0000357,
2443,15194,B,,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617332,BAO_0000357,
2444,4820,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617333,BAO_0000357,
2445,6736,B,,,107,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,8,,,1,,H,Autocuration,,,CHEMBL617334,BAO_0000357,
2446,5163,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,8,,,1,,H,Autocuration,,,CHEMBL617335,BAO_0000357,
2447,5163,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,8,,,1,,H,Autocuration,,,CHEMBL617336,BAO_0000357,
2448,6011,B,,,107,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL617337,BAO_0000357,
2449,14294,B,,,107,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617338,BAO_0000357,
2450,5014,B,,,107,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617339,BAO_0000357,
2451,17066,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617340,BAO_0000357,
2452,17515,B,,,107,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617341,BAO_0000357,
2453,6736,B,,,107,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617342,BAO_0000357,
2454,5163,B,,,107,Affinity for 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617343,BAO_0000357,
2455,16911,B,NIH3T3,,107,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,8,723.0,,1,,H,Expert,,,CHEMBL617344,BAO_0000219,
2456,6841,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,8,,,1,,H,Expert,,,CHEMBL617345,BAO_0000357,
2457,6119,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,8,,,1,,H,Expert,,,CHEMBL617346,BAO_0000357,
2458,3962,B,,,107,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617347,BAO_0000357,
2459,4373,B,,,107,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617348,BAO_0000357,
2460,4373,B,,,107,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617349,BAO_0000357,
2461,3962,F,,,107,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617350,BAO_0000019,
2462,1633,B,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,8,,,1,,H,Expert,,,CHEMBL872339,BAO_0000357,
2463,4373,B,,,107,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617351,BAO_0000357,
2464,6576,B,,,107,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617352,BAO_0000357,
2465,4687,B,,,107,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617353,BAO_0000357,
2466,16946,B,,,107,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617354,BAO_0000357,
2467,14159,B,,,107,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617355,BAO_0000357,
2468,3032,B,CHO,,107,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,8,449.0,Mus musculus,1,10090.0,H,Expert,,,CHEMBL617356,BAO_0000219,
2469,16655,B,,,107,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617357,BAO_0000357,
2470,13964,B,,,107,Binding affinity at 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617358,BAO_0000357,
2471,16989,B,,,107,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617359,BAO_0000357,
2472,16117,B,,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617360,BAO_0000357,
2473,16700,B,,,107,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL875913,BAO_0000357,
2474,3269,B,,,107,Affinity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617361,BAO_0000357,
2475,1274,B,,,107,Binding affinity against 5-Hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617362,BAO_0000357,
2476,1317,B,,,107,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL617363,BAO_0000357,
2477,12146,B,,,107,Tested against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617364,BAO_0000357,
2478,12652,B,,,105075,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617365,BAO_0000224,
2479,12652,B,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617366,BAO_0000224,
2480,12652,B,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,4,,,1,,H,Autocuration,,,CHEMBL617367,BAO_0000224,
2481,12652,B,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617368,BAO_0000224,
2482,16647,B,,,107,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,8,,,1,,H,Autocuration,,,CHEMBL617369,BAO_0000357,
2483,15851,B,HEK293,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617370,BAO_0000219,
2484,6857,F,CHO,,227,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617371,BAO_0000219,
2485,3805,B,,,227,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL617372,BAO_0000357,
2486,6491,B,,,227,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617373,BAO_0000357,
2487,14093,F,,,227,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617374,BAO_0000019,
2488,13481,F,,,227,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617375,BAO_0000019,
2489,14093,F,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617376,BAO_0000019,
2490,14093,F,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617377,BAO_0000019,
2491,14093,F,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617378,BAO_0000019,
2492,13481,F,,,227,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617379,BAO_0000019,
2493,14442,B,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617380,BAO_0000357,
2494,14442,B,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617381,BAO_0000357,
2495,14442,B,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617382,BAO_0000357,
2496,12369,B,,,107,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617383,BAO_0000357,
2497,12369,B,,,107,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,8,,,1,,H,Expert,,,CHEMBL617384,BAO_0000357,
2498,12369,B,,,107,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,8,,,1,,H,Expert,,,CHEMBL617385,BAO_0000357,
2499,14447,B,,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,8,,,1,,H,Autocuration,,,CHEMBL617386,BAO_0000019,
2500,14447,B,,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,8,,,1,,H,Autocuration,,,CHEMBL617387,BAO_0000019,
2501,17451,B,NIH3T3,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,723.0,,1,,H,Autocuration,,,CHEMBL617388,BAO_0000219,
2502,6857,F,CHO,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL617389,BAO_0000219,
2503,6857,F,CHO,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617390,BAO_0000219,
2504,5635,B,,,104817,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,4,,,1,,H,Autocuration,,,CHEMBL617391,BAO_0000224,
2505,12861,B,,,107,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617392,BAO_0000357,
2506,12861,B,,,107,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617393,BAO_0000019,
2507,5105,B,L929,,107,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,8,307.0,,1,,H,Autocuration,,,CHEMBL617394,BAO_0000219,
2508,5104,B,L929,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,8,307.0,,1,,H,Expert,,,CHEMBL617395,BAO_0000219,
2509,5105,B,L929,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,8,307.0,,1,,H,Expert,,,CHEMBL617396,BAO_0000219,
2510,5105,B,L929,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,8,307.0,,1,,H,Autocuration,,,CHEMBL617397,BAO_0000219,
2511,5254,B,,,107,Binding affinity against 5-HT2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617398,BAO_0000357,
2512,5254,B,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617399,BAO_0000357,
2513,13267,B,HEK293,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617400,BAO_0000219,
2514,13267,B,HEK293,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617401,BAO_0000219,
2515,14157,B,HEK293,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617402,BAO_0000219,
2516,12936,B,HEK293,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617403,BAO_0000219,
2517,14068,B,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,8,,,1,,H,Expert,,,CHEMBL617404,BAO_0000357,
2518,12936,B,HEK293,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL857981,BAO_0000219,
2519,12936,B,HEK293,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617405,BAO_0000219,
2520,4540,B,HEK293,,107,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617253,BAO_0000219,
2521,6166,B,,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,8,,,1,,H,Expert,,,CHEMBL617254,BAO_0000357,
2522,17296,B,HEK293,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617255,BAO_0000219,
2523,17296,B,HEK293,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617256,BAO_0000219,
2524,17296,B,HEK293,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616874,BAO_0000219,
2525,15779,B,HEK293,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616875,BAO_0000219,
2526,14391,B,HEK293,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL616876,BAO_0000219,
2527,15851,B,HEK293,,107,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,8,722.0,,1,,H,Expert,,,CHEMBL616877,BAO_0000219,
2528,15851,B,HEK293,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616878,BAO_0000219,
2529,3832,B,HEK293,,107,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,8,722.0,,1,,H,Expert,,,CHEMBL616879,BAO_0000219,
2530,3833,B,HEK293,,107,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,8,722.0,,1,,H,Expert,,,CHEMBL616880,BAO_0000219,
2531,12936,B,HEK293,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616881,BAO_0000219,
2532,17451,B,NIH3T3,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,8,723.0,,1,,H,Autocuration,,,CHEMBL616882,BAO_0000219,
2533,17451,B,NIH3T3,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,723.0,,1,,H,Autocuration,,,CHEMBL616883,BAO_0000219,
2534,17451,B,NIH3T3,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,723.0,,1,,H,Autocuration,,,CHEMBL616884,BAO_0000219,
2535,4199,B,HEK293,,107,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616885,BAO_0000219,
2536,1883,B,CHO-K1,,107,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,8,485.0,,1,,H,Autocuration,,,CHEMBL616886,BAO_0000219,
2537,1883,B,CHO-K1,,107,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,8,485.0,,1,,H,Expert,,,CHEMBL616887,BAO_0000219,
2538,14875,B,,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616888,BAO_0000357,
2539,15146,B,HEK293,,107,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,8,722.0,,1,,H,Autocuration,,,CHEMBL616889,BAO_0000219,
2540,5213,B,HEK293,,107,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL616890,BAO_0000219,
2541,16404,B,CHO,,107,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL616891,BAO_0000219,
2542,14818,B,HEK293,,107,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,8,722.0,,1,,H,Autocuration,,,CHEMBL616892,BAO_0000219,
2543,4829,B,HEK293,,107,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL616893,BAO_0000219,
2544,12652,F,NIH3T3,,10620,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,8,723.0,,1,,H,Autocuration,,,CHEMBL616894,BAO_0000219,
2545,4682,B,NIH3T3,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,8,723.0,,1,,H,Expert,,,CHEMBL616895,BAO_0000219,
2546,12652,F,,,10620,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL616896,BAO_0000019,
2547,4921,B,,,10621,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617099,BAO_0000357,
2548,4921,B,,,10621,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,8,,,1,,H,Autocuration,,,CHEMBL617100,BAO_0000357,
2549,16312,B,,,107,Binding affinity against rabbit aorta 5-HT2A receptor,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL884532,BAO_0000357,
2550,14998,B,,,107,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL617101,BAO_0000357,
2551,14025,B,,,107,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL617102,BAO_0000357,
2552,13047,B,,,107,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617103,BAO_0000019,
2553,13047,B,,,107,The compound was tested for binding affinity against 5-HT2A receptor,,8,,Oryctolagus cuniculus,1,9986.0,H,Expert,,,CHEMBL617104,BAO_0000357,
2554,1883,B,CHO-K1,,10576,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL857979,BAO_0000219,
2555,13463,B,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,8,,,1,,H,Autocuration,,,CHEMBL857502,BAO_0000019,
2556,13463,B,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,8,,,1,,H,Autocuration,,,CHEMBL617105,BAO_0000019,
2557,13463,B,,945.0,12687,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Stomach,8,,,1,,H,Autocuration,,,CHEMBL858021,BAO_0000019,
2558,13463,B,,945.0,12687,Binding affinity for 5-HT 2A in rat stomach fundus,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL875910,BAO_0000019,
2559,13463,B,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,8,,,1,,H,Autocuration,,,CHEMBL617106,BAO_0000019,
2560,16326,B,NIH3T3,,12687,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,8,723.0,,1,,H,Expert,,,CHEMBL617107,BAO_0000219,
2561,14093,F,,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617108,BAO_0000019,
2562,14093,F,,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617109,BAO_0000019,
2563,15740,B,,,12687,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617110,BAO_0000357,
2564,16633,B,,,12687,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,8,,,1,,H,Autocuration,,,CHEMBL617111,BAO_0000357,
2565,17200,F,,,12687,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617112,BAO_0000019,
2566,17133,B,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617113,BAO_0000357,
2567,17133,B,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617114,BAO_0000357,
2568,17133,B,,,12687,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617115,BAO_0000357,
2569,17200,F,,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,8,,,1,,H,Autocuration,,,CHEMBL617116,BAO_0000219,
2570,15363,F,,,12687,Efficacy at 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617117,BAO_0000019,
2571,17200,B,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,8,,,1,,H,Autocuration,,,CHEMBL617118,BAO_0000357,
2572,17200,B,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617119,BAO_0000357,
2573,17200,B,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617120,BAO_0000357,
2574,17200,F,,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617121,BAO_0000219,
2575,17200,F,,,12687,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,8,,,1,,H,Autocuration,,,CHEMBL617122,BAO_0000219,
2576,17211,B,,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617123,BAO_0000019,
2577,17331,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,8,,,1,,H,Expert,,,CHEMBL617124,BAO_0000019,
2578,13565,B,,,12687,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,8,,,1,,H,Expert,,,CHEMBL617600,BAO_0000249,
2579,13730,B,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL617601,BAO_0000357,
2580,12416,B,,,12687,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,8,,,1,,H,Expert,,,CHEMBL882923,BAO_0000019,
2581,15295,B,,,12687,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617602,BAO_0000357,
2582,1742,B,,,12687,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,8,,,1,,H,Autocuration,,,CHEMBL617603,BAO_0000019,
2583,15295,B,,,12687,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617604,BAO_0000357,
2584,14970,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL617605,BAO_0000019,
2585,16693,B,,,12687,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL617606,BAO_0000019,
2586,14776,B,,,12687,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617607,BAO_0000019,
2587,14286,B,,,12687,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL617455,BAO_0000249,
2588,17200,B,,,12687,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617456,BAO_0000019,
2589,15306,B,,,12687,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,8,,,1,,H,Expert,,,CHEMBL617457,BAO_0000357,
2590,14178,B,,,12687,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617458,BAO_0000357,
2591,14229,B,,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617459,BAO_0000019,
2592,12884,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,8,,,1,,H,Expert,,,CHEMBL617460,BAO_0000357,
2593,13149,B,,,12687,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,8,,,1,,H,Expert,,,CHEMBL617461,BAO_0000357,
2594,15295,B,,,12687,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617462,BAO_0000019,
2595,15740,B,,,12687,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,8,,,1,,H,Autocuration,,,CHEMBL617463,BAO_0000357,
2596,15185,B,,,12687,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,8,,,1,,H,Autocuration,,,CHEMBL617464,BAO_0000019,
2597,15185,B,,,12687,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,8,,,1,,H,Autocuration,,,CHEMBL617465,BAO_0000019,
2598,17529,B,,,12687,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,8,,,1,,H,Expert,,,CHEMBL617466,BAO_0000019,
2599,14826,B,,,12687,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,8,,,1,,H,Autocuration,,,CHEMBL617467,BAO_0000019,
2600,17211,B,,,12687,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,8,,,1,,H,Expert,,,CHEMBL617468,BAO_0000019,
2601,14826,B,,,12687,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,8,,,1,,H,Autocuration,,,CHEMBL617469,BAO_0000019,
2602,14093,B,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617470,BAO_0000019,
2603,14093,B,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617471,BAO_0000019,
2604,13246,B,NIH3T3,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,8,723.0,,1,,H,Expert,,,CHEMBL617472,BAO_0000219,
2605,13246,B,,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,8,,,1,,H,Expert,,,CHEMBL617473,BAO_0000357,
2606,15436,B,,,12687,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617474,BAO_0000019,
2607,15436,B,,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617475,BAO_0000019,
2608,14442,B,,955.0,12687,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Brain,8,,,1,,H,Autocuration,,,CHEMBL617476,BAO_0000221,
2609,12457,B,,,12687,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617477,BAO_0000357,
2610,12457,B,NIH3T3,,12687,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,8,723.0,,1,,H,Expert,,,CHEMBL617478,BAO_0000219,
2611,14755,F,,,12687,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,8,,,1,,H,Autocuration,,,CHEMBL617479,BAO_0000221,
2612,4707,B,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617480,BAO_0000357,
2613,13297,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Expert,,,CHEMBL617481,BAO_0000357,
2614,17331,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,8,,,1,,H,Expert,,,CHEMBL617482,BAO_0000019,
2615,4664,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617483,BAO_0000019,
2616,16633,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL621528,BAO_0000357,
2617,4664,B,NIH3T3,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,9,723.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL621529,BAO_0000219,
2618,16133,B,,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,1,,H,Expert,,,CHEMBL621530,BAO_0000357,
2619,16133,B,,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL621531,BAO_0000357,
2620,14060,B,,,12687,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL621532,BAO_0000019,
2621,16326,B,,,12687,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,1,,H,Expert,,,CHEMBL621533,BAO_0000357,
2622,16659,B,CHO,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL621534,BAO_0000219,
2623,14776,B,,,12687,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,8,,,1,,H,Autocuration,,,CHEMBL621535,BAO_0000019,
2624,13481,B,,,12687,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL621536,BAO_0000357,
2625,17386,B,,,12687,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL621537,BAO_0000357,
2626,6611,B,,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL621538,BAO_0000357,
2627,14423,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL621539,BAO_0000019,
2628,15412,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,8,,,1,,H,Autocuration,,,CHEMBL621540,BAO_0000019,
2629,15412,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,8,,,1,,H,Autocuration,,,CHEMBL621541,BAO_0000019,
2630,6238,B,,,12687,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL621542,BAO_0000019,
2631,6648,B,,,12687,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,8,,,1,,H,Expert,,,CHEMBL621543,BAO_0000357,
2632,5667,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL621544,BAO_0000357,
2633,6611,B,,,12687,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL621545,BAO_0000357,
2634,13481,B,,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL621546,BAO_0000357,
2635,13481,B,,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL621547,BAO_0000357,
2636,15558,B,NIH3T3,,12687,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,8,723.0,,1,,H,Expert,,,CHEMBL618692,BAO_0000219,
2637,6013,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618693,BAO_0000357,
2638,16633,B,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872922,BAO_0000357,
2639,6013,B,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618694,BAO_0000357,
2640,6013,B,,,12687,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618695,BAO_0000357,
2641,6013,B,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,8,,,1,,H,Autocuration,,,CHEMBL618696,BAO_0000357,
2642,6013,B,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,8,,,1,,H,Expert,,,CHEMBL618697,BAO_0000357,
2643,6013,B,,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618892,BAO_0000357,
2644,6013,B,,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618893,BAO_0000357,
2645,16293,B,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618894,BAO_0000357,
2646,17175,B,NIH3T3,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,8,723.0,,1,,H,Expert,,,CHEMBL618895,BAO_0000219,
2647,13278,B,,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618896,BAO_0000357,
2648,3682,B,,5383.0,12687,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,8,,,1,,H,Autocuration,,,CHEMBL618897,BAO_0000019,
2649,2014,B,,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618898,BAO_0000357,
2650,2014,B,,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL618899,BAO_0000357,
2651,4932,B,,,12687,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,8,,,1,,H,Autocuration,,,CHEMBL618900,BAO_0000357,
2652,4932,B,,,12687,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,8,,,1,,H,Autocuration,,,CHEMBL618901,BAO_0000019,
2653,3935,B,,,12687,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618902,BAO_0000357,
2654,5432,B,,10000000.0,12687,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Hippocampus,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618903,BAO_0000221,
2655,15818,B,,,12687,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618904,BAO_0000357,
2656,13672,B,,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL618905,BAO_0000357,
2657,13672,B,,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL618906,BAO_0000357,
2658,14749,B,NIH3T3,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,8,723.0,,1,,H,Expert,,,CHEMBL618907,BAO_0000219,
2659,13462,B,,,12687,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,8,,,1,,H,Autocuration,,,CHEMBL618908,BAO_0000019,
2660,15740,B,,,12687,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617909,BAO_0000357,
2661,16647,B,,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,8,,,1,,H,Expert,,,CHEMBL617910,BAO_0000019,
2662,13345,B,,955.0,12687,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Brain,8,,,1,,H,Autocuration,,,CHEMBL617911,BAO_0000221,
2663,16740,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL872923,BAO_0000249,
2664,16740,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL617912,BAO_0000249,
2665,15535,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617913,BAO_0000019,
2666,16740,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Expert,,,CHEMBL617914,BAO_0000249,
2667,16740,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL617915,BAO_0000249,
2668,16740,B,,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL617916,BAO_0000249,
2669,4795,B,,,12687,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617917,BAO_0000019,
2670,8,B,,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,8,,,1,,H,Expert,,,CHEMBL617918,BAO_0000019,
2671,8,B,,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,8,,,1,,H,Autocuration,,,CHEMBL617919,BAO_0000019,
2672,17200,B,,,12687,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617920,BAO_0000019,
2673,2148,B,,,12687,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617921,BAO_0000019,
2674,13345,B,,,105102,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,5,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617922,BAO_0000224,
2675,5088,B,,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617923,BAO_0000357,
2676,5088,B,,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617924,BAO_0000357,
2677,17133,B,,,12687,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617925,BAO_0000357,
2678,17133,B,,,12687,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617926,BAO_0000357,
2679,16532,B,,,12687,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,8,,,1,,H,Autocuration,,,CHEMBL617927,BAO_0000357,
2680,15086,B,,,12687,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617928,BAO_0000357,
2681,2309,B,,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617929,BAO_0000019,
2682,12953,B,,,12687,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,8,,,1,,H,Expert,,,CHEMBL617930,BAO_0000019,
2683,12953,B,,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617931,BAO_0000019,
2684,12953,B,,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617932,BAO_0000019,
2685,16659,B,CHO,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,8,449.0,,1,,H,Autocuration,,,CHEMBL617933,BAO_0000219,
2686,16740,B,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,8,,,1,,H,Autocuration,,,CHEMBL617934,BAO_0000019,
2687,16740,B,,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,8,,,1,,H,Autocuration,,,CHEMBL617935,BAO_0000019,
2688,17133,B,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL617936,BAO_0000357,
2689,17211,B,,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,8,,,1,,H,Autocuration,,,CHEMBL617937,BAO_0000019,
2690,17331,B,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617938,BAO_0000019,
2691,16633,B,,,12687,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,8,,,1,,H,Autocuration,,,CHEMBL617939,BAO_0000218,
2692,16633,B,,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,8,,,1,,H,Autocuration,,,CHEMBL617940,BAO_0000218,
2693,16633,B,,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,8,,,1,,H,Autocuration,,,CHEMBL617941,BAO_0000218,
2694,15026,B,,,12687,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,8,,,1,,H,Expert,,,CHEMBL617942,BAO_0000357,
2695,15026,B,,,12687,Ratio of pKi of 5-HT2A to that of D2 receptor,,8,,,1,,H,Expert,,,CHEMBL617943,BAO_0000357,
2696,16404,B,,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,4,,,1,,H,Expert,,,CHEMBL617944,BAO_0000224,
2697,16404,B,,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,4,,,1,,H,Expert,,,CHEMBL617945,BAO_0000224,
2698,16404,B,,,105075,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,4,,,1,,H,Expert,,,CHEMBL617946,BAO_0000224,
2699,16404,B,,,12687,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,8,,,1,,H,Autocuration,,,CHEMBL617947,BAO_0000357,
2700,16326,B,,,12687,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,8,,,1,,H,Expert,,,CHEMBL617948,BAO_0000357,
2701,15847,F,,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,8,,,1,,H,Autocuration,,,CHEMBL858116,BAO_0000019,
2702,15847,F,,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,8,,,1,,H,Autocuration,,,CHEMBL617949,BAO_0000019,
2703,15329,F,,,12687,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,8,,,1,,H,Autocuration,,,CHEMBL617950,BAO_0000019,
2704,16404,F,,1515.0,12687,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Thoracic aorta,8,,,1,,H,Expert,,,CHEMBL617951,BAO_0000019,
2705,16404,F,,1515.0,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Thoracic aorta,8,,,1,,H,Expert,,,CHEMBL617952,BAO_0000019,
2706,16404,F,,1515.0,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Thoracic aorta,8,,,1,,H,Autocuration,,,CHEMBL617953,BAO_0000019,
2707,12861,B,,,12687,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617954,BAO_0000357,
2708,12861,B,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,1,,H,Expert,,,CHEMBL617955,BAO_0000019,
2709,12861,B,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,8,,,1,,H,Autocuration,,,CHEMBL857071,BAO_0000019,
2710,12490,B,,,12687,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,8,,,1,,H,Expert,,,CHEMBL617270,BAO_0000019,
2711,12827,B,N1E-115,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,8,339.0,,1,,H,Autocuration,,,CHEMBL617271,BAO_0000219,
2712,12827,B,N1E-115,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,8,339.0,,1,,H,Autocuration,,,CHEMBL617272,BAO_0000219,
2713,12918,B,,,12687,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,8,,,1,,H,Autocuration,,,CHEMBL617273,BAO_0000019,
2714,12919,F,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617274,BAO_0000019,
2715,17723,B,,,108,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617275,BAO_0000357,
2716,6013,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617276,BAO_0000357,
2717,16293,B,,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617277,BAO_0000357,
2718,3857,B,,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617278,BAO_0000019,
2719,3857,B,,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,8,,,1,,H,Expert,,,CHEMBL617279,BAO_0000019,
2720,3857,B,,,108,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617280,BAO_0000019,
2721,15363,B,,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617281,BAO_0000357,
2722,15363,B,,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617282,BAO_0000357,
2723,16441,B,,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,8,,,1,,H,Expert,,,CHEMBL617283,BAO_0000019,
2724,16441,B,,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,8,,,1,,H,Expert,,,CHEMBL617284,BAO_0000019,
2725,4176,B,HEK293,,108,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617285,BAO_0000219,
2726,17085,B,,,108,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617286,BAO_0000019,
2727,17200,B,,,108,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617287,BAO_0000357,
2728,5088,B,,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,8,,,1,,H,Expert,,,CHEMBL617288,BAO_0000357,
2729,5088,B,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617289,BAO_0000357,
2730,5088,B,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872917,BAO_0000357,
2731,5088,B,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617290,BAO_0000357,
2732,16659,B,CHO,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL617291,BAO_0000219,
2733,16659,B,CHO,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,8,449.0,,1,,H,Autocuration,,,CHEMBL617292,BAO_0000219,
2734,17451,B,NIH3T3,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,723.0,,1,,H,Autocuration,,,CHEMBL617293,BAO_0000219,
2735,6857,F,CHO,,108,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617294,BAO_0000219,
2736,3857,B,,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,8,,,1,,H,Expert,,,CHEMBL617295,BAO_0000019,
2737,12861,B,,,108,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617296,BAO_0000357,
2738,12861,B,,,108,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617297,BAO_0000019,
2739,5104,B,CHO,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,8,449.0,,1,,H,Expert,,,CHEMBL617298,BAO_0000219,
2740,5105,B,CHO,,108,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,8,449.0,,1,,H,Expert,,,CHEMBL617299,BAO_0000219,
2741,5105,B,CHO,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,8,449.0,,1,,H,Autocuration,,,CHEMBL617300,BAO_0000219,
2742,5254,B,,,108,Binding affinity against 5-HT2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617454,BAO_0000357,
2743,13267,B,HEK293,,108,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617505,BAO_0000219,
2744,14157,B,HEK293,,108,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617506,BAO_0000219,
2745,12936,B,HEK293,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617507,BAO_0000219,
2746,14068,B,,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,8,,,1,,H,Expert,,,CHEMBL617508,BAO_0000357,
2747,12936,B,HEK293,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL857982,BAO_0000219,
2748,4540,B,HEK293,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617509,BAO_0000219,
2749,4540,B,HEK293,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617510,BAO_0000219,
2750,6166,B,,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617511,BAO_0000357,
2751,17296,B,HEK293,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617512,BAO_0000219,
2752,17296,B,HEK293,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617749,BAO_0000219,
2753,15779,B,HEK293,,108,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617750,BAO_0000219,
2754,15779,B,HEK293,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617751,BAO_0000219,
2755,14391,B,HEK293,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL617752,BAO_0000219,
2756,15779,B,HEK293,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL617753,BAO_0000219,
2757,15851,B,HEK293,,108,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,8,722.0,,1,,H,Expert,,,CHEMBL617754,BAO_0000219,
2758,15851,B,HEK293,,108,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617755,BAO_0000219,
2759,15779,B,HEK293,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,8,722.0,,1,,H,Autocuration,,,CHEMBL617756,BAO_0000219,
2760,3832,B,HEK293,,108,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,8,722.0,,1,,H,Expert,,,CHEMBL617757,BAO_0000219,
2761,3833,B,HEK293,,108,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,8,722.0,,1,,H,Expert,,,CHEMBL617758,BAO_0000219,
2762,17451,B,NIH3T3,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,8,723.0,,1,,H,Autocuration,,,CHEMBL617759,BAO_0000219,
2763,4199,B,HEK293,,108,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617760,BAO_0000219,
2764,1883,B,CHO-K1,,108,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,8,485.0,,1,,H,Expert,,,CHEMBL617761,BAO_0000219,
2765,4321,B,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617762,BAO_0000357,
2766,14875,B,,,108,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617763,BAO_0000357,
2767,15146,B,HEK293,,108,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,8,722.0,,1,,H,Autocuration,,,CHEMBL857983,BAO_0000219,
2768,5213,B,HEK293,,108,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617764,BAO_0000219,
2769,16404,B,HeLa,,108,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,8,308.0,,1,,H,Autocuration,,,CHEMBL617765,BAO_0000219,
2770,13267,F,,,108,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617766,BAO_0000019,
2771,13267,F,,10000000.0,108,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL617767,BAO_0000221,
2772,14818,B,HEK293,,108,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617768,BAO_0000219,
2773,4829,B,HEK293,,108,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL617769,BAO_0000219,
2774,13463,B,,,11864,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL858023,BAO_0000357,
2775,13463,B,,945.0,11864,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617770,BAO_0000019,
2776,13463,B,,945.0,11864,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617771,BAO_0000019,
2777,12652,F,A9,,11864,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,8,625.0,,1,,H,Autocuration,,,CHEMBL617772,BAO_0000219,
2778,4682,B,NIH3T3,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,8,723.0,,1,,H,Autocuration,,,CHEMBL617773,BAO_0000219,
2779,4682,B,NIH3T3,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,8,723.0,,1,,H,Autocuration,,,CHEMBL617850,BAO_0000219,
2780,4682,B,NIH3T3,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,8,723.0,,1,,H,Autocuration,,,CHEMBL617851,BAO_0000219,
2781,12652,F,,,11864,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617852,BAO_0000019,
2782,13463,B,,945.0,12689,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Stomach,8,,Mus musculus,1,10090.0,H,Autocuration,,,CHEMBL858024,BAO_0000019,
2783,13463,B,,945.0,12689,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617853,BAO_0000019,
2784,13969,B,,,108,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,8,,,1,,H,Expert,,,CHEMBL617854,BAO_0000357,
2785,13392,B,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL873477,BAO_0000357,
2786,13392,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617855,BAO_0000357,
2787,14430,B,,,108,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,8,,,1,,H,Expert,,,CHEMBL617856,BAO_0000019,
2788,1742,B,,,108,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,8,,,1,,H,Autocuration,,,CHEMBL617857,BAO_0000019,
2789,14286,B,,,108,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,8,,,1,,H,Autocuration,,,CHEMBL617858,BAO_0000249,
2790,5619,B,,,108,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617859,BAO_0000357,
2791,15086,B,,,108,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617860,BAO_0000357,
2792,12861,B,,,108,Binding activity radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617861,BAO_0000357,
2793,12861,B,,,108,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,1,,H,Expert,,,CHEMBL617862,BAO_0000019,
2794,12861,B,,,108,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,8,,,1,,H,Autocuration,,,CHEMBL617863,BAO_0000019,
2795,12827,B,,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,8,,,1,,H,Autocuration,,,CHEMBL617864,BAO_0000249,
2796,12827,B,,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL617649,BAO_0000249,
2797,12919,F,,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL617650,BAO_0000019,
2798,12919,F,,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,8,,Sus scrofa,1,9823.0,H,Expert,,,CHEMBL617651,BAO_0000019,
2799,16429,B,,,108,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617652,BAO_0000357,
2800,773,B,,,108,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL857072,BAO_0000019,
2801,5033,B,,,108,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617653,BAO_0000357,
2802,12861,B,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617654,BAO_0000019,
2803,14093,F,,,12689,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617655,BAO_0000019,
2804,14970,B,,,12689,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,8,,,1,,H,Expert,,,CHEMBL617656,BAO_0000357,
2805,14970,B,,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617657,BAO_0000357,
2806,14970,B,,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617658,BAO_0000357,
2807,14178,B,,,12689,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617659,BAO_0000357,
2808,14178,B,,,12689,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617838,BAO_0000357,
2809,14229,B,,,12689,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617839,BAO_0000249,
2810,16532,B,,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617840,BAO_0000357,
2811,14826,B,,,12689,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,8,,,1,,H,Autocuration,,,CHEMBL617841,BAO_0000019,
2812,17211,B,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL875915,BAO_0000019,
2813,17211,B,,,12689,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,8,,,1,,H,Expert,,,CHEMBL617842,BAO_0000219,
2814,13246,B,NIH3T3,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,8,723.0,,1,,H,Expert,,,CHEMBL617843,BAO_0000219,
2815,13246,B,,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,8,,,1,,H,Expert,,,CHEMBL617844,BAO_0000357,
2816,12457,B,,,12689,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617845,BAO_0000357,
2817,12457,B,NIH3T3,,12689,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,8,723.0,,1,,H,Expert,,,CHEMBL617846,BAO_0000219,
2818,4707,B,,,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617847,BAO_0000357,
2819,13297,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617848,BAO_0000357,
2820,16633,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617849,BAO_0000357,
2821,16133,B,,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,1,,H,Expert,,,CHEMBL621507,BAO_0000357,
2822,16326,B,,,12689,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,8,,,1,,H,Expert,,,CHEMBL621508,BAO_0000357,
2823,14423,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL621509,BAO_0000019,
2824,15412,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,8,,,1,,H,Autocuration,,,CHEMBL621510,BAO_0000019,
2825,15412,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,8,,,1,,H,Autocuration,,,CHEMBL621511,BAO_0000019,
2826,15558,B,A9,,12689,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,8,625.0,,1,,H,Expert,,,CHEMBL621512,BAO_0000219,
2827,16633,B,,,12689,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL621513,BAO_0000357,
2828,6013,B,,,12689,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,8,,,1,,H,Expert,,,CHEMBL621514,BAO_0000357,
2829,17175,B,,,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,8,,,1,,H,Expert,,,CHEMBL621515,BAO_0000219,
2830,12469,B,,,12689,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,8,,,1,,H,Autocuration,,,CHEMBL621516,BAO_0000219,
2831,3682,B,,5383.0,12689,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,8,,,1,,H,Autocuration,,,CHEMBL621517,BAO_0000019,
2832,4932,B,,,12689,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,8,,,1,,H,Autocuration,,,CHEMBL621518,BAO_0000357,
2833,4932,B,,,12689,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,8,,,1,,H,Autocuration,,,CHEMBL621519,BAO_0000019,
2834,3935,B,,,12689,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621520,BAO_0000357,
2835,15818,B,,,12689,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621521,BAO_0000357,
2836,15818,B,,,12689,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621522,BAO_0000357,
2837,14749,B,,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,8,,,1,,H,Expert,,,CHEMBL621523,BAO_0000219,
2838,15740,B,,,12689,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621524,BAO_0000357,
2839,17133,B,,,12689,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL621525,BAO_0000357,
2840,16532,B,,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,8,,,1,,H,Autocuration,,,CHEMBL872921,BAO_0000357,
2841,12369,B,,,12689,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621526,BAO_0000357,
2842,12369,B,,,12689,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,8,,,1,,H,Expert,,,CHEMBL621527,BAO_0000219,
2843,2309,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617865,BAO_0000019,
2844,12953,B,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617866,BAO_0000357,
2845,12953,B,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617867,BAO_0000019,
2846,12953,B,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL617487,BAO_0000357,
2847,12953,B,,,12689,Binding affinity for 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617488,BAO_0000357,
2848,17133,B,,,12689,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL617489,BAO_0000357,
2849,17211,B,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,8,,,1,,H,Autocuration,,,CHEMBL617490,BAO_0000019,
2850,17211,B,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,8,,,1,,H,Autocuration,,,CHEMBL617491,BAO_0000019,
2851,14025,B,,,12689,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,8,,,1,,H,Autocuration,,,CHEMBL617492,BAO_0000019,
2852,14998,B,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,8,,,1,,H,Autocuration,,,CHEMBL617493,BAO_0000019,
2853,4342,B,,,12689,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617494,BAO_0000357,
2854,13735,B,,,12689,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617495,BAO_0000019,
2855,13181,B,,,12689,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617496,BAO_0000357,
2856,1883,B,CHO-K1,,12689,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,8,485.0,,1,,H,Autocuration,,,CHEMBL617497,BAO_0000219,
2857,15194,B,,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617498,BAO_0000357,
2858,15194,B,,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617499,BAO_0000357,
2859,14579,F,,,12689,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617500,BAO_0000019,
2860,4639,B,,,108,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617501,BAO_0000357,
2861,4820,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL617502,BAO_0000357,
2862,14442,B,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,8,,,1,,H,Autocuration,,,CHEMBL617503,BAO_0000357,
2863,14755,B,,,227,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617504,BAO_0000357,
2864,14744,B,,,227,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617406,BAO_0000357,
2865,6857,B,,,227,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617407,BAO_0000019,
2866,16209,B,,,227,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617408,BAO_0000357,
2867,15363,B,,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617409,BAO_0000357,
2868,15363,B,,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617410,BAO_0000357,
2869,15363,B,,,227,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617411,BAO_0000357,
2870,17085,B,,,227,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617412,BAO_0000019,
2871,17200,B,,,227,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617774,BAO_0000357,
2872,15851,B,HEK293,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617775,BAO_0000219,
2873,15851,B,HEK293,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617776,BAO_0000219,
2874,6857,F,CHO,,227,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617777,BAO_0000219,
2875,6857,F,CHO,,227,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617778,BAO_0000219,
2876,15779,B,HEK293,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL617779,BAO_0000219,
2877,15851,B,HEK293,,227,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,8,722.0,,1,,H,Expert,,,CHEMBL617780,BAO_0000219,
2878,15779,B,HEK293,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,8,722.0,,1,,H,Autocuration,,,CHEMBL617781,BAO_0000219,
2879,14157,B,HEK293,,227,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617782,BAO_0000219,
2880,4540,B,HEK293,,227,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617783,BAO_0000219,
2881,6166,B,,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617784,BAO_0000357,
2882,15779,B,HEK293,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617785,BAO_0000219,
2883,14391,B,HEK293,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL857984,BAO_0000219,
2884,3832,B,HEK293,,227,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,8,722.0,,1,,H,Expert,,,CHEMBL617786,BAO_0000219,
2885,3833,B,HEK293,,227,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,8,722.0,,1,,H,Expert,,,CHEMBL617787,BAO_0000219,
2886,15851,B,HEK293,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617788,BAO_0000219,
2887,15851,B,HEK293,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617789,BAO_0000219,
2888,4199,B,HEK293,,227,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617790,BAO_0000219,
2889,1883,B,CHO-K1,,227,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,8,485.0,,1,,H,Expert,,,CHEMBL617791,BAO_0000219,
2890,4321,B,,,227,Binding affinity against 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Expert,,,CHEMBL617608,BAO_0000357,
2891,15146,B,HEK293,,227,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,8,722.0,,1,,H,Autocuration,,,CHEMBL617609,BAO_0000219,
2892,5213,B,HEK293,,227,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL617610,BAO_0000219,
2893,14818,B,HEK293,,227,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,8,722.0,,1,,H,Autocuration,,,CHEMBL617611,BAO_0000219,
2894,4829,B,HEK293,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL617612,BAO_0000219,
2895,4829,B,HEK293,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL617613,BAO_0000219,
2896,14025,B,,,227,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617614,BAO_0000019,
2897,13463,B,,945.0,12688,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Stomach,8,,,1,,H,Expert,,,CHEMBL617615,BAO_0000019,
2898,7259,B,,945.0,12688,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Stomach,8,,,1,,H,Expert,,,CHEMBL858114,BAO_0000357,
2899,7259,B,,945.0,12688,Affinity against serotonergic receptor in the isolated rat stomach fundus,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617616,BAO_0000357,
2900,7185,F,,945.0,12688,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617617,BAO_0000019,
2901,7185,F,,,12688,Antagonistic against 5-hydroxytryptamine 2B receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL875914,BAO_0000019,
2902,13267,F,,945.0,12688,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617618,BAO_0000019,
2903,13735,B,,945.0,12688,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617619,BAO_0000357,
2904,15738,F,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,8,,,1,,H,Autocuration,,,CHEMBL617620,BAO_0000019,
2905,15738,F,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,8,,,1,,H,Autocuration,,,CHEMBL617621,BAO_0000019,
2906,15738,F,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,8,,,1,,H,Autocuration,,,CHEMBL617622,BAO_0000019,
2907,12936,B,,945.0,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617623,BAO_0000357,
2908,12936,B,,945.0,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617624,BAO_0000357,
2909,12936,B,,945.0,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617625,BAO_0000357,
2910,12936,B,,945.0,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617626,BAO_0000357,
2911,16404,F,,945.0,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617627,BAO_0000019,
2912,16404,F,,945.0,12688,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,8,,,1,,H,Expert,,,CHEMBL617628,BAO_0000019,
2913,16404,F,,945.0,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Stomach,8,,,1,,H,Autocuration,,,CHEMBL617629,BAO_0000019,
2914,16404,F,,945.0,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Stomach,8,,,1,,H,Autocuration,,,CHEMBL858115,BAO_0000019,
2915,16404,F,,945.0,12688,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Stomach,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL617630,BAO_0000019,
2916,16404,F,,1515.0,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Thoracic aorta,8,,,1,,H,Autocuration,,,CHEMBL617631,BAO_0000019,
2917,7483,B,,,12688,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,1,,H,Autocuration,,,CHEMBL617632,BAO_0000357,
2918,7483,B,,,12688,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,8,,,1,,H,Expert,,,CHEMBL617633,BAO_0000357,
2919,7483,B,,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,1,,H,Autocuration,,,CHEMBL617634,BAO_0000357,
2920,7483,B,,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,1,,H,Autocuration,,,CHEMBL617635,BAO_0000357,
2922,16404,F,,945.0,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617637,BAO_0000019,
2923,6347,B,,,227,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL617638,BAO_0000357,
2924,4373,B,,,227,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617639,BAO_0000357,
2925,4373,B,,,227,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL617640,BAO_0000357,
2926,4687,B,,,227,Evaluated for the binding affinity to 5-HT 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617641,BAO_0000357,
2927,16946,B,,,227,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617642,BAO_0000357,
2928,16633,B,,,227,Binding affinities against 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617643,BAO_0000357,
2929,16633,B,,,227,Binding affinities towards 5-hydroxytryptamine 2B receptor,,8,,,1,,H,Autocuration,,,CHEMBL617644,BAO_0000357,
2930,16633,B,,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617645,BAO_0000357,
2931,15026,B,,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,8,,,1,,H,Expert,,,CHEMBL617646,BAO_0000357,
2932,15738,B,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617647,BAO_0000357,
2933,15738,B,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617648,BAO_0000357,
2934,15738,B,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617875,BAO_0000357,
2935,15738,B,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617876,BAO_0000357,
2936,16404,B,,,108,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL617877,BAO_0000357,
2937,15026,B,,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL617878,BAO_0000357,
2938,15738,B,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617879,BAO_0000357,
2939,16312,B,,,108,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617880,BAO_0000019,
2940,5486,B,,2435.0,20033,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617881,BAO_0000357,
2941,5254,B,,,51,Binding affinity against 5-HT1A receptor,,8,,,1,,H,Autocuration,,,CHEMBL857073,BAO_0000357,
2942,3857,F,CHO,,108,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,8,449.0,,1,,H,Expert,,,CHEMBL617882,BAO_0000219,
2943,6857,F,CHO,,108,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617883,BAO_0000219,
2944,4176,F,,,108,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,8,,,1,,H,Autocuration,,,CHEMBL617884,BAO_0000219,
2945,6347,B,CHO,,108,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL617885,BAO_0000219,
2946,6347,B,CHO,,108,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,8,449.0,,1,,H,Autocuration,,,CHEMBL617886,BAO_0000219,
2947,16146,B,,,108,Inhibition of human 5-hydroxytryptamine 2C receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617887,BAO_0000357,
2948,3805,B,,,108,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL617888,BAO_0000357,
2949,3857,B,,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL617889,BAO_0000019,
2950,5635,B,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL617890,BAO_0000357,
2951,5635,B,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,8,,,1,,H,Autocuration,,,CHEMBL617891,BAO_0000357,
2952,5635,B,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,8,,,1,,H,Autocuration,,,CHEMBL617892,BAO_0000357,
2953,4012,B,CHO,,108,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,8,449.0,,1,,H,Expert,,,CHEMBL617893,BAO_0000219,
2954,6366,B,CHO,,108,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL617894,BAO_0000219,
2955,15949,B,CHO,,108,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL617895,BAO_0000219,
2956,17211,B,CHO,,108,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,8,449.0,,1,,H,Autocuration,,,CHEMBL617896,BAO_0000219,
2957,6491,B,,,108,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617897,BAO_0000357,
2958,14093,F,,,108,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617898,BAO_0000019,
2959,13481,F,,,108,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617899,BAO_0000019,
2960,6347,B,CHO,,108,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,8,449.0,Rattus norvegicus,1,10116.0,H,Expert,,,CHEMBL617900,BAO_0000219,
2961,14093,F,,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617901,BAO_0000019,
2962,14093,F,,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL617902,BAO_0000019,
2963,13481,F,,,108,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617903,BAO_0000019,
2964,14442,B,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617904,BAO_0000357,
2965,14442,B,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617905,BAO_0000357,
2966,14442,B,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,8,,,1,,H,Autocuration,,,CHEMBL617906,BAO_0000357,
2967,14755,B,,,108,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL617907,BAO_0000357,
2968,14744,B,,,108,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL617908,BAO_0000357,
2969,16659,B,CHO,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL620617,BAO_0000219,
2970,6857,B,,,108,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620618,BAO_0000019,
2971,5635,B,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,8,,,1,,H,Expert,,,CHEMBL620619,BAO_0000357,
2972,4234,B,,,108,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620620,BAO_0000357,
2973,16209,B,,,108,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620621,BAO_0000357,
2974,5778,B,,,104698,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL872920,BAO_0000249,
2975,5094,B,,,104698,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,6,,,1,,H,Autocuration,,,CHEMBL620622,BAO_0000223,
2976,809,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL620623,BAO_0000019,
2977,1578,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,6,,,1,,H,Autocuration,,,CHEMBL620624,BAO_0000019,
2978,809,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,6,,,1,,H,Autocuration,,,CHEMBL620625,BAO_0000019,
2979,12469,B,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,6,,,1,,H,Autocuration,,,CHEMBL620626,BAO_0000219,
2980,14290,B,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,6,,,1,,H,Autocuration,,,CHEMBL621307,BAO_0000019,
2981,14290,B,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,6,,,1,,H,Autocuration,,,CHEMBL621308,BAO_0000019,
2982,10609,B,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,6,,,1,,H,Autocuration,,,CHEMBL621309,BAO_0000223,
2983,10609,B,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,6,,,1,,H,Autocuration,,,CHEMBL621310,BAO_0000223,
2984,10609,B,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,6,,,1,,H,Autocuration,,,CHEMBL621311,BAO_0000223,
2985,15253,B,,,104698,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,6,,,1,,H,Autocuration,,,CHEMBL621502,BAO_0000249,
2986,15253,B,,,104698,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,6,,,1,,H,Autocuration,,,CHEMBL621503,BAO_0000249,
2987,11683,B,,,104698,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,6,,,1,,H,Autocuration,,,CHEMBL621504,BAO_0000249,
2988,12092,B,,,104698,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL621505,BAO_0000223,
2989,1946,B,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,6,,,1,,H,Autocuration,,,CHEMBL621506,BAO_0000019,
2990,11623,B,,,104698,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,6,,,1,,H,Autocuration,,,CHEMBL619781,BAO_0000223,
2991,11623,B,,,104698,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,6,,,1,,H,Autocuration,,,CHEMBL619782,BAO_0000223,
2992,14788,B,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,6,,,1,,H,Autocuration,,,CHEMBL619783,BAO_0000019,
2993,5432,B,,,104698,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619784,BAO_0000019,
2994,14826,B,,,104698,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,1,,H,Autocuration,,,CHEMBL619785,BAO_0000249,
2995,2222,B,,,104698,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL619786,BAO_0000223,
2996,11963,B,,,104698,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,6,,,1,,H,Autocuration,,,CHEMBL619787,BAO_0000019,
2997,14145,B,,,104698,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,6,,,1,,H,Autocuration,,,CHEMBL872925,BAO_0000019,
2998,17819,B,,,104698,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,6,,,1,,H,Autocuration,,,CHEMBL619788,BAO_0000019,
2999,10394,B,,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,6,,,1,,H,Autocuration,,,CHEMBL619789,BAO_0000249,
3000,10394,B,,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,6,,,1,,H,Autocuration,,,CHEMBL619790,BAO_0000249,
3001,15034,B,,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL619791,BAO_0000019,
3002,691,B,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,6,,,1,,H,Autocuration,,,CHEMBL619792,BAO_0000019,
3003,12092,B,,,104698,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,6,,,1,,H,Autocuration,,,CHEMBL619793,BAO_0000249,
3004,11752,B,,,104698,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619794,BAO_0000223,
3005,11752,B,,955.0,104698,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Brain,6,,,1,,H,Autocuration,,,CHEMBL619795,BAO_0000221,
3006,301,B,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,6,,,1,,H,Autocuration,,,CHEMBL619796,BAO_0000019,
3007,16532,B,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,6,,,1,,H,Autocuration,,,CHEMBL620448,BAO_0000223,
3008,16532,B,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,6,,,1,,H,Autocuration,,,CHEMBL620449,BAO_0000223,
3009,12092,B,,,104698,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,6,,,1,,H,Autocuration,,,CHEMBL620450,BAO_0000223,
3010,11684,B,,,104698,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,6,,,1,,H,Autocuration,,,CHEMBL620451,BAO_0000223,
3011,11684,B,,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,6,,,1,,H,Autocuration,,,CHEMBL620631,BAO_0000223,
3012,12953,B,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL620632,BAO_0000019,
3013,12953,B,,,104698,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,6,,,1,,H,Autocuration,,,CHEMBL620633,BAO_0000019,
3014,12953,B,,,104698,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,6,,,1,,H,Autocuration,,,CHEMBL620634,BAO_0000223,
3015,12861,B,,,104698,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,6,,,1,,H,Autocuration,,,CHEMBL620635,BAO_0000019,
3016,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620636,BAO_0000218,
3017,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620637,BAO_0000218,
3018,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620638,BAO_0000218,
3019,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620639,BAO_0000218,
3020,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620640,BAO_0000218,
3021,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620641,BAO_0000218,
3022,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620642,BAO_0000218,
3023,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620643,BAO_0000218,
3024,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620644,BAO_0000218,
3025,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620645,BAO_0000218,
3026,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620646,BAO_0000218,
3027,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620647,BAO_0000218,
3028,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620648,BAO_0000218,
3029,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620649,BAO_0000218,
3030,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620650,BAO_0000218,
3031,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620651,BAO_0000218,
3032,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL872875,BAO_0000218,
3033,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL620652,BAO_0000218,
3034,10609,F,,,104698,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,6,,,1,,H,Autocuration,,,CHEMBL620653,BAO_0000019,
3035,12861,B,,,104698,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,6,,,1,,H,Autocuration,,,CHEMBL857076,BAO_0000019,
3036,12861,B,,,104698,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL620654,BAO_0000019,
3037,12861,B,,,104698,Binding activity radioligand.,,6,,,1,,H,Autocuration,,,CHEMBL620655,BAO_0000223,
3038,10728,B,,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,6,,,1,,H,Autocuration,,,CHEMBL620656,BAO_0000249,
3039,10728,B,,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,6,,,1,,H,Autocuration,,,CHEMBL620657,BAO_0000249,
3040,5163,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,8,,,1,,H,Autocuration,,,CHEMBL620658,BAO_0000357,
3041,5163,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,8,,,1,,H,Autocuration,,,CHEMBL620659,BAO_0000357,
3042,6011,B,,,108,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL620660,BAO_0000357,
3043,5014,B,,,108,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL620661,BAO_0000357,
3044,5635,B,,,108,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL620662,BAO_0000357,
3045,5163,B,,,108,Affinity for 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL620663,BAO_0000357,
3046,6841,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620664,BAO_0000357,
3047,6119,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,8,,,1,,H,Expert,,,CHEMBL620665,BAO_0000357,
3048,4373,B,,,108,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620666,BAO_0000357,
3049,1633,B,,,108,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,8,,,1,,H,Autocuration,,,CHEMBL620667,BAO_0000357,
3050,1633,B,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,8,,,1,,H,Expert,,,CHEMBL620668,BAO_0000357,
3051,4373,B,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620669,BAO_0000357,
3052,6576,B,,,108,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL620670,BAO_0000357,
3053,4687,B,,,108,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL620671,BAO_0000357,
3054,12146,B,,,108,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,8,,,1,,H,Autocuration,,,CHEMBL620672,BAO_0000357,
3055,12146,B,,,108,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,8,,,1,,H,Autocuration,,,CHEMBL620673,BAO_0000357,
3056,16946,B,,,108,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL620674,BAO_0000357,
3057,14159,B,,,108,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL620675,BAO_0000357,
3058,16700,B,,,108,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL620676,BAO_0000357,
3059,3269,B,,,108,Affinity against 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Autocuration,,,CHEMBL621382,BAO_0000357,
3060,1274,B,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621383,BAO_0000357,
3061,1317,B,,,108,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,8,,,1,,H,Autocuration,,,CHEMBL621384,BAO_0000357,
3062,5834,B,,,144,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL621385,BAO_0000357,
3063,11147,B,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,8,,Bos taurus,1,9913.0,H,Autocuration,,,CHEMBL617989,BAO_0000357,
3064,14145,F,,,104714,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,4,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL617990,BAO_0000019,
3065,10561,B,,2116.0,104714,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL875085,BAO_0000221,
3066,15847,F,,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617991,BAO_0000019,
3067,15847,F,,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617992,BAO_0000019,
3068,10561,B,,2116.0,104714,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617993,BAO_0000221,
3069,11454,B,,2116.0,104714,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617994,BAO_0000221,
3070,4639,F,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617995,BAO_0000019,
3071,4639,F,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617996,BAO_0000019,
3072,4639,F,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617997,BAO_0000019,
3073,4639,F,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617998,BAO_0000019,
3074,4639,F,,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617999,BAO_0000019,
3075,4639,F,,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618000,BAO_0000019,
3076,15253,F,,2116.0,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617815,BAO_0000221,
3077,15253,F,,2116.0,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617816,BAO_0000221,
3078,11963,F,,2116.0,104714,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617817,BAO_0000221,
3079,1946,B,,2116.0,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617818,BAO_0000221,
3080,1946,B,,2116.0,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617819,BAO_0000221,
3081,12045,B,,,104714,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617820,BAO_0000223,
3082,1559,B,,2116.0,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617821,BAO_0000221,
3083,273,F,,2116.0,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617822,BAO_0000221,
3084,273,F,,2116.0,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617823,BAO_0000221,
3085,188,F,,2116.0,104714,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617824,BAO_0000221,
3086,12919,F,,2116.0,104714,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617825,BAO_0000221,
3087,12918,F,,2116.0,104714,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617826,BAO_0000221,
3088,1559,B,,2116.0,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617827,BAO_0000221,
3089,273,F,,2116.0,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617828,BAO_0000221,
3090,1559,B,,2116.0,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617829,BAO_0000221,
3091,1559,B,,2116.0,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617830,BAO_0000221,
3092,1559,B,,2116.0,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617831,BAO_0000221,
3093,14424,B,,2116.0,104714,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL617832,BAO_0000221,
3094,13181,B,,,22226,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL617833,BAO_0000019,
3095,5486,B,,,51,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,8,,,1,,H,Autocuration,,,CHEMBL617834,BAO_0000357,
3096,6491,B,,,104714,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,5,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL617835,BAO_0000223,
3097,6013,B,,,104714,Binding affinity towards 5-HT3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL617836,BAO_0000223,
3098,12861,B,,,104714,Binding activity radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL617837,BAO_0000223,
3099,12861,B,,,104714,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL620392,BAO_0000019,
3100,5104,B,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL620393,BAO_0000223,
3101,5105,B,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL620394,BAO_0000223,
3102,5104,B,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,4,,,1,,H,Autocuration,,,CHEMBL620395,BAO_0000223,
3103,3935,B,,,22226,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,0,,,1,,U,Autocuration,,,CHEMBL620396,BAO_0000019,
3104,13657,B,NG108-15,,105030,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,4,433.0,,1,,H,Expert,,,CHEMBL620582,BAO_0000219,
3105,10369,B,,,105030,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,4,,,1,,H,Autocuration,,,CHEMBL620583,BAO_0000218,
3106,10369,B,,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,4,,,1,,H,Autocuration,,,CHEMBL620584,BAO_0000019,
3107,12918,B,,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,4,,,1,,H,Autocuration,,,CHEMBL620585,BAO_0000224,
3108,12918,B,,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL620586,BAO_0000224,
3109,10369,B,,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,4,,,1,,H,Autocuration,,,CHEMBL620587,BAO_0000019,
3110,773,B,,,105030,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,4,,,1,,H,Autocuration,,,CHEMBL620588,BAO_0000019,
3111,12918,F,,,105030,5-hydroxytryptamine 3 receptor agonism in mouse,,4,,,1,,H,Autocuration,,,CHEMBL620589,BAO_0000218,
3112,10561,B,,,105030,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,4,,,1,,H,Autocuration,,,CHEMBL620590,BAO_0000219,
3113,12827,B,,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617956,BAO_0000019,
3114,12827,B,,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,4,,,1,,H,Autocuration,,,CHEMBL617957,BAO_0000019,
3115,12918,B,,,105030,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,4,,,1,,H,Autocuration,,,CHEMBL617958,BAO_0000224,
3116,273,B,,,105030,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617959,BAO_0000219,
3117,273,B,,,105030,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL617960,BAO_0000219,
3118,10561,B,,,105030,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,4,,,1,,H,Autocuration,,,CHEMBL617961,BAO_0000224,
3119,5033,B,,,105030,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,4,,,1,,H,Autocuration,,,CHEMBL617962,BAO_0000219,
3120,16429,B,N1E-115,,105030,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,4,339.0,,1,,H,Autocuration,,,CHEMBL617963,BAO_0000219,
3121,10322,B,,,11765,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,8,,,1,,H,Autocuration,,,CHEMBL617964,BAO_0000019,
3122,14331,B,,,11765,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,8,,,1,,H,Autocuration,,,CHEMBL617965,BAO_0000219,
3123,13462,B,,,10630,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,9,,Mus musculus,1,10090.0,D,Autocuration,,,CHEMBL617966,BAO_0000357,
3124,12861,B,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL857074,BAO_0000019,
3125,15086,B,,,144,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617967,BAO_0000357,
3126,12861,B,,,144,Binding activity radioligand.,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL617968,BAO_0000357,
3127,10561,B,,,104714,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617969,BAO_0000223,
3128,10561,B,,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617970,BAO_0000223,
3129,10561,B,,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617971,BAO_0000223,
3130,10561,B,,,104714,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617972,BAO_0000019,
3131,273,F,,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617973,BAO_0000019,
3132,273,F,,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617974,BAO_0000019,
3133,273,F,,2116.0,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617975,BAO_0000221,
3134,273,F,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617976,BAO_0000019,
3135,273,F,,,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617977,BAO_0000019,
3136,273,F,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617978,BAO_0000019,
3137,273,F,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,4,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617979,BAO_0000019,
3138,13047,B,CHO,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,4,449.0,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL617980,BAO_0000219,
3139,1650,B,,,104698,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617981,BAO_0000019,
3140,16288,B,,,12020,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,8,,,1,,H,Autocuration,,,CHEMBL617982,BAO_0000019,
3141,16288,B,,,12020,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,8,,,1,,H,Autocuration,,,CHEMBL617983,BAO_0000357,
3142,10254,B,,,104698,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617984,BAO_0000019,
3143,14532,B,,,104698,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,6,,,1,,H,Autocuration,,,CHEMBL617985,BAO_0000019,
3144,13392,F,,948.0,104698,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,6,,,1,,H,Autocuration,,,CHEMBL617986,BAO_0000218,
3145,13392,F,,948.0,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,6,,,1,,H,Autocuration,,,CHEMBL617987,BAO_0000019,
3146,13392,F,,948.0,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,6,,,1,,H,Autocuration,,,CHEMBL617988,BAO_0000019,
3147,13392,F,,948.0,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Heart,6,,,1,,H,Autocuration,,,CHEMBL617792,BAO_0000019,
3148,13392,F,,948.0,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,6,,,1,,H,Autocuration,,,CHEMBL617793,BAO_0000019,
3149,13392,F,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,6,,,1,,H,Autocuration,,,CHEMBL617794,BAO_0000019,
3150,13392,F,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,6,,,1,,H,Autocuration,,,CHEMBL617795,BAO_0000019,
3151,13392,F,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,6,,,1,,H,Autocuration,,,CHEMBL617796,BAO_0000019,
3152,13392,F,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,6,,,1,,H,Autocuration,,,CHEMBL617797,BAO_0000019,
3153,1089,F,,,104698,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617798,BAO_0000218,
3154,1089,F,,,104698,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,6,,,1,,H,Autocuration,,,CHEMBL617799,BAO_0000218,
3155,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617800,BAO_0000218,
3156,11454,F,,,104698,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617801,BAO_0000019,
3157,12205,F,,,104698,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617802,BAO_0000218,
3158,1089,F,,,104698,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617803,BAO_0000019,
3159,5094,B,,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,,6,,,1,,H,Autocuration,,,CHEMBL617804,BAO_0000019,
3160,2622,B,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617805,BAO_0000019,
3161,245,B,,,104698,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL617806,BAO_0000223,
3162,14788,B,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,6,,,1,,H,Autocuration,,,CHEMBL617807,BAO_0000019,
3163,14788,B,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,6,,,1,,H,Autocuration,,,CHEMBL617808,BAO_0000019,
3164,3020,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL617809,BAO_0000249,
3165,1742,B,,,104698,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,6,,,1,,H,Autocuration,,,CHEMBL617810,BAO_0000019,
3166,17394,B,,955.0,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Brain,6,,,1,,H,Autocuration,,,CHEMBL617811,BAO_0000249,
3167,17394,B,,955.0,104698,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Brain,6,,,1,,H,Autocuration,,,CHEMBL617812,BAO_0000221,
3168,17394,B,,,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,1,,H,Autocuration,,,CHEMBL617813,BAO_0000249,
3169,14286,B,,,104698,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,1,,H,Autocuration,,,CHEMBL617814,BAO_0000249,
3170,14178,B,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,6,,,1,,H,Autocuration,,,CHEMBL617698,BAO_0000019,
3171,14178,B,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617699,BAO_0000019,
3172,14178,B,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617700,BAO_0000019,
3173,14178,B,,,104698,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617701,BAO_0000223,
3174,15034,B,,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL617702,BAO_0000019,
3175,1089,B,,,104698,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,6,,,1,,H,Autocuration,,,CHEMBL617703,BAO_0000249,
3176,1089,B,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617704,BAO_0000019,
3177,16532,B,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,6,,,1,,H,Autocuration,,,CHEMBL617705,BAO_0000223,
3178,12801,B,,,104698,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617706,BAO_0000223,
3179,15194,B,NG108-15,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,6,433.0,,1,,H,Autocuration,,,CHEMBL617707,BAO_0000219,
3180,15194,B,NG108-15,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,6,433.0,,1,,H,Autocuration,,,CHEMBL617708,BAO_0000219,
3181,15194,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL617709,BAO_0000019,
3182,15194,B,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,6,,,1,,H,Autocuration,,,CHEMBL617710,BAO_0000019,
3183,15194,B,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,6,,,1,,H,Autocuration,,,CHEMBL882925,BAO_0000019,
3184,15194,B,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,6,,,1,,H,Autocuration,,,CHEMBL617711,BAO_0000019,
3185,10610,F,,,104698,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,6,,,1,,H,Autocuration,,,CHEMBL617712,BAO_0000019,
3186,10355,F,,,104698,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617713,BAO_0000019,
3187,691,F,,,104698,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,6,,,1,,H,Autocuration,,,CHEMBL617714,BAO_0000019,
3188,10611,F,,,104698,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,6,,,1,,H,Autocuration,,,CHEMBL617715,BAO_0000218,
3189,12801,F,,,104698,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,6,,,1,,H,Autocuration,,,CHEMBL617716,BAO_0000218,
3190,10609,F,,,104698,Inhibition of 5-HT evoked reflex bradycardia in rat.,,6,,,1,,H,Autocuration,,,CHEMBL617717,BAO_0000218,
3191,11454,F,,,104698,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617718,BAO_0000218,
3192,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617719,BAO_0000218,
3193,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,6,,,1,,H,Autocuration,,,CHEMBL617720,BAO_0000218,
3194,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL617721,BAO_0000218,
3195,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617722,BAO_0000218,
3196,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617723,BAO_0000218,
3197,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617724,BAO_0000218,
3198,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617725,BAO_0000218,
3199,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617726,BAO_0000218,
3200,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617727,BAO_0000218,
3201,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617728,BAO_0000218,
3202,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617729,BAO_0000218,
3203,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617730,BAO_0000218,
3204,11454,F,,,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617731,BAO_0000218,
3205,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617732,BAO_0000218,
3206,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617733,BAO_0000218,
3207,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617734,BAO_0000218,
3208,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,6,,,1,,H,Autocuration,,,CHEMBL872874,BAO_0000218,
3209,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,6,,,1,,H,Autocuration,,,CHEMBL617735,BAO_0000218,
3210,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,6,,,1,,H,Autocuration,,,CHEMBL617736,BAO_0000218,
3211,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,6,,,1,,H,Autocuration,,,CHEMBL617737,BAO_0000218,
3212,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,6,,,1,,H,Autocuration,,,CHEMBL617738,BAO_0000218,
3213,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617739,BAO_0000218,
3214,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617740,BAO_0000218,
3215,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617741,BAO_0000218,
3216,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617742,BAO_0000218,
3217,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617743,BAO_0000218,
3218,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617744,BAO_0000218,
3219,11454,F,,,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,6,,,1,,H,Autocuration,,,CHEMBL617745,BAO_0000218,
3220,670,F,,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,6,,,1,,H,Autocuration,,,CHEMBL617746,BAO_0000218,
3221,670,F,,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,6,,,1,,H,Autocuration,,,CHEMBL617747,BAO_0000218,
3222,10321,F,,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,6,,,1,,H,Autocuration,,,CHEMBL617748,BAO_0000218,
3223,10321,F,,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,6,,,1,,H,Autocuration,,,CHEMBL618909,BAO_0000218,
3224,10321,F,,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,6,,,1,,H,Autocuration,,,CHEMBL618910,BAO_0000218,
3225,10321,F,,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,6,,,1,,H,Autocuration,,,CHEMBL618911,BAO_0000218,
3226,10321,F,,,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,6,,,1,,H,Autocuration,,,CHEMBL618912,BAO_0000218,
3227,10322,F,,,104698,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,6,,,1,,H,Autocuration,,,CHEMBL618913,BAO_0000218,
3228,15412,F,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,6,,,1,,H,Autocuration,,,CHEMBL618914,BAO_0000019,
3229,15412,F,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,6,,,1,,H,Autocuration,,,CHEMBL618915,BAO_0000019,
3230,15412,B,,,104698,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL618916,BAO_0000223,
3231,15412,F,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,6,,,1,,H,Autocuration,,,CHEMBL618917,BAO_0000019,
3232,15412,B,,10000000.0,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Hippocampus,7,,,1,,D,Intermediate,,,CHEMBL618918,BAO_0000221,
3233,15412,B,,,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL618919,BAO_0000019,
3234,17394,B,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL618920,BAO_0000019,
3235,12457,B,,,104698,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL618921,BAO_0000223,
3236,12457,B,,,104698,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL618922,BAO_0000019,
3237,12205,B,,,104698,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,6,,,1,,H,Autocuration,,,CHEMBL618923,BAO_0000019,
3238,14532,B,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,6,,,1,,H,Autocuration,,,CHEMBL618924,BAO_0000019,
3239,1122,B,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL618925,BAO_0000019,
3240,5094,B,,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,,6,,,1,,H,Autocuration,,,CHEMBL618926,BAO_0000019,
3241,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618927,BAO_0000221,
3242,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618928,BAO_0000221,
3243,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618929,BAO_0000221,
3244,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618930,BAO_0000221,
3245,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618931,BAO_0000221,
3246,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619594,BAO_0000221,
3247,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619595,BAO_0000221,
3248,13961,F,,2116.0,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619596,BAO_0000221,
3249,13961,F,,2116.0,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619755,BAO_0000221,
3250,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619756,BAO_0000221,
3251,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619757,BAO_0000221,
3252,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619758,BAO_0000221,
3253,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619759,BAO_0000221,
3254,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619760,BAO_0000221,
3255,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619761,BAO_0000221,
3256,14290,F,,2116.0,20033,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619762,BAO_0000221,
3257,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619763,BAO_0000221,
3258,14290,F,,2116.0,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617868,BAO_0000221,
3259,15034,B,,,20033,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617869,BAO_0000357,
3260,5094,B,,2435.0,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL882926,BAO_0000249,
3261,5094,B,,2435.0,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617870,BAO_0000249,
3262,5399,B,,2435.0,20033,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617871,BAO_0000357,
3263,17394,B,,2435.0,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617872,BAO_0000357,
3264,17394,B,,2435.0,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617873,BAO_0000357,
3265,17394,B,,2435.0,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL617874,BAO_0000357,
3266,13961,F,,2116.0,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619067,BAO_0000221,
3267,13961,F,,2116.0,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619068,BAO_0000221,
3268,13961,F,,2116.0,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619069,BAO_0000221,
3269,16946,B,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619070,BAO_0000357,
3270,16946,B,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619071,BAO_0000357,
3271,15034,F,,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619072,BAO_0000019,
3272,15034,F,,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619073,BAO_0000019,
3273,12918,F,,,20033,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619074,BAO_0000019,
3274,16946,B,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619075,BAO_0000357,
3275,17394,B,,2435.0,20033,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619076,BAO_0000357,
3276,15034,B,,2435.0,20033,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619077,BAO_0000357,
3277,5094,B,,2435.0,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619078,BAO_0000249,
3278,5094,B,,2435.0,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619079,BAO_0000249,
3279,17358,B,,2116.0,20033,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619080,BAO_0000221,
3280,12953,B,,,20033,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,9,,Cavia porcellus,1,10141.0,D,Expert,,,CHEMBL619081,BAO_0000357,
3281,12953,B,,,20033,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619082,BAO_0000357,
3282,12953,B,,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619083,BAO_0000357,
3283,12953,B,,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619084,BAO_0000357,
3284,273,F,,2116.0,20033,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL859397,BAO_0000221,
3285,12918,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619085,BAO_0000221,
3286,12919,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619086,BAO_0000221,
3287,273,F,,2116.0,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619087,BAO_0000221,
3288,273,F,,2116.0,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619088,BAO_0000221,
3289,13181,B,,,20033,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619089,BAO_0000357,
3290,13181,B,,,168,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619090,BAO_0000357,
3291,15034,F,,,20033,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619091,BAO_0000019,
3292,5033,B,,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619092,BAO_0000357,
3293,1980,B,,,20033,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619093,BAO_0000019,
3294,13181,B,HEK293,,168,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,8,722.0,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619094,BAO_0000219,
3295,14287,B,,,20033,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619095,BAO_0000019,
3296,1317,B,,,20033,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL857988,BAO_0000357,
3297,15316,B,,,20033,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619096,BAO_0000357,
3298,16429,B,,2435.0,20033,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Striatum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619097,BAO_0000357,
3299,14818,B,,10000000.0,20033,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Hippocampus,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619098,BAO_0000221,
3300,15194,B,,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619751,BAO_0000357,
3301,15194,B,,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619752,BAO_0000357,
3302,13961,F,,2116.0,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL875096,BAO_0000221,
3303,5486,B,,,108,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,8,,,1,,H,Autocuration,,,CHEMBL619004,BAO_0000357,
3304,16209,B,,,168,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL619005,BAO_0000357,
3305,17085,B,,,168,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619006,BAO_0000019,
3306,4199,B,HeLa,,168,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,8,308.0,,1,,H,Autocuration,,,CHEMBL619007,BAO_0000219,
3307,15146,B,,,168,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619008,BAO_0000357,
3308,5213,B,,,168,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619009,BAO_0000357,
3309,4829,B,HeLa,,168,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,8,308.0,,1,,H,Autocuration,,,CHEMBL619010,BAO_0000219,
3310,17358,B,,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,8,,,1,,H,Autocuration,,,CHEMBL619011,BAO_0000357,
3311,17358,B,,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,8,,,1,,H,Autocuration,,,CHEMBL619012,BAO_0000357,
3312,16946,B,,,10622,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,8,,,1,,H,Autocuration,,,CHEMBL619013,BAO_0000219,
3313,17358,B,,,10622,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,8,,,1,,H,Autocuration,,,CHEMBL619014,BAO_0000357,
3314,268,F,,2081.0,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Cardiac atrium,8,,,1,,H,Autocuration,,,CHEMBL857503,BAO_0000019,
3315,268,F,,2081.0,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Cardiac atrium,8,,,1,,H,Autocuration,,,CHEMBL619015,BAO_0000019,
3316,15086,B,,,11249,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619016,BAO_0000357,
3317,14875,B,,10000000.0,11249,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL619017,BAO_0000221,
3318,13267,B,,10000000.0,168,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Hippocampus,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL619018,BAO_0000221,
3319,13047,B,,,168,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL619019,BAO_0000019,
3320,1650,B,,,10623,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619020,BAO_0000357,
3321,567,F,,,10623,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL619021,BAO_0000019,
3322,17358,B,,,10623,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,8,,,1,,H,Autocuration,,,CHEMBL619022,BAO_0000357,
3323,188,B,,,10623,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,8,,,1,,H,Autocuration,,,CHEMBL619023,BAO_0000357,
3324,670,F,,,10623,lntrinsic activity relative to 5-HT receptor,,8,,,1,,H,Autocuration,,,CHEMBL619024,BAO_0000019,
3325,204,F,,,10623,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,8,,,1,,H,Autocuration,,,CHEMBL619025,BAO_0000019,
3326,1946,F,,,10623,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,8,,,1,,H,Expert,,,CHEMBL619026,BAO_0000019,
3327,6398,F,,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,8,,,1,,H,Autocuration,,,CHEMBL619027,BAO_0000019,
3328,6398,F,,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,8,,,1,,H,Autocuration,,,CHEMBL619028,BAO_0000019,
3329,17358,F,,,10623,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL619029,BAO_0000019,
3330,6398,F,,,10623,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,8,,,1,,H,Autocuration,,,CHEMBL619030,BAO_0000019,
3331,11752,B,,,10623,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,8,,,1,,H,Expert,,,CHEMBL619031,BAO_0000357,
3332,809,F,,,10623,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL619032,BAO_0000019,
3333,14178,B,,,10623,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619033,BAO_0000357,
3334,567,B,,,10623,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL619034,BAO_0000357,
3335,1946,B,,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,8,,,1,,H,Autocuration,,,CHEMBL619035,BAO_0000357,
3336,1946,B,,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,8,,,1,,H,Autocuration,,,CHEMBL619036,BAO_0000357,
3337,13961,B,,,10623,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619037,BAO_0000019,
3338,6238,B,,2435.0,10623,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619038,BAO_0000249,
3339,14290,B,,,10623,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL619039,BAO_0000249,
3340,14290,B,,,10623,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,8,,,1,,H,Expert,,,CHEMBL619040,BAO_0000249,
3341,809,B,,2435.0,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619041,BAO_0000019,
3342,1578,B,,2435.0,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619042,BAO_0000019,
3343,16709,B,,2435.0,10623,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Striatum,8,,,1,,H,Expert,,,CHEMBL619043,BAO_0000249,
3344,1946,B,,2435.0,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Striatum,8,,,1,,H,Expert,,,CHEMBL619044,BAO_0000019,
3345,15253,B,,2435.0,10623,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Striatum,8,,,1,,H,Expert,,,CHEMBL619045,BAO_0000249,
3346,4535,B,,2435.0,10623,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,8,,,1,,H,Expert,,,CHEMBL619046,BAO_0000249,
3347,13961,B,,,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,8,,,1,,H,Expert,,,CHEMBL619047,BAO_0000249,
3348,17358,F,,955.0,10623,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Brain,8,,,1,,H,Autocuration,,,CHEMBL619048,BAO_0000221,
3349,15847,F,,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,8,,,1,,H,Autocuration,,,CHEMBL859398,BAO_0000019,
3350,15847,F,,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,8,,,1,,H,Autocuration,,,CHEMBL619049,BAO_0000019,
3351,670,F,,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL857886,BAO_0000019,
3352,670,F,,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL619050,BAO_0000019,
3353,1317,F,,,10623,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,8,,,1,,H,Autocuration,,,CHEMBL620591,BAO_0000019,
3354,12936,B,,,10623,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620592,BAO_0000357,
3355,4535,B,,2435.0,10623,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,8,,,1,,H,Expert,,,CHEMBL620593,BAO_0000249,
3356,14424,F,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620594,BAO_0000019,
3357,14424,F,,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,8,,,1,,H,Expert,,,CHEMBL875079,BAO_0000019,
3358,14424,F,,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,8,,,1,,H,Expert,,,CHEMBL620595,BAO_0000019,
3359,14424,F,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620596,BAO_0000019,
3360,14424,F,,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,8,,,1,,H,Autocuration,,,CHEMBL620597,BAO_0000019,
3361,14424,F,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,8,,,1,,H,Expert,,,CHEMBL620598,BAO_0000019,
3362,14424,F,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,8,,,1,,H,Expert,,,CHEMBL620599,BAO_0000218,
3363,14424,F,,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,8,,,1,,H,Autocuration,,,CHEMBL620600,BAO_0000019,
3364,1980,F,,,168,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,8,,Rattus norvegicus,1,10116.0,H,Autocuration,,,CHEMBL620601,BAO_0000019,
3365,4639,F,,,168,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,8,,,1,,H,Autocuration,,,CHEMBL620602,BAO_0000019,
3366,17358,B,,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620603,BAO_0000357,
3367,17358,B,,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,8,,,1,,H,Autocuration,,,CHEMBL620604,BAO_0000357,
3368,17358,B,,,168,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,8,,,1,,H,Autocuration,,,CHEMBL620605,BAO_0000357,
3369,1558,B,,,168,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620606,BAO_0000357,
3370,17358,F,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,1,,H,Autocuration,,,CHEMBL620607,BAO_0000019,
3371,16117,B,,,168,In vitro binding affinity towards 5-HT4 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620608,BAO_0000357,
3372,17358,F,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,1,,H,Autocuration,,,CHEMBL620609,BAO_0000019,
3373,17358,F,,,168,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620610,BAO_0000019,
3374,17358,B,,,168,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620611,BAO_0000357,
3375,17358,B,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,8,,,1,,H,Autocuration,,,CHEMBL620612,BAO_0000357,
3376,17358,B,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,8,,,1,,H,Autocuration,,,CHEMBL620613,BAO_0000357,
3377,17358,B,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,8,,,1,,H,Autocuration,,,CHEMBL620614,BAO_0000357,
3378,1274,B,,,168,Binding affinity against 5-Hydroxytryptamine 4 receptor,,8,,,1,,H,Expert,,,CHEMBL620615,BAO_0000357,
3379,10728,B,,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,6,,,1,,H,Autocuration,,,CHEMBL857075,BAO_0000249,
3380,11695,B,,,104698,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,6,,,1,,H,Autocuration,,,CHEMBL620616,BAO_0000249,
3381,11695,B,,,104698,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,6,,,1,,H,Autocuration,,,CHEMBL619411,BAO_0000249,
3382,12490,B,,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,6,,,1,,H,Autocuration,,,CHEMBL619412,BAO_0000019,
3383,11828,B,,,104698,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619413,BAO_0000019,
3384,12253,B,,10000000.0,104698,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Hippocampus,6,,,1,,H,Autocuration,,,CHEMBL619414,BAO_0000221,
3385,10561,B,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,6,,,1,,H,Autocuration,,,CHEMBL619415,BAO_0000019,
3386,10561,B,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,6,,,1,,H,Autocuration,,,CHEMBL619416,BAO_0000019,
3387,14432,F,,,104698,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,6,,,1,,H,Autocuration,,,CHEMBL619417,BAO_0000019,
3388,12936,B,,,104698,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619418,BAO_0000223,
3389,1274,B,,,104698,Binding affinity against 5-Hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619419,BAO_0000223,
3390,1980,B,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,6,,,1,,H,Autocuration,,,CHEMBL619420,BAO_0000019,
3391,670,B,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,6,,,1,,H,Autocuration,,,CHEMBL619421,BAO_0000249,
3392,968,B,,,104698,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619422,BAO_0000019,
3393,14287,B,,,104698,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,6,,,1,,H,Autocuration,,,CHEMBL619423,BAO_0000019,
3394,567,B,,,104698,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,6,,,1,,H,Autocuration,,,CHEMBL875080,BAO_0000019,
3395,13267,B,,,104698,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL619424,BAO_0000019,
3396,14826,B,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,6,,,1,,H,Autocuration,,,CHEMBL619425,BAO_0000249,
3397,15194,B,,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,6,,,1,,H,Autocuration,,,CHEMBL619426,BAO_0000223,
3398,15194,B,,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,6,,,1,,H,Autocuration,,,CHEMBL619427,BAO_0000223,
3399,10394,B,,,104698,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,7,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619645,BAO_0000223,
3400,13657,B,,,10576,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,9,,,1,,D,Expert,,,CHEMBL619646,BAO_0000249,
3401,1879,F,,955.0,12020,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Brain,8,,,1,,H,Autocuration,,,CHEMBL619647,BAO_0000221,
3402,1879,F,,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619648,BAO_0000019,
3403,1879,F,,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,8,,,1,,H,Autocuration,,,CHEMBL619165,BAO_0000019,
3404,204,F,,,12020,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620719,BAO_0000218,
3405,1879,B,,,12020,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL872924,BAO_0000019,
3406,1879,B,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620720,BAO_0000357,
3407,1879,B,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL620721,BAO_0000019,
3408,1879,B,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL620722,BAO_0000019,
3409,10641,B,,,104698,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,6,,,1,,H,Autocuration,,,CHEMBL620723,BAO_0000019,
3410,773,B,,,12020,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,8,,,1,,H,Autocuration,,,CHEMBL620724,BAO_0000019,
3411,11952,B,,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,6,,,1,,H,Autocuration,,,CHEMBL620725,BAO_0000249,
3412,14145,F,,,12020,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL620726,BAO_0000019,
3413,17066,B,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Expert,,,CHEMBL620727,BAO_0000357,
3414,6398,B,,,104714,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,4,,,1,,H,Autocuration,,,CHEMBL620728,BAO_0000223,
3415,10321,B,,,22226,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,0,,,1,,U,Autocuration,,,CHEMBL620729,BAO_0000019,
3416,511,F,,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,4,,,1,,H,Autocuration,,,CHEMBL858288,BAO_0000019,
3417,4639,B,,,104714,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL620730,BAO_0000223,
3418,4639,B,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL620731,BAO_0000223,
3419,4639,F,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620732,BAO_0000019,
3420,4639,F,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618042,BAO_0000019,
3421,4639,F,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618043,BAO_0000019,
3422,1558,B,,,104714,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL618044,BAO_0000223,
3423,268,F,,,104714,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,4,,,1,,H,Autocuration,,,CHEMBL618045,BAO_0000019,
3424,2474,B,,,104714,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL618046,BAO_0000223,
3425,5067,F,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,4,,,1,,H,Autocuration,,,CHEMBL618047,BAO_0000019,
3426,5067,F,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,4,,,1,,H,Autocuration,,,CHEMBL875084,BAO_0000019,
3427,5067,F,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,4,,,1,,H,Autocuration,,,CHEMBL618048,BAO_0000019,
3428,5067,B,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,4,,,1,,H,Autocuration,,,CHEMBL618049,BAO_0000223,
3429,5067,F,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,4,,,1,,H,Autocuration,,,CHEMBL619764,BAO_0000019,
3430,5067,F,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,4,,,1,,H,Autocuration,,,CHEMBL619765,BAO_0000019,
3431,5067,F,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,4,,,1,,H,Autocuration,,,CHEMBL619766,BAO_0000019,
3432,5067,B,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,4,,,1,,H,Autocuration,,,CHEMBL619767,BAO_0000223,
3433,5067,B,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,4,,,1,,H,Autocuration,,,CHEMBL619768,BAO_0000223,
3434,5067,F,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,4,,,1,,H,Autocuration,,,CHEMBL619769,BAO_0000019,
3435,5067,B,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,4,,,1,,H,Autocuration,,,CHEMBL619770,BAO_0000223,
3436,5067,B,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL619771,BAO_0000223,
3437,14331,B,,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,4,,,1,,H,Autocuration,,,CHEMBL619772,BAO_0000219,
3438,5067,B,,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,4,,,1,,H,Autocuration,,,CHEMBL619773,BAO_0000223,
3439,6179,B,NG108-15,,104714,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,4,433.0,,1,,H,Autocuration,,,CHEMBL619774,BAO_0000219,
3440,4265,B,,,104714,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,4,,,1,,H,Autocuration,,,CHEMBL875083,BAO_0000019,
3441,4265,B,NG108-15,,104714,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,4,433.0,,1,,H,Autocuration,,,CHEMBL620718,BAO_0000219,
3442,17358,B,,,104714,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,4,,,1,,H,Autocuration,,,CHEMBL618127,BAO_0000223,
3443,17358,B,,,104714,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,4,,,1,,H,Autocuration,,,CHEMBL618128,BAO_0000223,
3444,13628,B,,,104714,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,4,,,1,,H,Autocuration,,,CHEMBL618129,BAO_0000219,
3445,4612,B,,,104714,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,4,,,1,,H,Autocuration,,,CHEMBL618130,BAO_0000223,
3446,17358,F,,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,4,,,1,,H,Autocuration,,,CHEMBL618131,BAO_0000019,
3447,4639,F,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618132,BAO_0000019,
3448,4639,F,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618133,BAO_0000019,
3449,4639,F,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618134,BAO_0000019,
3450,4639,F,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618135,BAO_0000019,
3451,511,B,,,104714,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,4,,,1,,H,Autocuration,,,CHEMBL618136,BAO_0000223,
3452,1479,B,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL618137,BAO_0000223,
3453,1317,B,,,104714,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,4,,,1,,H,Autocuration,,,CHEMBL618138,BAO_0000223,
3454,12146,B,,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,4,,,1,,H,Autocuration,,,CHEMBL618139,BAO_0000223,
3455,12146,B,,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,4,,,1,,H,Autocuration,,,CHEMBL618140,BAO_0000223,
3456,13969,B,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,4,,,1,,H,Autocuration,,,CHEMBL618141,BAO_0000223,
3457,13392,B,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,,8,,,1,,H,Expert,,,CHEMBL873478,BAO_0000357,
3458,13392,B,,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor,,6,,,1,,H,Autocuration,,,CHEMBL618142,BAO_0000223,
3459,14159,B,,,144,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618143,BAO_0000357,
3460,1558,B,,,144,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618144,BAO_0000357,
3461,16655,B,,,144,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618145,BAO_0000357,
3462,13020,B,,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,4,,,1,,H,Autocuration,,,CHEMBL618146,BAO_0000223,
3463,13021,B,,,104714,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,4,,,1,,H,Autocuration,,,CHEMBL618147,BAO_0000223,
3464,13020,B,,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,4,,,1,,H,Autocuration,,,CHEMBL618148,BAO_0000223,
3465,10321,B,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,8,,,1,,H,Autocuration,,,CHEMBL618149,BAO_0000019,
3466,15818,B,,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL872927,BAO_0000357,
3467,15818,B,,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618150,BAO_0000357,
3468,17358,B,,,144,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,8,,,1,,H,Autocuration,,,CHEMBL618151,BAO_0000357,
3469,2222,B,,,144,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,8,,,1,,H,Autocuration,,,CHEMBL875094,BAO_0000357,
3470,10322,B,,,144,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,8,,,1,,H,Autocuration,,,CHEMBL618152,BAO_0000019,
3471,16117,B,,,144,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL618153,BAO_0000357,
3472,17200,B,,,144,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618888,BAO_0000357,
3473,17358,F,,,144,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,8,,,1,,H,Autocuration,,,CHEMBL618889,BAO_0000019,
3474,16700,B,,,144,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL618890,BAO_0000357,
3475,1980,B,,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,8,,,1,,H,Autocuration,,,CHEMBL618891,BAO_0000019,
3476,1980,B,,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,8,,,1,,H,Autocuration,,,CHEMBL619054,BAO_0000019,
3477,12409,B,,,104714,Binding affinity against the 5-hydroxytryptamine 3 receptor,,4,,,1,,H,Autocuration,,,CHEMBL619055,BAO_0000223,
3478,4365,B,,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,,8,,,1,,H,Autocuration,,,CHEMBL619056,BAO_0000357,
3479,4365,F,,,144,Percent efficacy against 5-hydroxytryptamine 3A receptor,,8,,,1,,H,Autocuration,,,CHEMBL619057,BAO_0000019,
3480,4365,B,,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,,8,,,1,,H,Autocuration,,,CHEMBL619058,BAO_0000357,
3481,6769,F,Oocytes,,12020,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619059,BAO_0000219,
3482,6769,F,Oocytes,,12020,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619060,BAO_0000219,
3483,6769,F,Oocytes,,12020,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL875095,BAO_0000219,
3484,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619061,BAO_0000221,
3485,809,F,,2116.0,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619062,BAO_0000221,
3486,14290,F,,,20033,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619063,BAO_0000019,
3487,17358,B,,2116.0,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619064,BAO_0000221,
3488,17358,B,,,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619065,BAO_0000357,
3489,17358,B,,2116.0,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Ileum,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL619066,BAO_0000221,
3490,17386,B,,2116.0,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,8,,,1,,H,Autocuration,,,CHEMBL619775,BAO_0000221,
3491,3269,B,,,10209,Affinity against 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619776,BAO_0000357,
3492,7721,B,,,104841,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619777,BAO_0000224,
3493,7721,B,,,104841,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619778,BAO_0000224,
3494,9117,B,,2116.0,104841,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Ileum,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619779,BAO_0000221,
3495,7721,B,,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619780,BAO_0000224,
3496,7721,B,,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619166,BAO_0000224,
3497,15796,F,,,104841,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619167,BAO_0000019,
3498,15796,F,,,104841,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL619168,BAO_0000019,
3499,15650,B,,2081.0,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Cardiac atrium,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619169,BAO_0000219,
3500,15650,B,,2081.0,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Cardiac atrium,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619170,BAO_0000219,
3501,6866,F,,,104841,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,5,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL619171,BAO_0000019,
3502,15650,F,,2081.0,168,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Cardiac atrium,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619172,BAO_0000219,
3503,10063,B,,,22226,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619173,BAO_0000019,
3504,12665,B,,,22226,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619174,BAO_0000019,
3505,7504,B,,,104705,5-hydroxytryptamine receptor binding affinity was determined in rats,,4,,,1,,H,Autocuration,,,CHEMBL619175,BAO_0000019,
3506,7504,B,,,104705,Binding affinity at rat 5-hydroxytryptamine receptor.,,4,,,1,,H,Autocuration,,,CHEMBL619176,BAO_0000224,
3507,7038,B,,,104705,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,4,,,1,,H,Autocuration,,,CHEMBL619177,BAO_0000019,
3508,7626,B,,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,4,,,1,,H,Autocuration,,,CHEMBL619178,BAO_0000224,
3509,7626,B,,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,4,,,1,,H,Autocuration,,,CHEMBL619179,BAO_0000224,
3510,7185,F,,945.0,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Stomach,4,,,1,,H,Autocuration,,,CHEMBL619180,BAO_0000019,
3511,7185,F,,945.0,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Stomach,4,,,1,,H,Autocuration,,,CHEMBL619181,BAO_0000019,
3512,7185,F,,,104705,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,4,,,1,,H,Autocuration,,,CHEMBL619182,BAO_0000019,
3513,6960,B,,,104705,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,4,,,1,,H,Autocuration,,,CHEMBL619183,BAO_0000224,
3514,6960,B,,,104705,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,4,,,1,,H,Autocuration,,,CHEMBL619184,BAO_0000224,
3515,12416,B,,10000000.0,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL619185,BAO_0000221,
3516,15753,B,,,12198,Binding affinity for rat 5-hydroxytryptamine transporter.,,8,,,1,,H,Expert,,,CHEMBL619186,BAO_0000357,
3517,8062,B,,,104705,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,4,,,1,,H,Autocuration,,,CHEMBL619187,BAO_0000019,
3518,9036,B,,,104705,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619188,BAO_0000019,
3519,15067,B,,,104705,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619189,BAO_0000224,
3520,15753,F,,955.0,12198,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Brain,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619190,BAO_0000019,
3521,15753,F,,2037.0,12198,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Cerebellum,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619191,BAO_0000221,
3522,15295,B,,,104705,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619192,BAO_0000019,
3523,6347,B,,,104705,Percent binding affinity against 5-hydroxytryptamine receptor,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619193,BAO_0000224,
3524,6763,B,,,22226,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,0,,,1,,U,Autocuration,,,CHEMBL619194,BAO_0000019,
3525,12092,B,,,104705,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619195,BAO_0000224,
3526,1579,B,,,104705,Affinity against 5-hydroxytryptamine receptor was determined,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619196,BAO_0000224,
3527,1579,B,,945.0,104705,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Stomach,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619197,BAO_0000019,
3528,5963,B,,,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619198,BAO_0000219,
3529,5963,B,,,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL875081,BAO_0000219,
3530,5030,B,,,18065,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,8,,,1,,H,Autocuration,,,CHEMBL884712,BAO_0000357,
3531,15796,B,,,121,Inhibition of 5-hydroxytryptamine reuptake,,8,,,1,,H,Expert,,,CHEMBL884710,BAO_0000357,
3532,15413,F,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,8,,,1,,H,Autocuration,,,CHEMBL619199,BAO_0000019,
3533,15413,F,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,8,,,1,,H,Autocuration,,,CHEMBL619200,BAO_0000019,
3534,15413,F,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,8,,,1,,H,Autocuration,,,CHEMBL619201,BAO_0000019,
3535,12409,F,,,18065,Tested for 5-hydroxytryptamine receptor uptake,,8,,,1,,H,Autocuration,,,CHEMBL619202,BAO_0000019,
3536,16909,B,CHO,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619203,BAO_0000219,
3537,16909,F,,,51,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619204,BAO_0000019,
3538,15629,B,,,10576,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,8,,Homo sapiens,1,9606.0,H,Autocuration,,,CHEMBL619205,BAO_0000249,
3539,15629,B,,,10576,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,8,,,1,,H,Autocuration,,,CHEMBL619206,BAO_0000357,
3540,15629,B,,,10576,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,8,,,1,,H,Expert,,,CHEMBL619207,BAO_0000249,
3541,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619208,BAO_0000019,
3542,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619209,BAO_0000019,
3543,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619210,BAO_0000019,
3544,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619211,BAO_0000019,
3545,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL619212,BAO_0000019,
3546,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620681,BAO_0000019,
3547,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620682,BAO_0000019,
3548,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620683,BAO_0000019,
3549,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620684,BAO_0000019,
3550,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620685,BAO_0000019,
3551,10034,F,,2435.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,8,,,1,,H,Autocuration,,,CHEMBL620686,BAO_0000019,
3552,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620687,BAO_0000019,
3553,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620688,BAO_0000019,
3554,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620689,BAO_0000019,
3555,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620690,BAO_0000019,
3556,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620691,BAO_0000019,
3557,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620692,BAO_0000019,
3558,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL620693,BAO_0000019,
3559,1274,B,,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Expert,,,CHEMBL620694,BAO_0000357,
3560,17358,F,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,1,,H,Autocuration,,,CHEMBL857986,BAO_0000019,
3561,14532,B,,,168,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,8,,,1,,H,Autocuration,,,CHEMBL620695,BAO_0000357,
3562,16989,B,,,168,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Expert,,,CHEMBL620696,BAO_0000357,
3563,17200,B,,,168,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620697,BAO_0000357,
3564,15779,B,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620698,BAO_0000357,
3565,15779,B,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,8,,,1,,H,Autocuration,,,CHEMBL620699,BAO_0000357,
3566,15779,B,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,8,,,1,,H,Autocuration,,,CHEMBL620700,BAO_0000357,
3567,15650,B,COS-7,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,8,643.0,,1,,H,Autocuration,,,CHEMBL620701,BAO_0000219,
3568,15650,B,COS-7,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,8,643.0,,1,,H,Autocuration,,,CHEMBL875082,BAO_0000219,
3569,15650,B,COS-7,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,8,643.0,,1,,H,Autocuration,,,CHEMBL620702,BAO_0000219,
3570,15650,B,COS-7,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,8,643.0,,1,,H,Autocuration,,,CHEMBL620703,BAO_0000219,
3571,17046,B,C6,,168,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,8,673.0,,1,,H,Autocuration,,,CHEMBL620704,BAO_0000219,
3572,17046,B,C6,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,8,673.0,,1,,H,Expert,,,CHEMBL620705,BAO_0000219,
3573,15650,B,C6,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,8,673.0,,1,,H,Expert,,,CHEMBL620706,BAO_0000219,
3574,17046,B,C6,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,8,673.0,,1,,H,Expert,,,CHEMBL620707,BAO_0000219,
3575,17066,B,,,10624,Binding affinity towards 5-hydroxytryptamine 5 receptor,,8,,,1,,H,Expert,,,CHEMBL620708,BAO_0000357,
3576,17200,B,,,105,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620709,BAO_0000357,
3577,16146,B,,,10624,Binding affinity against 5-hydroxytryptamine 5A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620710,BAO_0000357,
3578,15250,B,CHO,,10624,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL620711,BAO_0000219,
3579,6491,B,,,10624,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620712,BAO_0000357,
3580,17066,B,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620713,BAO_0000357,
3581,17066,B,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620714,BAO_0000357,
3582,4234,B,,,10624,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620715,BAO_0000357,
3583,6013,B,,,10624,Binding affinity towards 5-HT5A receptor,,8,,,1,,H,Autocuration,,,CHEMBL620716,BAO_0000357,
3584,17175,B,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,8,,,1,,H,Expert,,,CHEMBL620717,BAO_0000357,
3585,15818,B,,,10624,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618072,BAO_0000357,
3586,6166,B,,,10624,Binding affinity towards cloned human 5-HT5A receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL857987,BAO_0000357,
3587,15779,B,HEK293,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL618073,BAO_0000219,
3588,15779,B,HEK293,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,8,722.0,,1,,H,Autocuration,,,CHEMBL618074,BAO_0000219,
3589,5213,B,HEK293,,10624,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,8,722.0,,1,,H,Autocuration,,,CHEMBL618075,BAO_0000219,
3590,17066,B,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618076,BAO_0000357,
3591,17066,B,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618077,BAO_0000357,
3592,17066,B,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618078,BAO_0000357,
3593,17066,B,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL881821,BAO_0000357,
3594,17066,B,,,10625,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618079,BAO_0000357,
3595,17175,B,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,8,,,1,,H,Expert,,,CHEMBL618080,BAO_0000357,
3596,16190,B,HEK293,,10576,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL618081,BAO_0000219,
3597,16190,B,HEK293,,10626,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,8,722.0,,1,,H,Autocuration,,,CHEMBL618082,BAO_0000219,
3598,4820,B,,,10624,Binding affinity towards 5-HT5a receptor,,8,,,1,,H,Expert,,,CHEMBL618083,BAO_0000357,
3599,17066,B,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618084,BAO_0000357,
3600,17066,B,,,10624,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,8,,,1,,H,Expert,,,CHEMBL618085,BAO_0000357,
3601,17175,B,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,8,,,1,,H,Expert,,,CHEMBL618086,BAO_0000357,
3602,16633,B,,,10624,Binding affinities against 5-hydroxytryptamine 5A receptor,,8,,,1,,H,Autocuration,,,CHEMBL875092,BAO_0000357,
3603,16633,B,,,10624,Binding affinities towards 5-hydroxytryptamine 5A receptor,,8,,,1,,H,Autocuration,,,CHEMBL618087,BAO_0000357,
3604,16700,B,,,10624,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL872926,BAO_0000357,
3605,4639,F,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,4,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618088,BAO_0000019,
3606,5486,B,,,104714,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,4,,,1,,H,Autocuration,,,CHEMBL618089,BAO_0000223,
3607,16146,B,,,10627,Inhibition of human 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618090,BAO_0000357,
3608,17273,B,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618091,BAO_0000357,
3609,17687,B,,,10627,Inhibition against human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618092,BAO_0000357,
3610,6491,B,,,10627,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618093,BAO_0000357,
3611,16190,B,HeLa,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,8,308.0,,1,,H,Expert,,,CHEMBL618094,BAO_0000219,
3612,17066,B,,,10627,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618095,BAO_0000357,
3613,17066,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL875093,BAO_0000357,
3614,17066,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618096,BAO_0000357,
3615,17066,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618118,BAO_0000357,
3616,3555,B,,,10627,Binding affinity against 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618119,BAO_0000357,
3617,5808,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL618120,BAO_0000357,
3618,6013,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618121,BAO_0000357,
3619,15818,B,HEK293,,10627,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,8,722.0,,1,,H,Expert,,,CHEMBL618122,BAO_0000219,
3620,16209,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618123,BAO_0000357,
3621,3935,B,HEK293,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL618124,BAO_0000219,
3622,15818,B,,,10627,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618125,BAO_0000357,
3623,3805,B,HEK293,,10627,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618126,BAO_0000219,
3624,16441,B,,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,8,,,1,,H,Expert,,,CHEMBL618236,BAO_0000019,
3625,16441,B,,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,8,,,1,,H,Expert,,,CHEMBL618237,BAO_0000019,
3626,6786,B,COS-7,,10627,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,8,643.0,,1,,H,Expert,,,CHEMBL618238,BAO_0000219,
3627,4234,B,,,10627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618239,BAO_0000357,
3628,17085,B,,,10627,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL618240,BAO_0000019,
3629,17200,B,,,10627,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,8,,,1,,H,Autocuration,,,CHEMBL618241,BAO_0000357,
3630,17451,B,HEK293,,10627,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,8,722.0,,1,,H,Autocuration,,,CHEMBL859399,BAO_0000219,
3631,3935,F,,,10627,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,8,,,1,,H,Autocuration,,,CHEMBL618242,BAO_0000019,
3632,5033,B,,,10627,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL857991,BAO_0000357,
3633,4540,B,,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL619951,BAO_0000357,
3634,4540,B,HeLa,,10627,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619952,BAO_0000219,
3635,4540,B,HeLa,,10627,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,9,308.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619953,BAO_0000219,
3636,17296,B,HeLa,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,8,308.0,,1,,H,Autocuration,,,CHEMBL619954,BAO_0000219,
3637,17296,B,HeLa,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,8,308.0,,1,,H,Autocuration,,,CHEMBL619955,BAO_0000219,
3638,17296,B,HeLa,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,8,308.0,,1,,H,Autocuration,,,CHEMBL619956,BAO_0000219,
3639,15779,B,CHO,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL619957,BAO_0000219,
3640,15779,B,HEK293,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL619958,BAO_0000219,
3641,15779,B,HEK293,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,8,722.0,,1,,H,Autocuration,,,CHEMBL620627,BAO_0000219,
3642,15779,B,HEK293,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,8,722.0,,1,,H,Autocuration,,,CHEMBL620628,BAO_0000219,
3643,15779,B,HeLa,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,8,308.0,,1,,H,Autocuration,,,CHEMBL620629,BAO_0000219,
3644,6166,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620630,BAO_0000357,
3645,17451,B,HeLa,,10627,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,8,308.0,,1,,H,Autocuration,,,CHEMBL620782,BAO_0000219,
3646,15316,B,,,10627,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620783,BAO_0000357,
3647,4199,B,,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL620784,BAO_0000357,
3648,15146,B,HeLa,,10627,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,8,308.0,,1,,H,Expert,,,CHEMBL620785,BAO_0000219,
3649,5213,B,,,10627,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,8,,,1,,H,Autocuration,,,CHEMBL857992,BAO_0000357,
3650,16429,B,,,10627,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620786,BAO_0000219,
3651,14818,B,HeLa,,10627,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,8,308.0,,1,,H,Autocuration,,,CHEMBL620787,BAO_0000219,
3652,4829,B,HeLa,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,8,308.0,,1,,H,Autocuration,,,CHEMBL620788,BAO_0000219,
3653,4829,B,HeLa,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,8,308.0,,1,,H,Autocuration,,,CHEMBL620789,BAO_0000219,
3654,4829,B,HeLa,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,8,308.0,,1,,H,Autocuration,,,CHEMBL620790,BAO_0000219,
3655,15250,B,CHO,,10628,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL620791,BAO_0000219,
3656,14423,B,,,10628,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL620792,BAO_0000019,
3657,15086,B,,,10628,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620793,BAO_0000357,
3658,4342,B,,,10628,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620794,BAO_0000357,
3659,16190,B,HeLa,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,9,308.0,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL620795,BAO_0000219,
3660,4820,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL620796,BAO_0000357,
3661,4639,B,,,10627,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,8,,,1,,H,Autocuration,,,CHEMBL620797,BAO_0000357,
3662,17066,F,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620798,BAO_0000019,
3663,6011,B,,,10627,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL620799,BAO_0000357,
3664,17066,B,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL620800,BAO_0000357,
3665,17515,B,,,10627,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL620801,BAO_0000357,
3666,5014,B,,,10627,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL875100,BAO_0000357,
3667,4373,B,,,10627,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620802,BAO_0000357,
3668,17066,F,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Expert,,,CHEMBL620803,BAO_0000019,
3669,17066,F,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,8,,,1,,H,Expert,,,CHEMBL620804,BAO_0000019,
3670,4373,B,,,10627,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620805,BAO_0000357,
3671,4687,B,,,10627,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620806,BAO_0000357,
3672,16946,B,,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,8,,,1,,H,Autocuration,,,CHEMBL620807,BAO_0000357,
3673,16946,B,,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,8,,,1,,H,Autocuration,,,CHEMBL620808,BAO_0000357,
3674,16633,B,,,10627,Binding affinities against 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620809,BAO_0000357,
3675,16633,B,,,10627,Binding affinities towards 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620810,BAO_0000357,
3676,17066,B,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620811,BAO_0000357,
3677,16700,B,,,10627,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL620812,BAO_0000357,
3678,3269,B,,,10627,Affinity against 5-hydroxytryptamine 6 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620813,BAO_0000357,
3679,5486,B,,,10627,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,8,,,1,,H,Autocuration,,,CHEMBL620814,BAO_0000357,
3680,16146,B,,,10209,Inhibition of human 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620815,BAO_0000357,
3681,5014,B,HEK293,,10209,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,8,722.0,,1,,H,Autocuration,,,CHEMBL620816,BAO_0000219,
3682,15463,B,,,10209,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620817,BAO_0000357,
3683,3805,B,,,10209,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,8,,,1,,H,Autocuration,,,CHEMBL620818,BAO_0000357,
3684,5014,B,HEK293,,10209,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,8,722.0,,1,,H,Expert,,,CHEMBL620819,BAO_0000219,
3685,6491,B,,,10209,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620820,BAO_0000357,
3686,16190,B,CHO,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL620821,BAO_0000219,
3687,17066,B,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620822,BAO_0000357,
3688,17066,B,,,10209,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620823,BAO_0000357,
3689,3555,B,,,10209,Binding affinity against 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620824,BAO_0000357,
3690,6588,B,CHO,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,8,449.0,,1,,H,Expert,,,CHEMBL620825,BAO_0000219,
3691,15463,B,,,10209,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL872930,BAO_0000357,
3692,6013,B,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620826,BAO_0000357,
3693,16209,B,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620827,BAO_0000357,
3694,3935,B,,,10209,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620828,BAO_0000357,
3695,15818,B,,,10209,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620829,BAO_0000357,
3696,5014,B,HEK293,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,8,722.0,,1,,H,Expert,,,CHEMBL620830,BAO_0000219,
3697,16441,B,,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,8,,,1,,H,Expert,,,CHEMBL620831,BAO_0000019,
3698,16441,B,,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,8,,,1,,H,Expert,,,CHEMBL620832,BAO_0000019,
3699,4234,B,,,10209,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621548,BAO_0000357,
3700,17085,B,,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL621549,BAO_0000019,
3701,17200,B,,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,8,,,1,,H,Autocuration,,,CHEMBL621550,BAO_0000357,
3702,17451,B,CHO,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,8,449.0,,1,,H,Autocuration,,,CHEMBL621551,BAO_0000219,
3703,17085,B,,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,8,,,1,,H,Autocuration,,,CHEMBL621552,BAO_0000019,
3704,5104,B,,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL857077,BAO_0000357,
3705,5104,B,,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL618158,BAO_0000357,
3706,5033,B,COS-7,,10209,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,9,643.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618159,BAO_0000219,
3707,5486,B,COS-7,,10209,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,8,643.0,,1,,H,Autocuration,,,CHEMBL875101,BAO_0000219,
3708,4540,B,HEK293,,10209,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618160,BAO_0000219,
3709,6166,B,,,10209,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,8,,,1,,H,Expert,,,CHEMBL618161,BAO_0000357,
3710,17342,B,HEK293,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL618162,BAO_0000219,
3711,17342,B,,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,8,,,1,,H,Expert,,,CHEMBL618163,BAO_0000357,
3712,17296,B,,,10209,Binding affinity against 5-hydroxytryptamine 7 human receptors,,8,,,1,,H,Autocuration,,,CHEMBL618164,BAO_0000357,
3713,16429,B,,,10209,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,8,,,1,,H,Expert,,,CHEMBL618165,BAO_0000219,
3714,15779,B,HEK293,,10209,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL618166,BAO_0000219,
3715,15779,B,HEK293,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL857989,BAO_0000219,
3716,15779,B,HEK293,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL619888,BAO_0000219,
3717,15779,B,HEK293,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL619889,BAO_0000219,
3718,15779,B,HEK293,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,8,722.0,,1,,H,Autocuration,,,CHEMBL619890,BAO_0000219,
3719,17451,B,CHO,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,8,449.0,,1,,H,Autocuration,,,CHEMBL619891,BAO_0000219,
3720,4199,B,HEK293,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,8,722.0,,1,,H,Autocuration,,,CHEMBL619892,BAO_0000219,
3721,4199,B,HEK293,,10209,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,9,722.0,,1,,D,Expert,,,CHEMBL619893,BAO_0000219,
3722,4199,B,HEK293,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,8,722.0,,1,,H,Autocuration,,,CHEMBL619894,BAO_0000219,
3723,3680,B,HEK293,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,9,722.0,,1,,D,Intermediate,,,CHEMBL619895,BAO_0000219,
3724,3680,B,,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,9,,,1,,D,Intermediate,,,CHEMBL619896,BAO_0000357,
3725,15316,B,COS-7,,10209,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,8,643.0,,1,,H,Autocuration,,,CHEMBL619897,BAO_0000219,
3726,15146,B,HEK293,,10209,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,8,722.0,,1,,H,Autocuration,,,CHEMBL619898,BAO_0000219,
3727,5213,B,HEK293,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,8,722.0,,1,,H,Expert,,,CHEMBL619899,BAO_0000219,
3728,5213,B,HEK293,,10209,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,8,722.0,,1,,H,Autocuration,,,CHEMBL619900,BAO_0000219,
3729,14818,B,HEK293,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619901,BAO_0000219,
3730,14818,B,HEK293,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,8,722.0,,1,,H,Autocuration,,,CHEMBL620580,BAO_0000219,
3731,14818,B,HEK293,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,8,722.0,,1,,H,Autocuration,,,CHEMBL620581,BAO_0000219,
3732,4829,B,HEK293,,10209,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,8,722.0,,1,,H,Autocuration,,,CHEMBL620733,BAO_0000219,
3733,17200,B,,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,9,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL620734,BAO_0000357,
3734,17066,B,,,10022,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL620735,BAO_0000357,
3735,14025,B,,,10209,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL620736,BAO_0000019,
3736,15250,B,CHO,,11923,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL620737,BAO_0000219,
3737,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620738,BAO_0000219,
3738,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620739,BAO_0000219,
3739,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620740,BAO_0000219,
3740,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL620741,BAO_0000219,
3741,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL620742,BAO_0000219,
3742,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,8,449.0,,1,,H,Autocuration,,,CHEMBL620743,BAO_0000219,
3743,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620744,BAO_0000219,
3744,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620745,BAO_0000219,
3745,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,8,449.0,,1,,H,Autocuration,,,CHEMBL620746,BAO_0000219,
3746,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL620747,BAO_0000219,
3747,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL620748,BAO_0000219,
3748,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,8,449.0,,1,,H,Autocuration,,,CHEMBL620749,BAO_0000219,
3749,17066,B,,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL620750,BAO_0000357,
3750,17066,B,,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620751,BAO_0000357,
3751,17386,B,,,11923,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL620752,BAO_0000357,
3752,14423,B,,,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL872929,BAO_0000019,
3753,15874,B,,,11923,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620753,BAO_0000357,
3754,15874,B,,,11923,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620754,BAO_0000357,
3755,16372,B,CHO,,11923,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,9,449.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620755,BAO_0000219,
3756,4622,B,,,11923,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620756,BAO_0000357,
3757,15086,B,,,11923,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL620757,BAO_0000357,
3758,16372,B,CHO,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,8,449.0,,1,,H,Autocuration,,,CHEMBL620758,BAO_0000219,
3759,16372,B,CHO,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,8,449.0,,1,,H,Autocuration,,,CHEMBL620759,BAO_0000219,
3760,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,8,449.0,,1,,H,Autocuration,,,CHEMBL620760,BAO_0000219,
3761,16372,B,CHO,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,8,449.0,,1,,H,Autocuration,,,CHEMBL620761,BAO_0000219,
3762,17386,F,,2116.0,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,8,,,1,,H,Autocuration,,,CHEMBL620762,BAO_0000221,
3763,17386,F,,2116.0,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,8,,,1,,H,Autocuration,,,CHEMBL620763,BAO_0000221,
3764,17386,F,,2116.0,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Ileum,8,,,1,,H,Autocuration,,,CHEMBL620764,BAO_0000221,
3765,5831,B,,,11923,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL857990,BAO_0000249,
3766,4342,B,,,11923,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL620765,BAO_0000357,
3767,17319,B,,,11923,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,8,,,1,,H,Expert,,,CHEMBL620766,BAO_0000357,
3768,17342,B,,1898.0,11923,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Hypothalamus,8,,,1,,H,Expert,,,CHEMBL620767,BAO_0000019,
3769,17342,B,,,11923,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,8,,,1,,H,Autocuration,,,CHEMBL620768,BAO_0000357,
3770,3680,B,,1898.0,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Hypothalamus,8,,,1,,H,Expert,,,CHEMBL619051,BAO_0000249,
3771,3680,B,,,11923,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL619052,BAO_0000357,
3772,17319,F,HEK293,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,9,722.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619053,BAO_0000219,
3773,17319,F,HEK293,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,9,722.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619703,BAO_0000219,
3774,17319,F,HEK293,,11923,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,9,722.0,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL619704,BAO_0000219,
3775,4820,B,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL619851,BAO_0000357,
3776,4639,B,,,10209,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,8,,,1,,H,Autocuration,,,CHEMBL619852,BAO_0000357,
3777,6011,B,,,10209,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,8,,,1,,H,Autocuration,,,CHEMBL619853,BAO_0000357,
3778,17066,B,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619854,BAO_0000357,
3779,17066,B,,,10209,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL619855,BAO_0000357,
3780,17515,B,,,10209,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL619856,BAO_0000357,
3781,4373,B,,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL619857,BAO_0000357,
3782,17066,F,,,10209,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,8,,,1,,H,Expert,,,CHEMBL619858,BAO_0000019,
3783,4373,B,,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL619859,BAO_0000357,
3784,4373,B,,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,8,,,1,,H,Autocuration,,,CHEMBL619860,BAO_0000357,
3785,4687,B,,,10209,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619861,BAO_0000357,
3786,17342,B,,,10209,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL619862,BAO_0000357,
3787,16946,B,,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,8,,,1,,H,Autocuration,,,CHEMBL619863,BAO_0000357,
3788,16946,B,,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,8,,,1,,H,Autocuration,,,CHEMBL619864,BAO_0000357,
3789,16633,B,,,10209,Binding affinities against 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL872928,BAO_0000357,
3790,16633,B,,,10209,Binding affinities towards 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Autocuration,,,CHEMBL619865,BAO_0000357,
3791,17066,B,,,10209,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,8,,,1,,H,Expert,,,CHEMBL619866,BAO_0000357,
3792,16700,B,,,10209,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,8,,,1,,H,Autocuration,,,CHEMBL619867,BAO_0000357,
3793,17386,B,,2116.0,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,8,,,1,,H,Autocuration,,,CHEMBL619868,BAO_0000221,
3794,14080,F,,,55,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,8,,,1,,H,Autocuration,,,CHEMBL619869,BAO_0000019,
3795,14080,F,,,55,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619870,BAO_0000019,
3796,409,B,,,55,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,8,,,1,,H,Autocuration,,,CHEMBL619871,BAO_0000357,
3797,409,B,,,55,In vitro inhibition of human recombinant lipoxygenase enzyme,,8,,,1,,H,Autocuration,,,CHEMBL619872,BAO_0000357,
3798,409,B,,,55,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,8,,,1,,H,Autocuration,,,CHEMBL619873,BAO_0000357,
3799,11090,B,,178.0,55,Inhibition of 5-lipoxygenase in human whole blood.,Blood,8,,,1,,H,Expert,,,CHEMBL619874,BAO_0000357,
3800,11090,B,,178.0,55,Inhibition of 5-lipoxygenase in human whole blood.,Blood,8,,,1,,H,Expert,,,CHEMBL619875,BAO_0000357,
3801,948,B,,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,8,,,1,,H,Autocuration,,,CHEMBL619876,BAO_0000357,
3802,948,B,,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,8,,,1,,H,Autocuration,,,CHEMBL619877,BAO_0000357,
3803,13622,F,,,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,8,,,1,,H,Expert,,,CHEMBL619878,BAO_0000219,
3804,13622,F,,178.0,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Blood,8,,,1,,H,Autocuration,,,CHEMBL619879,BAO_0000019,
3805,9637,B,,,55,In vitro inhibition of 5-lipoxygenase from human polymorphs,,8,,,1,,H,Autocuration,,,CHEMBL619880,BAO_0000357,
3806,11320,B,,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,8,,,1,,H,Autocuration,,,CHEMBL619881,BAO_0000357,
3807,11320,B,,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL619882,BAO_0000357,
3808,6838,B,,,55,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,8,,,1,,H,Autocuration,,,CHEMBL619883,BAO_0000357,
3809,17667,B,,178.0,55,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Blood,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619884,BAO_0000357,
3810,12703,B,,,55,In vitro potency against human 5-Lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL619885,BAO_0000357,
3811,14312,F,,,55,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619886,BAO_0000019,
3812,14312,F,,178.0,55,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Blood,8,,,1,,H,Autocuration,,,CHEMBL619887,BAO_0000019,
3813,5364,F,,,55,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,8,,,1,,H,Autocuration,,,CHEMBL875097,BAO_0000019,
3814,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,8,,,1,,H,Autocuration,,,CHEMBL618001,BAO_0000219,
3815,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,8,,,1,,H,Autocuration,,,CHEMBL618002,BAO_0000219,
3816,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,8,,,1,,H,Autocuration,,,CHEMBL618003,BAO_0000219,
3817,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,8,,,1,,H,Autocuration,,,CHEMBL618004,BAO_0000219,
3818,12365,B,,,55,Inhibition of human 5-lipoxygenase in human cells,,8,,,1,,H,Autocuration,,,CHEMBL618005,BAO_0000219,
3819,10603,B,,,55,Inhibition of human neutrophil 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL618006,BAO_0000357,
3820,10501,B,,,55,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,8,,,1,,H,Autocuration,,,CHEMBL875086,BAO_0000019,
3821,12281,B,,178.0,55,Inhibition of 5-lipoxygenase from human whole blood,Blood,8,,,1,,H,Expert,,,CHEMBL618007,BAO_0000357,
3822,2567,B,,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,8,,,1,,H,Autocuration,,,CHEMBL618008,BAO_0000357,
3823,2567,B,,,55,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,8,,,1,,H,Autocuration,,,CHEMBL618009,BAO_0000219,
3824,10193,B,,,55,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL618010,BAO_0000357,
3825,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL618011,BAO_0000357,
3826,13623,B,,,55,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL618012,BAO_0000357,
3827,12780,B,,,55,Tested against 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL882927,BAO_0000357,
3828,12780,B,,,55,Tested for activity against 5-Lipoxygenase (5-LO),,8,,,1,,H,Autocuration,,,CHEMBL618013,BAO_0000357,
3829,12780,B,,,55,Tested for activity against 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL618014,BAO_0000357,
3830,11966,B,,,55,Tested for inhibition of 5-HPETE production by human 5-LO,,8,,,1,,H,Autocuration,,,CHEMBL618015,BAO_0000357,
3831,5364,F,,,55,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,8,,,1,,H,Autocuration,,,CHEMBL618016,BAO_0000019,
3832,13165,B,,,55,Inhibition of Human 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL618017,BAO_0000357,
3833,5364,B,,,55,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,8,,,1,,H,Autocuration,,,CHEMBL618018,BAO_0000019,
3834,11311,B,,,55,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL875087,BAO_0000219,
3835,11311,B,,,55,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL618019,BAO_0000219,
3836,14863,B,,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,8,,,1,,H,Autocuration,,,CHEMBL618020,BAO_0000019,
3837,14863,B,,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,8,,,1,,H,Autocuration,,,CHEMBL618021,BAO_0000019,
3838,11087,B,,178.0,55,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Blood,8,,,1,,H,Autocuration,,,CHEMBL618022,BAO_0000357,
3839,455,B,,,55,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,8,,,1,,H,Autocuration,,,CHEMBL618023,BAO_0000357,
3840,13183,B,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,1,,H,Autocuration,,,CHEMBL618024,BAO_0000357,
3841,10319,B,,,55,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,8,,,1,,H,Expert,,,CHEMBL873950,BAO_0000019,
3842,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL618025,BAO_0000357,
3843,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL618026,BAO_0000219,
3844,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,8,,,1,,H,Autocuration,,,CHEMBL618027,BAO_0000219,
3845,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL618028,BAO_0000219,
3846,951,B,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,8,,,1,,H,Autocuration,,,CHEMBL618029,BAO_0000219,
3847,9859,B,,,55,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,8,,,1,,H,Expert,,,CHEMBL618030,BAO_0000357,
3848,9859,B,,,55,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,8,,,1,,H,Expert,,,CHEMBL618031,BAO_0000357,
3849,9859,B,,,55,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL618032,BAO_0000357,
3850,2567,B,,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,8,,,1,,H,Autocuration,,,CHEMBL618033,BAO_0000357,
3851,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL618034,BAO_0000357,
3852,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL875088,BAO_0000357,
3853,949,B,,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,8,,,1,,H,Autocuration,,,CHEMBL618035,BAO_0000019,
3854,949,B,,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,8,,,1,,H,Autocuration,,,CHEMBL618036,BAO_0000019,
3855,10603,B,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,8,,,1,,H,Expert,,,CHEMBL618037,BAO_0000357,
3856,10603,B,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,8,,,1,,H,Expert,,,CHEMBL618038,BAO_0000357,
3857,10603,F,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL618761,BAO_0000019,
3858,10603,B,,,55,Inhibition of lipoxygenase at the concentration of 0.1 uM,,8,,,1,,H,Expert,,,CHEMBL618762,BAO_0000357,
3859,10603,B,,,55,Inhibition of lipoxygenase at the concentration of 1 uM,,8,,,1,,H,Expert,,,CHEMBL618763,BAO_0000357,
3860,10193,B,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,8,,,1,,H,Autocuration,,,CHEMBL618764,BAO_0000357,
3861,14580,B,,,55,Inhibition of 5-Lipoxygenase (5-LOX),,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618765,BAO_0000357,
3862,11090,B,,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,,8,,,1,,H,Expert,,,CHEMBL618766,BAO_0000357,
3863,11090,B,,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,,8,,,1,,H,Expert,,,CHEMBL618767,BAO_0000357,
3864,6339,B,,,17087,Inhibitory activity against lipoxygenase-2 in mice,,8,,,1,,H,Autocuration,,,CHEMBL619380,BAO_0000357,
3865,6339,B,,,17087,Inhibitory activity against murine lipoxygenase-2.,,8,,,1,,H,Expert,,,CHEMBL619381,BAO_0000357,
3866,12281,B,,,17087,Inhibition of 5-lipoxygenase from mouse macrophage,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL619382,BAO_0000357,
3867,11311,B,,,17087,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,8,,,1,,H,Autocuration,,,CHEMBL619383,BAO_0000357,
3868,11089,B,,,55,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL619384,BAO_0000019,
3869,10091,B,,,55,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,8,,Sus scrofa,1,9823.0,H,Autocuration,,,CHEMBL619385,BAO_0000019,
3870,14352,B,,,55,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,8,,Oryctolagus cuniculus,1,9986.0,H,Autocuration,,,CHEMBL882928,BAO_0000019,
3871,13329,B,,,12166,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619386,BAO_0000019,
3872,13329,B,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,8,,,1,,H,Autocuration,,,CHEMBL619387,BAO_0000019,
3873,13329,B,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,8,,,1,,H,Autocuration,,,CHEMBL619388,BAO_0000019,
3874,13329,B,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,8,,,1,,H,Autocuration,,,CHEMBL619389,BAO_0000019,
3875,13329,B,,,12166,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,8,,,1,,H,Expert,,,CHEMBL619390,BAO_0000019,
3876,13329,B,,,12166,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,8,,,1,,H,Expert,,,CHEMBL619391,BAO_0000019,
3877,13329,B,,,12166,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,8,,,1,,H,Autocuration,,,CHEMBL619392,BAO_0000019,
3878,11311,B,,,12166,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,8,,,1,,H,Autocuration,,,CHEMBL619393,BAO_0000019,
3879,11311,B,,,12166,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,8,,,1,,H,Autocuration,,,CHEMBL619394,BAO_0000019,
3880,105,B,RBL-1,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,8,702.0,,1,,H,Autocuration,,,CHEMBL619395,BAO_0000219,
3881,105,B,RBL-1,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,8,702.0,,1,,H,Autocuration,,,CHEMBL619396,BAO_0000219,
3882,9138,B,,,12166,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,8,,,1,,H,Autocuration,,,CHEMBL619397,BAO_0000357,
3883,9138,B,,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,8,,,1,,H,Autocuration,,,CHEMBL619398,BAO_0000357,
3884,9138,B,,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,8,,,1,,H,Autocuration,,,CHEMBL619399,BAO_0000357,
3885,14427,B,,,12166,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL619400,BAO_0000357,
3886,13329,B,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,8,,,1,,H,Autocuration,,,CHEMBL619401,BAO_0000019,
3887,13329,B,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,8,,,1,,H,Autocuration,,,CHEMBL619402,BAO_0000019,
3888,14427,B,RBL-2H3,,12166,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,9,663.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619403,BAO_0000219,
3889,14427,B,,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL619404,BAO_0000357,
3890,14427,B,,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,8,,,1,,H,Autocuration,,,CHEMBL619405,BAO_0000357,
3891,10293,B,RBL-1,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,8,702.0,,1,,H,Expert,,,CHEMBL619406,BAO_0000219,
3892,338,B,RBL-1,,12166,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619407,BAO_0000219,
3893,303,B,,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,8,,,1,,H,Autocuration,,,CHEMBL619408,BAO_0000357,
3894,303,B,RBL-1,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,8,702.0,,1,,H,Autocuration,,,CHEMBL619409,BAO_0000219,
3895,9247,B,RBL-1,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,8,702.0,,1,,H,Expert,,,CHEMBL619410,BAO_0000219,
3896,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,8,702.0,,1,,H,Autocuration,,,CHEMBL619753,BAO_0000219,
3897,137,B,RBL-1,,12166,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,8,702.0,,1,,H,Autocuration,,,CHEMBL619754,BAO_0000219,
3898,11481,B,,,12166,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL619903,BAO_0000357,
3899,11481,B,,,12166,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,8,,,1,,H,Expert,,,CHEMBL619904,BAO_0000357,
3900,9029,B,,,12166,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,8,,,1,,H,Expert,,,CHEMBL619905,BAO_0000357,
3901,1701,B,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,8,,,1,,H,Autocuration,,,CHEMBL619906,BAO_0000019,
3902,1701,B,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,8,,,1,,H,Autocuration,,,CHEMBL619907,BAO_0000019,
3903,1701,B,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,8,,,1,,H,Autocuration,,,CHEMBL619908,BAO_0000019,
3904,1701,B,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,8,,,1,,H,Autocuration,,,CHEMBL619909,BAO_0000019,
3905,13358,F,RBL-1,,12166,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,8,702.0,,1,,H,Expert,,,CHEMBL619910,BAO_0000219,
3906,1175,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,8,702.0,,1,,H,Expert,,,CHEMBL882929,BAO_0000219,
3907,8797,B,RBL-1,,12166,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,8,702.0,,1,,H,Expert,,,CHEMBL619911,BAO_0000219,
3908,8797,B,,,12166,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,8,,,1,,H,Autocuration,,,CHEMBL619912,BAO_0000019,
3909,577,B,,,12166,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619913,BAO_0000357,
3910,9295,B,RBL-1,,12166,In vitro inhibitory activity against RBL-1 5-LO,,8,702.0,,1,,H,Expert,,,CHEMBL619914,BAO_0000219,
3911,9295,B,RBL-1,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,8,702.0,,1,,H,Autocuration,,,CHEMBL619915,BAO_0000219,
3912,9295,B,RBL-1,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,8,702.0,,1,,H,Autocuration,,,CHEMBL619916,BAO_0000219,
3913,9295,B,,,12166,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,8,,,1,,H,Autocuration,,,CHEMBL619917,BAO_0000218,
3914,9295,B,,,12166,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,8,,,1,,H,Autocuration,,,CHEMBL619918,BAO_0000357,
3915,216,B,,,12166,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,8,,,1,,H,Autocuration,,,CHEMBL619919,BAO_0000218,
3916,11090,B,RBL-1,,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,8,702.0,,1,,H,Autocuration,,,CHEMBL883710,BAO_0000219,
3917,11090,B,,178.0,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Blood,8,,,1,,H,Autocuration,,,CHEMBL619920,BAO_0000019,
3918,10091,B,,,12166,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL619921,BAO_0000357,
3919,10274,F,,,12166,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,8,,,1,,H,Autocuration,,,CHEMBL619922,BAO_0000019,
3920,13622,F,,,12166,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,8,,,1,,H,Autocuration,,,CHEMBL619923,BAO_0000219,
3921,12118,B,RBL-1,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,8,702.0,,1,,H,Expert,,,CHEMBL619924,BAO_0000219,
3922,12576,B,,,12166,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,8,,,1,,H,Expert,,,CHEMBL619925,BAO_0000357,
3923,9546,B,RBL-1,,12166,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,8,702.0,,1,,H,Expert,,,CHEMBL619926,BAO_0000219,
3924,9521,B,RBL-1,,12166,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL619927,BAO_0000219,
3925,10626,B,RBL-1,,12166,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,8,702.0,,1,,H,Expert,,,CHEMBL619928,BAO_0000219,
3926,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase,,8,702.0,,1,,H,Autocuration,,,CHEMBL619929,BAO_0000219,
3927,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,8,702.0,,1,,H,Autocuration,,,CHEMBL875089,BAO_0000219,
3928,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,8,702.0,,1,,H,Autocuration,,,CHEMBL619930,BAO_0000219,
3929,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,8,702.0,,1,,H,Autocuration,,,CHEMBL619931,BAO_0000219,
3930,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,8,702.0,,1,,H,Autocuration,,,CHEMBL619932,BAO_0000219,
3931,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,8,702.0,,1,,H,Autocuration,,,CHEMBL619933,BAO_0000219,
3932,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,8,702.0,,1,,H,Autocuration,,,CHEMBL619934,BAO_0000219,
3933,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,8,702.0,,1,,H,Autocuration,,,CHEMBL619935,BAO_0000219,
3934,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,8,702.0,,1,,H,Autocuration,,,CHEMBL619936,BAO_0000219,
3935,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,8,702.0,,1,,H,Autocuration,,,CHEMBL619937,BAO_0000219,
3936,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,8,702.0,,1,,H,Autocuration,,,CHEMBL619938,BAO_0000219,
3937,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,8,702.0,,1,,H,Autocuration,,,CHEMBL619939,BAO_0000219,
3938,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,8,702.0,,1,,H,Autocuration,,,CHEMBL619940,BAO_0000219,
3939,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,8,702.0,,1,,H,Autocuration,,,CHEMBL875090,BAO_0000219,
3940,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,8,702.0,,1,,H,Autocuration,,,CHEMBL619941,BAO_0000219,
3941,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,8,702.0,,1,,H,Autocuration,,,CHEMBL619942,BAO_0000219,
3942,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,8,702.0,,1,,H,Autocuration,,,CHEMBL883711,BAO_0000219,
3943,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,8,702.0,,1,,H,Autocuration,,,CHEMBL619943,BAO_0000219,
3944,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,8,702.0,,1,,H,Autocuration,,,CHEMBL619944,BAO_0000219,
3945,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,8,702.0,,1,,H,Autocuration,,,CHEMBL619945,BAO_0000219,
3946,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,8,702.0,,1,,H,Autocuration,,,CHEMBL619946,BAO_0000219,
3947,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,8,702.0,,1,,H,Autocuration,,,CHEMBL619947,BAO_0000219,
3948,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,8,702.0,,1,,H,Autocuration,,,CHEMBL619948,BAO_0000219,
3949,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,8,702.0,,1,,H,Autocuration,,,CHEMBL619949,BAO_0000219,
3950,9401,B,,,12166,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,8,,,1,,H,Expert,,,CHEMBL619950,BAO_0000019,
3951,10325,B,,,12166,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,8,,,1,,H,Autocuration,,,CHEMBL618050,BAO_0000019,
3952,1556,F,RBL-2H3,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,8,663.0,,1,,H,Expert,,,CHEMBL875091,BAO_0000219,
3953,1556,F,RBL-2H3,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,8,663.0,,1,,H,Expert,,,CHEMBL618051,BAO_0000219,
3954,961,B,RBL-1,,12166,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618052,BAO_0000219,
3955,6838,B,,,12166,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,8,,,1,,H,Autocuration,,,CHEMBL618053,BAO_0000019,
3956,10325,B,,,12166,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,8,,,1,,H,Expert,,,CHEMBL618054,BAO_0000019,
3957,9209,B,RBL-1,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618055,BAO_0000219,
3958,11520,B,RBL-1,,12166,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,8,702.0,,1,,H,Expert,,,CHEMBL618056,BAO_0000219,
3959,137,B,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined,,8,,,1,,H,Autocuration,,,CHEMBL618057,BAO_0000357,
3960,4717,B,RBL-1,,12166,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL618058,BAO_0000219,
3961,10636,B,RBL-1,,12166,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,8,702.0,,1,,H,Expert,,,CHEMBL618059,BAO_0000219,
3962,14312,F,,,12166,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618060,BAO_0000019,
3963,1203,B,RBL-1,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL618061,BAO_0000219,
3964,1203,B,,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,8,,,1,,H,Autocuration,,,CHEMBL618062,BAO_0000019,
3965,13622,B,RBL-1,,12166,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,8,702.0,,1,,H,Expert,,,CHEMBL618063,BAO_0000219,
3966,9793,B,,,12166,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,8,,,1,,H,Autocuration,,,CHEMBL618064,BAO_0000357,
3967,1143,B,RBL-1,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618065,BAO_0000219,
3968,11854,B,RBL-1,,12166,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618066,BAO_0000219,
3969,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,702.0,,1,,H,Autocuration,,,CHEMBL618067,BAO_0000219,
3970,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,8,702.0,,1,,H,Autocuration,,,CHEMBL618068,BAO_0000219,
3971,10501,B,RBL-1,,12166,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618069,BAO_0000219,
3972,12526,B,RBL-1,,12166,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,702.0,,1,,H,Expert,,,CHEMBL618070,BAO_0000219,
3973,10034,F,,349.0,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL618071,BAO_0000019,
3974,10034,F,,349.0,10825,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,8,,,1,,H,Autocuration,,,CHEMBL619247,BAO_0000019,
3975,10034,F,,,10825,Approximate dose levels for a half maximal reduction of 5-HTP levels,,8,,,1,,H,Autocuration,,,CHEMBL619248,BAO_0000019,
3976,10046,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL619249,BAO_0000221,
3977,10046,B,,10000000.0,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,8,,,1,,H,Autocuration,,,CHEMBL619250,BAO_0000221,
3978,10046,B,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL619251,BAO_0000019,
3979,12079,F,,178.0,55,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619252,BAO_0000019,
3980,12079,F,,178.0,55,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Blood,8,,,1,,H,Autocuration,,,CHEMBL619253,BAO_0000019,
3981,11311,B,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL619254,BAO_0000219,
3982,12338,B,,,17140,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,8,,,1,,H,Expert,,,CHEMBL619255,BAO_0000219,
3983,12143,B,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,8,,,1,,H,Expert,,,CHEMBL619256,BAO_0000219,
3984,12143,B,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,8,,,1,,H,Autocuration,,,CHEMBL875418,BAO_0000219,
3985,12143,B,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,8,,,1,,H,Expert,,,CHEMBL619257,BAO_0000219,
3986,12143,B,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL619258,BAO_0000219,
3987,12365,B,,,17140,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,8,,,1,,H,Expert,,,CHEMBL619259,BAO_0000357,
3988,13500,B,,,17140,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,8,,,1,,H,Expert,,,CHEMBL619260,BAO_0000357,
3989,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619261,BAO_0000218,
3990,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619263,BAO_0000218,
3991,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619264,BAO_0000218,
3992,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619265,BAO_0000218,
3993,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619266,BAO_0000218,
3994,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619902,BAO_0000218,
3995,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620058,BAO_0000218,
3996,12832,F,,178.0,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620059,BAO_0000218,
3997,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620060,BAO_0000218,
3998,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620061,BAO_0000218,
3999,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620062,BAO_0000218,
4000,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620063,BAO_0000218,
4001,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620064,BAO_0000218,
4002,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620065,BAO_0000218,
4003,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620066,BAO_0000218,
4004,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620067,BAO_0000218,
4005,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620068,BAO_0000218,
4006,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620069,BAO_0000218,
4007,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620070,BAO_0000218,
4008,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620071,BAO_0000218,
4009,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620072,BAO_0000218,
4010,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620036,BAO_0000218,
4011,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL857702,BAO_0000218,
4012,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620037,BAO_0000218,
4013,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620038,BAO_0000218,
4014,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620039,BAO_0000218,
4015,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620040,BAO_0000218,
4016,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620041,BAO_0000218,
4017,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620042,BAO_0000218,
4018,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620043,BAO_0000218,
4019,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620044,BAO_0000218,
4020,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620045,BAO_0000218,
4021,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620046,BAO_0000218,
4022,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620047,BAO_0000218,
4023,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620048,BAO_0000218,
4024,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL857703,BAO_0000218,
4025,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620049,BAO_0000218,
4026,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620050,BAO_0000218,
4027,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620051,BAO_0000218,
4028,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619213,BAO_0000218,
4029,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619214,BAO_0000218,
4030,12832,F,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619804,BAO_0000218,
4031,12832,F,,178.0,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619805,BAO_0000218,
4032,12832,F,,178.0,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619806,BAO_0000218,
4033,12832,F,,178.0,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619807,BAO_0000218,
4034,12832,F,,178.0,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619808,BAO_0000218,
4035,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619809,BAO_0000218,
4036,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619810,BAO_0000218,
4037,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL619811,BAO_0000218,
4038,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620769,BAO_0000218,
4039,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620770,BAO_0000218,
4040,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620771,BAO_0000218,
4041,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620772,BAO_0000218,
4042,3595,B,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,8,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL620773,BAO_0000218,
4043,9203,B,,,55,Ability to inhibit 5-lipoxygenase in guinea pig,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620774,BAO_0000357,
4044,82,B,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,8,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL620775,BAO_0000357,
4045,11090,B,,,55,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620776,BAO_0000357,
4046,12832,B,,178.0,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Blood,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620777,BAO_0000218,
4047,1065,B,,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620778,BAO_0000357,
4048,1065,B,,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL620779,BAO_0000357,
4049,12832,B,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,8,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL621500,BAO_0000019,
4050,12832,B,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,8,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL621501,BAO_0000019,
4051,12832,B,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618098,BAO_0000019,
4052,10504,B,,,55,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618099,BAO_0000019,
4053,7788,B,,,55,Inhibitory activity against 5-lipoxygenase,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618100,BAO_0000357,
4054,10001,B,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618101,BAO_0000357,
4055,10193,B,,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618102,BAO_0000357,
4056,13243,B,,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618103,BAO_0000357,
4057,13243,B,,,55,Inhibitory activity uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618104,BAO_0000357,
4058,969,B,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL883712,BAO_0000219,
4059,10001,B,,,55,Inhibitory activity against 5-lipoxygenase at 10 uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618105,BAO_0000357,
4060,7788,B,,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618106,BAO_0000357,
4061,10001,B,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618107,BAO_0000357,
4062,10193,B,,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618108,BAO_0000357,
4063,13243,B,,,55,Inhibitory activity uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618109,BAO_0000357,
4064,13243,B,,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618110,BAO_0000357,
4065,13243,B,,,55,Inhibitory activity uM,,8,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL618111,BAO_0000357,
4066,13243,F,,,55,Inhibitory activity uM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618112,BAO_0000019,
4067,10504,B,,,55,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618113,BAO_0000019,
4068,7788,B,,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,8,,Cavia porcellus,1,10141.0,H,Autocuration,,,CHEMBL618114,BAO_0000357,
4069,10546,F,,2116.0,55,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Ileum,8,,Cavia porcellus,1,10141.0,H,Expert,,,CHEMBL620871,BAO_0000221,
4070,13183,B,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,1,,H,Autocuration,,,CHEMBL620872,BAO_0000357,
4071,13183,B,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,1,,H,Autocuration,,,CHEMBL620873,BAO_0000357,
4072,2578,B,,,55,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,8,,,1,,H,Autocuration,,,CHEMBL620874,BAO_0000357,
4073,12780,B,,,55,In vitro inhibition of human 5-Lipoxygenase.,,8,,,1,,H,Expert,,,CHEMBL620875,BAO_0000357,
4074,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620876,BAO_0000251,
4075,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620877,BAO_0000251,
4076,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL857854,BAO_0000251,
4077,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620878,BAO_0000251,
4078,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620879,BAO_0000251,
4079,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620880,BAO_0000251,
4080,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620881,BAO_0000251,
4081,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620882,BAO_0000251,
4082,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620883,BAO_0000251,
4083,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620884,BAO_0000251,
4084,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620885,BAO_0000251,
4085,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620886,BAO_0000251,
4086,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620887,BAO_0000251,
4087,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618039,BAO_0000251,
4088,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618040,BAO_0000251,
4089,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618041,BAO_0000251,
4090,7411,B,,2107.0,22226,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618216,BAO_0000251,
4091,7411,B,,2107.0,22226,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618217,BAO_0000251,
4092,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618218,BAO_0000251,
4093,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618219,BAO_0000251,
4094,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618220,BAO_0000251,
4095,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618221,BAO_0000251,
4096,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618222,BAO_0000251,
4097,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618223,BAO_0000251,
4098,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618224,BAO_0000251,
4099,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618225,BAO_0000251,
4100,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618226,BAO_0000251,
4101,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618227,BAO_0000251,
4102,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618228,BAO_0000251,
4103,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618229,BAO_0000251,
4104,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618230,BAO_0000251,
4105,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618231,BAO_0000251,
4106,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618232,BAO_0000251,
4107,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618233,BAO_0000251,
4108,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618234,BAO_0000251,
4109,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618235,BAO_0000251,
4110,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618115,BAO_0000251,
4111,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618116,BAO_0000251,
4112,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618117,BAO_0000251,
4113,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619968,BAO_0000251,
4114,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619969,BAO_0000251,
4115,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619970,BAO_0000251,
4116,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619971,BAO_0000251,
4117,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619972,BAO_0000251,
4118,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619973,BAO_0000251,
4119,7411,B,,2107.0,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619974,BAO_0000251,
4120,7411,B,,2107.0,22226,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619975,BAO_0000251,
4121,7411,B,,,22226,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619976,BAO_0000251,
4122,7411,B,,2107.0,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619977,BAO_0000251,
4123,7411,B,,2107.0,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619978,BAO_0000251,
4124,7411,B,,2107.0,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619979,BAO_0000251,
4125,7411,B,,2107.0,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619980,BAO_0000251,
4126,7411,B,,2107.0,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619981,BAO_0000251,
4127,10797,F,RPMI-8226,,80433,In vitro inhibition of 7226/S myeloma cancer cell line,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619982,BAO_0000219,
4128,6881,F,BEL-7404 tumor cell line,,80698,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,1,993.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619983,BAO_0000219,
4129,3838,F,786-0,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620031,BAO_0000219,
4130,3838,F,786-0,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620032,BAO_0000219,
4131,12981,F,V79,,81264,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,1,505.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL620033,BAO_0000219,
4132,12981,F,V79,,81264,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,1,505.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL620034,BAO_0000219,
4133,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620035,BAO_0000219,
4134,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618318,BAO_0000219,
4135,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618319,BAO_0000219,
4136,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618320,BAO_0000219,
4137,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618321,BAO_0000219,
4138,7653,F,7800C1 cell line,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,1,1119.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL883118,BAO_0000219,
4139,17229,F,786-0,,80640,In vitro antitumor activity against renal 786-0 tumor cell lines,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883795,BAO_0000219,
4140,12858,F,786-0,,80640,Cytotoxic activity against 786-0 Renal cancer cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618322,BAO_0000219,
4141,16325,F,786-0,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618323,BAO_0000219,
4142,16325,F,786-0,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618324,BAO_0000219,
4143,5858,F,786-0,,80640,In vitro antitumor activity against human renal 786-0 cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618325,BAO_0000219,
4144,16325,F,786-0,,80640,Inhibition of Renal cancer in 786-0 cancer cell lines,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875416,BAO_0000219,
4145,14696,F,786-0,,80640,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618326,BAO_0000219,
4146,3786,F,786-0,,80640,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618327,BAO_0000219,
4147,14696,F,786-0,,80640,inhibition of the growth of renal cancer(786-0) cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619215,BAO_0000219,
4148,14769,F,786-0,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619216,BAO_0000219,
4149,15354,F,786-0,,80640,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619217,BAO_0000219,
4150,14255,F,786-0,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619218,BAO_0000219,
4151,14255,F,786-0,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619219,BAO_0000219,
4152,14255,F,786-0,,80640,The IC50 value was measured on 786-0 cell line in renal tumor type.,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619220,BAO_0000219,
4153,14696,F,786-0,,80640,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619221,BAO_0000219,
4154,12016,F,786-0,,80640,Tested for cytotoxic activity against renal cancer 786-0 cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619222,BAO_0000219,
4155,2597,F,786-0,,80640,Compound was tested for growth inhibitory activity against 786-0 cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL857454,BAO_0000219,
4156,12526,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL619223,BAO_0000219,
4157,12526,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,8,702.0,,1,,H,Autocuration,,,CHEMBL619224,BAO_0000219,
4158,14799,B,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,8,,,1,,H,Autocuration,,,CHEMBL619225,BAO_0000019,
4159,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,702.0,,1,,H,Expert,,,CHEMBL619226,BAO_0000219,
4160,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,8,702.0,,1,,H,Expert,,,CHEMBL619227,BAO_0000219,
4161,12767,B,,,12166,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL619228,BAO_0000357,
4162,10997,B,,,12166,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,8,,,1,,H,Autocuration,,,CHEMBL619229,BAO_0000219,
4163,11388,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,8,702.0,,1,,H,Autocuration,,,CHEMBL619230,BAO_0000219,
4164,167,B,,,12166,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,8,,,1,,H,Autocuration,,,CHEMBL619231,BAO_0000357,
4165,167,B,,,12166,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,8,,,1,,H,Autocuration,,,CHEMBL619232,BAO_0000357,
4166,13744,B,,,12166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,8,,,1,,H,Expert,,,CHEMBL619233,BAO_0000357,
4167,1630,B,,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL619234,BAO_0000357,
4168,1630,B,,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,8,,,1,,H,Autocuration,,,CHEMBL619235,BAO_0000357,
4169,969,B,,,12166,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL619236,BAO_0000019,
4170,13621,B,RBL-1,,12166,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL619237,BAO_0000219,
4171,10089,B,,,12166,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,8,,,1,,H,Autocuration,,,CHEMBL619238,BAO_0000357,
4172,10193,B,,,12166,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,8,,,1,,H,Expert,,,CHEMBL619239,BAO_0000357,
4173,11966,B,,,12166,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,8,,,1,,H,Autocuration,,,CHEMBL619240,BAO_0000357,
4174,12251,B,,,12166,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,8,,,1,,H,Autocuration,,,CHEMBL875417,BAO_0000019,
4175,211,B,RBL-1,,12166,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,8,702.0,,1,,H,Autocuration,,,CHEMBL619241,BAO_0000219,
4176,12251,F,,,12166,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,8,,,1,,H,Expert,,,CHEMBL619242,BAO_0000019,
4177,12495,B,RBL-1,,12166,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL883796,BAO_0000219,
4178,414,B,,,12166,Tested for its inhibitory activity against 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL619243,BAO_0000357,
4179,414,B,,,12166,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,8,,,1,,H,Autocuration,,,CHEMBL619244,BAO_0000357,
4180,10325,B,,,12166,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,8,,,1,,H,Expert,,,CHEMBL619245,BAO_0000019,
4181,11966,B,,,12166,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,8,,,1,,H,Expert,,,CHEMBL619246,BAO_0000019,
4182,165,B,RBL-1,,12166,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,702.0,,1,,H,Expert,,,CHEMBL619984,BAO_0000219,
4183,165,B,RBL-1,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL619985,BAO_0000219,
4184,165,B,RBL-1,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,702.0,,1,,H,Autocuration,,,CHEMBL619986,BAO_0000219,
4185,165,B,RBL-1,,12166,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,702.0,,1,,H,Expert,,,CHEMBL619987,BAO_0000219,
4186,11311,B,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,8,,,1,,H,Autocuration,,,CHEMBL619988,BAO_0000218,
4187,11311,B,RBL-1,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,8,702.0,,1,,H,Autocuration,,,CHEMBL619989,BAO_0000219,
4188,11311,B,RBL-1,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL619990,BAO_0000219,
4189,11311,B,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL619991,BAO_0000219,
4190,11311,B,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,8,,,1,,H,Autocuration,,,CHEMBL619992,BAO_0000219,
4191,11311,B,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,8,,,1,,H,Autocuration,,,CHEMBL619993,BAO_0000218,
4192,11311,F,RBL-2H3,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL619994,BAO_0000219,
4193,11311,F,RBL-2H3,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL619995,BAO_0000219,
4194,11311,B,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,8,,,1,,H,Autocuration,,,CHEMBL619996,BAO_0000019,
4195,11732,B,,,12166,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL619997,BAO_0000019,
4196,11732,B,,,12166,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,8,,,1,,H,Expert,,,CHEMBL619998,BAO_0000019,
4197,11087,B,,,12166,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,8,,,1,,H,Expert,,,CHEMBL619999,BAO_0000019,
4198,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,8,,,1,,H,Autocuration,,,CHEMBL620000,BAO_0000019,
4199,11087,B,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL620001,BAO_0000219,
4200,11087,B,,,12166,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620002,BAO_0000357,
4201,496,B,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,8,702.0,,1,,H,Autocuration,,,CHEMBL620003,BAO_0000219,
4202,13986,F,RBL-1,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,8,702.0,,1,,H,Expert,,,CHEMBL620004,BAO_0000219,
4203,11520,B,,,12166,Compound was evaluated for the inhibition of 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL874063,BAO_0000357,
4204,10293,B,RBL-1,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620005,BAO_0000219,
4205,303,B,RBL-1,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,8,702.0,,1,,H,Autocuration,,,CHEMBL620006,BAO_0000219,
4206,303,B,RBL-1,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,8,702.0,,1,,H,Autocuration,,,CHEMBL620007,BAO_0000219,
4207,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620008,BAO_0000219,
4208,9247,B,RBL-1,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620009,BAO_0000219,
4209,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,8,702.0,,1,,H,Autocuration,,,CHEMBL620010,BAO_0000219,
4210,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620011,BAO_0000219,
4211,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620677,BAO_0000219,
4212,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620678,BAO_0000219,
4213,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620679,BAO_0000219,
4214,9247,B,RBL-1,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620680,BAO_0000219,
4215,11481,B,,,12166,Inhibitory activity against 5-lipoxygenase at 10 uM,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620838,BAO_0000357,
4216,105,B,,,12166,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,8,,,1,,H,Autocuration,,,CHEMBL620839,BAO_0000357,
4217,9029,B,,,12166,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,8,,,1,,H,Expert,,,CHEMBL620840,BAO_0000357,
4218,1175,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,8,702.0,,1,,H,Expert,,,CHEMBL620841,BAO_0000219,
4219,12118,B,RBL-1,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620842,BAO_0000219,
4220,12118,B,RBL-1,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,8,702.0,,1,,H,Autocuration,,,CHEMBL620843,BAO_0000219,
4221,12118,B,RBL-1,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620844,BAO_0000219,
4222,9225,B,RBL-1,,12166,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620845,BAO_0000219,
4223,9401,B,,,12166,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL620846,BAO_0000019,
4224,137,B,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,8,,,1,,H,Autocuration,,,CHEMBL873951,BAO_0000357,
4225,137,B,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,8,,,1,,H,Autocuration,,,CHEMBL620847,BAO_0000357,
4226,4717,B,RBL-1,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,8,702.0,,1,,H,Autocuration,,,CHEMBL620848,BAO_0000219,
4227,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620849,BAO_0000219,
4228,10501,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,8,702.0,,1,,H,Autocuration,,,CHEMBL620850,BAO_0000219,
4229,10501,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620851,BAO_0000219,
4230,10501,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,8,702.0,,1,,H,Autocuration,,,CHEMBL620852,BAO_0000219,
4231,12526,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,702.0,,1,,H,Autocuration,,,CHEMBL875098,BAO_0000219,
4232,14799,B,RBL-1,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620853,BAO_0000219,
4233,14799,B,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,8,,,1,,H,Autocuration,,,CHEMBL620854,BAO_0000019,
4234,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620855,BAO_0000219,
4235,3595,B,RBL-1,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,8,702.0,,1,,H,Expert,,,CHEMBL839884,BAO_0000219,
4236,12526,B,RBL-1,,12166,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,702.0,,1,,H,Autocuration,,,CHEMBL620856,BAO_0000219,
4237,12526,B,RBL-1,,12166,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,702.0,,1,,H,Autocuration,,,CHEMBL620857,BAO_0000219,
4238,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL620858,BAO_0000019,
4239,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL620859,BAO_0000019,
4240,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,8,,,1,,H,Autocuration,,,CHEMBL620860,BAO_0000019,
4241,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,8,,,1,,H,Autocuration,,,CHEMBL620861,BAO_0000019,
4242,9138,B,,,12166,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,8,,,1,,H,Expert,,,CHEMBL620862,BAO_0000357,
4243,9138,B,,,12166,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,8,,,1,,H,Autocuration,,,CHEMBL620863,BAO_0000357,
4244,11966,B,,,12166,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,8,,,1,,H,Autocuration,,,CHEMBL620864,BAO_0000019,
4245,165,B,RBL-1,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620865,BAO_0000219,
4246,165,B,RBL-1,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620866,BAO_0000219,
4247,11311,B,RBL-2H3,,12166,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL620867,BAO_0000219,
4248,11311,B,RBL-2H3,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL620868,BAO_0000219,
4249,11311,F,RBL-2H3,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL620869,BAO_0000219,
4250,11311,F,,,12166,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL873952,BAO_0000019,
4251,11311,B,,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL875099,BAO_0000357,
4252,11311,F,RBL-2H3,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,8,663.0,,1,,H,Autocuration,,,CHEMBL620870,BAO_0000219,
4253,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL618261,BAO_0000019,
4254,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,8,,,1,,H,Autocuration,,,CHEMBL618262,BAO_0000019,
4255,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,8,,,1,,H,Autocuration,,,CHEMBL619428,BAO_0000019,
4256,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL619429,BAO_0000019,
4257,11087,B,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL619430,BAO_0000019,
4258,496,B,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620017,BAO_0000219,
4259,496,B,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620018,BAO_0000219,
4260,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620019,BAO_0000219,
4261,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620020,BAO_0000219,
4262,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620021,BAO_0000219,
4263,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620022,BAO_0000219,
4264,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,8,702.0,,1,,H,Autocuration,,,CHEMBL620023,BAO_0000219,
4265,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620024,BAO_0000219,
4266,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620025,BAO_0000219,
4267,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620026,BAO_0000219,
4268,13986,F,RBL-1,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL620027,BAO_0000219,
4269,13986,F,,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL620028,BAO_0000019,
4270,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL620029,BAO_0000357,
4271,9295,B,,,12166,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL620030,BAO_0000357,
4272,4717,B,RBL-1,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,8,702.0,,1,,H,Autocuration,,,CHEMBL875415,BAO_0000219,
4273,4717,B,RBL-1,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,8,702.0,,1,,H,Autocuration,,,CHEMBL618256,BAO_0000219,
4274,11854,B,RBL-1,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,8,702.0,,1,,H,Autocuration,,,CHEMBL618257,BAO_0000219,
4275,11854,B,RBL-1,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618258,BAO_0000219,
4276,11854,B,RBL-1,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618259,BAO_0000219,
4277,10193,B,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,8,,,1,,H,Autocuration,,,CHEMBL618260,BAO_0000019,
4278,9295,B,RBL-1,,12166,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618215,BAO_0000219,
4279,9295,B,RBL-1,,12166,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618390,BAO_0000219,
4280,9295,B,RBL-1,,12166,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618391,BAO_0000219,
4281,9295,B,RBL-1,,12166,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618392,BAO_0000219,
4282,165,B,RBL-1,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,8,702.0,,1,,H,Autocuration,,,CHEMBL618393,BAO_0000219,
4283,11311,B,,,12166,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,8,,,1,,H,Autocuration,,,CHEMBL618394,BAO_0000219,
4284,10489,B,RBL-1,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,8,702.0,Homo sapiens,1,9606.0,H,Expert,,,CHEMBL618395,BAO_0000219,
4285,10489,B,RBL-1,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618396,BAO_0000219,
4286,10489,B,RBL-1,,12166,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,9,702.0,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL858253,BAO_0000219,
4287,14799,B,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,9,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL618397,BAO_0000019,
4288,9295,B,,,12054,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,8,,Glycine max,1,3847.0,H,Autocuration,,,CHEMBL618398,BAO_0000357,
4289,16811,B,,,22226,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,0,,,1,,U,Autocuration,,,CHEMBL618399,BAO_0000019,
4290,168,B,,,55,In vitro inhibition of 5-Lipoxygenase; Inactive.,,8,,,1,,H,Expert,,,CHEMBL618400,BAO_0000357,
4291,6309,B,,,55,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,8,,,1,,H,Autocuration,,,CHEMBL618401,BAO_0000357,
4292,6309,B,,,55,Inhibitory concentration against 5-lipoxygenase; No inhibition,,8,,,1,,H,Autocuration,,,CHEMBL618402,BAO_0000357,
4293,3092,B,RBL-1,,55,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,8,702.0,,1,,H,Autocuration,,,CHEMBL876400,BAO_0000219,
4294,168,B,,,55,Inhibitory activity against 5-lipoxygenase.,,8,,,1,,H,Expert,,,CHEMBL618403,BAO_0000357,
4295,168,B,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,8,,,1,,H,Autocuration,,,CHEMBL618404,BAO_0000357,
4296,168,B,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,8,,,1,,H,Autocuration,,,CHEMBL618405,BAO_0000357,
4297,168,B,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,8,,,1,,H,Autocuration,,,CHEMBL618406,BAO_0000357,
4298,12338,F,,,55,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,8,,,1,,H,Expert,,,CHEMBL618407,BAO_0000019,
4299,4501,B,,,55,Tested for the inhibitory activity against 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL618408,BAO_0000357,
4300,1132,B,,,55,Compound was tested for its inhibitory activity against 5-lipoxygenase,,8,,,1,,H,Autocuration,,,CHEMBL618409,BAO_0000357,
4301,2117,B,,,55,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,8,,,1,,H,Autocuration,,,CHEMBL618410,BAO_0000357,
4302,168,B,,,55,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,8,,,1,,H,Autocuration,,,CHEMBL618411,BAO_0000357,
4303,168,B,,,55,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,8,,,1,,H,Autocuration,,,CHEMBL618412,BAO_0000357,
4304,13575,B,RBL-1,,12166,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,8,702.0,,1,,H,Autocuration,,,CHEMBL618413,BAO_0000219,
4305,11089,B,,,12166,,,8,,,1,,H,Autocuration,,,CHEMBL618414,BAO_0000357,
4306,216,B,,,10102,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,8,,,1,,H,Autocuration,,,CHEMBL618415,BAO_0000357,
4307,13165,B,,,10102,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,8,,,1,,H,Autocuration,,,CHEMBL618416,BAO_0000019,
4308,3278,B,,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,8,,,1,,H,Autocuration,,,CHEMBL876401,BAO_0000357,
4309,3278,B,,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,8,,,1,,H,Expert,,,CHEMBL618417,BAO_0000357,
4310,11966,B,,,10102,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,8,,,1,,H,Autocuration,,,CHEMBL618418,BAO_0000357,
4311,175,B,,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,8,,,1,,H,Autocuration,,,CHEMBL618419,BAO_0000357,
4312,175,B,,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,8,,,1,,H,Autocuration,,,CHEMBL618420,BAO_0000357,
4313,13449,B,,,10102,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,8,,,1,,H,Autocuration,,,CHEMBL618421,BAO_0000357,
4314,12014,B,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,8,,,1,,H,Autocuration,,,CHEMBL618422,BAO_0000019,
4315,12014,B,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,8,,,1,,H,Autocuration,,,CHEMBL618423,BAO_0000019,
4316,12014,B,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,8,,,1,,H,Autocuration,,,CHEMBL618424,BAO_0000019,
4317,99,B,,,100284,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,2,,,1,,S,Intermediate,,,CHEMBL618425,BAO_0000220,
4318,4349,F,,,22226,The dark toxicity against 543 human galactophore carcinoma cells,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618426,BAO_0000019,
4319,4071,F,Panel (56 tumour cell lines),,80623,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,1,390.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618427,BAO_0000219,
4320,17589,F,5637,,80008,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,1,345.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618428,BAO_0000219,
4321,15002,F,5637,,80008,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,1,345.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618429,BAO_0000219,
4322,13958,F,5637,,80008,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,1,345.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618430,BAO_0000219,
4323,17589,F,5637,,80008,Growth inhibition against human 5637 cell lines,,1,345.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618431,BAO_0000219,
4324,16748,F,5637,,80008,Antitumor activity against human bladder carcinoma 5637 cells.,,1,345.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL883799,BAO_0000219,
4325,16747,F,5637,,80008,Antitumor activity against human bladder carcinoma 5637 cells,,1,345.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618432,BAO_0000219,
4326,16747,F,5637,,80008,Antitumor activity against human bladder carcinoma 5637 cells,,1,345.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618433,BAO_0000219,
4327,15285,B,,,10443,In vitro inhibition of bovine trypsin(Trp).,,9,,Bos taurus,1,9913.0,D,Expert,,,CHEMBL618434,BAO_0000357,
4328,3726,B,CV-1,,240,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,8,407.0,Cercopithecidae,1,9527.0,H,Expert,,,CHEMBL618435,BAO_0000219,
4329,5033,B,,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,8,,,1,,H,Autocuration,,,CHEMBL876402,BAO_0000357,
4330,11756,F,,,104698,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,6,,,1,,H,Autocuration,,,CHEMBL618436,BAO_0000019,
4331,11953,F,,,22226,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,0,,,1,,U,Autocuration,,,CHEMBL618437,BAO_0000218,
4332,5033,B,,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,9,,Cavia porcellus,1,10141.0,D,Intermediate,,,CHEMBL618438,BAO_0000357,
4333,11347,A,,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,8,,Rattus norvegicus,1,10116.0,H,Expert,,,CHEMBL883800,BAO_0000251,
4334,11347,A,,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,8,,Rattus norvegicus,1,10116.0,H,Expert,,,CHEMBL618439,BAO_0000251,
4335,1229,F,,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL618440,BAO_0000019,
4336,1229,F,,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL618441,BAO_0000019,
4337,17588,B,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,8,,Trypanosoma brucei,1,5691.0,H,Expert,,,CHEMBL618442,BAO_0000019,
4338,17588,B,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,8,,Trypanosoma brucei,1,5691.0,H,Autocuration,,,CHEMBL618443,BAO_0000019,
4339,17588,B,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,8,,Ovis aries,1,9940.0,H,Expert,,,CHEMBL619158,BAO_0000019,
4340,17588,B,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,8,,Ovis aries,1,9940.0,H,Autocuration,,,CHEMBL620974,BAO_0000019,
4341,16485,B,,,11938,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,8,,,1,,H,Autocuration,,,CHEMBL620975,BAO_0000357,
4342,4337,F,,,22226,Average inhibitory concentration against 60 human cell lines was reported,,0,,Homo sapiens,1,9606.0,U,Intermediate,,,CHEMBL620976,BAO_0000019,
4343,4112,F,,,22226,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,0,,Homo sapiens,1,9606.0,U,Expert,,,CHEMBL620977,BAO_0000019,
4344,16160,F,Panel NCI-60 (60 carcinoma cell lines),,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,1,542.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620978,BAO_0000219,
4345,16160,F,Panel NCI-60 (60 carcinoma cell lines),,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,1,542.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620979,BAO_0000219,
4346,17376,F,Panel NCI-60 (60 carcinoma cell lines),,80315,In vitro mean growth inhibitory activity against 60-cell panel,,1,542.0,,1,,N,Expert,,,CHEMBL620980,BAO_0000219,
4347,17376,F,Panel NCI-60 (60 carcinoma cell lines),,80315,In vitro mean growth lethal concentration against 60-cell panel,,1,542.0,,1,,N,Expert,,,CHEMBL620981,BAO_0000219,
4348,17376,F,Panel NCI-60 (60 carcinoma cell lines),,80315,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,1,542.0,,1,,N,Expert,,,CHEMBL620982,BAO_0000219,
4349,17376,F,Panel NCI-60 (60 carcinoma cell lines),,80315,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,1,542.0,,1,,N,Expert,,,CHEMBL620983,BAO_0000219,
4350,3241,F,,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4,,,1,,H,Autocuration,,,CHEMBL620984,BAO_0000019,
4351,3241,F,,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4,,,1,,H,Autocuration,,,CHEMBL620985,BAO_0000019,
4352,3725,B,,,275,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,8,,,1,,H,Expert,,,CHEMBL620986,BAO_0000357,
4353,10805,F,,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,1,,Plasmodium falciparum,1,5833.0,N,Expert,,,CHEMBL620987,BAO_0000218,
4354,10805,F,,,50425,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,1,,Plasmodium falciparum,1,5833.0,N,Expert,,,CHEMBL620988,BAO_0000218,
4355,10805,F,,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,1,,Plasmodium falciparum,1,5833.0,N,Expert,,,CHEMBL620989,BAO_0000218,
4356,10805,F,,,50425,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,1,,Plasmodium falciparum,1,5833.0,N,Expert,,,CHEMBL620990,BAO_0000218,
4357,10805,F,,,50425,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,1,,Plasmodium falciparum,1,5833.0,N,Intermediate,,,CHEMBL620991,BAO_0000218,
4358,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620992,BAO_0000218,
4359,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620993,BAO_0000218,
4360,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620994,BAO_0000218,
4361,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620995,BAO_0000218,
4362,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620996,BAO_0000218,
4363,10144,F,6C3HED,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875581,BAO_0000218,
4364,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620997,BAO_0000218,
4365,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620998,BAO_0000218,
4366,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620999,BAO_0000218,
4367,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621000,BAO_0000218,
4368,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621001,BAO_0000218,
4369,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621002,BAO_0000218,
4370,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621003,BAO_0000218,
4371,10685,F,,,22224,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621004,BAO_0000218,
4372,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621005,BAO_0000218,
4373,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621006,BAO_0000218,
4374,10685,F,,,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621007,BAO_0000218,
4375,10144,F,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621008,BAO_0000218,
4376,10144,F,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL621009,BAO_0000218,
4377,10144,F,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL857705,BAO_0000218,
4378,10144,F,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619828,BAO_0000218,
4379,10685,F,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619829,BAO_0000218,
4380,10685,F,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619830,BAO_0000218,
4381,10685,F,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619831,BAO_0000218,
4382,10685,F,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619832,BAO_0000218,
4383,10685,A,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619833,BAO_0000218,
4384,10685,A,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619834,BAO_0000218,
4385,10685,A,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619835,BAO_0000218,
4386,10685,A,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL619836,BAO_0000218,
4387,8831,F,6C3HED,,80628,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619837,BAO_0000218,
4388,11704,F,,,22224,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL619838,BAO_0000218,
4389,11704,A,,,50594,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619839,BAO_0000218,
4390,10685,F,6C3HED,,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619840,BAO_0000218,
4391,10685,F,6C3HED,,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619841,BAO_0000218,
4392,11368,F,6C3HED,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,1,850.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL857704,BAO_0000218,
4393,11368,F,6C3HED,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,1,850.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619842,BAO_0000218,
4394,11368,F,6C3HED,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,1,850.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL619843,BAO_0000218,
4395,17763,B,,,22226,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,0,,Staphylococcus aureus,1,1280.0,U,Autocuration,,,CHEMBL619844,BAO_0000019,
4396,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL857855,BAO_0000251,
4397,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619845,BAO_0000251,
4398,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619846,BAO_0000251,
4399,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619847,BAO_0000251,
4400,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL619848,BAO_0000251,
4401,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620893,BAO_0000251,
4402,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620894,BAO_0000251,
4403,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620895,BAO_0000251,
4404,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620896,BAO_0000251,
4405,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620897,BAO_0000251,
4406,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620898,BAO_0000251,
4407,7411,B,,2107.0,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620899,BAO_0000251,
4408,347,A,,1969.0,22224,The apparent total plasma clearance in monkey,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620900,BAO_0000218,
4409,3341,A,,,22224,Compound was evaluated for Hepatic clearance in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620901,BAO_0000218,
4410,17853,A,,,22224,Lower clearance in monkey (i.v.) at 0.5 mpk,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620902,BAO_0000218,
4411,4514,A,,,22224,Plasma clearance in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620903,BAO_0000218,
4412,6062,A,,,22224,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620904,BAO_0000218,
4413,6821,A,,,22224,Plasma clearance of compound was determined in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620905,BAO_0000218,
4414,6057,A,,,22224,Plasma clearance was calculated in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620906,BAO_0000218,
4415,5145,A,,,22224,Plasma clearance in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL875420,BAO_0000218,
4416,6641,A,,,22224,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620907,BAO_0000218,
4417,5472,A,,,22224,Plasma clearance was evaluated in rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620908,BAO_0000218,
4418,4257,A,,,22224,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620909,BAO_0000218,
4419,5546,A,,,22224,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620910,BAO_0000218,
4420,5334,A,,,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620911,BAO_0000218,
4421,5334,A,,,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620912,BAO_0000218,
4422,17509,A,,,22224,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620913,BAO_0000218,
4423,6535,A,,,22224,Cmax in monkey after administration of 1 mg/kg iv,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620914,BAO_0000218,
4424,5668,A,,,22224,Cmax was determine after peroral administration at 10 mpk in Rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620915,BAO_0000218,
4425,5922,A,,,22224,Cmax in cynomolgus monkey by iv administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620916,BAO_0000218,
4426,5922,A,,,22224,Cmax in cynomolgus monkey by po administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620917,BAO_0000218,
4427,6078,A,,,22224,Cmax value evaluated in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620918,BAO_0000218,
4428,2661,A,,,22224,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620919,BAO_0000218,
4429,3249,A,,1969.0,22224,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620920,BAO_0000218,
4430,3249,A,,1969.0,22224,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620921,BAO_0000218,
4431,5553,A,,1969.0,22224,Maximal plasma concentration in squirrel monkeys,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620922,BAO_0000218,
4432,1916,A,,,22224,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620923,BAO_0000218,
4433,6227,A,,1969.0,22224,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620924,BAO_0000218,
4434,4809,A,,,22224,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620925,BAO_0000218,
4435,5355,A,,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620926,BAO_0000218,
4436,5355,A,,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620927,BAO_0000218,
4437,5355,A,,,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620928,BAO_0000218,
4438,5355,A,,,22224,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620929,BAO_0000218,
4439,6221,A,,1969.0,22224,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620930,BAO_0000218,
4440,167,A,,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620931,BAO_0000218,
4441,167,A,,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620932,BAO_0000218,
4442,4257,A,,,22224,Absolute bioavailability was evaluated in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620933,BAO_0000218,
4443,6221,A,,,22224,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620934,BAO_0000218,
4444,17667,A,,,22224,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620935,BAO_0000218,
4445,17267,A,,,22224,Bioavailability of compound was determined in rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620936,BAO_0000218,
4446,4256,A,,,22224,Bioavailability determined after oral administration in marmoset,,0,,marmosets,1,38020.0,U,Autocuration,,,CHEMBL620937,BAO_0000218,
4447,4256,A,,,22224,Oral bioavailability in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL620938,BAO_0000218,
4448,17853,A,,,22224,Bioavailability in monkey (p.o.) at 2.0 mpk,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620939,BAO_0000218,
4449,16365,A,,,22224,Bioavailability was evaluated after oral administration in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620940,BAO_0000218,
4450,1916,A,,,22224,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL620941,BAO_0000218,
4451,5334,A,,,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620942,BAO_0000218,
4452,5334,A,,,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620943,BAO_0000218,
4453,17592,A,,,22224,Bioavailability of the compound was determined in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620944,BAO_0000218,
4454,1399,A,,,22224,Bioavailability in squirrel monkey (dose 5 mg/kg),,0,,Saimiri sciureus,1,9521.0,U,Autocuration,,,CHEMBL620945,BAO_0000218,
4455,4809,A,,,22224,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620946,BAO_0000218,
4456,3341,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620947,BAO_0000218,
4457,64,A,,,22224,Compound was tested for bioavailability in squirrel monkey,,0,,Saimiri sciureus,1,9521.0,U,Autocuration,,,CHEMBL620948,BAO_0000218,
4458,5005,A,,,22224,Oral bioavailability in Rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620949,BAO_0000218,
4459,5005,A,,,22224,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620950,BAO_0000218,
4460,5237,A,,,22224,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL620951,BAO_0000218,
4461,5237,A,,,22224,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL620952,BAO_0000218,
4462,5302,A,,,22224,Oral bioavailability in monkey (dose 5 mg/kg),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL875421,BAO_0000218,
4463,17667,A,,,22224,Oral bioavailability of compound at 5 mg/kg in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620953,BAO_0000218,
4464,6161,A,,,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873491,BAO_0000218,
4465,6161,A,,,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620954,BAO_0000218,
4466,3854,A,,1969.0,50588,Plasma half life determined,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620955,BAO_0000218,
4467,993,A,,1969.0,50588,Plasma half life in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618097,BAO_0000218,
4468,4514,A,,1969.0,50588,Plasma half-life in Beagle dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618268,BAO_0000218,
4469,5334,A,,1969.0,50588,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618269,BAO_0000218,
4470,5334,A,,1969.0,50588,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618270,BAO_0000218,
4471,1466,A,,,50588,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618271,BAO_0000218,
4472,1466,A,,,50588,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873493,BAO_0000218,
4473,5313,A,,,50588,Tested for the half life period in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621031,BAO_0000218,
4474,5313,A,,,50588,Tested for the half life period in dog at dosage of 10 mpk,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621032,BAO_0000218,
4475,3880,A,,,50588,The compound was tested for half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621033,BAO_0000218,
4476,3639,A,,1969.0,50588,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621034,BAO_0000218,
4477,3880,A,,,50588,The half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621035,BAO_0000218,
4478,3918,A,,1969.0,50588,The plasma half-life in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621036,BAO_0000218,
4479,16452,A,,1969.0,50588,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621037,BAO_0000218,
4480,17796,A,,,50588,Half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619812,BAO_0000218,
4481,5983,A,,,50588,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619813,BAO_0000218,
4482,1466,A,,,50588,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873335,BAO_0000218,
4483,16456,A,,,50588,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619814,BAO_0000218,
4484,6113,A,,,50506,Cmax in ferrets after 30 mg/kg oral dose,,1,,Mustela putorius furo,1,9669.0,N,Expert,,,CHEMBL619815,BAO_0000218,
4485,6113,F,,,50506,Emesis in ferrets at 30 mg/kg oral dose,,1,,Mustela putorius furo,1,9669.0,N,Expert,,,CHEMBL619816,BAO_0000218,
4486,17796,A,,,22224,Bioavailability in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL619817,BAO_0000218,
4487,17796,A,,,100710,Volume of distribution in cynomolgus,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL619818,BAO_0000218,
4488,5308,A,,1969.0,22224,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Plasma,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619819,BAO_0000218,
4489,4877,A,,,22224,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619820,BAO_0000218,
4490,4876,A,,,22224,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL875419,BAO_0000218,
4491,4878,A,,1969.0,22224,AUC in guinea pig after 3mg/kg oral dose,Plasma,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619821,BAO_0000218,
4492,5308,A,,,22224,Bioavailability in guinea pig was tested,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619822,BAO_0000218,
4493,4877,A,,,22224,Tested for oral bioavailability in guinea pig at 5 mg/kg,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619823,BAO_0000218,
4494,4876,A,,,22224,Tested for the oral bioavailability of the compound,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619824,BAO_0000218,
4495,4876,A,,,22224,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619825,BAO_0000218,
4496,5308,A,,,22224,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619826,BAO_0000218,
4497,4877,A,,2048.0,22224,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Lung,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL619827,BAO_0000218,
4498,4878,A,,,22224,Cmax in guinea pig after 3mg/kg oral dose,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618167,BAO_0000218,
4499,5689,A,,178.0,22224,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Blood,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618168,BAO_0000019,
4500,5689,A,,955.0,22224,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Brain,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618169,BAO_0000019,
4501,5689,A,,,22224,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618170,BAO_0000019,
4502,5689,A,,160.0,22224,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Intestine,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618171,BAO_0000019,
4503,5689,A,,2113.0,22224,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Kidney,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618172,BAO_0000019,
4504,5689,A,,2107.0,22224,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Liver,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618173,BAO_0000019,
4505,5689,A,,,22224,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618174,BAO_0000019,
4506,5689,A,,2106.0,22224,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Spleen,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL875408,BAO_0000019,
4507,14465,A,,,22224,Elimination T1/2 in Guinea pig (PO dose),,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL839827,BAO_0000218,
4508,5689,A,,,22224,Partition coefficient was measured as -log (counts per min ),,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618175,BAO_0000019,
4509,611,A,,,22224,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618176,BAO_0000218,
4510,611,A,,,22224,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618177,BAO_0000218,
4511,14465,A,,,22224,Elimination T1/2 in Guinea pig (PO dose),,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618178,BAO_0000218,
4512,4876,A,,,22224,"Tested for the half life period of the compound, intravenously",,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618179,BAO_0000218,
4513,5689,A,,,22224,Half-life was measured,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL873489,BAO_0000019,
4514,7515,A,,,22224,The time required for onset of inotropy after addition of a single dose of delta F75,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618180,BAO_0000019,
4515,17667,A,,,22224,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618181,BAO_0000218,
4516,17667,A,,,22224,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL618182,BAO_0000218,
4517,4727,A,,,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618183,BAO_0000218,
4518,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618184,BAO_0000218,
4519,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618185,BAO_0000218,
4520,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618186,BAO_0000218,
4521,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618187,BAO_0000218,
4522,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618188,BAO_0000218,
4523,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875409,BAO_0000218,
4524,10107,A,,,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618189,BAO_0000218,
4525,3655,A,,178.0,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618190,BAO_0000218,
4526,3655,A,,178.0,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618191,BAO_0000218,
4527,3655,A,,178.0,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618192,BAO_0000218,
4528,3655,A,,10000001.0,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618193,BAO_0000218,
4529,3655,A,,10000001.0,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618194,BAO_0000218,
4530,3655,A,,10000001.0,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618195,BAO_0000218,
4531,3655,A,,955.0,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618196,BAO_0000218,
4532,3655,A,,955.0,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618197,BAO_0000218,
4533,3655,A,,955.0,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618198,BAO_0000218,
4534,3655,A,,948.0,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618199,BAO_0000218,
4535,3655,A,,948.0,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618200,BAO_0000218,
4536,3655,A,,948.0,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618201,BAO_0000218,
4537,3655,A,,160.0,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618202,BAO_0000218,
4538,3655,A,,160.0,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618203,BAO_0000218,
4539,3655,A,,160.0,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618204,BAO_0000218,
4540,3655,A,,2113.0,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618205,BAO_0000218,
4541,3655,A,,2113.0,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618206,BAO_0000218,
4542,3655,A,,2113.0,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618207,BAO_0000218,
4543,3655,A,,2107.0,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618208,BAO_0000218,
4544,3655,A,,2107.0,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618932,BAO_0000218,
4545,3655,A,,2107.0,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618933,BAO_0000218,
4546,3655,A,,2048.0,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618934,BAO_0000218,
4547,3655,A,,2048.0,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618935,BAO_0000218,
4548,3655,A,,2048.0,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618936,BAO_0000218,
4549,3655,A,,2385.0,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618937,BAO_0000218,
4550,3655,A,,2385.0,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618938,BAO_0000218,
4551,3655,A,,2385.0,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619104,BAO_0000218,
4552,3655,A,,2106.0,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619105,BAO_0000218,
4553,3655,A,,2106.0,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619106,BAO_0000218,
4554,3655,A,,2106.0,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619107,BAO_0000218,
4555,3655,A,,945.0,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875410,BAO_0000218,
4556,3655,A,,945.0,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619108,BAO_0000218,
4557,3655,A,,945.0,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619109,BAO_0000218,
4558,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619110,BAO_0000218,
4559,16597,F,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619111,BAO_0000218,
4560,16597,A,,,50594,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619112,BAO_0000218,
4561,16597,A,,,50594,MRT value at a dose of 10 mg/kg peroral administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619113,BAO_0000218,
4562,17764,A,,,50594,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619114,BAO_0000218,
4563,17764,F,,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619115,BAO_0000218,
4564,3830,F,A2780,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619116,BAO_0000219,
4565,3829,F,A2780,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619117,BAO_0000219,
4566,2040,F,A2780,,81034,Compound was evaluated for cytotoxicity against A2780 cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619118,BAO_0000219,
4567,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619119,BAO_0000219,
4568,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619120,BAO_0000219,
4569,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619121,BAO_0000219,
4570,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619122,BAO_0000219,
4571,15684,F,A2780,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619123,BAO_0000219,
4572,15684,F,A2780,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619124,BAO_0000219,
4573,2859,F,A2780,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619125,BAO_0000219,
4574,5618,F,A2780,,81034,In vitro inhibitory activity against human tumor cell line A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875411,BAO_0000219,
4575,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619126,BAO_0000219,
4576,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619127,BAO_0000219,
4577,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619128,BAO_0000219,
4578,15684,F,A2780,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619129,BAO_0000219,
4579,2113,F,A2780,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619130,BAO_0000219,
4580,2113,F,A2780,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619131,BAO_0000219,
4581,16745,F,A2780,,81034,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619132,BAO_0000219,
4582,16597,F,A2780,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619133,BAO_0000218,
4583,15684,F,A2780,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619134,BAO_0000219,
4584,15684,F,A2780,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619135,BAO_0000219,
4585,2040,F,A2780,,81034,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619136,BAO_0000219,
4586,2040,F,A2780,,81034,Relative resistance factor in A2780 cisplatin-resistant line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619137,BAO_0000219,
4587,16165,F,A2780,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883713,BAO_0000219,
4588,16165,F,A2780,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875412,BAO_0000219,
4589,16597,F,A2780,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619138,BAO_0000218,
4590,16597,F,A2780,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619262,BAO_0000218,
4591,3992,F,A2780,,81034,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619139,BAO_0000219,
4592,10553,F,A2780,,81034,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619140,BAO_0000219,
4593,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619141,BAO_0000219,
4594,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619142,BAO_0000219,
4595,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619143,BAO_0000219,
4596,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619144,BAO_0000219,
4597,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619145,BAO_0000219,
4598,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619146,BAO_0000219,
4599,15569,F,A2780,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619147,BAO_0000219,
4600,17420,F,A2780,,81034,Antiproliferative effect of compound on A2780/DX cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619148,BAO_0000219,
4601,17420,F,A2780,,81034,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619149,BAO_0000219,
4602,15099,F,A2780,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619150,BAO_0000219,
4603,15099,F,A2780,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619151,BAO_0000219,
4604,17672,F,A2780,,81034,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883794,BAO_0000219,
4605,17672,F,A2780,,81034,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619152,BAO_0000219,
4606,17270,F,A2780,,81034,In vitro cytotoxicity against A2780ADR cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619153,BAO_0000219,
4607,17270,F,A2780,,81034,In vitro cytotoxicity against A2780CIS cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619154,BAO_0000219,
4608,5574,F,A2780,,81034,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619155,BAO_0000219,
4609,2113,F,A2780,,81034,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619156,BAO_0000219,
4610,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619157,BAO_0000219,
4611,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619797,BAO_0000219,
4612,17839,A,,,22224,Oral bioavailability of compound in rhesus macaques,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL619798,BAO_0000218,
4613,6821,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL619799,BAO_0000218,
4614,6078,A,,,22224,Oral bioavailability evaluated in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL619800,BAO_0000218,
4615,6535,A,,,22224,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL619801,BAO_0000218,
4616,4449,A,,,22224,Oral bioavailability in Rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL619802,BAO_0000218,
4617,6057,A,,,22224,Oral bioavailability was calculated in rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL619803,BAO_0000218,
4618,5922,A,,,22224,Oral bioavailability in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL619965,BAO_0000218,
4619,5940,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL619966,BAO_0000218,
4620,6265,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL619967,BAO_0000218,
4621,6265,A,,,22224,Oral bioavailability in monkey (dose 1 mg/kg),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620073,BAO_0000218,
4622,6265,A,,,22224,Oral bioavailability in monkey (dose 5 mg/kg),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620074,BAO_0000218,
4623,5940,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620075,BAO_0000218,
4624,5940,A,,,22224,Oral bioavailability in monkey,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620076,BAO_0000218,
4625,4514,A,,,22224,Oral bioavailability in rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620077,BAO_0000218,
4626,5546,A,,,22224,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620078,BAO_0000218,
4627,5553,A,,,22224,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,0,,Saimiri sciureus,1,9521.0,U,Autocuration,,,CHEMBL620079,BAO_0000218,
4628,6641,A,,,22224,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620080,BAO_0000218,
4629,5472,A,,,22224,Oral bioavailability in Rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620081,BAO_0000218,
4630,5668,A,,,22224,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620082,BAO_0000218,
4631,5711,A,,,22224,Oral bioavailability in monkey at 10 mg/kg of the compound,,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL620083,BAO_0000218,
4632,5145,A,,,22224,Bioavailability in Rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620084,BAO_0000218,
4633,3443,A,,,22224,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620085,BAO_0000218,
4634,3443,A,,,22224,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL874595,BAO_0000218,
4635,3249,A,,,22224,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL873352,BAO_0000218,
4636,3249,A,,,22224,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620086,BAO_0000218,
4637,5355,A,,,22224,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620087,BAO_0000218,
4638,5355,A,,,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620088,BAO_0000218,
4639,5355,A,,,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620089,BAO_0000218,
4640,4809,A,,,22224,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620090,BAO_0000218,
4641,4809,A,,,22224,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620091,BAO_0000218,
4642,14294,A,,,22224,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620092,BAO_0000251,
4643,14294,A,,,22224,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620093,BAO_0000251,
4644,14294,A,,,22224,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620094,BAO_0000251,
4645,14294,A,,,22224,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620095,BAO_0000251,
4646,3443,A,,,22224,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620096,BAO_0000218,
4647,3443,A,,,22224,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620097,BAO_0000218,
4648,11271,A,,,22224,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620098,BAO_0000019,
4649,3443,A,,,22224,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620099,BAO_0000218,
4650,3443,A,,,22224,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620100,BAO_0000218,
4651,6821,A,,,22224,Elimination Half-life of compound was determined in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620101,BAO_0000019,
4652,17267,A,,,22224,Half life of compound was determined in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620102,BAO_0000019,
4653,5819,A,,1969.0,22224,Half life in monkey plasma,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620103,BAO_0000366,
4654,5819,A,,1969.0,22224,Half life in monkey plasma; Not detected,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620104,BAO_0000366,
4655,1916,A,,,22224,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL874596,BAO_0000218,
4656,17509,A,,,22224,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL873490,BAO_0000218,
4657,1399,A,,,22224,Terminal half life of the compound.,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620105,BAO_0000019,
4658,1916,A,,,22224,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620780,BAO_0000218,
4659,4809,A,,,22224,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620781,BAO_0000218,
4660,5546,A,,,22224,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620956,BAO_0000218,
4661,3443,A,,1088.0,22224,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620957,BAO_0000218,
4662,3443,A,,1088.0,22224,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620958,BAO_0000218,
4663,4257,A,,,22224,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620959,BAO_0000218,
4664,6221,A,,,22224,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620960,BAO_0000218,
4665,5472,A,,,22224,Volume of distribution was evaluated in rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL620961,BAO_0000218,
4666,4727,A,,,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620962,BAO_0000218,
4667,4727,A,,,22224,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620963,BAO_0000218,
4668,4727,A,,,22224,Bioavailability in hamster was determined,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620964,BAO_0000218,
4669,4727,A,,,22224,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620965,BAO_0000218,
4670,4727,A,,,22224,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620966,BAO_0000218,
4671,4727,A,,178.0,22224,Half life of compound was determined in hamster blood,Blood,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620967,BAO_0000221,
4672,1452,A,,,22224,Michaelis-Menten constant of the compound.,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL620968,BAO_0000019,
4673,1452,A,,,22224,Vmax value was measured at 0 uM concentration of silyl ether.,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL874597,BAO_0000019,
4674,1452,A,,,22224,Vmax value was measured at 10 uM concentration of silyl ether.,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL620969,BAO_0000019,
4675,1452,A,,,22224,Vmax value was measured at 5 uM concentration of silyl ether.,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL620970,BAO_0000019,
4676,11706,B,,,235,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620971,BAO_0000357,
4677,1916,A,,,22224,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620972,BAO_0000218,
4678,17791,A,,,22224,Compound was evaluated for area under the curve expressed as (h*ug/ml),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620973,BAO_0000019,
4679,7766,A,,,22224,Active metabolite of ifosfamide determined in humans; A-Active,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618243,BAO_0000019,
4680,6567,A,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618244,BAO_0000019,
4681,6567,A,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618245,BAO_0000019,
4682,6567,A,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618246,BAO_0000019,
4683,6567,A,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618247,BAO_0000019,
4684,17791,A,,,22224,Compound was evaluated for oral bioavailability in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618248,BAO_0000218,
4685,7766,A,,1088.0,22224,Metabolite of ifosfamide determined in urine; NF-Not found,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618249,BAO_0000019,
4686,6852,A,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618250,BAO_0000019,
4687,6852,A,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL874598,BAO_0000019,
4688,6852,A,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618251,BAO_0000019,
4689,6852,A,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618252,BAO_0000019,
4690,6852,A,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618253,BAO_0000019,
4691,6852,A,,,22224,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618254,BAO_0000019,
4692,6852,A,,,22224,Percent of compound in healthy individuals (Group D),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618255,BAO_0000019,
4693,4397,A,,2107.0,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618983,BAO_0000251,
4694,17409,A,,,22224,Binding towards human plasma protein at 10 uM,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618984,BAO_0000019,
4695,17409,A,,,22224,Binding towards human plasma protein at 100 uM,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618985,BAO_0000019,
4696,17176,A,,,22224,Human plasma protein binding activity was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618986,BAO_0000019,
4697,15444,A,,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618987,BAO_0000019,
4698,17267,A,,,22224,Percent binding of compound towards human plasma protein was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618988,BAO_0000019,
4699,5944,A,,2107.0,22224,Plasma clearance in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618989,BAO_0000251,
4700,5668,A,,2107.0,22224,In vitro intrinsic clearance in human liver microsome,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618990,BAO_0000251,
4701,5669,A,,2107.0,22224,In vitro intrinsic clearance in human liver microsome,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618991,BAO_0000251,
4702,5041,A,,,22224,In vitro microsome metabolism clearance in human was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL876725,BAO_0000251,
4703,5041,A,,,22224,In vitro microsome metabolism clearance in human was determined; High,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618992,BAO_0000251,
4704,5041,A,,,22224,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618993,BAO_0000251,
4705,5676,A,,2107.0,22224,Pharmacokinetic property (clearance) in human liver microsome,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618994,BAO_0000251,
4706,5944,A,,2107.0,22224,Plasma clearance in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618995,BAO_0000251,
4707,17538,A,,2107.0,22224,In vitro clearance in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618996,BAO_0000251,
4708,6331,A,,2107.0,22224,Intrinsic clearance in human liver microsomes was determined,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618997,BAO_0000251,
4709,5948,A,,2107.0,22224,Intrinsic clearance in human liver microsomes was determined,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618998,BAO_0000251,
4710,5965,A,,,22224,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618999,BAO_0000218,
4711,1916,A,,,22224,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620223,BAO_0000218,
4712,5965,A,,,22224,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620224,BAO_0000218,
4713,1299,A,,,22224,Stability in human plasma 2 hr after incubation expressed as percent concentration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620225,BAO_0000019,
4714,1299,A,,,22224,Stability in human plasma 4 hr after incubation expressed as percent concentration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620226,BAO_0000019,
4715,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620227,BAO_0000019,
4716,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL876726,BAO_0000019,
4717,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620228,BAO_0000019,
4718,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620229,BAO_0000019,
4719,17764,F,,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620230,BAO_0000218,
4720,17764,F,,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620231,BAO_0000218,
4721,17764,F,,,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620232,BAO_0000218,
4722,17764,F,,,50594,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620233,BAO_0000218,
4723,14294,A,,,50594,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620234,BAO_0000218,
4724,14294,A,,,50594,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620235,BAO_0000218,
4725,14294,A,,,50594,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620236,BAO_0000218,
4726,6251,A,,2107.0,50594,In vitro metabolic potential in mouse liver microsomes,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620237,BAO_0000218,
4727,17582,A,,,50594,Ability of compound to bind to plasma protein was evaluated in HSA cells,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620238,BAO_0000218,
4728,17811,A,,2369.0,50594,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Adrenal gland,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620239,BAO_0000218,
4729,17811,A,,955.0,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620240,BAO_0000218,
4730,17811,A,,955.0,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620241,BAO_0000218,
4731,17811,A,,,50594,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876727,BAO_0000218,
4732,17811,A,,2113.0,50594,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620242,BAO_0000218,
4733,17811,A,,,50594,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620243,BAO_0000218,
4734,5288,A,,,50594,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620244,BAO_0000218,
4735,2717,A,,1977.0,50594,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Serum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620245,BAO_0000218,
4736,2717,A,,1977.0,50594,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Serum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620246,BAO_0000218,
4737,2717,A,,1977.0,50594,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Serum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620247,BAO_0000218,
4738,17753,A,,1969.0,50594,Half life of compound was determined in plasma of mice at 24 mg/Kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620248,BAO_0000218,
4739,17753,A,,1969.0,50594,Half life of compound was determined in plasma of mice at 40 mg/Kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL873497,BAO_0000218,
4740,17753,A,,1969.0,50594,Half life of compound was determined in plasma of mice at 5 mg/Kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620249,BAO_0000218,
4741,17764,F,,,50594,Half life after intraperitoneal administration in mice at 18 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620250,BAO_0000218,
4742,17764,F,,,50594,Half life after intraperitoneal administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620251,BAO_0000218,
4743,17764,F,,,50594,Half life after intraperitoneal administration in mice at 25 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620252,BAO_0000218,
4744,17764,F,,,50594,Half life after intraperitoneal administration in mice at 26 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620253,BAO_0000218,
4745,17764,F,,,50594,Half life after intravenous administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620254,BAO_0000218,
4746,17764,A,,,50594,Half life after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620255,BAO_0000218,
4747,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620256,BAO_0000218,
4748,2675,A,,,50594,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876728,BAO_0000218,
4749,2675,A,,,50594,Maximum time required to reach Cp max was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620257,BAO_0000218,
4750,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620258,BAO_0000218,
4751,4890,A,,,50594,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620259,BAO_0000218,
4752,429,A,,,50594,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620260,BAO_0000218,
4753,17837,A,,178.0,50594,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620261,BAO_0000218,
4754,16597,A,,,50594,Half life at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620262,BAO_0000218,
4755,16597,A,,,50594,Half life at a dose of 10 mg/kg peroral administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620263,BAO_0000218,
4756,6619,A,,,50594,Half life in ob/ob mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620264,BAO_0000218,
4757,4066,A,,,50594,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620265,BAO_0000218,
4758,4239,A,,,50594,Half-life was measured in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620266,BAO_0000218,
4759,5969,A,,,50594,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620267,BAO_0000218,
4760,8999,A,,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619364,BAO_0000218,
4761,8999,A,,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619365,BAO_0000218,
4762,17641,A,,955.0,50594,T2 in brain of mice at the oral dose of 50 mg/kg,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619366,BAO_0000218,
4763,17641,A,,2113.0,50594,T2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619367,BAO_0000218,
4764,17641,A,,2107.0,50594,T2 in liver of mice at the oral dose of 50 mg/kg,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619368,BAO_0000218,
4765,17641,A,,2048.0,50594,T2 in lungs of mice at the oral dose of 50 mg/kg,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619369,BAO_0000218,
4766,17641,A,,2106.0,50594,T2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876729,BAO_0000218,
4767,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619370,BAO_0000218,
4768,4890,A,,,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619371,BAO_0000218,
4769,429,A,,,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619372,BAO_0000218,
4770,429,A,,,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620012,BAO_0000218,
4771,5969,A,,,50594,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620013,BAO_0000218,
4772,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620014,BAO_0000219,
4773,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620015,BAO_0000219,
4774,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621010,BAO_0000219,
4775,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621011,BAO_0000219,
4776,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621012,BAO_0000219,
4777,16913,F,A2780,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621013,BAO_0000219,
4778,17270,F,A2780,,81034,In vitro cytotoxicity against A2780TAX cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621014,BAO_0000219,
4779,5618,F,A2780cisR,,80017,In vitro inhibitory activity against human tumor cell line A2780cis,,1,481.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618154,BAO_0000219,
4780,17777,F,A2780,,81034,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618155,BAO_0000219,
4781,16112,F,A2780cisR,,80017,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,1,481.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618156,BAO_0000219,
4782,15748,F,A2780cisR,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,1,481.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618157,BAO_0000219,
4783,6633,F,A2780,,81034,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618328,BAO_0000219,
4784,16930,F,A2780,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618329,BAO_0000219,
4785,17496,F,A2780,,81034,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618330,BAO_0000219,
4786,12989,F,A2780,,81034,In vitro antitumor activity against A2780cisR cell line.,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618331,BAO_0000219,
4787,4840,F,A2780,,81034,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618332,BAO_0000219,
4788,12989,F,A2780,,81034,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618333,BAO_0000219,
4789,16745,F,A2780cisR,,80017,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,1,481.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618334,BAO_0000219,
4790,16597,F,A2780,,81034,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618335,BAO_0000219,
4791,16547,B,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618336,BAO_0000019,
4792,16547,F,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,8,,,1,,H,Expert,,,CHEMBL618337,BAO_0000019,
4793,16547,F,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL618338,BAO_0000019,
4794,15856,F,HEK293,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618339,BAO_0000219,
4795,15856,F,HEK293,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,9,722.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL618340,BAO_0000219,
4796,16547,B,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618341,BAO_0000019,
4797,16547,F,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,8,,,1,,H,Expert,,,CHEMBL618342,BAO_0000019,
4798,16547,F,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,9,,Mus musculus,1,10090.0,D,Expert,,,CHEMBL618343,BAO_0000019,
4799,17402,B,,,280,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,8,,,1,,H,Expert,,,CHEMBL621038,BAO_0000357,
4800,11746,F,T-cells,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,0,574.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL621039,BAO_0000219,
4801,11746,F,T-cells,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,0,574.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL621040,BAO_0000219,
4802,5455,F,A-375,,80018,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621041,BAO_0000219,
4803,2068,F,A-375,,80018,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621042,BAO_0000219,
4804,2683,F,A-375,,80018,In vitro antitumor activity against A375cell line extracted form melanoma,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621043,BAO_0000219,
4805,15313,F,A-375,,80018,Inhibition of cell growth in (A375) melan cell line,,1,455.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621044,BAO_0000219,
4806,13739,F,A-375,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621045,BAO_0000219,
4807,13739,F,A-375,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621046,BAO_0000219,
4808,14750,F,A-375,,80018,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621047,BAO_0000219,
4809,14777,F,A-427,,80019,Antiproliferative activity measured against A427 human lung carcinoma,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621048,BAO_0000219,
4810,14777,F,A-427,,80019,Antiproliferative activity measured against A427 human lung carcinoma,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883798,BAO_0000219,
4811,17672,F,A-427,,80019,Cytotoxicity against lung carcinoma A427 tumor cell lines,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621049,BAO_0000219,
4812,14368,F,A-427,,80019,Inhibition of large cell lung carcinoma (A427),,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621050,BAO_0000219,
4813,14368,F,A-427,,80019,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621051,BAO_0000219,
4814,13866,F,A-427,,80019,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621052,BAO_0000219,
4815,2545,F,A-427,,80019,Inhibitory concentration in human lung carcinoma A427 cell line,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621053,BAO_0000219,
4816,2545,F,A-427,,80019,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621054,BAO_0000219,
4817,6062,A,,,22224,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621055,BAO_0000218,
4818,4578,A,,,22224,Tested for volume of distribution upon iv administration to african green monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876398,BAO_0000218,
4819,17592,A,,,22224,Volume of distribution in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621056,BAO_0000218,
4820,5005,A,,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL621057,BAO_0000218,
4821,5005,A,,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL621058,BAO_0000218,
4822,5922,A,,,22224,Pharmacokinetic property(Vdss) in cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621059,BAO_0000218,
4823,5355,A,,,22224,The distribution volume after intravenous administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621060,BAO_0000218,
4824,5355,A,,,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621061,BAO_0000218,
4825,5355,A,,,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621062,BAO_0000218,
4826,6057,A,,,22224,Volume displacement was calculated in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621063,BAO_0000218,
4827,5145,A,,,22224,Volume of distribution in steady state was determined in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621064,BAO_0000218,
4828,6821,A,,,22224,Volume of distribution of compound was determined in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621065,BAO_0000218,
4829,5334,A,,,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621066,BAO_0000218,
4830,5334,A,,,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621067,BAO_0000218,
4831,6641,A,,,22224,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621068,BAO_0000218,
4832,2661,A,,,22224,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876399,BAO_0000218,
4833,6535,A,,,22224,Volume distribution in monkey after administration of 1 mg/kg iv,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621069,BAO_0000218,
4834,4809,A,,,22224,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621070,BAO_0000218,
4835,6062,A,,,22224,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621071,BAO_0000218,
4836,3443,A,,,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621072,BAO_0000218,
4837,4578,A,,,22224,Oral systemic bioavailability upon iv administration to african green monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618209,BAO_0000218,
4838,4809,A,,,22224,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618210,BAO_0000218,
4839,11271,A,,,22224,Baboon plasma free fraction. ,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618211,BAO_0000019,
4840,6057,A,,,22224,Area under the curve was calculated in rhesus monkey after iv administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618212,BAO_0000218,
4841,6057,A,,,22224,Area under the curve was calculated in rhesus monkey after peroral administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618213,BAO_0000019,
4842,17853,A,,,22224,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618214,BAO_0000019,
4843,5302,A,,,22224,Half life period in monkey after 5 mg/kg dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL873492,BAO_0000218,
4844,4257,A,,,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618272,BAO_0000218,
4845,4257,A,,,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618273,BAO_0000218,
4846,13501,A,,1969.0,22224,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618274,BAO_0000218,
4847,5394,A,,,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618275,BAO_0000218,
4848,2661,A,,,22224,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618276,BAO_0000218,
4849,3341,A,,,22224,Compound was evaluated for terminal half life in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618277,BAO_0000019,
4850,3045,A,,,22224,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618278,BAO_0000218,
4851,5005,A,,1969.0,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL618279,BAO_0000218,
4852,4847,A,,,22224,Half life of compound was determined in squirrel monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618280,BAO_0000019,
4853,4256,A,,,22224,Half life after iv administration in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL618281,BAO_0000218,
4854,6535,A,,1969.0,22224,Half life in monkey plasma after administration of 1 mg/kg iv,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618282,BAO_0000218,
4855,6057,A,,,22224,Half life was calculated in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618283,BAO_0000019,
4856,17592,A,,,22224,Half life in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618284,BAO_0000019,
4857,6641,A,,,22224,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618285,BAO_0000218,
4858,5472,A,,,22224,Half life was evaluated in rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618286,BAO_0000019,
4859,6221,A,,,22224,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618287,BAO_0000218,
4860,5668,A,,,22224,Half life period was determine after peroral administration at 10 mpk in Rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618288,BAO_0000218,
4861,4809,A,,,22224,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876393,BAO_0000218,
4862,5546,A,,,22224,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618289,BAO_0000218,
4863,5553,A,,,22224,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618290,BAO_0000218,
4864,6078,A,,,22224,Half-life was calculated in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618291,BAO_0000019,
4865,5147,A,,,22224,Half-life in Squirrel monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618292,BAO_0000019,
4866,5145,A,,,22224,Half-life in rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618293,BAO_0000019,
4867,6062,A,,,22224,Half-life was measured in monkey after an iv dose of 1 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618294,BAO_0000218,
4868,5355,A,,,22224,Half-life period after intravenous administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618295,BAO_0000218,
4869,5355,A,,,22224,Half-life period after oral administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618296,BAO_0000218,
4870,5355,A,,,22224,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618297,BAO_0000218,
4871,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618298,BAO_0000019,
4872,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618299,BAO_0000019,
4873,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618300,BAO_0000019,
4874,7766,A,,1088.0,22224,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618301,BAO_0000019,
4875,7766,A,,1088.0,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618302,BAO_0000019,
4876,7766,A,,1088.0,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL876394,BAO_0000019,
4877,7766,A,,1088.0,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618303,BAO_0000019,
4878,7766,A,,1088.0,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618304,BAO_0000019,
4879,1916,A,,,22224,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618305,BAO_0000218,
4880,16643,A,,,22224,Oral bioavailability in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618306,BAO_0000218,
4881,17248,A,,,22224,Compound was tested for human plasma protein binding,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618307,BAO_0000019,
4882,17248,A,,,22224,Compound was tested for human plasma protein binding; Not determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618308,BAO_0000019,
4883,6241,A,,,22224,Protein binding activity of compound in human plasma; % Free,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618309,BAO_0000019,
4884,17716,A,,,22224,Unbound fraction (plasma),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618310,BAO_0000019,
4885,17605,A,,1969.0,22224,Half life for the hydrolysis of compound in human blood serum,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL873353,BAO_0000366,
4886,17625,A,,1969.0,22224,Half life period in human plasma using phosphate buffer (0.08 M),Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618311,BAO_0000366,
4887,17625,A,,1969.0,22224,Half life period in human plasma using phosphate buffer (0.1 M),Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618312,BAO_0000366,
4888,17747,A,,1969.0,22224,Half-life in human plasma was determined,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618313,BAO_0000366,
4889,15613,A,,,22224,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618314,BAO_0000019,
4890,354,A,,,22224,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618315,BAO_0000019,
4891,3741,A,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618316,BAO_0000019,
4892,3741,A,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618317,BAO_0000019,
4893,3741,A,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620138,BAO_0000019,
4894,17599,A,,,22224,Partition coefficient (logP),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL858280,BAO_0000019,
4895,5486,A,,,22224,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620139,BAO_0000019,
4896,5600,A,,,22224,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620140,BAO_0000251,
4897,14294,A,,,22224,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620141,BAO_0000019,
4898,14294,A,,,22224,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620142,BAO_0000019,
4899,14294,A,,,22224,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620143,BAO_0000019,
4900,14294,A,,,22224,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620144,BAO_0000251,
4901,14294,A,,,22224,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620145,BAO_0000251,
4902,14294,A,,,22224,Metabolism of compound in human microsomes; Trace,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620146,BAO_0000251,
4903,6260,A,,2107.0,22224,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620147,BAO_0000251,
4904,6187,A,,,22224,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620148,BAO_0000251,
4905,6251,A,,2107.0,22224,In vitro metabolic potential in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620149,BAO_0000251,
4906,3246,A,,,22224,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL876412,BAO_0000019,
4907,17313,A,,,22224,Tested for human plasma protein binding of the compound; Not tested,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619352,BAO_0000019,
4908,6227,A,,,22224,Compound was tested for percent protein binding (PB) in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619353,BAO_0000019,
4909,5530,A,,1969.0,22224,Protein binding in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619354,BAO_0000019,
4910,6108,A,,,22224,Permeability coefficient (B to A) in Caco-2 cell,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619355,BAO_0000019,
4911,6108,A,,,22224,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619356,BAO_0000019,
4912,2774,A,,,22224,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619357,BAO_0000019,
4913,16643,A,,,22224,In vitro rate of absorption observed as Caco-2 permeability in humans,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619358,BAO_0000019,
4914,17582,A,Caco-2,,22224,Cellular permeability of compound was determined in Caco-2 cells; High,,0,495.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619359,BAO_0000219,
4915,6838,A,Caco-2,,22224,Permeability in Caco-2 cells of compound,,0,495.0,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619360,BAO_0000219,
4916,6108,A,,,22224,Permeability coefficient (A to B) in Caco-2 cell,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619361,BAO_0000019,
4917,6108,A,,,22224,Permeability coefficient (B to A) in Caco-2 cell,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619362,BAO_0000019,
4918,6108,A,,,22224,Permeability coefficient (Papp) (Caco-2 cell monolayer),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619363,BAO_0000019,
4919,2146,A,,,22224,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618942,BAO_0000019,
4920,4514,A,,,22224,Compound was tested for protein binding in human plasma,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618943,BAO_0000019,
4921,6108,A,,,22224,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618944,BAO_0000019,
4922,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618945,BAO_0000019,
4923,5969,A,,,50594,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618946,BAO_0000218,
4924,3277,A,,,50594,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876413,BAO_0000218,
4925,3802,A,,,50594,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618947,BAO_0000218,
4926,2862,A,,1969.0,50594,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618948,BAO_0000218,
4927,6348,A,,1969.0,50594,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618949,BAO_0000218,
4928,17764,F,,,50594,Tmax after intraperitoneal administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618950,BAO_0000218,
4929,5781,A,,,50594,Tmax after oral administration at 30 mg/kg in ICR mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618951,BAO_0000218,
4930,17764,A,,,50594,Tmax after peroral administration in mice at 2.4 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618952,BAO_0000218,
4931,4066,A,,,50594,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618953,BAO_0000218,
4932,17641,A,,955.0,50594,Tmax in brain of mice at the oral dose of 50 mg/kg,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618954,BAO_0000218,
4933,17641,A,,2113.0,50594,Tmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618955,BAO_0000218,
4934,17641,A,,2107.0,50594,Tmax in liver of mice at the oral dose of 50 mg/kg,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618956,BAO_0000218,
4935,17641,A,,2048.0,50594,Tmax in lungs of mice at the oral dose of 50 mg/kg,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618957,BAO_0000218,
4936,17764,F,,,50594,Tmax in mice at 18 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618958,BAO_0000218,
4937,17764,F,,,50594,Tmax in mice at 23 uM/kg i.v. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618959,BAO_0000218,
4938,17764,F,,,50594,Tmax in mice at 25 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618960,BAO_0000218,
4939,17764,F,,,50594,Tmax in mice at 26 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876723,BAO_0000218,
4940,17641,A,,2106.0,50594,Tmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618961,BAO_0000218,
4941,16597,A,,,50594,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618962,BAO_0000218,
4942,16597,A,,,50594,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618963,BAO_0000218,
4943,5951,A,,,50594,Tmax value in IRC mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618964,BAO_0000218,
4944,5506,A,,,50594,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618965,BAO_0000218,
4945,5506,A,,,50594,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618966,BAO_0000218,
4946,429,A,,1088.0,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618967,BAO_0000218,
4947,429,A,,1088.0,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618968,BAO_0000218,
4948,4066,A,,1088.0,50594,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618969,BAO_0000218,
4949,17734,A,,,50594,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618970,BAO_0000218,
4950,17734,A,,,50594,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618971,BAO_0000218,
4951,6062,A,,,50594,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618972,BAO_0000218,
4952,5969,A,,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618973,BAO_0000218,
4953,5969,A,,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618974,BAO_0000218,
4954,5969,A,,,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618975,BAO_0000218,
4955,5980,A,,,50594,Vd in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618976,BAO_0000218,
4956,17592,A,,,50594,Volume of distribution in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618977,BAO_0000218,
4957,6348,A,,,50594,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876724,BAO_0000218,
4958,17753,A,,,50594,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618978,BAO_0000218,
4959,17753,A,,,50594,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618979,BAO_0000218,
4960,17753,A,,,50594,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618980,BAO_0000218,
4961,4239,A,,,50594,Pharmacokinetic property (vdss) was measured in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618981,BAO_0000218,
4962,2862,A,,,50594,Value distribution upon iv administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618982,BAO_0000218,
4963,17734,A,,,50594,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620150,BAO_0000218,
4964,2675,A,,,50594,Volume of distribution was evaluated in mice after intravenous administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620151,BAO_0000218,
4965,2675,A,,,50594,Volume of distribution was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620152,BAO_0000218,
4966,17837,A,,,50594,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620153,BAO_0000218,
4967,5727,A,,,50594,Steady state volume of distribution was determined in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876395,BAO_0000218,
4968,17852,A,,,50594,Volume distribution (steady state) of compound was determined in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620154,BAO_0000218,
4969,17764,A,,,50594,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620155,BAO_0000218,
4970,16597,A,,,50594,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620156,BAO_0000218,
4971,6062,A,,,50594,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620157,BAO_0000218,
4972,16438,A,,2113.0,50594,Biodistribution of compound (oxidized form) in in kidney tissue,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620158,BAO_0000218,
4973,16438,A,,178.0,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620159,BAO_0000218,
4974,16438,A,,178.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620160,BAO_0000218,
4975,16438,A,,178.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620161,BAO_0000218,
4976,10708,F,A-427,,80019,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620162,BAO_0000219,
4977,16597,F,A-431,,80852,Inhibition of A431 human squamous cell carcinoma cell proliferation,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620163,BAO_0000219,
4978,16062,F,A-431,,80852,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620833,BAO_0000219,
4979,16062,F,A-431,,80852,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL876396,BAO_0000219,
4980,16958,F,A-431,,80852,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620834,BAO_0000219,
4981,6700,F,A-431,,80852,Inhibition of A431 human carcinoma cell proliferation,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620835,BAO_0000219,
4982,17226,F,A-431,,80852,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620836,BAO_0000219,
4983,6828,F,A-431,,80852,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620837,BAO_0000219,
4984,12314,F,A-431,,80852,In vitro cytotoxicity against epidermoid carcinoma cell line,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621017,BAO_0000219,
4985,13412,F,A-431,,9,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621018,BAO_0000218,
4986,13299,F,A-431,,80852,Antiproliferative activity of compound was measured on human tumor cell line A431.,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621019,BAO_0000219,
4987,17420,F,A-431,,80852,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621020,BAO_0000219,
4988,13678,F,A-431,,80852,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621021,BAO_0000219,
4989,14171,F,A-431,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,8,500.0,,1,,H,Expert,,,CHEMBL621022,BAO_0000219,
4990,6333,F,A-431,,80852,Tested for antiproliferative activity against human A431 cells,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621023,BAO_0000219,
4991,2356,F,A-431,,9,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621024,BAO_0000219,
4992,15578,F,A-431,,80852,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621025,BAO_0000219,
4993,5126,F,A-431,,80852,Inhibition of A431 cell proliferation,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621026,BAO_0000219,
4994,6844,F,A-431,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621027,BAO_0000219,
4995,6844,F,A-431,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL876397,BAO_0000219,
4996,4925,F,A-431,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883797,BAO_0000219,
4997,4925,F,A-431,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621028,BAO_0000219,
4998,13978,F,A-431,,80852,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621029,BAO_0000219,
4999,16786,F,A-431,,80852,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621030,BAO_0000219,
5000,13412,F,A-431,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,8,500.0,,1,,H,Expert,,,CHEMBL621147,BAO_0000219,
5001,17824,F,A-431,,80852,In vivo antiproliferative activity against A431 cell line,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621148,BAO_0000218,
5002,12751,F,A-431,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621149,BAO_0000219,
5003,12380,F,A-431,,80852,Inhibition of A431 human epidermoid carcinoma cell proliferation,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621150,BAO_0000219,
5004,4959,F,A-431,,9,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621151,BAO_0000219,
5005,6333,F,A-431,,80852,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621152,BAO_0000219,
5006,6333,F,A-431,,80852,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621153,BAO_0000219,
5007,6333,F,A-431,,80852,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884000,BAO_0000219,
5008,5296,F,,,9,Inhibition of EGFR overexpressing A431 cell proliferation,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621154,BAO_0000019,
5009,12624,F,A-431,,80852,Inhibition of A431 cell proliferation,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621155,BAO_0000219,
5010,14926,F,A-431,,9,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621156,BAO_0000219,
5011,14926,F,A-431,,9,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621157,BAO_0000219,
5012,14926,F,A-431,,9,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,8,500.0,,1,,H,Expert,,,CHEMBL621158,BAO_0000219,
5013,15144,F,A-431,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621159,BAO_0000219,
5014,15144,F,A-431,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621160,BAO_0000219,
5015,5245,F,A-431,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621161,BAO_0000219,
5016,5245,F,A-431,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621162,BAO_0000219,
5017,5245,F,A-431,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621163,BAO_0000219,
5018,5245,F,A-431,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621164,BAO_0000219,
5019,5245,F,A-431,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621165,BAO_0000219,
5020,5922,A,,,22224,Half-life period in cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619159,BAO_0000019,
5021,1116,A,,1969.0,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619160,BAO_0000366,
5022,17853,A,,,22224,Longer half-life in monkey (i.v.) at 0.5 mpk,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619161,BAO_0000218,
5023,993,A,,1969.0,22224,Plasma half life in monkey,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619162,BAO_0000366,
5024,4514,A,,1969.0,22224,Plasma half-life in rhesus monkey,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619163,BAO_0000366,
5025,5334,A,,1969.0,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619164,BAO_0000218,
5026,5334,A,,1969.0,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619320,BAO_0000218,
5027,4578,A,,,22224,Tested for half life upon iv administration to african green monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619321,BAO_0000218,
5028,2661,A,,,22224,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL873336,BAO_0000218,
5029,5355,A,,,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619322,BAO_0000218,
5030,5355,A,,,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619323,BAO_0000218,
5031,5355,A,,,22224,The time for peak concentration value after oral administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619324,BAO_0000218,
5032,11271,A,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619325,BAO_0000019,
5033,11271,A,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876411,BAO_0000019,
5034,11271,A,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619326,BAO_0000019,
5035,11271,A,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619327,BAO_0000019,
5036,11271,A,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619328,BAO_0000019,
5037,11271,A,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619329,BAO_0000019,
5038,11271,A,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619330,BAO_0000019,
5039,11271,A,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619331,BAO_0000019,
5040,11271,A,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619332,BAO_0000019,
5041,11271,A,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619333,BAO_0000019,
5042,11271,A,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619334,BAO_0000019,
5043,11271,A,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619335,BAO_0000019,
5044,11271,A,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619336,BAO_0000019,
5045,11271,A,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619337,BAO_0000019,
5046,11271,A,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619338,BAO_0000019,
5047,11271,A,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL619339,BAO_0000019,
5048,5809,A,,,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619340,BAO_0000218,
5049,17720,A,,1969.0,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873496,BAO_0000218,
5050,3546,A,,1969.0,50597,AUC value in rat after IV administration at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619341,BAO_0000218,
5051,3546,A,,1969.0,50597,AUC value in rat after oral administration at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619342,BAO_0000218,
5052,3546,A,,,50597,Cmax value in rat after oral administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619343,BAO_0000218,
5053,3546,A,,,50597,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619344,BAO_0000218,
5054,3546,A,,,50597,Tmax value in rat after oral administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619345,BAO_0000218,
5055,3546,A,,,50597,Vc value in rat after IV administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619346,BAO_0000218,
5056,3546,A,,,50597,Half life period in rat after IV administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619347,BAO_0000218,
5057,10625,A,,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL619348,BAO_0000019,
5058,10625,A,,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL619349,BAO_0000019,
5059,10625,A,,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL619350,BAO_0000019,
5060,10625,A,,,22224,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL619351,BAO_0000019,
5061,10625,A,,,22224,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL875953,BAO_0000019,
5062,10625,A,,,22224,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL621716,BAO_0000019,
5063,10625,A,,,22224,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL621717,BAO_0000019,
5064,10625,A,,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,0,,Papio hamadryas,1,9557.0,U,Autocuration,,,CHEMBL621718,BAO_0000019,
5065,3510,A,,,22224,Area under curve after 1 mpk peroral administration to beagles,,0,,beagle,1,9615.0,U,Autocuration,,,CHEMBL621719,BAO_0000019,
5066,3510,A,,,22224,Area under curve after 2 mpk peroral administration to beagles,,0,,beagle,1,9615.0,U,Autocuration,,,CHEMBL621720,BAO_0000019,
5067,3510,A,,,22224,Cmax value after 1 mpk peroral administration to beagles,,0,,beagle,1,9615.0,U,Autocuration,,,CHEMBL621721,BAO_0000218,
5068,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL621722,BAO_0000019,
5069,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL621723,BAO_0000019,
5070,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL621724,BAO_0000019,
5071,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623443,BAO_0000019,
5072,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623444,BAO_0000019,
5073,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623445,BAO_0000019,
5074,7766,A,,1088.0,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Urine,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623446,BAO_0000019,
5075,16643,A,,2107.0,22224,Metabolic stability observed at 30 min after administration in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623447,BAO_0000251,
5076,6852,A,,,22224,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623448,BAO_0000019,
5077,6852,A,,,22224,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623449,BAO_0000019,
5078,6852,A,,,22224,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623450,BAO_0000019,
5079,6567,A,,2107.0,22224,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623451,BAO_0000251,
5080,6570,A,,,22224,Metabolic stability (% remaining at 30 mins) in human S9.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623452,BAO_0000019,
5081,6570,A,,,22224,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623453,BAO_0000019,
5082,5237,A,,2107.0,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623454,BAO_0000251,
5083,5237,A,,2107.0,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL623455,BAO_0000251,
5084,5237,A,,2107.0,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624371,BAO_0000251,
5085,5202,A,,,22224,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624372,BAO_0000218,
5086,5481,A,,,22224,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624373,BAO_0000019,
5087,5481,A,,,22224,Percent remaining in human plasma after incubation for 60 min at 37 C.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624374,BAO_0000019,
5088,3956,A,,,22224,The percent remaining in human plasma after 30 min was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624556,BAO_0000019,
5089,5074,A,,1969.0,22224,Conversion rate of the prodrug in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624557,BAO_0000366,
5090,5074,A,,1969.0,22224,Conversion rate of the prodrug in human plasma; ND means no data,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624558,BAO_0000366,
5091,4727,A,,178.0,22224,Half life of compound was determined in human blood,Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624559,BAO_0000221,
5092,5965,A,,,22224,Half life of compound was determined in man with once daily dosing,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624560,BAO_0000019,
5093,5732,A,,,22224,Half life in human microsomes,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624561,BAO_0000251,
5094,5819,A,,1969.0,22224,Half life in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624562,BAO_0000366,
5095,5819,A,,1969.0,22224,Half life in human plasma; Not detected,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624563,BAO_0000366,
5096,1916,A,,,22224,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624564,BAO_0000218,
5097,6597,A,,2107.0,22224,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624565,BAO_0000251,
5098,5229,A,,1969.0,22224,Half-life in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL875152,BAO_0000366,
5099,5229,A,,1969.0,22224,Half-life of the parent prodrug in plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624566,BAO_0000366,
5100,2192,A,,1969.0,22224,In vitro half life in human plasma was determined,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL873805,BAO_0000366,
5101,3032,A,,2107.0,22224,The compound was tested In Vitro for half life in human liver microsomes.,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624567,BAO_0000251,
5102,1916,A,,,22224,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624568,BAO_0000218,
5103,17716,A,,,22224,Observed volume of distribution,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624569,BAO_0000218,
5104,15778,A,,,22224,Oral bioavailability in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624570,BAO_0000218,
5105,17313,A,,,22224,Tested for human plasma protein binding of the compound,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624571,BAO_0000019,
5106,4231,A,,,22224,"First order rate constant, k was determined in human plasma",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624572,BAO_0000019,
5107,4755,A,,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624573,BAO_0000019,
5108,4755,A,,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL875153,BAO_0000019,
5109,16907,A,,2107.0,22224,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624574,BAO_0000251,
5110,10839,A,,,22224,The compound was tested for the plasma binding in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624575,BAO_0000019,
5111,10839,A,,,22224,Plasma protein binding (human),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624576,BAO_0000019,
5112,3199,A,,2107.0,22224,Compound was evaluated for half-life in human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624577,BAO_0000251,
5113,1345,A,,178.0,22224,Half life measured in vitro for its stability in human blood,Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL624578,BAO_0000221,
5114,4297,A,,1977.0,22224,Half life in human serum,Serum,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622796,BAO_0000019,
5115,4297,A,,1977.0,22224,Half life in human serum; ND=not determined,Serum,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622797,BAO_0000019,
5116,4297,A,,,22224,Half life were determined in CEM-SS cell extract in decomposition step 1,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622798,BAO_0000019,
5117,4297,A,,,22224,Half life were determined in CEM-SS cell extract in decomposition step 2,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622799,BAO_0000019,
5118,4231,A,,1969.0,22224,Half life of the in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622800,BAO_0000366,
5119,5633,A,,,22224,Half life period in human hepatic S9 fraction was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622801,BAO_0000220,
5120,5633,A,,2107.0,22224,Half life period in human liver microsome was determined,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622802,BAO_0000251,
5121,17791,A,,,22224,Half life period was determined; 6-7,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622803,BAO_0000019,
5122,17791,A,,,22224,Half life period was evaluated in human,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL875154,BAO_0000019,
5123,3160,A,,1969.0,22224,Half life time in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622804,BAO_0000366,
5124,16438,A,,955.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622805,BAO_0000218,
5125,16438,A,,948.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622611,BAO_0000218,
5126,16438,A,,948.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622612,BAO_0000218,
5127,16438,A,,2113.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875160,BAO_0000218,
5128,16438,A,,2113.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622613,BAO_0000218,
5129,16438,A,,2113.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622614,BAO_0000218,
5130,16438,A,,2107.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622615,BAO_0000218,
5131,16438,A,,2107.0,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622616,BAO_0000218,
5132,16438,A,,2107.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622617,BAO_0000218,
5133,16438,A,,2106.0,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622618,BAO_0000218,
5134,16438,A,,2106.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622619,BAO_0000218,
5135,16438,A,,2106.0,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622620,BAO_0000218,
5136,16438,A,,955.0,50594,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622621,BAO_0000218,
5137,16438,A,,178.0,50594,Biodistribution of compound (oxidized form) in blood tissue,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622622,BAO_0000218,
5138,16438,A,,178.0,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622623,BAO_0000218,
5139,16438,A,,178.0,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622624,BAO_0000218,
5140,16438,A,,178.0,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622625,BAO_0000218,
5141,16438,A,,178.0,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622626,BAO_0000218,
5142,16438,A,,178.0,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622627,BAO_0000218,
5143,16438,A,,955.0,50594,Biodistribution of compound (oxidized form) in brain tissue of mice,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622628,BAO_0000218,
5144,16438,A,,955.0,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622629,BAO_0000218,
5145,16438,A,,955.0,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622630,BAO_0000218,
5146,16438,A,,955.0,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622631,BAO_0000218,
5147,16438,A,,955.0,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622632,BAO_0000218,
5148,16438,A,,955.0,50594,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622633,BAO_0000218,
5149,16438,A,,948.0,50594,Biodistribution of compound (oxidized form) in heart tissue of mice,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622634,BAO_0000218,
5150,16438,A,,948.0,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622635,BAO_0000218,
5151,16438,A,,948.0,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875161,BAO_0000218,
5152,16438,A,,948.0,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622636,BAO_0000218,
5153,16438,A,,948.0,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623335,BAO_0000218,
5154,16438,A,,948.0,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623336,BAO_0000218,
5155,16438,A,,2113.0,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623337,BAO_0000218,
5156,16438,A,,2113.0,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623338,BAO_0000218,
5157,16438,A,,2113.0,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623339,BAO_0000218,
5158,16438,A,,2113.0,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623524,BAO_0000218,
5159,16438,A,,2113.0,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623525,BAO_0000218,
5160,16438,A,,2107.0,50594,Biodistribution of compound (oxidized form) in liver tissue,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623526,BAO_0000218,
5161,16438,A,,2107.0,50594,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623527,BAO_0000218,
5162,16438,A,,2107.0,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623528,BAO_0000218,
5163,5245,F,A-431,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624615,BAO_0000219,
5164,5245,F,A-431,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621672,BAO_0000219,
5165,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,1,500.0,,1,,N,Expert,,,CHEMBL621673,BAO_0000218,
5166,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,1,500.0,,1,,N,Expert,,,CHEMBL621674,BAO_0000218,
5167,16093,F,A-431,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL884002,BAO_0000219,
5168,16825,F,A-431,,80852,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621850,BAO_0000219,
5169,4848,F,A-431,,80852,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621851,BAO_0000219,
5170,14827,F,A-431,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621852,BAO_0000219,
5171,14827,F,A-431,,9,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621853,BAO_0000219,
5172,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,1,500.0,,1,,N,Expert,,,CHEMBL621854,BAO_0000218,
5173,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,1,500.0,,1,,N,Expert,,,CHEMBL621855,BAO_0000218,
5174,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,1,500.0,,1,,N,Expert,,,CHEMBL623724,BAO_0000218,
5175,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,1,500.0,,1,,N,Expert,,,CHEMBL623725,BAO_0000218,
5176,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,1,500.0,,1,,N,Expert,,,CHEMBL623726,BAO_0000218,
5177,16289,F,A-431,,9,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL623727,BAO_0000219,
5178,16289,F,A-431,,9,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,8,500.0,,1,,H,Expert,,,CHEMBL623728,BAO_0000219,
5179,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,1,500.0,,1,,N,Expert,,,CHEMBL623729,BAO_0000218,
5180,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,1,500.0,,1,,N,Expert,,,CHEMBL623730,BAO_0000218,
5181,16289,F,A-431,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,1,500.0,,1,,N,Expert,,,CHEMBL623731,BAO_0000218,
5182,14555,F,A-431,,80852,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,1,500.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL623732,BAO_0000218,
5183,14555,F,A-431,,80852,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,1,500.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL623733,BAO_0000218,
5184,14555,F,A-431,,80852,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,1,500.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL623734,BAO_0000218,
5185,14555,F,A-431,,80852,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,1,500.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL623735,BAO_0000218,
5186,1937,F,A-431,,80852,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623736,BAO_0000219,
5187,13739,F,A-431,,80852,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623737,BAO_0000219,
5188,3558,F,A-431,,80852,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623738,BAO_0000219,
5189,3558,F,A-431,,80852,Dose giving a 50% decrease in the living cell number (A437 cells),,1,500.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875168,BAO_0000219,
5190,17686,F,A549,,80682,In vitro inhibitory concentration against proliferation of A459 cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623739,BAO_0000219,
5191,5305,F,A549,,80682,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623740,BAO_0000219,
5192,3614,F,A549,,80682,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624424,BAO_0000219,
5193,17229,F,A498,,80021,In vitro antitumor activity against renal A498 tumor cell lines,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624425,BAO_0000219,
5194,15935,F,A498,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624426,BAO_0000219,
5195,15935,F,A498,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624427,BAO_0000219,
5196,15560,F,A498,,80021,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624428,BAO_0000219,
5197,13891,F,A498,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624429,BAO_0000219,
5198,13891,F,A498,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624620,BAO_0000219,
5199,13788,F,A498,,80021,Cytotoxicity on kidney carcinoma (A-498) cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624621,BAO_0000219,
5200,15403,F,A498,,80021,Compound was evaluated against Human cell line renal A498,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624622,BAO_0000219,
5201,1009,F,A498,,80021,Compound was tested for inhibition of A498 human renal cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624623,BAO_0000219,
5202,1043,F,A498,,80021,Growth inhibitory activity against A498 human cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL874365,BAO_0000219,
5203,5858,F,A498,,80021,In vitro antitumor activity against human renal A498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624624,BAO_0000219,
5204,5958,F,A498,,80021,In vitro cytotoxic activity against renal (A498) cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624625,BAO_0000219,
5205,5506,F,A498,,80021,In vitro cytotoxic activity against human renal cancer (A498) cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624626,BAO_0000219,
5206,12781,F,A498,,80021,Tested for cytostatic activity against renal A498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624627,BAO_0000219,
5207,14399,F,A498,,80021,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883157,BAO_0000219,
5208,5958,F,A498,,80021,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,1,624.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624628,BAO_0000219,
5209,3510,A,,,22224,Cmax value after 2 mpk peroral administration to beagles,,0,,beagle,1,9615.0,U,Autocuration,,,CHEMBL624629,BAO_0000218,
5210,3510,A,,,22224,Bioavailability,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,beagle,,CHEMBL623551,BAO_0000218,
5211,3510,A,,,22224,Bioavailability after 1 mpk peroral administration to beagles,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,beagle,,CHEMBL623552,BAO_0000218,
5212,3510,A,,,22224,Bioavailability after 2 mpk peroral administration to beagles,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,beagle,,CHEMBL623553,BAO_0000218,
5213,3085,A,,,22224,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623554,BAO_0000019,
5214,3085,A,,,22224,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623555,BAO_0000019,
5215,3085,A,,,22224,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623556,BAO_0000019,
5216,9372,A,,,22224,Solubility against bovine alpha-chymotrypsin,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623557,BAO_0000019,
5217,3085,A,,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623558,BAO_0000019,
5218,3085,A,,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623559,BAO_0000019,
5219,1469,A,,2106.0,22224,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Spleen,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623560,BAO_0000221,
5220,4297,A,,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623561,BAO_0000019,
5221,4297,A,,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623562,BAO_0000019,
5222,17585,A,,,22224,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623563,BAO_0000019,
5223,1336,A,,2106.0,22224,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Spleen,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623564,BAO_0000221,
5224,3085,A,,,22224,Half life in presence of 2 mg/mL BSA at pH 8.8,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL873806,BAO_0000019,
5225,2857,A,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623565,BAO_0000019,
5226,2857,A,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623566,BAO_0000019,
5227,2857,A,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623567,BAO_0000019,
5228,1540,A,,,22224,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,0,,Bos taurus,1,9913.0,U,Autocuration,,,CHEMBL623568,BAO_0000019,
5229,6316,A,,1969.0,50588,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623569,BAO_0000218,
5230,17594,A,,1969.0,50588,AUC after administration at 100 mg/kg/day in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623570,BAO_0000218,
5231,4953,A,,1969.0,50588,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624254,BAO_0000218,
5232,16907,A,,1969.0,50588,AUC value after 15 mg/kg iv dose in Dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624255,BAO_0000218,
5233,16907,A,,1969.0,50588,AUC value after 30 mg/kg po dose in Dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624256,BAO_0000218,
5234,2959,A,,1969.0,50588,AUC value after administration of 4 mg/Kg oral dose in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624257,BAO_0000218,
5235,17594,A,,1969.0,50588,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624258,BAO_0000218,
5236,5356,A,,,50588,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875277,BAO_0000218,
5237,16807,A,,,50588,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622667,BAO_0000218,
5238,4527,A,,,50588,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622668,BAO_0000218,
5239,4527,A,,,50588,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622669,BAO_0000218,
5240,15660,A,,,50588,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622670,BAO_0000218,
5241,15660,A,,,50588,Area under curve determined in dogs after oral administration of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622671,BAO_0000218,
5242,5802,A,,,50588,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622672,BAO_0000218,
5243,3598,A,,,50588,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL622673,BAO_0000218,
5244,3598,A,,,50588,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL622674,BAO_0000218,
5245,5944,A,,,50588,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622675,BAO_0000218,
5246,5944,A,,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622676,BAO_0000218,
5247,5944,A,,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622677,BAO_0000218,
5248,5944,A,,,50588,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622678,BAO_0000218,
5249,4186,A,,,50588,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622679,BAO_0000218,
5250,5007,A,,,50588,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622680,BAO_0000218,
5251,5668,A,,,50588,Area under curve was determine after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622681,BAO_0000218,
5252,5668,A,,,50588,Area under curve was determine after peroral administration at 5 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875278,BAO_0000218,
5253,5006,A,,,50588,Area under curve was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622682,BAO_0000218,
5254,5006,A,,,50588,Area under curve in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622683,BAO_0000218,
5255,3771,A,,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622684,BAO_0000218,
5256,3771,A,,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622685,BAO_0000218,
5257,3771,A,,,50588,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622686,BAO_0000218,
5258,1916,A,,,50588,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618344,BAO_0000218,
5259,5302,A,,,50588,Area under curve value in dog at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875582,BAO_0000218,
5260,5600,A,,,50588,Area under curve was determined after 0.1 mg/kg iv administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618345,BAO_0000218,
5261,5600,A,,,50588,Area under curve was determined after 0.3 mg/kg po administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618346,BAO_0000218,
5262,17764,A,,,50588,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618347,BAO_0000218,
5263,4368,A,,,50588,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618348,BAO_0000218,
5264,5318,A,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618349,BAO_0000019,
5265,5318,A,,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618350,BAO_0000019,
5266,5318,A,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618351,BAO_0000019,
5267,5318,A,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618352,BAO_0000019,
5268,14518,A,,178.0,22224,Time taken to reduce 50% of the concentration of compound in blood plasma,Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL873494,BAO_0000221,
5269,2209,A,,1969.0,22224,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618353,BAO_0000366,
5270,6787,A,,1969.0,22224,Half life in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618354,BAO_0000366,
5271,4898,A,,1969.0,22224,Half life in human plasma was reported,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL875583,BAO_0000366,
5272,6072,A,,1977.0,22224,Half life in human serum,Serum,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618355,BAO_0000019,
5273,16907,A,,1969.0,22224,Half life upon exposure to human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618356,BAO_0000366,
5274,5656,A,,,22224,t1/2 in human microsomes,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618357,BAO_0000251,
5275,4755,A,,1969.0,22224,Half life period in 80% human plasma at 37 degree Centigrade,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618358,BAO_0000366,
5276,17503,A,,14.0,22224,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Zone of skin,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618359,BAO_0000221,
5277,12357,A,,1969.0,22224,Half-life measured in in vitro Cathepsin B assay in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618360,BAO_0000366,
5278,3076,A,,,22224,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618361,BAO_0000019,
5279,6410,A,,2107.0,22224,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618362,BAO_0000251,
5280,3741,A,,1969.0,22224,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618363,BAO_0000366,
5281,3741,A,,1969.0,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618364,BAO_0000366,
5282,3741,A,,1969.0,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL875584,BAO_0000366,
5283,1540,A,,,22224,Half-life in the CEM cell extracts,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618365,BAO_0000019,
5284,2905,A,,1969.0,22224,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL873495,BAO_0000366,
5285,2905,A,,1969.0,22224,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618366,BAO_0000366,
5286,5523,A,,,22224,Half-life was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618367,BAO_0000019,
5287,1499,A,,178.0,22224,Half-life (human blood stability),Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618368,BAO_0000221,
5288,1499,A,,178.0,22224,Half-life (human blood stability); no data,Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618369,BAO_0000221,
5289,17065,A,,1969.0,22224,Half-life in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618370,BAO_0000366,
5290,6861,A,,,22224,CYP3A4 metabolism half-life (t1/2),,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618371,BAO_0000019,
5291,1499,A,,178.0,22224,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Blood,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618372,BAO_0000221,
5292,530,A,,1969.0,22224,In vitro half life in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618373,BAO_0000366,
5293,1116,A,,1969.0,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618374,BAO_0000366,
5294,6695,A,,1969.0,22224,In vitro hydrolysis in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618375,BAO_0000366,
5295,6695,A,,1969.0,22224,In vitro hydrolysis in human plasma; no data,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618376,BAO_0000366,
5296,10,A,,2107.0,22224,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618377,BAO_0000251,
5297,993,A,,1969.0,22224,Plasma half life in human,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618378,BAO_0000366,
5298,15429,A,,1969.0,22224,Stability after incubation with human plasma (at 37 degree C),Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618379,BAO_0000366,
5299,1675,A,,1969.0,22224,T1/2 was evaluated in human plasma,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618380,BAO_0000366,
5300,2209,A,,1969.0,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618381,BAO_0000366,
5301,2209,A,,1969.0,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618382,BAO_0000366,
5302,5318,A,,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618383,BAO_0000019,
5303,2412,A,,,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618384,BAO_0000019,
5304,2412,A,,,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL618385,BAO_0000019,
5305,2906,A,,1969.0,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619099,BAO_0000366,
5306,2906,A,,1969.0,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619100,BAO_0000366,
5307,5495,A,,,22224,Time taken for 50% to be consumed by serum PON1 was determined,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619101,BAO_0000019,
5308,5495,A,,,22224,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619102,BAO_0000019,
5309,4397,A,,2107.0,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619103,BAO_0000251,
5310,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL619268,BAO_0000218,
5311,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL619269,BAO_0000218,
5312,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL619270,BAO_0000218,
5313,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL619271,BAO_0000218,
5314,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL875585,BAO_0000218,
5315,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL619272,BAO_0000218,
5316,6058,F,786-0,,80640,Compound tested for growth inhibition of renal cancer cell line 786-0,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619273,BAO_0000219,
5317,17708,F,786-0,,80640,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619274,BAO_0000219,
5318,14017,F,786-0,,80640,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,1,391.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619275,BAO_0000219,
5319,16818,F,786-0,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619276,BAO_0000219,
5320,16818,F,786-0,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619277,BAO_0000219,
5321,16818,F,786-0,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619278,BAO_0000219,
5322,11970,F,786-0,,80640,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619279,BAO_0000219,
5323,12400,F,786-0,,80640,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL858458,BAO_0000219,
5324,12888,F,786-0,,80640,Cytotoxic effect on renal cancer line 786-0,,1,391.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619280,BAO_0000219,
5325,15300,F,786-0,,80640,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619281,BAO_0000219,
5326,14769,F,786-0,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619282,BAO_0000219,
5327,15895,F,786-0,,80640,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619283,BAO_0000219,
5328,17376,F,786-0,,80640,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619284,BAO_0000219,
5329,14882,F,786-0,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619285,BAO_0000219,
5330,14882,F,786-0,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619286,BAO_0000219,
5331,15176,F,786-0,,80640,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619287,BAO_0000219,
5332,12696,F,786-0,,80640,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL857455,BAO_0000219,
5333,2496,F,786-0,,80640,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883801,BAO_0000219,
5334,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619288,BAO_0000219,
5335,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619289,BAO_0000219,
5336,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619290,BAO_0000219,
5337,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619291,BAO_0000219,
5338,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619292,BAO_0000219,
5339,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619293,BAO_0000219,
5340,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619294,BAO_0000219,
5341,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619295,BAO_0000219,
5342,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619296,BAO_0000219,
5343,11831,F,791T cell line,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,1,972.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619297,BAO_0000219,
5344,12782,F,786-0,,80640,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,1,391.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619298,BAO_0000219,
5345,1229,F,,,22226,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL619299,BAO_0000019,
5346,15313,F,RPMI-8226,,80433,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,1,741.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619300,BAO_0000219,
5347,15313,F,RPMI-8226,,80433,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,1,741.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619301,BAO_0000219,
5348,11544,F,RPMI-8226,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619302,BAO_0000219,
5349,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619303,BAO_0000219,
5350,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619304,BAO_0000219,
5351,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL857706,BAO_0000219,
5352,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619305,BAO_0000219,
5353,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619306,BAO_0000219,
5354,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619307,BAO_0000219,
5355,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619308,BAO_0000219,
5356,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619309,BAO_0000219,
5357,9424,F,RPMI-8226,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619310,BAO_0000219,
5358,14769,F,A498,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619311,BAO_0000219,
5359,15354,F,A498,,80021,Compound was tested for the growth inhibition of A498 renal tumor cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619312,BAO_0000219,
5360,17445,F,A498,,80021,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619313,BAO_0000219,
5361,4337,F,A498,,80021,In vitro inhibitory concentration against renal cancer cell line A498,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619314,BAO_0000219,
5362,15277,F,A498,,80021,Cytotoxicity against A 498 tumor cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619959,BAO_0000219,
5363,4812,F,A498,,80021,In vitro antitumor activity against A498 human cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619960,BAO_0000219,
5364,4812,F,A498,,80021,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619961,BAO_0000219,
5365,4995,F,A498,,80021,Inhibitory dose required against A498 human tumor cell lines,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619962,BAO_0000219,
5366,5847,F,A498,,80021,Anticancer activity against one renal cancer (A498 cell line),,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875586,BAO_0000219,
5367,6557,F,A498,,80021,In vitro cytotoxicity against melanoma A498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619963,BAO_0000219,
5368,2597,F,A498,,80021,Compound was tested for growth inhibitory activity against A498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619964,BAO_0000219,
5369,6058,F,A498,,80021,Compound tested for growth inhibition of renal cancer cell line A498,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620108,BAO_0000219,
5370,17708,F,A498,,80021,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620109,BAO_0000219,
5371,15176,F,A498,,80021,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620110,BAO_0000219,
5372,15300,F,A498,,80021,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620111,BAO_0000219,
5373,11970,F,A498,,80021,Tested for cytotoxicity against A498 cell lines in renal cancer,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620112,BAO_0000219,
5374,12400,F,A498,,80021,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620113,BAO_0000219,
5375,12888,F,A498,,80021,Cytotoxic effect on renal cancer lines A498,,1,624.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620114,BAO_0000219,
5376,3030,F,A498,,80021,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620115,BAO_0000219,
5377,14769,F,A498,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620116,BAO_0000219,
5378,17376,F,A498,,80021,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620117,BAO_0000219,
5379,16558,F,A498,,80021,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620118,BAO_0000219,
5380,5194,F,A498,,80021,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620119,BAO_0000219,
5381,10708,F,A498,,80021,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620120,BAO_0000219,
5382,16880,F,A549,,80682,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620121,BAO_0000219,
5383,10196,F,A549,,80682,Antitumor activity against A549 human lung carcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620122,BAO_0000219,
5384,10196,F,A549,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620123,BAO_0000219,
5385,10196,F,A549,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620124,BAO_0000219,
5386,12083,F,A549,,80682,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620125,BAO_0000219,
5387,16464,F,A549,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620126,BAO_0000219,
5388,16464,F,A549,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883027,BAO_0000219,
5389,16470,F,A549,,80682,In vitro cytotoxic activity against human lung A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620127,BAO_0000219,
5390,16470,F,A549,,80682,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620128,BAO_0000219,
5391,16470,F,A549,,80682,In vitro cytotoxic activity against human lung A549 cell line),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620129,BAO_0000219,
5392,16470,F,A549,,80682,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620130,BAO_0000219,
5393,16582,F,A549,,80682,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620131,BAO_0000219,
5394,15935,F,A549,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620132,BAO_0000219,
5395,15935,F,A549,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620133,BAO_0000219,
5396,16597,F,A549,,80682,Inhibition of A549 human lung carcinoma cell proliferation,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620134,BAO_0000219,
5397,17376,F,A549,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620135,BAO_0000219,
5398,16496,F,A549,,80682,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620136,BAO_0000219,
5399,16152,F,A549,,80682,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620137,BAO_0000219,
5400,16152,F,A549,,80682,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620268,BAO_0000219,
5401,16464,F,A549,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620269,BAO_0000219,
5402,2288,F,A549,,80682,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620270,BAO_0000219,
5403,17350,F,A549,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620271,BAO_0000219,
5404,4090,F,A549,,80682,Inhibition of A549 cancer cell proliferation,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620272,BAO_0000219,
5405,4090,F,A549,,80682,Inhibition of A549 cancer cell proliferation (Not tested),,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620273,BAO_0000219,
5406,17350,F,A549,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620274,BAO_0000219,
5407,4197,F,A549,,80682,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620275,BAO_0000219,
5408,17072,F,A549,,80682,Antiproliferative potency determined as inhibitory concentration against A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620276,BAO_0000219,
5409,17072,F,A549,,80682,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620277,BAO_0000219,
5410,5194,F,A549,,80682,Cytotoxicity against Renal cell lines A549 was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620278,BAO_0000219,
5411,4257,A,,,50588,Area under curve was determined in dog after a 3 mg/kg of oral dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620279,BAO_0000218,
5412,6123,A,,,50588,Area under curve was determined in dog after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620280,BAO_0000218,
5413,1337,A,,,50588,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620281,BAO_0000218,
5414,1337,A,,,50588,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620282,BAO_0000218,
5415,8833,A,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621134,BAO_0000218,
5416,8833,A,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621135,BAO_0000218,
5417,8833,A,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621136,BAO_0000218,
5418,8833,A,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621137,BAO_0000218,
5419,17657,A,,1969.0,50588,Area under plasma concentration time curve in dog upon oral administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621138,BAO_0000218,
5420,17650,A,,1969.0,50588,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875587,BAO_0000218,
5421,1977,A,,,50588,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621139,BAO_0000218,
5422,1977,A,,,50588,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621140,BAO_0000218,
5423,3132,A,,,50588,Area under the curve for the compound was obtained when tested in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621141,BAO_0000218,
5424,5473,A,,,50588,Area under the curve at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621142,BAO_0000218,
5425,5474,A,,,50588,Area under the curve at a dose of 1 mg/kg (oral),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621143,BAO_0000218,
5426,5474,A,,,50588,Area under the curve at i.v. dose of 0.2 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621144,BAO_0000218,
5427,6062,A,,,50588,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621145,BAO_0000218,
5428,4709,A,,,50588,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621146,BAO_0000218,
5429,2652,A,,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622567,BAO_0000218,
5430,2652,A,,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622568,BAO_0000218,
5431,2877,A,,,50588,Compound was evaluated for area under the curve in dog blood.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622569,BAO_0000218,
5432,5444,A,,,50588,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622570,BAO_0000218,
5433,5130,A,,1969.0,50588,AUC in dog after oral dose (1 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622571,BAO_0000218,
5434,6265,A,,,50588,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622572,BAO_0000218,
5435,4657,A,,,50588,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622573,BAO_0000218,
5436,16367,A,,,50588,Pharmacokinetic parameter AUC after intravenous administration to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622574,BAO_0000218,
5437,16367,A,,,50588,Pharmacokinetic parameter AUC after oral administration to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622575,BAO_0000218,
5438,9579,A,,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622576,BAO_0000218,
5439,9579,A,,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622577,BAO_0000218,
5440,5983,A,,,50588,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622578,BAO_0000218,
5441,6241,A,,,50588,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622579,BAO_0000218,
5442,5313,A,,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622580,BAO_0000218,
5443,5313,A,,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622581,BAO_0000218,
5444,6642,A,,,50588,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622582,BAO_0000218,
5445,6642,A,,,50588,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622583,BAO_0000218,
5446,6641,A,,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622584,BAO_0000218,
5447,6642,A,,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622585,BAO_0000218,
5448,17791,A,,,50588,Compound was evaluated for oral bioavailability in dog; 90-100,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622586,BAO_0000218,
5449,17655,A,,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623281,BAO_0000218,
5450,17655,A,,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623282,BAO_0000218,
5451,6596,A,,,50588,PAPP (membrane permeability) in dog kidney cell monolayer assay,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623283,BAO_0000218,
5452,3880,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623284,BAO_0000218,
5453,16367,A,,,50588,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623285,BAO_0000218,
5454,17409,A,,1969.0,50588,Plasma protein binding towards dog plasma at 10 uM,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623463,BAO_0000218,
5455,17409,A,,1969.0,50588,Plasma protein binding towards dog plasma at 100 uM,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875952,BAO_0000218,
5456,2959,A,,,50588,Bioavailability in dog (dose 4 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621705,BAO_0000218,
5457,13501,A,,,50588,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621706,BAO_0000218,
5458,4527,A,,,50588,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621707,BAO_0000218,
5459,15145,A,,,50588,Bioavailability in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621708,BAO_0000218,
5460,4219,A,,,50588,Bioavailability,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621709,BAO_0000218,
5461,17538,A,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621710,BAO_0000218,
5462,17538,A,,,50588,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621711,BAO_0000218,
5463,1466,A,,,50588,Bioavailability in dog (dose 10.0 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621712,BAO_0000218,
5464,17650,A,,,50588,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621713,BAO_0000218,
5465,3132,A,,,50588,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621714,BAO_0000218,
5466,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL621715,BAO_0000218,
5467,2413,A,,2107.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Liver,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623717,BAO_0000218,
5468,2413,A,,2107.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Liver,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623718,BAO_0000218,
5469,2413,A,,2107.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Liver,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623719,BAO_0000218,
5470,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623720,BAO_0000218,
5471,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623721,BAO_0000218,
5472,2413,A,,2385.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Muscle tissue,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623722,BAO_0000218,
5473,2413,A,,2385.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Muscle tissue,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623723,BAO_0000218,
5474,2413,A,,2385.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Muscle tissue,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL618543,BAO_0000218,
5475,2413,A,,2106.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Spleen,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL618544,BAO_0000218,
5476,2413,A,,2106.0,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Spleen,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL875155,BAO_0000218,
5477,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL618545,BAO_0000218,
5478,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL618546,BAO_0000218,
5479,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623529,BAO_0000218,
5480,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL623530,BAO_0000218,
5481,2413,A,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,0,,Mus sp.,1,10095.0,U,Autocuration,,,CHEMBL621764,BAO_0000218,
5482,17827,A,,,22224,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621765,BAO_0000019,
5483,17827,A,,2037.0,22224,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621766,BAO_0000019,
5484,17827,A,,1870.0,22224,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621767,BAO_0000019,
5485,17827,A,,,22224,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621768,BAO_0000019,
5486,17827,A,,2435.0,22224,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Striatum,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621769,BAO_0000019,
5487,17827,A,,,22224,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621770,BAO_0000019,
5488,17827,A,,2037.0,22224,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621771,BAO_0000019,
5489,17827,A,,1870.0,22224,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621772,BAO_0000019,
5490,17827,A,,,22224,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621773,BAO_0000019,
5491,17827,A,,2435.0,22224,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Striatum,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621774,BAO_0000019,
5492,17791,A,,,22224,Compound was evaluated for oral bioavailability in rats,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621775,BAO_0000218,
5493,17667,A,,1969.0,22224,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621776,BAO_0000218,
5494,17791,A,,,22224,Half life period was evaluated in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621777,BAO_0000019,
5495,110,A,,,22224,Half-life in rhesus monkeys by intravenous administration of dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL875162,BAO_0000218,
5496,5781,A,,1969.0,50594,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621778,BAO_0000218,
5497,17734,A,,1969.0,50594,AUC after intraperitoneal administration of 100 mg/kg in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621779,BAO_0000218,
5498,17718,A,,1969.0,50594,AUC value was determined after oral administration,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622479,BAO_0000218,
5499,4573,A,,,50594,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622480,BAO_0000218,
5500,3277,A,,,50594,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622481,BAO_0000218,
5501,2862,A,,,50594,Area under curve by ioral administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622482,BAO_0000218,
5502,2862,A,,,50594,Area under curve by iv administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622483,BAO_0000218,
5503,5951,A,,,50594,Area under curve at 0-8 hr in IRC mice after peroral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622484,BAO_0000218,
5504,17729,A,,,50594,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622641,BAO_0000218,
5505,17728,A,,,50594,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622642,BAO_0000218,
5506,17728,A,,,50594,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622643,BAO_0000218,
5507,17729,A,,,50594,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622644,BAO_0000218,
5508,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622645,BAO_0000219,
5509,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622646,BAO_0000219,
5510,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621238,BAO_0000219,
5511,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621239,BAO_0000219,
5512,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621240,BAO_0000219,
5513,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621241,BAO_0000219,
5514,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621242,BAO_0000219,
5515,9424,F,RPMI-8226,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620350,BAO_0000219,
5516,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620351,BAO_0000219,
5517,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620352,BAO_0000219,
5518,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620353,BAO_0000219,
5519,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620354,BAO_0000219,
5520,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620355,BAO_0000219,
5521,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620356,BAO_0000219,
5522,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620357,BAO_0000219,
5523,9424,F,RPMI-8226,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620358,BAO_0000219,
5524,9424,F,RPMI-8226,,80433,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,1,741.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620359,BAO_0000219,
5525,11544,F,RPMI-8226,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620360,BAO_0000219,
5526,17378,F,RPMI-8226,,80433,Cytotoxicity of compound against 8226/DOX1V cells,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620361,BAO_0000219,
5527,17378,F,RPMI-8226,,80433,Cytotoxicity of compound against 8226/S cells,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620362,BAO_0000219,
5528,17079,F,RPMI-8226,,80433,Inhibitory concentration against 8226 myeloma cancer cell line,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620363,BAO_0000219,
5529,17079,F,RPMI-8226,,80433,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,1,741.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620364,BAO_0000219,
5530,13466,F,833K,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,1,854.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620365,BAO_0000219,
5531,13466,F,833K,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,1,854.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620366,BAO_0000219,
5532,2392,F,833K,,80647,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,1,854.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620367,BAO_0000219,
5533,2392,F,833K,,80647,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,1,854.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620368,BAO_0000219,
5534,6608,B,,,22226,Inhibitory activity against caspase-1,,0,,,1,,U,Autocuration,,,CHEMBL620369,BAO_0000019,
5535,10199,B,,,45,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,8,,Enterococcus faecalis,1,1351.0,H,Autocuration,,,CHEMBL620370,BAO_0000357,
5536,17749,F,8701-BC,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,1,705.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620371,BAO_0000219,
5537,17749,F,8701-BC,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,1,705.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620372,BAO_0000219,
5538,1229,F,,,22226,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL876492,BAO_0000019,
5539,1229,F,,,22226,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL620373,BAO_0000019,
5540,1229,F,,,22226,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,0,,,1,,U,Intermediate,,,CHEMBL620374,BAO_0000019,
5541,6390,B,,,22226,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,0,,,1,,U,Autocuration,,,CHEMBL620375,BAO_0000019,
5542,16219,F,,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,0,,Streptococcus pyogenes,1,1314.0,U,Autocuration,,,CHEMBL857902,BAO_0000019,
5543,16219,F,,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,0,,Streptococcus pyogenes,1,1314.0,U,Autocuration,,,CHEMBL620376,BAO_0000019,
5544,17043,B,,,11922,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,8,,,1,,H,Autocuration,,,CHEMBL620377,BAO_0000357,
5545,6929,F,KB ,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,,1,324.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620378,BAO_0000219,
5546,6929,A,KB ,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,,1,324.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620379,BAO_0000219,
5547,7083,F,,,22226,In vitro cytotoxicity of compound was tested against 9KB cells.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL620380,BAO_0000219,
5548,12446,F,9L,,80653,Cytotoxic concentration against 9L cells was determined on day 3,,1,392.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL884006,BAO_0000219,
5549,15345,F,9L,,80653,Tested in vitro for anticancer activity against 9L cells,,1,392.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL620381,BAO_0000219,
5550,15345,F,9L,,80653,Tested in vitro for anticancer activity against 9L cells; Not determined,,1,392.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL620382,BAO_0000219,
5551,6301,F,A549,,80682,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620383,BAO_0000219,
5552,4833,F,A549,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876493,BAO_0000219,
5553,4833,F,A549,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620384,BAO_0000219,
5554,4833,F,A549,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620385,BAO_0000219,
5555,13330,F,A549,,80682,Cytotoxicity against human lung carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620386,BAO_0000219,
5556,17517,F,A549,,25,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,9,646.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL620387,BAO_0000219,
5557,17517,F,A549,,25,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,9,646.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL621404,BAO_0000219,
5558,14425,F,A549,,80682,"In vitro growth inhibition of A549, lung carcinoma",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621405,BAO_0000219,
5559,14425,F,A549,,80682,"In vitro growth inhibition of A549, lung carcinoma.",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621406,BAO_0000219,
5560,5228,F,A549,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621407,BAO_0000219,
5561,5351,F,A549,,80682,Cytotoxic activity against human lung cancer A549 cell line was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621408,BAO_0000219,
5562,12198,F,A549,,80682,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL885345,BAO_0000219,
5563,13891,F,A549,,80682,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621409,BAO_0000219,
5564,5677,F,A549,,80682,Cytotoxicity in A549 (human carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL876034,BAO_0000219,
5565,13788,F,A549,,80682,Cytotoxicity on lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621410,BAO_0000219,
5566,13384,F,A549,,80682,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621411,BAO_0000219,
5567,6726,F,A549,,80682,Effective dose of compound against replication of A549 cell line was evaluated,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621412,BAO_0000219,
5568,3455,F,A549,,80682,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621413,BAO_0000219,
5569,5726,F,A549,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621414,BAO_0000219,
5570,5726,F,A549,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621415,BAO_0000219,
5571,3936,F,A549,,80682,The compound was evaluated for antiproliferative activity against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621416,BAO_0000219,
5572,14991,F,A549,,80682,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621417,BAO_0000219,
5573,5243,F,A549,,80682,Concentration required for growth inhibition of human lung carcinoma cell line A549,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621418,BAO_0000219,
5574,12858,F,A549,,80682,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621419,BAO_0000219,
5575,6776,F,A549,,80682,Growth inhibition against A549 cell line was evaluated,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621420,BAO_0000219,
5576,16558,F,A549,,80682,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875823,BAO_0000219,
5577,4583,F,A549,,80682,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621421,BAO_0000219,
5578,13514,F,A549,,80682,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621422,BAO_0000219,
5579,15166,F,A549,,80682,Chemosensitivity against DT-diaphorase rich A549 cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL884014,BAO_0000219,
5580,13873,F,A549,,80682,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621423,BAO_0000219,
5581,6447,F,A549,,80682,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621424,BAO_0000219,
5582,2068,F,A549,,80682,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621425,BAO_0000219,
5583,1863,F,A549,,80682,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621426,BAO_0000219,
5584,13873,F,A549,,80682,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621427,BAO_0000219,
5585,13873,F,A549,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621428,BAO_0000219,
5586,13873,F,A549,,80682,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621429,BAO_0000219,
5587,579,F,A549,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621430,BAO_0000219,
5588,579,F,A549,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621431,BAO_0000219,
5589,4584,F,A549,,80682,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621432,BAO_0000219,
5590,5421,F,A549,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621433,BAO_0000219,
5591,5421,F,A549,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875824,BAO_0000219,
5592,5421,F,A549,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621434,BAO_0000219,
5593,5421,F,A549,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621435,BAO_0000219,
5594,14188,F,A549,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621436,BAO_0000219,
5595,14188,F,A549,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621437,BAO_0000219,
5596,15354,F,A549,,80682,Compound was tested for the growth inhibition of A549 lung tumor cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621438,BAO_0000219,
5597,14253,F,A549,,80682,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621439,BAO_0000219,
5598,13873,F,A549,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621440,BAO_0000219,
5599,3043,A,,,50588,Oral bioavailability in dog (conscious),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621441,BAO_0000218,
5600,3045,A,,,50588,Compound was evaluated for the oral bioavailability after oral administration in dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621442,BAO_0000218,
5601,3022,A,,,50588,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621443,BAO_0000218,
5602,4453,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621444,BAO_0000218,
5603,1696,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625133,BAO_0000218,
5604,5045,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625134,BAO_0000218,
5605,5356,A,,,50588,Oral bioavailability in dog (fasted),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625135,BAO_0000218,
5606,17764,A,,,50588,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625136,BAO_0000218,
5607,6448,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625137,BAO_0000218,
5608,1475,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625138,BAO_0000218,
5609,3788,A,,,50588,Percent bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625139,BAO_0000218,
5610,3639,A,,,50588,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL872264,BAO_0000218,
5611,13397,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625140,BAO_0000218,
5612,2137,A,,,50588,The compound was evaluated for bioavailability in dogs; 34-44,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624436,BAO_0000218,
5613,2959,A,,,50588,Bioavailability in dog (dose 4 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624437,BAO_0000218,
5614,6448,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL872261,BAO_0000218,
5615,6084,A,,,50588,8 hour trough Blood level in dog was measured after administration of compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624438,BAO_0000218,
5616,3639,A,,1969.0,50588,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624439,BAO_0000218,
5617,6316,A,,,50588,C24 after oral administration at 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624440,BAO_0000218,
5618,5238,A,,,50588,Clearance after oral and iv dosing in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624441,BAO_0000218,
5619,17796,A,,1969.0,50588,Clearance of the drug was measured in the plasma of dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624442,BAO_0000218,
5620,2652,A,,,50588,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624443,BAO_0000218,
5621,5654,A,,,50588,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624444,BAO_0000218,
5622,6621,A,,,50588,Clearance of compound was determined in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624445,BAO_0000218,
5623,6505,A,,,50588,Clearance on i.v. administration of 2 mg/kg was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624446,BAO_0000218,
5624,5802,A,,,50588,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624447,BAO_0000218,
5625,17267,A,,,50588,Plasma clearance in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624448,BAO_0000218,
5626,4521,A,,,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624449,BAO_0000218,
5627,6535,A,,,50588,Plasma clearance in dog after administration of 0.25 mg/kg iv,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624450,BAO_0000218,
5628,6535,A,,,50588,Plasma clearance in dog after administration of 1 mg/kg iv,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875942,BAO_0000218,
5629,6535,A,,,50588,Plasma clearance in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624451,BAO_0000218,
5630,5542,A,,,50588,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624452,BAO_0000218,
5631,5199,A,,,50588,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624453,BAO_0000218,
5632,16907,A,,,50588,Plasma clearance after 15 mg/kg iv dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624454,BAO_0000218,
5633,16907,A,,,50588,Plasma clearance after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624455,BAO_0000218,
5634,16367,A,,,50588,Plasma administration to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624456,BAO_0000218,
5635,5505,A,,,50588,Plasma clearance was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624457,BAO_0000218,
5636,6215,A,,,50588,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624458,BAO_0000218,
5637,1466,A,,,50588,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624459,BAO_0000218,
5638,5007,A,,2107.0,102164,Intrinsic clearance in human liver microsomes,Liver,2,,Homo sapiens,1,9606.0,S,Intermediate,,,CHEMBL624460,BAO_0000251,
5639,5007,A,,2107.0,102164,Intrinsic clearance in human liver microsomes,Liver,2,,Homo sapiens,1,9606.0,S,Intermediate,,,CHEMBL624461,BAO_0000251,
5640,16452,A,,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875943,BAO_0000218,
5641,16452,A,,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624462,BAO_0000218,
5642,16452,A,,,50588,Clearance in dog (dose 1 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624463,BAO_0000218,
5643,6221,A,,,50588,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624464,BAO_0000218,
5644,5007,A,,,50588,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624465,BAO_0000218,
5645,5668,A,,,50588,Plasma clearance after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624466,BAO_0000218,
5646,5668,A,,,50588,Plasma clearance after peroral administration at 5 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624467,BAO_0000218,
5647,5668,A,,,50588,Plasma clearance after peroral administration at 5 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624468,BAO_0000218,
5648,15660,A,,,50588,Plasma clearance was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624469,BAO_0000218,
5649,15660,A,,,50588,Plasma clearance was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624470,BAO_0000218,
5650,5983,A,,,50588,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624471,BAO_0000218,
5651,5600,A,,,50588,Total clearance was determined after 0.1 mg/kg iv administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624472,BAO_0000218,
5652,17764,A,,,50588,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622775,BAO_0000218,
5653,6039,A,,,50588,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622776,BAO_0000218,
5654,6039,A,,,50588,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622777,BAO_0000218,
5655,6039,A,,,50588,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622778,BAO_0000218,
5656,4368,A,,,50588,Clearance by intravenous administration of 1.2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622779,BAO_0000218,
5657,4305,A,,,50588,Clearance by iv administration in dogs at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622780,BAO_0000218,
5658,1918,A,,1969.0,50588,Clearance value was evaluated in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622781,BAO_0000218,
5659,6005,A,,,50588,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622782,BAO_0000218,
5660,4839,A,,1969.0,50588,Compound was tested for plasma clearance in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622783,BAO_0000218,
5661,4239,A,,,50588,Pharmacokinetic property (Plasma clearance) was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622784,BAO_0000218,
5662,17729,A,,,50594,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622785,BAO_0000218,
5663,17728,A,,,50594,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622786,BAO_0000218,
5664,5302,A,,,50594,Area under curve value in mouse at a dose of 10 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622787,BAO_0000218,
5665,5506,A,,,50594,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875949,BAO_0000218,
5666,5506,A,,,50594,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622788,BAO_0000218,
5667,17764,F,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622789,BAO_0000218,
5668,17764,F,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622790,BAO_0000218,
5669,17764,F,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622791,BAO_0000218,
5670,17764,F,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622792,BAO_0000218,
5671,17764,A,,,50594,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622793,BAO_0000218,
5672,17753,A,,,50594,Area under curve was determined for the compound at 24 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622794,BAO_0000218,
5673,17753,A,,,50594,Area under curve was determined for the compound at 40 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622795,BAO_0000218,
5674,17753,A,,,50594,Area under curve was determined for the compound at 5 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621803,BAO_0000218,
5675,3132,A,,,50594,Area under the curve for the compound is obtained at dose 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621804,BAO_0000218,
5676,3132,A,,,50594,Area under the curve for the compound was obtained when tested in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621805,BAO_0000218,
5677,17837,A,,,50594,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621806,BAO_0000218,
5678,17837,A,,,50594,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621807,BAO_0000218,
5679,6062,A,,,50594,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621808,BAO_0000218,
5680,4066,A,,,50594,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621809,BAO_0000218,
5681,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621810,BAO_0000218,
5682,14239,A,,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875164,BAO_0000218,
5683,14239,A,,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621811,BAO_0000218,
5684,4890,A,,,50594,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621812,BAO_0000218,
5685,429,A,,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621813,BAO_0000218,
5686,429,A,,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621814,BAO_0000218,
5687,5969,A,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621815,BAO_0000218,
5688,5969,A,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621816,BAO_0000218,
5689,5969,A,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621817,BAO_0000218,
5690,6091,A,,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621818,BAO_0000218,
5691,6091,A,,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621819,BAO_0000218,
5692,6091,A,,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621820,BAO_0000218,
5693,6091,A,,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621821,BAO_0000218,
5694,6178,A,,,50594,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621822,BAO_0000218,
5695,6178,A,,,50594,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619474,BAO_0000218,
5696,6619,A,,,50594,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619475,BAO_0000218,
5697,6619,A,,,50594,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619476,BAO_0000218,
5698,3760,A,,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619477,BAO_0000218,
5699,3760,A,,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619478,BAO_0000218,
5700,3760,A,,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619479,BAO_0000218,
5701,3760,A,,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619480,BAO_0000218,
5702,3192,A,,,50594,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619481,BAO_0000218,
5703,3192,A,,,50594,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619482,BAO_0000218,
5704,2675,A,,,50594,Area under the curve was evaluated in mice after intravenous administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619483,BAO_0000218,
5705,2675,A,,,50594,Area under the curve was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619484,BAO_0000218,
5706,16597,A,,1969.0,50594,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619485,BAO_0000218,
5707,16597,A,,1969.0,50594,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619486,BAO_0000218,
5708,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619487,BAO_0000218,
5709,17734,A,,,50594,AUMC after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619488,BAO_0000218,
5710,7767,A,,178.0,50594,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620106,BAO_0000218,
5711,15345,F,9L,,80653,The compound was tested in vitro for anticancer activity against 9L cells,,1,392.0,,1,,N,Intermediate,,,CHEMBL620107,BAO_0000219,
5712,2181,F,,,22226,Anti proliferation activity determined; Weak effect,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620283,BAO_0000019,
5713,2181,F,,,22226,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL875176,BAO_0000219,
5714,2181,F,,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620284,BAO_0000219,
5715,2181,F,,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL623515,BAO_0000219,
5716,10486,F,,,22226,The cytotoxic activity was in vitro tested by 9PS assay method,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL623516,BAO_0000019,
5717,10486,F,,,22226,The cytotoxic activity was in vitro tested by 9PS assay method.,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL623517,BAO_0000019,
5718,15508,A,,,22224,Partition coefficient (logD6.5),,0,,,1,,U,Autocuration,,,CHEMBL857878,BAO_0000019,
5719,5242,F,A2780,,81034,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623518,BAO_0000219,
5720,16167,F,A-375,,80018,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624195,BAO_0000219,
5721,4782,F,A-431,,80852,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624196,BAO_0000219,
5722,16093,F,A-431,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9,500.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL624197,BAO_0000219,
5723,2596,F,A498,,80021,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624198,BAO_0000219,
5724,2596,F,A498,,80021,in vitro cytotoxicity against A 498 cancer cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621287,BAO_0000219,
5725,3239,F,A498,,80021,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621288,BAO_0000219,
5726,1847,F,A498,,80021,Cytotoxic activity against A 498 renal cancer cell lines.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876496,BAO_0000219,
5727,10553,F,A498,,80021,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621289,BAO_0000219,
5728,16219,F,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,0,,Staphylococcus aureus,1,1280.0,U,Autocuration,,,CHEMBL621290,BAO_0000019,
5729,16219,F,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,0,,Staphylococcus aureus,1,1280.0,U,Autocuration,,,CHEMBL621291,BAO_0000019,
5730,16219,F,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,0,,Staphylococcus aureus,1,1280.0,U,Autocuration,,,CHEMBL621292,BAO_0000019,
5731,16219,F,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,0,,Staphylococcus aureus,1,1280.0,U,Autocuration,,,CHEMBL621293,BAO_0000019,
5732,4782,F,A549,,80682,Inhibitory concentration required against A 549 lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621294,BAO_0000219,
5733,11805,F,A549,,80682,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621295,BAO_0000219,
5734,11805,F,A549,,80682,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884007,BAO_0000219,
5735,2007,F,A549,,80682,In vitro cytotoxicity against lung cancer A 549 cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621296,BAO_0000219,
5736,4594,F,A549,,80682,Compound was tested for its cytotoxicity against A 549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621297,BAO_0000219,
5737,6018,F,A549,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL839828,BAO_0000219,
5738,6018,F,A549,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620397,BAO_0000219,
5739,3599,F,A549,,80682,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620398,BAO_0000219,
5740,2551,F,A549,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620399,BAO_0000219,
5741,16132,F,A549,,80682,In vitro inhibition of A549 (human lung cancer) cell growth.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620400,BAO_0000219,
5742,16132,F,A549,,80682,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620401,BAO_0000219,
5743,2551,F,A549,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620402,BAO_0000219,
5744,2551,F,A549,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620403,BAO_0000219,
5745,11913,F,,,22226,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,0,,,1,,U,Autocuration,,,CHEMBL620404,BAO_0000218,
5746,12621,F,,,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,4,,,1,,H,Autocuration,,,CHEMBL620405,BAO_0000218,
5747,12621,F,,,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,4,,,1,,H,Autocuration,,,CHEMBL620406,BAO_0000218,
5748,12621,F,,,104694,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,4,,,1,,H,Autocuration,,,CHEMBL620407,BAO_0000218,
5749,12621,F,,,104694,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,4,,,1,,H,Autocuration,,,CHEMBL620408,BAO_0000218,
5750,12621,F,,,104694,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,4,,,1,,H,Autocuration,,,CHEMBL620409,BAO_0000218,
5751,3600,F,A498,,80021,Inhibition of A-498 human Renal cell proliferation,,1,624.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620410,BAO_0000219,
5752,1796,F,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620411,BAO_0000019,
5753,1796,F,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620412,BAO_0000019,
5754,1796,F,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL876596,BAO_0000019,
5755,16464,F,A 172,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,1,622.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620413,BAO_0000219,
5756,16464,F,A 172,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620414,BAO_0000219,
5757,16464,F,A 172,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620415,BAO_0000219,
5758,13617,F,A549,,80682,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620416,BAO_0000219,
5759,4584,F,A549,,80682,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620417,BAO_0000219,
5760,13799,F,A549,,80682,Cytotoxic activity evaluated against A549 tumor cells,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620418,BAO_0000219,
5761,16726,F,A549,,80682,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620419,BAO_0000219,
5762,16109,F,A549,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620420,BAO_0000219,
5763,16109,F,A549,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620421,BAO_0000219,
5764,15474,F,A549,,80682,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620422,BAO_0000219,
5765,6851,F,A549,,80682,Cytotoxicity of compound against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620423,BAO_0000219,
5766,17534,F,A549,,80682,Cytotoxicity against human lung cell carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620424,BAO_0000219,
5767,2621,F,A549,,80682,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620425,BAO_0000219,
5768,830,F,A549,,80682,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620426,BAO_0000219,
5769,14255,F,A549,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620427,BAO_0000219,
5770,14255,F,A549,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620428,BAO_0000219,
5771,1590,F,A549,,80682,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620429,BAO_0000219,
5772,6146,F,A549,,80682,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620430,BAO_0000219,
5773,17427,F,A549,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL839887,BAO_0000219,
5774,5280,F,A549,,80682,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620431,BAO_0000219,
5775,16786,F,A549,,80682,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884010,BAO_0000219,
5776,5895,F,A549,,80682,In vitro cytotoxicity against A549 (human lung cancer),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620538,BAO_0000219,
5777,14297,F,A549,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620539,BAO_0000219,
5778,17824,F,A549,,80682,In vivo antiproliferative activity against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623373,BAO_0000218,
5779,14368,F,A549,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623374,BAO_0000219,
5780,14368,F,A549,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623375,BAO_0000219,
5781,14254,F,A549,,80682,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623376,BAO_0000219,
5782,15897,F,A549,,80682,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623377,BAO_0000219,
5783,13866,F,A549,,80682,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623378,BAO_0000219,
5784,13370,F,A549,,80682,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623379,BAO_0000219,
5785,4862,F,A549,,80682,Inhibitory activity against A549 lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623380,BAO_0000219,
5786,4862,F,A549,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623381,BAO_0000219,
5787,4862,F,A549,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623382,BAO_0000219,
5788,15970,F,A549,,80682,Inhibitory concentration against A549 (lung cancer) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623383,BAO_0000219,
5789,17713,F,A549,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623384,BAO_0000219,
5790,4833,F,A549,,80682,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623385,BAO_0000219,
5791,13736,F,A549,,80682,Activity against A549 cancer cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623386,BAO_0000219,
5792,4312,F,A549,,80682,The compound was evaluated for cytotoxicity against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884105,BAO_0000219,
5793,5421,F,A549,,80682,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623387,BAO_0000219,
5794,5421,F,A549,,80682,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621568,BAO_0000219,
5795,14717,F,A549,,80682,Growth inhibitory activity was measured for human A549 tumor cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621569,BAO_0000219,
5796,4634,F,A549,,80682,Inhibitory activity against A549 lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621570,BAO_0000219,
5797,1149,F,A549,,80682,Inhibitory activity against A549 cell line; inactive,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621571,BAO_0000219,
5798,5421,F,A549,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621572,BAO_0000219,
5799,5421,F,A549,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621573,BAO_0000219,
5800,5421,F,A549,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621574,BAO_0000219,
5801,3320,F,A549,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621575,BAO_0000219,
5802,3320,F,A549,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621576,BAO_0000219,
5803,3320,F,A549,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621577,BAO_0000219,
5804,3320,F,A549,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621578,BAO_0000219,
5805,3320,F,A549,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621579,BAO_0000219,
5806,5726,F,A549,,80682,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621580,BAO_0000219,
5807,17800,A,,,50588,Plasma clearance (in vivo) in mongrel dogs was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621581,BAO_0000218,
5808,5985,A,,,50588,Plasma clearance was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621582,BAO_0000218,
5809,5530,A,,,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621583,BAO_0000218,
5810,5530,A,,,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621584,BAO_0000218,
5811,4839,A,,1969.0,50588,Tested for plasma clearance in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621585,BAO_0000218,
5812,3639,A,,,50588,The compound was tested for clearance in dog plasma.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621586,BAO_0000218,
5813,4838,A,,,50588,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875835,BAO_0000218,
5814,4137,A,,,50588,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621587,BAO_0000218,
5815,5017,A,,1969.0,50588,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621588,BAO_0000218,
5816,17538,A,,2107.0,50588,In vitro clearance in dog liver microsomes,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621589,BAO_0000218,
5817,6161,A,,,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621590,BAO_0000218,
5818,6161,A,,,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621591,BAO_0000218,
5819,1696,A,,,50588,Plasma clearance in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621592,BAO_0000218,
5820,6762,A,,,50588,Clearance rate in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621593,BAO_0000218,
5821,5932,A,,1969.0,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621594,BAO_0000218,
5822,6305,A,,,50588,Clearance in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621595,BAO_0000218,
5823,4942,A,,,50588,Plasma clearance in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621596,BAO_0000218,
5824,4219,A,,,50588,Plasma clearance was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621597,BAO_0000218,
5825,17853,A,,,50588,Lower clearance in dog (i.v.) at 0.5 mpk,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621598,BAO_0000218,
5826,4514,A,,,50588,Plasma clearance in Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621599,BAO_0000218,
5827,6448,A,,,50588,Plasma clearance (Clp) in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875836,BAO_0000218,
5828,6227,A,,,50588,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621600,BAO_0000218,
5829,6227,A,,,50588,Plasma clearance (pharmacokinetic parameter) in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621601,BAO_0000218,
5830,6062,A,,,50588,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618474,BAO_0000218,
5831,6821,A,,,50588,Plasma clearance of compound was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618475,BAO_0000218,
5832,4709,A,,,50588,Plasma clearance after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624524,BAO_0000218,
5833,4521,A,,,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624525,BAO_0000218,
5834,5374,A,,,50588,Plasma clearance in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624526,BAO_0000218,
5835,6057,A,,,50588,Plasma clearance was calculated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624527,BAO_0000218,
5836,4727,A,,,50588,Plasma clearance at the dose of 2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624528,BAO_0000218,
5837,5145,A,,,50588,Plasma clearance in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624529,BAO_0000218,
5838,17657,A,,,50588,Plasma clearance in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624530,BAO_0000218,
5839,17657,A,,,50588,Plasma clearance in dog; Unable to calculate,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624531,BAO_0000218,
5840,5145,A,,,50588,Plasma clearance in rhesus monkey,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624532,BAO_0000218,
5841,6642,A,,,50588,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624533,BAO_0000218,
5842,6641,A,,,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624534,BAO_0000218,
5843,6642,A,,,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624535,BAO_0000218,
5844,5472,A,,,50588,Plasma clearance was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624536,BAO_0000218,
5845,5472,A,,,50588,Plasma clearance was evaluated in dog; Not tested,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624537,BAO_0000218,
5846,5472,A,,,50588,Plasma clearance was evaluated in rhesus,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624538,BAO_0000218,
5847,5472,A,,,50588,Plasma clearance was evaluated in rhesus; Not tested,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624539,BAO_0000218,
5848,4257,A,,,50588,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624540,BAO_0000218,
5849,6679,A,,,50588,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624541,BAO_0000218,
5850,5546,A,,,50588,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624542,BAO_0000218,
5851,6348,A,,,50588,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624543,BAO_0000218,
5852,5474,A,,,50588,Clearance value at a dose of 0.2 mg/kg i.v.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624544,BAO_0000218,
5853,6316,A,,1969.0,50588,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624545,BAO_0000218,
5854,17594,A,,,50588,Cmax after oral dose of compound at 3 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624546,BAO_0000218,
5855,17594,A,,,50588,Cmax after single intravenous bolus of 1 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875957,BAO_0000218,
5856,5802,A,,,50588,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624547,BAO_0000218,
5857,6535,A,,,50588,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624548,BAO_0000218,
5858,6535,A,,,50588,Cmax in dog after administration of 1 mg/kg iv,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624549,BAO_0000218,
5859,1466,A,,1969.0,50588,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624550,BAO_0000218,
5860,6505,A,,,50588,Cmax on p.o. administration of 10 mg/kg was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621613,BAO_0000218,
5861,5668,A,,,50588,Cmax was determine after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621614,BAO_0000218,
5862,5668,A,,,50588,Cmax was determine after peroral administration at 5 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623431,BAO_0000218,
5863,5668,A,,,50588,Cmax was determine after peroral administration at 5 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623432,BAO_0000218,
5864,5600,A,,,50588,Cmax after 0.3 mg/kg po administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623433,BAO_0000218,
5865,17764,A,,,50588,Cmax after peroral administration in dogs at 2.4 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623434,BAO_0000218,
5866,6123,A,,,50588,Cmax in dog after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623435,BAO_0000218,
5867,6123,A,,,50588,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623436,BAO_0000218,
5868,6757,A,,,50588,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875958,BAO_0000218,
5869,16907,A,,,50588,Cmax value after 15 mg/kg iv dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623437,BAO_0000218,
5870,7767,A,,178.0,50594,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623438,BAO_0000218,
5871,7767,A,,178.0,50594,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623439,BAO_0000218,
5872,7767,A,,10000001.0,50594,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623440,BAO_0000218,
5873,7767,A,,10000001.0,50594,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623441,BAO_0000218,
5874,7767,A,,10000001.0,50594,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623442,BAO_0000218,
5875,7767,A,,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623469,BAO_0000218,
5876,7767,A,,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623470,BAO_0000218,
5877,7767,A,,,50594,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623471,BAO_0000218,
5878,7767,A,,948.0,50594,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623472,BAO_0000218,
5879,7767,A,,948.0,50594,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623473,BAO_0000218,
5880,7767,A,,948.0,50594,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623474,BAO_0000218,
5881,7767,A,,2113.0,50594,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623475,BAO_0000218,
5882,7767,A,,2113.0,50594,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623476,BAO_0000218,
5883,7767,A,,2113.0,50594,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623477,BAO_0000218,
5884,7767,A,,160.0,50594,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621896,BAO_0000218,
5885,7767,A,,160.0,50594,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621897,BAO_0000218,
5886,7767,A,,160.0,50594,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621898,BAO_0000218,
5887,7767,A,,2107.0,50594,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621899,BAO_0000218,
5888,7767,A,,2107.0,50594,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621900,BAO_0000218,
5889,7767,A,,2107.0,50594,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621901,BAO_0000218,
5890,7767,A,,2048.0,50594,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621902,BAO_0000218,
5891,7767,A,,2048.0,50594,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621903,BAO_0000218,
5892,7767,A,,2048.0,50594,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622587,BAO_0000218,
5893,7767,A,,2385.0,50594,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620285,BAO_0000218,
5894,7767,A,,2385.0,50594,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875285,BAO_0000218,
5895,7767,A,,2385.0,50594,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620286,BAO_0000218,
5896,7767,A,,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620287,BAO_0000218,
5897,7767,A,,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620288,BAO_0000218,
5898,7767,A,,,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620289,BAO_0000218,
5899,7767,A,,160.0,50594,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620290,BAO_0000218,
5900,7767,A,,160.0,50594,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620291,BAO_0000218,
5901,7767,A,,160.0,50594,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620292,BAO_0000218,
5902,7767,A,,2106.0,50594,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620293,BAO_0000218,
5903,7767,A,,2106.0,50594,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620294,BAO_0000218,
5904,7767,A,,2106.0,50594,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618614,BAO_0000218,
5905,7767,A,,945.0,50594,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618615,BAO_0000218,
5906,7767,A,,945.0,50594,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618616,BAO_0000218,
5907,2036,F,A 172,,80012,Cytotoxicity against A-172 human tumor cell lines,,1,622.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618617,BAO_0000219,
5908,2357,F,A 172,,80012,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618618,BAO_0000219,
5909,1457,F,A204,,80014,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,1,623.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618619,BAO_0000219,
5910,4379,F,A2780,,81034,Tested for antiproliferative activity against A-2780 tumoral cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618620,BAO_0000219,
5911,1093,F,A-375,,80018,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618621,BAO_0000219,
5912,12152,F,A-375,,80018,Tested in vitro against A-375 cell line human melanoma,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618622,BAO_0000219,
5913,16464,F,A-427,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,1,797.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618623,BAO_0000219,
5914,16464,F,A-427,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618624,BAO_0000219,
5915,16582,F,A-427,,80019,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,1,797.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618625,BAO_0000219,
5916,16464,F,A-427,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618626,BAO_0000219,
5917,10413,F,A-427,,80019,Antitumor activity on A-427 lung carcinoma cell lines,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618627,BAO_0000219,
5918,6418,F,A-427,,80019,Cytotoxic activity against human A-427 lung tumor cell line,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618628,BAO_0000219,
5919,17134,F,A-427,,80019,In vitro antitumor effects against human A-427 cell lines.,,1,797.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618629,BAO_0000219,
5920,16132,F,A-427,,80019,In vitro inhibition of A-427 (human lung cancer) cell growth.,,1,797.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618630,BAO_0000219,
5921,16132,F,A-427,,80019,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618631,BAO_0000219,
5922,16780,F,A-427,,80019,Cytotoxic activity of compound against A-427 lung human tumor cell line,,1,797.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618632,BAO_0000219,
5923,4085,F,A-431,,80852,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,1,500.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618633,BAO_0000219,
5924,1276,F,A498,,80021,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619315,BAO_0000219,
5925,3498,F,A498,,80021,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,1,624.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619316,BAO_0000219,
5926,1169,F,A498,,80021,Cytotoxicity against human kidney carcinoma A-498cell lines,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619317,BAO_0000219,
5927,4450,F,A498,,80021,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619318,BAO_0000219,
5928,3311,F,A498,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619319,BAO_0000219,
5929,4461,F,A498,,80021,Antitumor cytotoxic activity against A-498 cell line was determined,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619739,BAO_0000219,
5930,3311,F,A498,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619740,BAO_0000219,
5931,3311,F,A498,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883158,BAO_0000219,
5932,1457,F,A498,,80021,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884012,BAO_0000219,
5933,3664,F,A498,,80021,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619741,BAO_0000219,
5934,15895,F,A498,,80021,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,1,624.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619742,BAO_0000219,
5935,11843,F,A549,,80682,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876610,BAO_0000219,
5936,11843,F,A549,,80682,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619743,BAO_0000219,
5937,17705,F,A549,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619744,BAO_0000219,
5938,17705,F,A549,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619745,BAO_0000219,
5939,4369,F,A549,,80682,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619746,BAO_0000219,
5940,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619747,BAO_0000219,
5941,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619748,BAO_0000219,
5942,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619749,BAO_0000219,
5943,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619750,BAO_0000219,
5944,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624014,BAO_0000219,
5945,4369,F,A549,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624015,BAO_0000219,
5946,4787,F,A549,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL885344,BAO_0000219,
5947,4787,F,A549,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623224,BAO_0000219,
5948,6513,F,A549,,80682,Cytotoxic activity against A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623225,BAO_0000219,
5949,6690,F,A549,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622698,BAO_0000219,
5950,6690,F,A549,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622699,BAO_0000219,
5951,12263,F,A549,,80682,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622700,BAO_0000219,
5952,1054,F,A549,,80682,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622701,BAO_0000219,
5953,1359,F,A549,,80682,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622702,BAO_0000219,
5954,3547,F,A549,,80682,Cytotoxic activity against human lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622703,BAO_0000219,
5955,5771,F,A549,,80682,Cytotoxic activity towards A-549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622704,BAO_0000219,
5956,14425,F,A549,,80682,"In vitro percent inhibition of A549, lung carcinoma.",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622705,BAO_0000219,
5957,14425,F,A549,,80682,"In vitro percent inhibition of A549, lung carcinoma",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622706,BAO_0000219,
5958,14425,F,A549,,80682,"In vitro percent inhibition of A549, lung carcinoma.",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622707,BAO_0000219,
5959,14425,F,A549,,80682,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622708,BAO_0000219,
5960,5280,F,A549,,80682,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622709,BAO_0000219,
5961,15176,F,A549,,80682,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622710,BAO_0000219,
5962,15300,F,A549,,80682,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622711,BAO_0000219,
5963,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622712,BAO_0000218,
5964,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622713,BAO_0000218,
5965,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622714,BAO_0000218,
5966,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622715,BAO_0000218,
5967,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622716,BAO_0000218,
5968,17824,F,A549,,80682,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622717,BAO_0000219,
5969,17528,F,A549,,80682,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622718,BAO_0000218,
5970,6870,F,A549,,80682,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622719,BAO_0000219,
5971,6870,F,A549,,80682,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622720,BAO_0000219,
5972,6870,F,A549,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622721,BAO_0000219,
5973,6870,F,A549,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622722,BAO_0000219,
5974,16726,F,A549,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876030,BAO_0000219,
5975,6170,F,A549,,80682,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620206,BAO_0000219,
5976,6583,F,A549,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620207,BAO_0000219,
5977,6583,F,A549,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620208,BAO_0000219,
5978,6583,F,A549,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620209,BAO_0000219,
5979,6583,F,A549,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620210,BAO_0000219,
5980,6583,F,A549,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621639,BAO_0000219,
5981,17321,F,A549,,80682,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621640,BAO_0000219,
5982,17528,F,A549,,80682,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621641,BAO_0000219,
5983,12888,F,A549,,80682,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621642,BAO_0000219,
5984,4312,F,A549,,80682,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621643,BAO_0000219,
5985,4312,F,A549,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621644,BAO_0000219,
5986,4312,F,A549,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621645,BAO_0000219,
5987,17737,F,A549,,80682,In vitro antiproliferative activity against A549 cell line,,1,646.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621646,BAO_0000219,
5988,6630,F,A549,,80682,Synergism with indomethacin in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621647,BAO_0000219,
5989,6630,F,A549,,80682,Synergism with tolmetin in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621648,BAO_0000219,
5990,6630,F,A549,,80682,Synergism with sulindac in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621649,BAO_0000219,
5991,6630,F,A549,,80682,Antagonism of indomethacin in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621650,BAO_0000219,
5992,6630,F,A549,,80682,Antagonism of sulindac in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621651,BAO_0000219,
5993,6630,F,A549,,80682,Antagonism of tolmetin in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621652,BAO_0000219,
5994,6630,F,A549,,80682,Synergism with indomethacin in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621653,BAO_0000219,
5995,6630,F,A549,,80682,Synergism with sulindac in A549 cells,,1,646.0,,1,,N,Intermediate,,,CHEMBL621654,BAO_0000219,
5996,6630,F,A549,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,1,646.0,,1,,N,Intermediate,,,CHEMBL621655,BAO_0000219,
5997,16907,A,,,50588,Cmax value after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621656,BAO_0000218,
5998,5944,A,,,50588,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621657,BAO_0000218,
5999,5944,A,,,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621658,BAO_0000218,
6000,5944,A,,,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621659,BAO_0000218,
6001,5944,A,,,50588,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621660,BAO_0000218,
6002,2959,A,,,50588,Cmax value after administration of 4 mg/Kg oral dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621661,BAO_0000218,
6003,6241,A,,,50588,Cmax value in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621662,BAO_0000218,
6004,6241,A,,,50588,Cmax value in dogs after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621663,BAO_0000218,
6005,2652,A,,,50588,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621664,BAO_0000218,
6006,1806,A,,1969.0,50588,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621665,BAO_0000218,
6007,1806,A,,1969.0,50588,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621666,BAO_0000218,
6008,1021,A,,,50588,Concentration maxima after oral dosing in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621667,BAO_0000218,
6009,1021,A,,,50588,Concentration maxima after oral dosing in dogs; not available,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876738,BAO_0000218,
6010,1021,A,,,50588,Concentration maxima after oral dosing in dogs; not available,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621668,BAO_0000218,
6011,5444,A,,,50588,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621669,BAO_0000218,
6012,5444,A,,,50588,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621670,BAO_0000218,
6013,5444,A,,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621671,BAO_0000218,
6014,5444,A,,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622360,BAO_0000218,
6015,5444,A,,,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622361,BAO_0000218,
6016,5130,A,,1969.0,50588,Cmax in dog plasma after oral dose (1 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622362,BAO_0000218,
6017,3249,A,,1969.0,50588,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622363,BAO_0000218,
6018,5473,A,,1969.0,50588,Maximal plasma concentration at a dose of 1 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622364,BAO_0000218,
6019,5474,A,,1969.0,50588,Maximal plasma concentration at a dose of 1 mg/kg (oral),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622365,BAO_0000218,
6020,4657,A,,1969.0,50588,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622533,BAO_0000218,
6021,3031,A,,,50588,Maximum concentration of compound in dog was evaluated.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622534,BAO_0000218,
6022,4527,A,,,50588,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622535,BAO_0000218,
6023,4186,A,,,50588,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876739,BAO_0000218,
6024,5007,A,,,50588,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622536,BAO_0000218,
6025,3132,A,,1969.0,50588,Maximum concentration obtained in dog plasma was determined,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622537,BAO_0000218,
6026,5006,A,,,50588,Maximum concentration was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622538,BAO_0000218,
6027,4727,A,,,50588,Maximum concentration at the dose of 2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627867,BAO_0000218,
6028,1916,A,,,50588,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627868,BAO_0000218,
6029,1918,A,,1969.0,50588,Maximum concentration was evaluated in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627869,BAO_0000218,
6030,3045,A,,,50588,Maximum concentration was evaluated after 75 min after administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627870,BAO_0000218,
6031,9579,A,,1969.0,50588,Maximum plasma concentration determined in dog after oral administration of 17b,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627871,BAO_0000218,
6032,9579,A,,1969.0,50588,Maximum plasma concentration determined in dog after oral administration of 2b,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627872,BAO_0000218,
6033,933,A,,1969.0,50588,Maximum plasma concentration in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627873,BAO_0000218,
6034,17839,A,,1969.0,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627874,BAO_0000218,
6035,17839,A,,1969.0,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627875,BAO_0000218,
6036,17839,A,,1969.0,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627876,BAO_0000218,
6037,17839,A,,1969.0,50588,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627877,BAO_0000218,
6038,6348,A,,1969.0,50588,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627878,BAO_0000218,
6039,16367,A,,1969.0,50588,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627879,BAO_0000218,
6040,1337,A,,1969.0,50588,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875355,BAO_0000218,
6041,1337,A,,1969.0,50588,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627880,BAO_0000218,
6042,5199,A,,1969.0,50588,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627881,BAO_0000218,
6043,17650,A,,1969.0,50588,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627882,BAO_0000218,
6044,6679,A,,1969.0,50588,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627883,BAO_0000218,
6045,5356,A,,1969.0,50588,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628526,BAO_0000218,
6046,5356,A,,1969.0,50588,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628527,BAO_0000218,
6047,6227,A,,1969.0,50588,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628528,BAO_0000218,
6048,6227,A,,1969.0,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628529,BAO_0000218,
6049,6227,A,,1969.0,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628530,BAO_0000218,
6050,6227,A,,1969.0,50588,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625243,BAO_0000218,
6051,3598,A,,1969.0,50588,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL625244,BAO_0000218,
6052,4368,A,,,50588,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625245,BAO_0000218,
6053,6265,A,,,50588,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625246,BAO_0000218,
6054,7767,A,,945.0,50594,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625247,BAO_0000218,
6055,7767,A,,1088.0,50594,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625248,BAO_0000218,
6056,7767,A,,1088.0,50594,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625249,BAO_0000218,
6057,7767,A,,1088.0,50594,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625250,BAO_0000218,
6058,17811,A,,,50594,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625251,BAO_0000218,
6059,17811,A,,,50594,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875356,BAO_0000218,
6060,17827,A,,,50594,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625252,BAO_0000218,
6061,17827,A,,178.0,50594,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625253,BAO_0000218,
6062,17827,A,,,50594,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625254,BAO_0000218,
6063,17827,A,,,50594,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625255,BAO_0000218,
6064,17827,A,,,50594,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625256,BAO_0000218,
6065,17827,A,,178.0,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625257,BAO_0000218,
6066,17827,A,,178.0,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625258,BAO_0000218,
6067,17827,A,,,50594,Compound was evaluated for washout rate in mice (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625259,BAO_0000218,
6068,17827,A,,,50594,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625260,BAO_0000218,
6069,17827,A,,,50594,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625261,BAO_0000218,
6070,17827,A,,,50594,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625262,BAO_0000218,
6071,17827,A,,,50594,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622639,BAO_0000218,
6072,17257,A,,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622640,BAO_0000218,
6073,17257,A,,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622812,BAO_0000218,
6074,17257,A,,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622813,BAO_0000218,
6075,17257,A,,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622814,BAO_0000218,
6076,17827,A,,,50594,Time at maximum activity in mice (Radiolabeled compound),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622815,BAO_0000218,
6077,3760,A,,,50594,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625342,BAO_0000218,
6078,3760,A,,,50594,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625343,BAO_0000218,
6079,17409,A,,,50594,Binding towards mouse plasma protein at 10 uM,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL877591,BAO_0000218,
6080,17409,A,,,50594,Binding towards mouse plasma protein at 100 uM,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625344,BAO_0000218,
6081,2675,A,,,50594,Bioavailability was evaluated in mice after intravenous administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625345,BAO_0000218,
6082,2675,A,,,50594,Bioavailability was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625346,BAO_0000218,
6083,3132,A,,,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625347,BAO_0000218,
6084,3132,A,,,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625348,BAO_0000218,
6085,16597,A,,,50594,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625349,BAO_0000218,
6086,2862,A,,,50594,Oral bioavailability in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625350,BAO_0000218,
6087,17764,A,,,50594,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL882952,BAO_0000218,
6088,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625351,BAO_0000218,
6089,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625352,BAO_0000218,
6090,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL877592,BAO_0000218,
6091,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625353,BAO_0000218,
6092,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625354,BAO_0000218,
6093,846,A,,955.0,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626019,BAO_0000218,
6094,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626020,BAO_0000218,
6095,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626021,BAO_0000218,
6096,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626022,BAO_0000218,
6097,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626192,BAO_0000218,
6098,1276,F,A549,,80682,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626193,BAO_0000219,
6099,3498,F,A549,,80682,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL626194,BAO_0000219,
6100,1169,F,A549,,80682,Cytotoxicity against human lung carcinoma A-549 cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626195,BAO_0000219,
6101,4450,F,A549,,80682,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626196,BAO_0000219,
6102,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626197,BAO_0000219,
6103,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626198,BAO_0000219,
6104,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626199,BAO_0000219,
6105,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626200,BAO_0000219,
6106,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626201,BAO_0000219,
6107,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626202,BAO_0000219,
6108,358,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626203,BAO_0000219,
6109,15167,F,A549,,80682,In vitro cytotoxicity against A-549 human lung cancer cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626204,BAO_0000219,
6110,4139,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624701,BAO_0000219,
6111,833,F,A549,,80682,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624702,BAO_0000219,
6112,15718,F,A549,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624703,BAO_0000219,
6113,12373,F,A549,,80682,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624704,BAO_0000219,
6114,637,F,A549,,80682,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624705,BAO_0000219,
6115,14867,F,A549,,80682,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624706,BAO_0000219,
6116,4461,F,A549,,80682,Antitumor cytotoxic activity against A-549 cell line was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624707,BAO_0000219,
6117,5406,F,A549,,80682,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624708,BAO_0000219,
6118,4457,F,A549,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624709,BAO_0000219,
6119,1386,F,A549,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL884107,BAO_0000219,
6120,3265,F,A549,,80682,Antitumoral activity was assayed against A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624710,BAO_0000219,
6121,2359,F,A549,,80682,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624711,BAO_0000219,
6122,4457,F,A549,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624712,BAO_0000219,
6123,12454,F,A549,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624713,BAO_0000219,
6124,1481,F,A549,,80682,Compound was tested for inhibition of cell growth of A-549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624714,BAO_0000219,
6125,1750,F,A549,,80682,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624715,BAO_0000219,
6126,5065,F,A549,,80682,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624716,BAO_0000219,
6127,808,F,A549,,80682,In vitro cytotoxicity against A549-human lung carcinoma cells.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619505,BAO_0000219,
6128,16364,F,A549,,80682,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619506,BAO_0000219,
6129,1847,F,A549,,80682,Cytotoxic activity against A-549 cell lines.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619507,BAO_0000219,
6130,1747,F,A549,,80682,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619508,BAO_0000219,
6131,1003,F,A549,,80682,Cytotoxicity against human A549 non small cell lung cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619509,BAO_0000219,
6132,15313,F,A549,,80682,Inhibition of cell growth in (A-549) lung cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619510,BAO_0000219,
6133,3122,F,A549,,80682,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619511,BAO_0000219,
6134,16049,F,A549,,80682,In vitro antitumor activity against A-549 tumor cells.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619512,BAO_0000219,
6135,17134,F,A549,,80682,In vitro antitumor effects against human A-549 cell lines.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619513,BAO_0000219,
6136,6406,F,A549,,80682,In vitro cytotoxic activity of compound against A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619514,BAO_0000219,
6137,627,F,A549,,80682,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619515,BAO_0000219,
6138,12307,F,A549,,80682,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619516,BAO_0000219,
6139,17861,F,A549,,80682,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884005,BAO_0000219,
6140,6682,F,A549,,80682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619517,BAO_0000219,
6141,6663,F,A549,,80682,Inhibitory concentration of compound against A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619518,BAO_0000219,
6142,2454,F,A549,,80682,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619519,BAO_0000219,
6143,14709,F,A549,,80682,cytotoxic activity against leukemia (A-549) cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876489,BAO_0000219,
6144,15718,F,A549,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619520,BAO_0000219,
6145,15718,F,A549,,80682,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619521,BAO_0000219,
6146,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619522,BAO_0000219,
6147,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619523,BAO_0000219,
6148,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619524,BAO_0000219,
6149,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619525,BAO_0000219,
6150,6630,F,A549,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,1,646.0,,1,,N,Intermediate,,,CHEMBL619526,BAO_0000219,
6151,16726,F,A549,,80682,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619527,BAO_0000219,
6152,17846,F,A549,,80682,Cytotoxicity against A549 cells; No cytotoxicity,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619528,BAO_0000219,
6153,3415,F,A549,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619529,BAO_0000219,
6154,3415,F,A549,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619530,BAO_0000219,
6155,5609,F,A549,,80682,In vitro anticancer activity against human lung (A549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876490,BAO_0000219,
6156,17206,F,A549,,80682,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619531,BAO_0000219,
6157,17206,F,A549,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619532,BAO_0000219,
6158,17206,F,A549,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619533,BAO_0000219,
6159,17206,F,A549,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619534,BAO_0000219,
6160,17206,F,A549,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620164,BAO_0000219,
6161,17206,F,A549,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620165,BAO_0000219,
6162,16295,F,A549,,80682,Inhibition of A549 human lung tumor cell proliferation,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620166,BAO_0000219,
6163,16825,F,A549,,80682,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620167,BAO_0000219,
6164,3439,F,A549,,80682,In vitro cytotoxicity against human tumor cell line A549,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620168,BAO_0000219,
6165,10870,F,A549,,80682,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620338,BAO_0000219,
6166,4845,F,A549,,80682,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620339,BAO_0000219,
6167,5822,F,A549,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620340,BAO_0000219,
6168,5822,F,A549,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620341,BAO_0000219,
6169,5822,F,A549,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876491,BAO_0000219,
6170,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620342,BAO_0000219,
6171,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620343,BAO_0000219,
6172,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620344,BAO_0000219,
6173,5609,F,A549,,80682,In vitro anticancer activity against human lung (A549) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620345,BAO_0000219,
6174,4644,F,A549,,80682,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620346,BAO_0000219,
6175,4644,F,A549,,80682,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620347,BAO_0000219,
6176,4644,F,A549,,80682,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620348,BAO_0000219,
6177,4644,F,A549,,80682,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620349,BAO_0000219,
6178,5822,F,A549,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618667,BAO_0000219,
6179,3415,F,A549,,80682,Percentage inhibition of human lung carcinoma (A549) cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618668,BAO_0000219,
6180,16726,F,A549,,80682,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876031,BAO_0000219,
6181,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618759,BAO_0000219,
6182,17206,F,A549,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618760,BAO_0000219,
6183,17206,F,A549,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619000,BAO_0000219,
6184,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619001,BAO_0000219,
6185,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619002,BAO_0000219,
6186,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619003,BAO_0000219,
6187,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619597,BAO_0000219,
6188,17206,F,A549,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619598,BAO_0000219,
6189,17206,F,A549,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619599,BAO_0000219,
6190,17206,F,A549,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619600,BAO_0000219,
6191,16726,F,A549,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619601,BAO_0000219,
6192,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619602,BAO_0000219,
6193,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619603,BAO_0000219,
6194,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619604,BAO_0000219,
6195,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619605,BAO_0000219,
6196,6084,A,,,50588,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619606,BAO_0000218,
6197,6084,A,,,50588,Pharmacokinetic activity (Cmax) in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876032,BAO_0000218,
6198,4809,A,,,50588,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619607,BAO_0000218,
6199,5983,A,,,50588,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619608,BAO_0000218,
6200,6251,A,,,50588,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619609,BAO_0000218,
6201,5932,A,,1969.0,50588,Cmax in dog plasma after 30mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619610,BAO_0000218,
6202,4273,A,,178.0,50588,Tested for the peak blood level in dog,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619611,BAO_0000218,
6203,5313,A,,,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619612,BAO_0000218,
6204,5313,A,,,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619613,BAO_0000218,
6205,6221,A,,178.0,50588,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619614,BAO_0000218,
6206,4709,A,,,50588,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619615,BAO_0000218,
6207,167,A,,,50588,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619616,BAO_0000218,
6208,6241,A,,1969.0,50588,Final plasma concentration in dogs after oral administration at 1 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619617,BAO_0000218,
6209,344,A,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619618,BAO_0000218,
6210,344,A,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876033,BAO_0000218,
6211,344,A,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619619,BAO_0000218,
6212,2189,A,,,50588,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619620,BAO_0000218,
6213,2189,A,,1088.0,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619621,BAO_0000218,
6214,2189,A,,1088.0,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619622,BAO_0000218,
6215,2189,A,,1088.0,50588,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618874,BAO_0000218,
6216,4257,A,,,50588,Absolute bioavailability was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618875,BAO_0000218,
6217,6221,A,,,50588,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618876,BAO_0000218,
6218,6215,A,,,50588,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618877,BAO_0000218,
6219,17267,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618878,BAO_0000218,
6220,6621,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618879,BAO_0000218,
6221,3854,A,,,50588,Bioavailability after intravenous administration in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618880,BAO_0000218,
6222,3854,A,,,50588,Bioavailability after peroral administration in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618881,BAO_0000218,
6223,5007,A,,,50588,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618882,BAO_0000218,
6224,4333,A,,,50588,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624226,BAO_0000218,
6225,4333,A,,1969.0,50588,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624227,BAO_0000218,
6226,5006,A,,,50588,Bioavailability,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624228,BAO_0000218,
6227,5199,A,,,50588,Bioavailability,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624229,BAO_0000218,
6228,4368,A,,,50588,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624230,BAO_0000218,
6229,3771,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624231,BAO_0000218,
6230,4953,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624232,BAO_0000218,
6231,5064,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625127,BAO_0000218,
6232,17657,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625128,BAO_0000218,
6233,17796,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621675,BAO_0000218,
6234,17853,A,,,50588,Bioavailability in dog (p.o.) at 2.0 mpk,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621676,BAO_0000218,
6235,4521,A,,,50588,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621677,BAO_0000218,
6236,4521,A,,,50588,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621678,BAO_0000218,
6237,5006,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621679,BAO_0000218,
6238,16365,A,,,50588,Bioavailability was evaluated after oral administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621680,BAO_0000218,
6239,1916,A,,,50588,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621681,BAO_0000218,
6240,1918,A,,,50588,Bioavailability was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876740,BAO_0000218,
6241,4239,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621682,BAO_0000218,
6242,6505,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621683,BAO_0000218,
6243,5334,A,,,50588,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621684,BAO_0000218,
6244,5334,A,,,50588,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621685,BAO_0000218,
6245,4809,A,,,50588,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621686,BAO_0000218,
6246,6348,A,,,50588,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621687,BAO_0000218,
6247,6005,A,,,50588,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621688,BAO_0000218,
6248,17804,A,,,50588,Bioavailability of compound in dog was determined after peroral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621689,BAO_0000218,
6249,3184,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621690,BAO_0000218,
6250,1806,A,,,50588,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621691,BAO_0000218,
6251,1806,A,,,50588,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875941,BAO_0000218,
6252,1806,A,,,50588,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621692,BAO_0000218,
6253,4839,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621693,BAO_0000218,
6254,5017,A,,,50588,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621694,BAO_0000218,
6255,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621695,BAO_0000218,
6256,846,A,,948.0,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621696,BAO_0000218,
6257,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621697,BAO_0000218,
6258,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621698,BAO_0000218,
6259,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623420,BAO_0000218,
6260,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623421,BAO_0000218,
6261,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623422,BAO_0000218,
6262,846,A,,2113.0,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623423,BAO_0000218,
6263,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623424,BAO_0000218,
6264,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623425,BAO_0000218,
6265,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623426,BAO_0000218,
6266,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623427,BAO_0000218,
6267,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623428,BAO_0000218,
6268,846,A,,2107.0,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875947,BAO_0000218,
6269,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623429,BAO_0000218,
6270,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623430,BAO_0000218,
6271,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622588,BAO_0000218,
6272,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622589,BAO_0000218,
6273,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622751,BAO_0000218,
6274,846,A,,2048.0,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622752,BAO_0000218,
6275,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622753,BAO_0000218,
6276,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622647,BAO_0000218,
6277,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875163,BAO_0000218,
6278,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622648,BAO_0000218,
6279,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622649,BAO_0000218,
6280,6599,A,CCRF S-180,955.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Brain,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622650,BAO_0000218,
6281,6599,A,CCRF S-180,955.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Brain,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622651,BAO_0000218,
6282,6599,A,CCRF S-180,955.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Brain,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622652,BAO_0000218,
6283,6599,A,CCRF S-180,955.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Brain,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622653,BAO_0000218,
6284,6599,A,CCRF S-180,955.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Brain,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622654,BAO_0000218,
6285,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622655,BAO_0000218,
6286,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622656,BAO_0000218,
6287,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622657,BAO_0000218,
6288,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622658,BAO_0000218,
6289,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622659,BAO_0000218,
6290,6599,A,CCRF S-180,2113.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Kidney,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624630,BAO_0000218,
6291,6599,A,CCRF S-180,2113.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Kidney,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624631,BAO_0000218,
6292,6599,A,CCRF S-180,2113.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Kidney,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624632,BAO_0000218,
6293,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624633,BAO_0000219,
6294,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624634,BAO_0000219,
6295,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624635,BAO_0000219,
6296,17130,F,A549,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624636,BAO_0000219,
6297,3263,F,A549,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL857055,BAO_0000219,
6298,6663,F,A549,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624637,BAO_0000219,
6299,6663,F,A549,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624638,BAO_0000219,
6300,6663,F,A549,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL874366,BAO_0000219,
6301,6663,F,A549,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624639,BAO_0000219,
6302,6663,F,A549,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624640,BAO_0000219,
6303,6663,F,A549,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624641,BAO_0000219,
6304,6663,F,A549,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624642,BAO_0000219,
6305,6663,F,A549,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624643,BAO_0000219,
6306,6663,F,A549,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624644,BAO_0000219,
6307,6663,F,A549,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624645,BAO_0000219,
6308,3983,F,A549,,80682,The compound was evaluated for its cytotoxic potency against A-549 cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619445,BAO_0000219,
6309,11141,F,A549,,80682,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL839886,BAO_0000219,
6310,5076,F,A549,,80682,Cytotoxic activity of compound against A-549 tumor cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619446,BAO_0000219,
6311,3311,F,A549,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619447,BAO_0000219,
6312,3311,F,A549,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619448,BAO_0000219,
6313,3311,F,A549,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619449,BAO_0000219,
6314,5076,F,A549,,80682,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619450,BAO_0000219,
6315,4150,F,A549,,80682,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619451,BAO_0000219,
6316,2150,F,A549,,80682,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619452,BAO_0000219,
6317,4644,F,A549,,80682,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619453,BAO_0000219,
6318,263,F,A549,,80682,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL874367,BAO_0000219,
6319,11333,F,A549,,80682,Cytotoxic concentration against A-549 tumor cells.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619454,BAO_0000219,
6320,11333,F,A549,,80682,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619455,BAO_0000219,
6321,15895,F,A549,,80682,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619456,BAO_0000219,
6322,16677,F,,,50191,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,1,,Acinetobacter baumannii,1,470.0,N,Expert,,,CHEMBL619457,BAO_0000218,
6323,10624,F,,,50192,Activity against Acinetobacter calcoaceticus (AC54),,1,,Acinetobacter calcoaceticus,1,471.0,N,Intermediate,,,CHEMBL619458,BAO_0000218,
6324,16717,F,,,50274,In vitro antifungal activity against Aspergillus flavus CM74,,1,,Aspergillus flavus,1,5059.0,N,Expert,,,CHEMBL619459,BAO_0000218,
6325,16717,F,,,50274,In vitro antifungal activity against Aspergillus flavus CM74,,1,,Aspergillus flavus,1,5059.0,N,Expert,,,CHEMBL619460,BAO_0000218,
6326,5513,F,,,50416,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,1,,Aspergillus fumigatus,1,746128.0,N,Intermediate,,,CHEMBL619461,BAO_0000218,
6327,15962,F,,,50416,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,1,,Aspergillus fumigatus,1,746128.0,N,Intermediate,,,CHEMBL619462,BAO_0000218,
6328,15962,F,,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),,1,,Aspergillus fumigatus,1,746128.0,N,Intermediate,,,CHEMBL620388,BAO_0000218,
6329,15962,F,,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),,1,,Aspergillus fumigatus,1,746128.0,N,Intermediate,,,CHEMBL620389,BAO_0000218,
6330,15962,F,,,50416,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,1,,Aspergillus fumigatus,1,746128.0,N,Intermediate,,,CHEMBL620390,BAO_0000218,
6331,16717,F,,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,,1,,Aspergillus fumigatus,1,746128.0,N,Expert,,,CHEMBL620391,BAO_0000218,
6332,16717,F,,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,,1,,Aspergillus fumigatus,1,746128.0,N,Expert,,,CHEMBL621073,BAO_0000218,
6333,8117,F,,,50296,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL621074,BAO_0000218,
6334,8117,F,,,50366,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL621075,BAO_0000218,
6335,15472,F,,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL619554,BAO_0000218,
6336,15472,F,,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL619555,BAO_0000218,
6337,16443,F,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,1,,Aggregatibacter actinomycetemcomitans,1,714.0,N,Intermediate,,,CHEMBL619556,BAO_0000218,
6338,16443,F,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,1,,Aggregatibacter actinomycetemcomitans,1,714.0,N,Intermediate,,,CHEMBL619557,BAO_0000218,
6339,16443,F,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,1,,Aggregatibacter actinomycetemcomitans,1,714.0,N,Intermediate,,,CHEMBL619558,BAO_0000218,
6340,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619559,BAO_0000219,
6341,17206,F,A549,,80682,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619560,BAO_0000219,
6342,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619561,BAO_0000219,
6343,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619562,BAO_0000219,
6344,16381,F,A549,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619563,BAO_0000219,
6345,16381,F,A549,,80682,GI values against A549 cells (lung cancer),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL857457,BAO_0000219,
6346,17206,F,A549,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619564,BAO_0000219,
6347,16325,F,A549,,80682,Inhibitory activity against A549 human adenocarcinoma,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619565,BAO_0000219,
6348,10708,F,A549,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619566,BAO_0000218,
6349,10708,F,A549,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619567,BAO_0000218,
6350,17376,F,A549,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619568,BAO_0000219,
6351,17376,F,A549,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619569,BAO_0000219,
6352,17488,F,A549,,80682,Cytotoxicity against human A549 lung cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619570,BAO_0000219,
6353,17404,F,A549,,80682,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619571,BAO_0000218,
6354,10958,F,A549,,80682,Growth inhibition of A549 (human lung carcinoma) cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619572,BAO_0000219,
6355,17099,F,A549,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619573,BAO_0000219,
6356,17099,F,A549,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619574,BAO_0000219,
6357,4096,F,A549,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619575,BAO_0000219,
6358,4096,F,A549,,80682,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619576,BAO_0000219,
6359,4096,F,A549,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619577,BAO_0000219,
6360,2525,F,A549,,80682,In vitro inhibitory activity against A549 tumor cell culture,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619578,BAO_0000219,
6361,2525,F,A549,,80682,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884009,BAO_0000219,
6362,5302,F,A549,,80682,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619579,BAO_0000219,
6363,16325,F,A549,,80682,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619580,BAO_0000219,
6364,16939,F,A549,,80682,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619581,BAO_0000219,
6365,17229,F,A549,,80682,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619582,BAO_0000219,
6366,17380,F,A549,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619583,BAO_0000219,
6367,17380,F,A549,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876502,BAO_0000219,
6368,1903,F,A549,,80682,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619584,BAO_0000219,
6369,3838,F,A549,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619585,BAO_0000219,
6370,14696,F,A549,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619586,BAO_0000219,
6371,3838,F,A549,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619587,BAO_0000219,
6372,1522,F,A549,,80682,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619588,BAO_0000219,
6373,12400,F,A549,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619589,BAO_0000219,
6374,14696,F,A549,,80682,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619590,BAO_0000219,
6375,14769,F,A549,,80682,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619591,BAO_0000219,
6376,14696,F,A549,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619592,BAO_0000219,
6377,1888,F,A549,,80682,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619593,BAO_0000219,
6378,12016,F,A549,,80682,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620217,BAO_0000219,
6379,6058,F,A549,,80682,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620218,BAO_0000219,
6380,17708,F,A549,,80682,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620219,BAO_0000219,
6381,12301,F,A549,,80682,Antitumor activity against A549/ATCC cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620220,BAO_0000219,
6382,11970,F,A549,,80682,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625141,BAO_0000219,
6383,11818,F,A549,,80682,In vitro cytotoxicity against A549/ATCC cell line.,,1,646.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL625142,BAO_0000219,
6384,12400,F,A549,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625143,BAO_0000219,
6385,3381,F,A549,,80682,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625144,BAO_0000219,
6386,17376,F,A549,,80682,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622474,BAO_0000219,
6387,10708,F,A549,,80682,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,1,646.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884104,BAO_0000219,
6388,2964,F,,,22226,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL622475,BAO_0000219,
6389,5005,A,,,22224,Compound was tested for oral bioavailability in dogs,,0,,Canis lupus familiaris,1,9615.0,U,Intermediate,,,CHEMBL622476,BAO_0000218,
6390,6229,A,,,50588,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875831,BAO_0000218,
6391,6229,A,,,50588,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622477,BAO_0000218,
6392,5374,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622478,BAO_0000218,
6393,5374,A,,,50588,Compound was tested for the oral bioavailability in dog; No availability,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623172,BAO_0000218,
6394,6265,A,,,50588,Oral bioavailability in dog (dose 5 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623173,BAO_0000218,
6395,5654,A,,,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623174,BAO_0000218,
6396,5654,A,,,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623175,BAO_0000218,
6397,16456,A,,,50588,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623340,BAO_0000218,
6398,5302,A,,,50588,Oral bioavailability in dog (dose 5 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623341,BAO_0000218,
6399,3624,A,,,50588,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623342,BAO_0000218,
6400,16452,A,,,50588,Oral bioavailability of active FTIs in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623343,BAO_0000218,
6401,5802,A,,,50588,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623344,BAO_0000218,
6402,3598,A,,,50588,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL623345,BAO_0000218,
6403,17839,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875832,BAO_0000218,
6404,6762,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623346,BAO_0000218,
6405,6821,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623347,BAO_0000218,
6406,6821,A,,,50588,Oral bioavailability of compound was determined in dog; Not tested,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623348,BAO_0000218,
6407,5210,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623349,BAO_0000218,
6408,6227,A,,,50588,Oral bioavailability (10 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623350,BAO_0000218,
6409,761,A,,,50588,Oral bioavailability,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623351,BAO_0000218,
6410,761,A,,,50588,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623352,BAO_0000218,
6411,761,A,,,50588,Oral bioavailability administered in solution in rats,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623353,BAO_0000218,
6412,16907,A,,,50588,Oral bioavailability after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875833,BAO_0000218,
6413,5474,A,,,50588,Oral bioavailability at a dose of 1 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623354,BAO_0000218,
6414,6535,A,,,50588,Oral bioavailability in dog (dose 1 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623355,BAO_0000218,
6415,6535,A,,,50588,Oral bioavailability in Dog; ND = not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623356,BAO_0000218,
6416,3352,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623357,BAO_0000218,
6417,6168,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623358,BAO_0000218,
6418,5988,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623359,BAO_0000218,
6419,4942,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623360,BAO_0000218,
6420,4942,A,,,50588,Oral bioavailability in dogs; No data,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623361,BAO_0000218,
6421,14541,A,,,50588,Oral bioavailability measured in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623362,BAO_0000218,
6422,4449,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623363,BAO_0000218,
6423,6057,A,,,50588,Oral bioavailability was calculated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623364,BAO_0000218,
6424,5600,A,,,50588,Oral bioavailability after 0.3 mg/kg po administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875834,BAO_0000218,
6425,5542,A,,,50588,Oral bioavailability in dog (i.v. dosing),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623365,BAO_0000218,
6426,5542,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623366,BAO_0000218,
6427,5546,A,,,50588,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623367,BAO_0000218,
6428,4514,A,,,50588,Oral bioavailability in Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623368,BAO_0000218,
6429,3624,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623369,BAO_0000218,
6430,3854,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623370,BAO_0000218,
6431,5836,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623371,BAO_0000218,
6432,5940,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623372,BAO_0000218,
6433,6168,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621351,BAO_0000218,
6434,6227,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621352,BAO_0000218,
6435,6251,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621353,BAO_0000218,
6436,6448,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621354,BAO_0000218,
6437,6647,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621355,BAO_0000218,
6438,5940,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621356,BAO_0000218,
6439,933,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621357,BAO_0000218,
6440,5210,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621358,BAO_0000218,
6441,6642,A,,,50588,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621359,BAO_0000218,
6442,6641,A,,,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621360,BAO_0000218,
6443,6642,A,,,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621361,BAO_0000218,
6444,5472,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621362,BAO_0000218,
6445,5985,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621363,BAO_0000218,
6446,15660,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621364,BAO_0000218,
6447,5530,A,,,50588,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621166,BAO_0000218,
6448,5530,A,,,50588,Oral bioavailability in dog (dose 1 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621167,BAO_0000218,
6449,6305,A,,,50588,Oral bioavailability (F) in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621168,BAO_0000218,
6450,5210,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621169,BAO_0000218,
6451,5238,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875950,BAO_0000218,
6452,5668,A,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621170,BAO_0000218,
6453,5668,A,,,50588,Oral bioavailability after peroral administration at 5 mpk in Dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621171,BAO_0000218,
6454,5668,A,,,50588,Oral bioavailability in dog (dose 5 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621172,BAO_0000218,
6455,6084,A,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621173,BAO_0000218,
6456,6599,A,CCRF S-180,2113.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Kidney,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621174,BAO_0000218,
6457,6599,A,CCRF S-180,2113.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Kidney,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621175,BAO_0000218,
6458,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621176,BAO_0000218,
6459,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621177,BAO_0000218,
6460,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621178,BAO_0000218,
6461,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621179,BAO_0000218,
6462,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621180,BAO_0000218,
6463,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875951,BAO_0000218,
6464,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621181,BAO_0000218,
6465,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621182,BAO_0000218,
6466,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621183,BAO_0000218,
6467,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621184,BAO_0000218,
6468,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621185,BAO_0000218,
6469,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621186,BAO_0000218,
6470,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621187,BAO_0000218,
6471,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621188,BAO_0000218,
6472,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621189,BAO_0000218,
6473,6599,A,CCRF S-180,2106.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Spleen,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621190,BAO_0000218,
6474,6599,A,CCRF S-180,2106.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Spleen,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618520,BAO_0000218,
6475,6599,A,CCRF S-180,2106.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Spleen,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621739,BAO_0000218,
6476,6599,A,CCRF S-180,2106.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Spleen,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621740,BAO_0000218,
6477,6599,A,CCRF S-180,2106.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Spleen,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621741,BAO_0000218,
6478,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621742,BAO_0000218,
6479,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621743,BAO_0000218,
6480,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621744,BAO_0000218,
6481,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621745,BAO_0000218,
6482,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621746,BAO_0000218,
6483,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621747,BAO_0000218,
6484,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621748,BAO_0000218,
6485,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621749,BAO_0000218,
6486,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621750,BAO_0000218,
6487,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621751,BAO_0000218,
6488,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621752,BAO_0000218,
6489,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621753,BAO_0000218,
6490,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875955,BAO_0000218,
6491,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621754,BAO_0000218,
6492,6599,A,CCRF S-180,948.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Heart,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621755,BAO_0000218,
6493,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621756,BAO_0000218,
6494,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624199,BAO_0000218,
6495,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624200,BAO_0000218,
6496,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624375,BAO_0000218,
6497,6599,A,CCRF S-180,2107.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Liver,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624376,BAO_0000218,
6498,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624377,BAO_0000218,
6499,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624378,BAO_0000218,
6500,12269,F,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,1,,aeinetobacter anitrotap,1,107673.0,N,Intermediate,,,CHEMBL857901,BAO_0000218,
6501,12269,F,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,1,,Acinetobacter calcoaceticus subsp. anitratus,1,107673.0,N,Intermediate,,,CHEMBL875274,BAO_0000218,
6502,12269,F,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,1,,Acinetobacter calcoaceticus subsp. anitratus,1,107673.0,N,Intermediate,,,CHEMBL624379,BAO_0000218,
6503,12269,F,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,1,,aeinetobacter anitrotap,1,107673.0,N,Intermediate,,,CHEMBL624380,BAO_0000218,
6504,10624,F,,,50192,Activity against Acinetobacter calcoaceticus (AC54),,1,,Acinetobacter calcoaceticus,1,471.0,N,Intermediate,,,CHEMBL624381,BAO_0000218,
6505,17216,F,,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,1,,Anolis carolinensis,1,28377.0,N,Intermediate,,,CHEMBL624382,BAO_0000218,
6506,17216,F,,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,1,,Anolis carolinensis,1,28377.0,N,Intermediate,,,CHEMBL624383,BAO_0000218,
6507,9560,F,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii 631,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624384,BAO_0000218,
6508,9560,F,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii B74,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624385,BAO_0000218,
6509,9560,F,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624386,BAO_0000218,
6510,9560,F,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624387,BAO_0000218,
6511,9560,F,,,50296,Plaque bactericidal index against Actinomyces naeslundii 631,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624388,BAO_0000218,
6512,9560,F,,,50296,Plaque bactericidal index against Actinomyces naeslundii N/9,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624389,BAO_0000218,
6513,9560,F,,,50296,Plaque bactericidal index against Actinomyces naeslundii B74,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL624390,BAO_0000218,
6514,9560,F,,,50296,Plaque bactericidal index against Actinomyces naeslundii N/3,,1,,Actinomyces naeslundii,1,1655.0,N,Intermediate,,,CHEMBL875275,BAO_0000218,
6515,114,F,,,50056,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,1,,Artemia salina,1,85549.0,N,Intermediate,,,CHEMBL624391,BAO_0000218,
6516,114,F,,,50056,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,1,,Artemia salina,1,85549.0,N,Intermediate,,,CHEMBL623636,BAO_0000218,
6517,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623637,BAO_0000218,
6518,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623638,BAO_0000218,
6519,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623639,BAO_0000218,
6520,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623640,BAO_0000218,
6521,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623641,BAO_0000218,
6522,10841,F,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623642,BAO_0000218,
6523,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623643,BAO_0000218,
6524,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623644,BAO_0000218,
6525,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623645,BAO_0000218,
6526,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623646,BAO_0000218,
6527,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623647,BAO_0000218,
6528,10841,F,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,1,,Ascaris suum,1,6253.0,N,Intermediate,,,CHEMBL623648,BAO_0000218,
6529,8117,F,,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623649,BAO_0000218,
6530,8117,F,,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623650,BAO_0000218,
6531,9560,F,,,50366,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623651,BAO_0000218,
6532,9560,F,,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-100,,1,,Actinomyces viscosus,1,1656.0,N,Expert,,,CHEMBL623652,BAO_0000218,
6533,9560,F,,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-626,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623653,BAO_0000218,
6534,9560,F,,,50366,Chlorohexidine coefficient for Actinomyces viscosus T14V,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623654,BAO_0000218,
6535,9560,F,,,50366,Plaque bactericidal index against Actinomyces viscosus 8A06,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623655,BAO_0000218,
6536,9560,F,,,50366,Plaque bactericidal index against Actinomyces viscosus M-100,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623656,BAO_0000218,
6537,9560,F,,,50366,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,1,,Actinomyces viscosus,1,1656.0,N,Expert,,,CHEMBL623657,BAO_0000218,
6538,9560,F,,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623658,BAO_0000218,
6539,9560,F,,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623659,BAO_0000218,
6540,9560,F,,,50366,Plaque bactericidal index against Actinomyces viscosus 626,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623660,BAO_0000218,
6541,9560,F,,,50366,Plaque bactericidal index against Actinomyces viscosus T14V,,1,,Actinomyces viscosus,1,1656.0,N,Intermediate,,,CHEMBL623661,BAO_0000218,
6542,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL875281,BAO_0000218,
6543,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL623662,BAO_0000218,
6544,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL623663,BAO_0000218,
6545,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL623664,BAO_0000218,
6546,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL623665,BAO_0000218,
6547,10708,F,A673,,80023,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,1,165.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621856,BAO_0000219,
6548,10708,F,A704,,80661,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,1,645.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620432,BAO_0000219,
6549,416,F,,,22226,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620433,BAO_0000219,
6550,14354,F,A9,,80024,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620434,BAO_0000219,
6551,14354,F,A9,,80024,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620435,BAO_0000219,
6552,5116,F,A9,,80024,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,1,625.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL620436,BAO_0000219,
6553,5116,F,A9,,80024,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,1,625.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876597,BAO_0000219,
6554,15694,F,Human ovarian carcinoma cell line,,81037,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,1,874.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL620437,BAO_0000219,
6555,13038,F,A9,,80024,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,1,625.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL620438,BAO_0000219,
6556,13038,F,A9,,80024,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,1,625.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL620439,BAO_0000219,
6557,10923,F,A9,,80024,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,1,625.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL619657,BAO_0000219,
6558,10923,F,A9,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619658,BAO_0000219,
6559,10923,F,A9,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619659,BAO_0000219,
6560,10923,F,,,10649,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,8,,,1,,H,Expert,,,CHEMBL619660,BAO_0000019,
6561,10923,F,A9,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619661,BAO_0000219,
6562,10923,F,A9,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,1,625.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619662,BAO_0000219,
6563,8158,F,AA6,,80663,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,1,975.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619663,BAO_0000219,
6564,15494,F,,,22226,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619664,BAO_0000219,
6565,15494,F,,,22226,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL619665,BAO_0000219,
6566,12348,F,AA5,,80662,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,1,974.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883244,BAO_0000219,
6567,12348,F,AA5,,80662,Cytotoxicity was measured against AA5/HIV-1(IIIB),,1,974.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884011,BAO_0000219,
6568,2726,F,AA5,,80662,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,1,974.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619666,BAO_0000219,
6569,2726,F,U-937,,80566,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,1,379.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619667,BAO_0000219,
6570,10747,F,UV4,,80578,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,1,274.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619668,BAO_0000219,
6571,11005,F,CHO-AA8,,80089,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL619669,BAO_0000219,
6572,12687,F,CHO-AA8,,80089,Average intracellular compound concentration when the hypoxic SER=1.6,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL876608,BAO_0000219,
6573,12687,F,CHO-AA8,,80089,Average intracellular compound concentration when the hypoxic SER=1.6.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619670,BAO_0000219,
6574,12687,F,CHO-AA8,,80089,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619671,BAO_0000219,
6575,12687,F,CHO-AA8,,80089,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619672,BAO_0000219,
6576,12687,F,CHO-AA8,,80089,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619673,BAO_0000219,
6577,13436,F,CHO-AA8,,80089,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619674,BAO_0000219,
6578,13435,F,CHO-AA8,,80089,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619675,BAO_0000219,
6579,13302,F,CHO-AA8,,80089,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619676,BAO_0000219,
6580,12687,F,CHO-AA8,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619677,BAO_0000219,
6581,12687,A,CHO-AA8,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619678,BAO_0000219,
6582,12687,A,CHO-AA8,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL619679,BAO_0000219,
6583,12878,A,CHO-AA8,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL619680,BAO_0000219,
6584,12878,A,CHO-AA8,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL621457,BAO_0000219,
6585,14367,F,CHO-AA8,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL876609,BAO_0000219,
6586,14367,F,CHO-AA8,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL621458,BAO_0000219,
6587,12398,F,CHO-AA8,,80089,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,1,185.0,hampster,1,36483.0,N,Expert,,,CHEMBL621459,BAO_0000219,
6588,12878,F,CHO-AA8,,80089,Aerobic growth inhibition in Chinese hamster cell line AA8,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL621460,BAO_0000219,
6589,13820,F,CHO-AA8,,80089,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL621461,BAO_0000219,
6590,13436,F,CHO-AA8,,80089,Inhibition of growth under aerobic conditions in AA8 cells,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL621462,BAO_0000219,
6591,6084,A,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621463,BAO_0000218,
6592,5711,A,,,50588,Oral bioavailability in dog at 10 mg/kg of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621464,BAO_0000218,
6593,4353,A,,,50588,Oral bioavailability in dog (dose 5 uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621465,BAO_0000218,
6594,4353,A,,,50588,Oral bioavailability in dog (dose 5 uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621466,BAO_0000218,
6595,17800,A,,,50588,Oral bioavailability in dog (mongrel),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621467,BAO_0000218,
6596,3994,A,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621468,BAO_0000218,
6597,3994,F,,,50588,Oral bioavailability in dog (dose 10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876734,BAO_0000218,
6598,5145,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618476,BAO_0000218,
6599,16452,A,,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618477,BAO_0000218,
6600,16452,A,,,50588,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618478,BAO_0000218,
6601,5983,A,,,50588,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618479,BAO_0000218,
6602,4273,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618480,BAO_0000218,
6603,12500,A,,,50588,Bioavailability in dog (dose 3-10 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618481,BAO_0000218,
6604,12500,A,,1969.0,50588,The compound was tested for bioavailability of compound in plasma of dog; Complete,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618482,BAO_0000218,
6605,3639,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618483,BAO_0000218,
6606,3880,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618484,BAO_0000218,
6607,4838,A,,,50588,Bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618485,BAO_0000218,
6608,15600,A,,,50588,oral bioavailability was measured in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618486,BAO_0000218,
6609,17248,A,,,50588,Compound was tested for plasma protein binding in dog; Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618487,BAO_0000218,
6610,17248,A,,,50588,Compound was tested for plasma protein binding of dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618488,BAO_0000218,
6611,17248,A,,,50588,Compound was tested for plasma protein binding of dog; Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876735,BAO_0000218,
6612,17443,A,,,50588,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618489,BAO_0000218,
6613,4186,A,,,50588,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618490,BAO_0000218,
6614,3749,A,,,50588,Half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618491,BAO_0000218,
6615,3249,A,,,50588,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618492,BAO_0000218,
6616,3022,A,,,50588,Half life was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873354,BAO_0000218,
6617,3749,A,,,50588,Half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618493,BAO_0000218,
6618,2517,A,,,50588,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618494,BAO_0000218,
6619,2517,A,,948.0,50588,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Heart,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618495,BAO_0000218,
6620,2517,A,,2113.0,50588,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Kidney,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618496,BAO_0000218,
6621,2517,A,,2107.0,50588,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618497,BAO_0000218,
6622,2517,A,,2048.0,50588,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Lung,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618498,BAO_0000218,
6623,2517,A,,2106.0,50588,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Spleen,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618499,BAO_0000218,
6624,3639,A,,,50588,LogP in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876736,BAO_0000218,
6625,6227,A,,,50588,Partition coefficient (logP),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618500,BAO_0000218,
6626,6227,A,,,50588,Partition coefficient in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL857831,BAO_0000218,
6627,17764,A,,,50588,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618501,BAO_0000218,
6628,4809,A,,,50588,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618502,BAO_0000218,
6629,5600,A,,,50588,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618503,BAO_0000218,
6630,14294,A,,,50588,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618504,BAO_0000218,
6631,14294,A,,,50588,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618505,BAO_0000218,
6632,14294,A,,,50588,Metabolism of compound in dog S9 microsomes; Trace,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618506,BAO_0000218,
6633,6251,A,,2107.0,50588,In vitro metabolic potential in dog liver microsomes,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618507,BAO_0000218,
6634,3748,A,,,50588,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876737,BAO_0000218,
6635,2713,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618508,BAO_0000218,
6636,6512,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618509,BAO_0000218,
6637,6679,A,,,50588,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618510,BAO_0000218,
6638,3749,A,,,50588,The compound was tested for bioavailability in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618511,BAO_0000218,
6639,3749,A,,,50588,The compound was tested for oral bioavailability in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618512,BAO_0000218,
6640,6742,A,,,50588,Oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618513,BAO_0000218,
6641,6227,A,,,50588,Compound was tested for percent protein binding (PB) in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618514,BAO_0000218,
6642,6874,A,,,50588,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620052,BAO_0000218,
6643,2877,A,,1969.0,50588,Compound was evaluated for plasma clearance.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620053,BAO_0000218,
6644,12500,A,,1969.0,50588,The compound was tested for plasma clearance in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620054,BAO_0000218,
6645,12500,A,,1969.0,50588,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620055,BAO_0000218,
6646,4709,A,,,50588,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620056,BAO_0000218,
6647,5542,A,,2107.0,50588,In vitro relative rate of metabolism was determined in dog liver microsomes,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620057,BAO_0000218,
6648,17594,A,,,50588,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618939,BAO_0000218,
6649,2652,A,,,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618940,BAO_0000218,
6650,17764,A,,,50588,Half life after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618941,BAO_0000218,
6651,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624473,BAO_0000218,
6652,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624474,BAO_0000218,
6653,6599,A,CCRF S-180,2048.0,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Lung,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624475,BAO_0000218,
6654,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624476,BAO_0000218,
6655,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623478,BAO_0000218,
6656,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623479,BAO_0000218,
6657,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623480,BAO_0000218,
6658,6599,A,CCRF S-180,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,1,42.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623481,BAO_0000218,
6659,17641,A,,955.0,50594,C2 in brain of mice at the oral dose of 50 mg/kg,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623482,BAO_0000218,
6660,17641,A,,2113.0,50594,C2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623483,BAO_0000218,
6661,17641,A,,2107.0,50594,C2 in liver of mice at the oral dose of 50 mg/kg,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623484,BAO_0000218,
6662,17641,A,,2048.0,50594,C2 in lungs of mice at the oral dose of 50 mg/kg,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623485,BAO_0000218,
6663,17641,A,,2106.0,50594,C2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623486,BAO_0000218,
6664,17852,A,,,50594,Plasma clearance in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623487,BAO_0000218,
6665,17764,A,,,50594,Clearance of compound after intravenous administration in mice at 24 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623488,BAO_0000218,
6666,17837,A,,,50594,Clearance from mouse blood following i.v. administration of 10 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623489,BAO_0000218,
6667,2675,A,,,50594,Clearance was evaluated in mice after intravenous administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875157,BAO_0000218,
6668,2675,A,,,50594,Clearance was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623490,BAO_0000218,
6669,4239,A,,,50594,Pharmacokinetic property (Plasma clearance) was measured in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623491,BAO_0000218,
6670,17753,A,,,50594,Plasma clearance of compound was determined at 40 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623492,BAO_0000218,
6671,17753,A,,,50594,Plasma clearance of at 24 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623493,BAO_0000218,
6672,17753,A,,,50594,Plasma clearance at 24 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623494,BAO_0000218,
6673,17753,A,,,50594,Plasma clearance at 5 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623495,BAO_0000218,
6674,5727,A,,,50594,Plasma clearance in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623496,BAO_0000218,
6675,2862,A,,,50594,Plasma clearance value upon iv administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623497,BAO_0000218,
6676,5980,A,,1969.0,50594,Total plasma clearance in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623498,BAO_0000218,
6677,17592,A,,,50594,Clearance in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623499,BAO_0000218,
6678,17718,A,,,50594,Clearance value was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623500,BAO_0000218,
6679,16597,A,,,50594,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623501,BAO_0000218,
6680,17384,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Intermediate,,,CHEMBL875158,BAO_0000100,
6681,6062,A,,,50594,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623502,BAO_0000218,
6682,17734,A,,,50594,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623503,BAO_0000218,
6683,6348,A,,,50594,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623504,BAO_0000218,
6684,5969,A,,,50594,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623505,BAO_0000218,
6685,5969,A,,,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623506,BAO_0000218,
6686,5969,A,,,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623507,BAO_0000218,
6687,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623508,BAO_0000218,
6688,5781,A,,,50594,Cmax after oral administration at 30 mg/kg in ICR mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623509,BAO_0000218,
6689,17764,A,,,50594,Cmax after peroral administration in mice at 2.4 uM/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875159,BAO_0000218,
6690,17641,A,,955.0,50594,Cmax in brain of mice at the oral dose of 50 mg/kg,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623510,BAO_0000218,
6691,17641,A,,2113.0,50594,Cmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623511,BAO_0000218,
6692,17641,A,,2107.0,50594,Cmax in liver of mice at the oral dose of 50 mg/kg,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623512,BAO_0000218,
6693,17641,A,,2048.0,50594,Cmax in lungs of mice at the oral dose of 50 mg/kg,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623513,BAO_0000218,
6694,17764,F,,,50594,Cmax in mice at 18 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623514,BAO_0000218,
6695,17764,F,,,50594,Cmax in mice at 23 uM/kg i.v. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622609,BAO_0000218,
6696,17764,F,,,50594,Cmax in mice at 24 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622610,BAO_0000218,
6697,17764,F,,,50594,Cmax in mice at 25 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621823,BAO_0000218,
6698,17764,F,,,50594,Cmax in mice at 26 uM/kg i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621824,BAO_0000218,
6699,17641,A,,2106.0,50594,Cmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621825,BAO_0000218,
6700,16597,A,,,50594,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621826,BAO_0000218,
6701,16597,A,,,50594,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621827,BAO_0000218,
6702,5727,A,,,50594,Cmax value was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621828,BAO_0000218,
6703,5951,A,,,50594,Cmax value in IRC mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621829,BAO_0000218,
6704,5506,A,,,50594,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621830,BAO_0000218,
6705,5506,A,,,50594,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621831,BAO_0000218,
6706,14239,A,,1969.0,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621832,BAO_0000218,
6707,4890,A,,1969.0,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624579,BAO_0000218,
6708,429,A,,,50594,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624580,BAO_0000218,
6709,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL624581,BAO_0000218,
6710,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL624582,BAO_0000218,
6711,10986,F,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,1,,Acanthocheilonema viteae,1,6277.0,N,Intermediate,,,CHEMBL624583,BAO_0000218,
6712,13227,F,A-375,,80018,Inhibitory activity against human tumor cell line A0375 melanoma.,,1,455.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624584,BAO_0000219,
6713,4481,B,,,12512,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,9,,Rattus norvegicus,1,10116.0,D,Expert,,,CHEMBL624585,BAO_0000249,
6714,16931,F,,,114,Forskolin-induced cAMP production at human A1 adenosine receptor,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL875165,BAO_0000019,
6715,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL619490,BAO_0000219,
6716,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL619491,BAO_0000219,
6717,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,8,449.0,,1,,H,Expert,,,CHEMBL619492,BAO_0000219,
6718,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,8,449.0,,1,,H,Expert,,,CHEMBL619493,BAO_0000219,
6719,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL619494,BAO_0000219,
6720,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,8,449.0,,1,,H,Autocuration,,,CHEMBL619495,BAO_0000219,
6721,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL619496,BAO_0000219,
6722,3850,F,CHO,,114,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,9,449.0,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL619497,BAO_0000219,
6723,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,8,449.0,,1,,H,Autocuration,,,CHEMBL619498,BAO_0000219,
6724,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL619499,BAO_0000219,
6725,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,8,449.0,,1,,H,Expert,,,CHEMBL619500,BAO_0000219,
6726,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL619501,BAO_0000219,
6727,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,8,449.0,,1,,H,Expert,,,CHEMBL619502,BAO_0000219,
6728,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,8,449.0,,1,,H,Autocuration,,,CHEMBL619503,BAO_0000219,
6729,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL619504,BAO_0000219,
6730,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL621298,BAO_0000219,
6731,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,8,449.0,,1,,H,Expert,,,CHEMBL621299,BAO_0000219,
6732,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,8,449.0,,1,,H,Autocuration,,,CHEMBL621300,BAO_0000219,
6733,3850,F,CHO,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,8,449.0,,1,,H,Autocuration,,,CHEMBL621301,BAO_0000219,
6734,3850,F,CHO,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,8,449.0,,1,,H,Expert,,,CHEMBL621302,BAO_0000219,
6735,12680,F,A10,,80013,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,1,164.0,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL621303,BAO_0000219,
6736,1313,F,A10,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,0,164.0,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL621304,BAO_0000219,
6737,1313,F,A10,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,0,164.0,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL621305,BAO_0000219,
6738,17567,F,A10,,80013,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,1,164.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621306,BAO_0000219,
6739,17567,F,A10,,80013,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,1,164.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618444,BAO_0000219,
6740,11819,F,A10,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,1,164.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618445,BAO_0000219,
6741,13436,F,CHO-AA8,,80089,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618446,BAO_0000219,
6742,12687,F,CHO-AA8,,80089,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618447,BAO_0000219,
6743,12651,F,CHO-AA8,,80089,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618448,BAO_0000219,
6744,13300,F,CHO-AA8,,80089,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618449,BAO_0000219,
6745,15296,F,CHO-AA8,,80089,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618637,BAO_0000219,
6746,15328,F,CHO-AA8,,80089,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618638,BAO_0000219,
6747,13302,F,CHO-AA8,,80089,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618639,BAO_0000219,
6748,14367,F,CHO-AA8,,80089,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL618640,BAO_0000219,
6749,17002,F,CHO-AA8,,80089,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL618641,BAO_0000219,
6750,13436,F,CHO-AA8,,80089,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618642,BAO_0000219,
6751,13435,F,CHO-AA8,,80089,Inhibitory activity against aerobic growth of AA8 cells.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL618643,BAO_0000219,
6752,10503,A,CHO-AA8,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL884013,BAO_0000219,
6753,10503,F,CHO-AA8,,80089,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL622723,BAO_0000219,
6754,10503,F,CHO-AA8,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622724,BAO_0000219,
6755,15090,F,CHO-AA8,,80089,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL622725,BAO_0000219,
6756,10368,F,CHO-AA8,,80089,Cytotoxicity against AA8 cell line,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL622726,BAO_0000219,
6757,12651,F,CHO-AA8,,80089,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622727,BAO_0000219,
6758,12687,A,CHO-AA8,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622728,BAO_0000219,
6759,12687,F,CHO-AA8,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622729,BAO_0000219,
6760,12687,A,CHO-AA8,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622730,BAO_0000219,
6761,1890,F,CHO-AA8,,80089,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622731,BAO_0000219,
6762,10747,F,CHO-AA8,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622732,BAO_0000219,
6763,10747,F,CHO-AA8,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,1,185.0,Cricetulus griseus,1,10029.0,N,Intermediate,,,CHEMBL622733,BAO_0000219,
6764,11616,F,,,22224,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL622734,BAO_0000218,
6765,11616,F,CHO-AA8,,80089,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL622735,BAO_0000219,
6766,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618746,BAO_0000219,
6767,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618747,BAO_0000219,
6768,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620540,BAO_0000219,
6769,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620541,BAO_0000219,
6770,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620542,BAO_0000219,
6771,3471,F,CHO-AA8,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL620543,BAO_0000219,
6772,3471,F,CHO-AA8,,22224,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618832,BAO_0000219,
6773,11616,F,CHO-AA8,,80089,Concentration required to reduce AA8 cell survival by 10%,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL618833,BAO_0000219,
6774,2656,F,CHO-AA8,,22224,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618834,BAO_0000219,
6775,10518,F,CHO-AA8,,22224,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618835,BAO_0000219,
6776,10518,F,CHO-AA8,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618836,BAO_0000219,
6777,10518,F,CHO-AA8,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618837,BAO_0000219,
6778,10518,F,CHO-AA8,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618838,BAO_0000219,
6779,16156,F,CHO-AA8,,22224,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618839,BAO_0000219,
6780,2656,F,CHO-AA8,,22224,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618840,BAO_0000219,
6781,11005,F,,,22224,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618841,BAO_0000019,
6782,11942,F,CHO-AA8,,22224,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618842,BAO_0000219,
6783,2128,F,CHO-AA8,,22224,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL618843,BAO_0000219,
6784,16907,A,,,50588,Half life period after 15 mg/kg iv dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618844,BAO_0000218,
6785,16907,A,,,50588,Half life period after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618845,BAO_0000218,
6786,9579,A,,,50588,Half life was measured after oral 2b administration (tested in 6 dogs),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618846,BAO_0000218,
6787,9579,A,,,50588,Half life was measured in dog after oral 17b administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618847,BAO_0000218,
6788,9579,A,,,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618848,BAO_0000218,
6789,9579,A,,,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618849,BAO_0000218,
6790,16907,A,,,50588,Tmax value after 15 mg/kg iv dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618850,BAO_0000218,
6791,16907,A,,,50588,Tmax value after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618851,BAO_0000218,
6792,3184,A,,,50588,Compound was evaluated for its half life when administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873815,BAO_0000218,
6793,5017,A,,1969.0,50588,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618852,BAO_0000218,
6794,6821,A,,,50588,Elimination Half-life of compound was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618853,BAO_0000218,
6795,17839,A,,,50588,Half life of compound in dog following oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618854,BAO_0000218,
6796,17267,A,,,50588,Half life of compound was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618855,BAO_0000218,
6797,4727,A,,178.0,50588,Half life of compound was determined in dog blood,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618856,BAO_0000218,
6798,5238,A,,,50588,Half life after oral and iv dosing in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875827,BAO_0000218,
6799,4942,A,,,50588,Half life in dogs in hours,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618857,BAO_0000218,
6800,6505,A,,,50588,Half life on i.v. administration of 2 mg/kg was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618858,BAO_0000218,
6801,5130,A,,,50588,t1/2 in dog after oral dose (1 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618859,BAO_0000218,
6802,1475,A,,,50588,Half life was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618860,BAO_0000218,
6803,17804,A,,,50588,Half life period of compound was determined after intravenous administration at 2 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618861,BAO_0000218,
6804,17804,A,,,50588,Half life period of compound was determined after peroral administration at 2 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622539,BAO_0000218,
6805,6084,A,,,50588,Half life period (10 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622540,BAO_0000218,
6806,6084,A,,,50588,Half life period (10 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873803,BAO_0000218,
6807,5542,A,,,50588,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873804,BAO_0000218,
6808,5542,A,,,50588,Half life period by po administration in dog at a dose of 0.3 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624311,BAO_0000218,
6809,6084,A,,,50588,Half life period in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624312,BAO_0000218,
6810,6241,A,,,50588,Half life period in dogs after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624313,BAO_0000218,
6811,1916,A,,,50588,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624314,BAO_0000218,
6812,6621,A,,,50588,Half-life of compound was determined in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624315,BAO_0000218,
6813,1696,A,,1969.0,50588,Half-life in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624316,BAO_0000218,
6814,17800,A,,,50588,Half-life in mongrel dogs was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624317,BAO_0000218,
6815,17657,A,,,50588,Half-life in dog upon oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624318,BAO_0000218,
6816,17657,A,,,50588,Half-life in dog upon oral administration; Unable to calculate,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624319,BAO_0000218,
6817,4239,A,,,50588,Half-life was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624496,BAO_0000218,
6818,5985,A,,,50588,Half-life was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624497,BAO_0000218,
6819,9932,A,,,50588,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624498,BAO_0000218,
6820,5199,A,,,50588,Oral half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624499,BAO_0000218,
6821,5199,A,,1969.0,50588,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624500,BAO_0000218,
6822,1475,A,,1969.0,50588,Plasma half life was evaluated,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624501,BAO_0000218,
6823,1475,A,,1969.0,50588,Plasma half life was evaluated in Dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623666,BAO_0000218,
6824,1475,A,,1969.0,50588,Plasma half life was evaluated in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623667,BAO_0000218,
6825,6316,A,,,50588,T1/2 (Half-life) was after oral administration at 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623668,BAO_0000218,
6826,4883,A,,,50588,Tested for the half life value in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623669,BAO_0000218,
6827,4727,A,,,50588,Maximum time at the dose of 2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623670,BAO_0000218,
6828,1916,A,,,50588,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623671,BAO_0000218,
6829,1337,A,,178.0,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875945,BAO_0000218,
6830,1337,A,,178.0,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623672,BAO_0000218,
6831,6265,A,,,50588,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623673,BAO_0000218,
6832,4809,A,,,50588,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623674,BAO_0000218,
6833,5983,A,,,50588,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623675,BAO_0000218,
6834,5313,A,,,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL872526,BAO_0000218,
6835,5313,A,,,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623676,BAO_0000218,
6836,17650,A,,1969.0,50588,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623677,BAO_0000218,
6837,5199,A,,1969.0,50588,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623678,BAO_0000218,
6838,933,A,,1969.0,50588,Time taken for maximum plasma concentration in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623679,BAO_0000218,
6839,16367,A,,,50588,Time to reach Cmax after oral administration to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623680,BAO_0000218,
6840,6348,A,,1969.0,50588,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623681,BAO_0000218,
6841,6316,A,,,50588,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623682,BAO_0000218,
6842,6215,A,,,50588,Tmax after peroral administration (1 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623683,BAO_0000218,
6843,3598,A,,,50588,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL623684,BAO_0000218,
6844,4527,A,,,50588,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622745,BAO_0000218,
6845,17764,A,,,50588,Tmax after peroral administration in dogs at 2.4 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622746,BAO_0000218,
6846,5969,A,,,50594,In vivo Cmax in mice at dose of 100 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622747,BAO_0000218,
6847,5969,A,,,50594,In vivo Cmax in mice at dose of 50 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622748,BAO_0000218,
6848,4573,A,,,50594,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622749,BAO_0000218,
6849,3277,A,,1969.0,50594,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622750,BAO_0000218,
6850,17734,A,,1969.0,50594,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623411,BAO_0000218,
6851,3132,A,,1969.0,50594,Maximum concentration obtained in mouse plasma was determined,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875946,BAO_0000218,
6852,3132,A,,1969.0,50594,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623412,BAO_0000218,
6853,6348,A,,1969.0,50594,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623413,BAO_0000218,
6854,17729,A,,1969.0,50594,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623414,BAO_0000218,
6855,17729,A,,1969.0,50594,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623415,BAO_0000218,
6856,17729,A,,1969.0,50594,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623416,BAO_0000218,
6857,17728,A,,1969.0,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623417,BAO_0000218,
6858,17728,A,,1969.0,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623418,BAO_0000218,
6859,17728,A,,1969.0,50594,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623419,BAO_0000218,
6860,4066,A,,,50594,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622816,BAO_0000218,
6861,6178,A,,,50594,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623313,BAO_0000218,
6862,6178,A,,,50594,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623314,BAO_0000218,
6863,3760,A,,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876788,BAO_0000218,
6864,3760,A,,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623315,BAO_0000218,
6865,3760,A,,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623316,BAO_0000218,
6866,3760,A,,,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623317,BAO_0000218,
6868,5961,A,,,50594,Cmax in male mice after 2 mg/kg oral dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623319,BAO_0000218,
6869,6137,A,,,50594,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623320,BAO_0000218,
6870,3802,A,,,50594,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623321,BAO_0000218,
6871,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623322,BAO_0000218,
6872,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623323,BAO_0000218,
6873,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623324,BAO_0000218,
6874,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623325,BAO_0000218,
6875,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623326,BAO_0000218,
6876,3535,A,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623327,BAO_0000218,
6877,2862,A,,1969.0,50594,Maximum concentration in plasma upon oral administration in mouse,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623328,BAO_0000218,
6878,2675,A,,1969.0,50594,Maximum plasma concentration was evaluated in mice after oral administration,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623329,BAO_0000218,
6879,2675,A,,1969.0,50594,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623330,BAO_0000218,
6880,5399,A,,,50594,Dose at which the compound induced fecal excretion in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876789,BAO_0000218,
6893,11819,F,A10,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,1,164.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL623333,BAO_0000219,
6894,11819,F,A10,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,1,164.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL623334,BAO_0000219,
6895,11819,F,A10,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,1,164.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL627536,BAO_0000219,
6896,11819,F,A10,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,1,164.0,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL627537,BAO_0000219,
6897,16361,F,A10,,80013,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,1,164.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627538,BAO_0000219,
6898,2288,F,A121,,80655,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884106,BAO_0000219,
6899,10404,F,A121,,80655,Anticancer activity against human ovarian carcinoma A121 cells,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625294,BAO_0000219,
6900,14790,F,A121,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625295,BAO_0000219,
6901,14790,F,A121,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625296,BAO_0000219,
6902,14253,F,A121,,80655,Growth inhibition of human ovarian carcinoma (A121) cell line,,1,393.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL625297,BAO_0000219,
6903,13617,F,A121,,80655,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,1,393.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL625298,BAO_0000219,
6904,1003,F,A121,,80655,Cytotoxicity against human A121 ovarian cells,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625960,BAO_0000219,
6905,830,F,A121,,80655,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625961,BAO_0000219,
6906,12307,F,A121,,80655,In vitro cytotoxicity against human ovarian carcinoma A21,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625962,BAO_0000219,
6907,14254,F,A121,,80655,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624717,BAO_0000219,
6908,13370,F,A121,,80655,Inhibitory activity of compound against human A121 ovarian cell line.,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624718,BAO_0000219,
6909,14790,F,A121,,80655,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624719,BAO_0000219,
6910,3614,F,A121,,80655,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,1,393.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624720,BAO_0000219,
6911,2664,F,A 172,,80012,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624721,BAO_0000219,
6912,2037,F,A 172,,80012,In vitro cytotoxicity against A172 human tumor cell lines.,,1,622.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624722,BAO_0000219,
6913,14539,F,A 172,,80012,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL877597,BAO_0000219,
6914,2836,F,A 172,,80012,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624723,BAO_0000219,
6915,10708,F,A 172,,80012,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,1,622.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624724,BAO_0000219,
6916,8975,B,,,104729,Association constant against A2 adenosine receptor,,4,,Canis lupus familiaris,1,9615.0,H,Autocuration,,,CHEMBL624725,BAO_0000224,
6917,7645,F,A2,,80656,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,1,1085.0,fish,1,,N,Intermediate,,,CHEMBL624726,BAO_0000219,
6918,11377,B,,,104713,Ratio of Ki for adenosine A2 and A1 receptor binding,,5,,Rattus norvegicus,1,10116.0,D,Autocuration,,,CHEMBL857535,BAO_0000224,
6919,13528,F,A204,,80014,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,1,623.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624727,BAO_0000219,
6920,10160,F,A204,,80014,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,1,623.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624728,BAO_0000219,
6921,15144,F,A2058,,80015,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,1,404.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624729,BAO_0000219,
6922,13160,F,A253 cell line,,80657,Growth inhibition against Human squamous cell line(A 253),,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624730,BAO_0000219,
6923,12898,F,A253 cell line,,80657,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624731,BAO_0000219,
6924,13069,F,A253 cell line,,80657,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624732,BAO_0000219,
6925,15984,F,A253 cell line,,80657,Growth inhibition of A253 cell lines.,,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL883245,BAO_0000219,
6926,15564,F,A253 cell line,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624733,BAO_0000219,
6927,15564,F,A253 cell line,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624734,BAO_0000219,
6928,15564,F,A253 cell line,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,1,973.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624735,BAO_0000219,
6929,4720,F,A2780,,81034,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621780,BAO_0000219,
6930,16112,F,A2780,,81034,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL877598,BAO_0000219,
6931,16597,F,A2780,,81034,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621781,BAO_0000219,
6932,16378,F,A2780,,81034,Cytotoxicity against human cancer cell lines A2780 (ovarian),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621782,BAO_0000219,
6933,16085,F,A2780,,81034,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621783,BAO_0000219,
6934,16317,F,A2780,,81034,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621784,BAO_0000219,
6935,15748,F,A2780,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621785,BAO_0000219,
6936,16597,F,A2780,,81034,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621968,BAO_0000219,
6937,16597,F,A2780,,81034,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621969,BAO_0000219,
6938,16597,F,A2780,,81034,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621970,BAO_0000219,
6939,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621971,BAO_0000219,
6940,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621972,BAO_0000219,
6941,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884108,BAO_0000219,
6942,15296,F,,,22224,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623826,BAO_0000019,
6943,10251,A,CHO-AA8,,22224,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623827,BAO_0000219,
6944,10251,F,CHO-AA8,,22224,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623828,BAO_0000219,
6945,10251,F,CHO-AA8,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623829,BAO_0000219,
6946,10251,F,CHO-AA8,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623830,BAO_0000219,
6947,11858,F,,,22224,Growth inhibition against CHO-derived cell line AA8,,0,,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623831,BAO_0000019,
6948,11858,F,CHO-AA8,,22224,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623832,BAO_0000219,
6949,11616,F,CHO-AA8,,80089,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,1,185.0,hampster,1,36483.0,N,Expert,,,CHEMBL623833,BAO_0000219,
6950,11616,F,CHO-AA8,,80089,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL623834,BAO_0000219,
6951,10518,F,CHO-AA8,,22224,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623835,BAO_0000219,
6952,11396,F,CHO-AA8,,22224,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623836,BAO_0000219,
6953,10518,F,CHO-AA8,,22224,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,0,185.0,Cricetulus griseus,1,10029.0,U,Autocuration,,,CHEMBL623837,BAO_0000219,
6954,11616,F,CHO-AA8,,80089,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,1,185.0,Cricetulus griseus,1,10029.0,N,Expert,,,CHEMBL623838,BAO_0000219,
6955,14837,F,,,12675,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,8,,,1,,H,Autocuration,,,CHEMBL623839,BAO_0000019,
6956,14837,F,,,12675,Number of binding sites (n) of isolated serum protein AAG,,8,,,1,,H,Autocuration,,,CHEMBL623840,BAO_0000019,
6957,16037,B,,,22222,Association constant for binding to AATT duplex,,3,,,1,,M,Intermediate,,,CHEMBL623841,BAO_0000225,
6958,16597,F,ABAE,,100090,Inhibition of ABAE human fibroblast cell proliferation,,1,416.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623842,BAO_0000219,
6959,8831,F,AC755,,80668,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,1,1064.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623843,BAO_0000218,
6960,13419,F,,,102444,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,9,,Oryctolagus cuniculus,1,9986.0,D,Expert,,,CHEMBL618669,BAO_0000218,
6961,13419,F,,,102444,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,9,,Oryctolagus cuniculus,1,9986.0,D,Expert,,,CHEMBL618670,BAO_0000218,
6962,15778,B,,,69,Inhibitory activity against angiotensin-converting enzyme (ACE).,,8,,,1,,H,Autocuration,,,CHEMBL618671,BAO_0000357,
6963,15778,B,,,69,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,8,,,1,,H,Autocuration,,,CHEMBL618672,BAO_0000357,
6964,12988,F,ACH-2 cell line,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,1,978.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618673,BAO_0000219,
6965,12988,F,ACH-2 cell line,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,1,978.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618674,BAO_0000219,
6966,12988,F,T cell line,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,0,998.0,Human immunodeficiency virus 1,1,11676.0,U,Autocuration,,,CHEMBL618675,BAO_0000219,
6967,12988,F,T cell line,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,0,998.0,Human immunodeficiency virus 1,1,11676.0,U,Autocuration,,,CHEMBL618676,BAO_0000219,
6968,12988,F,T cell line,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,0,998.0,Human immunodeficiency virus 1,1,11676.0,U,Autocuration,,,CHEMBL618677,BAO_0000219,
6969,11843,F,ACHN,,80025,Inhibition of growth of renal cancer ACHN cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618678,BAO_0000219,
6970,16939,F,ACHN,,80025,Inhibition of growth of ACHN renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618679,BAO_0000219,
6971,4782,F,ACHN,,80025,Inhibitory concentration required against ACHN renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618680,BAO_0000219,
6972,6310,F,ACHN,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line,,1,626.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618681,BAO_0000219,
6973,6310,F,ACHN,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618682,BAO_0000219,
6974,12858,F,ACHN,,80025,Cytotoxic activity against ACHN Renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618683,BAO_0000219,
6975,17380,F,ACHN,,80025,Cytotoxicity evaluation against ACHN renal cancer cells,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618684,BAO_0000219,
6976,5858,F,ACHN,,80025,In vitro antitumor activity against human renal ACHN cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618685,BAO_0000219,
6977,3838,F,ACHN,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL876499,BAO_0000219,
6978,3838,F,ACHN,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618686,BAO_0000219,
6979,5406,F,ACHN,,80025,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618687,BAO_0000219,
6980,4071,F,ACHN,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618688,BAO_0000219,
6981,4071,F,ACHN,,80025,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,1,626.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618689,BAO_0000219,
6982,4071,F,ACHN,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618690,BAO_0000219,
6983,15002,F,ACHN,,80025,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618691,BAO_0000219,
6984,14769,F,ACHN,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619373,BAO_0000219,
6985,13958,F,ACHN,,80025,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884008,BAO_0000219,
6986,1665,F,ACHN,,80025,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619374,BAO_0000219,
6987,15354,F,ACHN,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619375,BAO_0000219,
6988,15354,F,ACHN,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619376,BAO_0000219,
6989,13978,F,ACHN,,80025,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619377,BAO_0000219,
6990,6798,F,ACHN,,80025,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619378,BAO_0000219,
6991,2959,A,,,50588,Tmax value after administration of 4 mg/Kg oral dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL872527,BAO_0000218,
6992,9932,A,,,50588,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876500,BAO_0000218,
6993,5546,A,,,50588,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619379,BAO_0000218,
6994,16907,A,,,50588,Volume distribution after 15 mg/kg iv dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619538,BAO_0000218,
6995,16907,A,,,50588,Volume distribution after 30 mg/kg po dose in Dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619539,BAO_0000218,
6996,4257,A,,,50588,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619540,BAO_0000218,
6997,4305,A,,,50588,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619541,BAO_0000218,
6998,5472,A,,,50588,Volume of distribution was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619542,BAO_0000218,
6999,6062,A,,,50588,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619543,BAO_0000218,
7000,3598,A,,,50588,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL619544,BAO_0000218,
7001,12500,A,,,50588,The compound was tested for volume of distribution in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619545,BAO_0000218,
7002,12500,A,,,50588,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619546,BAO_0000218,
7003,6227,A,,,50588,Vd (1 mg/kg) was determined in dog (in vivo),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619547,BAO_0000218,
7004,6227,A,,,50588,Vd in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619548,BAO_0000218,
7005,4219,A,,,50588,Volume distribution was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619549,BAO_0000218,
7006,1696,A,,,50588,Volume of distribution in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619550,BAO_0000218,
7007,5542,A,,,50588,Volume of distribution by as 4 fold increase by iv administration in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876501,BAO_0000218,
7008,5199,A,,,50588,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619551,BAO_0000218,
7009,6348,A,,,50588,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619552,BAO_0000218,
7010,4727,A,,,50588,Volume distribution at the dose of 2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619553,BAO_0000218,
7011,16367,A,,,50588,Steady state volume of distribution was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618722,BAO_0000218,
7012,2652,A,,,50588,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618723,BAO_0000218,
7013,16452,A,,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618724,BAO_0000218,
7014,16452,A,,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618725,BAO_0000218,
7015,16452,A,,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618726,BAO_0000218,
7016,5334,A,,,50588,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618727,BAO_0000218,
7017,4239,A,,,50588,Pharmacokinetic property (vdss) was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624233,BAO_0000218,
7018,4709,A,,,50588,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624234,BAO_0000218,
7019,5600,A,,,50588,Vdss was determined after iv 0.1 mg/kg administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624235,BAO_0000218,
7020,6057,A,,,50588,Volume displacement was calculated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624236,BAO_0000218,
7021,5654,A,,,50588,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624237,BAO_0000218,
7022,5505,A,,,50588,Volume distribution constant was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624238,BAO_0000218,
7023,4527,A,,,50588,Volume distribution at a dose of 1 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624239,BAO_0000218,
7024,4521,A,,,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875829,BAO_0000218,
7025,4521,A,,,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624240,BAO_0000218,
7026,15660,A,,,50588,Volume distribution (Vdss) was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624241,BAO_0000218,
7027,15660,A,,,50588,Volume distribution (Vdss) was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624242,BAO_0000218,
7028,6679,A,,,50588,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624243,BAO_0000218,
7029,5145,A,,,50588,Volume of distribution in steady state was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624244,BAO_0000218,
7030,6821,A,,,50588,Volume of distribution of compound was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624245,BAO_0000218,
7031,4137,A,,,50588,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624246,BAO_0000218,
7032,5334,A,,,50588,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624247,BAO_0000218,
7033,15660,A,,,50588,Volume of distribution (Vdss) was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624248,BAO_0000218,
7034,6642,A,,,50588,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624249,BAO_0000218,
7035,6641,A,,,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624250,BAO_0000218,
7036,6642,A,,,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624251,BAO_0000218,
7037,11659,A,,,50588,Maximum rate of depolarization of the upstroke of the action potential,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624252,BAO_0000218,
7038,6448,A,,,50588,Steady state volume distribution in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624253,BAO_0000218,
7039,5474,A,,,50588,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624950,BAO_0000218,
7040,1466,A,,,50588,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624951,BAO_0000218,
7041,6535,A,,,50588,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875830,BAO_0000218,
7042,6535,A,,,50588,Volume distribution in dog after administration of 1 mg/kg iv,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624952,BAO_0000218,
7043,17764,A,,,50588,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624953,BAO_0000218,
7044,6215,A,,,50588,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624954,BAO_0000218,
7045,6505,A,,,50588,Vss on i.v. administration of 2 mg/kg was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624955,BAO_0000218,
7046,3639,A,,,50588,Vss was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624956,BAO_0000218,
7047,3639,A,,,50588,Vss in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625129,BAO_0000218,
7048,6062,A,,,50588,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625130,BAO_0000218,
7049,4942,A,,,50588,Volume distribution in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625131,BAO_0000218,
7050,17796,A,,,50588,Volume of distribution in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625132,BAO_0000218,
7051,4883,A,,,50588,Tested for the oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL872263,BAO_0000218,
7060,17837,A,,,50594,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624336,BAO_0000218,
7061,17729,A,,,50594,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624337,BAO_0000218,
7062,17729,A,,,50594,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624338,BAO_0000218,
7063,4239,A,,,50594,Bioavailability was measured in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624339,BAO_0000218,
7064,17592,A,,,50594,Bioavailability in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624340,BAO_0000218,
7065,6348,A,,,50594,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624341,BAO_0000218,
7066,2801,A,,,50594,Bioavailability in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624342,BAO_0000218,
7067,2801,A,,,50594,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624343,BAO_0000218,
7068,17718,A,,,50594,Oral bioavailability in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624344,BAO_0000218,
7069,5727,A,,,50594,Oral availability at 50 mg/kg po in male mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624345,BAO_0000218,
7070,5302,A,,,50594,Oral bioavailability in mouse (dose 10 mg/kg),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624346,BAO_0000218,
7071,3598,A,,,50594,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,1,,Mus musculus,1,10090.0,N,Expert,,,CHEMBL624347,BAO_0000218,
7072,5961,A,,,50594,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624348,BAO_0000218,
7074,6091,A,,,50594,Oral bioavailability in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622754,BAO_0000218,
7075,6091,A,,,50594,Oral bioavailability in vivo in mice;ND=Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622755,BAO_0000218,
7076,5711,A,,,50594,Oral bioavailability in mouse at 10 mg/kg of the compound,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622756,BAO_0000218,
7077,17728,A,,,50594,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622757,BAO_0000218,
7078,17728,A,,,50594,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622758,BAO_0000218,
7079,3802,A,,,50594,Tested for bioavailability of the compound,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622759,BAO_0000218,
7080,3802,A,,,50594,Tested for half life at the dose of 10 mg/kg when administered intravenously,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622760,BAO_0000218,
7081,14029,A,,1969.0,50594,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622761,BAO_0000218,
7082,14029,A,,1969.0,50594,The plasma half life of compound was determined on heparin prepared by human plasma. ,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622762,BAO_0000218,
7083,14029,A,,1969.0,50594,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622763,BAO_0000218,
7084,14029,A,,1969.0,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622764,BAO_0000218,
7085,14029,A,,1969.0,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622765,BAO_0000218,
7086,17753,F,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622766,BAO_0000218,
7087,17753,A,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622767,BAO_0000218,
7088,17753,A,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622768,BAO_0000218,
7089,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875948,BAO_0000218,
7090,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622769,BAO_0000218,
7091,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622770,BAO_0000218,
7092,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622771,BAO_0000218,
7093,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622772,BAO_0000218,
7094,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622773,BAO_0000218,
7095,10107,A,,178.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622774,BAO_0000218,
7096,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621725,BAO_0000218,
7097,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621726,BAO_0000218,
7098,15608,F,A2780,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621727,BAO_0000219,
7099,3290,F,A2780,,81034,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622413,BAO_0000219,
7100,2859,F,A2780,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622414,BAO_0000219,
7101,15688,F,A2780,,81034,Inhibition of A2780 cell clonogenic assay,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622415,BAO_0000219,
7102,5642,F,A2780,,81034,Cytotoxic effect on ovarian cancer cell line (A2780),,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL884001,BAO_0000219,
7103,6633,F,A2780,,81034,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622416,BAO_0000219,
7104,3906,F,A2780,,81034,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622417,BAO_0000219,
7105,6788,F,A2780,,81034,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622590,BAO_0000219,
7106,17582,F,A2780,,81034,Antiproliferative activity against human A2780 cells,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622591,BAO_0000219,
7107,17764,F,A2780,,81034,Inhibition of human A2780 cell proliferation,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622592,BAO_0000219,
7108,17764,F,A2780,,81034,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622593,BAO_0000219,
7109,17764,F,A2780,,81034,Inhibition of human A2780 cell proliferation (No data),,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622594,BAO_0000219,
7110,2815,F,A2780,,81034,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622595,BAO_0000219,
7111,16930,F,A2780,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622596,BAO_0000219,
7112,17777,F,A2780,,81034,Growth inhibition against A2780 wild-type ovarian cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622597,BAO_0000219,
7113,17777,F,A2780,,81034,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622598,BAO_0000219,
7114,16936,F,,,104766,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,5,,Homo sapiens,1,9606.0,D,Autocuration,,,CHEMBL622599,BAO_0000019,
7115,13759,F,A2780,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622600,BAO_0000219,
7116,13759,F,A2780,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622601,BAO_0000219,
7117,13759,F,A2780,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622602,BAO_0000219,
7118,13759,F,A2780,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622603,BAO_0000219,
7119,15292,F,A2780,,81034,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622604,BAO_0000219,
7120,15292,F,A2780,,81034,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622605,BAO_0000219,
7121,15069,F,A2780,,81034,In vitro inhibition of human ovarian cell line A2780,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL622606,BAO_0000219,
7122,15069,F,A2780,,81034,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619463,BAO_0000219,
7123,14073,F,A2780,,81034,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619464,BAO_0000219,
7124,14553,F,A2780,,81034,Concentration required to inhibit A2780-cell growth by 50%,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619465,BAO_0000219,
7125,13040,F,A2780,,81034,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619466,BAO_0000219,
7126,6891,F,A2780,,81034,Cytotoxic effect on human ovarian (A2780) cancer cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619467,BAO_0000219,
7127,15569,F,A2780,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619468,BAO_0000219,
7128,14190,F,A2780,,81034,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619469,BAO_0000219,
7129,15014,F,A2780,,81034,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL619470,BAO_0000219,
7130,15014,F,A2780,,81034,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619471,BAO_0000219,
7131,17496,F,A2780,,81034,Cytotoxicity against human ovarian carcinoma A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619472,BAO_0000219,
7132,13617,F,A2780,,81034,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL619473,BAO_0000219,
7133,13617,F,A2780,,81034,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL874368,BAO_0000219,
7134,13617,F,A2780,,81034,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884003,BAO_0000219,
7135,13617,F,A2780,,81034,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622690,BAO_0000219,
7136,17672,F,A2780,,81034,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622691,BAO_0000219,
7137,4544,F,A2780,,81034,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622692,BAO_0000219,
7138,4544,F,A2780,,81034,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623406,BAO_0000219,
7139,16317,F,A2780,,81034,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL884004,BAO_0000219,
7140,15099,F,A2780,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623407,BAO_0000219,
7141,13978,F,A2780,,81034,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623408,BAO_0000219,
7142,12989,F,A2780,,81034,In vitro antitumor activity against A2780 cell line.,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623409,BAO_0000219,
7143,5574,F,A2780,,81034,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623410,BAO_0000219,
7144,13528,F,A2780,,81034,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623576,BAO_0000219,
7145,12782,F,ACHN,,80025,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623577,BAO_0000219,
7146,14255,F,ACHN,,80025,The IC50 value was measured on ACHN cell line in renal tumor type.,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623578,BAO_0000219,
7147,16364,F,ACHN,,80025,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623579,BAO_0000219,
7148,17376,F,ACHN,,80025,In vitro lethal concentration against most sensitive ACHN cell line,,1,626.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623580,BAO_0000219,
7149,12016,F,ACHN,,80025,Tested for cytotoxic activity against renal cancer ACHN cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623581,BAO_0000219,
7150,6058,F,ACHN,,80025,Compound tested for growth inhibition of renal cancer cell line ACHN,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL857456,BAO_0000219,
7151,17708,F,ACHN,,80025,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623582,BAO_0000219,
7152,15176,F,ACHN,,80025,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623583,BAO_0000219,
7153,2806,F,ACHN,,80025,In vitro anticancer activity against ACHN renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623584,BAO_0000219,
7154,15300,F,ACHN,,80025,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623585,BAO_0000219,
7155,16364,F,ACHN,,80025,Percent selectivity was evaluated in renal ACHN cell lines,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623586,BAO_0000219,
7156,13859,F,ACHN,,80025,In vitro inhibitory activity against renal ACHN cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623587,BAO_0000219,
7157,11970,F,ACHN,,80025,Tested for cytotoxicity against ACHN cell lines in renal cancer,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875279,BAO_0000219,
7158,2450,F,ACHN,,80025,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623588,BAO_0000219,
7159,12696,F,ACHN,,80025,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623589,BAO_0000219,
7160,12400,F,ACHN,,80025,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623590,BAO_0000219,
7161,12888,F,ACHN,,80025,Cytotoxic effect on renal cancer line ACHN,,1,626.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL623591,BAO_0000219,
7162,3156,F,ACHN,,80025,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623592,BAO_0000219,
7163,3381,F,ACHN,,80025,In vitro inhibition of Renal Cancer ACHN cell lines,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623593,BAO_0000219,
7164,16747,F,ACHN,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623594,BAO_0000219,
7165,16748,F,ACHN,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells.,,1,626.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621833,BAO_0000219,
7166,12062,F,ACHN,,80025,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621834,BAO_0000219,
7167,14769,F,ACHN,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621835,BAO_0000219,
7168,15895,F,ACHN,,80025,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621836,BAO_0000219,
7169,17376,F,ACHN,,80025,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621837,BAO_0000219,
7170,14882,F,ACHN,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875280,BAO_0000219,
7171,14882,F,ACHN,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621838,BAO_0000219,
7172,15661,F,ACHN,,80025,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,1,626.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621839,BAO_0000219,
7173,9680,A,,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL621840,BAO_0000019,
7174,14579,F,,,10647,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,8,,,1,,H,Autocuration,,,CHEMBL621841,BAO_0000019,
7175,17290,F,HEL,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,1,468.0,Cytomegalovirus,1,10358.0,N,Expert,,,CHEMBL622979,BAO_0000218,
7176,17290,F,,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,1,,Cytomegalovirus,1,10358.0,N,Intermediate,,,CHEMBL876595,BAO_0000218,
7177,15891,B,,,12159,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,8,,,1,,H,Autocuration,,,CHEMBL620221,BAO_0000357,
7178,15890,B,,,12159,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,8,,,1,,H,Autocuration,,,CHEMBL620222,BAO_0000357,
7179,3801,F,ADDP cell line,,80670,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,1,979.0,Bos taurus,1,9913.0,N,Intermediate,,,CHEMBL620506,BAO_0000219,
7180,9222,F,ADJ/PC6,,80671,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620507,BAO_0000219,
7181,9222,F,ADJ/PC6,,80671,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620508,BAO_0000219,
7182,7257,F,ADJ/PC6,,80671,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620509,BAO_0000219,
7183,7257,F,ADJ/PC6,,80671,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620510,BAO_0000219,
7184,7257,A,ADJ/PC6,,80671,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620511,BAO_0000219,
7185,8084,F,ADJ/PC6,,80671,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,1,980.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620512,BAO_0000219,
7186,14943,F,,,22224,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620513,BAO_0000019,
7187,14943,F,,,22224,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620514,BAO_0000019,
7188,14943,F,,,22224,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620515,BAO_0000019,
7189,10524,A,,,22224,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,0,,Bacillus subtilis,1,1423.0,U,Autocuration,,,CHEMBL620516,BAO_0000218,
7190,3546,A,,1969.0,50588,AUC value in dog after IV administration at a dose of 5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620517,BAO_0000218,
7191,3546,A,,1969.0,50588,AUC value in dog after oral administration at a dose of 5 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620518,BAO_0000218,
7192,3546,A,,,50588,Cmax value in dog after oral administration at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620519,BAO_0000218,
7193,3546,A,,,50588,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621386,BAO_0000218,
7194,3546,A,,,50588,Tmax value in dog after oral administration at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621387,BAO_0000218,
7195,3184,A,,,50588,Compound was evaluated for its clearance when administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621388,BAO_0000218,
7196,16456,A,,,50588,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621389,BAO_0000218,
7197,4809,A,,,50588,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621390,BAO_0000218,
7198,4219,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Intermediate,,,CHEMBL621391,BAO_0000100,
7199,3748,A,,,50588,Half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621392,BAO_0000218,
7200,3132,A,,,50588,Time taken for EC90 was determined when tested in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621393,BAO_0000218,
7201,4219,A,,,50588,Half life (iv) was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621394,BAO_0000218,
7202,16907,A,,2107.0,50588,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621395,BAO_0000218,
7203,6057,A,,,50588,Area under the curve was calculated in dog after iv administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621396,BAO_0000218,
7204,6057,A,,,50588,Area under the curve was calculated in dog after peroral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621397,BAO_0000218,
7205,17853,A,,,50588,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621398,BAO_0000218,
7206,3639,A,,,50588,pKa was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618818,BAO_0000218,
7207,14541,A,,,50588,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618819,BAO_0000218,
7208,16456,A,,,50588,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618820,BAO_0000218,
7209,16456,A,,,50588,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873810,BAO_0000218,
7210,2652,A,,,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876606,BAO_0000218,
7211,3624,A,,,50588,Compound was evaluated for the half-life (t 1/2) in hours,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618821,BAO_0000218,
7212,1337,A,,178.0,50588,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618822,BAO_0000218,
7213,1337,A,,178.0,50588,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618823,BAO_0000218,
7214,4709,A,,,50588,Half life after intravenous administration of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618824,BAO_0000218,
7215,15660,A,,,50588,Half life was measured in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618825,BAO_0000218,
7216,5302,A,,,50588,Half life period in dog after 5 mg/kg dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618826,BAO_0000218,
7217,17791,A,,,50588,Half life period was evaluated in dog; 4-4.8,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618827,BAO_0000218,
7218,6348,A,,,50588,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618828,BAO_0000218,
7219,4257,A,,,50588,Half-life was determined in dog after a3 mg/kg of iv dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618829,BAO_0000218,
7220,3771,A,,,50588,Half-life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618830,BAO_0000218,
7221,6305,A,,,50588,Half life in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618831,BAO_0000218,
7222,13501,A,,1969.0,50588,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619489,BAO_0000218,
7223,17594,A,,,50588,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619649,BAO_0000218,
7224,3045,A,,,50588,Compound was evaluated for the half life period after iv administration in Beagle dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876607,BAO_0000218,
7225,3043,A,,,50588,Compound was evaluated for the half life period after oral administration in conscious dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619650,BAO_0000218,
7226,4839,A,,,50588,Compound was tested for half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619651,BAO_0000218,
7227,4839,A,,,50588,Compound was tested for its half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619652,BAO_0000218,
7228,5802,A,,,50588,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619653,BAO_0000218,
7229,17839,A,,,50588,Half life of compound in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619654,BAO_0000218,
7230,4219,A,,,50588,Half life (iv) was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619655,BAO_0000218,
7231,13966,A,,178.0,50588,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619656,BAO_0000218,
7232,3994,A,,1969.0,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873812,BAO_0000218,
7233,3994,F,,1969.0,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621365,BAO_0000218,
7234,4453,A,,,50588,Half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621366,BAO_0000218,
7235,6535,A,,1969.0,50588,Half life in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621367,BAO_0000218,
7236,6535,A,,1969.0,50588,Half life in dog plasma after administration of 0.25 mg/kg iv,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621368,BAO_0000218,
7237,6535,A,,1969.0,50588,Half life in dog plasma after administration of 1 mg/kg iv,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621369,BAO_0000218,
7238,3132,A,,1969.0,50588,Half life in dog plasma was determined at dose 10 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621370,BAO_0000218,
7239,5374,A,,,50588,Half life in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621371,BAO_0000218,
7240,5007,A,,,50588,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621372,BAO_0000218,
7241,16907,A,,1969.0,50588,Half life upon exposure to human plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621373,BAO_0000218,
7242,6057,A,,,50588,Half life was calculated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621374,BAO_0000218,
7243,5006,A,,,50588,Half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621375,BAO_0000218,
7244,5473,A,,,50588,Half life was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621376,BAO_0000218,
7245,4368,A,,,50588,Half life by intravenous administration of 1.2 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619624,BAO_0000218,
7246,6448,A,,,50588,Half life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875840,BAO_0000218,
7247,4353,A,,,50588,Half life in dog after intra venous administration of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619625,BAO_0000218,
7248,4353,A,,,50588,Half life in dog after intra venous administration of the compound; ND means Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619626,BAO_0000218,
7249,4353,A,,,50588,Half life in dog after po administration of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619627,BAO_0000218,
7250,4353,A,,,50588,Half life in dog after po administration of the compound; ND means Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873817,BAO_0000218,
7251,6265,A,,,50588,Half life in dog at the single oral dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619628,BAO_0000218,
7252,5006,A,,,50588,Half life in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619629,BAO_0000218,
7253,5356,A,,,50588,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619630,BAO_0000218,
7254,405,A,,,50588,Half life in rat,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619631,BAO_0000218,
7255,6642,A,,,50588,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL619632,BAO_0000218,
7256,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619633,BAO_0000218,
7257,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875841,BAO_0000218,
7258,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619634,BAO_0000218,
7259,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619635,BAO_0000218,
7260,10107,A,,10000001.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619636,BAO_0000218,
7261,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619637,BAO_0000218,
7262,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619638,BAO_0000218,
7263,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619639,BAO_0000218,
7264,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619640,BAO_0000218,
7265,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619641,BAO_0000218,
7266,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619642,BAO_0000218,
7267,10107,A,,10000004.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Gut,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619643,BAO_0000218,
7268,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619644,BAO_0000218,
7269,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621112,BAO_0000218,
7270,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621113,BAO_0000218,
7271,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621114,BAO_0000218,
7272,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621115,BAO_0000218,
7273,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621116,BAO_0000218,
7274,10107,A,,948.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621117,BAO_0000218,
7275,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621118,BAO_0000218,
7276,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621119,BAO_0000218,
7277,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621120,BAO_0000218,
7278,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621757,BAO_0000218,
7279,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621758,BAO_0000218,
7280,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621759,BAO_0000218,
7281,10107,A,,2113.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621760,BAO_0000218,
7282,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621761,BAO_0000218,
7283,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621762,BAO_0000218,
7284,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621763,BAO_0000218,
7285,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624502,BAO_0000218,
7286,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624503,BAO_0000218,
7287,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624504,BAO_0000218,
7288,10107,A,,2107.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624505,BAO_0000218,
7289,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624506,BAO_0000218,
7290,5895,F,A2780,,81034,In vitro cytotoxicity against A2780 (human ovarian cancer),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624507,BAO_0000219,
7291,6338,F,A2780,,81034,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624508,BAO_0000219,
7292,15163,F,A2780,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624509,BAO_0000219,
7293,15163,F,A2780,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624510,BAO_0000219,
7294,15000,F,A2780,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL875956,BAO_0000219,
7295,15000,F,A2780,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL839885,BAO_0000219,
7296,14729,F,A2780,,81034,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL624511,BAO_0000219,
7297,17270,F,A2780,,81034,In vitro cytotoxicity against A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624512,BAO_0000219,
7298,5685,F,A2780,,81034,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624513,BAO_0000219,
7299,3563,F,A2780,,81034,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624514,BAO_0000219,
7300,17753,F,A2780,,81034,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618547,BAO_0000218,
7301,16317,F,A2780,,81034,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618548,BAO_0000219,
7302,16936,F,A2780,,81034,Inhibition of tubulin polymerization in analogy of ca.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618549,BAO_0000219,
7303,3801,F,A2780,,81034,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618550,BAO_0000219,
7304,6181,F,A2780,,81034,Cytotoxic effect in ovarian cancer cell line (A2780),,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618551,BAO_0000219,
7305,5318,F,A2780,,81034,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618552,BAO_0000219,
7306,4840,F,A2780,,81034,Tested for the cytotoxicity in A2780 ovarian cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618553,BAO_0000219,
7307,15748,F,A2780,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618554,BAO_0000219,
7308,15748,F,A2780,,81034,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618555,BAO_0000219,
7309,15748,F,A2780cisR,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,1,481.0,,1,,N,Intermediate,,,CHEMBL618556,BAO_0000219,
7310,15748,F,A2780cisR,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,1,481.0,,1,,N,Intermediate,,,CHEMBL618557,BAO_0000219,
7311,15748,F,A2780cisR,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,1,481.0,,1,,N,Intermediate,,,CHEMBL618558,BAO_0000219,
7312,15748,F,A2780cisR,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,1,481.0,,1,,N,Intermediate,,,CHEMBL618559,BAO_0000219,
7313,17753,F,A2780,,81034,In vivo log of cells killed after administration of compound in A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618560,BAO_0000218,
7314,17753,F,A2780,,81034,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618561,BAO_0000218,
7315,16936,F,A2780,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618562,BAO_0000219,
7316,16936,F,A2780,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618563,BAO_0000219,
7317,16936,F,A2780,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618564,BAO_0000219,
7318,16936,F,A2780,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618565,BAO_0000219,
7319,17528,F,A2780,,81034,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618566,BAO_0000218,
7320,6633,F,A2780,,81034,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL618567,BAO_0000219,
7321,15000,F,A2780,,81034,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618568,BAO_0000219,
7322,17528,F,A2780,,81034,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL618569,BAO_0000219,
7323,16936,F,A2780,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621857,BAO_0000219,
7324,16936,F,A2780,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621858,BAO_0000219,
7325,16936,F,A2780,,81034,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621859,BAO_0000219,
7326,16936,F,A2780,,81034,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621860,BAO_0000219,
7327,16936,F,A2780,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621861,BAO_0000219,
7328,16936,F,A2780,,81034,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,1,478.0,Homo sapiens,1,9606.0,N,Expert,,,CHEMBL621862,BAO_0000219,
7329,16936,F,A2780,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621863,BAO_0000219,
7330,16936,F,A2780,,81034,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621864,BAO_0000219,
7331,16936,F,A2780,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621865,BAO_0000219,
7332,17737,F,A2780,,81034,In vitro antiproliferative activity against A2780 cell line,,1,478.0,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621866,BAO_0000219,
7333,17764,F,A2780,,81034,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,1,478.0,Mus musculus,1,10090.0,N,Expert,,,CHEMBL621867,BAO_0000219,
7334,3830,F,A2780,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL621868,BAO_0000219,
7335,3829,F,A2780,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,1,478.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875282,BAO_0000219,
7336,3546,A,,,50588,Vc value in dog after IV administration at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621869,BAO_0000218,
7337,3546,A,,,50588,Half life period in dog after IV administration at a dose of 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621870,BAO_0000218,
7338,5668,A,,,22224,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621871,BAO_0000019,
7339,3443,A,,1969.0,22224,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621243,BAO_0000218,
7340,3443,A,,1969.0,22224,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621244,BAO_0000218,
7341,4256,A,,,22224,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL621245,BAO_0000218,
7342,4256,A,,,22224,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL621246,BAO_0000218,
7343,4256,A,,,22224,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL621247,BAO_0000218,
7344,4256,A,,,22224,Oral Bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL618386,BAO_0000218,
7345,1916,A,,,22224,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618387,BAO_0000218,
7346,5302,A,,,22224,Area under curve value in monkey at a dose of 5 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618388,BAO_0000218,
7347,4257,A,,,22224,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618389,BAO_0000218,
7348,5355,A,,,22224,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618574,BAO_0000019,
7349,5355,A,,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618575,BAO_0000019,
7350,5355,A,,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618576,BAO_0000019,
7351,6078,A,,,22224,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618577,BAO_0000218,
7352,6078,A,,,22224,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876487,BAO_0000218,
7353,6062,A,,,22224,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618578,BAO_0000218,
7354,2661,A,,,22224,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618579,BAO_0000218,
7355,2661,A,,,22224,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618580,BAO_0000019,
7356,5394,A,,,22224,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618581,BAO_0000218,
7357,4397,A,,,22224,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618582,BAO_0000218,
7358,17509,A,,,22224,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618583,BAO_0000218,
7359,17509,A,,,22224,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618584,BAO_0000218,
7360,6641,A,,,22224,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618585,BAO_0000218,
7361,5355,A,,,22224,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618586,BAO_0000218,
7362,3443,A,,,22224,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618587,BAO_0000218,
7363,3443,A,,,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618588,BAO_0000218,
7364,17409,A,,,22224,Binding towards monkey plasma protein at 10 uM,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618589,BAO_0000019,
7365,17409,A,,,22224,Binding towards monkey plasma protein at 100 uM,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618590,BAO_0000019,
7366,1052,A,,,22224,Apparent bioavailability in squirrel monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL872262,BAO_0000218,
7367,13501,A,,,22224,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618591,BAO_0000218,
7368,17509,A,,,22224,Bioavailability in monkey (dose 2 mg/kg),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL618592,BAO_0000218,
7369,5394,A,,,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL876488,BAO_0000218,
7370,2661,A,,,22224,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618593,BAO_0000218,
7371,11219,A,,,22224,Bioavailability in monkey (i.d. dosing),,0,,monkey,1,9443.0,U,Autocuration,,,CHEMBL618594,BAO_0000218,
7372,3045,A,,,22224,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL618595,BAO_0000218,
7373,17796,A,,,22224,Clearance of the drug was measured in cynomolgus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621469,BAO_0000019,
7374,1399,A,,,22224,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621470,BAO_0000218,
7375,2661,A,,,22224,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621471,BAO_0000218,
7376,5005,A,,1969.0,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL621472,BAO_0000218,
7377,17267,A,,,22224,Plasma clearance in rhesus monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621473,BAO_0000218,
7378,6535,A,,,22224,Plasma clearance in monkey after administration of 1 mg/kg iv,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621474,BAO_0000218,
7379,5922,A,,,22224,Plasma clearance in cynomolgus monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621475,BAO_0000218,
7380,6221,A,,,22224,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL621476,BAO_0000218,
7381,5668,A,,,22224,Plasma clearance after peroral administration at 10 mpk in Rhesus,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624290,BAO_0000218,
7382,5355,A,,,22224,The total clearance was determined after intravenous administration in cynomolgus monkeys,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624291,BAO_0000218,
7383,5355,A,,,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624292,BAO_0000218,
7384,5355,A,,,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624293,BAO_0000218,
7385,4578,A,,,22224,Tested for Clearance upon iv administration to african green monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624294,BAO_0000218,
7386,17592,A,,,22224,Clearance in monkey,,0,,Cercopithecidae,1,9527.0,U,Autocuration,,,CHEMBL624295,BAO_0000218,
7387,6641,A,,,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624296,BAO_0000218,
7388,6642,A,,,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624297,BAO_0000218,
7389,16367,A,,,50588,Half life was evaluated after intravenous administration to dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624298,BAO_0000218,
7390,5472,A,,,50588,Half life was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624299,BAO_0000218,
7391,5474,A,,,50588,Half life was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624300,BAO_0000218,
7392,5654,A,,,50588,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624301,BAO_0000218,
7393,6227,A,,,50588,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624302,BAO_0000218,
7394,6227,A,,,50588,Half life period after intravenous administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876026,BAO_0000218,
7395,6221,A,,,50588,Half life period after oral administration (2.5 mg/kg) in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624303,BAO_0000218,
7396,4527,A,,,50588,Half life period at a dose of 1 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624304,BAO_0000218,
7397,5668,A,,,50588,Half life period was determine after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624305,BAO_0000218,
7398,5668,A,,,50588,Half life period was determine after peroral administration at 5 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624306,BAO_0000218,
7399,3854,A,,,50588,Half life period was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624307,BAO_0000218,
7400,5505,A,,,50588,Half life period was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624308,BAO_0000218,
7401,6251,A,,,50588,Half life period by iv administration in dog at a dose of 6 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624309,BAO_0000218,
7402,1918,A,,,50588,Half life period was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624310,BAO_0000218,
7403,5546,A,,,50588,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625003,BAO_0000218,
7404,4809,A,,,50588,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625004,BAO_0000218,
7405,6215,A,,,50588,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625005,BAO_0000218,
7406,4527,A,,,50588,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873813,BAO_0000218,
7407,17594,A,,,50588,Half-life after oral dose of compound at 3 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625006,BAO_0000218,
7408,17839,A,,,50588,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625007,BAO_0000218,
7409,17839,A,,,50588,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876027,BAO_0000218,
7410,17839,A,,,50588,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625008,BAO_0000218,
7411,17839,A,,,50588,Half-life of compound in dog following p.o. administration of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625009,BAO_0000218,
7412,5210,A,,1969.0,50588,Half-life of compound in plasma of dog was determined,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625010,BAO_0000218,
7413,5210,A,,,50588,Half-life of compound was determined in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625011,BAO_0000218,
7414,2959,A,,,50588,Half-life after administration of 4 mg/Kg oral dose in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621553,BAO_0000218,
7415,4137,A,,,50588,Half-life after intravenous administration of 1 mg/kg/h in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621554,BAO_0000218,
7416,5064,A,,,50588,Half-life in Dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621555,BAO_0000218,
7417,5147,A,,,50588,Half-life in Dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621556,BAO_0000218,
7418,5145,A,,,50588,Half-life in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621557,BAO_0000218,
7419,6123,A,,,50588,Half-life in dog after oral administration at 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621558,BAO_0000218,
7420,6123,A,,,50588,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621559,BAO_0000218,
7421,4333,A,,,50588,Half-life in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621560,BAO_0000218,
7422,4333,A,,,50588,Half-life in dogs; ND indicates not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876028,BAO_0000218,
7423,12500,A,,1969.0,50588,Half-life in plasma of dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621561,BAO_0000218,
7424,12500,A,,1969.0,50588,Half-life in plasma of dog at dose of 3-10 mgkg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621562,BAO_0000218,
7425,6005,A,,,50588,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621563,BAO_0000218,
7426,6062,A,,,50588,Half-life was measured in dog after an iv dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621564,BAO_0000218,
7427,17650,A,,,50588,Half-life was measured in dogs after an oral dose of 10 uM/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621565,BAO_0000218,
7428,5530,A,,,50588,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621566,BAO_0000218,
7429,5530,A,,,50588,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621567,BAO_0000218,
7430,5600,A,,,50588,Half-life of the compound after 0.3 mg/kg po administration in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622978,BAO_0000218,
7431,6039,A,,,50588,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL873814,BAO_0000218,
7432,6039,A,,,50588,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623219,BAO_0000218,
7433,6039,A,,,50588,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624477,BAO_0000218,
7434,6227,A,,,50588,t1/2 in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624478,BAO_0000218,
7435,14541,A,,,50588,Half-life period measured in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624479,BAO_0000218,
7436,4521,A,,,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624480,BAO_0000218,
7437,4521,A,,,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623595,BAO_0000218,
7438,6679,A,,,50588,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623596,BAO_0000218,
7439,1116,A,,1969.0,50588,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623597,BAO_0000218,
7440,5444,A,,,50588,In vivo half life period was calculated at 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623598,BAO_0000218,
7441,5444,A,,,50588,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623599,BAO_0000218,
7442,17853,A,,,50588,Longer half-life in dog (i.v.) at 0.5 mpk,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623600,BAO_0000218,
7443,4353,A,,,50588,Oral bioavailability in dog (dose 5 uM/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623601,BAO_0000218,
7444,16452,A,,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623602,BAO_0000218,
7445,16452,A,,,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623603,BAO_0000218,
7446,16452,A,,,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623604,BAO_0000218,
7447,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623605,BAO_0000218,
7448,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623606,BAO_0000218,
7449,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623607,BAO_0000218,
7450,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623608,BAO_0000218,
7451,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623609,BAO_0000218,
7452,10107,A,,2048.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623610,BAO_0000218,
7453,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623611,BAO_0000218,
7454,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623612,BAO_0000218,
7455,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623613,BAO_0000218,
7456,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623614,BAO_0000218,
7457,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623615,BAO_0000218,
7458,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623616,BAO_0000218,
7459,10107,A,,2385.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623617,BAO_0000218,
7460,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875944,BAO_0000218,
7461,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623618,BAO_0000218,
7462,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623619,BAO_0000218,
7463,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623620,BAO_0000218,
7464,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623621,BAO_0000218,
7465,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623622,BAO_0000218,
7466,10107,A,,14.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623623,BAO_0000218,
7467,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623624,BAO_0000218,
7468,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618521,BAO_0000218,
7469,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618522,BAO_0000218,
7470,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618523,BAO_0000218,
7471,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618524,BAO_0000218,
7472,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618525,BAO_0000218,
7473,10107,A,,2106.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624586,BAO_0000218,
7474,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624587,BAO_0000218,
7475,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624588,BAO_0000218,
7476,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624589,BAO_0000218,
7477,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624590,BAO_0000218,
7478,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624591,BAO_0000218,
7479,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624592,BAO_0000218,
7480,10107,A,,945.0,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624593,BAO_0000218,
7481,4689,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624594,BAO_0000218,
7482,4950,A,,,50597,Tested for the bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624595,BAO_0000218,
7483,5328,A,,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624596,BAO_0000218,
7484,406,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624597,BAO_0000218,
7485,12500,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624598,BAO_0000218,
7486,12500,A,,,50597,Bioavailability in rat (dose 3-10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624599,BAO_0000218,
7487,5247,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875166,BAO_0000218,
7488,4186,A,,1969.0,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624600,BAO_0000218,
7489,4186,A,,1969.0,50597,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624601,BAO_0000218,
7490,6647,A,,,50597,Half life after oral administration was determined in rats at 6 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624602,BAO_0000218,
7491,6484,A,,,50597,Half life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624603,BAO_0000218,
7492,3249,A,,,50597,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624604,BAO_0000218,
7493,6281,A,,1969.0,50597,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624605,BAO_0000218,
7494,3307,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624606,BAO_0000218,
7495,12058,A,,178.0,50597,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624607,BAO_0000218,
7496,8833,A,,,50597,Hill coefficient of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624608,BAO_0000218,
7497,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624609,BAO_0000218,
7498,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624610,BAO_0000218,
7499,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624611,BAO_0000218,
7500,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624612,BAO_0000218,
7501,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875167,BAO_0000218,
7502,3193,A,,178.0,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624613,BAO_0000218,
7503,3193,A,,178.0,50597,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624614,BAO_0000218,
7504,5960,A,,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624392,BAO_0000218,
7505,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624393,BAO_0000218,
7506,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624394,BAO_0000218,
7507,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624395,BAO_0000218,
7508,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624396,BAO_0000218,
7509,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624397,BAO_0000218,
7510,13950,A,,2046.0,50597,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624398,BAO_0000218,
7511,13950,A,,2046.0,50597,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624399,BAO_0000218,
7512,13950,A,,2046.0,50597,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624400,BAO_0000218,
7513,13950,A,,2046.0,50597,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624401,BAO_0000218,
7514,13950,A,,2046.0,50597,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624402,BAO_0000218,
7515,9866,A,,178.0,50597,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624403,BAO_0000218,
7516,9866,A,,178.0,50597,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624404,BAO_0000218,
7517,9866,A,,178.0,50597,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624405,BAO_0000218,
7518,9866,A,,10000001.0,50597,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624406,BAO_0000218,
7519,9866,A,,10000001.0,50597,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624407,BAO_0000218,
7520,9866,A,,10000001.0,50597,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624408,BAO_0000218,
7521,9866,A,,948.0,50597,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618644,BAO_0000218,
7522,9866,A,,948.0,50597,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618645,BAO_0000218,
7523,9866,A,,948.0,50597,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618646,BAO_0000218,
7524,9866,A,,2113.0,50597,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618647,BAO_0000218,
7525,9866,A,,2113.0,50597,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618648,BAO_0000218,
7526,9866,A,,2113.0,50597,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618649,BAO_0000218,
7527,9866,A,,2107.0,50597,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618650,BAO_0000218,
7528,9866,A,,2107.0,50597,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618651,BAO_0000218,
7529,9866,A,,2107.0,50597,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876497,BAO_0000218,
7530,9866,A,,2048.0,50597,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618652,BAO_0000218,
7531,9866,A,,2048.0,50597,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618653,BAO_0000218,
7532,9866,A,,2048.0,50597,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618654,BAO_0000218,
7533,6351,A,,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618655,BAO_0000218,
7534,1465,A,,,50597,Compound was tested for solubility in water,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618656,BAO_0000218,
7535,5182,P,,,22229,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,0,,,1,,U,Intermediate,,,CHEMBL618657,BAO_0000100,
7536,17847,A,,,50597,Solubility was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618658,BAO_0000218,
7537,15339,A,,,50597,solubility in water (ug/mL) at 37 degree C.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618659,BAO_0000218,
7538,5202,A,,,50597,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618660,BAO_0000218,
7539,1088,A,,,50597,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618661,BAO_0000218,
7540,3169,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873807,BAO_0000218,
7541,5353,A,,,50597,Half life in Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618662,BAO_0000218,
7542,2864,A,,,50597,Half life period after 3 mg/kg iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618663,BAO_0000218,
7543,2864,A,,,50597,Half life period after 3 mg/kg iv administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618664,BAO_0000218,
7544,2864,A,,,50597,Half life period after 3 mg/kg iv administration in the rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618665,BAO_0000218,
7545,6362,A,,,50597,Half life period in female Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876498,BAO_0000218,
7546,6249,A,,,50597,Half life period in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618666,BAO_0000218,
7547,3169,A,,,50597,Half-life in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620440,BAO_0000218,
7548,3169,A,,,50597,Half-life in rats with metabolic oxidation,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620441,BAO_0000218,
7549,3169,A,,,50597,Half-life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620442,BAO_0000218,
7550,17260,A,,,50597,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620443,BAO_0000218,
7551,17260,A,,,50597,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620444,BAO_0000218,
7552,17260,A,,,50597,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620445,BAO_0000218,
7553,17260,A,,,50597,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620446,BAO_0000218,
7554,2879,A,,1969.0,50597,Biological half-life measured in plasma of rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620447,BAO_0000218,
7555,2879,A,,1969.0,50597,Biological half-life measured in plasma of rat; 22-25,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621129,BAO_0000218,
7556,2879,A,,1969.0,50597,Biological half-life measured in plasma of rat; 9-16,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621130,BAO_0000218,
7557,3184,A,,,50597,Compound was evaluated for its half life when administered intravenously in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873808,BAO_0000218,
7558,4891,A,,,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876598,BAO_0000218,
7559,429,A,,,50597,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621131,BAO_0000218,
7560,5656,A,,,50597,Half life (T1/2) after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621132,BAO_0000218,
7561,4413,A,,,50597,Half life of compound after iv administration of 20 mg/kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621133,BAO_0000218,
7562,3598,A,,,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL621312,BAO_0000218,
7563,17267,A,,,50597,Half life of compound was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621313,BAO_0000218,
7564,4727,A,,178.0,50597,Half life of compound was determined in rat blood,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621314,BAO_0000218,
7565,17651,A,,,50597,Half life at 1 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621315,BAO_0000218,
7566,17651,A,,,50597,Half life at 10 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621316,BAO_0000218,
7567,401,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621317,BAO_0000218,
7568,4942,A,,,50597,Half life in rats in hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621318,BAO_0000218,
7569,17735,A,,,50597,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621319,BAO_0000218,
7570,6056,A,,,50597,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621377,BAO_0000218,
7571,5213,A,,,50597,Half life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621378,BAO_0000218,
7572,6616,A,,,50597,Half life after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876599,BAO_0000218,
7573,5937,A,,,50597,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621379,BAO_0000218,
7574,5819,A,,1969.0,50597,Half life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621380,BAO_0000218,
7575,5819,A,,1969.0,50597,Half life in rat plasma; Not detected,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621381,BAO_0000218,
7576,6803,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618515,BAO_0000218,
7577,17804,A,,,50597,Half life period of compound was determined after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618516,BAO_0000218,
7578,17804,A,,,50597,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618517,BAO_0000218,
7579,5948,A,,,50597,Half life period in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618518,BAO_0000218,
7580,1916,A,,,50597,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618519,BAO_0000218,
7581,1916,A,,,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618698,BAO_0000218,
7582,1916,A,,,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618862,BAO_0000218,
7583,4890,A,,,50597,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618863,BAO_0000218,
7584,17764,A,,,50597,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618864,BAO_0000218,
7585,4727,A,,,50597,Half life time in rat the dose of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618865,BAO_0000218,
7586,17509,A,,,50597,Half-life 24 hr after 10 mg/kg iv administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618866,BAO_0000218,
7587,17509,A,,,50597,Half-life 24 hr after 2 mg/kg iv administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618867,BAO_0000218,
7588,6597,A,,,50597,Half-life consistent with the observed metabolic steady state in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875828,BAO_0000218,
7589,17735,A,,,50597,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618868,BAO_0000218,
7590,6597,A,,,50597,Half-life for oxidative metabolic stability was determined using male human,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618869,BAO_0000218,
7591,17670,A,,,50597,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618870,BAO_0000218,
7592,1696,A,,1969.0,50597,Half-life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618871,BAO_0000218,
7593,1742,A,,1969.0,50597,Half-life in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618872,BAO_0000218,
7594,17800,A,,,50597,Half-life in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873816,BAO_0000218,
7595,12923,A,,,22224,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,0,,,1,,U,Autocuration,,,CHEMBL618873,BAO_0000218,
7596,11954,A,,,22224,Area under curve after oral dose of 0.1 mg//kg,,0,,,1,,U,Autocuration,,,CHEMBL621602,BAO_0000019,
7597,11954,A,,,22224,Area under curve after oral dose of 0.3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621603,BAO_0000218,
7598,11954,A,,,22224,Area under curve after oral dose of 1 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621604,BAO_0000218,
7599,11954,A,,,22224,Area under curve after oral dose of 10 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621605,BAO_0000218,
7600,11954,A,,,22224,Area under curve after oral dose of 23.4 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621606,BAO_0000218,
7601,11954,A,,,22224,Area under curve after oral dose of 3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621607,BAO_0000218,
7602,11954,A,,,22224,Area under curve after oral dose of 3.87 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621608,BAO_0000218,
7603,5237,A,,,22224,Area under curve was determined,,0,,,1,,U,Autocuration,,,CHEMBL621609,BAO_0000019,
7604,4026,A,,,22224,Area under curve at a dose of 10 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621610,BAO_0000218,
7605,5237,A,,,50597,Area under curve was determined; ND=No data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621611,BAO_0000218,
7606,14793,A,,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621612,BAO_0000218,
7607,14793,A,,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622308,BAO_0000218,
7608,14793,A,,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622309,BAO_0000218,
7609,14793,A,,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622310,BAO_0000218,
7610,14793,A,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622311,BAO_0000218,
7611,14793,A,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622312,BAO_0000218,
7612,14793,A,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622931,BAO_0000218,
7613,14793,A,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622932,BAO_0000218,
7614,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622736,BAO_0000218,
7615,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622737,BAO_0000218,
7616,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622738,BAO_0000218,
7617,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622739,BAO_0000218,
7618,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622740,BAO_0000218,
7619,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622741,BAO_0000218,
7620,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622742,BAO_0000218,
7621,14793,A,,1969.0,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622743,BAO_0000218,
7622,11637,A,,1969.0,50594,AUC in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622744,BAO_0000218,
7623,11149,A,,,22224,Area under curve was measured from the graph obtained from concentration Vs time,,0,,,1,,U,Autocuration,,,CHEMBL624134,BAO_0000019,
7624,10016,A,,,22224,Area under curve value of compound per hour after oral administration,,0,,,1,,U,Autocuration,,,CHEMBL624135,BAO_0000019,
7625,17796,A,,,50597,Area under curve was determined after oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624136,BAO_0000218,
7626,17796,A,,,50597,Area under curve was determined after oral administration in rats; No data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624137,BAO_0000218,
7627,17796,A,,,50597,Area under curve was determined after oral administration in rats;No data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624320,BAO_0000218,
7628,12923,A,,,50588,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624321,BAO_0000218,
7629,15372,A,,,50597,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624322,BAO_0000218,
7630,15372,A,,,50597,Area under curve was determined for the compound after iv dose of 5.06 in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624323,BAO_0000218,
7631,15372,A,,,50597,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624324,BAO_0000218,
7632,15372,A,,,50597,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624325,BAO_0000218,
7633,15372,A,,,50597,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624326,BAO_0000218,
7634,15372,A,,,50597,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624327,BAO_0000218,
7635,15372,A,,,50597,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624328,BAO_0000218,
7636,14169,A,,,50588,Area under curve was determined in Dogs after peroral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627848,BAO_0000218,
7637,14169,A,,,50597,Area under curve was determined in Rats after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627849,BAO_0000218,
7638,14258,A,,,50597,Area under curve was determined in carotid blood of rat when administered intradermally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627850,BAO_0000218,
7639,14258,A,,,50597,Area under curve was determined in portal blood of rat when administered intradermally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627851,BAO_0000218,
7640,15011,A,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627852,BAO_0000218,
7641,15011,A,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627853,BAO_0000218,
7642,15011,A,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627854,BAO_0000218,
7643,15011,A,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627855,BAO_0000218,
7644,15011,A,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627856,BAO_0000218,
7645,15011,A,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875339,BAO_0000218,
7646,15011,A,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627857,BAO_0000218,
7647,11195,A,,2106.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627858,BAO_0000218,
7648,10130,A,,178.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627859,BAO_0000218,
7649,10130,A,,955.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627860,BAO_0000218,
7650,10130,A,,948.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627019,BAO_0000218,
7651,10130,A,,2107.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627020,BAO_0000218,
7652,10130,A,,2048.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627021,BAO_0000218,
7653,10130,A,,2385.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627022,BAO_0000218,
7654,10130,A,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627023,BAO_0000218,
7655,10130,A,,2106.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627024,BAO_0000218,
7656,10130,A,,2046.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627025,BAO_0000218,
7657,10130,A,,2113.0,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627026,BAO_0000218,
7658,10130,A,,178.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627027,BAO_0000218,
7659,10130,A,,955.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627028,BAO_0000218,
7660,10130,A,,948.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627029,BAO_0000218,
7661,10130,A,,2113.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627030,BAO_0000218,
7662,10130,A,,2107.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627031,BAO_0000218,
7663,10130,A,,2048.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627032,BAO_0000218,
7664,10130,A,,2385.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627033,BAO_0000218,
7665,10130,A,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627034,BAO_0000218,
7666,10130,A,,2106.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627035,BAO_0000218,
7667,10130,A,,2046.0,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627036,BAO_0000218,
7668,10130,A,,178.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875340,BAO_0000218,
7669,10130,A,,948.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627037,BAO_0000218,
7670,10130,A,,2113.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627038,BAO_0000218,
7671,10130,A,,2107.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627039,BAO_0000218,
7672,10130,A,,2385.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627040,BAO_0000218,
7673,10130,A,,2106.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624663,BAO_0000218,
7674,10130,A,,2046.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625963,BAO_0000218,
7675,10130,A,,955.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876799,BAO_0000218,
7676,10130,A,,2048.0,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626133,BAO_0000218,
7677,10130,A,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626134,BAO_0000218,
7678,6295,A,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626135,BAO_0000218,
7679,6296,A,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626136,BAO_0000218,
7680,6296,A,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626137,BAO_0000218,
7681,6295,A,,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626138,BAO_0000218,
7682,6296,A,,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626139,BAO_0000218,
7683,17260,A,,,50597,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626140,BAO_0000218,
7684,17260,A,,,50597,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626141,BAO_0000218,
7685,17686,A,,,50597,C24h in rat p.o. at 20 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626142,BAO_0000218,
7686,9866,A,,2385.0,50597,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627930,BAO_0000218,
7687,9866,A,,2385.0,50597,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627931,BAO_0000218,
7688,9866,A,,2385.0,50597,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627932,BAO_0000218,
7689,9866,A,,2106.0,50597,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627933,BAO_0000218,
7690,9866,A,,2106.0,50597,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627934,BAO_0000218,
7691,9866,A,,2106.0,50597,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627935,BAO_0000218,
7692,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627936,BAO_0000218,
7693,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627937,BAO_0000218,
7694,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627938,BAO_0000218,
7695,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627939,BAO_0000218,
7696,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627940,BAO_0000218,
7697,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627941,BAO_0000218,
7698,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876800,BAO_0000218,
7699,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627942,BAO_0000218,
7700,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627943,BAO_0000218,
7701,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627944,BAO_0000218,
7702,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627945,BAO_0000218,
7703,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628584,BAO_0000218,
7704,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628585,BAO_0000218,
7705,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628586,BAO_0000218,
7706,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628587,BAO_0000218,
7707,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628588,BAO_0000218,
7708,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628589,BAO_0000218,
7709,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625304,BAO_0000218,
7710,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625305,BAO_0000218,
7711,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625306,BAO_0000218,
7712,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625307,BAO_0000218,
7713,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625308,BAO_0000218,
7714,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627740,BAO_0000218,
7715,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627741,BAO_0000218,
7716,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627742,BAO_0000218,
7717,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627743,BAO_0000218,
7718,9866,A,,178.0,50597,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627744,BAO_0000218,
7719,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627745,BAO_0000218,
7720,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627746,BAO_0000218,
7721,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627747,BAO_0000218,
7722,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876810,BAO_0000218,
7723,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627748,BAO_0000218,
7724,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627749,BAO_0000218,
7725,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627750,BAO_0000218,
7726,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618728,BAO_0000218,
7727,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618729,BAO_0000218,
7728,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618730,BAO_0000218,
7729,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618731,BAO_0000218,
7730,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618732,BAO_0000218,
7731,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618733,BAO_0000218,
7732,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618734,BAO_0000218,
7733,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618735,BAO_0000218,
7734,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876602,BAO_0000218,
7735,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618736,BAO_0000218,
7736,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618737,BAO_0000218,
7737,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618738,BAO_0000218,
7738,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618739,BAO_0000218,
7739,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618740,BAO_0000218,
7740,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618741,BAO_0000218,
7741,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618742,BAO_0000218,
7742,9866,A,,10000001.0,50597,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618743,BAO_0000218,
7743,17752,A,,1969.0,50597,Half-life from rat plasma at a single oral dose of 25 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618744,BAO_0000218,
7744,5610,A,,,50597,Half-life in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618745,BAO_0000218,
7745,5939,A,,,50597,Half-life in rat after peroral administration at 10 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620479,BAO_0000218,
7746,5939,A,,,50597,Half-life in rat after peroral administration at 5 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620480,BAO_0000218,
7747,17771,A,,,50597,Half-life in rat at a dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620481,BAO_0000218,
7748,1974,A,,,50597,Half-life was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620482,BAO_0000218,
7749,4239,A,,,50597,Half-life was measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876603,BAO_0000218,
7750,6681,A,,,50597,Half-life period for the compound was determined in rats at 50 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620483,BAO_0000218,
7751,17752,A,,,50597,Half-life period in rats after intravenous administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620484,BAO_0000218,
7752,6046,A,,,50597,Half-life period in rat at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620485,BAO_0000218,
7753,6685,A,,,50597,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620486,BAO_0000218,
7754,6685,A,,,50597,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620487,BAO_0000218,
7755,6685,A,,,50597,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620488,BAO_0000218,
7756,4727,A,,,50597,Half-life time in rat the dose of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620489,BAO_0000218,
7757,1088,A,,,50597,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620490,BAO_0000218,
7758,5610,A,,,50597,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620491,BAO_0000218,
7759,3032,A,,1969.0,50597,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876604,BAO_0000218,
7760,5199,A,,,50597,Oral half life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620492,BAO_0000218,
7761,14941,A,,,50597,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620493,BAO_0000218,
7762,4408,A,,,50597,Pharmacokinetic property (t1/2) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620494,BAO_0000218,
7763,2552,A,,1969.0,50597,Plasma elimination half-life was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620495,BAO_0000218,
7764,5199,A,,1969.0,50597,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620496,BAO_0000218,
7765,15662,A,,1969.0,50597,Plasma half life was observed after intravenous administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620497,BAO_0000218,
7766,1465,A,,1969.0,50597,Plasma half-life was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620498,BAO_0000218,
7767,1446,A,,1969.0,50597,Plasma half-life following oral administration in Fisher rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620499,BAO_0000218,
7768,6824,A,,1969.0,50597,Plasma half-life in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620500,BAO_0000218,
7769,17533,A,,1969.0,50597,Plasmatic Half-life after intravenous administration to rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873809,BAO_0000218,
7770,5979,A,,,50597,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620501,BAO_0000218,
7771,4689,A,,,50597,Terminal half life after intravenous administration (1 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620502,BAO_0000218,
7772,4689,A,,,50597,Terminal half life in Rat at a oral dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620503,BAO_0000218,
7773,2463,A,,,50597,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620504,BAO_0000218,
7774,4883,A,,,50597,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876605,BAO_0000218,
7775,4883,A,,,50597,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620505,BAO_0000218,
7776,15662,A,,1969.0,50597,plasma half life was observed after intravenous administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873811,BAO_0000218,
7777,3598,A,,,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL624016,BAO_0000218,
7778,4576,A,,,50597,Half life of compound determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624017,BAO_0000218,
7779,4576,A,,,50597,Mean residence time determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624018,BAO_0000218,
7780,4576,A,,,50597,Plasma half life determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624019,BAO_0000218,
7781,4910,A,,955.0,50597,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624020,BAO_0000218,
7782,4891,A,,,50597,Compound was evaluated for pharmacokinetic parameter maximum time period,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624201,BAO_0000218,
7783,429,A,,,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL872528,BAO_0000218,
7784,5974,A,,,50597,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624202,BAO_0000218,
7785,5974,A,,,50597,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624203,BAO_0000218,
7786,5974,A,,,50597,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624350,BAO_0000218,
7787,5974,A,,,50597,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621320,BAO_0000218,
7788,17582,A,,,50597,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621321,BAO_0000218,
7789,4026,A,,,50597,Maximum time (Tmax) required to reach Cmax in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621322,BAO_0000218,
7790,4890,A,,,50597,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621323,BAO_0000218,
7791,6571,A,,,50597,Maximum time of clearance of compound in rats after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621324,BAO_0000218,
7792,4727,A,,,50597,Maximum time at the dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621325,BAO_0000218,
7793,17651,A,,1969.0,50597,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875837,BAO_0000218,
7794,17651,A,,1969.0,50597,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621326,BAO_0000218,
7795,14465,A,,,50597,Tmax in Guinea pig (PO dose),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621327,BAO_0000218,
7796,14941,A,,,50597,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621328,BAO_0000218,
7797,5960,A,,,50597,Pharmacokinetic parameter (Tmax) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621329,BAO_0000218,
7798,5022,A,,,50597,Pharmacokinetic parameter (Tmax) was estimated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621330,BAO_0000218,
7799,4408,A,,,50597,Pharmacokinetic property (Tmax) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621331,BAO_0000218,
7800,5983,A,,,50597,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621332,BAO_0000218,
7801,4689,A,,,50597,T max in Rat at a oral dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621333,BAO_0000218,
7802,2792,A,,,50597,T max was determined at 10 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621334,BAO_0000218,
7803,15011,A,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621335,BAO_0000218,
7804,14180,A,,,50588,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621336,BAO_0000218,
7805,14180,A,,,50597,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621337,BAO_0000218,
7806,14599,A,,,50588,Area under curve was measured after i.v. administration into Beagle dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621338,BAO_0000218,
7807,14599,A,,,50588,Area under curve was measured after iv administration into Beagle dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875838,BAO_0000218,
7808,14599,A,,,50588,Area under curve was measured after po administration into Beagle dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621339,BAO_0000218,
7809,14599,A,,,50588,Area under curve was measured after po administration into Beagle dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621340,BAO_0000218,
7810,15675,A,,,22224,Area under curve was measured at peroral dose of 3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL621341,BAO_0000218,
7811,12706,A,,,22224,Area under curve was measured by using concentration Vs time,,0,,,1,,U,Autocuration,,,CHEMBL621342,BAO_0000019,
7812,12706,A,,,22224,Area under curve was measured by using concentration Vs time; not tested,,0,,,1,,U,Autocuration,,,CHEMBL621343,BAO_0000019,
7813,9750,A,,,50594,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621344,BAO_0000218,
7814,9750,A,,,50594,Area under curve(AUC) was measured in mice after oral administration.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621345,BAO_0000218,
7815,14691,A,,,22224,Area under curve(AUC) value of the compound,,0,,,1,,U,Autocuration,,,CHEMBL621346,BAO_0000019,
7816,14691,A,,,22224,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,0,,,1,,U,Autocuration,,,CHEMBL621347,BAO_0000218,
7817,14691,A,,,50588,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621348,BAO_0000218,
7818,2939,A,,178.0,22224,Area under curve(carotid artery) was determined by the availability in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL621349,BAO_0000019,
7819,2939,A,,178.0,22224,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Blood,0,,,1,,U,Autocuration,,,CHEMBL621350,BAO_0000019,
7820,2939,A,,178.0,22224,Area under curve(carotid artery) was determined by the availability in blood; No data,Blood,0,,,1,,U,Autocuration,,,CHEMBL875839,BAO_0000019,
7821,2939,A,,178.0,22224,Area under curve(portal vein) was determined by the availability in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL620211,BAO_0000019,
7822,2939,A,,178.0,22224,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Blood,0,,,1,,U,Autocuration,,,CHEMBL620212,BAO_0000019,
7823,2939,A,,178.0,22224,Area under curve(portal vein) was determined by the availability in blood; No data,Blood,0,,,1,,U,Autocuration,,,CHEMBL620213,BAO_0000019,
7824,9552,A,,1969.0,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL620214,BAO_0000218,
7825,9552,A,,1969.0,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL620215,BAO_0000218,
7826,9552,A,,1969.0,50797,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL620216,BAO_0000218,
7827,9552,A,,1969.0,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620888,BAO_0000218,
7828,9552,A,,1969.0,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620889,BAO_0000218,
7829,9552,A,,1969.0,22224,Area under plasma concentration vs time curve observed in rats for 0-3 h,Plasma,0,,,1,,U,Autocuration,,,CHEMBL620890,BAO_0000019,
7830,11911,A,,1969.0,50597,Area under plasma time curve determined in male rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620891,BAO_0000218,
7831,16618,A,,,22224,Area under the MAP curve measured over 5 min.,,0,,,1,,U,Autocuration,,,CHEMBL620892,BAO_0000019,
7832,14387,A,,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621079,BAO_0000218,
7833,14387,A,,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621080,BAO_0000218,
7834,12836,A,,,50588,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621081,BAO_0000218,
7835,12836,A,,,100712,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL621082,BAO_0000218,
7836,12836,A,,,50597,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621083,BAO_0000218,
7837,14339,A,,,50588,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621084,BAO_0000218,
7838,14339,A,,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621085,BAO_0000218,
7839,14339,A,,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621086,BAO_0000218,
7840,10524,A,,,50588,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621087,BAO_0000218,
7841,9994,A,,,50588,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622607,BAO_0000218,
7842,11325,A,,,50588,Serum AUC in marmosets (IV dose),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622608,BAO_0000218,
7843,12536,A,,,22224,Area under the curve after intravenous administration at a dose of 10 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL624481,BAO_0000019,
7844,12536,A,,,22224,Area under the curve after intravenous administration at a dose of 2 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL624482,BAO_0000019,
7845,12536,A,,,22224,Area under the curve after intravenous administration at a dose of 4 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL624483,BAO_0000019,
7846,12536,A,,,22224,Area under the curve after intravenous administration at a dose of 40 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL624484,BAO_0000019,
7847,12536,A,,,22224,Area under the curve after intravenous administration at a dose of 5 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL624485,BAO_0000019,
7848,15556,A,,,50597,Area under the curve for fumarate salt was evaluated in F344 Rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624486,BAO_0000218,
7849,2809,A,,,22224,Area under the curve for the compound was calculated.,,0,,,1,,U,Autocuration,,,CHEMBL624487,BAO_0000019,
7850,9511,A,,,22224,Area under the curve in concentration/ time,,0,,,1,,U,Autocuration,,,CHEMBL624488,BAO_0000019,
7851,12818,A,,,50597,Area under the curve administered intraintestinal in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624489,BAO_0000218,
7852,12818,A,,,50597,Area under the curve administered intravenously in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625184,BAO_0000218,
7853,15118,A,,,22224,Area under the curve during intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL625185,BAO_0000019,
7854,15118,A,,,22224,Area under the curve during intravenous administration; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL875954,BAO_0000019,
7855,15118,A,,,22224,Area under the curve during systemic administration,,0,,,1,,U,Autocuration,,,CHEMBL625186,BAO_0000019,
7856,15118,A,,,22224,Area under the curve during systemic administration; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL625187,BAO_0000019,
7857,2632,A,,,22224,Area under the curve was calculated for the compound.,,0,,,1,,U,Autocuration,,,CHEMBL625188,BAO_0000019,
7858,14346,A,,,50588,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625189,BAO_0000218,
7859,14346,A,,,50588,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625190,BAO_0000218,
7860,14346,A,,,50597,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621733,BAO_0000218,
7861,14346,A,,,50597,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621734,BAO_0000218,
7862,11149,A,,,50597,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621735,BAO_0000218,
7863,17796,A,,1969.0,50597,Clearance of the drug was measured in the plasma of rat; No data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621736,BAO_0000218,
7864,5247,A,,1969.0,50597,The pharmacokinetic parameter plasma clearance in vivo in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621737,BAO_0000218,
7865,4727,A,,,50597,Plasma clearance at the dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621738,BAO_0000218,
7866,5654,A,,,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622806,BAO_0000218,
7867,5654,A,,,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623519,BAO_0000218,
7868,17260,A,,,50597,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623520,BAO_0000218,
7869,17065,A,,,50597,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623521,BAO_0000218,
7870,17671,A,,,50597,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623522,BAO_0000218,
7871,6672,A,,,50597,Clearance rate in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623523,BAO_0000218,
7872,6673,A,,,50597,Clearance rate in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623690,BAO_0000218,
7873,5978,A,,,50597,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623691,BAO_0000218,
7874,5978,A,,,50597,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623692,BAO_0000218,
7875,5978,A,,,50597,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623693,BAO_0000218,
7876,5978,A,,,50597,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623694,BAO_0000218,
7877,4413,A,,,50597,Clearance of compound after iv administration of 20 mg/kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623695,BAO_0000218,
7878,2661,A,,,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623696,BAO_0000218,
7879,2661,A,,,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623697,BAO_0000218,
7880,5005,A,,1969.0,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,0,,Macaca mulatta,1,9544.0,U,Intermediate,,,CHEMBL623698,BAO_0000218,
7881,5005,A,,1969.0,22224,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Plasma,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL623699,BAO_0000218,
7882,15765,A,,,50597,Mean (%CV) PK parameters for CL(mL/min/kg).,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623700,BAO_0000218,
7883,3747,A,,,50597,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623701,BAO_0000218,
7884,16366,A,,1969.0,50597,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623702,BAO_0000218,
7885,4199,A,,,50597,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623703,BAO_0000218,
7886,17267,A,,,50597,Plasma clearance in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623704,BAO_0000218,
7887,6535,A,,,50597,Plasma clearance in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623705,BAO_0000218,
7888,6535,A,,,50597,Plasma clearance in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623706,BAO_0000218,
7889,5041,A,,,50597,Plasma clearance was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623707,BAO_0000218,
7890,5960,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623708,BAO_0000218,
7891,5937,A,,,50597,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623709,BAO_0000218,
7892,5871,A,,,50597,Plasma clearance in rat by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623710,BAO_0000218,
7893,5874,A,,,50597,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623711,BAO_0000218,
7894,6504,A,,,50597,Plasma clearance in rat p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623712,BAO_0000218,
7895,6803,A,,,50597,Plasma clearance in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623713,BAO_0000218,
7896,5041,A,,,50597,Plasma clearance was determined; ND denotes no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623714,BAO_0000218,
7897,5041,A,,,50597,Plasma clearance was determined; ND denotes not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623715,BAO_0000218,
7898,1916,A,,,50597,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623716,BAO_0000218,
7899,5199,A,,,50597,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622980,BAO_0000218,
7900,16367,A,,,50597,Plasma administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622981,BAO_0000218,
7901,6362,A,,,50597,Plasma clearance of the compound in female Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622982,BAO_0000218,
7902,15662,A,,,50597,Plasma clearance was observed after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622983,BAO_0000218,
7903,6215,A,,,50597,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622984,BAO_0000218,
7904,1466,A,,,50597,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622985,BAO_0000218,
7905,15662,A,,1969.0,50597,plasma clearance was observed after intravenous administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623631,BAO_0000218,
7906,4723,A,,,50597,In vivo CL/F determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623632,BAO_0000218,
7907,2792,A,,1969.0,50597,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623633,BAO_0000218,
7908,2792,A,,1969.0,50597,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623634,BAO_0000218,
7909,5213,A,,,50597,Compound was tested for the lower blood clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623635,BAO_0000218,
7910,4687,A,,,50597,Evaluated for the low clearance in rat (in vivo),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621195,BAO_0000218,
7911,3371,A,,,50597,Pharmacokinetic property (CLb)of the compound was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621196,BAO_0000218,
7912,4690,A,,,50597,Rapid clearance after intravenous administration in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875287,BAO_0000218,
7913,5702,A,,,50597,Clearance measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621197,BAO_0000218,
7914,740,A,,1969.0,50597,Compound was evaluated for plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621198,BAO_0000218,
7915,4853,A,,1969.0,50597,Low plasma clearance was calculated in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621199,BAO_0000218,
7916,5789,A,,,50597,Pharmacokinetic property (Clp) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621200,BAO_0000218,
7917,4527,A,,,50597,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621201,BAO_0000218,
7918,4527,A,,,50597,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621202,BAO_0000218,
7919,6518,A,,,50597,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621203,BAO_0000218,
7920,6518,A,,,50597,Plasma clearance after IV dosing at 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621204,BAO_0000218,
7921,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621205,BAO_0000218,
7922,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621206,BAO_0000218,
7923,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621207,BAO_0000218,
7924,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621208,BAO_0000218,
7925,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621209,BAO_0000218,
7926,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876484,BAO_0000218,
7927,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621210,BAO_0000218,
7928,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621211,BAO_0000218,
7929,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621212,BAO_0000218,
7930,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621213,BAO_0000218,
7931,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621214,BAO_0000218,
7932,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621215,BAO_0000218,
7933,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621216,BAO_0000218,
7934,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621217,BAO_0000218,
7935,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621218,BAO_0000218,
7936,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621219,BAO_0000218,
7937,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621220,BAO_0000218,
7938,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621221,BAO_0000218,
7939,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621222,BAO_0000218,
7940,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621223,BAO_0000218,
7941,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876485,BAO_0000218,
7942,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621224,BAO_0000218,
7943,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621225,BAO_0000218,
7944,9866,A,,948.0,50597,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621226,BAO_0000218,
7945,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621227,BAO_0000218,
7946,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621228,BAO_0000218,
7947,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621229,BAO_0000218,
7948,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621230,BAO_0000218,
7949,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621231,BAO_0000218,
7950,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621232,BAO_0000218,
7951,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621233,BAO_0000218,
7952,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621234,BAO_0000218,
7953,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621235,BAO_0000218,
7954,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621236,BAO_0000218,
7955,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621237,BAO_0000218,
7956,9866,A,,2113.0,50597,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876486,BAO_0000218,
7957,9866,A,,160.0,50597,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622436,BAO_0000218,
7958,9866,A,,160.0,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622437,BAO_0000218,
7959,9866,A,,160.0,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622438,BAO_0000218,
7960,9866,A,,2107.0,50597,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622439,BAO_0000218,
7961,9866,A,,2107.0,50597,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622440,BAO_0000218,
7962,9866,A,,2107.0,50597,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622441,BAO_0000218,
7963,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622442,BAO_0000218,
7964,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622443,BAO_0000218,
7965,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622444,BAO_0000218,
7966,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622445,BAO_0000218,
7967,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622446,BAO_0000218,
7968,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622447,BAO_0000218,
7969,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622448,BAO_0000218,
7970,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622449,BAO_0000218,
7971,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622450,BAO_0000218,
7972,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622451,BAO_0000218,
7973,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622452,BAO_0000218,
7974,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622453,BAO_0000218,
7975,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622454,BAO_0000218,
7976,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622455,BAO_0000218,
7977,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876024,BAO_0000218,
7978,2792,A,,,50597,T max was determined at 3 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622456,BAO_0000218,
7979,15078,A,,,50597,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622457,BAO_0000218,
7980,15078,A,,,50597,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622458,BAO_0000218,
7981,15022,A,,,50597,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622459,BAO_0000218,
7982,15022,A,,,50597,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873343,BAO_0000218,
7983,15022,A,,,50597,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622460,BAO_0000218,
7984,4576,A,,1969.0,50597,Time for maximum plasma concentration determined in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622461,BAO_0000218,
7985,6681,A,,1969.0,50597,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622462,BAO_0000218,
7986,16365,A,,,50597,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622463,BAO_0000218,
7987,16365,A,,,50597,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622464,BAO_0000218,
7988,16365,A,,,50597,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622465,BAO_0000218,
7989,16365,A,,,50597,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622466,BAO_0000218,
7990,16365,A,,,50597,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622467,BAO_0000218,
7991,6824,A,,1969.0,50597,Time of maximum plasma concentration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622468,BAO_0000218,
7992,6685,A,,1969.0,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876025,BAO_0000218,
7993,6685,A,,1969.0,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622469,BAO_0000218,
7994,6685,A,,1969.0,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622470,BAO_0000218,
7995,15662,A,,,50597,Time required to reach maximum concentration (Cmax) after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622471,BAO_0000218,
7996,1742,A,,1969.0,50597,Time required to reach maximum concentration in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622472,BAO_0000218,
7997,2774,A,,1969.0,50597,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622473,BAO_0000218,
7998,5199,A,,1969.0,50597,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624282,BAO_0000218,
7999,12873,A,,1969.0,50597,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624283,BAO_0000218,
8000,12873,A,,1969.0,50597,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624284,BAO_0000218,
8001,1916,A,,1969.0,50597,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624285,BAO_0000218,
8002,16367,A,,,50597,Time to reach Cmax after oral administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624286,BAO_0000218,
8003,16366,A,,,50597,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624287,BAO_0000218,
8004,216,A,,,50597,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624288,BAO_0000218,
8005,6410,A,,1969.0,50597,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624289,BAO_0000218,
8006,6410,A,,1969.0,50597,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873344,BAO_0000218,
8007,6215,A,,,50597,Tmax after peroral administration (10 mg/kg) was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619623,BAO_0000218,
8008,3598,A,,,50597,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL621399,BAO_0000218,
8009,4527,A,,,50597,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621400,BAO_0000218,
8010,17670,A,,,50597,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621401,BAO_0000218,
8011,1465,A,,,50597,Tmax was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621402,BAO_0000218,
8012,2552,A,,,50597,Tmax was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621403,BAO_0000218,
8013,5656,A,,,50597,Tmax after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621121,BAO_0000218,
8014,17764,A,,,50597,Tmax after peroral administration in rats at 2.4 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL872525,BAO_0000218,
8015,5610,A,,,50597,Tmax in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621122,BAO_0000218,
8016,6046,A,,,50597,Tmax in rat at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621123,BAO_0000218,
8017,5874,A,,,50597,Tmax in rat by po administration at a dose of 40 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621124,BAO_0000218,
8018,17596,A,,,50597,Tmax in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621125,BAO_0000218,
8019,17804,A,,,50597,Tmax was measured in rats after peroral administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621126,BAO_0000218,
8020,1908,A,,,50597,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621127,BAO_0000218,
8021,2959,A,,,50597,Tmax value after administration of 20 mg/Kg oral dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621128,BAO_0000218,
8022,6757,A,,,50597,Tmax value at a dose of 10 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618263,BAO_0000218,
8023,6757,A,,,50597,Tmax value at a dose of 100 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618264,BAO_0000218,
8024,6757,A,,,50597,Tmax value at a dose of 50 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618265,BAO_0000218,
8025,4186,A,,1969.0,50597,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618266,BAO_0000218,
8026,15662,A,,,50597,time required to reach maximum concentration (Cmax) after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618267,BAO_0000218,
8027,429,A,,1088.0,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618450,BAO_0000218,
8028,429,A,,1088.0,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618451,BAO_0000218,
8029,5546,A,,,50597,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618452,BAO_0000218,
8030,3173,A,,1088.0,50597,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618453,BAO_0000218,
8031,3173,A,,1088.0,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618454,BAO_0000218,
8032,3173,A,,1088.0,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618455,BAO_0000218,
8033,4257,A,,,50597,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618456,BAO_0000218,
8034,6011,A,,,50597,Compound distribution in rat tissues was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618457,BAO_0000218,
8035,5472,A,,,50597,Volume of distribution was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618458,BAO_0000218,
8036,14346,A,,,50597,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618459,BAO_0000218,
8037,14346,A,,,50597,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876733,BAO_0000218,
8038,14346,A,,,50588,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618460,BAO_0000218,
8039,14346,A,,,50597,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618461,BAO_0000218,
8040,15469,A,,,22224,Area under the curve was determined after oral administration (300 uM/Kg),,0,,,1,,U,Autocuration,,,CHEMBL618462,BAO_0000019,
8041,14346,A,,,50597,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618463,BAO_0000218,
8042,14346,A,,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618464,BAO_0000218,
8043,14346,A,,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618465,BAO_0000218,
8044,14346,A,,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618466,BAO_0000218,
8045,14346,A,,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618467,BAO_0000218,
8046,15372,A,,,50597,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618468,BAO_0000218,
8047,12935,A,,1969.0,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618469,BAO_0000218,
8048,12935,A,,1969.0,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL618470,BAO_0000218,
8049,14813,A,,,22224,Plasma drug AUC in rat (PO dose),,0,,,1,,U,Autocuration,,,CHEMBL618471,BAO_0000218,
8050,15792,A,,,50594,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618472,BAO_0000218,
8051,3579,A,,,22224,Area under was determined at a dose of 30 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL618473,BAO_0000218,
8052,12487,A,,,50506,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL621699,BAO_0000218,
8053,12487,A,,,50597,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621700,BAO_0000218,
8054,12487,A,,,50597,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621701,BAO_0000218,
8055,12487,A,,,50506,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL621702,BAO_0000218,
8056,12487,A,,,50588,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621703,BAO_0000218,
8057,12487,A,,,50588,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621704,BAO_0000218,
8058,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624259,BAO_0000218,
8059,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624260,BAO_0000218,
8060,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624430,BAO_0000218,
8061,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624431,BAO_0000218,
8062,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624432,BAO_0000218,
8063,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624433,BAO_0000218,
8064,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624434,BAO_0000218,
8065,12902,A,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624435,BAO_0000218,
8066,12745,A,,,50594,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618570,BAO_0000218,
8067,12745,A,,,50594,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618571,BAO_0000218,
8068,12745,A,,,50594,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618572,BAO_0000218,
8069,12745,A,,,50594,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618573,BAO_0000218,
8070,12745,A,,,50594,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619267,BAO_0000218,
8071,12745,A,,,50594,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619431,BAO_0000218,
8072,12745,A,,,50594,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619432,BAO_0000218,
8073,12745,A,,,50594,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619433,BAO_0000218,
8074,13298,A,,1969.0,22224,AUC in mice after oral dose (50 mg/kg),Plasma,0,,,1,,U,Autocuration,,,CHEMBL619434,BAO_0000218,
8075,12226,A,,1977.0,50594,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Serum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619435,BAO_0000218,
8076,12634,A,,1969.0,22224,AUC (0-4 hr) ug/ml/h,Plasma,0,,,1,,U,Autocuration,,,CHEMBL619436,BAO_0000019,
8077,14810,A,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619437,BAO_0000218,
8078,13889,A,,,22224,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,0,,,1,,U,Autocuration,,,CHEMBL619438,BAO_0000218,
8079,10018,A,,,50594,Compound was evaluated for Area under curve in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619439,BAO_0000218,
8080,8758,A,,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619440,BAO_0000218,
8081,8758,F,,,22224,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,0,,,1,,U,Autocuration,,,CHEMBL619441,BAO_0000218,
8082,8758,A,,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619442,BAO_0000218,
8083,2249,A,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,0,,,1,,U,Autocuration,,,CHEMBL875156,BAO_0000019,
8084,2249,A,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,0,,,1,,U,Autocuration,,,CHEMBL619443,BAO_0000019,
8085,2249,A,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,0,,,1,,U,Autocuration,,,CHEMBL619444,BAO_0000019,
8086,2249,A,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,0,,,1,,U,Autocuration,,,CHEMBL623464,BAO_0000019,
8087,15115,A,,,50594,Compound was evaluated for area under curve when administered through oral route in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623465,BAO_0000218,
8088,6518,A,,,50597,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623466,BAO_0000218,
8089,6518,A,,,50597,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623467,BAO_0000218,
8090,6249,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623468,BAO_0000218,
8091,2463,A,,,50597,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622660,BAO_0000218,
8092,4969,A,,,50597,Plasma clearance rate in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622661,BAO_0000218,
8093,17720,F,,,50597,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622662,BAO_0000218,
8094,3457,A,,,50597,Pharmacokinetic property (total body clearance) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622663,BAO_0000218,
8095,5983,A,,,50597,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622664,BAO_0000218,
8096,6295,A,,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622665,BAO_0000218,
8097,6296,A,,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622666,BAO_0000218,
8098,17686,A,,,50597,Cl in rat i.v. at 2 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621615,BAO_0000218,
8099,17764,A,,,50597,Clearance of compound after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621616,BAO_0000218,
8100,5503,A,,,50597,Clearance was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621617,BAO_0000218,
8101,4368,A,,,50597,Clearance by intravenous administration of 3.4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621618,BAO_0000218,
8102,6005,A,,,50597,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621619,BAO_0000218,
8103,5031,A,,,50597,Clearance rate after i.v. administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621620,BAO_0000218,
8104,4890,A,,,50597,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621786,BAO_0000218,
8105,5182,A,,,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621787,BAO_0000218,
8106,5979,A,,,50597,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621788,BAO_0000218,
8107,5656,A,,,50597,Clearance (Cl) after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621789,BAO_0000218,
8108,17804,A,,,50597,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621790,BAO_0000218,
8109,4839,A,,1969.0,50597,Compound was tested for plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621791,BAO_0000218,
8110,5041,A,,,50597,In vitro microsome metabolism clearance in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621792,BAO_0000218,
8111,5041,A,,,50597,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621793,BAO_0000218,
8112,5974,A,,,50597,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621794,BAO_0000218,
8113,5496,A,,1969.0,50597,In vivo plasma clearance was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621795,BAO_0000218,
8114,5739,A,,,50597,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621796,BAO_0000218,
8115,5676,A,Hepatocyte,2107.0,50597,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Liver,1,401.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621797,BAO_0000218,
8116,4239,A,,,50597,Pharmacokinetic property (Plasma clearance) was measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621798,BAO_0000218,
8117,5676,A,,,50597,Pharmacokinetic property (clearance) in rat i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621799,BAO_0000218,
8118,1918,A,,,50597,"Plasma Clearance was evaluated in rats, iv",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621800,BAO_0000218,
8119,17800,A,,,50597,Plasma clearance (in vivo) in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621801,BAO_0000218,
8120,6056,A,,,50597,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621802,BAO_0000218,
8121,5496,A,,,50597,Plasma clearance was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618596,BAO_0000218,
8122,5939,A,,,50597,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618597,BAO_0000218,
8123,5939,A,,,50597,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618598,BAO_0000218,
8124,17752,A,,,50597,Plasma clearance in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618599,BAO_0000218,
8125,4576,A,,,50597,Plasma clearance rate determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618600,BAO_0000218,
8126,6011,A,,,50597,Plasma clearance was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618601,BAO_0000218,
8127,5510,A,,,50597,Plasma clearance was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618602,BAO_0000218,
8128,5948,A,,,50597,Plasma clearance value in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618603,BAO_0000218,
8129,6125,A,,2107.0,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618604,BAO_0000218,
8130,4839,A,,,50597,Clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618605,BAO_0000218,
8131,17686,A,,,50597,Total body clearance in rat i.v. at 2 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618606,BAO_0000218,
8132,6571,A,,,50597,Clearance of compound in rats after intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618607,BAO_0000218,
8133,3364,A,,,50597,Clearance after iv administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618608,BAO_0000218,
8134,13569,A,,,50597,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618609,BAO_0000218,
8135,13569,A,,,50597,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618610,BAO_0000218,
8136,13569,A,,,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618611,BAO_0000218,
8137,13569,A,,,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618612,BAO_0000218,
8138,13569,A,,,50597,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618613,BAO_0000218,
8139,13569,A,,,50597,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621076,BAO_0000218,
8140,13569,A,,,50597,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621077,BAO_0000218,
8141,17670,A,,,50597,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621078,BAO_0000218,
8142,5970,A,,,50597,Clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621251,BAO_0000218,
8143,6495,A,,,50597,Clearance in rat after oral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621252,BAO_0000218,
8144,4590,A,,,50597,Clearance in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621253,BAO_0000218,
8145,6193,A,,,50597,Clearance rate following an oral dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621254,BAO_0000218,
8146,2832,A,,,50597,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621255,BAO_0000218,
8147,1052,A,,1969.0,50597,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621256,BAO_0000218,
8148,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621257,BAO_0000218,
8149,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621258,BAO_0000218,
8150,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621259,BAO_0000218,
8151,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621260,BAO_0000218,
8152,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876494,BAO_0000218,
8153,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621261,BAO_0000218,
8154,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621262,BAO_0000218,
8155,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621263,BAO_0000218,
8156,9866,A,,2107.0,50597,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621264,BAO_0000218,
8157,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621265,BAO_0000218,
8158,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621266,BAO_0000218,
8159,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621267,BAO_0000218,
8160,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621268,BAO_0000218,
8161,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621269,BAO_0000218,
8162,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621270,BAO_0000218,
8163,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621271,BAO_0000218,
8164,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621272,BAO_0000218,
8165,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621273,BAO_0000218,
8166,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621274,BAO_0000218,
8167,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876495,BAO_0000218,
8168,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621275,BAO_0000218,
8169,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621276,BAO_0000218,
8170,9866,A,,2385.0,50597,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621277,BAO_0000218,
8171,9866,A,,160.0,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621278,BAO_0000218,
8172,9866,A,,160.0,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621279,BAO_0000218,
8173,9866,A,,160.0,50597,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621280,BAO_0000218,
8174,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621281,BAO_0000218,
8175,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621282,BAO_0000218,
8176,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621283,BAO_0000218,
8177,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621284,BAO_0000218,
8178,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621285,BAO_0000218,
8179,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621286,BAO_0000218,
8180,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623220,BAO_0000218,
8181,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623221,BAO_0000218,
8182,9866,A,,2106.0,50597,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876029,BAO_0000218,
8183,9866,A,,945.0,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623222,BAO_0000218,
8184,9866,A,,945.0,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623223,BAO_0000218,
8185,9866,A,,945.0,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621445,BAO_0000218,
8186,13950,A,,178.0,50597,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621446,BAO_0000218,
8187,13950,A,,178.0,50597,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621447,BAO_0000218,
8188,13950,A,,178.0,50597,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619681,BAO_0000218,
8189,13950,A,,178.0,50597,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619682,BAO_0000218,
8190,13950,A,,178.0,50597,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619683,BAO_0000218,
8191,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619684,BAO_0000218,
8192,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619685,BAO_0000218,
8193,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619686,BAO_0000218,
8194,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619687,BAO_0000218,
8195,13950,A,,955.0,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619688,BAO_0000218,
8196,13950,A,,948.0,50597,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619689,BAO_0000218,
8197,13950,A,,948.0,50597,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619690,BAO_0000218,
8198,13950,A,,948.0,50597,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619691,BAO_0000218,
8199,6062,A,,,50597,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619692,BAO_0000218,
8200,3598,A,,,50597,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL619693,BAO_0000218,
8201,1908,A,,,50597,Vc value after IV dose at a dose of 5 mg/kg in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619694,BAO_0000218,
8202,17596,A,,,50597,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619695,BAO_0000218,
8203,4891,A,,,50597,Compound was evaluated for pharmacokinetic parameter volume of distribution,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619696,BAO_0000218,
8204,740,A,,,50597,Compound was evaluated for volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619697,BAO_0000218,
8205,16366,A,,,50597,Steady state volume distribution was determined; steady state(ss),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619698,BAO_0000218,
8206,3364,A,,,50597,Steady state volume of distribution after iv administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619699,BAO_0000218,
8207,2552,A,,,50597,Steady state volume of distribution dosing at 3 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619700,BAO_0000218,
8208,406,A,,,50597,The compound was evaluated for volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619701,BAO_0000218,
8209,12500,A,,,50597,The compound was tested for volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619702,BAO_0000218,
8210,12500,A,,,50597,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620335,BAO_0000218,
8211,5656,A,,,50597,Volume distribution (VD) after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620336,BAO_0000218,
8212,17671,A,,,50597,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620337,BAO_0000218,
8213,1094,A,,,50597,Volume distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620520,BAO_0000218,
8214,5833,A,,,50597,Volume distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620521,BAO_0000218,
8215,5939,A,,,50597,Volume distribution in rat after peroral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875825,BAO_0000218,
8216,5939,A,,,50597,Volume distribution in rat after peroral administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620522,BAO_0000218,
8217,6005,A,,,50597,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620523,BAO_0000218,
8218,1696,A,,,50597,Volume of distribution in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620524,BAO_0000218,
8219,6672,A,,,50597,Volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620525,BAO_0000218,
8220,6673,A,,,50597,Volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620526,BAO_0000218,
8221,5871,A,,,50597,Volume of distribution in rat by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620527,BAO_0000218,
8222,6803,A,,,50597,Volume of distribution in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620528,BAO_0000218,
8223,5199,A,,,50597,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620529,BAO_0000218,
8224,4727,A,,,50597,Volume distribution at the dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620530,BAO_0000218,
8225,16367,A,,,50597,Steady state volume of distribution was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620531,BAO_0000218,
8226,5005,A,,,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,0,,Macaca mulatta,1,9544.0,U,Intermediate,,,CHEMBL620532,BAO_0000218,
8227,5005,A,,,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL620533,BAO_0000218,
8228,5005,A,,,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL620534,BAO_0000218,
8229,15765,A,,,50597,Mean (%CV) PK parameters for Vdss(mL/kg).,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620535,BAO_0000218,
8230,2792,A,,,50597,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875826,BAO_0000218,
8231,2792,A,,,50597,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620536,BAO_0000218,
8232,5334,A,,,50597,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620537,BAO_0000218,
8233,5334,A,,,50597,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618526,BAO_0000218,
8234,5739,A,,,50597,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618527,BAO_0000218,
8235,5789,A,,,50597,Pharmacokinetic property (Vdss) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618528,BAO_0000218,
8236,4239,A,,,50597,Pharmacokinetic property (vdss) was measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618529,BAO_0000218,
8237,4709,A,,,50597,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618530,BAO_0000218,
8238,6642,A,,,50597,Volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618531,BAO_0000218,
8239,5247,A,,,50597,The pharmacokinetic parameter volume of distribution in vivo in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618532,BAO_0000218,
8240,17720,F,,,50597,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618533,BAO_0000218,
8241,17686,A,,,50597,Vdss in rat i.v. at 2 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618534,BAO_0000218,
8242,4689,A,,,50597,Volume distribution after intravenous administration (1 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618535,BAO_0000218,
8243,5654,A,,,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618536,BAO_0000218,
8244,5654,A,,,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618537,BAO_0000218,
8245,4527,A,,,50597,Volume distribution at a dose of 10 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618538,BAO_0000218,
8246,4521,A,,,50597,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618539,BAO_0000218,
8247,6057,A,,,50597,Volume distribution was calculated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618540,BAO_0000218,
8248,5510,A,,,50597,Volume distribution was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618541,BAO_0000218,
8249,2938,A,,,50597,Volume of distribution after intravenous administration was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618542,BAO_0000218,
8250,6679,A,,,50597,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622544,BAO_0000218,
8251,6685,A,,,50597,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622545,BAO_0000218,
8252,6685,A,,,50597,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622546,BAO_0000218,
8253,6685,A,,,50597,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622547,BAO_0000218,
8254,5145,A,,,50597,Volume of distribution in steady state was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622548,BAO_0000218,
8255,6467,A,,,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622549,BAO_0000218,
8256,6467,A,,,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622550,BAO_0000218,
8257,15115,A,,,50594,Compound was evaluated for area under curve when administered through oral route to mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622551,BAO_0000218,
8258,8758,A,,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622552,BAO_0000218,
8259,8758,A,,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622553,BAO_0000218,
8260,8267,F,,,22224,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,0,,,1,,U,Autocuration,,,CHEMBL622554,BAO_0000218,
8261,8267,A,,,50588,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622555,BAO_0000218,
8262,14239,A,,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622556,BAO_0000218,
8263,14239,A,,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622557,BAO_0000218,
8264,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622558,BAO_0000218,
8265,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622559,BAO_0000218,
8266,10754,A,,,50588,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622560,BAO_0000218,
8267,14681,A,,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622561,BAO_0000218,
8268,14681,A,,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622562,BAO_0000218,
8269,14681,A,,,50597,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622563,BAO_0000218,
8270,13118,A,,,22224,Concentration of compound in Central nervous system,,0,,,1,,U,Autocuration,,,CHEMBL622564,BAO_0000019,
8271,13118,A,,,22224,Concentration of compound in Central nervous system; Not detectable,,0,,,1,,U,Autocuration,,,CHEMBL622565,BAO_0000019,
8272,13318,A,,,50594,"Concentration of diester in the blood, following oral administration in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622566,BAO_0000218,
8273,13318,A,,,50594,"Concentration of monoester in the blood, following oral administration in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624515,BAO_0000218,
8274,13318,A,,,50594,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624516,BAO_0000218,
8275,15692,A,,,22224,Evaluated for Pharmacokinetic property: Area under the curve,,0,,,1,,U,Autocuration,,,CHEMBL624517,BAO_0000019,
8276,14839,A,,,50594,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624518,BAO_0000218,
8277,14839,A,,,100710,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624519,BAO_0000218,
8278,14839,A,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624520,BAO_0000218,
8279,14839,A,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624521,BAO_0000218,
8280,14839,A,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624522,BAO_0000218,
8281,14839,A,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624523,BAO_0000218,
8282,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624409,BAO_0000218,
8283,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624410,BAO_0000218,
8284,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL624411,BAO_0000218,
8285,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623531,BAO_0000218,
8286,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623532,BAO_0000218,
8287,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623533,BAO_0000218,
8288,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623534,BAO_0000218,
8289,14839,A,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623535,BAO_0000218,
8290,14839,A,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623536,BAO_0000218,
8291,14839,A,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623537,BAO_0000218,
8292,14839,A,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623538,BAO_0000218,
8293,14839,A,,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623539,BAO_0000218,
8294,14839,A,,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623540,BAO_0000218,
8295,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623541,BAO_0000218,
8296,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623542,BAO_0000218,
8297,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623543,BAO_0000218,
8298,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623544,BAO_0000218,
8299,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623545,BAO_0000218,
8300,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623546,BAO_0000218,
8301,5408,A,,1969.0,50597,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623547,BAO_0000218,
8302,6827,A,,,50597,High i.v. clearance in Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623548,BAO_0000218,
8303,17538,A,,2107.0,50597,In vitro clearance in rat liver microsomes,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623549,BAO_0000218,
8304,6331,A,,2107.0,50597,Intrinsic clearance in rat liver microsomes was determined,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623550,BAO_0000218,
8305,5948,A,Hepatocyte,2107.0,50597,Intrinsic clearance in rat hepatocytes was determined,Liver,1,401.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875276,BAO_0000218,
8306,4026,A,,,50597,Plasma Clearance was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621872,BAO_0000218,
8307,6647,A,,,50597,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621873,BAO_0000218,
8308,1696,A,,,50597,Plasma clearance in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621874,BAO_0000218,
8309,6597,A,,,50597,Plasma clearance in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621875,BAO_0000218,
8310,347,A,,,50597,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621876,BAO_0000218,
8311,16423,A,,,50597,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621877,BAO_0000218,
8312,2879,A,,,50597,Plasma clearance was measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621878,BAO_0000218,
8313,4883,A,,,50597,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621879,BAO_0000218,
8314,5328,A,,1969.0,50597,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621880,BAO_0000218,
8315,5160,A,,,50597,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621881,BAO_0000218,
8316,17582,A,,,50597,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621882,BAO_0000218,
8317,17651,A,,,50597,Total clearance at 1 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875283,BAO_0000218,
8318,17651,A,,,50597,Total clearance at 10 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621883,BAO_0000218,
8319,6596,A,,,50597,Clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621884,BAO_0000218,
8320,4796,A,,,50597,Plasma clearance rate determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621885,BAO_0000218,
8321,6850,A,,,50597,Clearance of compound in rat was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621886,BAO_0000218,
8322,5932,A,,1969.0,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621887,BAO_0000218,
8323,3371,A,,,50597,Pharmacokinetic property (blood clearance) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621888,BAO_0000218,
8324,2083,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621889,BAO_0000218,
8325,4942,A,,,50597,Plasma clearance in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621890,BAO_0000218,
8326,6838,A,,2107.0,50597,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621891,BAO_0000218,
8327,5353,A,,,50597,Clearance in Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621892,BAO_0000218,
8328,6641,A,,,50597,Clearance rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621893,BAO_0000218,
8329,6641,A,,,50597,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621894,BAO_0000218,
8330,6641,A,,,50597,Clearance rat; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621895,BAO_0000218,
8331,6444,A,,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875284,BAO_0000218,
8332,6444,A,,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618699,BAO_0000218,
8333,6444,A,,,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618700,BAO_0000218,
8334,6211,A,,,50597,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618701,BAO_0000218,
8335,12873,A,,1969.0,50597,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876600,BAO_0000218,
8336,6570,A,,,50597,Clearance of compound in rat after 1 mg/kg i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618702,BAO_0000218,
8337,3341,A,,,50597,Compound was evaluated for Hepatic clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618703,BAO_0000218,
8338,4891,A,,,50597,In vivo clearance after 5 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618704,BAO_0000218,
8339,1094,A,,1969.0,50597,Compound was tested for plasma clearance in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618705,BAO_0000218,
8340,2938,A,,,50597,Hepatic clearance after intravenous administration was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618706,BAO_0000218,
8341,17853,A,,,50597,Lower clearance in rat (i.v.) at 0.5 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618707,BAO_0000218,
8342,6049,A,,1969.0,50597,Pharmacokinetic parameter expressed as plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618708,BAO_0000218,
8343,5789,A,,,50597,Pharmacokinetic property (Clp) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618709,BAO_0000218,
8344,4514,A,,,50597,Plasma clearance in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618710,BAO_0000218,
8345,6448,A,,,50597,Plasma clearance (Clp) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618711,BAO_0000218,
8346,6062,A,,,50597,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618712,BAO_0000218,
8347,5710,A,,,50597,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618713,BAO_0000218,
8348,4709,A,,,50597,Plasma clearance after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618714,BAO_0000218,
8349,4521,A,,,50597,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618715,BAO_0000218,
8350,1742,A,,,50597,Plasma clearance in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618716,BAO_0000218,
8351,6057,A,,,50597,Plasma clearance measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876601,BAO_0000218,
8352,6057,A,,,50597,Plasma clearance was calculated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618717,BAO_0000218,
8353,5145,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618718,BAO_0000218,
8354,5833,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618719,BAO_0000218,
8355,6453,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618720,BAO_0000218,
8356,6640,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618721,BAO_0000218,
8357,6305,A,,,50597,Plasma clearance in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621477,BAO_0000218,
8358,6642,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621478,BAO_0000218,
8359,5472,A,,,50597,Plasma clearance was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621479,BAO_0000218,
8360,5472,A,,,50597,Plasma clearance was evaluated in rat; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621480,BAO_0000218,
8361,5144,A,,,50597,Plasma clearance rate was determined for the compound in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621481,BAO_0000218,
8362,6685,A,,,50597,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621482,BAO_0000218,
8363,6685,A,,,50597,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621483,BAO_0000218,
8364,6685,A,,,50597,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621484,BAO_0000218,
8365,13950,A,,948.0,50597,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621485,BAO_0000218,
8366,13950,A,,948.0,50597,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621486,BAO_0000218,
8367,13950,A,,160.0,50597,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621487,BAO_0000218,
8368,13950,A,,160.0,50597,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621488,BAO_0000218,
8369,13950,A,,160.0,50597,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621489,BAO_0000218,
8370,13950,A,,160.0,50597,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621490,BAO_0000218,
8371,13950,A,,160.0,50597,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621491,BAO_0000218,
8372,13950,A,,2113.0,50597,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621492,BAO_0000218,
8373,13950,A,,2113.0,50597,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621493,BAO_0000218,
8374,13950,A,,2113.0,50597,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621494,BAO_0000218,
8375,13950,A,,2113.0,50597,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621495,BAO_0000218,
8376,13950,A,,2113.0,50597,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621496,BAO_0000218,
8377,13950,A,,2107.0,50597,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621497,BAO_0000218,
8378,13950,A,,2107.0,50597,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621498,BAO_0000218,
8379,13950,A,,2107.0,50597,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621499,BAO_0000218,
8380,13950,A,,2107.0,50597,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618634,BAO_0000218,
8381,13950,A,,2107.0,50597,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618635,BAO_0000218,
8382,13950,A,,2048.0,50597,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618636,BAO_0000218,
8383,13950,A,,2048.0,50597,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619737,BAO_0000218,
8384,13950,A,,2048.0,50597,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619738,BAO_0000218,
8385,13950,A,,2048.0,50597,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624329,BAO_0000218,
8386,13950,A,,2048.0,50597,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624330,BAO_0000218,
8387,13950,A,,2385.0,50597,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624331,BAO_0000218,
8388,13950,A,,2385.0,50597,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624332,BAO_0000218,
8389,13950,A,,2385.0,50597,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624333,BAO_0000218,
8390,13950,A,,2385.0,50597,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624334,BAO_0000218,
8391,13950,A,,2385.0,50597,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624335,BAO_0000218,
8392,13950,A,,2106.0,50597,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620016,BAO_0000218,
8393,13950,A,,2106.0,50597,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620169,BAO_0000218,
8394,13950,A,,2106.0,50597,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620170,BAO_0000218,
8395,13950,A,,2106.0,50597,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620171,BAO_0000218,
8396,13950,A,,2106.0,50597,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620172,BAO_0000218,
8397,13950,A,,945.0,50597,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620173,BAO_0000218,
8398,13950,A,,945.0,50597,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620174,BAO_0000218,
8399,13950,A,,945.0,50597,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620175,BAO_0000218,
8400,13950,A,,945.0,50597,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620176,BAO_0000218,
8401,13950,A,,945.0,50597,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620177,BAO_0000218,
8402,13950,A,,2037.0,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620178,BAO_0000218,
8403,13950,A,,2037.0,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620179,BAO_0000218,
8404,13950,A,,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620180,BAO_0000218,
8405,6570,A,,,50597,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620181,BAO_0000218,
8406,6571,A,,,50597,Volume of distribution of compound in rats after intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620182,BAO_0000218,
8407,6453,A,,,50597,Volume of distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620183,BAO_0000218,
8408,6444,A,,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620184,BAO_0000218,
8409,6444,A,,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620185,BAO_0000218,
8410,6444,A,,,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620186,BAO_0000218,
8411,5353,A,,,50597,Volume of distribution was determined in Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620187,BAO_0000218,
8412,5334,A,,,50597,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620188,BAO_0000218,
8413,5334,A,,,50597,Volume of distribution was reported in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620189,BAO_0000218,
8414,6641,A,,,50597,Volumes of distribution in rat after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620190,BAO_0000218,
8415,6641,A,,,50597,Volumes of distribution in rat after po administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620191,BAO_0000218,
8416,6641,A,,,50597,Volumes of distribution in rat after po administration; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620192,BAO_0000218,
8417,5676,A,,,50597,Pharmacokinetic property (Volume) in rat i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620193,BAO_0000218,
8418,6410,A,,,50597,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620194,BAO_0000218,
8419,17670,A,,,50597,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876730,BAO_0000218,
8420,6495,A,,,50597,Volume distribution in rat after oral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620195,BAO_0000218,
8421,5408,A,,,50597,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620196,BAO_0000218,
8422,4883,A,,,50597,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620197,BAO_0000218,
8423,6647,A,,,50597,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620198,BAO_0000218,
8424,6495,A,,,50597,Volume of distribution in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620199,BAO_0000218,
8425,2661,A,,,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620200,BAO_0000218,
8426,2661,A,,,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620201,BAO_0000218,
8427,5974,A,,,50597,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620202,BAO_0000218,
8428,5974,A,,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620203,BAO_0000218,
8429,5974,A,,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620204,BAO_0000218,
8430,5974,A,,,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620205,BAO_0000218,
8431,5960,A,,,50597,Pharmacokinetic parameter (Vss) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624664,BAO_0000218,
8432,5676,A,,,50597,Pharmacokinetic property (Volume) in rat i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624665,BAO_0000218,
8433,5948,A,,,50597,Pharmacokinetic property (Vss) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624666,BAO_0000218,
8434,5979,A,,,50597,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624667,BAO_0000218,
8435,5978,A,,,50597,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624668,BAO_0000218,
8436,5978,A,,,50597,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624669,BAO_0000218,
8437,5978,A,,,50597,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624670,BAO_0000218,
8438,5978,A,,,50597,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624671,BAO_0000218,
8439,6448,A,,,50597,Steady state volume distribution in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624672,BAO_0000218,
8440,12873,A,,1969.0,50597,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624673,BAO_0000218,
8441,4576,A,,,50597,Steady state volume of distribution determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624674,BAO_0000218,
8442,17582,A,,,50597,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624675,BAO_0000218,
8443,1466,A,,,50597,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621728,BAO_0000218,
8444,5182,A,,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621729,BAO_0000218,
8445,5182,A,,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621730,BAO_0000218,
8446,6535,A,,,50597,Volume distribution in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621731,BAO_0000218,
8447,6535,A,,,50597,Volume distribution in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621732,BAO_0000218,
8448,5041,A,,,50597,Volume in steady state distribution value was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621908,BAO_0000218,
8449,5041,A,,,50597,Volume in steady state distribution value was determined; ND denotes no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875347,BAO_0000218,
8450,5041,A,,,50597,Volume in steady state distribution value was determined; ND denotes not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621909,BAO_0000218,
8451,17065,A,,,50597,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621910,BAO_0000218,
8452,6597,A,,,50597,Volume of distribution at steady state was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621911,BAO_0000218,
8453,15662,A,,,50597,Volume of distribution at steady state was observed after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621912,BAO_0000218,
8454,6485,A,,,50597,Volume of distribution in steady state was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621913,BAO_0000218,
8455,17655,A,,,50597,Volume of distribution in steady state was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621914,BAO_0000218,
8456,6616,A,,,50597,Volume of distribution after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621915,BAO_0000218,
8457,1916,A,,,50597,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621916,BAO_0000218,
8458,16438,A,,2107.0,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621917,BAO_0000218,
8459,16438,A,,2107.0,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621918,BAO_0000218,
8460,16438,A,,2106.0,50594,Biodistribution of compound (oxidized form) in spleen tissue,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621919,BAO_0000218,
8461,16438,A,,2106.0,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621920,BAO_0000218,
8462,16438,A,,2106.0,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621921,BAO_0000218,
8463,16438,A,,2106.0,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622401,BAO_0000218,
8464,16438,A,,2106.0,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875348,BAO_0000218,
8465,16438,A,,2106.0,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622402,BAO_0000218,
8466,16438,A,,178.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622403,BAO_0000218,
8467,16438,A,,178.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622404,BAO_0000218,
8468,16438,A,,955.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622405,BAO_0000218,
8469,16438,A,,955.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622406,BAO_0000218,
8470,16438,A,,955.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622407,BAO_0000218,
8471,16438,A,,948.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622408,BAO_0000218,
8472,16438,A,,948.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622409,BAO_0000218,
8473,16438,A,,948.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622410,BAO_0000218,
8474,16438,A,,2113.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622411,BAO_0000218,
8475,16438,A,,2113.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627864,BAO_0000218,
8476,16438,A,,2113.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627865,BAO_0000218,
8477,16438,A,,2107.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627866,BAO_0000218,
8478,16438,A,,2107.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627751,BAO_0000218,
8479,16438,A,,2106.0,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627752,BAO_0000218,
8480,16438,A,,2106.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627753,BAO_0000218,
8481,16438,A,,2106.0,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627754,BAO_0000218,
8482,12467,A,,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627755,BAO_0000218,
8483,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627756,BAO_0000218,
8484,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627757,BAO_0000218,
8485,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627758,BAO_0000218,
8486,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627759,BAO_0000218,
8487,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627760,BAO_0000218,
8488,17208,A,,955.0,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627761,BAO_0000218,
8489,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876811,BAO_0000218,
8490,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627762,BAO_0000218,
8491,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627763,BAO_0000218,
8492,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627764,BAO_0000218,
8493,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627765,BAO_0000218,
8494,17208,A,,948.0,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627766,BAO_0000218,
8495,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627767,BAO_0000218,
8496,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627768,BAO_0000218,
8497,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628422,BAO_0000218,
8498,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628423,BAO_0000218,
8499,5089,A,,,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628424,BAO_0000218,
8500,5089,A,,,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628425,BAO_0000218,
8501,4257,A,,,50597,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628426,BAO_0000218,
8502,6679,A,,,50597,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628427,BAO_0000218,
8503,5546,A,,,50597,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626938,BAO_0000218,
8504,6141,A,,,50597,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626939,BAO_0000218,
8505,5334,A,,,50597,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626940,BAO_0000218,
8506,5334,A,,,50597,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626941,BAO_0000218,
8507,5334,A,,,50597,Plasma clearance was reported in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626942,BAO_0000218,
8508,4689,A,,,50597,Plasma clearance after intravenous administration (1 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876812,BAO_0000218,
8509,6848,A,,,50597,Plasma clearance of compound in rats was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626943,BAO_0000218,
8510,6848,A,,,50597,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626944,BAO_0000218,
8511,6467,A,,,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626945,BAO_0000218,
8512,6467,A,,,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626946,BAO_0000218,
8513,4956,A,,,50597,Plasma clearance rate in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626856,BAO_0000218,
8514,5529,A,,,50597,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626857,BAO_0000218,
8515,406,A,,1969.0,50597,The compound was evaluated for plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626858,BAO_0000218,
8516,17655,A,,1969.0,50597,Total plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627018,BAO_0000218,
8517,3293,A,,178.0,50597,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625331,BAO_0000218,
8518,4075,A,,178.0,50597,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625332,BAO_0000218,
8519,2792,A,,,50597,C max was determined at 10 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877590,BAO_0000218,
8520,2792,A,,,50597,C max was determined at 3 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625333,BAO_0000218,
8521,17594,A,,,50597,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625334,BAO_0000218,
8522,17594,A,,,50597,Cmax after single intravenous bolus of 1 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625335,BAO_0000218,
8523,4762,A,,,50597,Cmax of compound at 5 mg/kg after po administration was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625336,BAO_0000218,
8524,17509,A,,,50597,Cmax 24 hr after 10 mg/kg oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625337,BAO_0000218,
8525,17509,A,,,50597,Cmax 24 hr after 2 mg/kg oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625338,BAO_0000218,
8526,1466,A,,1969.0,50597,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625339,BAO_0000218,
8527,6535,A,,,50597,Cmax in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625340,BAO_0000218,
8528,6535,A,,,50597,Cmax in rat after administration of 2 mg/kg iv,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625341,BAO_0000218,
8529,3169,A,,,50597,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622687,BAO_0000218,
8530,6515,A,,1969.0,50597,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622688,BAO_0000218,
8531,11149,A,,178.0,50597,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622689,BAO_0000218,
8532,11149,A,,178.0,50597,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620295,BAO_0000218,
8533,17858,A,,,50597,Cmax after 10 mg/kg oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620296,BAO_0000218,
8534,6518,A,,,50597,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620297,BAO_0000218,
8535,6518,A,,,50597,Cmax after IV dosing at 1 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620298,BAO_0000218,
8536,4426,A,,,50597,Cmax after oral administration at 20 mpk in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620299,BAO_0000218,
8537,4426,A,,,50597,Cmax after oral administration at 20 mpk in rats; Not performed.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620300,BAO_0000218,
8538,4426,A,,,50597,Cmax after oral administration at 20 mpk in rats d; Not performed.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620301,BAO_0000218,
8539,5656,A,,,50597,Cmax after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620302,BAO_0000218,
8540,6518,A,,,50597,Cmax after oral administration at a dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620303,BAO_0000218,
8541,6518,A,,,50597,Cmax after oral administration at a dose of 4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620304,BAO_0000218,
8542,6113,A,,,50597,Cmax in rats after 20 mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620305,BAO_0000218,
8543,17764,A,,,50597,Cmax after peroral administration in rats at 2.4 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620306,BAO_0000218,
8544,4756,A,,,50597,Cmax at the dose of 2 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620307,BAO_0000218,
8545,4756,A,,,50597,Cmax at the dose of 5 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620308,BAO_0000218,
8546,6402,A,,,50597,Cmax by administering at 20 mg/kg p.o. in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620309,BAO_0000218,
8547,5610,A,,,50597,Cmax in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620310,BAO_0000218,
8548,5207,A,,,50597,Cmax in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620311,BAO_0000218,
8549,6011,A,,,50597,Cmax in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620312,BAO_0000218,
8550,6504,A,,,50597,Cmax in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620313,BAO_0000218,
8551,6046,A,,,50597,Cmax in rat at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620314,BAO_0000218,
8552,6504,A,,,50597,Cmax in rat at the dose of 1 mg/kg i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620315,BAO_0000218,
8553,5874,A,,,50597,Cmax in rat by po administration at a dose of 40 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620316,BAO_0000218,
8554,17686,A,,,50597,Cmax in rat p.o. at 20 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620317,BAO_0000218,
8555,5836,A,,,50597,Cmax in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620318,BAO_0000218,
8556,17596,A,,,50597,Cmax in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620319,BAO_0000218,
8557,16423,A,,,50597,Cmax was evaluated after 20 uM/kg of peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620320,BAO_0000218,
8558,17804,A,,,50597,Cmax was measured in rats after peroral administration at 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620321,BAO_0000218,
8559,1908,A,,,50597,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620322,BAO_0000218,
8560,13950,A,,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620323,BAO_0000218,
8561,13950,A,,1870.0,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Frontal cortex,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620324,BAO_0000218,
8562,13950,A,,1870.0,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Frontal cortex,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620325,BAO_0000218,
8563,13950,A,,10000000.0,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620326,BAO_0000218,
8564,13950,A,,10000000.0,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620327,BAO_0000218,
8565,13950,A,,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620328,BAO_0000218,
8566,13950,A,,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620329,BAO_0000218,
8567,13950,A,,1891.0,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Midbrain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620330,BAO_0000218,
8568,13950,A,,1891.0,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Midbrain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875286,BAO_0000218,
8569,13950,A,,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620331,BAO_0000218,
8570,13950,A,,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620332,BAO_0000218,
8571,13950,A,,2435.0,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620333,BAO_0000218,
8572,13950,A,,2435.0,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620334,BAO_0000218,
8573,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621015,BAO_0000218,
8574,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621016,BAO_0000218,
8575,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621191,BAO_0000218,
8576,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621192,BAO_0000218,
8577,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621193,BAO_0000218,
8578,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621194,BAO_0000218,
8579,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624204,BAO_0000218,
8580,16434,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624205,BAO_0000218,
8581,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624206,BAO_0000218,
8582,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624207,BAO_0000218,
8583,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624208,BAO_0000218,
8584,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624209,BAO_0000218,
8585,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624210,BAO_0000218,
8586,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624211,BAO_0000218,
8587,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624212,BAO_0000218,
8588,16435,A,,178.0,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624213,BAO_0000218,
8589,16434,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876611,BAO_0000218,
8590,16434,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624214,BAO_0000218,
8591,16434,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624215,BAO_0000218,
8592,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624216,BAO_0000218,
8593,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624217,BAO_0000218,
8594,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624218,BAO_0000218,
8595,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624219,BAO_0000218,
8596,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624220,BAO_0000218,
8597,16435,A,,178.0,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624221,BAO_0000218,
8598,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624222,BAO_0000218,
8599,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624223,BAO_0000218,
8600,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624224,BAO_0000218,
8601,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624225,BAO_0000218,
8602,17764,A,,,50597,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622420,BAO_0000218,
8603,5031,A,,,50597,Volume of steady state distribution after i.v. administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622421,BAO_0000218,
8604,6215,A,,,50597,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622422,BAO_0000218,
8605,17671,A,,,50597,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622423,BAO_0000218,
8606,17752,A,,,50597,Vss was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622424,BAO_0000218,
8607,6596,A,,,50597,Vss in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622425,BAO_0000218,
8608,16423,A,,,50597,Vss was evaluated after 10 uM/kg of intra arterial administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876612,BAO_0000218,
8609,15662,A,,,50597,volume of distribution at steady state was observed after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622426,BAO_0000218,
8610,6062,A,,,50597,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622427,BAO_0000218,
8611,5874,A,,,50597,Pharmacokinetic (PK) parameter Vz in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622428,BAO_0000218,
8612,4942,A,,,50597,Volume distribution in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622429,BAO_0000218,
8613,17796,A,,,50597,Volume of distribution in rat; No data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622430,BAO_0000218,
8614,4890,A,,,50597,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622431,BAO_0000218,
8615,15765,A,,2116.0,50597,% absorption predicted from in vitro rat ileum transport studies,Ileum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622432,BAO_0000218,
8616,13569,A,,,50597,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622433,BAO_0000218,
8617,13569,A,,,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622434,BAO_0000218,
8618,13569,A,,,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622435,BAO_0000218,
8619,13569,A,,,50597,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618748,BAO_0000218,
8620,13569,A,,,50597,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618749,BAO_0000218,
8621,13569,A,,,50597,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618750,BAO_0000218,
8622,13569,A,,,50597,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618751,BAO_0000218,
8623,13569,A,,,50597,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618752,BAO_0000218,
8624,4576,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618753,BAO_0000218,
8625,750,A,,1969.0,50597,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618754,BAO_0000218,
8626,750,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618755,BAO_0000218,
8627,4590,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618756,BAO_0000218,
8628,1716,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618757,BAO_0000218,
8629,1974,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618758,BAO_0000218,
8630,4502,A,,,50597,Oral bioavailability in rat (dose 30 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621088,BAO_0000218,
8631,3371,A,,,50597,Pharmacokinetic property (cLogP) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621089,BAO_0000218,
8632,9099,F,,178.0,50597,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621090,BAO_0000218,
8633,9099,F,,178.0,50597,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621091,BAO_0000218,
8634,4590,A,,,50597,Clearance in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876731,BAO_0000218,
8635,3184,A,,,50597,Compound was evaluated for its clearance when administered intravenously in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621092,BAO_0000218,
8636,16456,A,,,50597,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621093,BAO_0000218,
8637,4199,A,,,50597,Blood: Brain distribution ratio is determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621094,BAO_0000218,
8638,4199,A,,,50597,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621095,BAO_0000218,
8639,4199,A,,,50597,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621096,BAO_0000218,
8640,8677,A,,2113.0,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621097,BAO_0000218,
8641,7449,F,,,50597,Percent dose excreted in 0-48 hours administered ip to male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621098,BAO_0000218,
8642,11977,A,,2037.0,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621099,BAO_0000218,
8643,11977,A,,2037.0,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621100,BAO_0000218,
8644,11977,A,,2037.0,50597,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621101,BAO_0000218,
8645,11977,A,,2037.0,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621102,BAO_0000218,
8646,11977,A,,2037.0,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876732,BAO_0000218,
8647,11977,A,,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621103,BAO_0000218,
8648,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621104,BAO_0000218,
8649,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621105,BAO_0000218,
8650,11977,A,,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621106,BAO_0000218,
8651,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621107,BAO_0000218,
8652,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621108,BAO_0000218,
8653,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621109,BAO_0000218,
8654,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621110,BAO_0000218,
8655,17208,A,,2113.0,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621111,BAO_0000218,
8656,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622541,BAO_0000218,
8657,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622542,BAO_0000218,
8658,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622543,BAO_0000218,
8659,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624412,BAO_0000218,
8660,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624413,BAO_0000218,
8661,17208,A,,2107.0,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624414,BAO_0000218,
8662,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624415,BAO_0000218,
8663,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624416,BAO_0000218,
8664,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624417,BAO_0000218,
8665,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624418,BAO_0000218,
8666,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624419,BAO_0000218,
8667,17208,A,,2048.0,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624420,BAO_0000218,
8668,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624421,BAO_0000218,
8669,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624422,BAO_0000218,
8670,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624423,BAO_0000218,
8671,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625123,BAO_0000218,
8672,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625124,BAO_0000218,
8673,17208,A,,2385.0,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625125,BAO_0000218,
8674,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625126,BAO_0000218,
8675,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626947,BAO_0000218,
8676,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626948,BAO_0000218,
8677,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626949,BAO_0000218,
8678,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626950,BAO_0000218,
8679,17208,A,,14.0,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626951,BAO_0000218,
8680,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626952,BAO_0000218,
8681,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626953,BAO_0000218,
8682,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626954,BAO_0000218,
8683,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626955,BAO_0000218,
8684,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626956,BAO_0000218,
8685,17208,A,,2106.0,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626957,BAO_0000218,
8686,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626958,BAO_0000218,
8687,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626959,BAO_0000218,
8688,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626960,BAO_0000218,
8689,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626961,BAO_0000218,
8690,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627589,BAO_0000218,
8691,17208,A,,178.0,50594,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627590,BAO_0000218,
8692,3132,A,,,50594,Time taken for EC90 was determined when tested in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627591,BAO_0000218,
8693,3132,A,,,50594,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627592,BAO_0000218,
8694,16597,A,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627593,BAO_0000218,
8695,5727,A,,,50594,Half life in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627594,BAO_0000218,
8696,5302,A,,,50594,Half life period in mouse after 10 mg/Kg dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876813,BAO_0000218,
8697,5302,A,,,50594,Half life period in mouse after 10 mg/kg dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627595,BAO_0000218,
8698,6348,A,,,50594,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627596,BAO_0000218,
8699,5964,A,,,50597,Cmax value at 5 mg/kg po was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627597,BAO_0000218,
8700,6078,A,,,50597,Cmax value evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627598,BAO_0000218,
8701,5206,A,,955.0,50597,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627599,BAO_0000218,
8702,2959,A,,,50597,Cmax value after administration of 20 mg/Kg oral dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627600,BAO_0000218,
8703,5964,A,,,50597,Cmax value at 1 mg/kg po in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627601,BAO_0000218,
8704,5964,A,,,50597,Cmax value at 5 mg/kg po in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627776,BAO_0000218,
8705,6757,A,,,50597,Cmax value at a dose of 10 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627777,BAO_0000218,
8706,6757,A,,,50597,Cmax value at a dose of 100 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627778,BAO_0000218,
8707,6757,A,,,50597,Cmax value at a dose of 50 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627779,BAO_0000218,
8708,17617,A,,,50597,Cmax value in rats at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876814,BAO_0000218,
8709,1445,A,,,50597,Cmax value was evaluated in rats at a dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627780,BAO_0000218,
8710,6082,A,,,50597,Cmax value was determined after peroral administration of 20 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627781,BAO_0000218,
8711,1446,A,,,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627782,BAO_0000218,
8712,5407,A,,1969.0,50597,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627783,BAO_0000218,
8713,2690,A,,1969.0,50597,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627784,BAO_0000218,
8714,2661,A,,,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627785,BAO_0000218,
8715,2661,A,,,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627786,BAO_0000218,
8716,4891,A,,1969.0,50597,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627787,BAO_0000218,
8717,2807,A,,1969.0,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627788,BAO_0000218,
8718,2807,A,,1969.0,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626579,BAO_0000218,
8719,2807,A,,1969.0,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626580,BAO_0000218,
8720,3634,A,,,50597,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876815,BAO_0000218,
8721,1881,A,,1969.0,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626581,BAO_0000218,
8722,1881,A,,1969.0,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626582,BAO_0000218,
8723,429,A,,,50597,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626583,BAO_0000218,
8724,5974,A,,,50597,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626205,BAO_0000218,
8725,5974,A,,,50597,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626206,BAO_0000218,
8726,5974,A,,,50597,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626207,BAO_0000218,
8727,5974,A,,,50597,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623882,BAO_0000218,
8728,17582,A,,,50597,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623883,BAO_0000218,
8729,17582,A,,,50597,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623884,BAO_0000218,
8730,3032,A,,1969.0,50597,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623885,BAO_0000218,
8731,6295,A,,1969.0,50597,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623886,BAO_0000218,
8732,6619,A,,,50597,Maximal concentration in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623887,BAO_0000218,
8733,6616,A,,,50597,Maximal concentration after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623888,BAO_0000218,
8734,3249,A,,1969.0,50597,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623889,BAO_0000218,
8735,17791,A,,1969.0,50597,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623890,BAO_0000218,
8736,17791,A,,1969.0,50597,Cmax in rat plasma after oral dose (50 mg/Kg),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623891,BAO_0000218,
8737,1360,A,,1969.0,50597,Maximal plasma concentration was determined.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623892,BAO_0000218,
8738,2552,A,,1969.0,50597,Maximal plasma drug concentration was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623893,BAO_0000218,
8739,6571,A,,,50597,Maximal concentration in rats after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877616,BAO_0000218,
8740,6570,A,,,50597,Maximum concentration in rat after 2 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623894,BAO_0000218,
8741,6567,A,,1969.0,50597,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623895,BAO_0000218,
8742,3031,A,,,50597,Maximum concentration of compound in rat was evaluated.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623896,BAO_0000218,
8743,3436,A,,,50597,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623897,BAO_0000218,
8744,3436,A,,,50597,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623898,BAO_0000218,
8745,2083,A,,,50597,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623899,BAO_0000218,
8746,3436,A,,,50597,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623900,BAO_0000218,
8747,4527,A,,,50597,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623901,BAO_0000218,
8748,1974,A,,,50597,Maximum concentration was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623902,BAO_0000218,
8749,3307,A,,1359.0,50597,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Cerebrospinal fluid,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623903,BAO_0000218,
8750,3307,A,,1969.0,50597,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623904,BAO_0000218,
8751,1916,A,,1969.0,50597,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877617,BAO_0000218,
8752,1500,A,,,50597,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623905,BAO_0000218,
8753,1500,A,,,50597,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623906,BAO_0000218,
8754,4186,A,,1969.0,50597,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623907,BAO_0000218,
8755,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623908,BAO_0000218,
8756,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623909,BAO_0000218,
8757,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623910,BAO_0000218,
8758,16434,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623911,BAO_0000218,
8759,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623912,BAO_0000218,
8760,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624616,BAO_0000218,
8761,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624617,BAO_0000218,
8762,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624618,BAO_0000218,
8763,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624619,BAO_0000218,
8764,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624794,BAO_0000218,
8765,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624795,BAO_0000218,
8766,16435,A,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623921,BAO_0000218,
8767,16434,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623922,BAO_0000218,
8768,16434,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623923,BAO_0000218,
8769,16434,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623924,BAO_0000218,
8770,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623925,BAO_0000218,
8771,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623926,BAO_0000218,
8772,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623927,BAO_0000218,
8773,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623928,BAO_0000218,
8774,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623929,BAO_0000218,
8775,16435,A,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623930,BAO_0000218,
8776,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623931,BAO_0000218,
8777,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622165,BAO_0000218,
8778,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621249,BAO_0000218,
8779,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621250,BAO_0000218,
8780,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621448,BAO_0000218,
8781,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621449,BAO_0000218,
8782,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621450,BAO_0000218,
8783,16434,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621451,BAO_0000218,
8784,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621452,BAO_0000218,
8785,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621453,BAO_0000218,
8786,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621454,BAO_0000218,
8787,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621455,BAO_0000218,
8788,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621456,BAO_0000218,
8789,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625145,BAO_0000218,
8790,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875847,BAO_0000218,
8791,16435,A,,955.0,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625146,BAO_0000218,
8792,16434,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625147,BAO_0000218,
8793,16434,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625148,BAO_0000218,
8794,16434,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625149,BAO_0000218,
8795,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625150,BAO_0000218,
8796,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625151,BAO_0000218,
8797,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625152,BAO_0000218,
8798,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625153,BAO_0000218,
8799,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625154,BAO_0000218,
8800,16435,A,,955.0,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625155,BAO_0000218,
8801,11977,A,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625156,BAO_0000218,
8802,11977,A,,,50597,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624354,BAO_0000218,
8803,11977,A,,10000000.0,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624355,BAO_0000218,
8804,11977,A,,10000000.0,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624356,BAO_0000218,
8805,11977,A,,10000000.0,50597,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624357,BAO_0000218,
8806,11977,A,,10000000.0,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624358,BAO_0000218,
8807,11977,A,,2435.0,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624359,BAO_0000218,
8808,11977,A,,2435.0,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624360,BAO_0000218,
8809,11977,A,,2435.0,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624361,BAO_0000218,
8810,11977,A,,2435.0,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624362,BAO_0000218,
8811,11977,A,,2435.0,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624363,BAO_0000218,
8812,11977,A,,178.0,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624364,BAO_0000218,
8813,11977,A,,178.0,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624365,BAO_0000218,
8814,11977,A,,178.0,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624366,BAO_0000218,
8815,11977,A,,178.0,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624367,BAO_0000218,
8816,11977,A,,955.0,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624368,BAO_0000218,
8817,11977,A,,955.0,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624369,BAO_0000218,
8818,11977,A,,955.0,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624370,BAO_0000218,
8819,11977,A,,955.0,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625069,BAO_0000218,
8820,11977,A,,955.0,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625070,BAO_0000218,
8821,11977,A,,948.0,50597,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626051,BAO_0000218,
8822,11977,A,,948.0,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626052,BAO_0000218,
8823,11977,A,,948.0,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626053,BAO_0000218,
8824,11977,A,,948.0,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626054,BAO_0000218,
8825,11977,A,,948.0,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626055,BAO_0000218,
8826,11977,A,,2113.0,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626056,BAO_0000218,
8827,11977,A,,2113.0,50597,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626057,BAO_0000218,
8828,11977,A,,2113.0,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625193,BAO_0000218,
8829,11977,A,,2113.0,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625194,BAO_0000218,
8830,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625195,BAO_0000218,
8831,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625196,BAO_0000218,
8832,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625197,BAO_0000218,
8833,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625198,BAO_0000218,
8834,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627929,BAO_0000218,
8835,11977,A,,2048.0,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627074,BAO_0000218,
8836,11977,A,,2048.0,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627075,BAO_0000218,
8837,11977,A,,2048.0,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627076,BAO_0000218,
8838,11977,A,,2048.0,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627077,BAO_0000218,
8839,11977,A,,2048.0,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627078,BAO_0000218,
8840,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627079,BAO_0000218,
8841,4573,A,,,50594,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL873824,BAO_0000218,
8842,3132,A,,1969.0,50594,Half life in mouse plasma was determined at dose 25 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627080,BAO_0000218,
8843,17718,A,,,50594,Half life was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627081,BAO_0000218,
8844,17728,A,,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627082,BAO_0000218,
8845,5961,A,,,50594,Half-life in male mice after 1 mg/kg intravenous dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627083,BAO_0000218,
8847,17731,A,,1969.0,50594,Half life in mice plasma,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627085,BAO_0000218,
8848,17592,A,,,50594,Half life in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627086,BAO_0000218,
8849,3132,A,,1969.0,50594,Half life in mouse plasma at dose 25 mg/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627087,BAO_0000218,
8850,17729,A,,,50594,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627088,BAO_0000218,
8851,17729,A,,,50594,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627089,BAO_0000218,
8852,17729,A,,,50594,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627090,BAO_0000218,
8853,3277,A,,,50594,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627091,BAO_0000218,
8854,3760,A,,,50594,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627092,BAO_0000218,
8855,3760,A,,,50594,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876785,BAO_0000218,
8856,2862,A,,,50594,Half-life by iv administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627093,BAO_0000218,
8857,2862,A,,,50594,Half-life by oral administration in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627094,BAO_0000218,
8858,5980,A,,,50594,Half-life in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627095,BAO_0000218,
8859,6159,A,,955.0,50594,Half-life using mouse brain homogenate,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627096,BAO_0000218,
8860,6254,A,,,50594,Half-life was measured in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627097,BAO_0000218,
8861,6062,A,,,50594,Half-life was measured in mouse after an iv dose of 1 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627098,BAO_0000218,
8862,1574,A,,178.0,50594,Half-life period was determined in mouse blood,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627099,BAO_0000218,
8863,56,A,,955.0,50594,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627100,BAO_0000218,
8864,993,A,,1969.0,50594,Plasma half life in mouse,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627101,BAO_0000218,
8865,6652,A,,,50594,Stability of the peptide in the presence of mouse serum,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627102,BAO_0000218,
8866,17852,A,,,50594,Terminal half life of compound was determined in mouse,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627103,BAO_0000218,
8867,2675,A,,,50594,Terminal half life was evaluated in mice after intravenous administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627104,BAO_0000218,
8868,2675,A,,,50594,Terminal half life was evaluated in mice after oral administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627105,BAO_0000218,
8869,499,A,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876786,BAO_0000218,
8870,499,A,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL873825,BAO_0000218,
8871,499,A,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627106,BAO_0000218,
8872,14239,A,,,50594,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626336,BAO_0000218,
8873,5506,A,,,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL877462,BAO_0000218,
8874,5506,A,,,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626337,BAO_0000218,
8875,17734,A,,,50594,Half life after intraperitoneal administration of 100 mg/kg in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626338,BAO_0000218,
8876,17728,A,,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626339,BAO_0000218,
8877,17728,A,,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626340,BAO_0000218,
8878,17728,A,,,50594,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625377,BAO_0000218,
8879,17728,A,,,50594,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625378,BAO_0000218,
8880,17728,A,,,50594,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625379,BAO_0000218,
8881,14294,A,,,22224,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625380,BAO_0000251,
8882,14294,A,,,22224,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625381,BAO_0000251,
8883,6056,A,,,22224,Stability to porcine renal DHP-I,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625382,BAO_0000019,
8884,1317,A,,,22224,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL873828,BAO_0000218,
8885,1317,A,,,22224,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625383,BAO_0000218,
8886,5229,A,,,22224,Half-life of the parent prodrug in porcine esterase solution,,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625384,BAO_0000019,
8887,4231,A,,,22224,"First order rate constant, k was determined in in pig liver Esterase",,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625385,BAO_0000019,
8888,4231,A,,2107.0,22224,Half life of the in pig liver Esterase,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL625386,BAO_0000221,
8889,5318,A,,2107.0,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623571,BAO_0000221,
8890,5318,A,,2107.0,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623572,BAO_0000221,
8891,5318,A,,2107.0,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623573,BAO_0000221,
8892,3305,A,,2107.0,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623574,BAO_0000221,
8893,3305,A,,2107.0,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623575,BAO_0000221,
8894,2842,A,,2107.0,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623749,BAO_0000221,
8895,2842,A,,2107.0,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623750,BAO_0000221,
8896,889,A,,2107.0,22224,Half-life in vitro in pig liver,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623751,BAO_0000221,
8897,1904,A,,2107.0,22224,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Liver,0,,Sus scrofa,1,9823.0,U,Autocuration,,,CHEMBL623752,BAO_0000221,
8898,4186,A,,1969.0,50597,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623753,BAO_0000218,
8899,2774,A,,1969.0,50597,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623754,BAO_0000218,
8900,1742,A,,1969.0,50597,Maximum concentration in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623755,BAO_0000218,
8901,3169,A,,,50597,Maximum concentration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623756,BAO_0000218,
8902,3169,A,,,50597,Maximum concentration in rats at 1-2 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623757,BAO_0000218,
8903,2081,A,,,50597,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623758,BAO_0000218,
8904,3307,A,,955.0,50597,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623759,BAO_0000218,
8905,4727,A,,,50597,Maximum concentration at the dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623760,BAO_0000218,
8906,6597,A,,,50597,Maximum concentration was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623761,BAO_0000218,
8907,16365,A,,1969.0,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623762,BAO_0000218,
8908,16365,A,,1969.0,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877594,BAO_0000218,
8909,16365,A,,1969.0,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623763,BAO_0000218,
8910,16365,A,,1969.0,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623764,BAO_0000218,
8911,16365,A,,1969.0,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623765,BAO_0000218,
8912,2591,A,,178.0,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623766,BAO_0000218,
8913,2591,A,,178.0,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623767,BAO_0000218,
8914,2591,A,,178.0,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623768,BAO_0000218,
8915,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623769,BAO_0000218,
8916,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623770,BAO_0000218,
8917,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623771,BAO_0000218,
8918,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623772,BAO_0000218,
8919,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623773,BAO_0000218,
8920,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623774,BAO_0000218,
8921,5978,A,,1969.0,50597,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623775,BAO_0000218,
8922,14465,A,,,50597,Cmax in rat (PO dose),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623776,BAO_0000218,
8923,4723,A,,1969.0,50597,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622191,BAO_0000218,
8924,4723,A,,1969.0,50597,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622192,BAO_0000218,
8925,4576,A,,1969.0,50597,Maximum plasma concentration determined in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622193,BAO_0000218,
8926,12873,A,,1969.0,50597,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622194,BAO_0000218,
8927,12873,A,,1969.0,50597,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622195,BAO_0000218,
8928,6824,A,,1969.0,50597,Maximum plasma concentration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622196,BAO_0000218,
8929,17065,A,,1969.0,50597,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622197,BAO_0000218,
8930,2932,A,,1969.0,50597,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622198,BAO_0000218,
8931,2932,A,,1969.0,50597,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622199,BAO_0000218,
8932,2879,A,,1969.0,50597,Maximum plasma concentration of compound was measured in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622200,BAO_0000218,
8933,2864,A,,1969.0,50597,Maximum plasma concentration after 20 mg/kg oral administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622201,BAO_0000218,
8934,16367,A,,1969.0,50597,Maximum plasma concentration after oral administration to rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623990,BAO_0000218,
8935,17717,A,,1969.0,50597,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623991,BAO_0000218,
8936,17717,A,,1969.0,50597,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623992,BAO_0000218,
8937,17717,A,,1969.0,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623993,BAO_0000218,
8938,17717,A,,1969.0,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623994,BAO_0000218,
8939,17720,F,,1969.0,50597,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623995,BAO_0000218,
8940,17720,F,,1969.0,50597,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623996,BAO_0000218,
8941,17720,F,,1969.0,50597,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623997,BAO_0000218,
8942,4516,A,,1969.0,50597,Maximum plasma concentration dosed orally in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623998,BAO_0000218,
8943,4516,A,,1969.0,50597,Maximum plasma concentration dosed orally in rats after 6 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623999,BAO_0000218,
8944,4516,A,,1969.0,50597,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624000,BAO_0000218,
8945,5199,A,,1969.0,50597,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624001,BAO_0000218,
8946,17538,A,,1969.0,50597,Maximum plasma concentration in rat after po administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624002,BAO_0000218,
8947,6685,A,,1969.0,50597,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624003,BAO_0000218,
8948,6685,A,,1969.0,50597,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624004,BAO_0000218,
8949,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624005,BAO_0000218,
8950,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624006,BAO_0000218,
8951,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624007,BAO_0000218,
8952,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624008,BAO_0000218,
8953,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624009,BAO_0000218,
8954,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874387,BAO_0000218,
8955,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624010,BAO_0000218,
8956,16434,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624011,BAO_0000218,
8957,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624012,BAO_0000218,
8958,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624013,BAO_0000218,
8959,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624736,BAO_0000218,
8960,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624737,BAO_0000218,
8961,16434,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624738,BAO_0000218,
8962,16434,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624739,BAO_0000218,
8963,16434,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624740,BAO_0000218,
8964,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624896,BAO_0000218,
8965,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624897,BAO_0000218,
8966,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624108,BAO_0000218,
8967,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624109,BAO_0000218,
8968,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624110,BAO_0000218,
8969,16435,A,,948.0,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624111,BAO_0000218,
8970,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624112,BAO_0000218,
8971,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624113,BAO_0000218,
8972,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619709,BAO_0000218,
8973,16435,A,,948.0,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619710,BAO_0000218,
8974,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619711,BAO_0000218,
8975,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619712,BAO_0000218,
8976,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619713,BAO_0000218,
8977,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619714,BAO_0000218,
8978,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619715,BAO_0000218,
8979,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619716,BAO_0000218,
8980,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619717,BAO_0000218,
8981,16434,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619718,BAO_0000218,
8982,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619719,BAO_0000218,
8983,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875329,BAO_0000218,
8984,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619720,BAO_0000218,
8985,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619721,BAO_0000218,
8986,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619722,BAO_0000218,
8987,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619723,BAO_0000218,
8988,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619724,BAO_0000218,
8989,16435,A,,2113.0,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619725,BAO_0000218,
8990,16434,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619726,BAO_0000218,
8991,16434,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619727,BAO_0000218,
8992,16434,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619728,BAO_0000218,
8993,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619729,BAO_0000218,
8994,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619730,BAO_0000218,
8995,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619731,BAO_0000218,
8996,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619732,BAO_0000218,
8997,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619733,BAO_0000218,
8998,11977,A,,2385.0,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619734,BAO_0000218,
8999,11977,A,,14.0,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619735,BAO_0000218,
9000,11977,A,,14.0,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875330,BAO_0000218,
9001,11977,A,,14.0,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628465,BAO_0000218,
9002,11977,A,,14.0,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628466,BAO_0000218,
9003,11977,A,,14.0,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628467,BAO_0000218,
9004,11977,A,,2106.0,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628468,BAO_0000218,
9005,11977,A,,2106.0,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628469,BAO_0000218,
9006,11977,A,,2106.0,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628470,BAO_0000218,
9007,11977,A,,2106.0,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628471,BAO_0000218,
9008,11977,A,,2106.0,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628472,BAO_0000218,
9009,11977,A,,2046.0,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625191,BAO_0000218,
9010,11977,A,,2046.0,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625192,BAO_0000218,
9011,11977,A,,2046.0,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875337,BAO_0000218,
9012,11977,A,,2046.0,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626341,BAO_0000218,
9013,11977,A,,2046.0,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626342,BAO_0000218,
9014,11977,A,,2107.0,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621943,BAO_0000218,
9015,3748,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621944,BAO_0000218,
9016,15765,A,,,50597,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621945,BAO_0000218,
9017,4871,A,,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621946,BAO_0000218,
9018,4871,A,,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621947,BAO_0000218,
9019,4872,A,,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621948,BAO_0000218,
9020,4872,A,,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621949,BAO_0000218,
9021,5413,A,,,50597,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621950,BAO_0000218,
9022,5413,A,,,50597,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621951,BAO_0000218,
9023,15272,A,,178.0,50597,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621952,BAO_0000218,
9024,4689,A,,2107.0,50597,Stability (%) in rat liver microsomes,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621953,BAO_0000218,
9025,6057,A,,,50597,Area under curve was calculated after intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621954,BAO_0000218,
9026,6057,A,,,50597,Area under the curve was calculated after iv administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621955,BAO_0000218,
9027,6057,A,,,50597,Area under the curve was calculated in rat after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621956,BAO_0000218,
9028,6211,A,,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621957,BAO_0000218,
9029,5710,A,,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621958,BAO_0000218,
9030,5710,A,,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621959,BAO_0000218,
9031,17853,A,,,50597,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621960,BAO_0000218,
9032,17853,A,,,50597,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621961,BAO_0000218,
9033,15765,A,,,50597,p value of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621962,BAO_0000218,
9034,15765,F,,,50597,p value of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876787,BAO_0000218,
9035,15765,A,,,50597,p value of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621963,BAO_0000218,
9036,6175,A,,945.0,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622637,BAO_0000218,
9037,6175,A,,945.0,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622638,BAO_0000218,
9038,6175,A,,945.0,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626561,BAO_0000218,
9039,7991,F,,,22224,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626562,BAO_0000019,
9040,429,A,,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626563,BAO_0000218,
9041,429,A,,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626564,BAO_0000218,
9042,6253,A,,,22224,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626565,BAO_0000218,
9043,6253,A,,,22224,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626566,BAO_0000218,
9044,3615,A,,,22224,Clearance rate in rabbits,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626567,BAO_0000218,
9045,4059,A,,,22224,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626568,BAO_0000218,
9046,5124,A,,,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626569,BAO_0000218,
9047,5124,A,,,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626570,BAO_0000218,
9048,5124,A,,,22224,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626571,BAO_0000218,
9049,429,A,,,22224,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626572,BAO_0000218,
9050,4059,A,,1969.0,22224,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Plasma,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626573,BAO_0000218,
9051,9659,A,,2107.0,22224,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Liver,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626574,BAO_0000251,
9052,9659,A,,2107.0,22224,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Liver,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626575,BAO_0000251,
9053,3639,A,,,22224,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626576,BAO_0000218,
9054,3639,A,,,22224,Dose at which bioavailability of perorally administered compound was tested in rabbit,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626577,BAO_0000218,
9055,3639,A,,,22224,The compound was tested for its bioavailability in rabbit (by oral dosage).,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL626578,BAO_0000218,
9056,5124,A,,,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625263,BAO_0000218,
9057,5124,A,,,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625264,BAO_0000218,
9058,5124,A,,,22224,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625265,BAO_0000218,
9059,14294,A,,,22224,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625266,BAO_0000251,
9060,14294,A,,,22224,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL876796,BAO_0000251,
9061,429,A,,,22224,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625267,BAO_0000218,
9062,5124,A,,1969.0,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Plasma,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625268,BAO_0000218,
9063,5124,A,,1969.0,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Plasma,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL625269,BAO_0000218,
9064,5124,A,,1969.0,22224,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Plasma,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624689,BAO_0000218,
9065,429,A,,,22224,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624690,BAO_0000218,
9066,429,A,,1088.0,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Urine,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624691,BAO_0000218,
9067,429,A,,1088.0,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Urine,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624692,BAO_0000218,
9068,4059,A,,,22224,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624693,BAO_0000218,
9069,4137,A,,,22224,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624694,BAO_0000218,
9070,11672,A,,,22224,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL877596,BAO_0000221,
9071,12886,A,,,22224,Time within which only 10% of the drug was degraded,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624695,BAO_0000019,
9072,3853,A,,2107.0,22224,Half life period in rabbit liver homogenate,Liver,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624696,BAO_0000221,
9073,3615,A,,,22224,Half life value in rabbits,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624697,BAO_0000019,
9074,6253,A,,178.0,22224,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Blood,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624698,BAO_0000218,
9075,6253,A,,178.0,22224,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Blood,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624699,BAO_0000218,
9076,6077,A,,,22224,Half-life period in rabbits following intravenous administration at 2 mg/kg,,0,,Oryctolagus cuniculus,1,9986.0,U,Autocuration,,,CHEMBL624700,BAO_0000218,
9077,17617,A,,1969.0,50597,AUC 0-8 hr value in rats at 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622903,BAO_0000218,
9078,17594,A,,1969.0,50597,AUC after administration at 2000 mg/kg/day in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622904,BAO_0000218,
9079,6149,A,,1969.0,50597,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622905,BAO_0000218,
9080,17260,A,,1969.0,50597,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622906,BAO_0000218,
9081,17260,A,,1969.0,50597,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622907,BAO_0000218,
9082,6644,A,,1969.0,50597,AUC in rat after oral administration at 10.5 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622908,BAO_0000218,
9083,6644,A,,1969.0,50597,AUC in rat after oral administration at 11.2 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622909,BAO_0000218,
9084,6644,A,,1969.0,50597,AUC in rat after oral administration at 9.7 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622910,BAO_0000218,
9085,6495,A,,955.0,50597,AUC in rat brain after oral administration at 10 mg/kg,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622911,BAO_0000218,
9086,6504,A,,1969.0,50597,AUC in rat p.o.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622912,BAO_0000218,
9087,17686,A,,1969.0,50597,AUC in rat p.o. at 20 mg/kg concentration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622913,BAO_0000218,
9088,6495,A,,1969.0,50597,AUC in rat plasma after oral administration at 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622914,BAO_0000218,
9089,216,A,,1969.0,50597,AUC in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622915,BAO_0000218,
9090,1908,A,,1969.0,50597,AUC value after IV dose at a dose of 5 mg/kg in rats.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622916,BAO_0000218,
9091,1908,A,,1969.0,50597,AUC value after oral dose at a dose of 10 mg/kg in rats.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622917,BAO_0000218,
9092,6685,A,,1969.0,50597,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622918,BAO_0000218,
9093,216,A,,1969.0,50597,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622919,BAO_0000218,
9094,6049,A,,1969.0,50597,Maximum plasma concentration was evaluated in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622920,BAO_0000218,
9095,2463,A,,1969.0,50597,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622921,BAO_0000218,
9096,6679,A,,1969.0,50597,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622922,BAO_0000218,
9097,6681,A,,1969.0,50597,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622923,BAO_0000218,
9098,4890,A,,1969.0,50597,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877604,BAO_0000218,
9099,6410,A,,1969.0,50597,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622924,BAO_0000218,
9100,6410,A,,1969.0,50597,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622925,BAO_0000218,
9101,16366,A,,1969.0,50597,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622926,BAO_0000218,
9102,6227,A,,1969.0,50597,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623625,BAO_0000218,
9103,3598,A,,1969.0,50597,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL623626,BAO_0000218,
9104,1465,A,,1969.0,50597,Maximum plasma drug concentration was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623627,BAO_0000218,
9105,4368,A,,,50597,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623628,BAO_0000218,
9106,15662,A,,1969.0,50597,Mean peak plasma concentration was observed after intravenous administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623629,BAO_0000218,
9107,15662,A,,1969.0,50597,Mean peak plasma concentration was observed after oral administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623630,BAO_0000218,
9108,5355,A,,,50597,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623804,BAO_0000218,
9109,5355,A,,,50597,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623805,BAO_0000218,
9110,1567,A,,1969.0,50597,Peak oral plasma concentration was determined in rats by oral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623806,BAO_0000218,
9111,4026,A,,1969.0,50597,Peak plasma concentration (Cmax) was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623807,BAO_0000218,
9112,6193,A,,1969.0,50597,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623808,BAO_0000218,
9113,4026,A,,1969.0,50597,Peak plasma concentration (Cmax) in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623809,BAO_0000218,
9114,6485,A,,1969.0,50597,Peak plasma concentration at 1 mg/kg peroral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623810,BAO_0000218,
9115,17655,A,,1969.0,50597,Peak plasma concentration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623811,BAO_0000218,
9116,14941,A,,1969.0,50597,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623812,BAO_0000218,
9117,5394,A,,,50597,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877605,BAO_0000218,
9118,4408,A,,,50597,Pharmacokinetic property (Cmax) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623813,BAO_0000218,
9119,5983,A,,,50597,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623814,BAO_0000218,
9120,4878,A,,,50597,Cmax in rat after 3mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623815,BAO_0000218,
9121,5862,A,,,50597,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,Sprague-Dawley,,CHEMBL623816,BAO_0000218,
9122,4517,A,,,50597,Cmax in rats after 20 mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623145,BAO_0000218,
9123,5932,A,,1969.0,50597,Cmax in rat plasma after 30mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623146,BAO_0000218,
9124,5436,A,,1969.0,50597,Plasma concentration after oral administration of 100 mg/kg to rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623147,BAO_0000218,
9125,4910,A,,955.0,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623042,BAO_0000218,
9126,4950,A,,,50597,Tested for the Cmax in rat at 10 mg/kg per orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623043,BAO_0000218,
9127,15078,A,,,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623044,BAO_0000218,
9128,15078,A,,,50597,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623045,BAO_0000218,
9129,3360,A,,,50597,Bioavailability as oral Cmax in rats at 30 mins,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623046,BAO_0000218,
9130,3360,A,,,50597,Bioavailability as oral Cmax in rats at 6hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623226,BAO_0000218,
9131,15022,A,,,50597,The maximum concentration of compound was measured at the dose of 100 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623227,BAO_0000218,
9132,15022,A,,,50597,The maximum concentration of compound was measured at the dose of 300 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623228,BAO_0000218,
9133,15022,A,,,50597,The maximum concentration of compound was measured at the dose of 30 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623229,BAO_0000218,
9134,5160,A,,1969.0,50597,The maximum plasma levels for the compounds were determined by LC-MS.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623230,BAO_0000218,
9135,15662,A,,1969.0,50597,mean peak plasma concentration was observed after intravenous administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623231,BAO_0000218,
9136,15662,A,,1969.0,50597,mean peak plasma concentration was observed after oral administration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623232,BAO_0000218,
9137,4709,A,,,50597,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623233,BAO_0000218,
9138,3535,A,,,50597,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623234,BAO_0000218,
9139,3535,A,,,50597,Concentration in plasma (portal) following oral dose in rats at 1 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623235,BAO_0000218,
9140,3535,A,,,50597,Concentration in plasma (portal) following oral dose in rats at 2 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623236,BAO_0000218,
9141,3535,A,,,50597,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623237,BAO_0000218,
9142,3535,A,,,50597,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623238,BAO_0000218,
9143,3535,A,,,50597,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623239,BAO_0000218,
9144,5005,A,,1969.0,22224,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Plasma,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL623240,BAO_0000218,
9145,6326,A,,1898.0,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623241,BAO_0000218,
9146,6326,A,,1898.0,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623242,BAO_0000218,
9147,6326,A,,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874394,BAO_0000218,
9148,6326,A,,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623243,BAO_0000218,
9149,17411,A,,,50597,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623244,BAO_0000218,
9150,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623245,BAO_0000218,
9151,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623246,BAO_0000218,
9152,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623247,BAO_0000218,
9153,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623248,BAO_0000218,
9154,16435,A,,2113.0,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623249,BAO_0000218,
9155,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625072,BAO_0000218,
9156,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625073,BAO_0000218,
9157,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625074,BAO_0000218,
9158,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625075,BAO_0000218,
9159,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625076,BAO_0000218,
9160,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625077,BAO_0000218,
9161,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625078,BAO_0000218,
9162,16434,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874395,BAO_0000218,
9163,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625079,BAO_0000218,
9164,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625080,BAO_0000218,
9165,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625081,BAO_0000218,
9166,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625082,BAO_0000218,
9167,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625083,BAO_0000218,
9168,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625084,BAO_0000218,
9169,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625085,BAO_0000218,
9170,16435,A,,2107.0,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625086,BAO_0000218,
9171,16434,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625087,BAO_0000218,
9172,16434,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625088,BAO_0000218,
9173,16434,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622205,BAO_0000218,
9174,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622206,BAO_0000218,
9175,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622207,BAO_0000218,
9176,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622366,BAO_0000218,
9177,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622367,BAO_0000218,
9178,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875331,BAO_0000218,
9179,16435,A,,2107.0,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622368,BAO_0000218,
9180,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622369,BAO_0000218,
9181,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622370,BAO_0000218,
9182,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622371,BAO_0000218,
9183,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622372,BAO_0000218,
9184,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622373,BAO_0000218,
9185,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622374,BAO_0000218,
9186,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622375,BAO_0000218,
9187,16434,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622376,BAO_0000218,
9188,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622377,BAO_0000218,
9189,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622378,BAO_0000218,
9190,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622379,BAO_0000218,
9191,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622380,BAO_0000218,
9192,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622381,BAO_0000218,
9193,16435,A,,2048.0,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622382,BAO_0000218,
9194,16434,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622383,BAO_0000218,
9195,6175,A,,945.0,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875332,BAO_0000218,
9196,6175,A,,945.0,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622384,BAO_0000218,
9197,6175,A,,945.0,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622385,BAO_0000218,
9198,6175,A,,945.0,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622386,BAO_0000218,
9199,10839,A,,,50597,The compound was tested for the plasma binding in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622387,BAO_0000218,
9200,16459,A,,,50597,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622388,BAO_0000218,
9201,16459,A,,,50597,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622389,BAO_0000218,
9202,16459,A,,,50597,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622390,BAO_0000218,
9203,16459,A,,,50597,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622391,BAO_0000218,
9204,16459,A,,,50597,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622392,BAO_0000218,
9205,16459,A,,,50597,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622393,BAO_0000218,
9206,3278,A,,,50597,Plasma level at 2 hr after administration of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622394,BAO_0000218,
9207,3278,A,,,50597,plasma level at 2 hr after administration of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622395,BAO_0000218,
9208,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 1 min,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622396,BAO_0000218,
9209,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 10 min,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624894,BAO_0000218,
9210,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 10 mins,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624895,BAO_0000218,
9211,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 2 hr,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624058,BAO_0000218,
9212,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 3 min,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624059,BAO_0000218,
9213,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 3 mins,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624060,BAO_0000218,
9214,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 5 min,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624061,BAO_0000218,
9215,4684,A,,1977.0,50597,Stability in rat serum measured as % recovery at 5 mins,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624062,BAO_0000218,
9216,16456,A,,,50597,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624063,BAO_0000218,
9217,16456,A,,,50597,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624064,BAO_0000218,
9218,723,A,,1969.0,50597,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624065,BAO_0000218,
9219,723,A,,1969.0,50597,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624066,BAO_0000218,
9220,5160,A,,,50597,Half life tested in mature male rat at a dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877490,BAO_0000218,
9221,4709,A,,,50597,Half life after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874442,BAO_0000218,
9222,5633,A,,,50597,Half life period after administration (30 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626890,BAO_0000218,
9223,5302,A,,,50597,Half life period in rat after 5 mg/Kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626891,BAO_0000218,
9224,5302,A,,,50597,Half life period in rat after 5 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626892,BAO_0000218,
9225,17791,A,,,50597,Half life period was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626893,BAO_0000218,
9226,17791,A,,,50597,Half life period was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626894,BAO_0000218,
9227,17791,A,,,50597,Half life period was evaluated in rat; 0.5-1.0,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626895,BAO_0000218,
9228,17791,A,,,50597,Half life period was evaluated in rat; 5.9-7.5,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626896,BAO_0000218,
9229,14512,A,,1969.0,50597,Half-life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626897,BAO_0000218,
9230,6230,A,,,50597,Half-life time in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626898,BAO_0000218,
9231,3364,A,,,50597,Terminal half-life after iv administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626899,BAO_0000218,
9232,6874,A,,,50597,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626900,BAO_0000218,
9233,857,A,,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626901,BAO_0000218,
9234,858,A,,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626902,BAO_0000218,
9235,858,A,,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626903,BAO_0000218,
9236,5355,A,,,50597,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874443,BAO_0000218,
9237,5355,A,,,50597,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626904,BAO_0000218,
9238,6305,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626905,BAO_0000218,
9239,13501,A,,1969.0,50597,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873830,BAO_0000218,
9240,17594,A,,,50597,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626906,BAO_0000218,
9241,4186,A,,1969.0,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631076,BAO_0000218,
9242,2932,A,,1969.0,50597,Biological half-life was measured in plasma of rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631077,BAO_0000218,
9243,17065,A,,,50597,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631078,BAO_0000218,
9244,15765,A,,,50597,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631079,BAO_0000218,
9245,2713,A,,,50597,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631080,BAO_0000218,
9246,2661,A,,,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631081,BAO_0000218,
9247,2661,A,,,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631239,BAO_0000218,
9248,740,A,,1969.0,50597,Compound was evaluated for plasma half life in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631240,BAO_0000218,
9249,6597,A,,1969.0,50597,AUC value at a dose of 5 mg/kg (p.o.) in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631241,BAO_0000218,
9250,2959,A,,1969.0,50597,AUC value after administration of 20 mg/Kg oral dose in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631242,BAO_0000218,
9251,17594,A,,1969.0,50597,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631243,BAO_0000218,
9252,17596,A,,1969.0,50597,AUC0-96 after administration at 50 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874444,BAO_0000218,
9253,17594,A,,1969.0,50597,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631244,BAO_0000218,
9254,3293,A,,,50597,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631245,BAO_0000218,
9255,6757,A,,,50597,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627162,BAO_0000218,
9256,6757,A,,,50597,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627163,BAO_0000218,
9257,6757,A,,,50597,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627164,BAO_0000218,
9258,5979,A,,2113.0,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627165,BAO_0000218,
9259,5979,A,,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627166,BAO_0000218,
9260,5979,A,,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627167,BAO_0000218,
9261,4026,A,,,50597,Area under curve (AUC) at a dose of 30 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627822,BAO_0000218,
9262,5355,A,,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627823,BAO_0000218,
9263,5355,A,,,50597,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627824,BAO_0000218,
9264,5355,A,,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627825,BAO_0000218,
9265,5633,A,,,50597,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627826,BAO_0000218,
9266,1716,A,,,50597,Area under curve (Pharmacokinetic property) was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627827,BAO_0000218,
9267,1716,A,,,50597,Area under curve (Pharmacokinetic property) of the compound; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627828,BAO_0000218,
9268,4689,A,,,50597,Area under curve after intravenous administration (1 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627829,BAO_0000218,
9269,4527,A,,,50597,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627830,BAO_0000218,
9270,4527,A,,,50597,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627831,BAO_0000218,
9271,15662,A,,,50597,Area under curve in male SD rats was observed after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627832,BAO_0000218,
9272,4413,A,,,50597,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627833,BAO_0000218,
9273,3598,A,,,50597,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL627834,BAO_0000218,
9274,3598,A,,,50597,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL628004,BAO_0000218,
9275,5964,A,,,50597,Area under curve at 5 mg/kg po was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628005,BAO_0000218,
9276,4689,A,,,50597,Area under curve in Rat at a oral dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628006,BAO_0000218,
9277,4186,A,,,50597,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628007,BAO_0000218,
9278,5510,A,,,50597,Area under curve was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625676,BAO_0000218,
9279,17858,A,,,50597,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631309,BAO_0000218,
9280,17804,A,,,50597,Area under curve after intravenous administration at 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631310,BAO_0000218,
9281,6106,A,,,50597,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631311,BAO_0000218,
9282,5964,A,,,50597,Area under curve at 4 hr in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631312,BAO_0000218,
9283,4026,A,,,50597,Area under curve at a dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631313,BAO_0000218,
9284,4756,A,,,50597,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631314,BAO_0000218,
9285,4756,A,,,50597,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631315,BAO_0000218,
9286,5862,A,,,50597,Area under curve for a 2-mpk po dose in SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631316,BAO_0000218,
9287,5862,A,,,50597,Area under curve in SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631317,BAO_0000218,
9288,6644,A,,,50597,Area under curve in rat after oral administration at 13 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874471,BAO_0000218,
9289,5871,A,,,50597,Area under curve in rat by po administration at 0-24 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631318,BAO_0000218,
9290,5919,A,,1969.0,50597,Area under curve in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631319,BAO_0000218,
9291,5939,A,,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631320,BAO_0000218,
9292,5939,A,,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631321,BAO_0000218,
9293,10,A,,,50597,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631322,BAO_0000218,
9294,11149,A,,,50597,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631323,BAO_0000218,
9295,5302,A,,,50597,Area under curve value in rat at a dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631324,BAO_0000218,
9296,17796,A,,,50597,Area under curve was determined after oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631325,BAO_0000218,
9297,4890,A,,,50597,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631326,BAO_0000218,
9298,6011,A,,,50597,Area under curve was determined after peroral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631327,BAO_0000218,
9299,5375,A,,,50597,Area under curve was determined at a dose 30 mpk administered orally.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631328,BAO_0000218,
9300,17764,A,,,50597,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631329,BAO_0000218,
9301,4368,A,,,50597,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627217,BAO_0000218,
9302,5610,A,,,50597,Area under curve was determined in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626352,BAO_0000218,
9303,5833,A,,,50597,Area under curve was determined in rat after PO administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626353,BAO_0000218,
9304,4257,A,,,50597,Area under curve was determined in rat after a 3 mg/kg of oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626354,BAO_0000218,
9305,5937,A,,,50597,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626355,BAO_0000218,
9306,5932,A,,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626356,BAO_0000218,
9307,5932,A,,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626357,BAO_0000218,
9308,17411,A,,,50597,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626358,BAO_0000218,
9309,17411,A,,,50597,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626359,BAO_0000218,
9310,17771,A,,1969.0,50597,Peak plasma concentration in rat at a dose of 3 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626360,BAO_0000218,
9311,1628,A,,,50597,Plasma concentration at 2 hr in rats was evaluated.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626361,BAO_0000218,
9312,1628,A,,,50597,Plasma concentration at 2 hr in rats was evaluated; Not available,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626362,BAO_0000218,
9313,17411,A,,,50597,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626363,BAO_0000218,
9314,4910,A,,,50597,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626970,BAO_0000218,
9315,4910,A,,,50597,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626971,BAO_0000218,
9316,4910,A,,1969.0,50597,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626972,BAO_0000218,
9317,4910,A,,1969.0,50597,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626973,BAO_0000218,
9318,4910,A,,1969.0,50597,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626974,BAO_0000218,
9319,4910,A,,1969.0,50597,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874592,BAO_0000218,
9320,5510,A,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626975,BAO_0000218,
9321,5510,A,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626976,BAO_0000218,
9322,5510,A,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626977,BAO_0000218,
9323,5510,A,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626978,BAO_0000218,
9324,16427,A,,,50597,PK study was carried to determine the relative absorption ranking in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626979,BAO_0000218,
9325,4689,A,,1969.0,50597,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626980,BAO_0000218,
9326,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626981,BAO_0000218,
9327,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626982,BAO_0000218,
9328,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626983,BAO_0000218,
9329,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622522,BAO_0000218,
9330,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622523,BAO_0000218,
9331,11450,A,,178.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622524,BAO_0000218,
9332,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622525,BAO_0000218,
9333,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622526,BAO_0000218,
9334,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619849,BAO_0000218,
9335,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619850,BAO_0000218,
9336,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623864,BAO_0000218,
9337,11450,A,,955.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623865,BAO_0000218,
9338,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623866,BAO_0000218,
9339,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623867,BAO_0000218,
9340,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877615,BAO_0000218,
9341,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623868,BAO_0000218,
9342,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623869,BAO_0000218,
9343,11450,A,,948.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623870,BAO_0000218,
9344,16434,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623871,BAO_0000218,
9345,16434,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623872,BAO_0000218,
9346,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622129,BAO_0000218,
9347,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622130,BAO_0000218,
9348,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622131,BAO_0000218,
9349,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622132,BAO_0000218,
9350,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622133,BAO_0000218,
9351,16435,A,,2048.0,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622134,BAO_0000218,
9352,16435,A,,2048.0,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622135,BAO_0000218,
9353,16435,A,,2048.0,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622136,BAO_0000218,
9354,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622137,BAO_0000218,
9355,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622138,BAO_0000218,
9356,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623017,BAO_0000218,
9357,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623018,BAO_0000218,
9358,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623019,BAO_0000218,
9359,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623020,BAO_0000218,
9360,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623021,BAO_0000218,
9361,16434,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623022,BAO_0000218,
9362,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623023,BAO_0000218,
9363,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623024,BAO_0000218,
9364,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623025,BAO_0000218,
9365,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620545,BAO_0000218,
9366,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620546,BAO_0000218,
9367,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620547,BAO_0000218,
9368,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620548,BAO_0000218,
9369,16435,A,,2385.0,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620549,BAO_0000218,
9370,16434,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620550,BAO_0000218,
9371,16434,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620551,BAO_0000218,
9372,16434,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620552,BAO_0000218,
9373,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620553,BAO_0000218,
9374,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620554,BAO_0000218,
9375,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875845,BAO_0000218,
9376,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620555,BAO_0000218,
9377,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620556,BAO_0000218,
9378,16435,A,,2385.0,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620557,BAO_0000218,
9379,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620558,BAO_0000218,
9380,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620559,BAO_0000218,
9381,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622939,BAO_0000218,
9382,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622940,BAO_0000218,
9383,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622941,BAO_0000218,
9384,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622942,BAO_0000218,
9385,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622943,BAO_0000218,
9386,16434,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622944,BAO_0000218,
9387,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622945,BAO_0000218,
9388,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622946,BAO_0000218,
9389,3341,A,,,50597,Compound was evaluated for terminal half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622947,BAO_0000218,
9390,3634,A,,1969.0,50597,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622948,BAO_0000218,
9391,3634,A,,1969.0,50597,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622949,BAO_0000218,
9392,4839,A,,,50597,Compound was tested for its half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622950,BAO_0000218,
9393,5005,A,,1969.0,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Plasma,0,,Macaca mulatta,1,9544.0,U,Intermediate,,,CHEMBL622951,BAO_0000218,
9394,5005,A,,1969.0,22224,Compound was tested for its plasma half life in Sprague Dawley rats,Plasma,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL622952,BAO_0000366,
9395,5005,A,,1969.0,22224,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Plasma,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL622953,BAO_0000366,
9396,1094,A,,1969.0,50597,Compound was tested for plasma half-life period in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873818,BAO_0000218,
9397,5031,A,,,50597,Elimination half life after i.v. administration of compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622954,BAO_0000218,
9398,6518,A,,,50597,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622955,BAO_0000218,
9399,6518,A,,,50597,Elimination half-life after IV dosing at 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875229,BAO_0000218,
9400,6518,A,,,50597,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622956,BAO_0000218,
9401,6518,A,,,50597,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622957,BAO_0000218,
9402,5408,A,,955.0,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622958,BAO_0000218,
9403,5408,A,,1969.0,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622959,BAO_0000218,
9404,5408,A,,955.0,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622960,BAO_0000218,
9405,5408,A,,1969.0,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622961,BAO_0000218,
9406,4687,A,,,50597,Evaluated for the half life in rat (in vivo),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622962,BAO_0000218,
9407,6640,A,,,50597,Hafl life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622963,BAO_0000218,
9408,6640,A,,,50597,Hafl life rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622964,BAO_0000218,
9409,6641,A,,,50597,Hafl life rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622965,BAO_0000218,
9410,6640,A,,,50597,Hafl life rat; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622966,BAO_0000218,
9411,6641,A,,,50597,Hafl life rat; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622967,BAO_0000218,
9412,17411,A,,2113.0,50597,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622968,BAO_0000218,
9413,17411,A,,2107.0,50597,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622969,BAO_0000218,
9414,17411,A,,2048.0,50597,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875327,BAO_0000218,
9415,6570,A,,,50597,Half life in rat after 1 mg/kg i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628638,BAO_0000218,
9416,6570,A,,,50597,Half life in rat after 2 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628639,BAO_0000218,
9417,17411,A,,,50597,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625840,BAO_0000218,
9418,4722,A,,,50597,Half life of 10 mg/kg oral dose determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625841,BAO_0000218,
9419,5978,A,,,50597,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625842,BAO_0000218,
9420,5978,A,,,50597,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625843,BAO_0000218,
9421,5978,A,,,50597,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625844,BAO_0000218,
9422,5978,A,,,50597,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873822,BAO_0000218,
9423,5978,A,,,50597,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625845,BAO_0000218,
9424,5978,A,,,50597,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627059,BAO_0000218,
9425,5978,A,,,50597,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627060,BAO_0000218,
9426,5978,A,,,50597,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627061,BAO_0000218,
9427,4762,A,,,50597,Half life of compound at 5 mg/kg after po administration was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627709,BAO_0000218,
9428,5327,A,,,50597,Half life of compound determined after intravenous administration to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627710,BAO_0000218,
9429,4847,A,,,50597,Half life of compound was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627711,BAO_0000218,
9430,17720,A,,1969.0,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627712,BAO_0000218,
9431,4723,A,,,50597,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627713,BAO_0000218,
9432,4723,A,,,50597,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627714,BAO_0000218,
9433,4256,A,,,22224,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,0,,Macaca fascicularis,1,9541.0,U,Intermediate,,,CHEMBL627889,BAO_0000218,
9434,4256,A,,,22224,Half life determined in rat by intravenous administration,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL627890,BAO_0000218,
9435,4722,A,,,50597,Half life determined in rats after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627891,BAO_0000218,
9436,6535,A,,1969.0,50597,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627892,BAO_0000218,
9437,6535,A,,1969.0,50597,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627893,BAO_0000218,
9438,1435,A,,1969.0,50597,Half life in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627894,BAO_0000218,
9439,1435,A,,1969.0,50597,Half life in rat plasma was determined; NA means not applicable,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627895,BAO_0000218,
9440,5206,A,,,50597,Half life in rat was tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627896,BAO_0000218,
9441,6080,A,,1969.0,50597,Half life measured in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627897,BAO_0000218,
9442,4449,A,,,50597,Half life recorded in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627898,BAO_0000218,
9443,6057,A,,,50597,Half life was calculated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627899,BAO_0000218,
9444,6057,A,,,50597,Half life was calculated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873823,BAO_0000218,
9445,3747,A,,,50597,Half life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627900,BAO_0000218,
9446,17858,A,,,50597,Half life after 10 mg/kg oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627901,BAO_0000218,
9447,16365,A,,,50597,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627902,BAO_0000218,
9448,16365,A,,,50597,Half life after administering orally a dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627903,BAO_0000218,
9449,5031,A,,,50597,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627904,BAO_0000218,
9450,4722,A,,,50597,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627905,BAO_0000218,
9451,6078,A,,,50597,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627906,BAO_0000218,
9452,6078,A,,,50597,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627907,BAO_0000218,
9453,6078,A,,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876783,BAO_0000218,
9454,6078,A,,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627908,BAO_0000218,
9455,17065,A,,,50597,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627909,BAO_0000218,
9456,1353,A,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627910,BAO_0000218,
9457,1353,A,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627911,BAO_0000218,
9458,1353,A,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627912,BAO_0000218,
9459,1353,A,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627913,BAO_0000218,
9460,1353,A,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627914,BAO_0000218,
9461,16423,A,,,50597,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627915,BAO_0000218,
9462,16423,A,,,50597,Area under the curve was evaluated after 20 uM/kg of peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627916,BAO_0000218,
9463,6062,A,,,50597,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627917,BAO_0000218,
9464,6056,A,,,50597,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627918,BAO_0000218,
9465,5182,A,,,50597,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627919,BAO_0000218,
9466,6410,A,,,50597,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627920,BAO_0000218,
9467,6410,A,,,50597,Area under the curve was evaluated at an oral dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627921,BAO_0000218,
9468,4723,A,,,50597,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627922,BAO_0000218,
9469,4723,A,,,50597,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876784,BAO_0000218,
9470,4723,A,,,50597,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627923,BAO_0000218,
9471,4723,A,,,50597,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626208,BAO_0000218,
9472,4723,A,,,50597,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626209,BAO_0000218,
9473,4723,A,,,50597,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626210,BAO_0000218,
9474,2463,A,,1969.0,50597,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627994,BAO_0000218,
9475,4709,A,,,50597,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627995,BAO_0000218,
9476,4075,A,,,50597,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627996,BAO_0000218,
9477,5394,A,,,50597,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627997,BAO_0000218,
9478,2661,A,,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627998,BAO_0000218,
9479,2661,A,,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628640,BAO_0000218,
9480,2661,A,,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628641,BAO_0000218,
9481,2661,A,,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628642,BAO_0000218,
9482,17791,A,,,50597,Compound was evaluated for area under the curve expressed as (h*ug/ml),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628643,BAO_0000218,
9483,2591,A,,,50597,Compound was tested for area under curve in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628644,BAO_0000218,
9484,6567,A,,,50597,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628645,BAO_0000218,
9485,6211,A,,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628646,BAO_0000218,
9486,5529,A,,,50597,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628647,BAO_0000218,
9487,5408,A,,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628648,BAO_0000218,
9488,5408,A,,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625358,BAO_0000218,
9489,5408,A,,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625359,BAO_0000218,
9490,5408,A,,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625360,BAO_0000218,
9491,429,A,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625361,BAO_0000218,
9492,429,A,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625362,BAO_0000218,
9493,429,A,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625363,BAO_0000218,
9494,4796,A,,,50597,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625364,BAO_0000218,
9495,5974,A,,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625365,BAO_0000218,
9496,5974,A,,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625366,BAO_0000218,
9497,5974,A,,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625367,BAO_0000218,
9498,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625368,BAO_0000218,
9499,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625369,BAO_0000218,
9500,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625370,BAO_0000218,
9501,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625371,BAO_0000218,
9502,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625372,BAO_0000218,
9503,11450,A,,2113.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625373,BAO_0000218,
9504,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625374,BAO_0000218,
9505,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877593,BAO_0000218,
9506,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625375,BAO_0000218,
9507,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625376,BAO_0000218,
9508,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621973,BAO_0000218,
9509,11450,A,,2107.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621974,BAO_0000218,
9510,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621975,BAO_0000218,
9511,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622166,BAO_0000218,
9512,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622167,BAO_0000218,
9513,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622168,BAO_0000218,
9514,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622169,BAO_0000218,
9515,11450,A,,2048.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622170,BAO_0000218,
9516,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622171,BAO_0000218,
9517,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622172,BAO_0000218,
9518,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622173,BAO_0000218,
9519,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622174,BAO_0000218,
9520,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622175,BAO_0000218,
9521,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622176,BAO_0000218,
9522,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622177,BAO_0000218,
9523,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622178,BAO_0000218,
9524,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622179,BAO_0000218,
9525,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622180,BAO_0000218,
9526,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622181,BAO_0000218,
9527,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622182,BAO_0000218,
9528,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622183,BAO_0000218,
9529,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622184,BAO_0000218,
9530,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622185,BAO_0000218,
9531,16435,A,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622186,BAO_0000218,
9532,16434,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622187,BAO_0000218,
9533,16434,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625002,BAO_0000218,
9534,16434,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622090,BAO_0000218,
9535,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622091,BAO_0000218,
9536,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622092,BAO_0000218,
9537,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622093,BAO_0000218,
9538,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622094,BAO_0000218,
9539,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622095,BAO_0000218,
9540,16435,A,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622264,BAO_0000218,
9541,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622265,BAO_0000218,
9542,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622266,BAO_0000218,
9543,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622267,BAO_0000218,
9544,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622268,BAO_0000218,
9545,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622269,BAO_0000218,
9546,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625071,BAO_0000218,
9547,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621621,BAO_0000218,
9548,16434,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621622,BAO_0000218,
9549,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621623,BAO_0000218,
9550,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621624,BAO_0000218,
9551,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621625,BAO_0000218,
9552,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621626,BAO_0000218,
9553,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621627,BAO_0000218,
9554,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621628,BAO_0000218,
9555,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875328,BAO_0000218,
9556,16435,A,,2106.0,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621629,BAO_0000218,
9557,16434,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621630,BAO_0000218,
9558,16434,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621631,BAO_0000218,
9559,16434,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621632,BAO_0000218,
9560,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621633,BAO_0000218,
9561,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621634,BAO_0000218,
9562,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621635,BAO_0000218,
9563,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621636,BAO_0000218,
9564,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621637,BAO_0000218,
9565,16435,A,,2106.0,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621638,BAO_0000218,
9566,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618883,BAO_0000218,
9567,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618884,BAO_0000218,
9568,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628627,BAO_0000218,
9569,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628628,BAO_0000218,
9570,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628629,BAO_0000218,
9571,16365,A,,,50597,Half life after administering orally a dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628630,BAO_0000218,
9572,16365,A,,,50597,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628631,BAO_0000218,
9573,16365,A,,,50597,Half life after administering intravenously a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628632,BAO_0000218,
9574,526,A,,,50597,Half life after oral dosing in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628633,BAO_0000218,
9575,16365,A,,,50597,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628634,BAO_0000218,
9576,4368,A,,,50597,Half life by intravenous administration of 3.4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627789,BAO_0000218,
9577,3371,A,,,50597,Half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627790,BAO_0000218,
9578,6448,A,,,50597,Half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627791,BAO_0000218,
9579,6453,A,,,50597,Half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627792,BAO_0000218,
9580,4353,A,,,50597,Half life in rat after intravenous administration of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627793,BAO_0000218,
9581,4353,A,,1969.0,50597,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627794,BAO_0000218,
9582,4353,A,,,50597,Half life in rat after po administration of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627795,BAO_0000218,
9583,4353,A,,,50597,Half life in rat after po administration of the compound; ND means Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627796,BAO_0000218,
9584,4353,A,,1969.0,50597,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875335,BAO_0000218,
9585,4353,A,,1969.0,50597,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627797,BAO_0000218,
9586,5789,A,,,50597,Half life in rat i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627798,BAO_0000218,
9587,17686,A,,,50597,Half life in rat i.v. at 2 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627799,BAO_0000218,
9588,6495,A,,,50597,Half life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627800,BAO_0000218,
9589,484,A,,,50597,Half life in rats after intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627801,BAO_0000218,
9590,6467,A,,,50597,Half life in rats at the dose of 1.0 mpk by i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627802,BAO_0000218,
9591,6642,A,,,50597,Half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL627803,BAO_0000218,
9592,16367,A,,,50597,Half life was evaluated after intravenous administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873820,BAO_0000218,
9593,1369,A,,,50597,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627804,BAO_0000218,
9594,5472,A,,,50597,Half life was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627805,BAO_0000218,
9595,6049,A,,,50597,Half life was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627806,BAO_0000218,
9596,5472,A,,,50597,Half life was evaluated in rat; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627107,BAO_0000218,
9597,16366,A,,,50597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627108,BAO_0000218,
9598,11149,A,,,50597,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627109,BAO_0000218,
9599,11149,A,,178.0,50597,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627110,BAO_0000218,
9600,2891,A,,,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,,0,,Primates,1,9443.0,U,Intermediate,,,CHEMBL627111,BAO_0000218,
9601,2891,A,,,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,,0,,Primates,1,9443.0,U,Intermediate,,,CHEMBL627112,BAO_0000218,
9602,2891,A,,,22224,Half life was measured in rat at dose of 30 mg/kg by iv administration,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL627113,BAO_0000218,
9603,2891,A,,,22224,Half life was measured in rat at dose of 30 mg/kg by po administration,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL627114,BAO_0000218,
9604,4026,A,,,50597,Half life (t1/2) was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627115,BAO_0000218,
9605,4527,A,,,50597,Half life period at a dose of 10 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627116,BAO_0000218,
9606,4527,A,,,50597,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627117,BAO_0000218,
9607,5503,A,,,50597,Half life period was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627118,BAO_0000218,
9608,4426,A,,,50597,Half life period after intravenous administration at 20 mpk in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627119,BAO_0000218,
9609,4426,A,,,50597,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627120,BAO_0000218,
9610,6109,A,,,50597,Half life period after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626922,BAO_0000218,
9611,5654,A,,,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626923,BAO_0000218,
9612,5654,A,,,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626924,BAO_0000218,
9613,4755,A,,1969.0,50597,Half life period in 80% rat plasma at 37 degree Centigrade,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626925,BAO_0000218,
9614,5862,A,,,50597,Half life period in SD rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626926,BAO_0000218,
9615,1515,A,,1969.0,50597,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626927,BAO_0000218,
9616,1515,A,,1969.0,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626928,BAO_0000218,
9617,1515,A,,1969.0,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626929,BAO_0000218,
9618,1515,A,,1969.0,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626930,BAO_0000218,
9619,5960,A,,,50597,Half life period in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626931,BAO_0000218,
9620,6103,A,,,50597,Half life period in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626932,BAO_0000218,
9621,6317,A,,,50597,Half life period in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626933,BAO_0000218,
9622,6644,A,,,50597,Half life period in rat after oral administration at 10.5 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873826,BAO_0000218,
9623,6644,A,,,50597,Half life period in rat after oral administration at 11.2 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626934,BAO_0000218,
9624,6644,A,,,50597,Half life period in rat after oral administration at 13 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626935,BAO_0000218,
9625,6644,A,,,50597,Half life period in rat after oral administration at 9.7 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626936,BAO_0000218,
9626,5974,A,,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626937,BAO_0000218,
9627,6295,A,,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625906,BAO_0000218,
9628,6296,A,,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625907,BAO_0000218,
9629,16427,A,,,50597,PK study was carried to determine AUC (area under curve) value in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625908,BAO_0000218,
9630,16367,A,,,50597,Pharmacokinetic parameter AUC after intravenous administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625909,BAO_0000218,
9631,16367,A,,,50597,Pharmacokinetic parameter AUC after oral administration to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625910,BAO_0000218,
9632,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625911,BAO_0000218,
9633,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625912,BAO_0000218,
9634,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626538,BAO_0000218,
9635,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876794,BAO_0000218,
9636,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626539,BAO_0000218,
9637,16365,A,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626540,BAO_0000218,
9638,5394,A,,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626541,BAO_0000218,
9639,5394,A,,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626542,BAO_0000218,
9640,2792,A,,,50597,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626543,BAO_0000218,
9641,2792,A,,,50597,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626544,BAO_0000218,
9642,2792,A,,,50597,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626545,BAO_0000218,
9643,2792,A,,,50597,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626546,BAO_0000218,
9644,5334,A,,,50597,Pharmacokinetic parameter area under curve was reported,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626547,BAO_0000218,
9645,4408,A,,,50597,Pharmacokinetic property (AUC) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626548,BAO_0000218,
9646,5983,A,,,50597,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626549,BAO_0000218,
9647,4397,A,,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626550,BAO_0000218,
9648,4397,A,,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626551,BAO_0000218,
9649,5491,A,,,50597,Pharmacokinetic property was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623777,BAO_0000218,
9650,5491,A,,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623778,BAO_0000218,
9651,5491,A,,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623779,BAO_0000218,
9652,4199,A,,1969.0,50597,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623780,BAO_0000218,
9653,4199,A,,1969.0,50597,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622015,BAO_0000218,
9654,4199,A,,1969.0,50597,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622016,BAO_0000218,
9655,5173,A,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622017,BAO_0000218,
9656,5173,A,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622018,BAO_0000218,
9657,5173,A,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622019,BAO_0000218,
9658,5173,A,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622020,BAO_0000218,
9659,16366,A,,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622021,BAO_0000218,
9660,16366,A,,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622022,BAO_0000218,
9661,5327,A,,,50597,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622023,BAO_0000218,
9662,6681,A,,,50597,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622024,BAO_0000218,
9663,12873,A,,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622693,BAO_0000218,
9664,12873,A,,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622694,BAO_0000218,
9665,6685,A,,,50597,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622695,BAO_0000218,
9666,6685,A,,,50597,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622696,BAO_0000218,
9667,6685,A,,,50597,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622697,BAO_0000218,
9668,6619,A,,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622874,BAO_0000218,
9669,6619,A,,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622875,BAO_0000218,
9670,10363,A,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622876,BAO_0000218,
9671,4796,A,,,50597,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622877,BAO_0000218,
9672,4910,A,,,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622878,BAO_0000218,
9673,4910,A,,1969.0,50597,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622879,BAO_0000218,
9674,4839,A,,,50597,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877602,BAO_0000218,
9675,15078,A,,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622880,BAO_0000218,
9676,15078,A,,,50597,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622881,BAO_0000218,
9677,15078,A,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622882,BAO_0000218,
9678,15078,A,,,50597,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622883,BAO_0000218,
9679,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622884,BAO_0000218,
9680,11450,A,,2046.0,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622885,BAO_0000218,
9681,8151,A,,,50597,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622886,BAO_0000218,
9682,8151,A,,,50597,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622887,BAO_0000218,
9683,8151,A,,1088.0,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622888,BAO_0000218,
9684,8677,A,,178.0,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622889,BAO_0000218,
9685,8677,A,,178.0,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622890,BAO_0000218,
9686,8677,A,,178.0,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622891,BAO_0000218,
9687,8677,A,,178.0,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877603,BAO_0000218,
9688,8677,A,,955.0,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622892,BAO_0000218,
9689,8677,A,,955.0,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622893,BAO_0000218,
9690,8677,A,,955.0,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622894,BAO_0000218,
9691,8677,A,,955.0,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622895,BAO_0000218,
9692,8677,A,,955.0,50597,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622896,BAO_0000218,
9693,8677,A,,948.0,50597,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622897,BAO_0000218,
9694,8677,A,,948.0,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622898,BAO_0000218,
9695,8677,A,,948.0,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622899,BAO_0000218,
9696,8677,A,,2113.0,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622900,BAO_0000218,
9697,8677,A,,2113.0,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624114,BAO_0000218,
9698,8677,A,,2113.0,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624115,BAO_0000218,
9699,8677,A,,2113.0,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624116,BAO_0000218,
9700,8677,A,,2107.0,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624117,BAO_0000218,
9701,8677,A,,2107.0,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624118,BAO_0000218,
9702,8677,A,,2107.0,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624119,BAO_0000218,
9703,8677,A,,2107.0,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624120,BAO_0000218,
9704,8677,A,,2048.0,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624121,BAO_0000218,
9705,8677,A,,2048.0,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624122,BAO_0000218,
9706,8677,A,,2048.0,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624123,BAO_0000218,
9707,8677,A,,2048.0,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624124,BAO_0000218,
9708,8677,A,,2385.0,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624125,BAO_0000218,
9709,8677,A,,2385.0,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624126,BAO_0000218,
9710,8677,A,,2385.0,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624127,BAO_0000218,
9711,8677,A,,2385.0,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624128,BAO_0000218,
9712,8677,A,,14.0,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624129,BAO_0000218,
9713,8677,A,,14.0,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624130,BAO_0000218,
9714,8677,A,,14.0,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622340,BAO_0000218,
9715,8677,A,,14.0,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622341,BAO_0000218,
9716,8677,A,,160.0,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622342,BAO_0000218,
9717,8677,A,,160.0,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622343,BAO_0000218,
9718,8677,A,,160.0,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622344,BAO_0000218,
9719,8677,A,,160.0,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622345,BAO_0000218,
9720,8677,A,,2106.0,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622346,BAO_0000218,
9721,8677,A,,2106.0,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622347,BAO_0000218,
9722,8677,A,,2106.0,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622348,BAO_0000218,
9723,8677,A,,2106.0,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622349,BAO_0000218,
9724,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622350,BAO_0000218,
9725,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622351,BAO_0000218,
9726,16434,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622352,BAO_0000218,
9727,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622353,BAO_0000218,
9728,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622354,BAO_0000218,
9729,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622355,BAO_0000218,
9730,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622356,BAO_0000218,
9731,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622357,BAO_0000218,
9732,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622358,BAO_0000218,
9733,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622359,BAO_0000218,
9734,16435,A,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874393,BAO_0000218,
9735,16434,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622872,BAO_0000218,
9736,16434,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622873,BAO_0000218,
9737,16434,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623047,BAO_0000218,
9738,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623048,BAO_0000218,
9739,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623049,BAO_0000218,
9740,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623050,BAO_0000218,
9741,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623051,BAO_0000218,
9742,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623052,BAO_0000218,
9743,16435,A,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626343,BAO_0000218,
9744,16434,A,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626344,BAO_0000218,
9745,16434,A,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626345,BAO_0000218,
9746,16434,A,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626346,BAO_0000218,
9747,16434,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626347,BAO_0000218,
9748,16434,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626348,BAO_0000218,
9749,16434,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626349,BAO_0000218,
9750,16435,F,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626350,BAO_0000218,
9751,16435,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626351,BAO_0000218,
9752,16435,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627650,BAO_0000218,
9753,16435,F,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627651,BAO_0000218,
9754,16435,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627652,BAO_0000218,
9755,16435,A,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627653,BAO_0000218,
9756,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627654,BAO_0000218,
9757,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627835,BAO_0000218,
9758,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627836,BAO_0000218,
9759,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627837,BAO_0000218,
9760,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627838,BAO_0000218,
9761,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875338,BAO_0000218,
9762,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627839,BAO_0000218,
9763,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627840,BAO_0000218,
9764,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627841,BAO_0000218,
9765,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627842,BAO_0000218,
9766,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627843,BAO_0000218,
9767,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627844,BAO_0000218,
9768,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627845,BAO_0000218,
9769,5874,A,,,50597,Half life period in rat by iv administration at a dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627846,BAO_0000218,
9770,1515,A,,1969.0,50597,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627847,BAO_0000218,
9771,1515,A,,1969.0,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873821,BAO_0000218,
9772,1515,A,,1969.0,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626079,BAO_0000218,
9773,1515,A,,1969.0,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626080,BAO_0000218,
9774,5491,A,,1969.0,50597,Half life period was evaluated in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626081,BAO_0000218,
9775,5491,A,,1969.0,50597,Half life period was evaluated in rat plasma; Not tested,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875344,BAO_0000218,
9776,1918,A,,,50597,Half life period was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626082,BAO_0000218,
9777,1918,A,,,50597,"Half life period was evaluated in rats, iv",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626250,BAO_0000218,
9778,6113,A,,,50597,Half life period after intravenous administration at 5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626251,BAO_0000218,
9779,5546,A,,,50597,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626252,BAO_0000218,
9780,5553,A,,,50597,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626253,BAO_0000218,
9781,4188,A,,1969.0,50597,Half life stability of compound was evaluated in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626254,BAO_0000218,
9782,6215,A,,,50597,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626255,BAO_0000218,
9783,6141,A,,,50597,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626256,BAO_0000218,
9784,5182,A,,,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626257,BAO_0000218,
9785,5182,A,,,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626258,BAO_0000218,
9786,5710,A,,,50597,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626259,BAO_0000218,
9787,5789,A,,,50597,Half in rat i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626260,BAO_0000218,
9788,6011,A,,,50597,Half period in rat after intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875345,BAO_0000218,
9789,17594,A,,,50597,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626261,BAO_0000218,
9790,12357,A,,2107.0,50597,Half-life measured in in vitro Cathepsin B assay in rat liver,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626262,BAO_0000218,
9791,5210,A,,,50597,Half-life of compound was determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626263,BAO_0000218,
9792,17596,A,,,50597,Half-life at 10 mg/kg in rat upon intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625270,BAO_0000218,
9793,6672,A,,,50597,Half-life determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625271,BAO_0000218,
9794,6673,A,,,50597,Half-life determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625272,BAO_0000218,
9795,4910,A,,955.0,50597,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625273,BAO_0000218,
9796,3741,A,,1969.0,50597,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625274,BAO_0000218,
9797,17671,A,,,50597,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625275,BAO_0000218,
9798,4910,A,,1969.0,50597,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625276,BAO_0000218,
9799,17537,A,,1969.0,50597,Half-life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625277,BAO_0000218,
9800,4965,A,,1969.0,50597,Half-life in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625278,BAO_0000218,
9801,17537,A,,1969.0,50597,Half-life in rat plasma; Not tested,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625279,BAO_0000218,
9802,6124,A,,1977.0,50597,Half-life in rat serum,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625280,BAO_0000218,
9803,6124,A,,1977.0,50597,Half-life in rat serum; na is not available,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876797,BAO_0000218,
9804,6078,A,,,50597,Half-life was calculated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625281,BAO_0000218,
9805,17668,A,,1969.0,50597,Half-life was calculated in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873827,BAO_0000218,
9806,3185,A,,,50597,Half-life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625282,BAO_0000218,
9807,4883,A,,,50597,Half-life was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625283,BAO_0000218,
9808,2959,A,,,50597,Half-life after administration of 20 mg/Kg oral dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625284,BAO_0000218,
9809,4029,A,,,50597,Half-life after administration of 3.2 mg/kg intravenously in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625285,BAO_0000218,
9810,4029,A,,,50597,Half-life after intravenous administration in female rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625286,BAO_0000218,
9811,4029,A,,,50597,Half-life after intravenous administration in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625287,BAO_0000218,
9812,6180,A,,,50597,Half-life after intravenous dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625288,BAO_0000218,
9813,1557,A,,2107.0,50597,Half-life in a rat liver homogenate preparation,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625289,BAO_0000218,
9814,12500,A,,1969.0,50597,Half-life in plasma of rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625290,BAO_0000218,
9815,12500,A,,1969.0,50597,Half-life in plasma of rat at dose of 3-10 mgkg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876798,BAO_0000218,
9816,5064,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625291,BAO_0000218,
9817,5145,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625292,BAO_0000218,
9818,5147,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625293,BAO_0000218,
9819,5833,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622832,BAO_0000218,
9820,6596,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622833,BAO_0000218,
9821,17655,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622834,BAO_0000218,
9822,6495,A,,,50597,Half-life in rat after oral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622835,BAO_0000218,
9823,17538,A,,,50597,Half-life in rat after po administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622836,BAO_0000218,
9824,17538,A,,,50597,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622837,BAO_0000218,
9825,10,A,,,50597,Half-life in rat at 3 mg/kg dose administered intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622838,BAO_0000218,
9826,17669,A,,955.0,50597,Half-life in rat brain homogenate,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622839,BAO_0000218,
9827,17065,A,,1969.0,50597,Half-life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622840,BAO_0000218,
9828,4333,A,,,50597,Half-life in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622841,BAO_0000218,
9829,6827,A,,,50597,Half-life in Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622842,BAO_0000218,
9830,889,A,,1969.0,50597,Half-life in vitro in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622843,BAO_0000218,
9831,889,A,,1969.0,50597,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622844,BAO_0000218,
9832,3747,A,,,50597,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622845,BAO_0000218,
9833,15022,A,,,50597,The area under the curve of compound was measured at the dose of 100 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622846,BAO_0000218,
9834,15022,A,,,50597,The area under the curve of compound was measured at the dose of 300 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622847,BAO_0000218,
9835,15022,A,,,50597,The area under the curve of compound was measured at the dose of 30 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622848,BAO_0000218,
9836,3360,A,,,50597,Bioavailability as oral AUC in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622849,BAO_0000218,
9837,5334,A,,1969.0,50597,The plasma concentration versus time curve (AUC) was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622850,BAO_0000218,
9838,17411,A,,,50597,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876807,BAO_0000218,
9839,17411,A,,,50597,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622851,BAO_0000218,
9840,17411,A,,,50597,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622852,BAO_0000218,
9841,6570,A,,,50597,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622853,BAO_0000218,
9842,6570,A,,,50597,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622854,BAO_0000218,
9843,17411,A,,,50597,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622855,BAO_0000218,
9844,14941,A,,1969.0,50597,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622856,BAO_0000218,
9845,14941,A,,1969.0,50597,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622857,BAO_0000218,
9846,17538,A,,1969.0,50597,AUC in rat after po administration at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622858,BAO_0000218,
9847,17752,A,,1969.0,50597,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622859,BAO_0000218,
9848,17509,A,,,50597,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622860,BAO_0000218,
9849,17509,A,,,50597,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622861,BAO_0000218,
9850,17509,A,,,50597,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622862,BAO_0000218,
9851,17509,A,,,50597,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622863,BAO_0000218,
9852,17509,A,,,50597,Area under curve value 6 hr after po administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623817,BAO_0000218,
9853,17717,A,,,50597,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623818,BAO_0000218,
9854,17717,A,,,50597,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623819,BAO_0000218,
9855,17717,A,,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623820,BAO_0000218,
9856,17717,A,,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623821,BAO_0000218,
9857,6642,A,,1969.0,50597,AUC normalized for dose (AUCN) in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623822,BAO_0000218,
9858,6640,A,,,50597,Area under curve in rat after p.o. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623823,BAO_0000218,
9859,6641,A,,,50597,Area under curve in rat after p.o. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623824,BAO_0000218,
9860,6641,A,,,50597,Area under curve in rat after p.o. administration; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623825,BAO_0000218,
9861,6641,A,,,50597,Area under curve in rat after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622070,BAO_0000218,
9862,3603,A,,,50597,Area under curve (carotid artery) value of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622071,BAO_0000218,
9863,3550,A,,,50597,Bioavailability expressed as the area under curve of rat carotid artery,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622072,BAO_0000218,
9864,15662,A,,,50597,Area under curve in male SD rats was observed after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622073,BAO_0000218,
9865,17720,A,,,50597,Area under curve of the compound was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622074,BAO_0000218,
9866,5407,A,,,50597,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622075,BAO_0000218,
9867,17752,A,,1969.0,50597,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622076,BAO_0000218,
9868,17752,A,,1969.0,50597,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622077,BAO_0000218,
9869,3603,A,,,50597,Area under curve (portal vein) value of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622078,BAO_0000218,
9870,3550,A,,,50597,Bioavailability expressed as the area under curve of rat portal vein,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622079,BAO_0000218,
9871,17655,A,,1969.0,50597,Area Under plasma concentration time curve in rat upon peroral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622080,BAO_0000218,
9872,17582,A,,,50597,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877612,BAO_0000218,
9873,17582,A,,,50597,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622081,BAO_0000218,
9874,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622082,BAO_0000218,
9875,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622083,BAO_0000218,
9876,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats; 30-80,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622084,BAO_0000218,
9877,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats; 50-60,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622085,BAO_0000218,
9878,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622086,BAO_0000218,
9879,17791,A,,,50597,Compound was evaluated for oral bioavailability in rats; peptide,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622087,BAO_0000218,
9880,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622088,BAO_0000218,
9881,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622089,BAO_0000218,
9882,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623685,BAO_0000218,
9883,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623686,BAO_0000218,
9884,8677,A,,945.0,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623687,BAO_0000218,
9885,8677,A,,945.0,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623688,BAO_0000218,
9886,8677,A,,945.0,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623689,BAO_0000218,
9887,8677,A,,945.0,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622485,BAO_0000218,
9888,8677,A,,2046.0,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622486,BAO_0000218,
9889,8677,A,,2046.0,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877613,BAO_0000218,
9890,8677,A,,2046.0,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622487,BAO_0000218,
9891,8677,A,,2046.0,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622488,BAO_0000218,
9892,8677,A,,948.0,50597,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622489,BAO_0000218,
9893,6899,A,,1088.0,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622490,BAO_0000218,
9894,6899,A,,1088.0,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622491,BAO_0000218,
9895,6899,A,,2107.0,50597,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622492,BAO_0000218,
9896,6899,A,,1088.0,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622493,BAO_0000218,
9897,6899,A,,1088.0,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622494,BAO_0000218,
9898,8677,A,,2385.0,50597,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622495,BAO_0000218,
9899,6899,A,,,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622496,BAO_0000218,
9900,6899,A,,1088.0,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622497,BAO_0000218,
9901,2189,A,,,50597,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622498,BAO_0000218,
9902,2189,A,,1088.0,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624918,BAO_0000218,
9903,2189,A,,1088.0,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624919,BAO_0000218,
9904,10839,A,,178.0,50597,Biodistribution of compound in rat blood after 5 min of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624920,BAO_0000218,
9905,10839,A,,178.0,50597,Biodistribution of compound in rat blood after 5 min of administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624921,BAO_0000218,
9906,10839,A,,955.0,50597,Biodistribution of compound in rat brain after 5 min of administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624922,BAO_0000218,
9907,10839,A,,948.0,50597,Biodistribution of compound in rat heart after 5 min of administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624923,BAO_0000218,
9908,10839,A,,948.0,50597,Biodistribution of compound in rat heart after 5 min of administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624924,BAO_0000218,
9909,10839,A,,2113.0,50597,Biodistribution of compound in rat kidney after 5 min of administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624925,BAO_0000218,
9910,10839,A,,2113.0,50597,Biodistribution of compound in rat kidney after 5 min of administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624926,BAO_0000218,
9911,10839,A,,2107.0,50597,Biodistribution of compound in rat liver after 5 min of administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624927,BAO_0000218,
9912,10839,A,,2107.0,50597,Biodistribution of compound in rat liver after 5 min of administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874402,BAO_0000218,
9913,10839,A,,2048.0,50597,Biodistribution of compound in rat lung after 5 min of administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624928,BAO_0000218,
9914,10839,A,,2048.0,50597,Biodistribution of compound in rat lung after 5 min of administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624929,BAO_0000218,
9915,10839,A,,2385.0,50597,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624930,BAO_0000218,
9916,10839,A,,2385.0,50597,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624931,BAO_0000218,
9917,4043,A,,948.0,50597,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624932,BAO_0000218,
9918,4043,A,,948.0,50597,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624933,BAO_0000218,
9919,4043,A,,2107.0,50597,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624934,BAO_0000218,
9920,4043,A,,2107.0,50597,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624935,BAO_0000218,
9921,4043,A,,,50597,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624936,BAO_0000218,
9922,4043,A,,,50597,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624937,BAO_0000218,
9923,4043,A,,2106.0,50597,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624938,BAO_0000218,
9924,4043,A,,2106.0,50597,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624939,BAO_0000218,
9925,4043,A,,,50597,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624940,BAO_0000218,
9926,4043,A,,,50597,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874403,BAO_0000218,
9927,1446,A,,,50597,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624941,BAO_0000218,
9928,9971,A,,1088.0,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624942,BAO_0000218,
9929,9971,A,,1088.0,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624943,BAO_0000218,
9930,5765,A,,,50597,% Bioavailability after 1 day of the drug administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624944,BAO_0000218,
9931,5765,A,,,50597,% Bioavailability after 4 day of the drug administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624945,BAO_0000218,
9932,4257,A,,,50597,Absolute bioavailability was evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624946,BAO_0000218,
9933,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624947,BAO_0000218,
9934,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624948,BAO_0000218,
9935,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624949,BAO_0000218,
9936,13091,A,,2113.0,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622025,BAO_0000218,
9937,13091,A,,2113.0,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622026,BAO_0000218,
9938,13091,A,,2113.0,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622027,BAO_0000218,
9939,13091,A,,2113.0,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622028,BAO_0000218,
9940,13091,A,,2107.0,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622029,BAO_0000218,
9941,13091,A,,2107.0,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622208,BAO_0000218,
9942,13091,A,,2107.0,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622209,BAO_0000218,
9943,13091,A,,2107.0,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622210,BAO_0000218,
9944,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622211,BAO_0000218,
9945,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622212,BAO_0000218,
9946,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622213,BAO_0000218,
9947,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874404,BAO_0000218,
9948,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620452,BAO_0000218,
9949,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620453,BAO_0000218,
9950,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620454,BAO_0000218,
9951,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624067,BAO_0000218,
9952,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624068,BAO_0000218,
9953,13091,A,,992.0,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624069,BAO_0000218,
9954,13091,A,,992.0,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624070,BAO_0000218,
9955,13091,A,,992.0,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624071,BAO_0000218,
9956,13091,A,,995.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624072,BAO_0000218,
9957,13091,A,,995.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624073,BAO_0000218,
9958,13091,A,,995.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624788,BAO_0000218,
9959,13091,A,,995.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624789,BAO_0000218,
9960,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624790,BAO_0000218,
9961,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624791,BAO_0000218,
9962,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624792,BAO_0000218,
9963,13091,A,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624793,BAO_0000218,
9964,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877491,BAO_0000218,
9965,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624957,BAO_0000218,
9966,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624958,BAO_0000218,
9967,13091,A,,2385.0,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624959,BAO_0000218,
9968,11977,A,,,50597,Dissociation constant was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624960,BAO_0000218,
9969,14941,A,,,50597,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624961,BAO_0000218,
9970,15078,A,,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624962,BAO_0000218,
9971,15078,A,,,50597,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624963,BAO_0000218,
9972,4755,A,,,50597,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624964,BAO_0000218,
9973,589,A,,,50597,LogP value was evaluated in the in situ rat gut perfusion assay,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624965,BAO_0000218,
9974,17582,A,,,50597,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624966,BAO_0000218,
9975,5031,A,,,50597,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624967,BAO_0000218,
9976,17764,A,,,50597,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624968,BAO_0000218,
9977,17720,A,,,50597,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624969,BAO_0000218,
9978,2862,F,,,50597,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL624970,BAO_0000218,
9979,16423,A,,,50597,Half-life was evaluated after 10 uM/kg of intra arterial administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624971,BAO_0000218,
9980,16423,A,,,50597,Half-life was evaluated after 20 uM/kg of peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624972,BAO_0000218,
9981,6005,A,,,50597,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624973,BAO_0000218,
9982,2938,A,,1969.0,50597,Half-life was evaluated in plasma of rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624974,BAO_0000218,
9983,6410,A,,,50597,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624975,BAO_0000218,
9984,6410,A,,,50597,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877492,BAO_0000218,
9985,6062,A,,,50597,Half-life was measured in rat after an iv dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624976,BAO_0000218,
9986,6571,A,,,50597,Half-life period of compound in rats after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624977,BAO_0000218,
9987,3136,A,,1969.0,50597,Half-life period of compound was measured in rat plasma.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626848,BAO_0000218,
9988,3136,A,,1969.0,50597,Half-life period of compound was measured in rat plasma; ND is not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626849,BAO_0000218,
9989,3136,A,,1969.0,50597,Half-life period of compound was measured in rat plasma; not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626850,BAO_0000218,
9990,4521,A,,,50597,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626851,BAO_0000218,
9991,5871,A,,,50597,Half-life period in rat by iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626852,BAO_0000218,
9992,6077,A,,,50597,Half-life period in rats following intravenous administration at 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626853,BAO_0000218,
9993,6679,A,,,50597,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626854,BAO_0000218,
9994,5144,A,,,50597,Half-life period was determined for the compound in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627486,BAO_0000218,
9995,4498,A,,,50597,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627487,BAO_0000218,
9996,4498,A,,,50597,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627488,BAO_0000218,
9997,1908,A,,,50597,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627489,BAO_0000218,
9998,6211,A,,,50597,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627490,BAO_0000218,
9999,5529,A,,,50597,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873829,BAO_0000218,
10000,6444,A,,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627655,BAO_0000218,
10001,6444,A,,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625994,BAO_0000218,
10002,6444,A,,,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625995,BAO_0000218,
10003,5207,A,,,50597,Half-life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625996,BAO_0000218,
10004,530,A,,1969.0,50597,In vitro half life in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625850,BAO_0000218,
10005,1116,A,,1969.0,50597,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625851,BAO_0000218,
10006,3219,A,,,50597,In vitro half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625852,BAO_0000218,
10007,6109,A,,,50597,In vivo half life period after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625853,BAO_0000218,
10008,17582,A,,,50597,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625854,BAO_0000218,
10009,17582,A,,,50597,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874450,BAO_0000218,
10010,5974,A,,,50597,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625855,BAO_0000218,
10011,5974,A,,,50597,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625856,BAO_0000218,
10012,5974,A,,,50597,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625857,BAO_0000218,
10013,5974,A,,,50597,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873831,BAO_0000218,
10014,17853,A,,,50597,Longer half-life in rat (i.v.) at 0.5 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625858,BAO_0000218,
10015,17853,A,,,50597,Longer half-life in rat (p.o.) at 2.0 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625859,BAO_0000218,
10016,3457,A,,,50597,Pharmacokinetic property (half life) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625860,BAO_0000218,
10017,2792,A,,,50597,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625861,BAO_0000218,
10018,2792,A,,,50597,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625862,BAO_0000218,
10019,2792,A,,,50597,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625863,BAO_0000218,
10020,2792,A,,,50597,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625864,BAO_0000218,
10021,5739,A,,,50597,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625865,BAO_0000218,
10022,15765,A,,,50597,Pharmacokinetic half time was determined intravenously in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625866,BAO_0000218,
10023,6567,A,,1969.0,50597,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625867,BAO_0000218,
10024,2448,A,,1969.0,50597,Plasma half life of hydrolysis of the compound,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625868,BAO_0000218,
10025,5423,A,,1969.0,50597,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625869,BAO_0000218,
10026,4853,A,,1969.0,50597,Plasma half life period was calculated in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874451,BAO_0000218,
10027,4514,A,,1969.0,50597,Plasma half-life in Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625870,BAO_0000218,
10028,4514,A,,1969.0,50597,Plasma half-life in Sprague-Dawley rats; Not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625871,BAO_0000218,
10029,1500,A,,1969.0,50597,Plasma half-life in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625872,BAO_0000218,
10030,1500,A,,1969.0,50597,Plasma half-life in rats; <MQL,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625873,BAO_0000218,
10031,5334,A,,1969.0,50597,Plasma half-life period (0-8 h) was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625874,BAO_0000218,
10032,5334,A,,1969.0,50597,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625875,BAO_0000218,
10033,5334,A,,1969.0,50597,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625876,BAO_0000218,
10034,5334,A,,1969.0,50597,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631258,BAO_0000218,
10035,4956,A,,1969.0,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631259,BAO_0000218,
10036,4956,A,,1969.0,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631260,BAO_0000218,
10037,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631261,BAO_0000218,
10038,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631262,BAO_0000218,
10039,7768,A,,178.0,50597,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631263,BAO_0000218,
10040,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631264,BAO_0000218,
10041,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631265,BAO_0000218,
10042,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631266,BAO_0000218,
10043,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631267,BAO_0000218,
10044,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631268,BAO_0000218,
10045,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631269,BAO_0000218,
10046,7768,A,,,50597,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631270,BAO_0000218,
10047,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631271,BAO_0000218,
10048,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631272,BAO_0000218,
10049,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631273,BAO_0000218,
10050,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631274,BAO_0000218,
10051,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631275,BAO_0000218,
10052,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626984,BAO_0000218,
10053,7768,A,,948.0,50597,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626985,BAO_0000218,
10054,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626986,BAO_0000218,
10055,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626987,BAO_0000218,
10056,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626988,BAO_0000218,
10057,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626989,BAO_0000218,
10058,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626990,BAO_0000218,
10059,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626991,BAO_0000218,
10060,7768,A,,2107.0,50597,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626992,BAO_0000218,
10061,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626993,BAO_0000218,
10062,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874593,BAO_0000218,
10063,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626994,BAO_0000218,
10064,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626995,BAO_0000218,
10065,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626190,BAO_0000218,
10066,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626191,BAO_0000218,
10067,7768,A,,2048.0,50597,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626364,BAO_0000218,
10068,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626365,BAO_0000218,
10069,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626366,BAO_0000218,
10070,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626367,BAO_0000218,
10071,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626368,BAO_0000218,
10072,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626369,BAO_0000218,
10073,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626370,BAO_0000218,
10074,4498,A,,,50597,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626371,BAO_0000218,
10075,4498,A,,,50597,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626372,BAO_0000218,
10076,3603,A,,,50597,Bioavailability after a dose of 10 mg/kg p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626373,BAO_0000218,
10077,6215,A,,,50597,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626374,BAO_0000218,
10078,5710,A,,,50597,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626375,BAO_0000218,
10079,5710,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626376,BAO_0000218,
10080,5676,A,,,50597,Bioavailability in rat po was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626377,BAO_0000218,
10081,17667,A,,,50597,Bioavailability of compound at 10 mg/kg in rat after oral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626378,BAO_0000218,
10082,17667,A,,,50597,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626379,BAO_0000218,
10083,6848,A,,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626380,BAO_0000218,
10084,6848,A,,,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626381,BAO_0000218,
10085,17267,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626382,BAO_0000218,
10086,6362,A,,,50597,Bioavailability in rat (Sprague-Dawley) (female),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626383,BAO_0000218,
10087,17671,A,,,50597,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874652,BAO_0000218,
10088,17671,A,,,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626384,BAO_0000218,
10089,4333,A,,,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626385,BAO_0000218,
10090,6077,A,,,50597,Bioavailability in rat at an oral dose of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626386,BAO_0000218,
10091,3278,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626387,BAO_0000218,
10092,5964,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626388,BAO_0000218,
10093,4884,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626389,BAO_0000218,
10094,4905,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626390,BAO_0000218,
10095,4884,A,,,50597,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626391,BAO_0000218,
10096,6850,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626392,BAO_0000218,
10097,2864,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626393,BAO_0000218,
10098,5780,A,,,50597,Bioavailability was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623026,BAO_0000218,
10099,1465,A,,,50597,Bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623027,BAO_0000218,
10100,5199,A,,,50597,Bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623028,BAO_0000218,
10101,5765,A,,,50597,Bioavailability in rat after 1 day dosing,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623029,BAO_0000218,
10102,5765,A,,,50597,Bioavailability in rat after 4 day dosing,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623030,BAO_0000218,
10103,6518,A,,,50597,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623031,BAO_0000218,
10104,6518,A,,,50597,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623032,BAO_0000218,
10105,6518,A,,,50597,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623033,BAO_0000218,
10106,6518,A,,,50597,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623034,BAO_0000218,
10107,2083,A,,,50597,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623035,BAO_0000218,
10108,17260,A,,,50597,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623036,BAO_0000218,
10109,4956,A,,,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623037,BAO_0000218,
10110,4368,A,,,50597,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623038,BAO_0000218,
10111,17752,A,,1969.0,50597,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874385,BAO_0000218,
10112,1446,A,,,50597,Bioavailability in rat (Fisher) (fasted),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623039,BAO_0000218,
10113,2891,A,,,22224,Bioavailability in monkey after po administration of 10 mg/kg dose,,0,,Primates,1,9443.0,U,Intermediate,,,CHEMBL623040,BAO_0000218,
10114,2891,A,,,22224,Oral bioavailability in monkey (dose 10 mg/kg),,0,,Primates,1,9443.0,U,Intermediate,,,CHEMBL623041,BAO_0000218,
10115,6672,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623741,BAO_0000218,
10116,6673,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623742,BAO_0000218,
10117,17655,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623743,BAO_0000218,
10118,17796,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623744,BAO_0000218,
10119,17853,A,,,50597,Bioavailability in rat (dose 2.0 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623745,BAO_0000218,
10120,4521,A,,,50597,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623746,BAO_0000218,
10121,4940,A,,,50597,Oral bioavailability in rat (dose 5 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623747,BAO_0000218,
10122,2891,A,,,22224,Bioavailability in rat after po administration of 30 mg/kg dose,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL623748,BAO_0000218,
10123,2891,A,,,22224,Bioavailability in rat after po administration of 30 mg/kg dose,,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL623916,BAO_0000218,
10124,4521,A,,,50597,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623917,BAO_0000218,
10125,17686,A,,,50597,Bioavailability in rat (dose 2 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623918,BAO_0000218,
10126,17796,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874386,BAO_0000218,
10127,17796,A,,1969.0,50597,Bioavailability in rat; Only traces detected in rat plasma,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623919,BAO_0000218,
10128,5064,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623920,BAO_0000218,
10129,5147,A,,,50597,Bioavailability upon oral administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623148,BAO_0000218,
10130,1916,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623149,BAO_0000218,
10131,6049,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623150,BAO_0000218,
10132,1445,A,,,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623151,BAO_0000218,
10133,1445,A,,,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623152,BAO_0000218,
10134,2862,F,,,50597,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL623153,BAO_0000218,
10135,2862,F,,,50597,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL623154,BAO_0000218,
10136,4194,A,,,50597,In vitro and metabolic stability was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623155,BAO_0000218,
10137,4194,A,,,50597,In vitro metabolic stability in rat hepatocytes,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623156,BAO_0000218,
10138,5486,A,,,50597,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623157,BAO_0000218,
10139,17582,A,Hepatocyte,2107.0,50597,Metabolic rate for compound was observed in rat hepatocytes,Liver,1,401.0,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623158,BAO_0000218,
10140,5600,A,,,50597,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623159,BAO_0000218,
10141,14294,A,,,50597,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874390,BAO_0000218,
10142,14294,A,,,50597,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623160,BAO_0000218,
10143,14294,A,,,50597,Metabolism of compound in rat S9 microsomes; Trace,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623161,BAO_0000218,
10144,17847,A,,,50597,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623162,BAO_0000218,
10145,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623163,BAO_0000218,
10146,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623164,BAO_0000218,
10147,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623165,BAO_0000218,
10148,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623166,BAO_0000218,
10149,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624983,BAO_0000218,
10150,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624984,BAO_0000218,
10151,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624985,BAO_0000218,
10152,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622970,BAO_0000218,
10153,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622971,BAO_0000218,
10154,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622972,BAO_0000218,
10155,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622973,BAO_0000218,
10156,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622974,BAO_0000218,
10157,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622975,BAO_0000218,
10158,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622976,BAO_0000218,
10159,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622977,BAO_0000218,
10160,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624351,BAO_0000218,
10161,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624352,BAO_0000218,
10162,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624353,BAO_0000218,
10163,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622397,BAO_0000218,
10164,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622398,BAO_0000218,
10165,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622399,BAO_0000218,
10166,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622400,BAO_0000218,
10167,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628428,BAO_0000218,
10168,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628590,BAO_0000218,
10169,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628591,BAO_0000218,
10170,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628592,BAO_0000218,
10171,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628593,BAO_0000218,
10172,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875333,BAO_0000218,
10173,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628594,BAO_0000218,
10174,4969,A,,1969.0,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628595,BAO_0000218,
10175,6737,A,,1969.0,50597,Stability in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628596,BAO_0000218,
10176,6737,A,,1969.0,50597,Stability in rat plasma was determined; ND= no data,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628597,BAO_0000218,
10177,5089,A,,1969.0,50597,Tested for plasma half life period in rat (0-8 hr),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628598,BAO_0000218,
10178,5089,A,,1969.0,50597,Tested for plasma half life period in rat (0-8 hr); Not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628599,BAO_0000218,
10179,1466,A,,,50597,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628600,BAO_0000218,
10180,1466,A,,,50597,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628601,BAO_0000218,
10181,4950,A,,,50597,Tested for the half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628602,BAO_0000218,
10182,2412,A,,,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628603,BAO_0000218,
10183,2412,A,,,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628604,BAO_0000218,
10184,2412,A,,,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628605,BAO_0000218,
10185,2412,A,,,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628606,BAO_0000218,
10186,2412,A,,,50597,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628607,BAO_0000218,
10187,15022,A,,,50597,The biological half life the compound was measured at the dose of 100 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628608,BAO_0000218,
10188,15022,A,,,50597,The biological half life the compound was measured at the dose of 30 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628609,BAO_0000218,
10189,406,A,,1969.0,50597,The compound was evaluated for plasma half life period in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628610,BAO_0000218,
10190,15078,A,,,50597,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL873819,BAO_0000218,
10191,15078,A,,,50597,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628611,BAO_0000218,
10192,5247,A,,,50597,The pharmacokinetic parameter half-life period in vivo in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628612,BAO_0000218,
10193,5041,A,,,50597,"The pharmacokinetic property, Half-life was determined",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628613,BAO_0000218,
10194,5041,A,,,50597,"The pharmacokinetic property, Half-life in rat in vivo",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628614,BAO_0000218,
10195,5041,A,,,50597,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628615,BAO_0000218,
10196,5041,A,,,50597,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628616,BAO_0000218,
10197,3918,A,,1969.0,50597,The plasma half life period in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627924,BAO_0000218,
10198,2906,A,,2107.0,50597,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627925,BAO_0000218,
10199,6467,A,,,50597,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627926,BAO_0000218,
10200,5510,A,,,50597,t1/2 (apparent elimination)of the compound was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627927,BAO_0000218,
10201,3788,A,,,50597,t1/2 value in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627928,BAO_0000218,
10202,17796,A,,,50597,Half life in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627539,BAO_0000218,
10203,12873,A,,1969.0,50597,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876790,BAO_0000218,
10204,5983,A,,,50597,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL858186,BAO_0000218,
10205,15765,A,,,50597,Half-life period in fasted rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627540,BAO_0000218,
10206,2661,A,,,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627541,BAO_0000218,
10207,2661,A,,,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627715,BAO_0000218,
10208,429,A,,,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627716,BAO_0000218,
10209,17655,A,,,50597,Maximum time required to achieve Cmax was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627717,BAO_0000218,
10210,17717,A,,,50597,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627718,BAO_0000218,
10211,17717,A,,,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627719,BAO_0000218,
10212,17717,A,,,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627720,BAO_0000218,
10213,6570,A,,,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627721,BAO_0000218,
10214,6570,A,,,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627722,BAO_0000218,
10215,5978,A,,,50597,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627723,BAO_0000218,
10216,5978,A,,,50597,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626058,BAO_0000218,
10217,5978,A,,,50597,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626059,BAO_0000218,
10218,5978,A,,,50597,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626060,BAO_0000218,
10219,17720,A,,1969.0,50597,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626061,BAO_0000218,
10220,4723,A,,,50597,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876791,BAO_0000218,
10221,4723,A,,,50597,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626062,BAO_0000218,
10222,4756,A,,,50597,Tmax at the dose of 2 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626063,BAO_0000218,
10223,4756,A,,,50597,Tmax at the dose of 5 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626064,BAO_0000218,
10224,17720,A,,1969.0,50597,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626065,BAO_0000218,
10225,17720,A,,1969.0,50597,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626066,BAO_0000218,
10226,1466,A,,,50597,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626067,BAO_0000218,
10227,7449,F,,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626068,BAO_0000218,
10228,7449,F,,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626069,BAO_0000218,
10229,7449,F,,,50597,Percent total excretion of 3-methoxyacetaminophen glucuronide,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626070,BAO_0000218,
10230,7449,F,,,50597,Percent total excretion of N-methoxyacetaminophen glucuronide,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626071,BAO_0000218,
10231,7449,F,,,50597,Percent total excretion of N-methoxyacetaminophen sulfate,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626072,BAO_0000218,
10232,7449,F,,,50597,Percent total excretion of acetaminophen,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626073,BAO_0000218,
10233,7768,A,,2046.0,50597,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626741,BAO_0000218,
10234,17655,A,,,50597,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626742,BAO_0000218,
10235,17735,A,,,50597,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626743,BAO_0000218,
10236,5960,A,,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876792,BAO_0000218,
10237,17735,A,,,50597,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626744,BAO_0000218,
10238,7116,A,,,50597,Compound was tested for antidiuretic activity in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626745,BAO_0000218,
10239,4878,A,,1969.0,50597,AUC in rat after 3mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626746,BAO_0000218,
10240,5939,A,,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626747,BAO_0000218,
10241,5939,A,,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626748,BAO_0000218,
10242,16367,A,,,50597,Bioavailability administered orally at a dose of 10 mg/kg to rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626749,BAO_0000218,
10243,16366,A,,,50597,Oral Bioavailability was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626750,BAO_0000218,
10244,4426,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626751,BAO_0000218,
10245,4426,A,,,50597,Oral bioavailability in rat; Not performed.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626913,BAO_0000218,
10246,5041,A,,,50597,Bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626914,BAO_0000218,
10247,5041,A,,,50597,Bioavailability was determined; ND denotes no data,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626915,BAO_0000218,
10248,1500,A,,,50597,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626916,BAO_0000218,
10249,1500,A,,,50597,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626917,BAO_0000218,
10250,17409,A,,,50597,Binding towards rat plasma protein at 10 uM,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626918,BAO_0000218,
10251,17409,A,,,50597,Binding towards rat plasma protein at 100 uM,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626919,BAO_0000218,
10252,2959,A,,,50597,Bioavailability in rat (dose 20 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626920,BAO_0000218,
10253,13501,A,,,50597,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621976,BAO_0000218,
10254,6567,A,,,50597,Bioavailability in rat after 5 mg/kg oral gavage,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877599,BAO_0000218,
10255,6571,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621977,BAO_0000218,
10256,6715,A,,,50597,Bioavailability in rat (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621978,BAO_0000218,
10257,6715,A,,,50597,Bioavailability in rat (dose 3 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621979,BAO_0000218,
10258,2932,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621980,BAO_0000218,
10259,4171,A,,,50597,Bioavailability of the compound in rats after administration of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621981,BAO_0000218,
10260,17509,A,,,50597,Bioavailability after administration of 10 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621982,BAO_0000218,
10261,17509,A,,,50597,Bioavailability after administration of 2 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL882953,BAO_0000218,
10262,4527,A,,,50597,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621983,BAO_0000218,
10263,4026,A,,,50597,Bioavailability in dogs was determined; high,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621984,BAO_0000218,
10264,6659,A,,,50597,Bioavailability in monkey after intravenous administration at 1 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621985,BAO_0000218,
10265,6659,A,,,50597,Bioavailability in monkey after peroral administration at 10 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621986,BAO_0000218,
10266,6659,A,,,50597,Bioavailability in rat after intravenous administration at 1 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621987,BAO_0000218,
10267,6659,F,,,50597,Bioavailability in rat after intravenous administration at 2 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877600,BAO_0000218,
10268,6659,A,,,50597,Bioavailability in rat after peroral administration at 30 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621988,BAO_0000218,
10269,6659,F,,,50597,Bioavailability in rat after peroral administration at at 100 mpk,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621989,BAO_0000218,
10270,6597,A,,,50597,Bioavailability in rats was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621990,BAO_0000218,
10271,1202,A,,,50597,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621991,BAO_0000218,
10272,1202,A,,,50597,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621992,BAO_0000218,
10273,1202,A,,,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621993,BAO_0000218,
10274,1202,A,,,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621994,BAO_0000218,
10275,5207,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621995,BAO_0000218,
10276,5970,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621996,BAO_0000218,
10277,17538,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621997,BAO_0000218,
10278,17538,A,,,50597,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621998,BAO_0000218,
10279,1466,A,,,50597,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621999,BAO_0000218,
10280,2879,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622000,BAO_0000218,
10281,2879,A,,,50597,Bioavailability was measured in rat after oral administration; 2-4,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622001,BAO_0000218,
10282,2879,A,,,50597,Bioavailability was measured in rat after oral administration; 3-7,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622002,BAO_0000218,
10283,3777,A,,,50597,Bioavailability in rat (intraduodenal administration),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622003,BAO_0000218,
10284,3777,A,,,50597,Bioavailability in rat (intraduodenal administration),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877601,BAO_0000218,
10285,3777,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624871,BAO_0000218,
10286,3777,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622004,BAO_0000218,
10287,5423,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL882954,BAO_0000218,
10288,16365,A,,,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622005,BAO_0000218,
10289,16365,A,,,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622006,BAO_0000218,
10290,4239,A,,,50597,Bioavailability was measured in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622007,BAO_0000218,
10291,5438,A,,,50597,Bioavailability was reported,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622008,BAO_0000218,
10292,5334,A,,,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622009,BAO_0000218,
10293,5334,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622010,BAO_0000218,
10294,4199,A,,,50597,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622011,BAO_0000218,
10295,4199,A,,,50597,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622012,BAO_0000218,
10296,4199,A,,,50597,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622013,BAO_0000218,
10297,4890,A,,,50597,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622014,BAO_0000218,
10298,2792,A,,,50597,Bioavailability was determined at 3 mg/kg po dose in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624749,BAO_0000218,
10299,5529,A,,,50597,Oral bioavailability in rat (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624750,BAO_0000218,
10300,6685,A,,,50597,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624751,BAO_0000218,
10301,6685,A,,,50597,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624752,BAO_0000218,
10302,6685,A,,,50597,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624753,BAO_0000218,
10303,6005,A,,,50597,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624754,BAO_0000218,
10304,6410,A,,,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624755,BAO_0000218,
10305,6410,A,,,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624756,BAO_0000218,
10306,6103,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624757,BAO_0000218,
10307,6410,A,,,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624758,BAO_0000218,
10308,6410,A,,,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622270,BAO_0000218,
10309,5353,A,,,50597,Bioavailability in rat (Sprague-Dawley),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622271,BAO_0000218,
10310,4727,A,,,50597,Bioavailability in rat at the dose of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622272,BAO_0000218,
10311,17804,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622273,BAO_0000218,
10312,5809,A,,,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622274,BAO_0000218,
10313,17804,A,,,50597,Bioavailability value of compound in rats was determined after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622275,BAO_0000218,
10314,3634,A,,,50597,Oral bioavailability in rat (dose 20 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622276,BAO_0000218,
10315,3341,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622277,BAO_0000218,
10316,2690,A,,,50597,Oral bioavailability in rat (dose 5 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622278,BAO_0000218,
10317,3184,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622279,BAO_0000218,
10318,740,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622280,BAO_0000218,
10319,1806,A,,,50597,Compound was evaluated for oral bioavailability in rats; 15-27 %,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624083,BAO_0000218,
10320,4891,A,,,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624084,BAO_0000218,
10321,3634,A,,,50597,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624085,BAO_0000218,
10322,64,A,,,50597,Compound was tested for bioavailability in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624086,BAO_0000218,
10323,4839,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624087,BAO_0000218,
10324,1094,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624088,BAO_0000218,
10325,5005,A,,,22224,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,0,,Macaca mulatta,1,9544.0,U,Intermediate,,,CHEMBL624089,BAO_0000218,
10326,5005,A,,,22224,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,0,,Rattus norvegicus,1,10116.0,U,Intermediate,,,CHEMBL624090,BAO_0000218,
10327,4687,A,,,50597,Evaluated for the bioavailability in rat (in vivo),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624091,BAO_0000218,
10328,17804,A,,,50597,F value of compound in rats was determined after peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624092,BAO_0000218,
10329,5974,A,,,50597,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624093,BAO_0000218,
10330,5974,A,,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624094,BAO_0000218,
10331,5974,A,,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624095,BAO_0000218,
10332,5974,A,,,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624096,BAO_0000218,
10333,1088,A,,,50597,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624097,BAO_0000218,
10334,1742,A,,,50597,Maximum fall in carotid flow in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624098,BAO_0000218,
10335,4689,A,,,50597,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874392,BAO_0000218,
10336,2463,A,,,50597,Oral bioavailability in rat (dose 5 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624099,BAO_0000218,
10337,5654,A,,,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624100,BAO_0000218,
10338,5654,A,,,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624101,BAO_0000218,
10339,6874,A,,,50597,Oral bioavailability in rat (male Wistar),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624102,BAO_0000218,
10340,5633,A,,,50597,Oral bioavailability after administration (30 mg/kg) in rat; good,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624103,BAO_0000218,
10341,5496,A,,,50597,Oral bioavailability at the dose of 2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624104,BAO_0000218,
10342,2358,A,,,50597,Oral bioavailability determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624105,BAO_0000218,
10343,16456,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624106,BAO_0000218,
10344,5302,A,,,50597,Oral bioavailability in rat (dose single 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624107,BAO_0000218,
10345,5302,A,,,50597,Oral bioavailability in rat (dose single 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623943,BAO_0000218,
10346,5302,A,,,50597,Oral bioavailability in rat (dose 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623944,BAO_0000218,
10347,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623945,BAO_0000218,
10348,11020,A,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623946,BAO_0000218,
10349,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623947,BAO_0000218,
10350,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623948,BAO_0000218,
10351,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623949,BAO_0000218,
10352,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623950,BAO_0000218,
10353,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874398,BAO_0000218,
10354,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623951,BAO_0000218,
10355,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623952,BAO_0000218,
10356,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623953,BAO_0000218,
10357,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623954,BAO_0000218,
10358,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623955,BAO_0000218,
10359,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623956,BAO_0000218,
10360,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627807,BAO_0000218,
10361,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627808,BAO_0000218,
10362,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627809,BAO_0000218,
10363,11020,A,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627810,BAO_0000218,
10364,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627811,BAO_0000218,
10365,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627812,BAO_0000218,
10366,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627813,BAO_0000218,
10367,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627814,BAO_0000218,
10368,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875336,BAO_0000218,
10369,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627815,BAO_0000218,
10370,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627816,BAO_0000218,
10371,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627817,BAO_0000218,
10372,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627818,BAO_0000218,
10373,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627819,BAO_0000218,
10374,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627820,BAO_0000218,
10375,11020,A,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627821,BAO_0000218,
10376,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628464,BAO_0000218,
10377,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626239,BAO_0000218,
10378,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626240,BAO_0000218,
10379,11020,A,,,50597,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626241,BAO_0000218,
10380,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626242,BAO_0000218,
10381,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626243,BAO_0000218,
10382,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626244,BAO_0000218,
10383,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626907,BAO_0000218,
10384,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626908,BAO_0000218,
10385,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626909,BAO_0000218,
10386,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626910,BAO_0000218,
10387,7449,F,,,50597,Percent total excretion of acetaminophen cysteine conjugate,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875342,BAO_0000218,
10388,7449,F,,,50597,Percent total excretion of acetaminophen glucuronide,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626911,BAO_0000218,
10389,7449,F,,,50597,Percent total excretion of acetaminophen sulfate,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626912,BAO_0000218,
10390,7449,F,,,50597,Percent total excretion of acetaminophen-mercapturic acid,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627065,BAO_0000218,
10391,3172,A,,1088.0,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627066,BAO_0000218,
10392,16456,A,,,50597,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627067,BAO_0000218,
10393,10839,A,,2385.0,22224,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,0,,ratrat,1,8656.0,U,Autocuration,,,CHEMBL627068,BAO_0000218,
10394,10839,A,,2385.0,22224,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,0,,ratrat,1,8656.0,U,Autocuration,,,CHEMBL627069,BAO_0000218,
10395,5334,A,,,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL627070,BAO_0000218,
10396,5334,A,,,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL627071,BAO_0000218,
10397,5334,A,,,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL627072,BAO_0000218,
10398,5334,A,,,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL627073,BAO_0000218,
10399,5334,A,,,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL625387,BAO_0000218,
10400,5334,A,,,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL625388,BAO_0000218,
10401,5334,A,,1969.0,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Plasma,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL625389,BAO_0000218,
10402,5334,A,,1969.0,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Plasma,0,,Ovis aries,1,9940.0,U,Autocuration,,,CHEMBL875343,BAO_0000218,
10403,1735,A,,,50497,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,1,,Serpentes,1,8570.0,N,Intermediate,,,CHEMBL876795,BAO_0000218,
10404,1469,A,,,50497,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,1,,Serpentes,1,8570.0,N,Intermediate,,,CHEMBL626552,BAO_0000218,
10405,1336,A,,,50497,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,1,,Serpentes,1,8570.0,N,Intermediate,,,CHEMBL626553,BAO_0000218,
10406,12403,A,,1969.0,22224,The human biological plasma half life of the compound,Plasma,0,,Homo sapiens,1,9606.0,U,Autocuration,,,CHEMBL626554,BAO_0000366,
10407,8151,A,,1088.0,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626555,BAO_0000218,
10408,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626556,BAO_0000218,
10409,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626557,BAO_0000218,
10410,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626558,BAO_0000218,
10411,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626559,BAO_0000218,
10412,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626560,BAO_0000218,
10413,8004,A,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876803,BAO_0000218,
10414,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627964,BAO_0000218,
10415,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627965,BAO_0000218,
10416,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627966,BAO_0000218,
10417,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627967,BAO_0000218,
10418,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627968,BAO_0000218,
10419,8004,A,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627969,BAO_0000218,
10420,8004,A,,,50597,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627970,BAO_0000218,
10421,8004,A,,178.0,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627971,BAO_0000218,
10422,8004,A,,178.0,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627972,BAO_0000218,
10423,15917,B,,,180,Dissociation constant against binding to human cyclophilin A,,9,,Homo sapiens,1,9606.0,D,Expert,,,CHEMBL856029,BAO_0000357,
10424,12396,B,,,11591,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,8,,Bos taurus,1,9913.0,H,Expert,,,CHEMBL627973,BAO_0000019,
10425,7065,A,,,22224,-Log C was determined by performing the electroshock minimum test,,0,,,1,,U,Autocuration,,,CHEMBL627974,BAO_0000019,
10426,7065,A,,,22224,-Log C was determined by performing the foot shock test,,0,,,1,,U,Autocuration,,,CHEMBL627975,BAO_0000019,
10427,7065,A,,,22224,-Log C was determined by performing the incl screen test,,0,,,1,,U,Autocuration,,,CHEMBL627976,BAO_0000019,
10428,7065,A,,,22224,-Log C was determined by performing the maximum electroshock test,,0,,,1,,U,Autocuration,,,CHEMBL627977,BAO_0000019,
10429,7065,A,,,22224,-Log C was determined by performing the pentylenetetrazole test,,0,,,1,,U,Autocuration,,,CHEMBL627978,BAO_0000019,
10430,12415,A,,,22224,Tested for experimental arotinoid inhibitory dose,,0,,,1,,U,Autocuration,,,CHEMBL627979,BAO_0000019,
10431,10256,A,,,22224,Negative log transformed activity,,0,,,1,,U,Autocuration,,,CHEMBL876804,BAO_0000019,
10432,7991,A,,,22224,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,0,,,1,,U,Autocuration,,,CHEMBL627980,BAO_0000019,
10433,14342,A,,,50512,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL627981,BAO_0000218,
10434,14342,A,,,50512,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL627982,BAO_0000218,
10435,14342,A,,,50512,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL627983,BAO_0000218,
10436,14342,A,,2116.0,50512,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Ileum,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL627984,BAO_0000218,
10437,6047,P,,,22229,Solubility in water was determined; values expressed as -log,,0,,,1,,U,Autocuration,,,CHEMBL627985,BAO_0000100,
10438,17269,A,,,22224,Ratio of Kcat to that of Km was determined,,0,,,1,,U,Autocuration,,,CHEMBL627986,BAO_0000019,
10439,10026,A,,,22224,Observed first order rate constant,,0,,,1,,U,Autocuration,,,CHEMBL627987,BAO_0000019,
10440,14583,A,,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,0,,,1,,U,Autocuration,,,CHEMBL627988,BAO_0000019,
10441,2661,A,,,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627989,BAO_0000218,
10442,2661,A,,,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627990,BAO_0000218,
10443,4029,A,,,50597,Oral Bioavailability after administration of 10 mg/kg in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876805,BAO_0000218,
10444,17735,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627991,BAO_0000218,
10445,4576,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627992,BAO_0000218,
10446,17582,A,,,50597,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627993,BAO_0000218,
10447,17651,A,,,50597,Oral bioavailability at 1 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622817,BAO_0000218,
10448,17651,A,,,50597,Oral bioavailability at 10 mg/kg was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622818,BAO_0000218,
10449,17670,A,,,50597,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622819,BAO_0000218,
10450,5045,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL872267,BAO_0000218,
10451,1696,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622820,BAO_0000218,
10452,17764,A,,,50597,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622821,BAO_0000218,
10453,6448,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622822,BAO_0000218,
10454,6596,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622823,BAO_0000218,
10455,17547,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622824,BAO_0000218,
10456,17771,A,,,50597,Oral bioavailability in rat at a dose of 3 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622825,BAO_0000218,
10457,6495,A,,,50597,Oral bioavailability in rat after oral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622901,BAO_0000218,
10458,4558,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622902,BAO_0000218,
10459,17596,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621844,BAO_0000218,
10460,6827,A,,,50597,Oral bioavailability in Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621845,BAO_0000218,
10461,4026,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621846,BAO_0000218,
10462,10,A,,,50597,Oral bioavailability in rat (dose 30 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621847,BAO_0000218,
10463,17717,A,,,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877609,BAO_0000218,
10464,17717,A,,,50597,Bioavailability in rat (dose 3 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621848,BAO_0000218,
10465,17717,A,,,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621849,BAO_0000218,
10466,17717,A,,,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622030,BAO_0000218,
10467,4796,A,,,50597,Percent oral bioavailability determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622031,BAO_0000218,
10468,4883,A,,,50597,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622032,BAO_0000218,
10469,2137,A,,,50597,The compound was evaluated for bioavailability in rats; 32-51,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622033,BAO_0000218,
10470,2959,A,,,50597,Bioavailability in rat (dose 20 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622034,BAO_0000218,
10471,1361,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622035,BAO_0000218,
10472,4727,A,,,50597,Bioavailability percent in rat at the dose of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL882966,BAO_0000218,
10473,16423,A,,,50597,Bioavailability was evaluated after 20 uM/kg of peroral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622036,BAO_0000218,
10474,5206,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622037,BAO_0000218,
10475,6448,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622038,BAO_0000218,
10476,17723,A,,,50597,Bioavailability in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622039,BAO_0000218,
10477,17738,A,,178.0,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622040,BAO_0000218,
10478,17738,A,,178.0,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622041,BAO_0000218,
10479,17738,A,,178.0,50597,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622042,BAO_0000218,
10480,17738,A,,178.0,50597,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622043,BAO_0000218,
10481,17738,A,,178.0,50597,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622044,BAO_0000218,
10482,17738,A,,10000001.0,50597,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622045,BAO_0000218,
10483,17738,A,,10000001.0,50597,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622046,BAO_0000218,
10484,17738,A,,10000001.0,50597,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622047,BAO_0000218,
10485,17738,A,,10000001.0,50597,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877610,BAO_0000218,
10486,17738,A,,955.0,50597,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622048,BAO_0000218,
10487,17738,A,,955.0,50597,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622049,BAO_0000218,
10488,17738,A,,955.0,50597,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622050,BAO_0000218,
10489,17738,A,,955.0,50597,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622051,BAO_0000218,
10490,17738,A,,,50597,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622052,BAO_0000218,
10491,17738,A,,,50597,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622053,BAO_0000218,
10492,17738,A,,,50597,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622054,BAO_0000218,
10493,17738,A,,,50597,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622055,BAO_0000218,
10494,5237,A,,,50597,Oral bioavailability in rats was determined; High,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622056,BAO_0000218,
10495,5503,A,,,50597,Oral bioavailability in the rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622057,BAO_0000218,
10496,15765,A,,,50597,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628008,BAO_0000218,
10497,15660,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622058,BAO_0000218,
10498,5978,A,,,50597,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622059,BAO_0000218,
10499,5978,A,,,50597,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622060,BAO_0000218,
10500,5978,A,,,50597,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622061,BAO_0000218,
10501,5978,A,,,50597,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622062,BAO_0000218,
10502,5656,A,,,50597,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622063,BAO_0000218,
10503,3598,A,,,50597,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL877611,BAO_0000218,
10504,4216,A,,,50597,Oral bioavailability of compound in Sprague Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622064,BAO_0000218,
10505,17839,A,,,50597,Oral bioavailability of compound in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622065,BAO_0000218,
10506,6570,A,,,50597,Oral bioavailability in rat (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622066,BAO_0000218,
10507,5334,A,,,50597,Oral bioavailability of compound in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622067,BAO_0000218,
10508,6886,A,,,50597,Oral bioavailability of compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622068,BAO_0000218,
10509,5210,A,,,50597,Oral bioavailability of compound was determined in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622069,BAO_0000218,
10510,4170,A,,,50597,Oral bioavailability at a dose of 30 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624796,BAO_0000218,
10511,6028,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624797,BAO_0000218,
10512,6028,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623053,BAO_0000218,
10513,6078,A,,,50597,Oral bioavailability evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623054,BAO_0000218,
10514,6168,A,,,50597,Oral bioavailability in fasted rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623055,BAO_0000218,
10515,6168,A,,,50597,Oral bioavailability in fed rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623056,BAO_0000218,
10516,5160,A,,,50597,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623057,BAO_0000218,
10517,6057,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623058,BAO_0000218,
10518,6535,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623059,BAO_0000218,
10519,6535,A,,,50597,Oral bioavailability in rat after administration of 10 mg/kg po,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623060,BAO_0000218,
10520,4194,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623061,BAO_0000218,
10521,6230,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623062,BAO_0000218,
10522,6619,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623063,BAO_0000218,
10523,17607,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623064,BAO_0000218,
10524,4942,A,,,50597,Oral bioavailability in ratrs,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623065,BAO_0000218,
10525,4942,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623066,BAO_0000218,
10526,6646,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623067,BAO_0000218,
10527,5237,A,,,50597,Oral bioavailability in rats was determined; High,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623068,BAO_0000218,
10528,6646,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623069,BAO_0000218,
10529,4449,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623070,BAO_0000218,
10530,6057,A,,,50597,Oral bioavailability was calculated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623071,BAO_0000218,
10531,2552,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623072,BAO_0000218,
10532,5496,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623073,BAO_0000218,
10533,6484,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623074,BAO_0000218,
10534,6485,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623075,BAO_0000218,
10535,6616,A,,,50597,Oral bioavailability after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623076,BAO_0000218,
10536,4969,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623077,BAO_0000218,
10537,5862,A,,,50597,Oral bioavailability in rat (Sprague-Dawley),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623078,BAO_0000218,
10538,4514,A,,,50597,Oral bioavailability in Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623079,BAO_0000218,
10539,4514,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623080,BAO_0000218,
10540,4514,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623081,BAO_0000218,
10541,5546,A,,,50597,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623082,BAO_0000218,
10542,6168,A,,,50597,Oral bioavailability in fasted rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874400,BAO_0000218,
10543,6168,A,,,50597,Oral bioavailability in fed rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623083,BAO_0000218,
10544,3624,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623084,BAO_0000218,
10545,5213,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623085,BAO_0000218,
10546,5496,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623086,BAO_0000218,
10547,5553,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623087,BAO_0000218,
10548,5833,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623088,BAO_0000218,
10549,5836,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623089,BAO_0000218,
10550,5865,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623090,BAO_0000218,
10551,5960,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623091,BAO_0000218,
10552,6249,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623092,BAO_0000218,
10553,6448,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623093,BAO_0000218,
10554,6453,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874401,BAO_0000218,
10555,6640,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623094,BAO_0000218,
10556,17607,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623095,BAO_0000218,
10557,5939,A,,,50597,Oral bioavailability in rat after peroral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623096,BAO_0000218,
10558,5939,A,,,50597,Oral bioavailability in rat after peroral administration at 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624913,BAO_0000218,
10559,6281,A,,,50597,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624914,BAO_0000218,
10560,5874,A,,,50597,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624915,BAO_0000218,
10561,5213,A,,,50597,Oral bioavailability in rat; Not measured,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624916,BAO_0000218,
10562,4964,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624917,BAO_0000218,
10563,11020,A,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625157,BAO_0000218,
10564,6251,A,,2107.0,50597,In vitro metabolic potential in rat liver microsomes,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625158,BAO_0000218,
10565,1568,A,,,50597,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625159,BAO_0000218,
10566,3032,A,,,50597,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625160,BAO_0000218,
10567,3748,A,,,50597,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625161,BAO_0000218,
10568,401,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625162,BAO_0000218,
10569,6512,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625163,BAO_0000218,
10570,17617,A,,,50597,Oral bioavailability in rats at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625164,BAO_0000218,
10571,6679,A,,,50597,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625165,BAO_0000218,
10572,6742,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625166,BAO_0000218,
10573,589,A,,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625167,BAO_0000218,
10574,589,A,,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625168,BAO_0000218,
10575,3185,A,,,50597,Plasma clearance of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625169,BAO_0000218,
10576,17596,A,,,50597,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626264,BAO_0000218,
10577,2713,A,,,50597,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626265,BAO_0000218,
10578,12500,A,,1969.0,50597,The compound was tested for plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626266,BAO_0000218,
10579,12500,A,,1969.0,50597,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626267,BAO_0000218,
10580,2713,A,,,50597,Plasma concentration upon oral administration of 1 mg/Kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626268,BAO_0000218,
10581,1446,A,,,50597,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626269,BAO_0000218,
10582,6227,A,,,50597,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626270,BAO_0000218,
10583,4709,A,,,50597,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626271,BAO_0000218,
10584,5510,A,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626272,BAO_0000218,
10585,5510,A,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626273,BAO_0000218,
10586,5510,A,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875346,BAO_0000218,
10587,5510,A,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626274,BAO_0000218,
10588,4514,A,,,50597,Compound was tested for protein binding in rat plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626275,BAO_0000218,
10589,2713,A,,,50597,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624646,BAO_0000218,
10590,2713,A,,,50597,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624647,BAO_0000218,
10591,5340,A,,2107.0,50597,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624648,BAO_0000218,
10592,12058,A,,,50597,Area under curve ratio was determined (po/iv) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624649,BAO_0000218,
10593,11195,A,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624650,BAO_0000218,
10594,11195,A,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624651,BAO_0000218,
10595,11195,A,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624652,BAO_0000218,
10596,6495,A,,,50597,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624653,BAO_0000218,
10597,6078,A,,,50597,Ratio of AUCbrain to AUCplasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624654,BAO_0000218,
10598,5656,A,,,50597,Ratio of brain to plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624655,BAO_0000218,
10599,4910,A,,,50597,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624656,BAO_0000218,
10600,4910,A,,,50597,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624657,BAO_0000218,
10601,4910,A,,,50597,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624658,BAO_0000218,
10602,10130,A,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624659,BAO_0000218,
10603,10130,A,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624660,BAO_0000218,
10604,10130,A,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624661,BAO_0000218,
10605,5213,A,,,50597,Steady state brain :blood ratio was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624662,BAO_0000218,
10606,4910,A,,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625199,BAO_0000218,
10607,4910,A,,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625200,BAO_0000218,
10608,4910,A,,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625201,BAO_0000218,
10609,4910,A,,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625202,BAO_0000218,
10610,2083,A,,,50597,Percentage recovery after 3h incubation with rat hapatocytes was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625203,BAO_0000218,
10611,2082,A,,,50597,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625204,BAO_0000218,
10612,2082,A,,,50597,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625205,BAO_0000218,
10613,6351,A,,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625206,BAO_0000218,
10614,14583,A,,,22224,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,0,,,1,,U,Autocuration,,,CHEMBL625207,BAO_0000019,
10615,14583,A,,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,0,,,1,,U,Autocuration,,,CHEMBL625208,BAO_0000019,
10616,4608,A,Caco-2,,50587,In vivo absorption in Caco-2 cell line monolayers was determined,,1,495.0,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625209,BAO_0000218,
10617,13668,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625210,BAO_0000100,
10618,5669,A,,,50597,Area under curve was determine after peroral administration at 10 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625211,BAO_0000218,
10619,5669,A,,,50797,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL625212,BAO_0000218,
10620,5669,A,,,50597,Area under curve was determine after peroral administration at 160 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625213,BAO_0000218,
10621,5669,A,,,50597,Area under curve was determine after peroral administration at 20 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625214,BAO_0000218,
10622,5669,A,,,50597,Area under curve was determine after peroral administration at 50 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874542,BAO_0000218,
10623,6472,P,,,22229,Calculated partition coefficient (clogP) (AlogP),,0,,,1,,U,Autocuration,,,CHEMBL625215,BAO_0000100,
10624,15106,A,,,22224,Activated partial thromboplastin time measured,,0,,,1,,U,Autocuration,,,CHEMBL625216,BAO_0000019,
10625,15207,P,,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,0,,,1,,U,Autocuration,,,CHEMBL625217,BAO_0000100,
10626,15207,P,,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,0,,,1,,U,Autocuration,,,CHEMBL625218,BAO_0000100,
10627,13941,A,,1969.0,50588,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622864,BAO_0000218,
10628,13941,A,,1969.0,50597,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622865,BAO_0000218,
10629,13941,A,,1969.0,50597,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622866,BAO_0000218,
10630,13941,A,,1969.0,50588,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622867,BAO_0000218,
10631,15240,A,,1969.0,50512,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Plasma,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL876808,BAO_0000218,
10632,10655,A,,955.0,22224,AUC in brain,Brain,0,,,1,,U,Autocuration,,,CHEMBL627725,BAO_0000019,
10633,10655,A,,1977.0,22224,AUC in serum,Serum,0,,,1,,U,Autocuration,,,CHEMBL627726,BAO_0000019,
10634,6504,A,,1969.0,22224,AUC was determined,Plasma,0,,,1,,U,Autocuration,,,CHEMBL627727,BAO_0000019,
10635,10615,A,,1969.0,22224,AUC of the compound.,Plasma,0,,,1,,U,Autocuration,,,CHEMBL627728,BAO_0000019,
10636,10353,A,,1969.0,22224,AUC value (0-4 hr),Plasma,0,,,1,,U,Autocuration,,,CHEMBL627729,BAO_0000019,
10637,14907,A,,1969.0,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Plasma,0,,,1,,U,Autocuration,,,CHEMBL627730,BAO_0000019,
10638,14907,A,,1969.0,22224,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Plasma,0,,,1,,U,Autocuration,,,CHEMBL627731,BAO_0000019,
10639,14907,A,,1969.0,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Plasma,0,,,1,,U,Autocuration,,,CHEMBL627732,BAO_0000019,
10640,14907,A,,1969.0,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Plasma,0,,,1,,U,Autocuration,,,CHEMBL627733,BAO_0000019,
10641,16359,A,,1969.0,50597,AUC(area under curve) was determined after intravenous administration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627734,BAO_0000218,
10642,16359,A,,1969.0,50597,AUC(area under curve) was determined after oral administration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627735,BAO_0000218,
10643,15240,A,,1969.0,50512,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Plasma,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL627736,BAO_0000218,
10644,15240,A,,1969.0,50597,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876809,BAO_0000218,
10645,15469,A,,,22224,Area Under Curve after oral dosing of 100 uM/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627737,BAO_0000019,
10646,15469,A,,,22224,Area Under Curve after oral dosing of 30 uM/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627738,BAO_0000019,
10647,13520,A,,,22224,Area Under Curve was measured by ploting the graph between concentration verses time,,0,,,1,,U,Autocuration,,,CHEMBL627739,BAO_0000019,
10648,17025,A,,,50588,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626143,BAO_0000218,
10649,17025,A,,,22224,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626144,BAO_0000218,
10650,17025,A,,,50592,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL626145,BAO_0000218,
10651,17025,A,,,50597,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626146,BAO_0000218,
10652,12032,A,,178.0,50597,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626147,BAO_0000218,
10653,10291,A,,,22224,Area under curve (AUC) was determined,,0,,,1,,U,Autocuration,,,CHEMBL626148,BAO_0000019,
10654,5767,A,,,22224,Area under curve (AUC) following ip administration at 1 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626149,BAO_0000218,
10655,1434,A,,,22224,Area under curve (AUC) was determined; ND is Not determined,,0,,,1,,U,Autocuration,,,CHEMBL626150,BAO_0000019,
10656,14925,A,,,50588,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626151,BAO_0000218,
10657,14925,A,,,50588,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626152,BAO_0000218,
10658,14925,A,,,50588,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626153,BAO_0000218,
10659,1434,A,,,22224,Area under curve (AUR) was determined,,0,,,1,,U,Autocuration,,,CHEMBL626154,BAO_0000019,
10660,11883,A,,,22224,Area under curve at 1 uM/dg administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626155,BAO_0000019,
10661,11883,A,,,22224,Area under curve at 10 uM/dg administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626156,BAO_0000019,
10662,11883,A,,,22224,Area under curve at 2 uM/dg administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626157,BAO_0000019,
10663,11883,A,,,22224,Area under curve at 20 uM/dg administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626158,BAO_0000019,
10664,15233,A,,,50588,Area under curve at a peroral dose of 3 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626159,BAO_0000218,
10665,15233,A,,,50597,Area under curve at a peroral dose of 3 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626160,BAO_0000218,
10666,15233,A,,,50588,Area under curve at an iv dose of 1 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626161,BAO_0000218,
10667,15233,A,,,50597,Area under curve at an iv dose of 1 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626162,BAO_0000218,
10668,12978,A,,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,0,,,1,,U,Autocuration,,,CHEMBL626163,BAO_0000019,
10669,12978,A,,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,0,,,1,,U,Autocuration,,,CHEMBL626164,BAO_0000019,
10670,11355,A,,,50594,Area under curve measured as conc vs time after intravenous administration to mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626165,BAO_0000218,
10671,11355,A,,,50594,Area under curve measured as conc vs time after peroral administration to mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626166,BAO_0000218,
10672,12923,A,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626167,BAO_0000218,
10673,12923,A,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626168,BAO_0000218,
10674,12923,A,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL877463,BAO_0000218,
10675,12923,A,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626169,BAO_0000218,
10676,17738,A,,948.0,50597,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626170,BAO_0000218,
10677,17738,A,,948.0,50597,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626171,BAO_0000218,
10678,17738,A,,948.0,50597,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626172,BAO_0000218,
10679,17738,A,,948.0,50597,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626173,BAO_0000218,
10680,17738,A,,2113.0,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626174,BAO_0000218,
10681,17738,A,,2113.0,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626175,BAO_0000218,
10682,17738,A,,2113.0,50597,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626176,BAO_0000218,
10683,17738,A,,2113.0,50597,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626177,BAO_0000218,
10684,17738,A,,2113.0,50597,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622499,BAO_0000218,
10685,17738,A,,2107.0,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622500,BAO_0000218,
10686,17738,A,,2107.0,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622501,BAO_0000218,
10687,17738,A,,2107.0,50597,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622502,BAO_0000218,
10688,17738,A,,2107.0,50597,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622503,BAO_0000218,
10689,17738,A,,2107.0,50597,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877614,BAO_0000218,
10690,17738,A,,2048.0,50597,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624839,BAO_0000218,
10691,17738,A,,2048.0,50597,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624840,BAO_0000218,
10692,17738,A,,2048.0,50597,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624841,BAO_0000218,
10693,17738,A,,2048.0,50597,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624842,BAO_0000218,
10694,17738,A,,2385.0,50597,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624843,BAO_0000218,
10695,17738,A,,2385.0,50597,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624844,BAO_0000218,
10696,17738,A,,2385.0,50597,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624845,BAO_0000218,
10697,17738,A,,2385.0,50597,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621904,BAO_0000218,
10698,11195,A,,178.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621905,BAO_0000218,
10699,11195,A,,178.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874382,BAO_0000218,
10700,11195,A,,178.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621906,BAO_0000218,
10701,11195,A,,955.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621907,BAO_0000218,
10702,11195,A,,955.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622096,BAO_0000218,
10703,11195,A,,955.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622097,BAO_0000218,
10704,11195,A,,948.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622098,BAO_0000218,
10705,11195,A,,948.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622099,BAO_0000218,
10706,11195,A,,948.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622100,BAO_0000218,
10707,11195,A,,2113.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622101,BAO_0000218,
10708,11195,A,,2113.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622102,BAO_0000218,
10709,11195,A,,2113.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622103,BAO_0000218,
10710,11195,A,,2107.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622104,BAO_0000218,
10711,11195,A,,2107.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622105,BAO_0000218,
10712,11195,A,,2107.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622106,BAO_0000218,
10713,11195,A,,2048.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622107,BAO_0000218,
10714,11195,A,,2048.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622108,BAO_0000218,
10715,11195,A,,2048.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622109,BAO_0000218,
10716,11195,A,,2385.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622110,BAO_0000218,
10717,11195,A,,2385.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622111,BAO_0000218,
10718,11195,A,,2385.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874383,BAO_0000218,
10719,11195,A,,14.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622112,BAO_0000218,
10720,11195,A,,14.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622113,BAO_0000218,
10721,11195,A,,14.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622114,BAO_0000218,
10722,11195,A,,2106.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622115,BAO_0000218,
10723,11195,A,,2106.0,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622116,BAO_0000218,
10724,6193,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622117,BAO_0000218,
10725,6803,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622118,BAO_0000218,
10726,6647,A,,,50597,Oral bioavailability in rats at 6 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622119,BAO_0000218,
10727,6647,A,,,50597,Oral bioavailability in rat (dose 6 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622120,BAO_0000218,
10728,6647,A,,,50597,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622121,BAO_0000218,
10729,6640,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622122,BAO_0000218,
10730,6641,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622123,BAO_0000218,
10731,6641,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622124,BAO_0000218,
10732,6642,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622125,BAO_0000218,
10733,5472,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622126,BAO_0000218,
10734,6141,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620455,BAO_0000218,
10735,4390,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620456,BAO_0000218,
10736,5472,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620457,BAO_0000218,
10737,5472,A,,,50597,Oral bioavailability was evaluated; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620458,BAO_0000218,
10738,5438,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620459,BAO_0000218,
10739,4883,A,,,50597,Oral bioavailability in rat by oral dosing,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620460,BAO_0000218,
10740,1908,A,,,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620461,BAO_0000218,
10741,4853,A,,,50597,Oral bioavailability in rat (Sprague-Dawley),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620462,BAO_0000218,
10742,4853,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620463,BAO_0000218,
10743,4853,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620464,BAO_0000218,
10744,4853,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620465,BAO_0000218,
10745,4853,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620466,BAO_0000218,
10746,4853,A,,,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620467,BAO_0000218,
10747,4853,A,,,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620468,BAO_0000218,
10748,12873,A,,,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620469,BAO_0000218,
10749,12873,A,,,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620470,BAO_0000218,
10750,3169,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620471,BAO_0000218,
10751,6305,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620472,BAO_0000218,
10752,4762,A,,,50597,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620473,BAO_0000218,
10753,17847,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620474,BAO_0000218,
10754,6211,A,,,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620475,BAO_0000218,
10755,6011,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620476,BAO_0000218,
10756,6317,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620477,BAO_0000218,
10757,6644,A,,,50597,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620478,BAO_0000218,
10758,6644,A,,,50597,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618768,BAO_0000218,
10759,6644,A,,,50597,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618769,BAO_0000218,
10760,6644,A,,,50597,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618770,BAO_0000218,
10761,6113,A,,,50597,Oral bioavailability (dose 20 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618771,BAO_0000218,
10762,5937,A,,,50597,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618772,BAO_0000218,
10763,5711,A,,,50597,Oral bioavailability in rat at 10 mg/kg of the compound,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618773,BAO_0000218,
10764,17717,A,,,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875842,BAO_0000218,
10765,17717,A,,,50597,Bioavailability in rat (dose 3 mg/kg i.v.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618774,BAO_0000218,
10766,17717,A,,,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618775,BAO_0000218,
10767,17717,A,,,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618776,BAO_0000218,
10768,4722,A,,,50597,Percent bioavailability (F) in rats after iv administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618777,BAO_0000218,
10769,4722,A,,,50597,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618778,BAO_0000218,
10770,4353,A,,,50597,Bioavailability in rat (dose 5 uM/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618779,BAO_0000218,
10771,15662,A,,,50597,Oral bioavailability,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618780,BAO_0000218,
10772,4756,A,,,50597,Bioavailability in rat (dose 2 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618781,BAO_0000218,
10773,4756,A,,,50597,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618782,BAO_0000218,
10774,3436,A,,,50597,Oral bioavailability in rat (dose 20 mg/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618783,BAO_0000218,
10775,17800,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618784,BAO_0000218,
10776,15762,A,,,50597,Percent oral bioavailability evaluated in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618785,BAO_0000218,
10777,5089,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618786,BAO_0000218,
10778,5089,A,,,50597,Percent oral bioavailability in rat; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618787,BAO_0000218,
10779,3185,A,,,50597,Oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618788,BAO_0000218,
10780,5145,A,,,50597,Bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618789,BAO_0000218,
10781,3457,A,,,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618790,BAO_0000218,
10782,3457,A,,,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618791,BAO_0000218,
10783,5983,A,,,50597,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875843,BAO_0000218,
10784,5739,A,,,50597,Oral bioavailability in rat (dose 20 mg/kg p.o.),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL618792,BAO_0000218,
10785,3579,A,,,50597,Cmax at a dose of 30 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623395,BAO_0000218,
10786,17788,A,,,22224,Cmax in monkeys at a dose of 1 mg/kg,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623396,BAO_0000218,
10787,14956,A,,,50597,Cmax in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623397,BAO_0000218,
10788,17788,A,,,50597,Cmax in rats at a dose of 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623398,BAO_0000218,
10789,9750,A,,,50594,Cmax was measured in mice after an oral dose of 50 mg/kg.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623399,BAO_0000218,
10790,12767,A,,,22224,"Cmax value at a dose of 12.7 uM/kg, po",,0,,,1,,U,Autocuration,,,CHEMBL623400,BAO_0000218,
10791,12767,A,,,22224,"Cmax value at a dose of 6.3 uM/kg, iv",,0,,,1,,U,Autocuration,,,CHEMBL623401,BAO_0000218,
10792,12767,A,,,22224,"Cmax value at a dose of 7.1 uM/kg, iv",,0,,,1,,U,Autocuration,,,CHEMBL623402,BAO_0000218,
10793,12703,A,,,22224,Cmax value of compound was determined after 1 hr,,0,,,1,,U,Autocuration,,,CHEMBL623403,BAO_0000218,
10794,15778,A,,,22224,Cmax value of the compound,,0,,,1,,U,Autocuration,,,CHEMBL623404,BAO_0000218,
10795,12818,A,,,50597,Cmax value administered intraintestinal in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625997,BAO_0000218,
10796,14964,A,,,50597,Cmax value administered perorally was determined in rat; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625998,BAO_0000218,
10797,15808,A,,,22224,Cmax value at the dose of 2.3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL625999,BAO_0000218,
10798,15808,A,,,22224,Cmax value at the dose of 5 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626000,BAO_0000218,
10799,15778,A,,,22224,Cmax value in the period of 8 hr after dosing. ,,0,,,1,,U,Autocuration,,,CHEMBL626001,BAO_0000218,
10800,3715,A,,,22224,Cmax value at a oral dose of 20 mg/kg; Not tested,,0,,,1,,U,Autocuration,,,CHEMBL626002,BAO_0000218,
10801,3715,A,,,22224,Cmax value at a oral dose of 20 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626003,BAO_0000218,
10802,1446,A,,,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626004,BAO_0000218,
10803,15240,A,,,50512,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL626005,BAO_0000218,
10804,15240,A,,,50597,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626006,BAO_0000218,
10805,14810,A,,1969.0,50597,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626007,BAO_0000218,
10806,14239,A,,1969.0,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626008,BAO_0000218,
10807,12555,A,,2107.0,50588,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626009,BAO_0000218,
10808,10754,A,,,50588,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626010,BAO_0000218,
10809,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626011,BAO_0000218,
10810,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626012,BAO_0000218,
10811,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626013,BAO_0000218,
10812,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626014,BAO_0000218,
10813,10754,A,,178.0,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL877496,BAO_0000218,
10814,14600,F,,,50588,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626015,BAO_0000218,
10815,14600,F,,,50588,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626016,BAO_0000218,
10816,14600,F,,,50588,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626017,BAO_0000218,
10817,13543,A,,1969.0,50588,Bioavailability as maximal plasma concentration in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626018,BAO_0000218,
10818,13543,A,,1969.0,50588,Bioavailability as maximal plasma concentration in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626692,BAO_0000218,
10819,13543,A,,1969.0,50597,Bioavailability as maximal plasma concentration in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626693,BAO_0000218,
10820,13543,A,,1969.0,22224,Bioavailability as maximal plasma concentration in rats,Plasma,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL626694,BAO_0000218,
10821,14600,A,,178.0,50588,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626695,BAO_0000218,
10822,14600,A,,178.0,50588,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626696,BAO_0000218,
10823,14600,A,,178.0,50588,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626697,BAO_0000218,
10824,14600,A,,178.0,50588,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626859,BAO_0000218,
10825,14600,A,,178.0,50588,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626860,BAO_0000218,
10826,14600,A,,178.0,50588,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626861,BAO_0000218,
10827,14681,A,,,50597,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626296,BAO_0000218,
10828,15905,A,,,22224,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626297,BAO_0000218,
10829,15905,A,,1969.0,22224,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626298,BAO_0000218,
10830,13304,A,,1969.0,50597,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626299,BAO_0000218,
10831,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626300,BAO_0000218,
10832,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626301,BAO_0000218,
10833,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626962,BAO_0000218,
10834,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626963,BAO_0000218,
10835,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626964,BAO_0000218,
10836,14839,A,,1969.0,100710,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626965,BAO_0000218,
10837,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626966,BAO_0000218,
10838,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626967,BAO_0000218,
10839,14839,A,,1969.0,100710,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626968,BAO_0000218,
10840,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626969,BAO_0000218,
10841,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627126,BAO_0000218,
10842,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631276,BAO_0000218,
10843,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631277,BAO_0000218,
10844,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631278,BAO_0000218,
10845,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874457,BAO_0000218,
10846,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631279,BAO_0000218,
10847,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631280,BAO_0000218,
10848,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631281,BAO_0000218,
10849,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631968,BAO_0000218,
10850,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631969,BAO_0000218,
10851,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631970,BAO_0000218,
10852,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631971,BAO_0000218,
10853,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631972,BAO_0000218,
10854,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630435,BAO_0000218,
10855,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630436,BAO_0000218,
10856,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630437,BAO_0000218,
10857,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630438,BAO_0000218,
10858,8418,A,,948.0,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630439,BAO_0000218,
10859,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630440,BAO_0000218,
10860,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630441,BAO_0000218,
10861,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630442,BAO_0000218,
10862,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625234,BAO_0000218,
10863,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625235,BAO_0000218,
10864,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625236,BAO_0000218,
10865,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625237,BAO_0000218,
10866,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626125,BAO_0000218,
10867,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626126,BAO_0000218,
10868,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626127,BAO_0000218,
10869,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626128,BAO_0000218,
10870,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626129,BAO_0000218,
10871,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626130,BAO_0000218,
10872,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626131,BAO_0000218,
10873,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626132,BAO_0000218,
10874,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626752,BAO_0000218,
10875,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626753,BAO_0000218,
10876,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626754,BAO_0000218,
10877,8418,A,,2113.0,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626755,BAO_0000218,
10878,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626756,BAO_0000218,
10879,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626757,BAO_0000218,
10880,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626758,BAO_0000218,
10881,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626759,BAO_0000218,
10882,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626760,BAO_0000218,
10883,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626394,BAO_0000218,
10884,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626395,BAO_0000218,
10885,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626396,BAO_0000218,
10886,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626397,BAO_0000218,
10887,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626398,BAO_0000218,
10888,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626399,BAO_0000218,
10889,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874653,BAO_0000218,
10890,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626400,BAO_0000218,
10891,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626401,BAO_0000218,
10892,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626402,BAO_0000218,
10893,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626403,BAO_0000218,
10894,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626404,BAO_0000218,
10895,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626405,BAO_0000218,
10896,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625529,BAO_0000218,
10897,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625530,BAO_0000218,
10898,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625531,BAO_0000218,
10899,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625532,BAO_0000218,
10900,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625533,BAO_0000218,
10901,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875474,BAO_0000218,
10902,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625534,BAO_0000218,
10903,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625535,BAO_0000218,
10904,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625536,BAO_0000218,
10905,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625537,BAO_0000218,
10906,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625538,BAO_0000218,
10907,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625539,BAO_0000218,
10908,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625540,BAO_0000218,
10909,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625541,BAO_0000218,
10910,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625542,BAO_0000218,
10911,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625543,BAO_0000218,
10912,6996,A,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625544,BAO_0000218,
10913,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625545,BAO_0000218,
10914,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625546,BAO_0000218,
10915,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625547,BAO_0000218,
10916,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625548,BAO_0000218,
10917,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625549,BAO_0000218,
10918,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625550,BAO_0000218,
10919,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625551,BAO_0000218,
10920,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875475,BAO_0000218,
10921,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625552,BAO_0000218,
10922,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625553,BAO_0000218,
10923,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625554,BAO_0000218,
10924,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625555,BAO_0000218,
10925,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625556,BAO_0000218,
10926,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624986,BAO_0000218,
10927,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624987,BAO_0000218,
10928,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624988,BAO_0000218,
10929,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624989,BAO_0000218,
10930,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624990,BAO_0000218,
10931,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874391,BAO_0000218,
10932,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624991,BAO_0000218,
10933,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624992,BAO_0000218,
10934,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624993,BAO_0000218,
10935,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624994,BAO_0000218,
10936,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624995,BAO_0000218,
10937,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624996,BAO_0000218,
10938,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624997,BAO_0000218,
10939,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624998,BAO_0000218,
10940,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624999,BAO_0000218,
10941,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL882955,BAO_0000218,
10942,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625000,BAO_0000218,
10943,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625001,BAO_0000218,
10944,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625089,BAO_0000218,
10945,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625090,BAO_0000218,
10946,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625091,BAO_0000218,
10947,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625092,BAO_0000218,
10948,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625093,BAO_0000218,
10949,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625094,BAO_0000218,
10950,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625095,BAO_0000218,
10951,2249,A,,,50588,Compound was evaluated for its bioavailability in the dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625096,BAO_0000218,
10952,2249,A,,,50597,Compound was evaluated for its bioavailability in the rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625097,BAO_0000218,
10953,17515,A,,,22224,Compound was evaluated for oral bioavailability,,0,,,1,,U,Autocuration,,,CHEMBL882956,BAO_0000218,
10954,14541,A,,,50597,Compound was evaluated for percentage of Oral bioavailability in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625098,BAO_0000218,
10955,12797,A,,,22224,Bioavailability in guinea pig,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL625099,BAO_0000218,
10956,12797,A,,,50597,Compound was evaluated for the oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625100,BAO_0000218,
10957,12797,A,,,50588,Compound was evaluated for the oral bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625101,BAO_0000218,
10958,12797,A,,,50597,Compound was evaluated for the oral bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874396,BAO_0000218,
10959,11727,F,,,22224,Bioavailability in dog (dosed i.v.),,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL625102,BAO_0000218,
10960,13249,A,,,50588,Compound was tested for in vivo bioavailability in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625103,BAO_0000218,
10961,13249,A,,,100712,Compound was tested for in vivo bioavailability in hamsters,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL625104,BAO_0000218,
10962,13249,A,,,22224,Compound was tested for in vivo bioavailability in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625105,BAO_0000218,
10963,13249,A,,,50597,Compound was tested for in vivo bioavailability in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625106,BAO_0000218,
10964,9552,A,,,22224,Oral bioavailability in mouse,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL625107,BAO_0000218,
10965,9552,A,,,50594,Compound was tested for percent of oral bioavailability in mice; 56-74,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625108,BAO_0000218,
10966,14839,A,,,22224,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL625109,BAO_0000218,
10967,14839,A,,,22224,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL625110,BAO_0000218,
10968,14839,A,,,22224,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL625111,BAO_0000218,
10969,14839,A,,,50594,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625112,BAO_0000218,
10970,14839,A,,,50594,Oral bioavailability in nude mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875334,BAO_0000218,
10971,11219,A,,,22224,Bioavailability in monkey (i.d. dosing),,0,,Primates,1,9443.0,U,Autocuration,,,CHEMBL628617,BAO_0000218,
10972,9552,A,,,22224,Bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL628618,BAO_0000218,
10973,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,0,,,1,,U,Autocuration,,,CHEMBL628619,BAO_0000218,
10974,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,0,,,1,,U,Autocuration,,,CHEMBL628620,BAO_0000218,
10975,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628621,BAO_0000218,
10976,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628622,BAO_0000218,
10977,14839,A,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628623,BAO_0000218,
10978,14839,A,,1969.0,100710,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628624,BAO_0000218,
10979,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628625,BAO_0000218,
10980,14839,A,,1969.0,100710,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628626,BAO_0000218,
10981,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627041,BAO_0000218,
10982,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627042,BAO_0000218,
10983,14839,A,,1969.0,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627043,BAO_0000218,
10984,13932,A,,1969.0,22224,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Plasma,0,,,1,,U,Autocuration,,,CHEMBL627044,BAO_0000218,
10985,11637,A,,1969.0,50594,Cmax in mouse plasma,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627045,BAO_0000218,
10986,11637,A,,1969.0,22224,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Plasma,0,,,1,,U,Autocuration,,,CHEMBL627046,BAO_0000218,
10987,13960,A,,1969.0,50597,Maximal plasma concentration in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627047,BAO_0000218,
10988,15905,A,,1969.0,50597,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627048,BAO_0000218,
10989,14062,A,,,50597,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627049,BAO_0000218,
10990,14062,A,,,50597,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627050,BAO_0000218,
10991,14062,A,,,50597,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627051,BAO_0000218,
10992,14062,A,,,50597,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627052,BAO_0000218,
10993,14062,A,,,50597,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627053,BAO_0000218,
10994,14062,A,,,50597,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627054,BAO_0000218,
10995,15011,A,,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627055,BAO_0000218,
10996,15011,A,,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627056,BAO_0000218,
10997,15011,A,,,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627057,BAO_0000218,
10998,15011,A,,,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627058,BAO_0000218,
10999,15011,A,,,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626211,BAO_0000218,
11000,10291,A,,,22224,Maximum Concentration of the compound.,,0,,,1,,U,Autocuration,,,CHEMBL626212,BAO_0000218,
11001,14599,A,,,50588,Maximum Concentration was measured after iv administration into Beagle dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626213,BAO_0000218,
11002,14599,A,,,50588,Maximum Concentration was measured after iv administration into Beagle dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626214,BAO_0000218,
11003,14599,A,,,50588,Maximum Concentration was measured after po administration into Beagle dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626215,BAO_0000218,
11004,14599,A,,,50588,Maximum Concentration was measured after po administration into Beagle dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626216,BAO_0000218,
11005,12767,A,,178.0,22224,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Blood,0,,,1,,U,Autocuration,,,CHEMBL626217,BAO_0000218,
11006,12767,A,,178.0,22224,Maximum blood level reached after an iv dose of 12.2 uM/kg,Blood,0,,,1,,U,Autocuration,,,CHEMBL626218,BAO_0000218,
11007,12767,A,,178.0,22224,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Blood,0,,,1,,U,Autocuration,,,CHEMBL626219,BAO_0000218,
11008,12767,A,,178.0,22224,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Blood,0,,,1,,U,Autocuration,,,CHEMBL626220,BAO_0000218,
11009,12767,A,,178.0,22224,Maximum blood level reached after an oral dose of 5.0 mg/kg,Blood,0,,,1,,U,Autocuration,,,CHEMBL626221,BAO_0000218,
11010,12767,A,,178.0,22224,Maximum blood level reached at dose of 10.6 uM/kg orally,Blood,0,,,1,,U,Autocuration,,,CHEMBL626222,BAO_0000218,
11011,14706,A,,,50512,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL626223,BAO_0000218,
11012,14706,A,,,50512,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL626224,BAO_0000218,
11013,14793,A,,955.0,50597,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626225,BAO_0000218,
11014,14793,A,,955.0,50597,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626226,BAO_0000218,
11015,14793,A,,955.0,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626227,BAO_0000218,
11016,14793,A,,955.0,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626228,BAO_0000218,
11017,14793,A,,,50597,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626229,BAO_0000218,
11018,14793,A,,,50597,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626921,BAO_0000218,
11019,14793,A,,,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876793,BAO_0000218,
11020,14793,A,,,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625309,BAO_0000218,
11021,10524,A,,,50278,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,1,,Bacillus subtilis,1,1423.0,N,Intermediate,,,CHEMBL625310,BAO_0000218,
11022,11871,A,,,22224,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625311,BAO_0000218,
11023,11871,A,,,50597,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625312,BAO_0000218,
11024,3437,A,,,22224,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,0,,,1,,U,Autocuration,,,CHEMBL625313,BAO_0000218,
11025,12038,A,,,50594,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625314,BAO_0000218,
11026,12038,A,,,50597,Maximum concentration in male rats after iv administration of 20 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625315,BAO_0000218,
11027,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625316,BAO_0000218,
11028,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625317,BAO_0000218,
11029,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625318,BAO_0000218,
11030,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625319,BAO_0000218,
11031,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625320,BAO_0000218,
11032,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625321,BAO_0000218,
11033,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625322,BAO_0000218,
11034,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876801,BAO_0000218,
11035,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625323,BAO_0000218,
11036,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625324,BAO_0000218,
11037,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625325,BAO_0000218,
11038,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625326,BAO_0000218,
11039,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625327,BAO_0000218,
11040,8418,A,,2107.0,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625328,BAO_0000218,
11041,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625329,BAO_0000218,
11042,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625330,BAO_0000218,
11043,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627774,BAO_0000218,
11044,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627775,BAO_0000218,
11045,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627949,BAO_0000218,
11046,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627950,BAO_0000218,
11047,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627951,BAO_0000218,
11048,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627952,BAO_0000218,
11049,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627953,BAO_0000218,
11050,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627954,BAO_0000218,
11051,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627955,BAO_0000218,
11052,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627956,BAO_0000218,
11053,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876802,BAO_0000218,
11054,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627957,BAO_0000218,
11055,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627958,BAO_0000218,
11056,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627959,BAO_0000218,
11057,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627960,BAO_0000218,
11058,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627961,BAO_0000218,
11059,8418,A,,2048.0,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627962,BAO_0000218,
11060,9796,A,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627963,BAO_0000218,
11061,9796,A,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624759,BAO_0000218,
11062,9796,A,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624760,BAO_0000218,
11063,9796,A,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624761,BAO_0000218,
11064,9796,A,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877607,BAO_0000218,
11065,9796,A,,2107.0,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624762,BAO_0000218,
11066,9796,A,,2107.0,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624763,BAO_0000218,
11067,9796,A,,2107.0,50597,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624764,BAO_0000218,
11068,9796,A,,2107.0,50597,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624765,BAO_0000218,
11069,9796,A,,2107.0,50597,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624766,BAO_0000218,
11070,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624767,BAO_0000218,
11071,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624768,BAO_0000218,
11072,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624769,BAO_0000218,
11073,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624770,BAO_0000218,
11074,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624771,BAO_0000218,
11075,6996,A,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624772,BAO_0000218,
11076,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624773,BAO_0000218,
11077,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624774,BAO_0000218,
11078,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624775,BAO_0000218,
11079,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624776,BAO_0000218,
11080,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624777,BAO_0000218,
11081,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624778,BAO_0000218,
11082,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624779,BAO_0000218,
11083,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624780,BAO_0000218,
11084,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624781,BAO_0000218,
11085,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877608,BAO_0000218,
11086,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624782,BAO_0000218,
11087,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624783,BAO_0000218,
11088,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624784,BAO_0000218,
11089,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624785,BAO_0000218,
11090,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624786,BAO_0000218,
11091,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624787,BAO_0000218,
11092,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628676,BAO_0000218,
11093,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621842,BAO_0000218,
11094,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621843,BAO_0000218,
11095,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623873,BAO_0000218,
11096,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623874,BAO_0000218,
11097,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623875,BAO_0000218,
11098,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623876,BAO_0000218,
11099,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623877,BAO_0000218,
11100,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623878,BAO_0000218,
11101,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623879,BAO_0000218,
11102,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623880,BAO_0000218,
11103,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623881,BAO_0000218,
11104,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623957,BAO_0000218,
11105,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623958,BAO_0000218,
11106,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623959,BAO_0000218,
11107,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623960,BAO_0000218,
11108,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623961,BAO_0000218,
11109,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623962,BAO_0000218,
11110,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624676,BAO_0000218,
11111,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624677,BAO_0000218,
11112,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624678,BAO_0000218,
11113,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624679,BAO_0000218,
11114,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624680,BAO_0000218,
11115,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,0,,,1,,U,Autocuration,,,CHEMBL624849,BAO_0000218,
11116,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,0,,,1,,U,Autocuration,,,CHEMBL624850,BAO_0000218,
11117,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,0,,,1,,U,Autocuration,,,CHEMBL874399,BAO_0000218,
11118,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,0,,,1,,U,Autocuration,,,CHEMBL624851,BAO_0000218,
11119,11732,A,,,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,0,,,1,,U,Autocuration,,,CHEMBL624852,BAO_0000218,
11120,13359,A,,,22224,Oral bioavailability in rat (dose 10 mg/kg),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL624853,BAO_0000218,
11121,16618,A,,,22224,Oral bioavailability in rat (Sprague-Dawley),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL624854,BAO_0000218,
11122,13960,A,,,22224,Oral bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL624855,BAO_0000218,
11123,13917,A,,,22224,Oral bioavailability in rats was determined in vivo,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL624856,BAO_0000218,
11124,14266,A,,,22224,Oral bioavailability in dog,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL882957,BAO_0000218,
11125,12359,A,,,22224,Oral bioavailability of compound in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL624857,BAO_0000218,
11126,12359,A,,,50597,Oral bioavailability of compound in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622202,BAO_0000218,
11127,12359,A,,,22224,Bioavailability in rat of PMEA prodrug,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL622203,BAO_0000218,
11128,12359,A,,,50597,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625522,BAO_0000218,
11129,10791,A,,,22224,Serum conc at 3 hours following 25 mg/kg dose,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL622868,BAO_0000218,
11130,10791,A,,1088.0,22224,Urine conc 0-5 hours following 25 mg/kg dose,Urine,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL622869,BAO_0000218,
11131,10791,A,,1088.0,22224,Urine conc 0-24 hours following 25 mg/kg dose,Urine,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL622870,BAO_0000218,
11132,138,A,,,22224,Oral bioavailability in African green monkeys; 20-25,,0,,Chlorocebus aethiops,1,9534.0,U,Autocuration,,,CHEMBL622871,BAO_0000218,
11133,14521,A,,,100710,Oral bioavailability in cynomolgus monkey.,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL620560,BAO_0000218,
11134,13953,A,,,22224,Oral bioavailability in dog,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL620561,BAO_0000218,
11135,12836,A,,,50588,Oral bioavailability in dog at 10 mg/kg oral dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620562,BAO_0000218,
11136,12836,A,,,100712,Oral bioavailability in hamster at 10 mg/kg oral dose,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL620563,BAO_0000218,
11137,12836,A,,,50597,Oral bioavailability in rat at 10 mg/kg oral dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL620564,BAO_0000218,
11138,14521,A,,,22224,Oral bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL872265,BAO_0000218,
11139,13953,A,,,22224,Oral bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620565,BAO_0000218,
11140,6799,A,,,22224,Oral bioavailability,,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL620566,BAO_0000218,
11141,11311,A,,,22224,Oral bioavailability was determined; range 49-102%,,0,,,1,,U,Autocuration,,,CHEMBL620567,BAO_0000218,
11142,4013,A,,,50588,Oral bioavailability was determined in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL620568,BAO_0000218,
11143,4013,A,,,22224,Oral bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620569,BAO_0000218,
11144,17591,A,,,22224,Oral bioavailability,,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL620570,BAO_0000218,
11145,17591,A,,,22224,Oral bioavailability was determined; Not orally available,,0,,,1,,U,Autocuration,,,CHEMBL620571,BAO_0000218,
11146,15011,A,,,50594,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620572,BAO_0000218,
11147,15011,A,,,22224,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620573,BAO_0000218,
11148,15011,A,,,22224,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL620574,BAO_0000218,
11149,9552,A,,,22224,Oral bioavailability in Rhesus monkey,,0,,Macaca mulatta,1,9544.0,U,Autocuration,,,CHEMBL620575,BAO_0000218,
11150,9552,A,,,22224,Oral bioavailability in dog (female mongrel),,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL620576,BAO_0000218,
11151,3639,A,,,22224,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,0,,,1,,U,Autocuration,,,CHEMBL875846,BAO_0000218,
11152,13397,A,,,22224,Oral bioavailability in dog,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL620577,BAO_0000218,
11153,3031,A,,,22224,Percentage Bioavailability was evaluated.,,0,,,1,,U,Autocuration,,,CHEMBL620578,BAO_0000218,
11154,12818,A,,,22224,Bioavailability in rat administered i.d.,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL620579,BAO_0000218,
11155,4847,A,,,22224,Bioavailability,,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL621248,BAO_0000218,
11156,12421,A,,,22224,Bioavailability in dog (male Beagle) i.v. administration,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL625390,BAO_0000218,
11157,11966,A,,,22224,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625391,BAO_0000218,
11158,11218,A,,,22224,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,0,,Primates,1,9443.0,U,Autocuration,,,CHEMBL872266,BAO_0000218,
11159,13129,A,,,22224,Oral bioavailability in rat (Sprague-Dawley) (male),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625392,BAO_0000218,
11160,12350,A,,,50597,The oral bioavailability was measured on rats after oral administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625393,BAO_0000218,
11161,2231,A,,,50597,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625394,BAO_0000218,
11162,2231,A,,,50797,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL625395,BAO_0000218,
11163,12187,A,,,22224,Bioavailability in rat (dose 10 mg/kg i.d.),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625396,BAO_0000218,
11164,12421,A,,,22224,Bioavailability in dog (male Beagle) i.v. administration,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL625397,BAO_0000218,
11165,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625398,BAO_0000218,
11166,13256,A,,178.0,50594,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625399,BAO_0000218,
11167,13256,A,,2037.0,50594,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626074,BAO_0000218,
11168,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626075,BAO_0000218,
11169,2231,A,,1969.0,50597,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626076,BAO_0000218,
11170,2231,A,,1969.0,50797,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL626077,BAO_0000218,
11171,12178,A,,178.0,50597,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626078,BAO_0000218,
11172,12178,A,,178.0,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,0,,,1,,U,Autocuration,,,CHEMBL625846,BAO_0000218,
11173,12178,A,,178.0,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Blood,0,,,1,,U,Autocuration,,,CHEMBL625847,BAO_0000218,
11174,15633,A,,,50597,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL625848,BAO_0000218,
11175,14258,A,,1969.0,50597,Maximum concentration of compound in plasma administered orally to rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625849,BAO_0000218,
11176,14224,A,,1969.0,50588,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626023,BAO_0000218,
11177,14224,A,,1969.0,50588,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626024,BAO_0000218,
11178,14224,A,,1969.0,50588,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626025,BAO_0000218,
11179,5566,A,,,22224,Maximum concentration after 10 mg/kg by oral administration,,0,,,1,,U,Autocuration,,,CHEMBL626026,BAO_0000218,
11180,16935,A,,,22224,Maximum concentration at a dose of 1.5 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626027,BAO_0000218,
11181,16935,A,,,22224,Maximum concentration at a dose of 2.0 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626028,BAO_0000218,
11182,14224,A,,1969.0,50588,Maximum concentration in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626029,BAO_0000218,
11183,12536,A,,1969.0,22224,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626030,BAO_0000218,
11184,12536,A,,1969.0,22224,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626031,BAO_0000218,
11185,12536,A,,1969.0,22224,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626032,BAO_0000218,
11186,12536,A,,1969.0,22224,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626033,BAO_0000218,
11187,12536,A,,1969.0,22224,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626034,BAO_0000218,
11188,9994,A,,1969.0,50588,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626035,BAO_0000218,
11189,1434,A,,1969.0,22224,Maximum concentration in plasma at Tmax,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626036,BAO_0000218,
11190,12836,A,,1969.0,50588,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL626037,BAO_0000218,
11191,12836,A,,1969.0,100712,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Plasma,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL626038,BAO_0000218,
11192,12836,A,,1969.0,50597,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626039,BAO_0000218,
11193,12545,A,,1969.0,50597,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626040,BAO_0000218,
11194,13856,A,,1969.0,50592,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Plasma,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL626041,BAO_0000218,
11195,3550,A,,,22224,Maximum concentration was calculated,,0,,,1,,U,Autocuration,,,CHEMBL626042,BAO_0000218,
11196,2632,A,,,22224,Maximum concentration was calculated.,,0,,,1,,U,Autocuration,,,CHEMBL626043,BAO_0000218,
11197,5566,A,,,22224,Maximum concentration at a peroral dose of 10 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626044,BAO_0000218,
11198,11883,A,,,22224,Maximum concentration of the drug at 10 uM/dg administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626045,BAO_0000218,
11199,11883,A,,,22224,Maximum concentration of the drug at 2 uM/dg administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626046,BAO_0000218,
11200,14122,A,,1969.0,50588,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626047,BAO_0000218,
11201,14122,A,,1969.0,100712,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Plasma,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL626048,BAO_0000218,
11202,14122,A,,1969.0,50597,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626049,BAO_0000218,
11203,12542,A,,1969.0,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626050,BAO_0000218,
11204,12542,A,,1969.0,50588,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874541,BAO_0000218,
11205,12542,A,,1969.0,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Plasma,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL622826,BAO_0000218,
11206,12542,A,,1969.0,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Plasma,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL622827,BAO_0000218,
11207,12542,A,,1969.0,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622828,BAO_0000218,
11208,14080,A,,1969.0,50597,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622829,BAO_0000218,
11209,11911,A,,,50597,Maximum concentration reached following intravenous administration in male rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876806,BAO_0000218,
11210,13204,A,,,50588,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622830,BAO_0000218,
11211,13204,A,,,50597,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622831,BAO_0000218,
11212,14346,A,,,50588,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626794,BAO_0000218,
11213,14346,A,,,50597,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626795,BAO_0000218,
11214,14346,A,,,50597,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626796,BAO_0000218,
11215,14346,A,,,50597,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626797,BAO_0000218,
11216,14127,A,,,50597,Maximum drug concentration is determined after oral dosing in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626798,BAO_0000218,
11217,14339,A,,,50588,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626799,BAO_0000218,
11218,14339,A,,,50588,Maximum observed concentration in oral (5 mg/kg) fed dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626800,BAO_0000218,
11219,13494,A,,1969.0,22224,Maximum plasma concentration,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626801,BAO_0000218,
11220,14925,A,,1969.0,50597,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876816,BAO_0000218,
11221,14474,A,,1969.0,50597,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626802,BAO_0000218,
11222,14474,A,,1969.0,50588,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626803,BAO_0000218,
11223,13917,A,,1969.0,22224,Maximum plasma concentration following oral administration of 30 umol/kg,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626804,BAO_0000218,
11224,9796,A,,1969.0,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626805,BAO_0000218,
11225,9796,A,,1969.0,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626309,BAO_0000218,
11226,9796,A,,1969.0,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626310,BAO_0000218,
11227,9796,A,,1969.0,50597,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626311,BAO_0000218,
11228,9796,A,,1969.0,50597,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626312,BAO_0000218,
11229,9796,A,,995.0,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626313,BAO_0000218,
11230,9796,A,,995.0,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626314,BAO_0000218,
11231,9796,A,,995.0,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626315,BAO_0000218,
11232,9796,A,,995.0,50597,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626316,BAO_0000218,
11233,9796,A,,995.0,50597,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626317,BAO_0000218,
11234,8363,A,,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626318,BAO_0000218,
11235,8363,A,,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626319,BAO_0000218,
11236,8363,A,,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626320,BAO_0000218,
11237,8363,A,,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875053,BAO_0000218,
11238,8363,A,,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626321,BAO_0000218,
11239,8363,A,,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626322,BAO_0000218,
11240,8363,A,,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626323,BAO_0000218,
11241,8363,A,,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626324,BAO_0000218,
11242,8363,A,,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626325,BAO_0000218,
11243,8363,A,,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626326,BAO_0000218,
11244,8363,A,,,50597,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626327,BAO_0000218,
11245,8363,A,,,50597,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626328,BAO_0000218,
11246,8684,A,,178.0,50597,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626329,BAO_0000218,
11247,8684,A,,178.0,50597,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626330,BAO_0000218,
11248,8684,A,,178.0,50597,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626331,BAO_0000218,
11249,8684,A,,178.0,50597,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626332,BAO_0000218,
11250,8684,A,,178.0,50597,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626333,BAO_0000218,
11251,8684,A,,178.0,50597,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626334,BAO_0000218,
11252,8684,A,,178.0,50597,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626335,BAO_0000218,
11253,8684,A,,178.0,50597,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624798,BAO_0000218,
11254,8684,A,,955.0,50597,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624799,BAO_0000218,
11255,8684,A,,955.0,50597,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624800,BAO_0000218,
11256,8684,A,,955.0,50597,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624801,BAO_0000218,
11257,8684,A,,955.0,50597,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624802,BAO_0000218,
11258,8684,A,,955.0,50597,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624803,BAO_0000218,
11259,8684,A,,955.0,50597,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624804,BAO_0000218,
11260,8684,A,,955.0,50597,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624805,BAO_0000218,
11261,8684,A,,955.0,50597,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624806,BAO_0000218,
11262,8684,A,,,50597,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624807,BAO_0000218,
11263,8684,A,,,50597,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624808,BAO_0000218,
11264,8684,A,,,50597,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624809,BAO_0000218,
11265,8684,A,,,50597,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624810,BAO_0000218,
11266,8684,A,,,50597,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877618,BAO_0000218,
11267,8684,A,,,50597,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624811,BAO_0000218,
11268,8684,A,,,50597,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624812,BAO_0000218,
11269,8684,A,,,50597,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624813,BAO_0000218,
11270,8684,A,,,50597,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624814,BAO_0000218,
11271,8684,A,,,50597,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624815,BAO_0000218,
11272,8684,A,,,50597,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624816,BAO_0000218,
11273,8684,A,,,50597,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624817,BAO_0000218,
11274,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624818,BAO_0000218,
11275,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624819,BAO_0000218,
11276,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624820,BAO_0000218,
11277,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624821,BAO_0000218,
11278,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624822,BAO_0000218,
11279,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624823,BAO_0000218,
11280,15599,A,,,50212,Observed diffusion coefficient in organic solvent for Escherichia coli,,1,,Escherichia coli,1,562.0,N,Intermediate,,,CHEMBL624824,BAO_0000218,
11281,9614,A,,178.0,50597,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624825,BAO_0000218,
11282,9614,A,,178.0,50597,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624826,BAO_0000218,
11283,9614,A,,2081.0,50597,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876817,BAO_0000218,
11284,9614,A,,2081.0,50597,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624827,BAO_0000218,
11285,9614,A,,,50597,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624828,BAO_0000218,
11286,9614,A,,,50597,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624829,BAO_0000218,
11287,9614,A,,2107.0,50597,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624830,BAO_0000218,
11288,9614,A,,2107.0,50597,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624831,BAO_0000218,
11289,9614,A,,2081.0,50597,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624832,BAO_0000218,
11290,9614,A,,2081.0,50597,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624833,BAO_0000218,
11291,9614,A,,,50597,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624834,BAO_0000218,
11292,9614,A,,,50597,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624835,BAO_0000218,
11293,9614,A,,2106.0,50597,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624836,BAO_0000218,
11294,9614,A,,2106.0,50597,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624837,BAO_0000218,
11295,9071,A,,178.0,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624838,BAO_0000218,
11296,9071,A,,178.0,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622188,BAO_0000218,
11297,9071,A,,948.0,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622189,BAO_0000218,
11298,9071,A,,948.0,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622190,BAO_0000218,
11299,9071,A,,948.0,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625170,BAO_0000218,
11300,9071,A,,2113.0,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625171,BAO_0000218,
11301,9071,A,,2113.0,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625172,BAO_0000218,
11302,9071,A,,2113.0,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625173,BAO_0000218,
11303,9071,A,,2107.0,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625174,BAO_0000218,
11304,9071,A,,2107.0,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625175,BAO_0000218,
11305,9071,A,,2107.0,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625176,BAO_0000218,
11306,9071,A,,2048.0,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625177,BAO_0000218,
11307,9071,A,,2048.0,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625178,BAO_0000218,
11308,9071,A,,2048.0,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625179,BAO_0000218,
11309,9071,A,,2048.0,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625180,BAO_0000218,
11310,10677,A,,,22224,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,0,,,1,,U,Autocuration,,,CHEMBL625181,BAO_0000218,
11311,9750,A,,1088.0,50594,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625182,BAO_0000218,
11312,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625183,BAO_0000218,
11313,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875848,BAO_0000218,
11314,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622260,BAO_0000218,
11315,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622261,BAO_0000218,
11316,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622262,BAO_0000218,
11317,8319,A,,2113.0,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622263,BAO_0000218,
11318,8319,A,,2113.0,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622418,BAO_0000218,
11319,8319,A,,2107.0,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622419,BAO_0000218,
11320,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623388,BAO_0000218,
11321,13256,A,,2107.0,50594,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623389,BAO_0000218,
11322,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623390,BAO_0000218,
11323,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623391,BAO_0000218,
11324,13256,A,,178.0,50594,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623392,BAO_0000218,
11325,13256,A,,2037.0,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623393,BAO_0000218,
11326,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623394,BAO_0000218,
11327,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618885,BAO_0000218,
11328,13256,A,,2107.0,50594,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618886,BAO_0000218,
11329,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618887,BAO_0000218,
11330,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619535,BAO_0000218,
11331,13256,A,,178.0,50594,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619536,BAO_0000218,
11332,13256,A,,2037.0,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619537,BAO_0000218,
11333,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619705,BAO_0000218,
11334,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619706,BAO_0000218,
11335,13256,A,,2107.0,50594,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619707,BAO_0000218,
11336,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL619708,BAO_0000218,
11337,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625219,BAO_0000218,
11338,13256,A,,178.0,50594,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625220,BAO_0000218,
11339,13256,A,,2037.0,50594,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625221,BAO_0000218,
11340,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625222,BAO_0000218,
11341,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625223,BAO_0000218,
11342,13256,A,,2107.0,50594,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625224,BAO_0000218,
11343,13256,A,,,50594,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625225,BAO_0000218,
11344,8829,A,,178.0,50597,Biodistribution in Rat blood after 24 hours of iv administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625226,BAO_0000218,
11345,8829,A,,178.0,50597,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625227,BAO_0000218,
11346,8829,A,,178.0,50597,Biodistribution in Rat blood after 30 minutes of iv administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625228,BAO_0000218,
11347,8829,A,,178.0,50597,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875354,BAO_0000218,
11348,8829,A,,178.0,50597,Biodistribution in Rat blood after 5 minutes of iv administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625229,BAO_0000218,
11349,8829,A,,178.0,50597,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625230,BAO_0000218,
11350,8829,A,,948.0,50597,Biodistribution in Rat heart after 24 hours of iv administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625231,BAO_0000218,
11351,8829,A,,948.0,50597,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625900,BAO_0000218,
11352,8829,A,,948.0,50597,Biodistribution in Rat heart after 30 minutes of iv administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625901,BAO_0000218,
11353,8829,A,,948.0,50597,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625902,BAO_0000218,
11354,8829,A,,948.0,50597,Biodistribution in Rat heart after 5 minutes of iv administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625903,BAO_0000218,
11355,8829,A,,948.0,50597,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625904,BAO_0000218,
11356,8829,A,,2107.0,50597,Biodistribution in Rat liver after 24 hours of iv administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625905,BAO_0000218,
11357,8829,A,,2107.0,50597,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627861,BAO_0000218,
11358,8829,A,,2107.0,50597,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627862,BAO_0000218,
11359,8829,A,,2107.0,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627863,BAO_0000218,
11360,8829,A,,2107.0,50597,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627769,BAO_0000218,
11361,13249,A,,1969.0,50588,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627770,BAO_0000218,
11362,13622,A,,,100710,Cmax in cynomolgus monkey (PO dose),,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL627771,BAO_0000218,
11363,13622,A,,,50597,Cmax in rat (PO dose),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627772,BAO_0000218,
11364,13622,A,,,50597,Cmax in rat (PO dose),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627773,BAO_0000218,
11365,13494,A,,1969.0,50597,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621922,BAO_0000218,
11366,12170,A,,1969.0,50597,Cmax in rat plasma after oral dose (10 mg/kg),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621923,BAO_0000218,
11367,12170,A,,1969.0,22224,Cmax in plasma after oral dose (10 mg/kg),Plasma,0,,,1,,U,Autocuration,,,CHEMBL621924,BAO_0000218,
11368,17025,A,,1969.0,50588,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621925,BAO_0000218,
11369,17025,A,,1969.0,22224,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL621926,BAO_0000218,
11370,17025,A,,1969.0,50592,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Plasma,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL621927,BAO_0000218,
11371,17025,A,,1969.0,50597,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621928,BAO_0000218,
11372,14187,A,,1969.0,50597,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621929,BAO_0000218,
11373,14816,A,,1969.0,50594,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL621930,BAO_0000218,
11374,17820,A,,1969.0,50597,Maximum plasma concentration after oral dosing in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621931,BAO_0000218,
11375,14380,A,,1969.0,22224,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621932,BAO_0000218,
11376,14380,A,,1969.0,22224,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621933,BAO_0000218,
11377,14691,A,,1969.0,50588,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621934,BAO_0000218,
11378,14691,A,,1969.0,50588,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL621935,BAO_0000218,
11379,13375,A,,1969.0,50597,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621936,BAO_0000218,
11380,6236,A,,1969.0,22224,Maximum plasma concentration was determined,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621937,BAO_0000218,
11381,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621938,BAO_0000218,
11382,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621939,BAO_0000218,
11383,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621940,BAO_0000218,
11384,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621941,BAO_0000218,
11385,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL621942,BAO_0000218,
11386,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626178,BAO_0000218,
11387,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626179,BAO_0000218,
11388,14380,A,,1969.0,22224,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626180,BAO_0000218,
11389,13622,A,,1969.0,50597,Plasma Cmax in rat (PO dose),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626181,BAO_0000218,
11390,15372,A,,,50597,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626182,BAO_0000218,
11391,15372,A,,,50597,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626183,BAO_0000218,
11392,15372,A,,,50597,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626184,BAO_0000218,
11393,15372,A,,,50597,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626185,BAO_0000218,
11394,14925,A,,1969.0,50588,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626186,BAO_0000218,
11395,14925,A,,1969.0,50588,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL877589,BAO_0000218,
11396,11883,A,,,22224,Maximum concentration of the drug at 1 uM/dg administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626187,BAO_0000218,
11397,11883,A,,,22224,Maximum concentration of the drug at 20 uM/dg administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626188,BAO_0000218,
11398,13391,A,,,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL626189,BAO_0000218,
11399,13391,A,,178.0,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL626855,BAO_0000218,
11400,13391,A,,178.0,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL623781,BAO_0000218,
11401,13391,A,,178.0,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL623782,BAO_0000218,
11402,16360,A,,1969.0,50597,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623783,BAO_0000218,
11403,3673,A,,1969.0,50588,Cmax in dog plasma after 1mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623784,BAO_0000218,
11404,14431,A,,1969.0,50588,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623785,BAO_0000218,
11405,14431,A,,1969.0,50597,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623786,BAO_0000218,
11406,14964,A,,,50597,Oral maximum concentration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623787,BAO_0000218,
11407,14964,A,,,50597,Oral maximum concentration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623788,BAO_0000218,
11408,14209,A,,1969.0,50594,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623789,BAO_0000218,
11409,11355,A,,178.0,50594,Peak concentration in blood after intravenous administration to mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623790,BAO_0000218,
11410,11355,A,,178.0,50594,Peak concentration in blood after peroral administration to mice,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623791,BAO_0000218,
11411,11966,A,,1969.0,50597,Peak concentration in rat plasma was determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623792,BAO_0000218,
11412,8918,A,,1969.0,22224,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623793,BAO_0000218,
11413,8918,A,,1969.0,50594,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623794,BAO_0000218,
11414,8918,A,,1969.0,50597,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623795,BAO_0000218,
11415,8684,A,,,50597,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623796,BAO_0000218,
11416,8684,A,,,50597,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623797,BAO_0000218,
11417,8684,A,,,50597,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623798,BAO_0000218,
11418,8684,A,,,50597,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623799,BAO_0000218,
11419,8684,A,,160.0,50597,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624490,BAO_0000218,
11420,8684,A,,160.0,50597,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624491,BAO_0000218,
11421,8684,A,,160.0,50597,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624492,BAO_0000218,
11422,8684,A,,160.0,50597,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624493,BAO_0000218,
11423,8684,A,,160.0,50597,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877595,BAO_0000218,
11424,8684,A,,160.0,50597,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624494,BAO_0000218,
11425,8684,A,,160.0,50597,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624495,BAO_0000218,
11426,8684,A,,160.0,50597,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624681,BAO_0000218,
11427,8684,A,,,50597,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624682,BAO_0000218,
11428,8684,A,,,50597,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624683,BAO_0000218,
11429,8684,A,,,50597,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624684,BAO_0000218,
11430,8684,A,,,50597,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624685,BAO_0000218,
11431,8684,A,,,50597,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624686,BAO_0000218,
11432,8684,A,,,50597,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624687,BAO_0000218,
11433,8684,A,,,50597,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624688,BAO_0000218,
11434,8684,A,,,50597,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627161,BAO_0000218,
11435,8684,A,,,50597,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622127,BAO_0000218,
11436,8684,A,,,50597,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622128,BAO_0000218,
11437,8684,A,,,50597,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874384,BAO_0000218,
11438,8684,A,,,50597,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624898,BAO_0000218,
11439,8684,A,,,50597,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624899,BAO_0000218,
11440,8684,A,,,50597,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624900,BAO_0000218,
11441,8684,A,,,50597,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624901,BAO_0000218,
11442,8684,A,,,50597,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624902,BAO_0000218,
11443,8684,A,,,50597,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624903,BAO_0000218,
11444,8684,A,,,50597,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624904,BAO_0000218,
11445,8684,A,,,50597,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624905,BAO_0000218,
11446,8684,A,,,50597,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624906,BAO_0000218,
11447,8684,A,,,50597,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624907,BAO_0000218,
11448,8684,A,,,50597,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624908,BAO_0000218,
11449,8684,A,,,50597,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624909,BAO_0000218,
11450,8684,A,,,50597,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624910,BAO_0000218,
11451,8684,A,,2385.0,50597,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624911,BAO_0000218,
11452,8684,A,,2385.0,50597,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874388,BAO_0000218,
11453,8684,A,,2385.0,50597,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624912,BAO_0000218,
11454,8684,A,,2385.0,50597,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622930,BAO_0000218,
11455,8684,A,,2385.0,50597,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623121,BAO_0000218,
11456,8684,A,,2385.0,50597,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623122,BAO_0000218,
11457,8684,A,,2385.0,50597,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623123,BAO_0000218,
11458,8684,A,,2385.0,50597,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623124,BAO_0000218,
11459,8684,A,,,50597,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623125,BAO_0000218,
11460,8684,A,,,50597,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623126,BAO_0000218,
11461,8684,A,,,50597,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623127,BAO_0000218,
11462,8684,A,,,50597,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623128,BAO_0000218,
11463,8684,A,,,50597,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623129,BAO_0000218,
11464,8684,A,,,50597,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623130,BAO_0000218,
11465,8684,A,,,50597,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623131,BAO_0000218,
11466,8684,A,,,50597,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623132,BAO_0000218,
11467,8319,A,,2107.0,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623133,BAO_0000218,
11468,8319,A,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623134,BAO_0000218,
11469,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874389,BAO_0000218,
11470,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623135,BAO_0000218,
11471,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623136,BAO_0000218,
11472,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623137,BAO_0000218,
11473,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623138,BAO_0000218,
11474,8319,A,,2113.0,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623139,BAO_0000218,
11475,8319,A,,2113.0,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623140,BAO_0000218,
11476,8319,A,,2107.0,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623141,BAO_0000218,
11477,8319,A,,2107.0,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623142,BAO_0000218,
11478,8319,A,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623143,BAO_0000218,
11479,14571,A,,1088.0,50594,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623144,BAO_0000218,
11480,14571,A,,1088.0,50597,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623405,BAO_0000218,
11481,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624074,BAO_0000218,
11482,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624075,BAO_0000218,
11483,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624076,BAO_0000218,
11484,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624077,BAO_0000218,
11485,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624078,BAO_0000218,
11486,8319,A,,2113.0,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624079,BAO_0000218,
11487,8319,A,,2113.0,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624261,BAO_0000218,
11488,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624262,BAO_0000218,
11489,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624263,BAO_0000218,
11490,8319,A,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624264,BAO_0000218,
11491,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624265,BAO_0000218,
11492,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624266,BAO_0000218,
11493,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624267,BAO_0000218,
11494,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624268,BAO_0000218,
11495,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875227,BAO_0000218,
11496,8319,A,,2113.0,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624269,BAO_0000218,
11497,8319,A,,2113.0,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624270,BAO_0000218,
11498,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624271,BAO_0000218,
11499,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624272,BAO_0000218,
11500,8319,A,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624273,BAO_0000218,
11501,12064,A,,1088.0,50597,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624274,BAO_0000218,
11502,12064,A,,1088.0,50597,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624275,BAO_0000218,
11503,12064,A,,1088.0,50597,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624276,BAO_0000218,
11504,12038,A,,1088.0,50597,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624277,BAO_0000218,
11505,14314,A,,,22224,% dose converted to 2-amino-5-chlorophenyl sulfate,,0,,,1,,U,Autocuration,,,CHEMBL624278,BAO_0000019,
11506,14314,A,,,22224,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,0,,,1,,U,Autocuration,,,CHEMBL624279,BAO_0000019,
11507,11488,A,,1988.0,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624280,BAO_0000218,
11508,11488,A,,1988.0,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624281,BAO_0000218,
11509,11488,A,,1988.0,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622933,BAO_0000218,
11510,11488,A,,1988.0,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622934,BAO_0000218,
11511,8829,A,,2107.0,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622935,BAO_0000218,
11512,8829,A,,2107.0,50597,Biodistribution in Rat liver after 5 minutes of iv administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622936,BAO_0000218,
11513,8829,A,,2107.0,50597,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875228,BAO_0000218,
11514,8829,A,,2048.0,50597,Biodistribution in Rat lung after 24 hours of iv administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622937,BAO_0000218,
11515,8829,A,,2048.0,50597,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622938,BAO_0000218,
11516,8829,A,,2048.0,50597,Biodistribution in Rat lung after 30 minutes of iv administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL619736,BAO_0000218,
11517,8829,A,,2048.0,50597,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625117,BAO_0000218,
11518,8829,A,,2048.0,50597,Biodistribution in Rat lung after 5 minutes of iv administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625118,BAO_0000218,
11519,8829,A,,2048.0,50597,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625119,BAO_0000218,
11520,14972,A,,2037.0,50597,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625120,BAO_0000218,
11521,14972,A,,,50597,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625121,BAO_0000218,
11522,14972,A,,10000006.0,50597,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Thalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625122,BAO_0000218,
11523,14608,A,,178.0,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622204,BAO_0000218,
11524,14608,A,,178.0,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877503,BAO_0000218,
11525,14608,A,,178.0,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627127,BAO_0000218,
11526,14608,A,,10000000.0,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,0,,,1,,U,Autocuration,,,CHEMBL627128,BAO_0000218,
11527,14608,A,,10000000.0,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,0,,,1,,U,Autocuration,,,CHEMBL627129,BAO_0000218,
11528,14608,A,,10000000.0,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,0,,,1,,U,Autocuration,,,CHEMBL627130,BAO_0000218,
11529,14608,A,,955.0,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627131,BAO_0000218,
11530,14608,A,,955.0,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627132,BAO_0000218,
11531,14608,A,,955.0,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627133,BAO_0000218,
11532,14608,A,,2037.0,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627134,BAO_0000218,
11533,14608,A,,2037.0,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627135,BAO_0000218,
11534,14608,A,,2037.0,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627136,BAO_0000218,
11535,14608,A,,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628435,BAO_0000218,
11536,14608,A,,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628436,BAO_0000218,
11537,14608,A,,,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628437,BAO_0000218,
11538,14608,A,,948.0,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628438,BAO_0000218,
11539,14608,A,,948.0,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628439,BAO_0000218,
11540,14608,A,,948.0,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628440,BAO_0000218,
11541,14608,A,,10000000.0,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628441,BAO_0000218,
11542,14608,A,,10000000.0,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628442,BAO_0000218,
11543,14608,A,,10000000.0,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628443,BAO_0000218,
11544,14608,A,,2113.0,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628444,BAO_0000218,
11545,14608,A,,2113.0,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628445,BAO_0000218,
11546,14608,A,,2113.0,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877504,BAO_0000218,
11547,14608,A,,2107.0,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628446,BAO_0000218,
11548,14608,A,,2107.0,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626874,BAO_0000218,
11549,14608,A,,2107.0,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626875,BAO_0000218,
11550,14608,A,,2048.0,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626876,BAO_0000218,
11551,14608,A,,2048.0,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626877,BAO_0000218,
11552,14608,A,,2048.0,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626878,BAO_0000218,
11553,14608,A,,2385.0,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626879,BAO_0000218,
11554,8918,A,,1969.0,22224,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626880,BAO_0000218,
11555,8918,A,,1969.0,50594,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626881,BAO_0000218,
11556,8918,A,,1969.0,50597,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626882,BAO_0000218,
11557,14470,A,,1969.0,50588,Peak plasma concentration was measured in dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626883,BAO_0000218,
11558,14393,A,,,50597,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626884,BAO_0000218,
11559,14886,A,,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626885,BAO_0000218,
11560,14886,A,,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626886,BAO_0000218,
11561,14886,A,,,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626887,BAO_0000218,
11562,14393,A,,,50597,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626888,BAO_0000218,
11563,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626889,BAO_0000218,
11564,13465,A,,,22224,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626761,BAO_0000218,
11565,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626762,BAO_0000218,
11566,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626763,BAO_0000218,
11567,13465,A,,,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626764,BAO_0000218,
11568,13465,A,,,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626765,BAO_0000218,
11569,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626766,BAO_0000218,
11570,13465,A,,,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626767,BAO_0000218,
11571,13465,A,,,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626768,BAO_0000218,
11572,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626769,BAO_0000218,
11573,13465,A,,,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874463,BAO_0000218,
11574,13465,A,,,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626770,BAO_0000218,
11575,13465,A,,,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626771,BAO_0000218,
11576,13465,A,,,50597,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626772,BAO_0000218,
11577,14731,A,,,100710,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626773,BAO_0000218,
11578,14731,A,,,50594,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626774,BAO_0000218,
11579,13376,A,,,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626775,BAO_0000218,
11580,13376,A,,,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626776,BAO_0000218,
11581,14443,A,,,50597,Maximum concentration (Cmax) in rat when administered orally,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626777,BAO_0000218,
11582,13465,A,,1969.0,22224,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626778,BAO_0000218,
11583,16359,A,,,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL626779,BAO_0000218,
11584,16359,A,,,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL626780,BAO_0000218,
11585,15618,A,,1969.0,22224,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626781,BAO_0000218,
11586,14554,A,,,50597,Pharmacokinetic profile Cmax was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632164,BAO_0000218,
11587,11537,A,,,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632165,BAO_0000218,
11588,11537,A,,,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL632166,BAO_0000218,
11589,11537,A,,,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632167,BAO_0000218,
11590,11537,A,,,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL632168,BAO_0000218,
11591,2021,A,,1969.0,22224,Cmax in rat plasma,Plasma,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL632169,BAO_0000218,
11592,5932,A,,1969.0,50588,Cmax in dog plasma after 30mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632170,BAO_0000218,
11593,5932,A,,1969.0,50597,Cmax in rat plasma after 30mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632171,BAO_0000218,
11594,17320,A,,1969.0,50597,Plasma level in rats at 30 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632172,BAO_0000218,
11595,15831,A,,1969.0,50594,Tested for maximum plasma concentration in mice,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL632173,BAO_0000218,
11596,15078,A,,,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632174,BAO_0000218,
11597,14941,A,,,50597,The Cmax values in female wistar rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632175,BAO_0000218,
11598,15343,A,,1969.0,50588,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632176,BAO_0000218,
11599,15343,A,,1969.0,50597,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632177,BAO_0000218,
11600,14856,A,,1969.0,50597,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632178,BAO_0000218,
11601,13129,A,,,50597,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632179,BAO_0000218,
11602,13098,A,,178.0,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632180,BAO_0000218,
11603,13098,A,,178.0,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632181,BAO_0000218,
11604,13098,A,,178.0,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632182,BAO_0000218,
11605,15478,A,,178.0,22224,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Blood,0,,Mus musculus,1,10090.0,U,Autocuration,,,CHEMBL632183,BAO_0000218,
11606,15341,A,,,50588,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632184,BAO_0000218,
11607,15341,A,,,50597,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874470,BAO_0000218,
11608,8684,A,,,50597,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631302,BAO_0000218,
11609,8684,A,,,50597,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631303,BAO_0000218,
11610,8684,A,,,50597,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631304,BAO_0000218,
11611,8684,A,,,50597,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631305,BAO_0000218,
11612,8684,A,,,50597,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631306,BAO_0000218,
11613,8684,A,,,50597,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631307,BAO_0000218,
11614,8684,A,,,50597,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631308,BAO_0000218,
11615,8684,A,,,50597,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625557,BAO_0000218,
11616,8684,A,,2106.0,50597,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625558,BAO_0000218,
11617,8684,A,,2106.0,50597,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625559,BAO_0000218,
11618,8684,A,,2106.0,50597,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625560,BAO_0000218,
11619,8684,A,,2106.0,50597,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625561,BAO_0000218,
11620,8684,A,,2106.0,50597,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625562,BAO_0000218,
11621,8684,A,,2106.0,50597,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875320,BAO_0000218,
11622,8684,A,,2106.0,50597,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625563,BAO_0000218,
11623,8684,A,,2106.0,50597,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625564,BAO_0000218,
11624,8684,A,,995.0,50597,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625565,BAO_0000218,
11625,8684,A,,995.0,50597,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625566,BAO_0000218,
11626,8684,A,,995.0,50597,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625567,BAO_0000218,
11627,8684,A,,995.0,50597,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625568,BAO_0000218,
11628,8684,A,,995.0,50597,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628217,BAO_0000218,
11629,8684,A,,995.0,50597,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628218,BAO_0000218,
11630,8684,A,,995.0,50597,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628219,BAO_0000218,
11631,8684,A,,995.0,50597,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628220,BAO_0000218,
11632,8926,A,,,22224,Distribution in the blood after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628221,BAO_0000019,
11633,8926,A,,,22224,Distribution in the blood after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628222,BAO_0000019,
11634,8926,A,,,22224,Distribution in the blood after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628223,BAO_0000019,
11635,8926,A,,,22224,Distribution in the blood after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628224,BAO_0000019,
11636,8926,A,,,22224,Distribution in the blood after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628225,BAO_0000019,
11637,8926,A,,,22224,Distribution in the blood after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628226,BAO_0000019,
11638,8926,A,,,22224,Distribution in the bone after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628227,BAO_0000019,
11639,8926,A,,,22224,Distribution in the bone after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL875481,BAO_0000019,
11640,8926,A,,,22224,Distribution in the bone after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628228,BAO_0000019,
11641,8926,A,,,22224,Distribution in the bone after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628229,BAO_0000019,
11642,8926,A,,,22224,Distribution in the bone after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628230,BAO_0000019,
11643,8926,A,,,22224,Distribution in the bone after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628231,BAO_0000019,
11644,8926,A,,,22224,Distribution in the heart after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628232,BAO_0000019,
11645,8926,A,,,22224,Distribution in the heart after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628233,BAO_0000019,
11646,8926,A,,,22224,Distribution in the heart after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628234,BAO_0000019,
11647,8926,A,,,22224,Distribution in the heart after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628235,BAO_0000019,
11648,8926,A,,,22224,Distribution in the heart after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628236,BAO_0000019,
11649,8926,A,,,22224,Distribution in the heart after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628237,BAO_0000019,
11650,8926,A,,,22224,Distribution in the kidneys after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628238,BAO_0000019,
11651,8926,A,,,22224,Distribution in the kidneys after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628239,BAO_0000019,
11652,8926,A,,,22224,Distribution in the kidneys after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628240,BAO_0000019,
11653,8926,A,,,22224,Distribution in the kidneys after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628241,BAO_0000019,
11654,8926,A,,,22224,Distribution in the kidneys after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628242,BAO_0000019,
11655,8926,A,,,22224,Distribution in the kidneys after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL875482,BAO_0000019,
11656,8926,A,,,22224,Distribution in the liver after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628243,BAO_0000019,
11657,8926,A,,,22224,Distribution in the liver after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628244,BAO_0000019,
11658,8926,A,,,22224,Distribution in the liver after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628245,BAO_0000019,
11659,8926,A,,,22224,Distribution in the liver after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628246,BAO_0000019,
11660,8926,A,,,22224,Distribution in the liver after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628247,BAO_0000019,
11661,8926,A,,,22224,Distribution in the liver after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628248,BAO_0000019,
11662,8926,A,,,22224,Distribution in the lung after 120 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628249,BAO_0000019,
11663,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625452,BAO_0000218,
11664,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625453,BAO_0000218,
11665,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625454,BAO_0000218,
11666,14839,A,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623844,BAO_0000218,
11667,12178,A,,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623845,BAO_0000218,
11668,12178,A,,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623846,BAO_0000218,
11669,12178,A,,,22224,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,0,,,1,,U,Autocuration,,,CHEMBL623847,BAO_0000218,
11670,12186,A,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623848,BAO_0000218,
11671,12186,A,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623849,BAO_0000218,
11672,12186,A,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623850,BAO_0000218,
11673,12186,A,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623851,BAO_0000218,
11674,12187,A,,,22224,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623852,BAO_0000218,
11675,12187,A,,,50506,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL624551,BAO_0000218,
11676,12187,A,,,50506,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL624552,BAO_0000218,
11677,12187,A,,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL624553,BAO_0000218,
11678,12187,A,,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL624554,BAO_0000218,
11679,12187,A,,,50597,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624555,BAO_0000218,
11680,12187,A,,,50597,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624741,BAO_0000218,
11681,14122,A,,,50588,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624742,BAO_0000218,
11682,14122,A,,,100712,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL624743,BAO_0000218,
11683,14122,A,,,50597,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877606,BAO_0000218,
11684,13391,A,,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL624744,BAO_0000218,
11685,13391,A,,178.0,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL624745,BAO_0000218,
11686,13391,A,,178.0,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL624746,BAO_0000218,
11687,13391,A,,178.0,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,0,,,1,,U,Autocuration,,,CHEMBL624747,BAO_0000218,
11688,16360,A,,,22224,Oral absorption expressed as Area under curve was determined,,0,,,1,,U,Autocuration,,,CHEMBL624748,BAO_0000019,
11689,3673,A,,,50588,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622504,BAO_0000218,
11690,14122,A,,,50588,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622505,BAO_0000218,
11691,14122,A,,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL622506,BAO_0000218,
11692,14122,A,,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL622507,BAO_0000218,
11693,14122,A,,,50597,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622508,BAO_0000218,
11694,13889,A,,,22224,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,0,,,1,,U,Autocuration,,,CHEMBL622509,BAO_0000019,
11695,14393,A,,,50597,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622510,BAO_0000218,
11696,17279,A,,,50597,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622511,BAO_0000218,
11697,14548,A,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL622512,BAO_0000218,
11698,14548,A,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL622513,BAO_0000218,
11699,14548,A,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL622514,BAO_0000218,
11700,14548,A,,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622515,BAO_0000218,
11701,14548,A,,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622516,BAO_0000218,
11702,14548,A,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622517,BAO_0000218,
11703,14548,A,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622518,BAO_0000218,
11704,14548,A,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622519,BAO_0000218,
11705,14608,A,,2385.0,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622520,BAO_0000218,
11706,14608,A,,2385.0,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622521,BAO_0000218,
11707,14608,A,,14.0,50594,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625113,BAO_0000218,
11708,14608,A,,14.0,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625114,BAO_0000218,
11709,14608,A,,14.0,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874397,BAO_0000218,
11710,14608,A,,2106.0,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625115,BAO_0000218,
11711,14608,A,,2106.0,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625116,BAO_0000218,
11712,14608,A,,2106.0,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623932,BAO_0000218,
11713,14608,A,,2435.0,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623933,BAO_0000218,
11714,14608,A,,2435.0,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623934,BAO_0000218,
11715,14608,A,,2435.0,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623935,BAO_0000218,
11716,14608,A,,2046.0,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623936,BAO_0000218,
11717,14608,A,,2046.0,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623937,BAO_0000218,
11718,14608,A,,2046.0,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623938,BAO_0000218,
11719,15383,A,,,50594,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623939,BAO_0000218,
11720,15383,A,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623940,BAO_0000218,
11721,15383,A,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623941,BAO_0000218,
11722,15383,A,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627216,BAO_0000218,
11723,15383,A,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623942,BAO_0000218,
11724,15383,A,,955.0,50594,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618793,BAO_0000218,
11725,15383,A,,955.0,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618794,BAO_0000218,
11726,15383,A,,955.0,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618795,BAO_0000218,
11727,15383,A,,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618796,BAO_0000218,
11728,15383,A,,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618797,BAO_0000218,
11729,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618798,BAO_0000218,
11730,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618799,BAO_0000218,
11731,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618800,BAO_0000218,
11732,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618801,BAO_0000218,
11733,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618802,BAO_0000218,
11734,15383,A,,2113.0,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618803,BAO_0000218,
11735,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618804,BAO_0000218,
11736,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618805,BAO_0000218,
11737,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618806,BAO_0000218,
11738,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618807,BAO_0000218,
11739,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618808,BAO_0000218,
11740,15383,A,,2107.0,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618809,BAO_0000218,
11741,15383,A,,2385.0,50594,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618810,BAO_0000218,
11742,15383,A,,2385.0,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618811,BAO_0000218,
11743,15383,A,,2385.0,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875844,BAO_0000218,
11744,15383,A,,2385.0,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618812,BAO_0000218,
11745,15383,A,,2385.0,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618813,BAO_0000218,
11746,15383,A,,,50594,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618814,BAO_0000218,
11747,15383,A,,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618815,BAO_0000218,
11748,15383,A,,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618816,BAO_0000218,
11749,15383,A,,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL618817,BAO_0000218,
11750,15383,A,,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL620544,BAO_0000218,
11751,15341,A,,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626230,BAO_0000218,
11752,15341,A,,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626231,BAO_0000218,
11753,15341,A,,,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626232,BAO_0000218,
11754,14906,A,,1969.0,50588,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626233,BAO_0000218,
11755,14906,A,,1969.0,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626234,BAO_0000218,
11756,14906,A,,1969.0,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875341,BAO_0000218,
11757,14215,A,,1969.0,50587,The maximum plasma concentration (100 mg/kg) administered orally in human,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626235,BAO_0000218,
11758,14215,A,,1969.0,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Plasma,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL626236,BAO_0000218,
11759,14215,A,,1969.0,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626237,BAO_0000218,
11760,14215,A,,1969.0,50588,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626238,BAO_0000218,
11761,14215,A,,1969.0,50587,The maximum plasma concentration (200 mg/kg) administered orally in human,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL622412,BAO_0000218,
11762,14215,A,,1969.0,50597,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623114,BAO_0000218,
11763,14215,A,,1969.0,22224,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Plasma,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL623115,BAO_0000218,
11764,14215,A,,1969.0,22224,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623116,BAO_0000218,
11765,14215,A,,1969.0,22224,The maximum plasma concentration (30 mg/kg) administered orally in dog,Plasma,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL623117,BAO_0000218,
11766,14215,A,,1969.0,50587,The maximum plasma concentration (400 mg/kg) administered orally in human,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623118,BAO_0000218,
11767,14215,A,,1969.0,50597,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623119,BAO_0000218,
11768,14215,A,,1969.0,50597,The maximum plasma concentration (50 mg/kg) administered orally in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623120,BAO_0000218,
11769,14215,A,,1969.0,50587,The maximum plasma concentration (800 mg/kg) administered orally in human,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL623286,BAO_0000218,
11770,14067,A,,1969.0,50597,The maximum plasma concentration was measured on rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623287,BAO_0000218,
11771,12350,A,,1969.0,50597,The maximum plasma concentration was measured on rats after oral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623288,BAO_0000218,
11772,14813,A,,1969.0,50597,Plasma drug Cmax in rat (PO dose),Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623289,BAO_0000218,
11773,12536,A,,,22224,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,0,,,1,,U,Autocuration,,,CHEMBL623290,BAO_0000218,
11774,14169,A,,1969.0,50588,maximum Plasma concentration in Dog was determined after Peroral administration,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623291,BAO_0000218,
11775,14169,A,,1969.0,50597,maximum Plasma concentration in Rats was determined after Peroral administration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623292,BAO_0000218,
11776,15604,A,,1969.0,50588,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623293,BAO_0000218,
11777,15604,A,,1969.0,22224,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623294,BAO_0000218,
11778,15604,A,,1969.0,50597,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623295,BAO_0000218,
11779,14387,A,,,50594,maximum concentration was measured when administered through oral route in mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623296,BAO_0000218,
11780,15115,A,,,50594,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875349,BAO_0000218,
11781,15115,A,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623297,BAO_0000019,
11782,15115,A,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623298,BAO_0000019,
11783,15115,A,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL623299,BAO_0000019,
11784,16359,A,,,50597,Pharmacokinetic parameter was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623300,BAO_0000218,
11785,12829,A,,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623301,BAO_0000218,
11786,12829,A,,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623302,BAO_0000218,
11787,12829,A,,,50594,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623303,BAO_0000218,
11788,12829,A,,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623304,BAO_0000218,
11789,12829,A,,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623305,BAO_0000218,
11790,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623306,BAO_0000218,
11791,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623307,BAO_0000218,
11792,15137,A,,1969.0,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623308,BAO_0000218,
11793,15137,A,,1969.0,50594,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623309,BAO_0000218,
11794,13509,A,,,50594,Plasma Concentration after 120 min of oral administration to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623310,BAO_0000218,
11795,13509,A,,,50594,Plasma Concentration after 30 min of oral administration to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623311,BAO_0000218,
11796,13509,A,,,100710,Plasma Concentration after 60 min of oral administration to mice,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL623312,BAO_0000218,
11797,13509,A,,,50594,Plasma Concentration after 60 min of oral administration to mice; Not determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875350,BAO_0000218,
11798,13509,A,,,50594,Plasma Concentration after 90 min of oral administration to mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628635,BAO_0000218,
11799,12064,A,,,50597,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628636,BAO_0000218,
11800,12064,A,,,50597,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628637,BAO_0000218,
11801,12064,A,,,50597,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628058,BAO_0000218,
11802,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628059,BAO_0000218,
11803,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628060,BAO_0000218,
11804,8926,A,,,22224,Distribution in the lung after 15 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628061,BAO_0000019,
11805,8926,A,,,22224,Distribution in the lung after 30 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628062,BAO_0000019,
11806,8926,A,,,22224,Distribution in the lung after 5 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628063,BAO_0000019,
11807,8926,A,,,22224,Distribution in the lung after 60 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628064,BAO_0000019,
11808,8926,A,,,22224,Distribution in the lung after 90 min of intravenous administration,,0,,,1,,U,Autocuration,,,CHEMBL628065,BAO_0000019,
11809,8926,A,,2385.0,22224,Distribution in the muscle after 120 min of intravenous administration,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL628066,BAO_0000019,
11810,8926,A,,2385.0,22224,Distribution in the muscle after 15 min of intravenous administration,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL628067,BAO_0000019,
11811,8926,A,,2385.0,50594,Distribution in the muscle after 30 min of intravenous administration,Muscle tissue,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL874646,BAO_0000218,
11812,8926,A,,2385.0,22224,Distribution in the muscle after 5 min of intravenous administration,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL628068,BAO_0000019,
11813,8926,A,,2385.0,22224,Distribution in the muscle after 60 min of intravenous administration,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL628069,BAO_0000019,
11814,8926,A,,2385.0,22224,Distribution in the muscle after 90 min of intravenous administration,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL628070,BAO_0000019,
11815,8926,A,,2106.0,22224,Distribution in the spleen after 120 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628071,BAO_0000019,
11816,8926,A,,2106.0,22224,Distribution in the spleen after 15 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628072,BAO_0000019,
11817,8926,A,,2106.0,22224,Distribution in the spleen after 30 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628073,BAO_0000019,
11818,8926,A,,2106.0,22224,Distribution in the spleen after 5 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628074,BAO_0000019,
11819,8926,A,,2106.0,22224,Distribution in the spleen after 60 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628075,BAO_0000019,
11820,8926,A,,2106.0,22224,Distribution in the spleen after 90 min of intravenous administration,Spleen,0,,,1,,U,Autocuration,,,CHEMBL628076,BAO_0000019,
11821,7570,A,,1235.0,50597,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628077,BAO_0000218,
11822,7570,A,,178.0,50597,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628078,BAO_0000218,
11823,7570,A,,2107.0,50597,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628079,BAO_0000218,
11824,7570,A,,992.0,50597,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628080,BAO_0000218,
11825,7570,A,,2046.0,50597,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628081,BAO_0000218,
11826,7570,A,,1235.0,50597,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628082,BAO_0000218,
11827,7570,A,,178.0,50597,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874647,BAO_0000218,
11828,7570,A,,2107.0,50597,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626406,BAO_0000218,
11829,7570,A,,992.0,50597,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626407,BAO_0000218,
11830,7570,A,,2046.0,50597,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626408,BAO_0000218,
11831,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626409,BAO_0000218,
11832,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626410,BAO_0000218,
11833,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626411,BAO_0000218,
11834,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626412,BAO_0000218,
11835,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626413,BAO_0000218,
11836,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626414,BAO_0000218,
11837,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626415,BAO_0000218,
11838,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626416,BAO_0000218,
11839,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627062,BAO_0000218,
11840,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627063,BAO_0000218,
11841,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627064,BAO_0000218,
11842,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627227,BAO_0000218,
11843,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627228,BAO_0000218,
11844,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627229,BAO_0000218,
11845,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625792,BAO_0000218,
11846,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625793,BAO_0000218,
11847,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625794,BAO_0000218,
11848,8608,A,,178.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625795,BAO_0000218,
11849,13792,A,,,50594,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625796,BAO_0000218,
11850,13376,A,,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625797,BAO_0000218,
11851,13376,A,,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625798,BAO_0000218,
11852,14380,A,,,22224,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL875613,BAO_0000218,
11853,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625799,BAO_0000218,
11854,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625800,BAO_0000218,
11855,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625801,BAO_0000218,
11856,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625802,BAO_0000218,
11857,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625803,BAO_0000218,
11858,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,0,,,1,,U,Autocuration,,,CHEMBL625804,BAO_0000019,
11859,14380,A,,,22224,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL622530,BAO_0000218,
11860,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622531,BAO_0000218,
11861,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622532,BAO_0000218,
11862,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623176,BAO_0000218,
11863,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623177,BAO_0000218,
11864,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623178,BAO_0000218,
11865,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623179,BAO_0000218,
11866,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623180,BAO_0000218,
11867,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623181,BAO_0000218,
11868,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624131,BAO_0000218,
11869,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624132,BAO_0000218,
11870,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624133,BAO_0000218,
11871,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624846,BAO_0000218,
11872,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624847,BAO_0000218,
11873,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL624848,BAO_0000218,
11874,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625012,BAO_0000218,
11875,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625013,BAO_0000218,
11876,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625014,BAO_0000218,
11877,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625015,BAO_0000218,
11878,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625016,BAO_0000218,
11879,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625017,BAO_0000218,
11880,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625018,BAO_0000218,
11881,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625019,BAO_0000218,
11882,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625020,BAO_0000218,
11883,13701,A,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625021,BAO_0000218,
11884,14393,A,,,50597,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625022,BAO_0000218,
11885,14731,A,,,50594,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625023,BAO_0000218,
11886,14731,A,,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL625024,BAO_0000218,
11887,14731,A,,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL627626,BAO_0000218,
11888,13758,A,,955.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,0,,,1,,U,Autocuration,,,CHEMBL627627,BAO_0000218,
11889,13758,A,,1977.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Serum,0,,,1,,U,Autocuration,,,CHEMBL627628,BAO_0000218,
11890,13758,A,,955.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,0,,,1,,U,Autocuration,,,CHEMBL627629,BAO_0000218,
11891,13758,A,,1977.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Serum,0,,,1,,U,Autocuration,,,CHEMBL627630,BAO_0000218,
11892,16359,A,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,0,,,1,,U,Autocuration,,,CHEMBL627631,BAO_0000019,
11893,16359,A,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,0,,,1,,U,Autocuration,,,CHEMBL629515,BAO_0000218,
11894,15383,A,,2106.0,50594,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629516,BAO_0000218,
11895,15383,A,,2106.0,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629517,BAO_0000218,
11896,15383,A,,2106.0,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629518,BAO_0000218,
11897,15383,A,,,50594,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL877499,BAO_0000218,
11898,15383,A,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629519,BAO_0000218,
11899,15383,A,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629520,BAO_0000218,
11900,15383,A,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629521,BAO_0000218,
11901,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629522,BAO_0000218,
11902,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629523,BAO_0000218,
11903,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629524,BAO_0000218,
11904,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629525,BAO_0000218,
11905,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629526,BAO_0000218,
11906,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629527,BAO_0000218,
11907,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629528,BAO_0000218,
11908,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629529,BAO_0000218,
11909,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629530,BAO_0000218,
11910,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629531,BAO_0000218,
11911,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628656,BAO_0000218,
11912,14439,A,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628657,BAO_0000218,
11913,13751,A,,,50597,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628658,BAO_0000218,
11914,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628659,BAO_0000218,
11915,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877500,BAO_0000218,
11916,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628660,BAO_0000218,
11917,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628661,BAO_0000218,
11918,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628662,BAO_0000218,
11919,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628663,BAO_0000218,
11920,13751,A,,,50597,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628664,BAO_0000218,
11921,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628665,BAO_0000218,
11922,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628666,BAO_0000218,
11923,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628667,BAO_0000218,
11924,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628668,BAO_0000218,
11925,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628669,BAO_0000218,
11926,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628670,BAO_0000218,
11927,13751,A,,178.0,50597,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628671,BAO_0000218,
11928,13751,A,,10000001.0,50597,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628672,BAO_0000218,
11929,13751,A,,10000001.0,50597,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630300,BAO_0000218,
11930,13751,A,,10000001.0,50597,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629787,BAO_0000218,
11931,13751,A,,10000001.0,50597,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629788,BAO_0000218,
11932,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629789,BAO_0000218,
11933,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629790,BAO_0000218,
11934,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629791,BAO_0000218,
11935,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629792,BAO_0000218,
11936,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629793,BAO_0000218,
11937,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629794,BAO_0000218,
11938,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874459,BAO_0000218,
11939,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629795,BAO_0000218,
11940,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629796,BAO_0000218,
11941,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629797,BAO_0000218,
11942,10677,A,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629798,BAO_0000218,
11943,10911,A,,2369.0,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Adrenal gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629799,BAO_0000218,
11944,10911,A,,2369.0,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Adrenal gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629800,BAO_0000218,
11945,10911,A,,2369.0,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Adrenal gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629801,BAO_0000218,
11946,10911,A,,2369.0,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Adrenal gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629802,BAO_0000218,
11947,10911,A,,2369.0,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Adrenal gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629803,BAO_0000218,
11948,10911,A,,178.0,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629804,BAO_0000218,
11949,10911,A,,178.0,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629805,BAO_0000218,
11950,10911,A,,178.0,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629806,BAO_0000218,
11951,10911,A,,178.0,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629807,BAO_0000218,
11952,10911,A,,178.0,50597,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629808,BAO_0000218,
11953,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629809,BAO_0000218,
11954,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629810,BAO_0000218,
11955,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629811,BAO_0000218,
11956,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629812,BAO_0000218,
11957,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629813,BAO_0000218,
11958,10911,A,,955.0,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874460,BAO_0000218,
11959,10911,A,,,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629814,BAO_0000218,
11960,10911,A,,,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629815,BAO_0000218,
11961,10911,A,,,50597,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629816,BAO_0000218,
11962,10911,A,,,50597,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629817,BAO_0000218,
11963,10911,A,,2113.0,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626643,BAO_0000218,
11964,10911,A,,2113.0,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626644,BAO_0000218,
11965,10911,A,,2113.0,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626806,BAO_0000218,
11966,10911,A,,2113.0,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626807,BAO_0000218,
11967,10911,A,,2107.0,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627261,BAO_0000218,
11968,10911,A,,2107.0,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627262,BAO_0000218,
11969,10911,A,,2107.0,50597,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627263,BAO_0000218,
11970,10911,A,,2107.0,50597,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627264,BAO_0000218,
11971,10911,A,,2048.0,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627265,BAO_0000218,
11972,10911,A,,2048.0,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627266,BAO_0000218,
11973,10911,A,,2048.0,50597,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627267,BAO_0000218,
11974,10911,A,,2048.0,50597,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627268,BAO_0000218,
11975,10911,A,,2385.0,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627269,BAO_0000218,
11976,10911,A,,2385.0,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627270,BAO_0000218,
11977,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627271,BAO_0000218,
11978,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627946,BAO_0000218,
11979,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875472,BAO_0000218,
11980,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627947,BAO_0000218,
11981,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627948,BAO_0000218,
11982,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628113,BAO_0000218,
11983,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628114,BAO_0000218,
11984,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628115,BAO_0000218,
11985,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628116,BAO_0000218,
11986,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628117,BAO_0000218,
11987,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628118,BAO_0000218,
11988,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628119,BAO_0000218,
11989,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628120,BAO_0000218,
11990,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628121,BAO_0000218,
11991,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628122,BAO_0000218,
11992,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627297,BAO_0000218,
11993,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627298,BAO_0000218,
11994,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627299,BAO_0000218,
11995,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627300,BAO_0000218,
11996,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627301,BAO_0000218,
11997,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627302,BAO_0000218,
11998,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627303,BAO_0000218,
11999,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627304,BAO_0000218,
12000,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627305,BAO_0000218,
12001,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627306,BAO_0000218,
12002,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623982,BAO_0000218,
12003,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623983,BAO_0000218,
12004,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623984,BAO_0000218,
12005,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623985,BAO_0000218,
12006,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623986,BAO_0000218,
12007,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623987,BAO_0000218,
12008,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623988,BAO_0000218,
12009,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623989,BAO_0000218,
12010,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622215,BAO_0000218,
12011,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622216,BAO_0000218,
12012,8608,A,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877481,BAO_0000218,
12013,16359,A,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,0,,,1,,U,Autocuration,,,CHEMBL622217,BAO_0000218,
12014,13701,A,,,50594,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622218,BAO_0000218,
12015,14554,A,,,50597,Pharmacokinetic profile AUC was evaluated in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622219,BAO_0000218,
12016,6241,A,,,22224,Pharmacokinetic property (Area under curve),,0,,,1,,U,Autocuration,,,CHEMBL622220,BAO_0000019,
12017,11537,A,,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622221,BAO_0000218,
12018,11537,A,,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622222,BAO_0000218,
12019,11537,A,,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622223,BAO_0000218,
12020,11537,A,,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622224,BAO_0000218,
12021,13118,A,,,22224,Plasma concentration (AUC) was determined,,0,,,1,,U,Autocuration,,,CHEMBL622225,BAO_0000019,
12022,13118,A,,,22224,Plasma concentration (AUC) was determined; Not detectable,,0,,,1,,U,Autocuration,,,CHEMBL622226,BAO_0000019,
12023,9562,A,,,50512,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL624154,BAO_0000218,
12024,10363,A,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624155,BAO_0000218,
12025,10363,A,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624156,BAO_0000218,
12026,10363,A,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624157,BAO_0000218,
12027,10363,A,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624158,BAO_0000218,
12028,12504,A,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624159,BAO_0000218,
12029,12504,A,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624160,BAO_0000218,
12030,12504,A,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624161,BAO_0000218,
12031,12504,A,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624162,BAO_0000218,
12032,13317,A,,,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624163,BAO_0000218,
12033,15078,A,,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624164,BAO_0000218,
12034,14941,A,,,50597,The AUC(0-infinity) values in female wistar rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624165,BAO_0000218,
12035,15078,A,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624166,BAO_0000218,
12036,15078,A,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624167,BAO_0000218,
12037,14941,A,,,50597,The AUC(0-t)values in female wistar rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624168,BAO_0000218,
12038,14067,A,,,50597,The Area under the concentration time curve of compound was measured on rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624169,BAO_0000218,
12039,14215,A,,,50587,The area under curve (100 mg/kg) administered orally in humans,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624170,BAO_0000218,
12040,14215,A,,,22224,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL624171,BAO_0000218,
12041,14215,A,,,22224,The area under curve (12.5 mg/kg) administered intravenously in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL624172,BAO_0000218,
12042,14215,A,,,50588,The area under curve (15 mg/kg) administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624173,BAO_0000218,
12043,14215,A,,,50587,The area under curve (200 mg/kg) administered orally in humans,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL877488,BAO_0000218,
12044,14215,A,,,50597,The area under curve (25 mg/kg) administered intravenously in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624174,BAO_0000218,
12045,14215,A,,,22224,The area under curve (25 mg/kg) administered orally in marmoset,,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL624175,BAO_0000218,
12046,14215,A,,,22224,The area under curve (25 mg/kg) administered orally in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL624176,BAO_0000218,
12047,14215,A,,,50588,The area under curve (30 mg/kg) administered orally in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624177,BAO_0000218,
12048,14215,A,,,50587,The area under curve (400 mg/kg) administered orally in humans,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624178,BAO_0000218,
12049,14215,A,,,50597,The area under curve (50 mg/kg) administered orally in fasted rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624179,BAO_0000218,
12050,14215,A,,,50597,The area under curve (50 mg/kg) administered orally in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627689,BAO_0000218,
12051,14215,A,,,50587,The area under curve (800 mg/kg) administered orally in humans,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL627690,BAO_0000218,
12052,11324,A,,,22224,The compound was evaluated for area under the curve,,0,,,1,,U,Autocuration,,,CHEMBL627691,BAO_0000019,
12053,11324,A,,,22224,The compound was evaluated for area under the curve in marmosets,,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL627692,BAO_0000019,
12054,11324,A,,,22224,The compound was evaluated for area under the curve in marmosets,,0,,Callithrix,1,9481.0,U,Autocuration,,,CHEMBL627693,BAO_0000019,
12055,13875,A,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627694,BAO_0000218,
12056,13875,A,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627695,BAO_0000218,
12057,13875,A,,,22224,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,0,,,1,,U,Autocuration,,,CHEMBL627696,BAO_0000218,
12058,13875,A,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627697,BAO_0000218,
12059,13875,A,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627698,BAO_0000218,
12060,13875,A,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627699,BAO_0000218,
12061,13807,A,,,50597,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627700,BAO_0000218,
12062,14127,A,,,50597,Total drug exposure is determined after oral dosing in rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627701,BAO_0000218,
12063,15116,A,,,22224,Total drug exposure (5 mg/kg) when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL627702,BAO_0000218,
12064,15116,A,,,22224,Total drug exposure (5 mg/kg) when administered orally,,0,,,1,,U,Autocuration,,,CHEMBL627703,BAO_0000218,
12065,15604,A,,,22224,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626873,BAO_0000218,
12066,15604,A,,,50597,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629583,BAO_0000218,
12067,15604,A,,,50588,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629584,BAO_0000218,
12068,15604,A,,,50588,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629585,BAO_0000218,
12069,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629586,BAO_0000218,
12070,13751,A,,955.0,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629587,BAO_0000218,
12071,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629588,BAO_0000218,
12072,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629589,BAO_0000218,
12073,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629590,BAO_0000218,
12074,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629591,BAO_0000218,
12075,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629592,BAO_0000218,
12076,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629593,BAO_0000218,
12077,13751,A,,,50597,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629594,BAO_0000218,
12078,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629595,BAO_0000218,
12079,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630290,BAO_0000218,
12080,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627137,BAO_0000218,
12081,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627138,BAO_0000218,
12082,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627139,BAO_0000218,
12083,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627140,BAO_0000218,
12084,13751,A,,948.0,50597,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627141,BAO_0000218,
12085,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627142,BAO_0000218,
12086,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627143,BAO_0000218,
12087,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874449,BAO_0000218,
12088,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627144,BAO_0000218,
12089,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627145,BAO_0000218,
12090,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627146,BAO_0000218,
12091,13751,A,,2113.0,50597,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627147,BAO_0000218,
12092,13751,A,,2107.0,50597,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627148,BAO_0000218,
12093,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627149,BAO_0000218,
12094,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632160,BAO_0000218,
12095,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632161,BAO_0000218,
12096,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632162,BAO_0000218,
12097,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632163,BAO_0000218,
12098,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874469,BAO_0000218,
12099,13751,A,,2048.0,50597,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627182,BAO_0000218,
12100,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627183,BAO_0000218,
12101,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627184,BAO_0000218,
12102,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627185,BAO_0000218,
12103,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627186,BAO_0000218,
12104,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627187,BAO_0000218,
12105,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627188,BAO_0000218,
12106,13751,A,,2385.0,50597,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627189,BAO_0000218,
12107,13751,A,,,50597,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627190,BAO_0000218,
12108,13751,A,,2107.0,50597,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627191,BAO_0000218,
12109,13751,A,,2107.0,50597,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627192,BAO_0000218,
12110,13751,A,,2107.0,50597,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627193,BAO_0000218,
12111,10911,A,,2385.0,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874590,BAO_0000218,
12112,10911,A,,2385.0,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627194,BAO_0000218,
12113,10911,A,,2385.0,50597,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627195,BAO_0000218,
12114,10911,A,,992.0,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627196,BAO_0000218,
12115,10911,A,,992.0,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627197,BAO_0000218,
12116,10911,A,,992.0,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627198,BAO_0000218,
12117,10911,A,,992.0,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627199,BAO_0000218,
12118,10911,A,,992.0,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Female gonad,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627200,BAO_0000218,
12119,10911,A,,1969.0,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627201,BAO_0000218,
12120,10911,A,,1969.0,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627202,BAO_0000218,
12121,10911,A,,1969.0,50597,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627203,BAO_0000218,
12122,10911,A,,1969.0,50597,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627204,BAO_0000218,
12123,10911,A,,2106.0,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627205,BAO_0000218,
12124,10911,A,,2106.0,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627206,BAO_0000218,
12125,10911,A,,2106.0,50597,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627207,BAO_0000218,
12126,10911,A,,2106.0,50597,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627208,BAO_0000218,
12127,10911,A,,2046.0,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627209,BAO_0000218,
12128,10911,A,,2046.0,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627210,BAO_0000218,
12129,10911,A,,2046.0,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627211,BAO_0000218,
12130,10911,A,,2046.0,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627212,BAO_0000218,
12131,10911,A,,995.0,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627213,BAO_0000218,
12132,10911,A,,995.0,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626599,BAO_0000218,
12133,10911,A,,995.0,50597,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626600,BAO_0000218,
12134,10911,A,,995.0,50597,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626601,BAO_0000218,
12135,8081,A,,,22224,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,0,,,1,,U,Autocuration,,,CHEMBL627484,BAO_0000019,
12136,17248,A,,1969.0,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL627485,BAO_0000218,
12137,17248,A,,1969.0,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628147,BAO_0000218,
12138,17248,A,,1969.0,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628148,BAO_0000218,
12139,17248,A,,1969.0,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628149,BAO_0000218,
12140,17248,A,,1969.0,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628150,BAO_0000218,
12141,17248,A,,1969.0,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628318,BAO_0000218,
12142,17248,A,,1969.0,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628319,BAO_0000218,
12143,15592,A,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875609,BAO_0000218,
12144,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,0,,,1,,U,Autocuration,,,CHEMBL628320,BAO_0000019,
12145,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,0,,,1,,U,Autocuration,,,CHEMBL628321,BAO_0000019,
12146,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,0,,,1,,U,Autocuration,,,CHEMBL628322,BAO_0000019,
12147,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,0,,,1,,U,Autocuration,,,CHEMBL628323,BAO_0000019,
12148,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,0,,,1,,U,Autocuration,,,CHEMBL628324,BAO_0000019,
12149,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,0,,,1,,U,Autocuration,,,CHEMBL628325,BAO_0000019,
12150,7040,A,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,0,,,1,,U,Autocuration,,,CHEMBL628326,BAO_0000019,
12151,9614,A,,1236.0,50588,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628327,BAO_0000218,
12152,9614,A,,1236.0,50588,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628328,BAO_0000218,
12153,9614,A,,178.0,50588,"Concentration of compound in blood of dog 1, after administering intravenously",Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628329,BAO_0000218,
12154,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628330,BAO_0000218,
12155,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628331,BAO_0000218,
12156,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628332,BAO_0000218,
12157,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628333,BAO_0000218,
12158,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628334,BAO_0000218,
12159,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628335,BAO_0000218,
12160,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628336,BAO_0000218,
12161,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628337,BAO_0000218,
12162,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628338,BAO_0000218,
12163,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875610,BAO_0000218,
12164,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628339,BAO_0000218,
12165,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628340,BAO_0000218,
12166,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628341,BAO_0000218,
12167,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622214,BAO_0000218,
12168,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623167,BAO_0000218,
12169,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623168,BAO_0000218,
12170,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623169,BAO_0000218,
12171,8608,A,,2107.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623170,BAO_0000218,
12172,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627224,BAO_0000218,
12173,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875634,BAO_0000218,
12174,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627225,BAO_0000218,
12175,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627226,BAO_0000218,
12176,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626083,BAO_0000218,
12177,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626084,BAO_0000218,
12178,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626085,BAO_0000218,
12179,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626086,BAO_0000218,
12180,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626087,BAO_0000218,
12181,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626088,BAO_0000218,
12182,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626089,BAO_0000218,
12183,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626090,BAO_0000218,
12184,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626091,BAO_0000218,
12185,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626092,BAO_0000218,
12186,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626093,BAO_0000218,
12187,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626094,BAO_0000218,
12188,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626095,BAO_0000218,
12189,8608,A,,2048.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626096,BAO_0000218,
12190,15604,A,,,22224,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626097,BAO_0000218,
12191,15604,A,,,50597,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626098,BAO_0000218,
12192,1806,A,,1969.0,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626099,BAO_0000218,
12193,1806,A,,1969.0,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Plasma,0,,,1,,U,Autocuration,,,CHEMBL626100,BAO_0000218,
12194,17237,A,,1969.0,50588,AUC 0-inf in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626101,BAO_0000218,
12195,17237,A,,1969.0,50512,AUC 0-inf in guinea pig,Plasma,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL626102,BAO_0000218,
12196,17237,A,,1969.0,50588,AUC 0-t in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626103,BAO_0000218,
12197,17237,A,,1969.0,50512,AUC 0-t in guinea pig,Plasma,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL628391,BAO_0000218,
12198,15194,A,,,50597,The compound was tested for brain to plasma partition in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628392,BAO_0000218,
12199,15194,A,,,50597,The compound was tested for brain to plasma partition in rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628393,BAO_0000218,
12200,8787,A,,178.0,22224,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Blood,0,,,1,,U,Autocuration,,,CHEMBL628394,BAO_0000019,
12201,17025,A,,,50588,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628395,BAO_0000218,
12202,17025,A,,,22224,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628396,BAO_0000218,
12203,17025,A,,,50592,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628397,BAO_0000218,
12204,17025,A,,,50597,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628398,BAO_0000218,
12205,4236,A,,,50797,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL628399,BAO_0000218,
12206,15343,A,,,50588,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628400,BAO_0000218,
12207,15343,A,,,50597,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874907,BAO_0000218,
12208,17720,A,,,22224,Area under curve of the compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL628401,BAO_0000019,
12209,17788,A,,1969.0,22224,AUC in monkeys at a dose of 1 mg/kg,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628402,BAO_0000218,
12210,17788,A,,1969.0,50597,AUC in rats at a dose of 1 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628403,BAO_0000218,
12211,8778,A,,,22224,Compound was evaluated for the overall absorbance loss at pH of 2,,0,,,1,,U,Autocuration,,,CHEMBL628404,BAO_0000019,
12212,8778,A,,,22224,Compound was evaluated for the overall absorbance loss at pH of 4,,0,,,1,,U,Autocuration,,,CHEMBL628405,BAO_0000019,
12213,8778,A,,,22224,Compound was evaluated for the overall absorbance loss at pH of 7,,0,,,1,,U,Autocuration,,,CHEMBL628406,BAO_0000019,
12214,2249,A,,,50597,Compound was evaluated for its absorption in the rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628407,BAO_0000218,
12215,8881,A,,1088.0,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628408,BAO_0000218,
12216,8881,A,,1088.0,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629171,BAO_0000218,
12217,8881,A,,1088.0,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629172,BAO_0000218,
12218,8881,A,,1088.0,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629173,BAO_0000218,
12219,15286,A,,,50597,In vitro percent permeability into rat ileum,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629174,BAO_0000218,
12220,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 10-17,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629175,BAO_0000218,
12221,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 10-18,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629176,BAO_0000218,
12222,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 10-19,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629177,BAO_0000218,
12223,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 12-15,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629178,BAO_0000218,
12224,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 13-19,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631869,BAO_0000218,
12225,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 14-17,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631870,BAO_0000218,
12226,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 15-18,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631871,BAO_0000218,
12227,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 2-5,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631872,BAO_0000218,
12228,15286,A,,2116.0,22224,In vitro percent permeability into rat ileum; Range is 23-42,Ileum,0,,,1,,U,Autocuration,,,CHEMBL875775,BAO_0000221,
12229,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 28-36,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631873,BAO_0000218,
12230,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 29-35,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631874,BAO_0000218,
12231,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 46-66,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631875,BAO_0000218,
12232,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 50-68,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631876,BAO_0000218,
12233,15286,A,,,50597,In vitro percent permeability into rat ileum; Range is 78-81,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631877,BAO_0000218,
12234,15286,A,,,50597,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631878,BAO_0000218,
12235,15286,A,,,50597,In vitro percent permeability into rat ileum; nd indicates not detected,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631879,BAO_0000218,
12236,15286,A,,,50597,In vitro percent permeability into rat ileum; nt indicates not detected,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631880,BAO_0000218,
12237,15286,A,,,50597,In vitro percent permeability into rat ileum; nt indicates not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631881,BAO_0000218,
12238,13770,A,,,50597,Compound was tested for oral absorption in bile-duct cannulated rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631882,BAO_0000218,
12239,13770,A,,,50597,Compound was tested for oral absorption in bile-duct cannulated rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630749,BAO_0000218,
12240,5202,A,,,50587,Oral absorption using Caco-2 cell monolayers.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL630750,BAO_0000218,
12241,14920,A,,,50587,Percent of the drug absorbed after administration to humans was determined,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL630253,BAO_0000218,
12242,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630254,BAO_0000218,
12243,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630255,BAO_0000218,
12244,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630256,BAO_0000218,
12245,13751,A,,2107.0,50597,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875781,BAO_0000218,
12246,13751,A,,2107.0,50597,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630257,BAO_0000218,
12247,13751,A,,2107.0,50597,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630258,BAO_0000218,
12248,15807,A,,,50597,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630259,BAO_0000218,
12249,15807,A,,2435.0,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630260,BAO_0000218,
12250,15807,A,,2435.0,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630261,BAO_0000218,
12251,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630262,BAO_0000218,
12252,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630263,BAO_0000218,
12253,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630264,BAO_0000218,
12254,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630265,BAO_0000218,
12255,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630266,BAO_0000218,
12256,14950,A,,2113.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630267,BAO_0000218,
12257,14950,A,,2113.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630268,BAO_0000218,
12258,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630269,BAO_0000218,
12259,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630270,BAO_0000218,
12260,14950,A,,2048.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630141,BAO_0000218,
12261,14950,A,,2048.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630142,BAO_0000218,
12262,14950,A,,2385.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630143,BAO_0000218,
12263,14950,A,,2385.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630144,BAO_0000218,
12264,14950,A,,2367.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Prostate gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630145,BAO_0000218,
12265,14950,A,,2367.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Prostate gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630146,BAO_0000218,
12266,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630147,BAO_0000218,
12267,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630148,BAO_0000218,
12268,14950,A,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630149,BAO_0000218,
12269,14950,A,,2106.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630150,BAO_0000218,
12270,14950,A,,2106.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630151,BAO_0000218,
12271,14950,A,,2046.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632031,BAO_0000218,
12272,14950,A,,2046.0,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632032,BAO_0000218,
12273,14950,A,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632033,BAO_0000218,
12274,14950,A,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632034,BAO_0000218,
12275,14950,A,,2385.0,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632035,BAO_0000218,
12276,14950,A,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632036,BAO_0000218,
12277,14950,A,,2046.0,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632037,BAO_0000218,
12278,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632038,BAO_0000218,
12279,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632039,BAO_0000218,
12280,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632040,BAO_0000218,
12281,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632041,BAO_0000218,
12282,9614,A,,178.0,50588,"Concentration of compound in blood of dog 2, after administering intravenously",Blood,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632042,BAO_0000218,
12283,9614,A,,,50588,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632043,BAO_0000218,
12284,9614,A,,,50588,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632044,BAO_0000218,
12285,9614,A,,2107.0,50588,"Concentration of compound in liver of dog 1, after administering intravenously",Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632045,BAO_0000218,
12286,9614,A,,2107.0,50588,"Concentration of compound in liver of dog 2, after administering intravenously",Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632046,BAO_0000218,
12287,9614,A,,2048.0,50588,"Concentration of compound in lung of dog 1, after administering intravenously",Lung,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632047,BAO_0000218,
12288,9614,A,,2048.0,50588,"Concentration of compound in lung of dog 2, after administering intravenously",Lung,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632048,BAO_0000218,
12289,9614,A,,2385.0,50588,"Concentration of compound in muscle of dog 1, after administering intravenously",Muscle tissue,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632049,BAO_0000218,
12290,9614,A,,2385.0,50588,"Concentration of compound in muscle of dog 2, after administering intravenously",Muscle tissue,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL876418,BAO_0000218,
12291,9614,A,,2106.0,50588,"Concentration of compound in spleen of dog 1,after administering intravenously",Spleen,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632050,BAO_0000218,
12292,9614,A,,2106.0,50588,"Concentration of compound in spleen of dog 2, after administering intravenously",Spleen,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL632051,BAO_0000218,
12293,10353,F,,,22224,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,0,,,1,,U,Autocuration,,,CHEMBL632052,BAO_0000218,
12294,10353,F,,,22224,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,0,,,1,,U,Autocuration,,,CHEMBL632053,BAO_0000218,
12295,10353,A,,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,0,,,1,,U,Autocuration,,,CHEMBL632054,BAO_0000218,
12296,10353,F,,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,0,,,1,,U,Autocuration,,,CHEMBL632055,BAO_0000218,
12297,10353,F,,,22224,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,0,,,1,,U,Autocuration,,,CHEMBL631181,BAO_0000218,
12298,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL631182,BAO_0000218,
12299,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL631183,BAO_0000218,
12300,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL631184,BAO_0000218,
12301,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL629774,BAO_0000218,
12302,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL629775,BAO_0000218,
12303,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL876549,BAO_0000218,
12304,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628172,BAO_0000218,
12305,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628173,BAO_0000218,
12306,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628174,BAO_0000218,
12307,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628175,BAO_0000218,
12308,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628176,BAO_0000218,
12309,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628177,BAO_0000218,
12310,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628178,BAO_0000218,
12311,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628179,BAO_0000218,
12312,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,0,,,1,,U,Autocuration,,,CHEMBL628180,BAO_0000218,
12313,9196,A,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628181,BAO_0000218,
12314,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628182,BAO_0000218,
12315,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628183,BAO_0000218,
12316,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL628184,BAO_0000218,
12317,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628185,BAO_0000218,
12318,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL875617,BAO_0000218,
12319,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL628186,BAO_0000218,
12320,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628187,BAO_0000218,
12321,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628188,BAO_0000218,
12322,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628189,BAO_0000218,
12323,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL628190,BAO_0000218,
12324,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628191,BAO_0000218,
12325,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL626513,BAO_0000218,
12326,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626514,BAO_0000218,
12327,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626515,BAO_0000218,
12328,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626516,BAO_0000218,
12329,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626517,BAO_0000218,
12330,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626518,BAO_0000218,
12331,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626519,BAO_0000218,
12332,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626520,BAO_0000218,
12333,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626521,BAO_0000218,
12334,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626522,BAO_0000218,
12335,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626523,BAO_0000218,
12336,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626524,BAO_0000218,
12337,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626688,BAO_0000218,
12338,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626689,BAO_0000218,
12339,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626690,BAO_0000218,
12340,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626691,BAO_0000218,
12341,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627319,BAO_0000218,
12342,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624052,BAO_0000218,
12343,8608,A,,2046.0,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624053,BAO_0000218,
12344,8085,A,,,50597,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624054,BAO_0000218,
12345,8085,A,,,50597,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624055,BAO_0000218,
12346,8085,A,,,50597,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624056,BAO_0000218,
12347,8085,A,,995.0,50597,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624057,BAO_0000218,
12348,8085,A,,995.0,50597,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622281,BAO_0000218,
12349,8085,A,,995.0,50597,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622282,BAO_0000218,
12350,8085,A,,995.0,50597,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622283,BAO_0000218,
12351,8085,A,,995.0,50597,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622284,BAO_0000218,
12352,8085,A,,995.0,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622285,BAO_0000218,
12353,8085,A,,995.0,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622286,BAO_0000218,
12354,7657,P,,,22224,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL622287,BAO_0000100,
12355,8935,A,,,50594,Partition coefficient (logD7.4),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622288,BAO_0000218,
12356,13792,A,,,50594,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622289,BAO_0000218,
12357,13792,A,,955.0,50594,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622290,BAO_0000218,
12358,13792,A,,,50594,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622291,BAO_0000218,
12359,13792,A,,955.0,50594,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622292,BAO_0000218,
12360,13792,A,,,50594,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622293,BAO_0000218,
12361,13792,A,,955.0,50594,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622294,BAO_0000218,
12362,13792,A,,,50594,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL622295,BAO_0000218,
12363,13792,A,,955.0,50597,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622296,BAO_0000218,
12364,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874409,BAO_0000218,
12365,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622297,BAO_0000218,
12366,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622298,BAO_0000218,
12367,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622299,BAO_0000218,
12368,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622300,BAO_0000218,
12369,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622301,BAO_0000218,
12370,14103,A,,1969.0,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622302,BAO_0000218,
12371,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622303,BAO_0000218,
12372,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622304,BAO_0000218,
12373,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622305,BAO_0000218,
12374,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622306,BAO_0000218,
12375,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626864,BAO_0000218,
12376,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626865,BAO_0000218,
12377,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626866,BAO_0000218,
12378,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626867,BAO_0000218,
12379,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626868,BAO_0000218,
12380,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626869,BAO_0000218,
12381,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626870,BAO_0000218,
12382,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626871,BAO_0000218,
12383,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626872,BAO_0000218,
12384,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632185,BAO_0000218,
12385,14103,A,,1969.0,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632186,BAO_0000218,
12386,12904,A,,,22224,Amount of acetic acid produced by the compound,,0,,,1,,U,Autocuration,,,CHEMBL629310,BAO_0000019,
12387,12904,A,,,22224,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,0,,,1,,U,Autocuration,,,CHEMBL629311,BAO_0000019,
12388,9663,A,,,50597,Log of (Cbrain/Cblood) in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629312,BAO_0000218,
12389,7652,A,,,22224,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629313,BAO_0000221,
12390,7652,A,,,22224,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629314,BAO_0000221,
12391,7652,A,,,22224,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629315,BAO_0000221,
12392,7652,B,,,22224,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629316,BAO_0000219,
12393,7652,A,,,22224,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629317,BAO_0000221,
12394,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629318,BAO_0000019,
12395,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL877497,BAO_0000019,
12396,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629319,BAO_0000019,
12397,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629320,BAO_0000019,
12398,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629496,BAO_0000019,
12399,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629497,BAO_0000019,
12400,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629498,BAO_0000019,
12401,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629499,BAO_0000019,
12402,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629500,BAO_0000019,
12403,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629501,BAO_0000019,
12404,7652,A,,,22224,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,0,,,1,,U,Autocuration,,,CHEMBL629502,BAO_0000019,
12405,8267,F,,,22224,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,0,,,1,,U,Autocuration,,,CHEMBL629503,BAO_0000218,
12406,8267,A,,,50588,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629504,BAO_0000218,
12407,14479,A,,,22224,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,0,,,1,,U,Autocuration,,,CHEMBL629505,BAO_0000019,
12408,17515,A,,,22224,Compound was evaluated for total body clearance,,0,,,1,,U,Autocuration,,,CHEMBL629506,BAO_0000019,
12409,17515,A,,,22224,Compound was evaluated for volume of distribution at steady state,,0,,,1,,U,Autocuration,,,CHEMBL629507,BAO_0000019,
12410,8142,A,,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,0,,,1,,U,Autocuration,,,CHEMBL877498,BAO_0000019,
12411,14849,A,,,22224,Percentage of the diamine which is monoprotonated at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL629508,BAO_0000019,
12412,7653,A,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,0,,,1,,U,Autocuration,,,CHEMBL629509,BAO_0000019,
12413,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629510,BAO_0000218,
12414,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629511,BAO_0000218,
12415,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629512,BAO_0000218,
12416,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629513,BAO_0000218,
12417,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629514,BAO_0000218,
12418,8631,A,,178.0,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628447,BAO_0000218,
12419,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628448,BAO_0000218,
12420,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628449,BAO_0000218,
12421,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631119,BAO_0000218,
12422,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631120,BAO_0000218,
12423,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631121,BAO_0000218,
12424,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874458,BAO_0000218,
12425,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631122,BAO_0000218,
12426,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631123,BAO_0000218,
12427,8631,A,,178.0,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631124,BAO_0000218,
12428,8631,A,,178.0,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631125,BAO_0000218,
12429,8631,A,,178.0,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631290,BAO_0000218,
12430,8631,A,,178.0,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631291,BAO_0000218,
12431,8631,A,,178.0,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631292,BAO_0000218,
12432,8631,A,,178.0,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631293,BAO_0000218,
12433,8631,A,,178.0,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631294,BAO_0000218,
12434,8631,A,,178.0,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631295,BAO_0000218,
12435,8631,A,,178.0,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631296,BAO_0000218,
12436,8631,A,,178.0,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631297,BAO_0000218,
12437,10263,A,,,22224,Maximum biodistribution (Bmax) was determined.,,0,,,1,,U,Autocuration,,,CHEMBL631298,BAO_0000218,
12438,12364,A,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631299,BAO_0000218,
12439,12364,A,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631300,BAO_0000218,
12440,12364,A,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631301,BAO_0000218,
12441,12364,A,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630291,BAO_0000218,
12442,14793,A,,,22224,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,0,,,1,,U,Autocuration,,,CHEMBL630292,BAO_0000218,
12443,14793,A,,,22224,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL630293,BAO_0000218,
12444,14793,A,,,22224,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL630294,BAO_0000218,
12445,14793,A,,,22224,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,0,,,1,,U,Autocuration,,,CHEMBL630295,BAO_0000218,
12446,14793,A,,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL630296,BAO_0000218,
12447,14793,A,,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626782,BAO_0000218,
12448,14793,A,,,22224,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626783,BAO_0000218,
12449,14793,A,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,0,,,1,,U,Autocuration,,,CHEMBL626784,BAO_0000218,
12450,14793,A,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626785,BAO_0000218,
12451,14793,A,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626786,BAO_0000218,
12452,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626787,BAO_0000218,
12453,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL626788,BAO_0000218,
12454,9196,A,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL625927,BAO_0000218,
12455,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625928,BAO_0000218,
12456,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625929,BAO_0000218,
12457,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625930,BAO_0000218,
12458,8374,A,,178.0,50597,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625931,BAO_0000218,
12459,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627230,BAO_0000218,
12460,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627231,BAO_0000218,
12461,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627232,BAO_0000218,
12462,8374,A,,178.0,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627233,BAO_0000218,
12463,8374,A,,178.0,50597,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875470,BAO_0000218,
12464,8374,A,,178.0,50597,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627234,BAO_0000218,
12465,8374,A,,178.0,50597,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627235,BAO_0000218,
12466,8374,A,,178.0,50597,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627236,BAO_0000218,
12467,8374,A,,178.0,50597,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627237,BAO_0000218,
12468,8374,A,,178.0,50597,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627238,BAO_0000218,
12469,8374,A,,178.0,50597,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627239,BAO_0000218,
12470,8374,A,,178.0,50597,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627240,BAO_0000218,
12471,8374,A,,178.0,50597,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627241,BAO_0000218,
12472,8374,A,,178.0,50597,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627242,BAO_0000218,
12473,8374,A,,178.0,50597,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627243,BAO_0000218,
12474,8374,A,,178.0,50597,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627244,BAO_0000218,
12475,8374,A,,178.0,50597,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627245,BAO_0000218,
12476,8374,A,,178.0,50597,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627246,BAO_0000218,
12477,8374,A,,178.0,50597,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627247,BAO_0000218,
12478,8374,A,,178.0,50597,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627248,BAO_0000218,
12479,8374,A,,178.0,50597,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627249,BAO_0000218,
12480,8374,A,,178.0,50597,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625569,BAO_0000218,
12481,8374,A,,178.0,50597,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625570,BAO_0000218,
12482,8374,A,,178.0,50597,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625571,BAO_0000218,
12483,8374,A,,178.0,50597,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625572,BAO_0000218,
12484,8374,A,,178.0,50597,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625573,BAO_0000218,
12485,8374,A,,178.0,50597,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625574,BAO_0000218,
12486,8374,A,,178.0,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626245,BAO_0000218,
12487,8374,A,,178.0,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626246,BAO_0000218,
12488,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626247,BAO_0000218,
12489,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626248,BAO_0000218,
12490,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626249,BAO_0000218,
12491,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626420,BAO_0000218,
12492,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626421,BAO_0000218,
12493,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626422,BAO_0000218,
12494,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626423,BAO_0000218,
12495,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626424,BAO_0000218,
12496,12023,A,,,50588,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626425,BAO_0000218,
12497,12023,A,,,50597,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875476,BAO_0000218,
12498,12023,A,,,100710,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626426,BAO_0000218,
12499,10580,P,,,22224,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,0,,,1,,U,Autocuration,,,CHEMBL626427,BAO_0000100,
12500,10580,P,,,22224,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,0,,,1,,U,Autocuration,,,CHEMBL626428,BAO_0000100,
12501,16032,A,,,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,0,,,1,,U,Autocuration,,,CHEMBL626429,BAO_0000019,
12502,16032,A,,1088.0,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Urine,0,,,1,,U,Autocuration,,,CHEMBL625025,BAO_0000019,
12503,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625026,BAO_0000218,
12504,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625027,BAO_0000218,
12505,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874410,BAO_0000218,
12506,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625028,BAO_0000218,
12507,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625029,BAO_0000218,
12508,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625030,BAO_0000218,
12509,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625031,BAO_0000218,
12510,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625032,BAO_0000218,
12511,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625033,BAO_0000218,
12512,8594,A,,178.0,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625034,BAO_0000218,
12513,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624872,BAO_0000218,
12514,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624873,BAO_0000218,
12515,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624874,BAO_0000218,
12516,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624875,BAO_0000218,
12517,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624876,BAO_0000218,
12518,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624877,BAO_0000218,
12519,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624878,BAO_0000218,
12520,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624879,BAO_0000218,
12521,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624880,BAO_0000218,
12522,8594,A,,948.0,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624881,BAO_0000218,
12523,8594,A,,948.0,50597,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624882,BAO_0000218,
12524,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624883,BAO_0000218,
12525,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624884,BAO_0000218,
12526,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624885,BAO_0000218,
12527,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624886,BAO_0000218,
12528,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624887,BAO_0000218,
12529,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624888,BAO_0000218,
12530,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624889,BAO_0000218,
12531,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624890,BAO_0000218,
12532,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621964,BAO_0000218,
12533,8594,A,,2113.0,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621965,BAO_0000218,
12534,8594,A,,2107.0,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621966,BAO_0000218,
12535,8594,A,,2107.0,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL621967,BAO_0000218,
12536,8594,A,,2107.0,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622164,BAO_0000218,
12537,7653,A,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,0,,,1,,U,Autocuration,,,CHEMBL623097,BAO_0000019,
12538,7653,A,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,0,,,1,,U,Autocuration,,,CHEMBL623098,BAO_0000019,
12539,7653,A,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,0,,,1,,U,Autocuration,,,CHEMBL623099,BAO_0000019,
12540,7653,A,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,0,,,1,,U,Autocuration,,,CHEMBL623100,BAO_0000019,
12541,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628673,BAO_0000218,
12542,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628674,BAO_0000218,
12543,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628675,BAO_0000218,
12544,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627644,BAO_0000218,
12545,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627645,BAO_0000218,
12546,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627646,BAO_0000218,
12547,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627647,BAO_0000218,
12548,9104,A,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627648,BAO_0000218,
12549,12902,A,,,50597,Free level in rat plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627649,BAO_0000218,
12550,6614,A,,,22224,Level reaching in blood plasma of rat or human was determined,,0,,,1,,U,Autocuration,,,CHEMBL628313,BAO_0000019,
12551,9663,A,,,50597,Log (Cbrain/Cblood) in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628314,BAO_0000218,
12552,17658,A,,,22224,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,0,,,1,,U,Autocuration,,,CHEMBL628315,BAO_0000019,
12553,17658,A,,,22224,Mean percentage of compound transport through membrane; expressed as membrane transport,,0,,,1,,U,Autocuration,,,CHEMBL628316,BAO_0000019,
12554,14314,A,,,22224,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,0,,,1,,U,Autocuration,,,CHEMBL628317,BAO_0000218,
12555,7385,A,,,22224,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,0,,,1,,U,Autocuration,,,CHEMBL628473,BAO_0000019,
12556,7385,A,,,22224,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,0,,,1,,U,Autocuration,,,CHEMBL628474,BAO_0000019,
12557,7385,A,,,22224,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,0,,,1,,U,Autocuration,,,CHEMBL628475,BAO_0000019,
12558,1329,A,,,22224,Net water uptake by a carrier mediated transport (%cm) mechanism,,0,,,1,,U,Autocuration,,,CHEMBL628476,BAO_0000019,
12559,12187,A,,,22224,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628477,BAO_0000218,
12560,12187,A,,,50506,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL628478,BAO_0000218,
12561,12187,A,,,50506,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL628479,BAO_0000218,
12562,12187,A,,,22224,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628480,BAO_0000218,
12563,12187,A,,,22224,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628481,BAO_0000218,
12564,12187,A,,,50597,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628482,BAO_0000218,
12565,12187,A,,,50597,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628483,BAO_0000218,
12566,9278,A,,1969.0,50597,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628484,BAO_0000218,
12567,9278,A,,1969.0,50597,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628485,BAO_0000218,
12568,9278,A,,1969.0,100710,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628486,BAO_0000218,
12569,9278,A,,1969.0,50587,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL628487,BAO_0000218,
12570,9278,A,,1969.0,50597,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628488,BAO_0000218,
12571,9278,A,,1969.0,50597,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628489,BAO_0000218,
12572,9278,A,,1969.0,50597,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628490,BAO_0000218,
12573,12186,A,,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL628491,BAO_0000218,
12574,12186,A,,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL877507,BAO_0000218,
12575,12186,A,,,22224,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,0,,,1,,U,Autocuration,,,CHEMBL628492,BAO_0000218,
12576,12041,A,,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628493,BAO_0000019,
12577,12041,A,,,22224,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628494,BAO_0000019,
12578,12041,A,,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628495,BAO_0000019,
12579,6737,A,,,50587,Permeability in Caco-2 assay at 10E-6,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL628496,BAO_0000218,
12580,13758,A,,955.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,0,,,1,,U,Autocuration,,,CHEMBL628497,BAO_0000218,
12581,13758,A,,955.0,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,0,,,1,,U,Autocuration,,,CHEMBL628498,BAO_0000218,
12582,5676,A,,,22224,Plasma protein binding was determined,,0,,,1,,U,Autocuration,,,CHEMBL628499,BAO_0000019,
12583,14793,A,,,22224,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL627656,BAO_0000218,
12584,14793,A,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,0,,,1,,U,Autocuration,,,CHEMBL627657,BAO_0000218,
12585,14793,A,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL626808,BAO_0000218,
12586,14793,A,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626809,BAO_0000218,
12587,14793,A,,,22224,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626810,BAO_0000218,
12588,14793,A,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,0,,,1,,U,Autocuration,,,CHEMBL626811,BAO_0000218,
12589,14793,A,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,0,,,1,,U,Autocuration,,,CHEMBL874465,BAO_0000218,
12590,14793,A,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626812,BAO_0000218,
12591,14793,A,,,22224,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626813,BAO_0000218,
12592,14793,A,,,22224,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,0,,,1,,U,Autocuration,,,CHEMBL626814,BAO_0000218,
12593,14000,A,,,22224,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,0,,,1,,U,Autocuration,,,CHEMBL626815,BAO_0000019,
12594,5948,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL628566,BAO_0000019,
12595,13824,P,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,0,,,1,,U,Autocuration,,,CHEMBL628567,BAO_0000100,
12596,10778,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL628568,BAO_0000100,
12597,17237,A,,,50588,C max in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628569,BAO_0000218,
12598,17237,A,,,50512,C max in guinea pig,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL628570,BAO_0000218,
12599,2809,A,,,22224,C max value was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL628571,BAO_0000218,
12600,11954,A,,,22224,Cmax value after oral dose of 0.1 mg//kg,,0,,,1,,U,Autocuration,,,CHEMBL628572,BAO_0000218,
12601,11954,A,,,22224,Cmax value after oral dose of 0.3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628573,BAO_0000218,
12602,11954,A,,,22224,Cmax value after oral dose of 1 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628574,BAO_0000218,
12603,11954,A,,,22224,Cmax value after oral dose of 10 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628575,BAO_0000218,
12604,11954,A,,,22224,Cmax value after oral dose of 23.4 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628576,BAO_0000218,
12605,11954,A,,,22224,Cmax value after oral dose of 3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628577,BAO_0000218,
12606,11954,A,,,22224,Cmax value after oral dose of 3.87 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL628578,BAO_0000218,
12607,12768,A,,,50588,Cmax value in female Beagle dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874466,BAO_0000218,
12608,12768,A,,,50597,Cmax value in male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628579,BAO_0000218,
12609,12780,A,,1969.0,50597,Cmax value in rat plasma when administered 20 mg/kg perorally,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628580,BAO_0000218,
12610,15592,A,,1969.0,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628581,BAO_0000218,
12611,15592,A,,1969.0,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628582,BAO_0000218,
12612,17025,A,,,50588,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628583,BAO_0000218,
12613,17025,A,,,22224,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625782,BAO_0000218,
12614,17025,A,,,50592,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625783,BAO_0000218,
12615,17025,A,,,50597,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625784,BAO_0000218,
12616,4236,A,,1969.0,50797,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL625785,BAO_0000218,
12617,15791,A,,,50597,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625786,BAO_0000218,
12618,11149,A,,,22224,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,0,,,1,,U,Autocuration,,,CHEMBL874467,BAO_0000019,
12619,15592,A,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625787,BAO_0000218,
12620,15778,A,,,50677,cytotoxicity against HIV protease enzyme.,,1,,Human immunodeficiency virus,1,12721.0,N,Intermediate,,,CHEMBL625964,BAO_0000218,
12621,12745,A,,,50594,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625965,BAO_0000218,
12622,12745,A,,,50594,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625966,BAO_0000218,
12623,13941,A,,1969.0,50588,The plasma clearance in dog.,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625967,BAO_0000218,
12624,13941,A,,1969.0,50597,The plasma clearance in rat.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625968,BAO_0000218,
12625,16449,A,,1969.0,50597,Clearance from plasma in male Sprague-Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625969,BAO_0000218,
12626,16449,A,,1969.0,100710,Clearance from plasma in male cynomolgus monkeys,Plasma,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL625970,BAO_0000218,
12627,14224,A,,1969.0,50588,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625971,BAO_0000218,
12628,14224,A,,1969.0,50588,Clearance of compound in dog plasma,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625972,BAO_0000218,
12629,14224,A,,1969.0,50587,Clearance of compound in human plasma,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625973,BAO_0000218,
12630,14317,A,,,50588,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625974,BAO_0000218,
12631,14317,A,,,50588,Clearance of compound when administered intravenously as an individual dose to a single dog.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625975,BAO_0000218,
12632,14224,A,,1969.0,50588,"Clearance (10 mg/kg, intravenously) in dog plasma",Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625976,BAO_0000218,
12633,17237,A,,,50588,Clearance value in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625977,BAO_0000218,
12634,17237,A,,,50512,Clearance value in guinea pig,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL625978,BAO_0000218,
12635,14187,A,,,50597,Clearance values in rats after iv administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874468,BAO_0000218,
12636,4806,A,,1969.0,22224,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Plasma,0,,,1,,U,Autocuration,,,CHEMBL625421,BAO_0000218,
12637,15025,A,,,50592,In vivo clearance (5 mg/kg) was determined in rabbits,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625422,BAO_0000218,
12638,13197,A,,,50597,Plasma Clearance rate was determined for the compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625423,BAO_0000218,
12639,13197,A,,,22224,Plasma Clearance rate was determined for the compound in squirrel monkeys,,0,,Saimiri,1,9520.0,U,Autocuration,,,CHEMBL625424,BAO_0000218,
12640,13960,A,,,50597,Plasma clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625425,BAO_0000218,
12641,17820,A,,,22224,Plasma clearance of the compound,,0,,,1,,U,Autocuration,,,CHEMBL625426,BAO_0000218,
12642,14706,A,,,50512,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL625427,BAO_0000218,
12643,14706,A,,,50512,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL625428,BAO_0000218,
12644,6504,A,,,22224,Plasma clearance was determined,,0,,,1,,U,Autocuration,,,CHEMBL625429,BAO_0000218,
12645,14925,A,,,50588,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625430,BAO_0000218,
12646,13197,A,,,50597,Plasma clearance rate was determined for the compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625431,BAO_0000218,
12647,13197,A,,,22224,Plasma clearance rate was determined for the compound in squirrel monkeys,,0,,Saimiri,1,9520.0,U,Autocuration,,,CHEMBL627307,BAO_0000218,
12648,3437,A,,,22224,Slow clearance (CL) was determined,,0,,,1,,U,Autocuration,,,CHEMBL627308,BAO_0000218,
12649,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627309,BAO_0000218,
12650,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,0,,,1,,U,Autocuration,,,CHEMBL627310,BAO_0000218,
12651,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627311,BAO_0000218,
12652,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL627312,BAO_0000218,
12653,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627313,BAO_0000218,
12654,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627314,BAO_0000218,
12655,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL627315,BAO_0000218,
12656,9196,A,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL627316,BAO_0000218,
12657,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627317,BAO_0000218,
12658,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL627318,BAO_0000218,
12659,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL627999,BAO_0000218,
12660,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628000,BAO_0000218,
12661,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL628001,BAO_0000218,
12662,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL628002,BAO_0000218,
12663,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL625610,BAO_0000218,
12664,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL625611,BAO_0000218,
12665,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL625612,BAO_0000218,
12666,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL625613,BAO_0000218,
12667,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL875479,BAO_0000218,
12668,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL625614,BAO_0000218,
12669,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL625615,BAO_0000218,
12670,9196,A,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626302,BAO_0000218,
12671,8374,A,,178.0,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626303,BAO_0000218,
12672,8374,A,,178.0,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627420,BAO_0000218,
12673,13477,A,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627421,BAO_0000218,
12674,13477,A,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625695,BAO_0000218,
12675,13477,A,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625696,BAO_0000218,
12676,10009,A,,955.0,50594,Distribution of compound in mice brain was measured after 1 hr,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875606,BAO_0000218,
12677,10009,A,,955.0,50594,Distribution of compound in mice brain was measured after 24 hr r,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625697,BAO_0000218,
12678,10009,A,,955.0,50594,Distribution of compound in mice brain was measured after 2 hr,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625698,BAO_0000218,
12679,10009,A,,955.0,50594,Distribution of compound in mice brain was measured after 3 hr,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625699,BAO_0000218,
12680,10009,A,,955.0,50594,Distribution of compound in mice brain was measured after 6 hr,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625700,BAO_0000218,
12681,10009,A,,,50594,Distribution of compound in mice liver was measured after 1 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625701,BAO_0000218,
12682,10009,A,,,50594,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625702,BAO_0000218,
12683,10009,A,,,50594,Distribution of compound in mice liver was measured after 2 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625703,BAO_0000218,
12684,10009,A,,,50594,Distribution of compound in mice liver was measured after 3 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625704,BAO_0000218,
12685,10009,A,,,50594,Distribution of compound in mice liver was measured after 6 hr,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625705,BAO_0000218,
12686,8170,A,,1236.0,50588,Distribution in dog adrenal medulla 30 min after administration.,Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625706,BAO_0000218,
12687,8170,A,,1236.0,50588,Distribution in dog adrenal medulla 72 hours after administration.,Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625707,BAO_0000218,
12688,8170,A,,,50588,Distribution in female dog Ovary 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625708,BAO_0000218,
12689,8170,A,,,50588,Distribution in female dog Ovary 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625709,BAO_0000218,
12690,8170,A,,,50588,Distribution in female dog adipose 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624180,BAO_0000218,
12691,8170,A,,,50588,Distribution in female dog adipose 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624181,BAO_0000218,
12692,8170,A,,1235.0,50588,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624182,BAO_0000218,
12693,8170,A,,1235.0,50588,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624183,BAO_0000218,
12694,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624184,BAO_0000218,
12695,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877489,BAO_0000218,
12696,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624185,BAO_0000218,
12697,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624186,BAO_0000218,
12698,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624187,BAO_0000218,
12699,8594,A,,2107.0,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624188,BAO_0000218,
12700,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624189,BAO_0000218,
12701,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624190,BAO_0000218,
12702,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624191,BAO_0000218,
12703,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624192,BAO_0000218,
12704,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624193,BAO_0000218,
12705,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624194,BAO_0000218,
12706,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624891,BAO_0000218,
12707,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624892,BAO_0000218,
12708,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624893,BAO_0000218,
12709,8594,A,,2048.0,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627632,BAO_0000218,
12710,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627633,BAO_0000218,
12711,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627634,BAO_0000218,
12712,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627635,BAO_0000218,
12713,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627636,BAO_0000218,
12714,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626816,BAO_0000218,
12715,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626817,BAO_0000218,
12716,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626818,BAO_0000218,
12717,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626819,BAO_0000218,
12718,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626820,BAO_0000218,
12719,8594,A,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626821,BAO_0000218,
12720,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626822,BAO_0000218,
12721,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626823,BAO_0000218,
12722,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626824,BAO_0000218,
12723,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626825,BAO_0000218,
12724,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626826,BAO_0000218,
12725,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626827,BAO_0000218,
12726,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626828,BAO_0000218,
12727,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626829,BAO_0000218,
12728,8594,A,,2046.0,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626830,BAO_0000218,
12729,8594,A,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627150,BAO_0000218,
12730,8594,A,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627151,BAO_0000218,
12731,8594,A,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627152,BAO_0000218,
12732,8594,A,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627153,BAO_0000218,
12733,12904,A,,,22224,Rate of acetate production by the compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL627154,BAO_0000019,
12734,12904,A,,,22224,Rate of acetate production by the compound was determined; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL627155,BAO_0000019,
12735,3730,A,,,22224,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,0,,,1,,U,Autocuration,,,CHEMBL627156,BAO_0000019,
12736,3627,A,,,22224,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,0,,,1,,U,Autocuration,,,CHEMBL627157,BAO_0000019,
12737,13799,A,,,50592,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627158,BAO_0000218,
12738,13799,A,,1969.0,50592,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Plasma,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627159,BAO_0000218,
12739,13799,A,,,50594,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627160,BAO_0000218,
12740,13799,A,,,50597,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628540,BAO_0000218,
12741,13799,A,,1969.0,50597,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628541,BAO_0000218,
12742,13799,A,,1969.0,50597,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628542,BAO_0000218,
12743,6629,P,,,22229,Solubility after at a pH 1.2,,0,,,1,,U,Autocuration,,,CHEMBL628543,BAO_0000100,
12744,6629,P,,,22229,Solubility after at pH 1.2,,0,,,1,,U,Autocuration,,,CHEMBL628544,BAO_0000100,
12745,6629,P,,,22229,Solubility after injection of water,,0,,,1,,U,Autocuration,,,CHEMBL628545,BAO_0000100,
12746,14000,A,,,22224,Statistical significance of IC 50 values; Expressed as R value,,0,,,1,,U,Autocuration,,,CHEMBL628546,BAO_0000019,
12747,8267,A,,,22224,Systemic availability with respect to methyldopa was determined,,0,,,1,,U,Autocuration,,,CHEMBL874455,BAO_0000019,
12748,13799,A,,,50597,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628547,BAO_0000218,
12749,13799,A,,1969.0,50597,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628548,BAO_0000218,
12750,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628549,BAO_0000218,
12751,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628550,BAO_0000218,
12752,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628551,BAO_0000218,
12753,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628552,BAO_0000218,
12754,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628553,BAO_0000218,
12755,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628554,BAO_0000218,
12756,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628555,BAO_0000218,
12757,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628556,BAO_0000218,
12758,7132,A,,2113.0,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Kidney,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628557,BAO_0000218,
12759,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628558,BAO_0000218,
12760,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628559,BAO_0000218,
12761,7132,A,,1988.0,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628560,BAO_0000218,
12762,7132,A,,1088.0,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL874456,BAO_0000218,
12763,7132,A,,1988.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628561,BAO_0000218,
12764,7132,A,,1988.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628562,BAO_0000218,
12765,7132,A,,1088.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628563,BAO_0000218,
12766,7132,A,,1088.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628564,BAO_0000218,
12767,7132,A,,1088.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628565,BAO_0000218,
12768,7132,A,,1088.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL631248,BAO_0000218,
12769,7132,A,,1088.0,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL631249,BAO_0000218,
12770,7132,A,,2113.0,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Kidney,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627214,BAO_0000218,
12771,7132,A,,1988.0,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL874591,BAO_0000218,
12772,7132,A,,1988.0,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627215,BAO_0000218,
12773,7132,A,,1988.0,50592,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625471,BAO_0000218,
12774,7132,A,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625472,BAO_0000218,
12775,7132,A,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625473,BAO_0000218,
12776,13317,A,,,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625474,BAO_0000218,
12777,15341,A,,,50588,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625475,BAO_0000218,
12778,15341,A,,,50597,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625476,BAO_0000218,
12779,15341,A,,,50597,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625477,BAO_0000218,
12780,15341,A,,,50597,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625478,BAO_0000218,
12781,12801,A,,,50597,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625479,BAO_0000218,
12782,12801,A,,,50597,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625480,BAO_0000218,
12783,14856,A,,1969.0,50597,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625481,BAO_0000218,
12784,14062,A,,,50597,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625482,BAO_0000218,
12785,14062,A,,,50597,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625483,BAO_0000218,
12786,14062,A,,,50597,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625484,BAO_0000218,
12787,14062,A,,,50597,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625485,BAO_0000218,
12788,14346,A,,1969.0,50588,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625486,BAO_0000218,
12789,14346,A,,1969.0,50597,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625487,BAO_0000218,
12790,14346,A,,1969.0,50597,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625488,BAO_0000218,
12791,14346,A,,1969.0,50597,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625489,BAO_0000218,
12792,14346,A,,1969.0,50597,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625490,BAO_0000218,
12793,14346,A,,1969.0,50588,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625491,BAO_0000218,
12794,14346,A,,1969.0,50597,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625492,BAO_0000218,
12795,15711,A,,1969.0,50587,plasma clearance in human,Plasma,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625493,BAO_0000218,
12796,14886,A,,,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625494,BAO_0000218,
12797,14886,A,,,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625495,BAO_0000218,
12798,14886,A,,,50597,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625496,BAO_0000218,
12799,4115,P,,,22229,1-Octanol/water partition coefficient measured at 7.4,,0,,,1,,U,Autocuration,,,CHEMBL625497,BAO_0000100,
12800,13733,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625498,BAO_0000100,
12801,12102,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL625499,BAO_0000019,
12802,12676,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625500,BAO_0000100,
12803,13733,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625501,BAO_0000100,
12804,13740,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625502,BAO_0000100,
12805,12766,P,,,22229,Calculated partition coefficient (clogP) (relative to BAY K 8644),,0,,,1,,U,Autocuration,,,CHEMBL625503,BAO_0000100,
12806,2764,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625504,BAO_0000100,
12807,12355,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625505,BAO_0000100,
12808,11314,P,,,22229,Calculated partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL625506,BAO_0000100,
12809,12706,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL625507,BAO_0000019,
12810,12645,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625508,BAO_0000100,
12811,13668,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625509,BAO_0000100,
12812,12819,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625510,BAO_0000100,
12813,13668,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL883125,BAO_0000100,
12814,13017,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625511,BAO_0000100,
12815,2448,A,,,22224,Partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL874650,BAO_0000019,
12816,11526,A,,,22224,Partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL625512,BAO_0000019,
12817,12426,A,,,22224,Partition coefficient of compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL625513,BAO_0000019,
12818,2448,A,,,22224,Partition coefficient was determined,,0,,,1,,U,Autocuration,,,CHEMBL625514,BAO_0000019,
12819,12001,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625515,BAO_0000100,
12820,12426,P,,,22229,partition coefficient of compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL625516,BAO_0000100,
12821,13204,A,,,50588,The total body administered intravenously in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625517,BAO_0000218,
12822,13204,A,,,50597,The total body administered intravenously in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625518,BAO_0000218,
12823,13889,A,,,50594,Time taken for the administration to female NIH mice weighing 25-30 g.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625519,BAO_0000218,
12824,13889,A,,,22224,Time taken for the administration,,0,,,1,,U,Autocuration,,,CHEMBL625520,BAO_0000019,
12825,17025,A,,,50588,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874651,BAO_0000218,
12826,17025,A,,,22224,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625521,BAO_0000218,
12827,17025,A,,,50592,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL623171,BAO_0000218,
12828,17025,A,,,50597,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623853,BAO_0000218,
12829,15067,A,,,22224,Plasma clearance for the compound was determined.,,0,,,1,,U,Autocuration,,,CHEMBL623854,BAO_0000019,
12830,3091,P,,,22224,CLog P value of the compound,,0,,,1,,U,Autocuration,,,CHEMBL874405,BAO_0000100,
12831,15592,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL623855,BAO_0000100,
12832,14738,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL623856,BAO_0000100,
12833,14738,P,,,22224,ClogP value of the compound; nd ='no data',,0,,,1,,U,Autocuration,,,CHEMBL623857,BAO_0000100,
12834,14738,P,,,22224,ClogP value of the compound; nd ='not determined',,0,,,1,,U,Autocuration,,,CHEMBL623858,BAO_0000100,
12835,6076,P,,,22224,CLog P was determined,,0,,,1,,U,Autocuration,,,CHEMBL623859,BAO_0000100,
12836,17840,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL839829,BAO_0000100,
12837,13589,A,,,22224,CLogP was calculated,,0,,,1,,U,Autocuration,,,CHEMBL623860,BAO_0000019,
12838,17655,A,,,22224,CLogP value was determined,,0,,,1,,U,Autocuration,,,CHEMBL623861,BAO_0000019,
12839,5867,A,,,22224,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,0,,,1,,U,Autocuration,,,CHEMBL623862,BAO_0000019,
12840,5867,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL874406,BAO_0000100,
12841,10783,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL623863,BAO_0000100,
12842,14849,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624021,BAO_0000100,
12843,8170,A,,1236.0,50588,Distribution in female dog adrenal medulla 24 hours after administration.,Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624022,BAO_0000218,
12844,8170,A,,1236.0,50588,Distribution in female dog adrenal medulla 72 hours after administration.,Adrenal medulla,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624023,BAO_0000218,
12845,8170,A,,,50588,Distribution in female dog bile 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624024,BAO_0000218,
12846,8170,A,,,50588,Distribution in female dog bile 72 hr after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624025,BAO_0000218,
12847,8170,A,,,50588,Distribution in female dog blood 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624026,BAO_0000218,
12848,8170,A,,,50588,Distribution in female dog blood 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624027,BAO_0000218,
12849,8170,A,,,50588,Distribution in female dog heart 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624028,BAO_0000218,
12850,8170,A,,,50588,Distribution in female dog heart 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624029,BAO_0000218,
12851,8170,A,,,50588,Distribution in female dog kidney 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624030,BAO_0000218,
12852,8170,A,,,50588,Distribution in female dog kidney 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624031,BAO_0000218,
12853,8170,A,,160.0,50588,Distribution in female dog large intestine 24 hours after administration.,Intestine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624032,BAO_0000218,
12854,8170,A,,160.0,50588,Distribution in female dog large intestine 72 hours after administration.,Intestine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874407,BAO_0000218,
12855,8170,A,,,50588,Distribution in female dog liver 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624033,BAO_0000218,
12856,8170,A,,,50588,Distribution in female dog liver 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624034,BAO_0000218,
12857,8170,A,,,50588,Distribution in female dog lung 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624035,BAO_0000218,
12858,8170,A,,,50588,Distribution in female dog lung 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624036,BAO_0000218,
12859,8170,A,,2385.0,50588,Distribution in female dog muscle 24 hours after administration.,Muscle tissue,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624037,BAO_0000218,
12860,8170,A,,2385.0,50588,Distribution in female dog muscle 72 hours after administration.,Muscle tissue,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624038,BAO_0000218,
12861,8170,A,,,50588,Distribution in female dog pancreas 24 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624039,BAO_0000218,
12862,8170,A,,,50588,Distribution in female dog pancreas 72 hours after administration.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624040,BAO_0000218,
12863,8170,A,,160.0,50588,Distribution in female dog small intestine 24 hours after administration.,Intestine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624041,BAO_0000218,
12864,8170,A,,160.0,50588,Distribution in female dog small intestine 72 hours after administration.,Intestine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624042,BAO_0000218,
12865,8170,A,,2106.0,50588,Distribution in female dog spleen 24 hours after administration.,Spleen,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624043,BAO_0000218,
12866,8170,A,,2106.0,50588,Distribution in female dog spleen 72 hours after administration.,Spleen,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624044,BAO_0000218,
12867,8170,A,,945.0,50588,Distribution in female dog stomach 24 hours after administration.,Stomach,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624045,BAO_0000218,
12868,8170,A,,945.0,50588,Distribution in female dog stomach 72 hours after administration.,Stomach,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624046,BAO_0000218,
12869,8170,A,,2046.0,50588,Distribution in female dog thyroid 24 hours after administration.,Thyroid gland,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624047,BAO_0000218,
12870,8170,A,,2046.0,50588,Distribution in female dog thyroid 72 hours after administration.,Thyroid gland,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624048,BAO_0000218,
12871,8170,A,,1088.0,50588,Distribution in female dog urine 24 hours after administration.,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874408,BAO_0000218,
12872,8170,A,,1088.0,50588,Distribution in female dog urine 72 hr after administration.,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624049,BAO_0000218,
12873,14283,A,,1969.0,22224,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Plasma,0,,,1,,U,Autocuration,,,CHEMBL624050,BAO_0000218,
12874,5623,A,,,22224,Plasma concentration at 7 hr after intravenous dosing,,0,,,1,,U,Autocuration,,,CHEMBL624051,BAO_0000019,
12875,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623278,BAO_0000218,
12876,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623279,BAO_0000218,
12877,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623280,BAO_0000218,
12878,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623963,BAO_0000218,
12879,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623964,BAO_0000218,
12880,13477,A,,,50597,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623965,BAO_0000218,
12881,13477,A,,,50597,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623966,BAO_0000218,
12882,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874415,BAO_0000218,
12883,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623967,BAO_0000218,
12884,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623968,BAO_0000218,
12885,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623969,BAO_0000218,
12886,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628409,BAO_0000218,
12887,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628410,BAO_0000218,
12888,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628411,BAO_0000218,
12889,13477,A,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628412,BAO_0000218,
12890,12553,A,,,22224,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,0,,,1,,U,Autocuration,,,CHEMBL628413,BAO_0000019,
12891,14548,A,,1969.0,22224,The concentration in plasmat; Not determined,Plasma,0,,,1,,U,Autocuration,,,CHEMBL628414,BAO_0000019,
12892,14393,A,,,50597,Tissue level at 10 mg/kg/po in wistar rats in blood,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628415,BAO_0000218,
12893,14393,A,,,50597,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628416,BAO_0000218,
12894,14393,A,,,50597,Tissue level at 10 mg/kg/po in wistar rats in heart,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628417,BAO_0000218,
12895,14393,A,,2107.0,50597,Tissue level at 10 mg/kg/po in wistar rats in liver,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874908,BAO_0000218,
12896,14393,A,,,50597,Tissue level at 10 mg/kg/po in wistar rats in plasma,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628418,BAO_0000218,
12897,14393,A,,2385.0,50597,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628419,BAO_0000218,
12898,14393,A,,,50597,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628420,BAO_0000218,
12899,1629,A,,,22224,Water solubility at 37 degree C.,,0,,,1,,U,Autocuration,,,CHEMBL628421,BAO_0000019,
12900,8194,P,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626726,BAO_0000100,
12901,8194,P,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626727,BAO_0000100,
12902,8594,A,,178.0,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626728,BAO_0000218,
12903,8594,A,,178.0,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626729,BAO_0000218,
12904,8594,A,,178.0,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626730,BAO_0000218,
12905,8594,A,,178.0,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626731,BAO_0000218,
12906,8594,A,,178.0,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626732,BAO_0000218,
12907,8594,A,,948.0,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626733,BAO_0000218,
12908,8594,A,,948.0,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626734,BAO_0000218,
12909,8594,A,,948.0,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626735,BAO_0000218,
12910,8594,A,,948.0,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874909,BAO_0000218,
12911,8594,A,,948.0,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626736,BAO_0000218,
12912,8594,A,,2113.0,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626737,BAO_0000218,
12913,8594,A,,2113.0,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630999,BAO_0000218,
12914,8594,A,,2113.0,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631000,BAO_0000218,
12915,8594,A,,2113.0,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631001,BAO_0000218,
12916,8594,A,,2113.0,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631002,BAO_0000218,
12917,8594,A,,2107.0,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631003,BAO_0000218,
12918,8594,A,,2107.0,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631004,BAO_0000218,
12919,8594,A,,2107.0,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631005,BAO_0000218,
12920,8594,A,,2107.0,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631006,BAO_0000218,
12921,8594,A,,2107.0,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631007,BAO_0000218,
12922,8594,A,,2048.0,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631008,BAO_0000218,
12923,8594,A,,2048.0,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631009,BAO_0000218,
12924,8594,A,,2048.0,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631010,BAO_0000218,
12925,8594,A,,2048.0,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631011,BAO_0000218,
12926,8594,A,,2048.0,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631012,BAO_0000218,
12927,8594,A,,2046.0,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630271,BAO_0000218,
12928,8594,A,,2046.0,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630272,BAO_0000218,
12929,8594,A,,2046.0,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630273,BAO_0000218,
12930,8594,A,,2046.0,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630274,BAO_0000218,
12931,8594,A,,2046.0,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630275,BAO_0000218,
12932,8594,A,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875782,BAO_0000218,
12933,8594,A,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630276,BAO_0000218,
12934,8594,A,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630277,BAO_0000218,
12935,8594,A,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630278,BAO_0000218,
12936,8594,A,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630279,BAO_0000218,
12937,8151,A,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL630280,BAO_0000019,
12938,8151,A,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL630281,BAO_0000019,
12939,7132,A,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630282,BAO_0000218,
12940,7132,A,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630283,BAO_0000218,
12941,5797,A,,,22224,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,0,,,1,,U,Autocuration,,,CHEMBL630284,BAO_0000019,
12942,7849,A,,,22224,Alkylating activity was determined,,0,,,1,,U,Autocuration,,,CHEMBL630285,BAO_0000019,
12943,14220,A,,,22224,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,0,,,1,,U,Autocuration,,,CHEMBL630286,BAO_0000251,
12944,8650,A,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630069,BAO_0000218,
12945,8650,A,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630070,BAO_0000218,
12946,8650,A,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630071,BAO_0000218,
12947,8650,A,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630072,BAO_0000218,
12948,8650,A,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL875110,BAO_0000218,
12949,7116,A,,,50597,Compound was tested for antidiuretic activity in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630073,BAO_0000218,
12950,14131,A,,,22224,Compound was tested for inactivation kinetic values,,0,,,1,,U,Autocuration,,,CHEMBL630074,BAO_0000019,
12951,7415,A,,,22224,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,0,,,1,,U,Autocuration,,,CHEMBL630075,BAO_0000218,
12952,13178,A,,,22224,Dissociation rate calculated from the first-order equation using the t1/2 value,,0,,,1,,U,Autocuration,,,CHEMBL630076,BAO_0000019,
12953,8815,P,,,22229,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,0,,,1,,U,Autocuration,,,CHEMBL630077,BAO_0000100,
12954,1450,P,,,22229,Aqueous solubility was measured,,0,,,1,,U,Autocuration,,,CHEMBL630078,BAO_0000100,
12955,1450,P,,,22229,Aqueous solubility was measured at a pH 4,,0,,,1,,U,Autocuration,,,CHEMBL630079,BAO_0000100,
12956,1450,P,,,22229,Aqueous solubility (pH 7),,0,,,1,,U,Autocuration,,,CHEMBL630080,BAO_0000100,
12957,1450,P,,,22229,Aqueous solubility was measured at a pH 9,,0,,,1,,U,Autocuration,,,CHEMBL630081,BAO_0000100,
12958,12711,A,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,0,,,1,,U,Autocuration,,,CHEMBL630082,BAO_0000019,
12959,12711,A,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,0,,,1,,U,Autocuration,,,CHEMBL630083,BAO_0000019,
12960,12711,A,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,0,,,1,,U,Autocuration,,,CHEMBL630084,BAO_0000019,
12961,15032,P,,,22229,Aqueous solubility of the compound,,0,,,1,,U,Autocuration,,,CHEMBL629198,BAO_0000100,
12962,9964,P,,,22229,Aqueous solubility at 37 degree Celsius at pH 7.38,,0,,,1,,U,Autocuration,,,CHEMBL629199,BAO_0000100,
12963,14962,P,,,22229,Aqueous solubility in pH 7.4 phosphate buffer,,0,,,1,,U,Autocuration,,,CHEMBL629200,BAO_0000100,
12964,12487,A,,,50588,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629201,BAO_0000218,
12965,12487,A,,,50588,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629202,BAO_0000218,
12966,10026,A,,,50587,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL875111,BAO_0000218,
12967,10026,A,,,50587,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL629203,BAO_0000218,
12968,10026,A,,,50587,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL629204,BAO_0000218,
12969,10026,A,,,50587,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL629205,BAO_0000218,
12970,10026,A,,,50587,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL629206,BAO_0000218,
12971,10026,A,,,22224,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,0,,,1,,U,Autocuration,,,CHEMBL631185,BAO_0000019,
12972,7415,A,,,50597,Compound was evaluated for the average bile flow rat in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631186,BAO_0000218,
12973,17025,A,,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL631187,BAO_0000218,
12974,17025,A,,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL631188,BAO_0000218,
12975,10184,A,,,22224,Average half life period was determined,,0,,,1,,U,Autocuration,,,CHEMBL876419,BAO_0000019,
12976,10184,A,,,22224,Average half life period was determined,,0,,,1,,U,Autocuration,,,CHEMBL631189,BAO_0000019,
12977,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL631190,BAO_0000218,
12978,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL631191,BAO_0000218,
12979,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL631192,BAO_0000218,
12980,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632400,BAO_0000218,
12981,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL630564,BAO_0000218,
12982,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL630565,BAO_0000218,
12983,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL630566,BAO_0000218,
12984,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL631229,BAO_0000218,
12985,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL631230,BAO_0000218,
12986,6030,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL876428,BAO_0000100,
12987,6147,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631231,BAO_0000100,
12988,14556,P,,,22229,Calculated partition coefficient (clogP) (MacLogP),,0,,,1,,U,Autocuration,,,CHEMBL631232,BAO_0000100,
12989,768,A,,,22224,Hydrophilicity was determined,,0,,,1,,U,Autocuration,,,CHEMBL631233,BAO_0000019,
12990,14452,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631234,BAO_0000100,
12991,5237,A,,,22224,Increased absorption was determined,,0,,,1,,U,Autocuration,,,CHEMBL883126,BAO_0000019,
12992,14378,P,,,22224,Lipophilicity value was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL631235,BAO_0000100,
12993,14418,P,,,22224,Log P value of the compound.,,0,,,1,,U,Autocuration,,,CHEMBL631236,BAO_0000100,
12994,5249,A,,,22224,Partition coefficient of compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL631237,BAO_0000019,
12995,14621,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631238,BAO_0000100,
12996,12542,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL876429,BAO_0000100,
12997,12542,A,,,22224,Partition coefficient was measured by medchem software; Not calculated,,0,,,1,,U,Autocuration,,,CHEMBL631414,BAO_0000019,
12998,12542,P,,,22224,Partition coefficient was measured by octanol-water using standard shake-flask method,,0,,,1,,U,Autocuration,,,CHEMBL631415,BAO_0000100,
12999,15462,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631416,BAO_0000100,
13000,14884,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL631417,BAO_0000019,
13001,16526,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631418,BAO_0000100,
13002,13693,P,,,22229,The Octanol/Water partition coefficient CLogP,,0,,,1,,U,Autocuration,,,CHEMBL631419,BAO_0000100,
13003,13693,A,,,22224,The pharmacokinetic parameter C Log p was reported,,0,,,1,,U,Autocuration,,,CHEMBL631420,BAO_0000019,
13004,13779,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631421,BAO_0000100,
13005,14772,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631422,BAO_0000100,
13006,14393,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL631423,BAO_0000100,
13007,14793,A,,1969.0,50597,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876430,BAO_0000218,
13008,14793,A,,1969.0,50597,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631424,BAO_0000218,
13009,13744,A,,1969.0,50588,Compound was administered intravenously in dog to evaluate plasma clearance values,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631425,BAO_0000218,
13010,13744,A,,1969.0,22224,Compound was administered intravenously in monkey to evaluate plasma clearance values,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL631426,BAO_0000218,
13011,13744,A,,1969.0,50594,Compound was administered intravenously in mouse to evaluate plasma clearance values,Plasma,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631427,BAO_0000218,
13012,13207,A,,1969.0,50588,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631428,BAO_0000218,
13013,5669,A,,2107.0,50797,Intrinsic clearance in Rhesus liver microsome,Liver,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL631429,BAO_0000218,
13014,5669,A,,2107.0,50588,Intrinsic clearance in dog liver microsome,Liver,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631430,BAO_0000218,
13015,5669,A,,2107.0,50597,Intrinsic clearance in rat liver microsome,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631431,BAO_0000218,
13016,4853,A,,1969.0,50797,Low plasma clearance was calculated in rhesus monkey,Plasma,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL631432,BAO_0000218,
13017,16452,A,,,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631433,BAO_0000218,
13018,11954,A,,,22224,Plasma clearance after intravenous dose of 0.3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL631434,BAO_0000218,
13019,11954,A,,,22224,Plasma clearance after intravenous dose of 1 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL631435,BAO_0000218,
13020,11954,A,,,22224,Plasma clearance after intravenous dose of 3 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL631436,BAO_0000218,
13021,11954,A,,,22224,Plasma clearance after intravenous dose of 3.87 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL631437,BAO_0000218,
13022,5669,A,,,50597,Plasma clearance after peroral administration at 10 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631438,BAO_0000218,
13023,5669,A,,,50797,Plasma clearance after peroral administration at 10 mpk in Rhesus,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL876431,BAO_0000218,
13024,5669,A,,,50588,Plasma clearance after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631439,BAO_0000218,
13025,13662,A,,,50597,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631440,BAO_0000218,
13026,8272,A,,,22224,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,0,,,1,,U,Autocuration,,,CHEMBL631441,BAO_0000019,
13027,13410,A,,,22224,Critical Micellar concentration was determined,,0,,,1,,U,Autocuration,,,CHEMBL631442,BAO_0000019,
13028,13410,A,,,22224,Critical Micellar concentration of the compound. was determined,,0,,,1,,U,Autocuration,,,CHEMBL626525,BAO_0000019,
13029,12628,A,,,22224,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,0,,,1,,U,Autocuration,,,CHEMBL627168,BAO_0000019,
13030,9675,A,,,22224,Critical micellar concentration was measured in water by the dye solubilization method,,0,,,1,,U,Autocuration,,,CHEMBL875618,BAO_0000019,
13031,12628,B,,,22224,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,0,,,1,,U,Autocuration,,,CHEMBL626612,BAO_0000019,
13032,12766,A,,,22224,CMR value (relative to BAY K 8644),,0,,,1,,U,Autocuration,,,CHEMBL626613,BAO_0000019,
13033,7849,A,,,22224,Carbamoylating activity was determined,,0,,,1,,U,Autocuration,,,CHEMBL626614,BAO_0000019,
13034,12187,A,,,22224,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626615,BAO_0000218,
13035,2040,A,,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,0,,,1,,U,Autocuration,,,CHEMBL626616,BAO_0000019,
13036,2040,A,,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,0,,,1,,U,Autocuration,,,CHEMBL626617,BAO_0000019,
13037,14180,A,,1969.0,50588,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626618,BAO_0000218,
13038,14180,A,,1969.0,50597,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626619,BAO_0000218,
13039,14474,A,,,50588,"Clearance rate at 0.46 mg/kg, iv, in dogs",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626620,BAO_0000218,
13040,14474,A,,,50597,"Clearance rate at 5.5 mg/kg, iv, in rat",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626621,BAO_0000218,
13041,14548,A,,,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626622,BAO_0000218,
13042,14548,A,,,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL626623,BAO_0000218,
13043,14548,A,,,50588,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626624,BAO_0000218,
13044,14548,A,,,50597,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626625,BAO_0000218,
13045,6125,A,,2107.0,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626626,BAO_0000218,
13046,6874,A,,,22224,Tested for the total clearance of the compound,,0,,,1,,U,Autocuration,,,CHEMBL626627,BAO_0000218,
13047,15343,A,,,50588,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626628,BAO_0000218,
13048,6236,A,,,22224,Total body clearance was determined,,0,,,1,,U,Autocuration,,,CHEMBL626629,BAO_0000218,
13049,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626630,BAO_0000218,
13050,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626631,BAO_0000218,
13051,8194,P,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626632,BAO_0000100,
13052,8194,P,,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626633,BAO_0000100,
13053,8194,P,,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626634,BAO_0000100,
13054,8194,P,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,0,,,1,,U,Autocuration,,,CHEMBL626635,BAO_0000100,
13055,8194,P,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626636,BAO_0000100,
13056,8194,P,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,0,,,1,,U,Autocuration,,,CHEMBL626637,BAO_0000100,
13057,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL626638,BAO_0000218,
13058,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL626639,BAO_0000218,
13059,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL626640,BAO_0000218,
13060,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL626641,BAO_0000218,
13061,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL627272,BAO_0000218,
13062,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL627273,BAO_0000218,
13063,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL627441,BAO_0000218,
13064,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL628355,BAO_0000218,
13065,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL628356,BAO_0000218,
13066,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL628357,BAO_0000218,
13067,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL628358,BAO_0000218,
13068,13273,A,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,1,,Pneumocystis carinii,1,4754.0,N,Intermediate,,,CHEMBL622307,BAO_0000218,
13069,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,0,,,1,,U,Autocuration,,,CHEMBL622527,BAO_0000019,
13070,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,0,,,1,,U,Autocuration,,,CHEMBL622528,BAO_0000019,
13071,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,0,,,1,,U,Autocuration,,,CHEMBL622529,BAO_0000019,
13072,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,0,,,1,,U,Autocuration,,,CHEMBL622992,BAO_0000019,
13073,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,0,,,1,,U,Autocuration,,,CHEMBL622993,BAO_0000019,
13074,13118,A,,,22224,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,0,,,1,,U,Autocuration,,,CHEMBL622994,BAO_0000019,
13075,10633,A,,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622995,BAO_0000218,
13076,10633,A,,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622996,BAO_0000218,
13077,10633,A,,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622997,BAO_0000218,
13078,10633,A,,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622998,BAO_0000218,
13079,5767,A,,,22224,Cp max following ip administration at 1 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL622999,BAO_0000218,
13080,3302,A,,1969.0,22224,Maximum concentration in plasma was reported at 0.5 hour,Plasma,0,,,1,,U,Autocuration,,,CHEMBL623000,BAO_0000218,
13081,3302,A,,1969.0,22224,Maximum concentration in plasma was reported at 2 hour,Plasma,0,,,1,,U,Autocuration,,,CHEMBL623001,BAO_0000218,
13082,12467,A,,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL623002,BAO_0000218,
13083,11778,P,,,22229,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,0,,,1,,U,Autocuration,,,CHEMBL623003,BAO_0000100,
13084,4321,A,,,22224,Steady state concentration was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL623004,BAO_0000019,
13085,14884,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL623005,BAO_0000019,
13086,15234,A,,,22224,Partition coefficient (logD7.4),,0,,,1,,U,Autocuration,,,CHEMBL623006,BAO_0000019,
13087,14198,A,,2107.0,50597,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623007,BAO_0000218,
13088,14198,A,,10000001.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623008,BAO_0000218,
13089,14198,A,,2037.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876654,BAO_0000218,
13090,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623009,BAO_0000218,
13091,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623010,BAO_0000218,
13092,14198,A,,948.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623011,BAO_0000218,
13093,14198,A,,160.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623012,BAO_0000218,
13094,8151,A,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL623013,BAO_0000019,
13095,8151,A,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL623014,BAO_0000019,
13096,8151,A,,1088.0,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Urine,0,,,1,,U,Autocuration,,,CHEMBL623015,BAO_0000019,
13097,8151,A,,1088.0,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,0,,,1,,U,Autocuration,,,CHEMBL623016,BAO_0000019,
13098,8151,A,,1088.0,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Urine,0,,,1,,U,Autocuration,,,CHEMBL624858,BAO_0000019,
13099,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624859,BAO_0000218,
13100,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624860,BAO_0000218,
13101,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624861,BAO_0000218,
13102,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624862,BAO_0000218,
13103,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624863,BAO_0000218,
13104,8151,A,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876655,BAO_0000218,
13105,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624864,BAO_0000218,
13106,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624865,BAO_0000218,
13107,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624866,BAO_0000218,
13108,6996,F,,,50588,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Expert,,,CHEMBL624867,BAO_0000218,
13109,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624868,BAO_0000218,
13110,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628450,BAO_0000218,
13111,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628451,BAO_0000218,
13112,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628452,BAO_0000218,
13113,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628453,BAO_0000218,
13114,6996,A,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628454,BAO_0000218,
13115,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628455,BAO_0000218,
13116,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628456,BAO_0000218,
13117,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628457,BAO_0000218,
13118,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL877505,BAO_0000218,
13119,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628458,BAO_0000218,
13120,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628459,BAO_0000218,
13121,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628460,BAO_0000218,
13122,6996,A,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628461,BAO_0000218,
13123,6996,B,,,22224,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,0,,,1,,U,Autocuration,,,CHEMBL628462,BAO_0000218,
13124,6996,A,,,50588,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628463,BAO_0000218,
13125,6996,F,,,50597,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL625666,BAO_0000218,
13126,6996,B,,,22224,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,0,,,1,,U,Autocuration,,,CHEMBL625667,BAO_0000218,
13127,6996,A,,,50597,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,1,,Rattus norvegicus,1,10116.0,N,Expert,,,CHEMBL625668,BAO_0000218,
13128,6996,A,,,50597,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625669,BAO_0000218,
13129,7114,A,,,22224,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,0,,,1,,U,Autocuration,,,CHEMBL625670,BAO_0000019,
13130,7114,A,,,50597,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625671,BAO_0000218,
13131,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL625672,BAO_0000218,
13132,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL625673,BAO_0000218,
13133,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL625674,BAO_0000218,
13134,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL625675,BAO_0000218,
13135,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627637,BAO_0000218,
13136,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627638,BAO_0000218,
13137,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627639,BAO_0000218,
13138,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627640,BAO_0000218,
13139,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627641,BAO_0000218,
13140,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL627642,BAO_0000218,
13141,8613,A,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL877506,BAO_0000218,
13142,8613,A,,,50594,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627275,BAO_0000218,
13143,11219,A,,,50506,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL627643,BAO_0000218,
13144,11219,A,,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL631246,BAO_0000218,
13145,11219,A,,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL631247,BAO_0000218,
13146,11219,A,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL629532,BAO_0000218,
13147,11219,A,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL629533,BAO_0000218,
13148,11219,A,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL629534,BAO_0000218,
13149,11219,A,,,50506,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,1,,Mustela putorius furo,1,9669.0,N,Intermediate,,,CHEMBL629535,BAO_0000218,
13150,14837,A,,,22224,Pharmacokinetic parameter :drug bound to plasma was reported,,0,,,1,,U,Autocuration,,,CHEMBL625932,BAO_0000019,
13151,14837,A,,,22224,compound was evaluated for drug bound in plasma,,0,,,1,,U,Autocuration,,,CHEMBL625933,BAO_0000019,
13152,15343,A,,,50597,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625934,BAO_0000218,
13153,13761,A,,,22224,Bioavailability,,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL625935,BAO_0000218,
13154,14810,A,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625936,BAO_0000218,
13155,14810,A,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625937,BAO_0000218,
13156,13249,A,,,50588,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625938,BAO_0000218,
13157,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625939,BAO_0000218,
13158,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625940,BAO_0000218,
13159,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874464,BAO_0000218,
13160,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625941,BAO_0000218,
13161,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625942,BAO_0000218,
13162,9267,A,,1970.0,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Bile,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625943,BAO_0000218,
13163,15549,A,,1977.0,50587,In vitro protein binding in human serum at 5 ug/ml,Serum,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625944,BAO_0000218,
13164,10929,A,,,22224,Serum protein binding ability was measured,,0,,,1,,U,Autocuration,,,CHEMBL625945,BAO_0000019,
13165,15444,A,,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,0,,,1,,U,Autocuration,,,CHEMBL625946,BAO_0000019,
13166,12860,A,,,22224,Oral bioavailability in dog,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL625947,BAO_0000218,
13167,12170,A,,,50597,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625948,BAO_0000218,
13168,15173,A,,,22224,Absolute oral bioavailability at an iv dose of 14 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL625949,BAO_0000218,
13169,15173,A,,,22224,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL625950,BAO_0000218,
13170,15173,A,,,22224,Oral bioavailability (dose 15 mg/kg i.v.),,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL625951,BAO_0000218,
13171,15173,A,,,22224,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,0,,,1,,U,Autocuration,,,CHEMBL625952,BAO_0000218,
13172,15173,A,,,22224,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,0,,,1,,U,Autocuration,,,CHEMBL625953,BAO_0000218,
13173,15173,A,,,22224,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,0,,,1,,U,Autocuration,,,CHEMBL625954,BAO_0000218,
13174,15173,A,,,22224,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,0,,,1,,U,Autocuration,,,CHEMBL882959,BAO_0000218,
13175,11767,A,,,50588,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625955,BAO_0000218,
13176,11219,A,,,22224,Bioavailability in ferret,,0,,Mustela putorius furo,1,9669.0,U,Autocuration,,,CHEMBL625956,BAO_0000218,
13177,12186,A,,,100710,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL625957,BAO_0000218,
13178,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625958,BAO_0000218,
13179,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625959,BAO_0000218,
13180,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626642,BAO_0000218,
13181,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631330,BAO_0000218,
13182,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631331,BAO_0000218,
13183,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631332,BAO_0000218,
13184,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631333,BAO_0000218,
13185,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632018,BAO_0000218,
13186,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632019,BAO_0000218,
13187,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632020,BAO_0000218,
13188,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632021,BAO_0000218,
13189,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632022,BAO_0000218,
13190,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632023,BAO_0000218,
13191,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632024,BAO_0000218,
13192,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874472,BAO_0000218,
13193,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632025,BAO_0000218,
13194,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632026,BAO_0000218,
13195,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632027,BAO_0000218,
13196,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632028,BAO_0000218,
13197,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626430,BAO_0000218,
13198,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626431,BAO_0000218,
13199,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626432,BAO_0000218,
13200,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626433,BAO_0000218,
13201,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626434,BAO_0000218,
13202,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627280,BAO_0000218,
13203,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627281,BAO_0000218,
13204,11510,A,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627282,BAO_0000218,
13205,7199,A,,,22224,Total body clearance was measured at given dose,,0,,,1,,U,Autocuration,,,CHEMBL627283,BAO_0000019,
13206,7199,A,,,22224,Total body clearance was measured at given dose.,,0,,,1,,U,Autocuration,,,CHEMBL627284,BAO_0000218,
13207,7095,A,,,50597,Metabolic clearance from the body in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627285,BAO_0000218,
13208,7095,A,,,22224,Renal clearance from the body,,0,,,1,,U,Autocuration,,,CHEMBL627286,BAO_0000218,
13209,7095,A,,,50597,Renal clearance from the body in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875477,BAO_0000218,
13210,12528,A,,,50597,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627287,BAO_0000218,
13211,12528,A,,,50588,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627288,BAO_0000218,
13212,7095,A,,,50597,Total clearance from the body in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627289,BAO_0000218,
13213,14223,A,,1969.0,50597,Clearance into cortex from rat plasma or PBS,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627290,BAO_0000218,
13214,13569,A,,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627291,BAO_0000218,
13215,13569,A,,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627292,BAO_0000218,
13216,13569,A,,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627293,BAO_0000218,
13217,13569,A,,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL627294,BAO_0000218,
13218,13569,A,,,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,0,,,1,,U,Autocuration,,,CHEMBL875478,BAO_0000218,
13219,13979,A,,,22224,Clearance was determined,,0,,,1,,U,Autocuration,,,CHEMBL627295,BAO_0000218,
13220,14315,A,,,50594,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627296,BAO_0000218,
13221,14315,A,,,50592,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL626119,BAO_0000218,
13222,14315,A,,,50597,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626120,BAO_0000218,
13223,12174,A,,,50597,Clearance in rat after iv dose (100 ug/kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626121,BAO_0000218,
13224,12797,A,,,22224,Clearance in guinea pig,,0,,Cavia porcellus,1,10141.0,U,Autocuration,,,CHEMBL626122,BAO_0000218,
13225,12797,A,,,50597,Compound was evaluated for clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626123,BAO_0000218,
13226,12797,A,,,50588,Compound was evaluated for the clearance in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623456,BAO_0000218,
13227,12797,A,,,50597,Compound was evaluated for the clearance in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623457,BAO_0000218,
13228,11500,A,,,50597,Compound was tested in vivo for clearance after iv administration in the rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623458,BAO_0000218,
13229,15173,A,,,22224,IV clearance determined at an iv dose of 14 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL623459,BAO_0000218,
13230,15173,A,,,22224,IV clearance determined at an iv dose of 15.2 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL875484,BAO_0000218,
13231,15173,A,,,22224,IV clearance determined at an iv dose of 15 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL623460,BAO_0000218,
13232,15173,A,,,22224,IV clearance determined at an peroral dose of 30 mg/kg.,,0,,,1,,U,Autocuration,,,CHEMBL623461,BAO_0000218,
13233,15173,A,,,22224,IV clearance determined at an peroral dose of 30.2 mg/kg.,,0,,,1,,U,Autocuration,,,CHEMBL623462,BAO_0000218,
13234,15173,A,,,22224,IV clearance determined at an peroral dose of 30.3 mg/kg.,,0,,,1,,U,Autocuration,,,CHEMBL627386,BAO_0000218,
13235,14198,A,,2113.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627387,BAO_0000218,
13236,14198,A,,2107.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627388,BAO_0000218,
13237,14198,A,,2048.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627389,BAO_0000218,
13238,14198,A,,2385.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627390,BAO_0000218,
13239,14198,A,,1969.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627391,BAO_0000218,
13240,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627392,BAO_0000218,
13241,14198,A,,2106.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627393,BAO_0000218,
13242,14198,A,,3126.0,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627394,BAO_0000218,
13243,14198,A,,10000001.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627395,BAO_0000218,
13244,14198,A,,2037.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875485,BAO_0000218,
13245,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627396,BAO_0000218,
13246,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627397,BAO_0000218,
13247,14198,A,,948.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627398,BAO_0000218,
13248,14198,A,,10000001.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627399,BAO_0000218,
13249,14198,A,,2113.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627400,BAO_0000218,
13250,14198,A,,2107.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627401,BAO_0000218,
13251,14198,A,,2048.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627402,BAO_0000218,
13252,14198,A,,2385.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627403,BAO_0000218,
13253,14198,A,,1969.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627404,BAO_0000218,
13254,14198,A,,,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623101,BAO_0000218,
13255,14198,A,,2106.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877480,BAO_0000218,
13256,14198,A,,3126.0,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623102,BAO_0000218,
13257,14198,A,,10000001.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623103,BAO_0000218,
13258,14198,A,,2037.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623104,BAO_0000218,
13259,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623105,BAO_0000218,
13260,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623106,BAO_0000218,
13261,14198,A,,948.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623107,BAO_0000218,
13262,14198,A,,160.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623108,BAO_0000218,
13263,14198,A,,2113.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623109,BAO_0000218,
13264,14198,A,,2107.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623110,BAO_0000218,
13265,14198,A,,2048.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623111,BAO_0000218,
13266,14198,A,,2385.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625060,BAO_0000218,
13267,14198,A,,1969.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625061,BAO_0000218,
13268,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625062,BAO_0000218,
13269,14198,A,,2106.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625063,BAO_0000218,
13270,14198,A,,3126.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625064,BAO_0000218,
13271,14198,A,,10000001.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Bone,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625065,BAO_0000218,
13272,14198,A,,2037.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625066,BAO_0000218,
13273,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625067,BAO_0000218,
13274,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625068,BAO_0000218,
13275,14198,A,,948.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622159,BAO_0000218,
13276,14198,A,,160.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intestine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622160,BAO_0000218,
13277,14198,A,,2113.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622161,BAO_0000218,
13278,14198,A,,2048.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622162,BAO_0000218,
13279,14198,A,,2385.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622163,BAO_0000218,
13280,14198,A,,1969.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622313,BAO_0000218,
13281,14198,A,,,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622314,BAO_0000218,
13282,14198,A,,2106.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622315,BAO_0000218,
13283,14198,A,,3126.0,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622316,BAO_0000218,
13284,15599,A,,,50212,Normal diffusion coefficient in water for Escherichia coli,,1,,Escherichia coli,1,562.0,N,Intermediate,,,CHEMBL877486,BAO_0000218,
13285,8204,A,,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined,,0,,,1,,U,Autocuration,,,CHEMBL622317,BAO_0000019,
13286,8204,A,,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined.,,0,,,1,,U,Autocuration,,,CHEMBL622318,BAO_0000019,
13287,6154,A,,,22224,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL622319,BAO_0000019,
13288,6154,A,,,22224,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL622320,BAO_0000019,
13289,6154,A,,,22224,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,0,,,1,,U,Autocuration,,,CHEMBL622321,BAO_0000019,
13290,6154,A,,,22224,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL622322,BAO_0000019,
13291,7114,A,,,22224,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,0,,,1,,U,Autocuration,,,CHEMBL622323,BAO_0000019,
13292,7114,A,,,50597,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622324,BAO_0000218,
13293,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622325,BAO_0000218,
13294,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622326,BAO_0000218,
13295,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL877487,BAO_0000218,
13296,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622327,BAO_0000218,
13297,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622328,BAO_0000218,
13298,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622329,BAO_0000218,
13299,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622330,BAO_0000218,
13300,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622331,BAO_0000218,
13301,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622332,BAO_0000218,
13302,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622333,BAO_0000218,
13303,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL627658,BAO_0000218,
13304,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL630428,BAO_0000218,
13305,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL630429,BAO_0000218,
13306,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL630430,BAO_0000218,
13307,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL630431,BAO_0000218,
13308,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630432,BAO_0000218,
13309,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630433,BAO_0000218,
13310,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630434,BAO_0000218,
13311,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629372,BAO_0000218,
13312,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629553,BAO_0000218,
13313,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629554,BAO_0000218,
13314,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874447,BAO_0000218,
13315,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629555,BAO_0000218,
13316,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629556,BAO_0000218,
13317,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629557,BAO_0000218,
13318,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629558,BAO_0000218,
13319,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629559,BAO_0000218,
13320,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629560,BAO_0000218,
13321,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629561,BAO_0000218,
13322,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629562,BAO_0000218,
13323,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629563,BAO_0000218,
13324,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629564,BAO_0000218,
13325,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629565,BAO_0000218,
13326,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629566,BAO_0000218,
13327,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629567,BAO_0000218,
13328,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629568,BAO_0000218,
13329,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629569,BAO_0000218,
13330,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629570,BAO_0000218,
13331,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL629571,BAO_0000218,
13332,12170,A,,,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL629572,BAO_0000218,
13333,12170,A,,,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL629573,BAO_0000218,
13334,4985,A,,,22224,Bioavailability (dose 20 mg/kg),,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL629574,BAO_0000218,
13335,15145,A,,,22224,Bioavailability in dog,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL629575,BAO_0000218,
13336,14080,A,,,22224,Bioavailability in rat (Sprague-Dawley) (male),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL874448,BAO_0000218,
13337,11219,A,,,22224,Bioavailability in monkey (dose 10 mg/kg i.d.),,0,,Primates,1,9443.0,U,Autocuration,,,CHEMBL629576,BAO_0000218,
13338,15145,A,,,22224,Bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL629577,BAO_0000218,
13339,15145,A,,,22224,Bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL629578,BAO_0000218,
13340,1202,A,,,22224,Bioavailability in dog (dose 3.0 mg/kg p.o.),,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL629579,BAO_0000218,
13341,1202,A,,,22224,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL882958,BAO_0000218,
13342,1202,A,,,50505,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,1,,Pan troglodytes,1,9598.0,N,Intermediate,,,CHEMBL629580,BAO_0000218,
13343,4026,A,,,22224,Bioavailability,,0,,Eutheria,1,9347.0,U,Autocuration,,,CHEMBL629581,BAO_0000218,
13344,1492,A,,,22224,Bioavailability in squirrel monkey,,0,,Saimiri,1,9520.0,U,Autocuration,,,CHEMBL629582,BAO_0000218,
13345,12793,A,,,50588,Bioavailability was evaluated in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628522,BAO_0000218,
13346,12793,A,,,100712,Bioavailability was evaluated in hamster,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL625432,BAO_0000218,
13347,12793,A,,,22224,Bioavailability in rat,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625433,BAO_0000218,
13348,14793,A,,1969.0,50597,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625434,BAO_0000218,
13349,14793,A,,1969.0,50597,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625435,BAO_0000218,
13350,14793,A,,,22224,Bioavailability in rat (dose 10 mg/kg p.o.),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625436,BAO_0000218,
13351,14731,A,,,100710,Bioavailability was measured in cynomolgus monkeys.,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL874588,BAO_0000218,
13352,14731,A,,,50594,Bioavailability was measured in nude mice.,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625437,BAO_0000218,
13353,12187,A,,,22224,Bioavailability in ferret (dose 10 mg/kg i.d.),,0,,Mustela putorius furo,1,9669.0,U,Autocuration,,,CHEMBL625438,BAO_0000218,
13354,12187,A,,,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625439,BAO_0000218,
13355,12187,A,,,22224,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625440,BAO_0000218,
13356,12187,A,,,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL625441,BAO_0000218,
13357,12187,A,,,22224,Bioavailability in rat (dose 10 mg/kg i.d.),,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625442,BAO_0000218,
13358,12187,A,,,50597,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625443,BAO_0000218,
13359,17431,A,,,22224,Bioavailability was determined; extremely poor,,0,,,1,,U,Autocuration,,,CHEMBL625444,BAO_0000218,
13360,13318,A,,,50594,% bioavailability in mice after oral administration of prodrug,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625445,BAO_0000218,
13361,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625446,BAO_0000218,
13362,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL882960,BAO_0000218,
13363,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625447,BAO_0000218,
13364,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625448,BAO_0000218,
13365,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625449,BAO_0000218,
13366,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874589,BAO_0000218,
13367,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625450,BAO_0000218,
13368,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625451,BAO_0000218,
13369,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626584,BAO_0000218,
13370,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626585,BAO_0000218,
13371,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626586,BAO_0000218,
13372,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626587,BAO_0000218,
13373,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626588,BAO_0000218,
13374,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626589,BAO_0000218,
13375,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626590,BAO_0000218,
13376,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626591,BAO_0000218,
13377,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627181,BAO_0000218,
13378,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628083,BAO_0000218,
13379,15173,A,,,22224,IV clearance determined at an peroral dose of 15 mg/kg.,,0,,,1,,U,Autocuration,,,CHEMBL628084,BAO_0000218,
13380,7732,F,,,50064,Mouse oral clearance was measured against Hymenolepiasis nana.,,1,,Hymenolepis nana,1,102285.0,N,Expert,,,CHEMBL628085,BAO_0000218,
13381,7732,F,,,50545,Mouse oral clearance was measured against Nematospiroides dubius,,1,,Heligmosomoides polygyrus,1,6339.0,N,Expert,,,CHEMBL628086,BAO_0000218,
13382,7732,F,,,22224,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,0,,,1,,U,Autocuration,,,CHEMBL628087,BAO_0000218,
13383,7732,A,,,50594,Mouse oral clearance was measured against N. nana; NT is Not Tested,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628088,BAO_0000218,
13384,7732,B,,,22224,Mouse oral clearance was measured against N. nana; NT is Not Tested,,0,,,1,,U,Autocuration,,,CHEMBL628089,BAO_0000218,
13385,8328,A,,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL628090,BAO_0000218,
13386,8328,A,,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL628091,BAO_0000218,
13387,8328,A,,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL628092,BAO_0000218,
13388,8328,A,,,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL628093,BAO_0000218,
13389,8328,A,,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL875607,BAO_0000218,
13390,8328,A,,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL625710,BAO_0000218,
13391,8328,A,,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL625711,BAO_0000218,
13392,8328,A,,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL625712,BAO_0000218,
13393,8328,A,,,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,0,,,1,,U,Autocuration,,,CHEMBL625713,BAO_0000218,
13394,13376,A,,,50588,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625714,BAO_0000218,
13395,13477,A,,,50797,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL625715,BAO_0000218,
13396,13477,A,,,50597,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625716,BAO_0000218,
13397,13477,A,,,50597,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625717,BAO_0000218,
13398,13313,A,,,50597,Plasma clearance was determined for the compound in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625718,BAO_0000218,
13399,12504,A,,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625719,BAO_0000218,
13400,12504,A,,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625720,BAO_0000218,
13401,12504,A,,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625721,BAO_0000218,
13402,12504,A,,,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625722,BAO_0000218,
13403,13129,A,,,50597,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625723,BAO_0000218,
13404,7732,A,,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,1,,Heligmosomoides polygyrus,1,6339.0,N,Intermediate,,,CHEMBL625724,BAO_0000218,
13405,7732,A,,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,1,,Heligmosomoides polygyrus,1,6339.0,N,Intermediate,,,CHEMBL625725,BAO_0000218,
13406,7732,A,,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,1,,Heligmosomoides polygyrus,1,6339.0,N,Intermediate,,,CHEMBL625726,BAO_0000218,
13407,7732,A,,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,1,,Heligmosomoides polygyrus,1,6339.0,N,Intermediate,,,CHEMBL875608,BAO_0000218,
13408,7732,A,,,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,1,,Heligmosomoides polygyrus,1,6339.0,N,Intermediate,,,CHEMBL625727,BAO_0000218,
13409,9278,A,,1088.0,22224,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Urine,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625728,BAO_0000218,
13410,9278,A,,,22224,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625729,BAO_0000218,
13411,9278,A,,,22224,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625730,BAO_0000218,
13412,9278,A,,1088.0,22224,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Urine,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL625731,BAO_0000218,
13413,9278,A,,1088.0,22224,Urinary clearance was determined in rat at 25 mg/kg os dosage,Urine,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL626417,BAO_0000218,
13414,9278,A,,1088.0,50587,Urinary clearance was determined at 100 mg/kg oral dosage in human,Urine,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL626418,BAO_0000218,
13415,9278,A,,1088.0,50588,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626419,BAO_0000218,
13416,5932,A,,1969.0,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626592,BAO_0000218,
13417,5932,A,,1969.0,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626593,BAO_0000218,
13418,5182,A,,,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626594,BAO_0000218,
13419,10499,A,,,50588,Clearance rate in dogs,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625035,BAO_0000218,
13420,6051,A,,,22224,Compound was measured for intrinsic clearance,,0,,,1,,U,Autocuration,,,CHEMBL625036,BAO_0000019,
13421,17508,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625037,BAO_0000100,
13422,6228,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625038,BAO_0000100,
13423,6231,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625039,BAO_0000100,
13424,17740,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625040,BAO_0000100,
13425,6495,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625041,BAO_0000100,
13426,2171,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625042,BAO_0000100,
13427,3255,A,,,22224,Partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL874411,BAO_0000019,
13428,6821,A,,,22224,Permeability,,0,,,1,,U,Autocuration,,,CHEMBL625043,BAO_0000019,
13429,2685,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625044,BAO_0000100,
13430,17584,A,,,22224,Partition coefficient (logD),,0,,,1,,U,Autocuration,,,CHEMBL625045,BAO_0000019,
13431,13824,P,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,0,,,1,,U,Autocuration,,,CHEMBL625046,BAO_0000100,
13432,13824,P,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,0,,,1,,U,Autocuration,,,CHEMBL625047,BAO_0000100,
13433,16479,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625048,BAO_0000100,
13434,11997,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625049,BAO_0000100,
13435,2988,P,,,22229,Calculated logarithm of partition coefficient (P) was determined,,0,,,1,,U,Autocuration,,,CHEMBL625050,BAO_0000100,
13436,931,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625051,BAO_0000100,
13437,4381,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL874412,BAO_0000100,
13438,4397,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625052,BAO_0000100,
13439,5889,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL625053,BAO_0000100,
13440,6154,A,,,22224,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623250,BAO_0000019,
13441,6154,A,,,22224,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623251,BAO_0000019,
13442,6154,A,,,22224,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623252,BAO_0000019,
13443,6154,A,,,22224,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623253,BAO_0000019,
13444,6154,A,,,22224,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623254,BAO_0000019,
13445,6154,A,,,22224,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,0,,,1,,U,Autocuration,,,CHEMBL623255,BAO_0000019,
13446,6887,A,,,22224,Percent degradation of compound at a pH of 1 over a 18 hr period,,0,,,1,,U,Autocuration,,,CHEMBL626831,BAO_0000019,
13447,6887,A,,,22224,Percent degradation of compound at pH of 1 over an 18 hr period,,0,,,1,,U,Autocuration,,,CHEMBL877494,BAO_0000019,
13448,14116,A,,,22224,Delta Logarithm of Partition Coefficient value was determined.,,0,,,1,,U,Autocuration,,,CHEMBL626832,BAO_0000019,
13449,11137,A,,,22224,Delta logPoct-cyc,,0,,,1,,U,Autocuration,,,CHEMBL626833,BAO_0000019,
13450,7230,P,,,22224,Lipophilicity estimated on reversed phase TLC,,0,,,1,,U,Autocuration,,,CHEMBL626834,BAO_0000100,
13451,15741,A,,,22224,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,0,,,1,,U,Autocuration,,,CHEMBL626835,BAO_0000019,
13452,9663,A,,,22224,Delta logPoct-cyc,,0,,,1,,U,Autocuration,,,CHEMBL626836,BAO_0000019,
13453,9663,P,,,22229,Change in logarithm of partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL626837,BAO_0000100,
13454,13807,A,,,22224,Delta logD (pH 6.5),,0,,,1,,U,Autocuration,,,CHEMBL626838,BAO_0000019,
13455,13807,P,,,22224,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,0,,,1,,U,Autocuration,,,CHEMBL626839,BAO_0000100,
13456,17425,A,,,22224,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,0,,,1,,U,Autocuration,,,CHEMBL626840,BAO_0000019,
13457,12143,A,,,22224,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,0,,,1,,U,Autocuration,,,CHEMBL626841,BAO_0000019,
13458,12608,A,,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,0,,,1,,U,Autocuration,,,CHEMBL626842,BAO_0000219,
13459,12608,A,,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,0,,,1,,U,Autocuration,,,CHEMBL626843,BAO_0000219,
13460,8649,A,,,50597,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626844,BAO_0000218,
13461,8649,A,,,50597,Amount of deuterium retained was reported after normal workup in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877495,BAO_0000218,
13462,8649,A,,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626845,BAO_0000218,
13463,8649,A,,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626846,BAO_0000218,
13464,8649,A,,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626847,BAO_0000218,
13465,8649,A,,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628677,BAO_0000218,
13466,8649,A,,,50597,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628678,BAO_0000218,
13467,9659,A,,,22224,Compound was subjected to electrochemical oxidation,,0,,,1,,U,Autocuration,,,CHEMBL628679,BAO_0000019,
13468,9659,A,,,22224,Compound was subjected to photochemical oxidation,,0,,,1,,U,Autocuration,,,CHEMBL628680,BAO_0000019,
13469,9659,A,,,22224,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,0,,,1,,U,Autocuration,,,CHEMBL628681,BAO_0000019,
13470,9659,A,,,22224,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,0,,,1,,U,Autocuration,,,CHEMBL628682,BAO_0000019,
13471,9659,A,,,22224,Oxidation of compound by methemoglobin in presence of hydroperoxide,,0,,,1,,U,Autocuration,,,CHEMBL628683,BAO_0000019,
13472,9607,A,,,50597,Percent diffusion through fuzzy rat skin after 48 h of incubation,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628684,BAO_0000218,
13473,7057,P,,,22229,Dissociation constant (pKa),,0,,,1,,U,Autocuration,,,CHEMBL877501,BAO_0000100,
13474,7057,P,,,22224,Dissociation constant value of the compound; ND means not determined.,,0,,,1,,U,Autocuration,,,CHEMBL628685,BAO_0000100,
13475,7911,A,,178.0,50597,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628686,BAO_0000218,
13476,7911,A,,178.0,50597,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628687,BAO_0000218,
13477,7911,A,,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628688,BAO_0000218,
13478,7911,A,,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628689,BAO_0000218,
13479,7911,A,,2107.0,50597,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628690,BAO_0000218,
13480,7911,A,,2107.0,50597,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629363,BAO_0000218,
13481,7911,A,,2106.0,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629364,BAO_0000218,
13482,7911,A,,2106.0,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629365,BAO_0000218,
13483,7911,A,,,50597,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629366,BAO_0000218,
13484,7911,A,,1088.0,50597,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629367,BAO_0000218,
13485,7911,A,,1988.0,50597,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629368,BAO_0000218,
13486,7911,A,,1088.0,50597,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877502,BAO_0000218,
13487,13792,A,,2037.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Cerebellum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629369,BAO_0000218,
13488,13792,A,,955.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629370,BAO_0000218,
13489,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL629371,BAO_0000218,
13490,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626276,BAO_0000218,
13491,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL626277,BAO_0000218,
13492,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL631250,BAO_0000218,
13493,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631251,BAO_0000218,
13494,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631252,BAO_0000218,
13495,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631253,BAO_0000218,
13496,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631254,BAO_0000218,
13497,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631255,BAO_0000218,
13498,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631256,BAO_0000218,
13499,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631257,BAO_0000218,
13500,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628009,BAO_0000218,
13501,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628010,BAO_0000218,
13502,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628011,BAO_0000218,
13503,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628012,BAO_0000218,
13504,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628013,BAO_0000218,
13505,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628014,BAO_0000218,
13506,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628015,BAO_0000218,
13507,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628016,BAO_0000218,
13508,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL874461,BAO_0000218,
13509,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628017,BAO_0000218,
13510,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628018,BAO_0000218,
13511,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628019,BAO_0000218,
13512,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628020,BAO_0000218,
13513,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628021,BAO_0000218,
13514,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628022,BAO_0000218,
13515,8133,A,,1088.0,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628023,BAO_0000218,
13516,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628024,BAO_0000218,
13517,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628025,BAO_0000218,
13518,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628026,BAO_0000218,
13519,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628027,BAO_0000218,
13520,8133,A,,1088.0,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL628028,BAO_0000218,
13521,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628029,BAO_0000218,
13522,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628030,BAO_0000218,
13523,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628031,BAO_0000218,
13524,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628032,BAO_0000218,
13525,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628033,BAO_0000218,
13526,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628034,BAO_0000218,
13527,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628035,BAO_0000218,
13528,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628036,BAO_0000218,
13529,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874462,BAO_0000218,
13530,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628037,BAO_0000218,
13531,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628123,BAO_0000218,
13532,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628124,BAO_0000218,
13533,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628125,BAO_0000218,
13534,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628126,BAO_0000218,
13535,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628127,BAO_0000218,
13536,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628128,BAO_0000218,
13537,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628129,BAO_0000218,
13538,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628130,BAO_0000218,
13539,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628131,BAO_0000218,
13540,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628132,BAO_0000218,
13541,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628133,BAO_0000218,
13542,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628134,BAO_0000218,
13543,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628135,BAO_0000218,
13544,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628136,BAO_0000218,
13545,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628137,BAO_0000218,
13546,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628138,BAO_0000218,
13547,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628139,BAO_0000218,
13548,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628140,BAO_0000218,
13549,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628141,BAO_0000218,
13550,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628142,BAO_0000218,
13551,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628143,BAO_0000218,
13552,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628144,BAO_0000218,
13553,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628145,BAO_0000218,
13554,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL628146,BAO_0000218,
13555,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625355,BAO_0000218,
13556,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625356,BAO_0000218,
13557,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625357,BAO_0000218,
13558,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625527,BAO_0000218,
13559,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875473,BAO_0000218,
13560,9025,A,,,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625528,BAO_0000218,
13561,9025,A,,,50597,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626304,BAO_0000218,
13562,9025,A,,1637.0,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Artery,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624138,BAO_0000218,
13563,6448,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624139,BAO_0000100,
13564,17221,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624140,BAO_0000100,
13565,6545,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624141,BAO_0000100,
13566,577,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624142,BAO_0000100,
13567,6285,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624143,BAO_0000100,
13568,6500,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624144,BAO_0000100,
13569,6716,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624145,BAO_0000100,
13570,13658,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624146,BAO_0000100,
13571,6549,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624147,BAO_0000100,
13572,14685,P,,,22229,Calculated partition coefficient (clogP) (MacLogP),,0,,,1,,U,Autocuration,,,CHEMBL883123,BAO_0000100,
13573,6893,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL624148,BAO_0000019,
13574,3687,A,,,22224,Kinetic parameter was determined,,0,,,1,,U,Autocuration,,,CHEMBL874416,BAO_0000019,
13575,4207,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624149,BAO_0000100,
13576,4626,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL624150,BAO_0000100,
13577,1021,P,,,22224,Lipophilicity was determined,,0,,,1,,U,Autocuration,,,CHEMBL624151,BAO_0000100,
13578,3777,P,,,22224,Lipophilicity was determined,,0,,,1,,U,Autocuration,,,CHEMBL624152,BAO_0000100,
13579,17533,P,,,22224,Lipophilicity was determined,,0,,,1,,U,Autocuration,,,CHEMBL622139,BAO_0000100,
13580,6524,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL622140,BAO_0000100,
13581,17533,P,,,22224,Lipophilicity was determined,,0,,,1,,U,Autocuration,,,CHEMBL622141,BAO_0000100,
13582,6480,P,,,22224,Lipophilicity in octanol-water,,0,,,1,,U,Autocuration,,,CHEMBL622142,BAO_0000100,
13583,17606,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL622143,BAO_0000100,
13584,6863,P,,,22229,Octanol-water partition coefficient was determined,,0,,,1,,U,Autocuration,,,CHEMBL622144,BAO_0000100,
13585,1356,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL877473,BAO_0000019,
13586,3326,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL622145,BAO_0000100,
13587,1356,A,,,22224,Partition coefficient was determined; ND means not determined,,0,,,1,,U,Autocuration,,,CHEMBL622146,BAO_0000019,
13588,12984,P,,,22229,Calculated partition coefficient (clogP),,0,,,1,,U,Autocuration,,,CHEMBL622147,BAO_0000100,
13589,17363,A,,,22224,Partition coefficient of the compound,,0,,,1,,U,Autocuration,,,CHEMBL622148,BAO_0000019,
13590,6827,A,,,22224,Permeability was determined,,0,,,1,,U,Autocuration,,,CHEMBL883124,BAO_0000019,
13591,261,P,,,22229,The compound was evaluated for the partition coefficient,,0,,,1,,U,Autocuration,,,CHEMBL622149,BAO_0000100,
13592,2685,A,,,22224,Partition coefficient (logP),,0,,,1,,U,Autocuration,,,CHEMBL622150,BAO_0000019,
13593,414,P,,,22224,The lipophilicity was reported,,0,,,1,,U,Autocuration,,,CHEMBL622151,BAO_0000100,
13594,15769,P,,,22229,logarithm of the octanol-water partition coefficient for the compound,,0,,,1,,U,Autocuration,,,CHEMBL622152,BAO_0000100,
13595,17248,A,,,22224,Clogp value was determined,,0,,,1,,U,Autocuration,,,CHEMBL622153,BAO_0000019,
13596,16935,A,,,22224,Clp at a dose of 1.5 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL877474,BAO_0000218,
13597,16935,A,,,22224,Clp at a dose of 2.0 mg/kg,,0,,,1,,U,Autocuration,,,CHEMBL622154,BAO_0000218,
13598,14832,A,,1969.0,22224,"Clp, plasma clearance at a dose of 10 mg/kg",Plasma,0,,,1,,U,Autocuration,,,CHEMBL622155,BAO_0000218,
13599,14832,A,,1969.0,22224,"Clp, plasma clearance at a dose of 50 mg/kg",Plasma,0,,,1,,U,Autocuration,,,CHEMBL622156,BAO_0000218,
13600,2399,A,,1969.0,50597,Compound was tested for plasma clearance in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622157,BAO_0000218,
13601,2399,A,,1969.0,50597,Compound was tested for plasma clearance in rat; Not determined,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622158,BAO_0000218,
13602,6227,A,,,50597,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622807,BAO_0000218,
13603,6227,A,,,50797,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL622808,BAO_0000218,
13604,5623,A,,,22224,Plasma clearance by iv administration at a dose 0.003 ug/mL,,0,,,1,,U,Autocuration,,,CHEMBL622809,BAO_0000218,
13605,4854,A,,,22224,Plasma clearance determined,,0,,,1,,U,Autocuration,,,CHEMBL622810,BAO_0000218,
13606,4493,A,,,100712,Plasma clearance after iv administration at 3 mg/kg in hamster,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL876653,BAO_0000218,
13607,4493,A,,,100712,Plasma clearance after iv administration at 4 mg/kg in hamster,,1,,Cricetinae,1,10026.0,N,Intermediate,,,CHEMBL622811,BAO_0000218,
13608,14956,A,,,50597,Rate of clearance in rat was determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622986,BAO_0000218,
13609,15372,A,,1969.0,50597,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622987,BAO_0000218,
13610,15372,A,,1969.0,50597,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622988,BAO_0000218,
13611,15372,A,,1969.0,50597,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622989,BAO_0000218,
13612,15372,A,,1969.0,50597,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622990,BAO_0000218,
13613,15604,A,,1969.0,22224,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Plasma,0,,Simiiformes,1,314293.0,U,Autocuration,,,CHEMBL622991,BAO_0000218,
13614,15604,A,,1969.0,50597,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622227,BAO_0000218,
13615,15604,A,,1969.0,50588,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622228,BAO_0000218,
13616,14964,A,,,50597,Clpl value in rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622229,BAO_0000218,
13617,15240,A,,,50512,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL622230,BAO_0000218,
13618,16449,A,,,50597,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622231,BAO_0000218,
13619,16449,A,,,100710,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,1,,Macaca fascicularis,1,9541.0,N,Intermediate,,,CHEMBL622232,BAO_0000218,
13620,12902,A,,,22224,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622233,BAO_0000218,
13621,12902,A,,,22224,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622234,BAO_0000218,
13622,12902,A,,,22224,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622235,BAO_0000218,
13623,12902,A,,,22224,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622236,BAO_0000218,
13624,12902,A,,,22224,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622237,BAO_0000218,
13625,12902,A,,,22224,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL877482,BAO_0000218,
13626,12902,A,,,22224,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622238,BAO_0000218,
13627,12902,A,,,22224,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,0,,,1,,U,Autocuration,,,CHEMBL622239,BAO_0000218,
13628,11149,A,,178.0,22224,Cmax was calculated as maximum concentration reached in the blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL622240,BAO_0000218,
13629,11149,A,,178.0,22224,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Blood,0,,,1,,U,Autocuration,,,CHEMBL622241,BAO_0000218,
13630,5669,A,,,50597,Cmax was determine after peroral administration at 10 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631013,BAO_0000218,
13631,5669,A,,,50797,Cmax was determine after peroral administration at 10 mpk in Rhesus,,1,,Macaca mulatta,1,9544.0,N,Intermediate,,,CHEMBL631014,BAO_0000218,
13632,5669,A,,,50588,Cmax was determine after peroral administration at 10 mpk in dog,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631015,BAO_0000218,
13633,5669,A,,,50597,Cmax was determine after peroral administration at 160 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631016,BAO_0000218,
13634,5669,A,,,50597,Cmax was determine after peroral administration at 20 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631017,BAO_0000218,
13635,5669,A,,,50597,Cmax was determine after peroral administration at 50 mpk in Rat,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631018,BAO_0000218,
13636,4236,A,,,22224,Cmax was determined,,0,,,1,,U,Autocuration,,,CHEMBL631019,BAO_0000218,
13637,13792,A,,955.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL875761,BAO_0000218,
13638,13792,A,,955.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631020,BAO_0000218,
13639,13792,A,,955.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631669,BAO_0000218,
13640,13792,A,,955.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631670,BAO_0000218,
13641,13792,A,,2435.0,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Striatum,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631671,BAO_0000218,
13642,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631672,BAO_0000218,
13643,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631673,BAO_0000218,
13644,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631856,BAO_0000218,
13645,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631857,BAO_0000218,
13646,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631858,BAO_0000218,
13647,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631859,BAO_0000218,
13648,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631860,BAO_0000218,
13649,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631861,BAO_0000218,
13650,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631862,BAO_0000218,
13651,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631863,BAO_0000218,
13652,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631864,BAO_0000218,
13653,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631865,BAO_0000218,
13654,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631866,BAO_0000218,
13655,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629360,BAO_0000218,
13656,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629361,BAO_0000218,
13657,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629362,BAO_0000218,
13658,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630740,BAO_0000218,
13659,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630741,BAO_0000218,
13660,8418,A,,178.0,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630742,BAO_0000218,
13661,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630743,BAO_0000218,
13662,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630744,BAO_0000218,
13663,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630745,BAO_0000218,
13664,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630746,BAO_0000218,
13665,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630747,BAO_0000218,
13666,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630748,BAO_0000218,
13667,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632056,BAO_0000218,
13668,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632057,BAO_0000218,
13669,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632058,BAO_0000218,
13670,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632059,BAO_0000218,
13671,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632060,BAO_0000218,
13672,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632061,BAO_0000218,
13673,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629207,BAO_0000218,
13674,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629208,BAO_0000218,
13675,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629209,BAO_0000218,
13676,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629210,BAO_0000218,
13677,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629211,BAO_0000218,
13678,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629212,BAO_0000218,
13679,8418,A,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629213,BAO_0000218,
13680,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629214,BAO_0000218,
13681,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629215,BAO_0000218,
13682,8133,A,,1088.0,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL635154,BAO_0000218,
13683,6996,A,,,50597,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629216,BAO_0000218,
13684,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629217,BAO_0000218,
13685,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629218,BAO_0000218,
13686,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629219,BAO_0000218,
13687,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629220,BAO_0000218,
13688,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629221,BAO_0000218,
13689,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631127,BAO_0000218,
13690,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631128,BAO_0000218,
13691,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631129,BAO_0000218,
13692,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631130,BAO_0000218,
13693,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631131,BAO_0000218,
13694,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631132,BAO_0000218,
13695,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631133,BAO_0000218,
13696,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631134,BAO_0000218,
13697,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875120,BAO_0000218,
13698,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631135,BAO_0000218,
13699,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631136,BAO_0000218,
13700,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631137,BAO_0000218,
13701,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631138,BAO_0000218,
13702,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631139,BAO_0000218,
13703,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631140,BAO_0000218,
13704,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631141,BAO_0000218,
13705,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631142,BAO_0000218,
13706,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631143,BAO_0000218,
13707,6996,A,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631144,BAO_0000218,
13708,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631145,BAO_0000218,
13709,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631146,BAO_0000218,
13710,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631147,BAO_0000218,
13711,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631148,BAO_0000218,
13712,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631149,BAO_0000218,
13713,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631150,BAO_0000218,
13714,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631151,BAO_0000218,
13715,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631152,BAO_0000218,
13716,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631443,BAO_0000218,
13717,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631444,BAO_0000218,
13718,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631445,BAO_0000218,
13719,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631446,BAO_0000218,
13720,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631447,BAO_0000218,
13721,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631448,BAO_0000218,
13722,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631449,BAO_0000218,
13723,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL631450,BAO_0000218,
13724,6996,A,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629724,BAO_0000218,
13725,9716,A,,14.0,50594,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629725,BAO_0000218,
13726,9716,A,,14.0,50594,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629726,BAO_0000218,
13727,9716,A,,2106.0,50594,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629727,BAO_0000218,
13728,9716,A,,2106.0,50594,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630404,BAO_0000218,
13729,9716,A,,2106.0,50594,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630405,BAO_0000218,
13730,9716,A,,2106.0,50594,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630406,BAO_0000218,
13731,9716,A,,945.0,50594,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630407,BAO_0000218,
13732,9716,A,,945.0,50594,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630573,BAO_0000218,
13733,9716,A,,945.0,50594,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630574,BAO_0000218,
13734,9716,A,,945.0,50594,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630575,BAO_0000218,
13735,9716,A,,,50594,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630576,BAO_0000218,
13736,9716,A,,,50594,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630577,BAO_0000218,
13737,9716,A,,,50594,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630578,BAO_0000218,
13738,9716,A,,,50594,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630579,BAO_0000218,
13739,12192,A,,2113.0,50594,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630580,BAO_0000218,
13740,12192,A,,2113.0,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630581,BAO_0000218,
13741,12192,A,,2113.0,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630582,BAO_0000218,
13742,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630583,BAO_0000218,
13743,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630584,BAO_0000218,
13744,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630585,BAO_0000218,
13745,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630586,BAO_0000218,
13746,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630587,BAO_0000218,
13747,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630588,BAO_0000218,
13748,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630589,BAO_0000218,
13749,12192,A,,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630590,BAO_0000218,
13750,12192,A,,1988.0,22224,Removal of 238-Plutonium(IV) in feces at 24 h,Feces,0,,,1,,U,Autocuration,,,CHEMBL630591,BAO_0000019,
13751,12192,A,,1988.0,22224,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Feces,0,,,1,,U,Autocuration,,,CHEMBL630592,BAO_0000019,
13752,12192,A,,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,0,,,1,,U,Autocuration,,,CHEMBL630593,BAO_0000019,
13753,12192,A,,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,0,,,1,,U,Autocuration,,,CHEMBL630594,BAO_0000019,
13754,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630595,BAO_0000019,
13755,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630596,BAO_0000019,
13756,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 0-24 h,Urine,0,,,1,,U,Autocuration,,,CHEMBL630597,BAO_0000019,
13757,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630598,BAO_0000019,
13758,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 0-4 h,Urine,0,,,1,,U,Autocuration,,,CHEMBL630599,BAO_0000019,
13759,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630600,BAO_0000019,
13760,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 4-24 h,Urine,0,,,1,,U,Autocuration,,,CHEMBL630601,BAO_0000019,
13761,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630602,BAO_0000019,
13762,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630603,BAO_0000019,
13763,12192,A,,1088.0,22224,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Urine,0,,,1,,U,Autocuration,,,CHEMBL630604,BAO_0000019,
13764,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624869,BAO_0000218,
13765,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624870,BAO_0000218,
13766,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623189,BAO_0000218,
13767,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623190,BAO_0000218,
13768,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623191,BAO_0000218,
13769,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623192,BAO_0000218,
13770,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623193,BAO_0000218,
13771,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623194,BAO_0000218,
13772,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623195,BAO_0000218,
13773,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623196,BAO_0000218,
13774,11836,A,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623197,BAO_0000218,
13775,11836,A,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623198,BAO_0000218,
13776,11836,A,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623199,BAO_0000218,
13777,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623200,BAO_0000218,
13778,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623201,BAO_0000218,
13779,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623202,BAO_0000218,
13780,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623203,BAO_0000218,
13781,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623204,BAO_0000218,
13782,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623205,BAO_0000218,
13783,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623206,BAO_0000218,
13784,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623207,BAO_0000218,
13785,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623208,BAO_0000218,
13786,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623209,BAO_0000218,
13787,11836,A,,2385.0,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623210,BAO_0000218,
13788,11836,A,,,50597,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623211,BAO_0000218,
13789,11836,A,,995.0,50597,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623212,BAO_0000218,
13790,12640,A,,,22224,Tested in vitro for intrinsic activity relative to quinpirole,,0,,,1,,U,Autocuration,,,CHEMBL623213,BAO_0000019,
13791,14218,A,,,22224,"Relative ion enhancement, determined in pulsed ultrafiltration",,0,,,1,,U,Autocuration,,,CHEMBL623214,BAO_0000019,
13792,11296,A,,,22224,% ionization at the pH 7.4 at 37 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL623215,BAO_0000019,
13793,10929,A,,,22224,Percentage ionization was measured,,0,,,1,,U,Autocuration,,,CHEMBL623216,BAO_0000019,
13794,13841,A,,,50591,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,1,,Bos taurus,1,9913.0,N,Intermediate,,,CHEMBL623217,BAO_0000218,
13795,10431,A,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,0,,,1,,U,Autocuration,,,CHEMBL623218,BAO_0000019,
13796,10431,A,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,0,,,1,,U,Autocuration,,,CHEMBL623913,BAO_0000019,
13797,10431,A,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,0,,,1,,U,Autocuration,,,CHEMBL623914,BAO_0000019,
13798,8826,P,,,22229,Compound was evaluated for the partition coefficient in octanol/water,,0,,,1,,U,Autocuration,,,CHEMBL623915,BAO_0000100,
13799,8826,P,,,22229,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,0,,,1,,U,Autocuration,,,CHEMBL624080,BAO_0000100,
13800,9884,A,,,22224,Equilibrium constant measured by the pulse radiolysis at pH 7,,0,,,1,,U,Autocuration,,,CHEMBL624081,BAO_0000019,
13801,9827,A,,,50587,In vitro hydrolytic rate constant determined in human blood,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL624082,BAO_0000218,
13802,10009,A,,,50587,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625054,BAO_0000218,
13803,10009,A,,,22224,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,0,,,1,,U,Autocuration,,,CHEMBL877485,BAO_0000019,
13804,10009,A,,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625055,BAO_0000218,
13805,10009,A,,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625056,BAO_0000218,
13806,10009,A,,,50587,In vitro oxidation of compound in presence of human plasma,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625057,BAO_0000218,
13807,10009,A,,,22224,In vitro oxidation of compound in presence of hydrogen peroxide,,0,,,1,,U,Autocuration,,,CHEMBL625058,BAO_0000019,
13808,10009,A,,,50594,In vitro oxidation of compound in presence of mouse brain homogenate,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625059,BAO_0000218,
13809,10009,A,,,50594,In vitro oxidation of compound in presence of mouse liver homogenate,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629536,BAO_0000218,
13810,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629537,BAO_0000218,
13811,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629538,BAO_0000218,
13812,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629539,BAO_0000218,
13813,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874445,BAO_0000218,
13814,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629540,BAO_0000218,
13815,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629541,BAO_0000218,
13816,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629542,BAO_0000218,
13817,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630243,BAO_0000218,
13818,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630244,BAO_0000218,
13819,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630245,BAO_0000218,
13820,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630246,BAO_0000218,
13821,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630247,BAO_0000218,
13822,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630248,BAO_0000218,
13823,13100,A,,178.0,50597,Biodistribution in rat blood at 240 minutes after dose administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630249,BAO_0000218,
13824,13100,A,,178.0,50597,Biodistribution in rat blood at 30 minutes after dose administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630250,BAO_0000218,
13825,13100,A,,178.0,50597,Biodistribution in rat blood at 360 minutes after dose administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630251,BAO_0000218,
13826,13100,A,,178.0,50597,Biodistribution in rat blood at 3 hr after dose administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630252,BAO_0000218,
13827,13100,A,,178.0,50597,Biodistribution in rat blood at 60 minutes after dose administration.,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630408,BAO_0000218,
13828,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630409,BAO_0000218,
13829,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874446,BAO_0000218,
13830,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630410,BAO_0000218,
13831,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630411,BAO_0000218,
13832,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630412,BAO_0000218,
13833,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630413,BAO_0000218,
13834,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 3 hr after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630414,BAO_0000218,
13835,13100,A,,2037.0,50597,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630415,BAO_0000218,
13836,13100,A,,,50597,Biodistribution in rat cortex at 120 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630416,BAO_0000218,
13837,13100,A,,,50597,Biodistribution in rat cortex at 1440 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630417,BAO_0000218,
13838,13100,A,,,50597,Biodistribution in rat cortex at 15 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630418,BAO_0000218,
13839,13100,A,,,50597,Biodistribution in rat cortex at 240 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630419,BAO_0000218,
13840,13100,A,,,50597,Biodistribution in rat cortex at 30 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630420,BAO_0000218,
13841,13100,A,,,50597,Biodistribution in rat cortex at 360 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630421,BAO_0000218,
13842,13100,A,,,50597,Biodistribution in rat cortex at 3 hr after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630422,BAO_0000218,
13843,13100,A,,,50597,Biodistribution in rat cortex at 60 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630423,BAO_0000218,
13844,13100,A,,948.0,50597,Biodistribution in rat heart at 120 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630424,BAO_0000218,
13845,13100,A,,948.0,50597,Biodistribution in rat heart at 15 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630425,BAO_0000218,
13846,13100,A,,948.0,50597,Biodistribution in rat heart at 240 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629462,BAO_0000218,
13847,13100,A,,948.0,50597,Biodistribution in rat heart at 30 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630426,BAO_0000218,
13848,13100,A,,948.0,50597,Biodistribution in rat heart at 360 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630427,BAO_0000218,
13849,13100,A,,948.0,50597,Biodistribution in rat heart at 3 hr after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625877,BAO_0000218,
13850,13100,A,,948.0,50597,Biodistribution in rat heart at 60 minutes after dose administration.,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625878,BAO_0000218,
13851,13100,A,,10000000.0,50597,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625879,BAO_0000218,
13852,13100,A,,10000000.0,50597,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625880,BAO_0000218,
13853,13100,A,,10000000.0,50597,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625881,BAO_0000218,
13854,13100,A,,10000000.0,50597,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625882,BAO_0000218,
13855,13100,A,,10000000.0,50597,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625883,BAO_0000218,
13856,13100,A,,2113.0,50597,Biodistribution in rat kidney at 120 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625884,BAO_0000218,
13857,13100,A,,2113.0,50597,Biodistribution in rat kidney at 1440 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625885,BAO_0000218,
13858,13100,A,,2113.0,50597,Biodistribution in rat kidney at 15 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628649,BAO_0000218,
13859,13100,A,,2113.0,50597,Biodistribution in rat kidney at 240 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628650,BAO_0000218,
13860,13100,A,,2113.0,50597,Biodistribution in rat kidney at 30 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628651,BAO_0000218,
13861,13100,A,,2113.0,50597,Biodistribution in rat kidney at 360 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628652,BAO_0000218,
13862,13100,A,,2113.0,50597,Biodistribution in rat kidney at 60 minutes after dose administration.,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628653,BAO_0000218,
13863,13100,A,,2107.0,50597,Biodistribution in rat liver at 120 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628654,BAO_0000218,
13864,13100,A,,2107.0,50597,Biodistribution in rat liver at 1440 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628655,BAO_0000218,
13865,13100,A,,2107.0,50597,Biodistribution in rat liver at 15 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625238,BAO_0000218,
13866,13100,A,,2107.0,50597,Biodistribution in rat liver at 240 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625239,BAO_0000218,
13867,13100,A,,2107.0,50597,Biodistribution in rat liver at 30 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625240,BAO_0000218,
13868,13100,A,,2107.0,50597,Biodistribution in rat liver at 360 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625241,BAO_0000218,
13869,13100,A,,2107.0,50597,Biodistribution in rat liver at 60 minutes after dose administration.,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625242,BAO_0000218,
13870,13100,A,,2048.0,50597,Biodistribution in rat lung at 120 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874587,BAO_0000218,
13871,13100,A,,2048.0,50597,Biodistribution in rat lung at 1440 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625405,BAO_0000218,
13872,13100,A,,2048.0,50597,Biodistribution in rat lung at 15 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625406,BAO_0000218,
13873,13100,A,,2048.0,50597,Biodistribution in rat lung at 240 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625407,BAO_0000218,
13874,13100,A,,2048.0,50597,Biodistribution in rat lung at 30 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625408,BAO_0000218,
13875,13100,A,,2048.0,50597,Biodistribution in rat lung at 360 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625409,BAO_0000218,
13876,12361,A,,1515.0,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625410,BAO_0000218,
13877,12361,A,,1515.0,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625411,BAO_0000218,
13878,12361,A,,1515.0,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625412,BAO_0000218,
13879,12361,A,,1515.0,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625413,BAO_0000218,
13880,12361,A,,1515.0,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625414,BAO_0000218,
13881,12361,A,,1515.0,50597,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625415,BAO_0000218,
13882,12361,A,,1515.0,50597,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625416,BAO_0000218,
13883,12712,A,,1088.0,50597,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625417,BAO_0000218,
13884,7415,A,,1988.0,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625418,BAO_0000218,
13885,7415,A,,1088.0,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625419,BAO_0000218,
13886,7415,A,,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625420,BAO_0000218,
13887,7415,A,,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626996,BAO_0000218,
13888,7415,A,,1988.0,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626997,BAO_0000218,
13889,7415,A,,1088.0,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626998,BAO_0000218,
13890,7415,A,,,50597,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626999,BAO_0000218,
13891,8050,A,,,50594,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627000,BAO_0000218,
13892,8050,A,,,50594,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627001,BAO_0000218,
13893,8050,A,,,50594,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627002,BAO_0000218,
13894,8050,A,,,50594,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627003,BAO_0000218,
13895,8050,A,,1088.0,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627004,BAO_0000218,
13896,8050,A,,1088.0,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627005,BAO_0000218,
13897,8050,A,,1088.0,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL874594,BAO_0000218,
13898,8050,A,,1088.0,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627006,BAO_0000218,
13899,8050,A,,1088.0,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627007,BAO_0000218,
13900,8050,A,,1088.0,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627884,BAO_0000218,
13901,8050,A,,1088.0,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627885,BAO_0000218,
13902,8050,A,,1088.0,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627886,BAO_0000218,
13903,8050,A,,1088.0,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627887,BAO_0000218,
13904,8050,A,,1088.0,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627888,BAO_0000218,
13905,8050,A,,1088.0,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628057,BAO_0000218,
13906,8050,A,,1088.0,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627405,BAO_0000218,
13907,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627406,BAO_0000218,
13908,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627407,BAO_0000218,
13909,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627408,BAO_0000218,
13910,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627409,BAO_0000218,
13911,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875486,BAO_0000218,
13912,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627410,BAO_0000218,
13913,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627411,BAO_0000218,
13914,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627412,BAO_0000218,
13915,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627413,BAO_0000218,
13916,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627414,BAO_0000218,
13917,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627415,BAO_0000218,
13918,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627416,BAO_0000218,
13919,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627417,BAO_0000218,
13920,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627418,BAO_0000218,
13921,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627419,BAO_0000218,
13922,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627320,BAO_0000218,
13923,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627321,BAO_0000218,
13924,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627322,BAO_0000218,
13925,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627323,BAO_0000218,
13926,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627491,BAO_0000218,
13927,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627492,BAO_0000218,
13928,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627493,BAO_0000218,
13929,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627494,BAO_0000218,
13930,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627495,BAO_0000218,
13931,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627496,BAO_0000218,
13932,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627497,BAO_0000218,
13933,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627498,BAO_0000218,
13934,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627499,BAO_0000218,
13935,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627500,BAO_0000218,
13936,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627501,BAO_0000218,
13937,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625616,BAO_0000218,
13938,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625617,BAO_0000218,
13939,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625618,BAO_0000218,
13940,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625619,BAO_0000218,
13941,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625620,BAO_0000218,
13942,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625621,BAO_0000218,
13943,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625622,BAO_0000218,
13944,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625788,BAO_0000218,
13945,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625789,BAO_0000218,
13946,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625790,BAO_0000218,
13947,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625791,BAO_0000218,
13948,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622334,BAO_0000218,
13949,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622335,BAO_0000218,
13950,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622336,BAO_0000218,
13951,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622337,BAO_0000218,
13952,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622338,BAO_0000218,
13953,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622339,BAO_0000218,
13954,12017,A,,,50597,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624153,BAO_0000218,
13955,12017,A,,,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628430,BAO_0000218,
13956,12017,A,,,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628431,BAO_0000218,
13957,12017,A,,,50597,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628432,BAO_0000218,
13958,12017,A,,,50597,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628433,BAO_0000218,
13959,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628434,BAO_0000218,
13960,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626789,BAO_0000218,
13961,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626790,BAO_0000218,
13962,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626791,BAO_0000218,
13963,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626792,BAO_0000218,
13964,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626793,BAO_0000218,
13965,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627436,BAO_0000218,
13966,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627437,BAO_0000218,
13967,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627438,BAO_0000218,
13968,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627439,BAO_0000218,
13969,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627440,BAO_0000218,
13970,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627602,BAO_0000218,
13971,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627603,BAO_0000218,
13972,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627604,BAO_0000218,
13973,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627605,BAO_0000218,
13974,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627606,BAO_0000218,
13975,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627607,BAO_0000218,
13976,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627608,BAO_0000218,
13977,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627609,BAO_0000218,
13978,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627610,BAO_0000218,
13979,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627611,BAO_0000218,
13980,11510,A,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627612,BAO_0000218,
13981,8362,P,,,22229,Octanol:water partition coefficient is evaluated,,0,,,1,,U,Autocuration,,,CHEMBL627613,BAO_0000100,
13982,8257,P,,,22224,Partition coefficient in 1-octanol/water system,,0,,,1,,U,Autocuration,,,CHEMBL627614,BAO_0000100,
13983,8257,P,,,22224,Partition coefficient in 1-octanol/water system measured using radio active compounds,,0,,,1,,U,Autocuration,,,CHEMBL627615,BAO_0000100,
13984,9468,P,,,22224,Partition coefficient in octanol/water system was determined,,0,,,1,,U,Autocuration,,,CHEMBL627616,BAO_0000100,
13985,9468,P,,,22224,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,0,,,1,,U,Autocuration,,,CHEMBL627617,BAO_0000100,
13986,10568,A,,,22224,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL627618,BAO_0000019,
13987,10568,A,,,22224,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL627619,BAO_0000019,
13988,15359,A,,,22224,Pseudo-first-order rate constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL627620,BAO_0000019,
13989,15359,A,,,22224,Pseudo-first-order rate constant with 1-min time point,,0,,,1,,U,Autocuration,,,CHEMBL627621,BAO_0000019,
13990,15359,A,,,22224,Pseudo-first-order rate constant without 1-min time point,,0,,,1,,U,Autocuration,,,CHEMBL627622,BAO_0000019,
13991,10431,A,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,0,,,1,,U,Autocuration,,,CHEMBL627623,BAO_0000019,
13992,10431,A,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,0,,,1,,U,Autocuration,,,CHEMBL627624,BAO_0000019,
13993,10431,A,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,0,,,1,,U,Autocuration,,,CHEMBL627625,BAO_0000019,
13994,15704,A,,,22224,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL628523,BAO_0000019,
13995,15287,A,,,22224,The alkaline hydrolysis second order rate constant(K OH) of the compound,,0,,,1,,U,Autocuration,,,CHEMBL628524,BAO_0000019,
13996,7516,A,,,22224,The efflux rate constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL628525,BAO_0000019,
13997,12973,A,,,22224,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,0,,,1,,U,Autocuration,,,CHEMBL625732,BAO_0000019,
13998,12973,A,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,0,,,1,,U,Autocuration,,,CHEMBL625733,BAO_0000019,
13999,12973,F,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,0,,,1,,U,Autocuration,,,CHEMBL625734,BAO_0000019,
14000,12973,A,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,0,,,1,,U,Autocuration,,,CHEMBL625913,BAO_0000019,
14001,8696,A,,,22224,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,0,,,1,,U,Autocuration,,,CHEMBL625914,BAO_0000019,
14002,15052,A,,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,0,,,1,,U,Autocuration,,,CHEMBL625915,BAO_0000019,
14003,15052,A,,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,0,,,1,,U,Autocuration,,,CHEMBL625916,BAO_0000019,
14004,10503,A,,,22224,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,0,,,1,,U,Autocuration,,,CHEMBL625917,BAO_0000019,
14005,8354,A,,,22224,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625918,BAO_0000019,
14006,8354,A,,,22224,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625919,BAO_0000019,
14007,8354,A,,,22224,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625920,BAO_0000019,
14008,8354,A,,,22224,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL874453,BAO_0000019,
14009,8354,A,,,22224,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625921,BAO_0000019,
14010,10503,A,,,22224,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,0,,,1,,U,Autocuration,,,CHEMBL625922,BAO_0000019,
14011,8354,A,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625923,BAO_0000019,
14012,8354,A,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625924,BAO_0000019,
14013,8354,A,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625925,BAO_0000019,
14014,8354,A,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL625926,BAO_0000019,
14015,13100,A,,2048.0,50597,Biodistribution in rat lung at 60 minutes after dose administration.,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627704,BAO_0000218,
14016,13100,A,,,50597,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627705,BAO_0000218,
14017,13100,A,,,50597,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627706,BAO_0000218,
14018,13100,A,,,50597,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627707,BAO_0000218,
14019,13100,A,,,50597,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627708,BAO_0000218,
14020,13100,A,,,50597,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628361,BAO_0000218,
14021,13100,A,,,50597,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628362,BAO_0000218,
14022,13100,A,,2435.0,50597,Biodistribution in rat striatum at 120 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628363,BAO_0000218,
14023,13100,A,,2435.0,50597,Biodistribution in rat striatum at 1440 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628364,BAO_0000218,
14024,13100,A,,2435.0,50597,Biodistribution in rat striatum at 15 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628365,BAO_0000218,
14025,13100,A,,2435.0,50597,Biodistribution in rat striatum at 240 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874454,BAO_0000218,
14026,13100,A,,2435.0,50597,Biodistribution in rat striatum at 30 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628531,BAO_0000218,
14027,13100,A,,2435.0,50597,Biodistribution in rat striatum at 360 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628532,BAO_0000218,
14028,13100,A,,2435.0,50597,Biodistribution in rat striatum at 3 hr after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628533,BAO_0000218,
14029,13100,A,,2435.0,50597,Biodistribution in rat striatum at 60 minutes after dose administration.,Striatum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628534,BAO_0000218,
14030,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 120 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628535,BAO_0000218,
14031,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628536,BAO_0000218,
14032,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 15 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628537,BAO_0000218,
14033,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 240 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628538,BAO_0000218,
14034,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 30 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628539,BAO_0000218,
14035,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 360 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630297,BAO_0000218,
14036,13100,A,,2046.0,50597,Biodistribution in rat thyroid at 60 minutes after dose administration.,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630298,BAO_0000218,
14037,13100,A,,955.0,50597,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630299,BAO_0000218,
14038,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628094,BAO_0000218,
14039,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628095,BAO_0000218,
14040,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874648,BAO_0000218,
14041,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628096,BAO_0000218,
14042,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628097,BAO_0000218,
14043,13100,A,,955.0,50597,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628098,BAO_0000218,
14044,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,0,,,1,,U,Autocuration,,,CHEMBL628099,BAO_0000019,
14045,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,0,,,1,,U,Autocuration,,,CHEMBL628100,BAO_0000019,
14046,13331,A,,,22224,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,0,,,1,,U,Autocuration,,,CHEMBL628101,BAO_0000019,
14047,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,0,,,1,,U,Autocuration,,,CHEMBL628102,BAO_0000019,
14048,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,0,,,1,,U,Autocuration,,,CHEMBL628103,BAO_0000019,
14049,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,0,,,1,,U,Autocuration,,,CHEMBL628104,BAO_0000019,
14050,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,0,,,1,,U,Autocuration,,,CHEMBL628105,BAO_0000019,
14051,13331,A,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,0,,,1,,U,Autocuration,,,CHEMBL628106,BAO_0000019,
14052,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628107,BAO_0000218,
14053,10086,F,,1088.0,22224,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,0,,,1,,U,Autocuration,,,CHEMBL628108,BAO_0000218,
14054,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628109,BAO_0000218,
14055,10086,F,,1088.0,22224,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,0,,,1,,U,Autocuration,,,CHEMBL625299,BAO_0000218,
14056,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625300,BAO_0000218,
14057,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625301,BAO_0000218,
14058,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625302,BAO_0000218,
14059,10086,A,,1088.0,50597,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874649,BAO_0000218,
14060,13248,A,,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625303,BAO_0000218,
14061,13248,A,,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625463,BAO_0000218,
14062,14527,A,,2107.0,50587,In vitro metabolism in human liver microsomes,Liver,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625464,BAO_0000218,
14063,3008,A,,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL625465,BAO_0000218,
14064,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625466,BAO_0000218,
14065,12582,A,,1088.0,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625467,BAO_0000218,
14066,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625468,BAO_0000218,
14067,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625469,BAO_0000218,
14068,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625470,BAO_0000218,
14069,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632418,BAO_0000218,
14070,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627250,BAO_0000218,
14071,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627251,BAO_0000218,
14072,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627252,BAO_0000218,
14073,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627253,BAO_0000218,
14074,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627254,BAO_0000218,
14075,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875471,BAO_0000218,
14076,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627255,BAO_0000218,
14077,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627256,BAO_0000218,
14078,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627257,BAO_0000218,
14079,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627258,BAO_0000218,
14080,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627259,BAO_0000218,
14081,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627260,BAO_0000218,
14082,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623256,BAO_0000218,
14083,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874413,BAO_0000218,
14084,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623257,BAO_0000218,
14085,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623258,BAO_0000218,
14086,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623259,BAO_0000218,
14087,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623260,BAO_0000218,
14088,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623261,BAO_0000218,
14089,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623262,BAO_0000218,
14090,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623263,BAO_0000218,
14091,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623264,BAO_0000218,
14092,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623265,BAO_0000218,
14093,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623266,BAO_0000218,
14094,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623267,BAO_0000218,
14095,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623268,BAO_0000218,
14096,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623269,BAO_0000218,
14097,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623270,BAO_0000218,
14098,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623271,BAO_0000218,
14099,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623272,BAO_0000218,
14100,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623273,BAO_0000218,
14101,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623274,BAO_0000218,
14102,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874414,BAO_0000218,
14103,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623275,BAO_0000218,
14104,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629150,BAO_0000218,
14105,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623276,BAO_0000218,
14106,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623277,BAO_0000218,
14107,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623112,BAO_0000218,
14108,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623113,BAO_0000218,
14109,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623800,BAO_0000218,
14110,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623801,BAO_0000218,
14111,12017,A,,2106.0,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623802,BAO_0000218,
14112,12017,A,,995.0,50597,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623803,BAO_0000218,
14113,12017,A,,995.0,50597,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623970,BAO_0000218,
14114,12017,A,,995.0,50597,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623971,BAO_0000218,
14115,14045,A,,178.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623972,BAO_0000218,
14116,14045,A,,178.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623973,BAO_0000218,
14117,14045,A,,178.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623974,BAO_0000218,
14118,14045,A,,178.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623975,BAO_0000218,
14119,14045,A,,955.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623976,BAO_0000218,
14120,14045,A,,955.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623977,BAO_0000218,
14121,14045,A,,955.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623978,BAO_0000218,
14122,14045,A,,955.0,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623979,BAO_0000218,
14123,14045,A,,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623980,BAO_0000218,
14124,14045,A,,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623981,BAO_0000218,
14125,14045,A,,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626278,BAO_0000218,
14126,14045,A,,,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626279,BAO_0000218,
14127,14045,A,,,50594,Biodistribution in mice bladder plus excreted urine was determined,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626280,BAO_0000218,
14128,14045,A,,,50594,"Percentage biodistribution in mouse blood, 10 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626281,BAO_0000218,
14129,14045,A,,,50594,"Percentage biodistribution in mouse blood, 30 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626282,BAO_0000218,
14130,14045,A,,,50594,"Percentage biodistribution in mouse blood, 5 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626283,BAO_0000218,
14131,14045,A,,,50594,"Percentage biodistribution in mouse blood, 60 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626284,BAO_0000218,
14132,14045,A,,955.0,50594,"Percentage biodistribution in mouse brain, 10 minutes post injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626285,BAO_0000218,
14133,14045,A,,955.0,50594,"Percentage biodistribution in mouse brain, 30 minutes post injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626286,BAO_0000218,
14134,14045,A,,955.0,50594,"Percentage biodistribution in mouse brain, 5 minutes post injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626287,BAO_0000218,
14135,14045,A,,955.0,50594,"Percentage biodistribution in mouse brain, 60 minutes post injection",Brain,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626288,BAO_0000218,
14136,14045,A,,,50594,"Percentage biodistribution in mouse heart, 10 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626289,BAO_0000218,
14137,14045,A,,,50594,"Percentage biodistribution in mouse heart, 30 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626290,BAO_0000218,
14138,14045,A,,,50594,"Percentage biodistribution in mouse heart, 5 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626291,BAO_0000218,
14139,14045,A,,,50594,"Percentage biodistribution in mouse heart, 60 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL839888,BAO_0000218,
14140,14045,A,,160.0,50594,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626292,BAO_0000218,
14141,14045,A,,160.0,50594,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626293,BAO_0000218,
14142,14045,A,,160.0,50594,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626294,BAO_0000218,
14143,14045,A,,160.0,50594,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intestine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL626295,BAO_0000218,
14144,14045,A,,2107.0,50594,"Percentage biodistribution in mouse liver, 10 minutes post injection",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627659,BAO_0000218,
14145,14045,A,,2107.0,50594,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627660,BAO_0000218,
14146,14045,A,,2107.0,50594,"Percentage biodistribution in mouse liver, 5 minutes post injection",Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627661,BAO_0000218,
14147,14045,A,,2107.0,50594,Biodistribution in mice liver at 60 minutes of post injection,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627662,BAO_0000218,
14148,14045,A,,2048.0,50594,Biodistribution in mice lungs at 10 min of post injection,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627663,BAO_0000218,
14149,14045,A,,,50594,"Percentage biodistribution in mouse lung, 30 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627664,BAO_0000218,
14150,14045,A,,,50594,"Percentage biodistribution in mousee lung, 5 minutes post injection",,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627665,BAO_0000218,
14151,14045,A,,2048.0,50594,Biodistribution in mice lungs at 60 min of post injection,Lung,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627666,BAO_0000218,
14152,14045,A,,2106.0,50594,Percentage biodistribution in mouse spleen,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627667,BAO_0000218,
14153,14045,A,,945.0,50594,Percentage biodistribution in mouse stomach,Stomach,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627668,BAO_0000218,
14154,11745,A,,1088.0,50594,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Urine,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL627669,BAO_0000218,
14155,13257,A,,1255.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Urinary bladder,0,,,1,,U,Autocuration,,,CHEMBL627670,BAO_0000218,
14156,13257,A,,178.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL627671,BAO_0000218,
14157,13257,A,,1474.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Bone element,0,,,1,,U,Autocuration,,,CHEMBL627672,BAO_0000218,
14158,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,0,,,1,,U,Autocuration,,,CHEMBL627673,BAO_0000218,
14159,13257,A,,2113.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Kidney,0,,,1,,U,Autocuration,,,CHEMBL627674,BAO_0000218,
14160,13257,A,,2107.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Liver,0,,,1,,U,Autocuration,,,CHEMBL627675,BAO_0000218,
14161,13257,A,,2048.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Lung,0,,,1,,U,Autocuration,,,CHEMBL627676,BAO_0000218,
14162,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627677,BAO_0000218,
14163,8354,A,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL627678,BAO_0000019,
14164,7095,A,,1977.0,50597,Affinity for protein binding expressed as association constant in fresh rat serum,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627679,BAO_0000218,
14165,12185,A,,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,0,,,1,,U,Autocuration,,,CHEMBL627680,BAO_0000019,
14166,12185,A,,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,0,,,1,,U,Autocuration,,,CHEMBL627681,BAO_0000019,
14167,12185,A,,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,0,,,1,,U,Autocuration,,,CHEMBL627682,BAO_0000019,
14168,12185,A,,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,0,,,1,,U,Autocuration,,,CHEMBL627683,BAO_0000019,
14169,12686,A,,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,0,,,1,,U,Autocuration,,,CHEMBL627684,BAO_0000019,
14170,12686,A,,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,0,,,1,,U,Autocuration,,,CHEMBL874441,BAO_0000019,
14171,12686,A,,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,0,,,1,,U,Autocuration,,,CHEMBL627685,BAO_0000019,
14172,12686,A,,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,0,,,1,,U,Autocuration,,,CHEMBL627686,BAO_0000019,
14173,8057,A,,,22224,Apparent rate constant Koff for inactivation of dTMP synthase.,,0,,,1,,U,Autocuration,,,CHEMBL627687,BAO_0000019,
14174,15778,A,,,22224,The irreversible inhibitor activity by second order rate equation.,,0,,,1,,U,Autocuration,,,CHEMBL627688,BAO_0000019,
14175,12375,A,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628038,BAO_0000218,
14176,12375,A,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628039,BAO_0000218,
14177,12375,A,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628040,BAO_0000218,
14178,13588,A,,,22224,Dissociation rate calculated from the first-order equation using t1/2 value,,0,,,1,,U,Autocuration,,,CHEMBL628041,BAO_0000019,
14179,15039,A,,,22224,The compound was tested for Binding constant against DNA,,0,,,1,,U,Autocuration,,,CHEMBL630226,BAO_0000019,
14180,9500,A,,,22224,First order rate constant for cyclization of the compound,,0,,,1,,U,Autocuration,,,CHEMBL628042,BAO_0000019,
14181,10014,A,,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,0,,,1,,U,Autocuration,,,CHEMBL625232,BAO_0000019,
14182,10014,A,,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,0,,,1,,U,Autocuration,,,CHEMBL625233,BAO_0000019,
14183,568,A,,,22224,Hydrolysis rate constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL625979,BAO_0000019,
14184,10026,A,,,22224,Observed first order rate constant,,0,,,1,,U,Autocuration,,,CHEMBL625980,BAO_0000019,
14185,10281,A,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL625981,BAO_0000019,
14186,10281,A,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL625982,BAO_0000019,
14187,9680,A,,,22224,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL625983,BAO_0000019,
14188,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625984,BAO_0000019,
14189,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625985,BAO_0000019,
14190,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625986,BAO_0000019,
14191,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625987,BAO_0000019,
14192,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625988,BAO_0000019,
14193,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625989,BAO_0000019,
14194,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625990,BAO_0000019,
14195,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625991,BAO_0000019,
14196,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625992,BAO_0000019,
14197,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL625993,BAO_0000019,
14198,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL631973,BAO_0000019,
14199,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632143,BAO_0000019,
14200,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632144,BAO_0000019,
14201,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632145,BAO_0000019,
14202,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632146,BAO_0000019,
14203,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632147,BAO_0000019,
14204,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632148,BAO_0000019,
14205,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632149,BAO_0000019,
14206,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632150,BAO_0000019,
14207,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL632151,BAO_0000019,
14208,3008,A,,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL632152,BAO_0000218,
14209,4509,A,,,50587,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL632153,BAO_0000218,
14210,4509,A,,,50587,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL632154,BAO_0000218,
14211,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632155,BAO_0000218,
14212,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632156,BAO_0000218,
14213,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632157,BAO_0000218,
14214,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632158,BAO_0000218,
14215,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL632159,BAO_0000218,
14216,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626305,BAO_0000218,
14217,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626306,BAO_0000218,
14218,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626307,BAO_0000218,
14219,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626308,BAO_0000218,
14220,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626479,BAO_0000218,
14221,8613,A,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,1,,Human herpesvirus 1,1,10298.0,N,Intermediate,,,CHEMBL626480,BAO_0000218,
14222,6021,P,,,22229,Calculated partition coefficient (clogP) (MlogP),,0,,,1,,U,Autocuration,,,CHEMBL626481,BAO_0000100,
14223,9348,A,,,22224,Equipotent potent ratio relative to carbachol (nicotinic activity),,0,,,1,,U,Autocuration,,,CHEMBL626482,BAO_0000019,
14224,15592,A,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626483,BAO_0000218,
14225,15592,A,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626484,BAO_0000218,
14226,15592,P,,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes available,,0,,,1,,U,Autocuration,,,CHEMBL626485,BAO_0000100,
14227,15592,P,,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,0,,,1,,U,Autocuration,,,CHEMBL626486,BAO_0000100,
14228,15592,P,,,22229,Solubility at pH 7.4 in ug/mL;NA denotes not available,,0,,,1,,U,Autocuration,,,CHEMBL626487,BAO_0000100,
14229,15592,A,,1969.0,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL626488,BAO_0000218,
14230,7095,A,,1977.0,50597,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Serum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626489,BAO_0000218,
14231,16618,A,,,22224,Area under the MAP curve measured over 5 min; ND means Not determined,,0,,,1,,U,Autocuration,,,CHEMBL626490,BAO_0000019,
14232,16835,P,,,22224,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,0,,,1,,U,Autocuration,,,CHEMBL626491,BAO_0000100,
14233,15284,P,,,22229,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,0,,,1,,U,Autocuration,,,CHEMBL626492,BAO_0000100,
14234,15750,A,,,22224,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,0,,,1,,U,Autocuration,,,CHEMBL626493,BAO_0000019,
14235,16618,A,,,50597,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626494,BAO_0000218,
14236,16618,A,,,22224,Half life after oral tested,,0,,,1,,U,Autocuration,,,CHEMBL626495,BAO_0000218,
14237,15812,A,,1969.0,50597,Half life was determined in plasma of rat; NT indicates not tested,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626496,BAO_0000218,
14238,16618,A,,,50597,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626497,BAO_0000218,
14239,16618,A,,,22224,Oral bioavailability after oral tested,,0,,,1,,U,Autocuration,,,CHEMBL626498,BAO_0000218,
14240,13098,A,,,50597,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626499,BAO_0000218,
14241,13098,A,,,50597,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626500,BAO_0000218,
14242,15812,A,,1969.0,50597,half life was determined in plasma of rat; NT indicates not tested,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626501,BAO_0000218,
14243,15812,A,,1969.0,50597,half life was determined in plasma of rat; NT means not tested,Plasma,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626502,BAO_0000218,
14244,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626503,BAO_0000218,
14245,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626504,BAO_0000218,
14246,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626505,BAO_0000218,
14247,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626506,BAO_0000218,
14248,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626507,BAO_0000218,
14249,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626508,BAO_0000218,
14250,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626509,BAO_0000218,
14251,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875480,BAO_0000218,
14252,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626510,BAO_0000218,
14253,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626511,BAO_0000218,
14254,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626512,BAO_0000218,
14255,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628208,BAO_0000218,
14256,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628209,BAO_0000218,
14257,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628210,BAO_0000218,
14258,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628211,BAO_0000218,
14259,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628212,BAO_0000218,
14260,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628213,BAO_0000218,
14261,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628214,BAO_0000218,
14262,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628215,BAO_0000218,
14263,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628216,BAO_0000218,
14264,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626595,BAO_0000218,
14265,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626596,BAO_0000218,
14266,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626597,BAO_0000218,
14267,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626598,BAO_0000218,
14268,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622242,BAO_0000218,
14269,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622243,BAO_0000218,
14270,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622244,BAO_0000218,
14271,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622245,BAO_0000218,
14272,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622246,BAO_0000218,
14273,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622247,BAO_0000218,
14274,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622248,BAO_0000218,
14275,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877483,BAO_0000218,
14276,12582,A,,1088.0,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL622249,BAO_0000218,
14277,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622250,BAO_0000218,
14278,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622251,BAO_0000218,
14279,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622252,BAO_0000218,
14280,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622253,BAO_0000218,
14281,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622254,BAO_0000218,
14282,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622255,BAO_0000218,
14283,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622256,BAO_0000218,
14284,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622257,BAO_0000218,
14285,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622258,BAO_0000218,
14286,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622259,BAO_0000218,
14287,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622927,BAO_0000218,
14288,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622928,BAO_0000218,
14289,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL622929,BAO_0000218,
14290,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623182,BAO_0000218,
14291,12582,A,,1088.0,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL623183,BAO_0000218,
14292,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623184,BAO_0000218,
14293,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623185,BAO_0000218,
14294,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877484,BAO_0000218,
14295,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627274,BAO_0000218,
14296,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623186,BAO_0000218,
14297,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623187,BAO_0000218,
14298,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL623188,BAO_0000218,
14299,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628055,BAO_0000218,
14300,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628056,BAO_0000218,
14301,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628200,BAO_0000218,
14302,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628201,BAO_0000218,
14303,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628202,BAO_0000218,
14304,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628203,BAO_0000218,
14305,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628204,BAO_0000218,
14306,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628205,BAO_0000218,
14307,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628206,BAO_0000218,
14308,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL628207,BAO_0000218,
14309,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627220,BAO_0000218,
14310,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627221,BAO_0000218,
14311,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627222,BAO_0000218,
14312,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,0,,,1,,U,Autocuration,,,CHEMBL627223,BAO_0000218,
14313,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL632062,BAO_0000218,
14314,13257,A,,2106.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Spleen,0,,,1,,U,Autocuration,,,CHEMBL632063,BAO_0000218,
14315,13257,A,,1255.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Urinary bladder,0,,,1,,U,Autocuration,,,CHEMBL632064,BAO_0000218,
14316,13257,A,,178.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL632065,BAO_0000218,
14317,13257,A,,1474.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Bone element,0,,,1,,U,Autocuration,,,CHEMBL632066,BAO_0000218,
14318,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,0,,,1,,U,Autocuration,,,CHEMBL632067,BAO_0000218,
14319,13257,A,,2113.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Kidney,0,,,1,,U,Autocuration,,,CHEMBL629188,BAO_0000218,
14320,13257,A,,2107.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Liver,0,,,1,,U,Autocuration,,,CHEMBL629189,BAO_0000218,
14321,13257,A,,2048.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Lung,0,,,1,,U,Autocuration,,,CHEMBL629190,BAO_0000218,
14322,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629191,BAO_0000218,
14323,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629192,BAO_0000218,
14324,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629193,BAO_0000218,
14325,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629194,BAO_0000218,
14326,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,0,,,1,,U,Autocuration,,,CHEMBL629195,BAO_0000218,
14327,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629373,BAO_0000218,
14328,13257,A,,2106.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Spleen,0,,,1,,U,Autocuration,,,CHEMBL629374,BAO_0000218,
14329,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629375,BAO_0000218,
14330,13257,A,,1255.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Urinary bladder,0,,,1,,U,Autocuration,,,CHEMBL629376,BAO_0000218,
14331,13257,A,,178.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL629377,BAO_0000218,
14332,13257,A,,1474.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Bone element,0,,,1,,U,Autocuration,,,CHEMBL629378,BAO_0000218,
14333,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,0,,,1,,U,Autocuration,,,CHEMBL629379,BAO_0000218,
14334,13257,A,,2113.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Kidney,0,,,1,,U,Autocuration,,,CHEMBL629151,BAO_0000218,
14335,13257,A,,2107.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Liver,0,,,1,,U,Autocuration,,,CHEMBL629152,BAO_0000218,
14336,13257,A,,2048.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Lung,0,,,1,,U,Autocuration,,,CHEMBL629153,BAO_0000218,
14337,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629154,BAO_0000218,
14338,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629155,BAO_0000218,
14339,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629156,BAO_0000218,
14340,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629157,BAO_0000218,
14341,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL629158,BAO_0000218,
14342,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,0,,,1,,U,Autocuration,,,CHEMBL629159,BAO_0000218,
14343,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629160,BAO_0000218,
14344,13257,A,,2106.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Spleen,0,,,1,,U,Autocuration,,,CHEMBL629161,BAO_0000218,
14345,13257,A,,1255.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Urinary bladder,0,,,1,,U,Autocuration,,,CHEMBL629162,BAO_0000218,
14346,13257,A,,178.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL629163,BAO_0000218,
14347,13257,A,,1474.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Bone element,0,,,1,,U,Autocuration,,,CHEMBL629164,BAO_0000218,
14348,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,0,,,1,,U,Autocuration,,,CHEMBL629165,BAO_0000218,
14349,13257,A,,2107.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Liver,0,,,1,,U,Autocuration,,,CHEMBL629166,BAO_0000218,
14350,13257,A,,2048.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Lung,0,,,1,,U,Autocuration,,,CHEMBL629167,BAO_0000218,
14351,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL629168,BAO_0000218,
14352,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,0,,,1,,U,Autocuration,,,CHEMBL629169,BAO_0000019,
14353,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,0,,,1,,U,Autocuration,,,CHEMBL629170,BAO_0000019,
14354,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,0,,,1,,U,Autocuration,,,CHEMBL631153,BAO_0000019,
14355,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,0,,,1,,U,Autocuration,,,CHEMBL875121,BAO_0000019,
14356,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,0,,,1,,U,Autocuration,,,CHEMBL631154,BAO_0000019,
14357,2193,A,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,0,,,1,,U,Autocuration,,,CHEMBL631155,BAO_0000019,
14358,568,A,,,22224,Hydrolysis rate constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL631156,BAO_0000019,
14359,9680,A,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL631157,BAO_0000019,
14360,9680,A,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL631158,BAO_0000019,
14361,9680,A,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL631159,BAO_0000019,
14362,10026,A,,,22224,Observed second order rate constant,,0,,,1,,U,Autocuration,,,CHEMBL631160,BAO_0000019,
14363,10281,A,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL631161,BAO_0000019,
14364,10014,A,,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,0,,,1,,U,Autocuration,,,CHEMBL631162,BAO_0000019,
14365,10014,A,,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,0,,,1,,U,Autocuration,,,CHEMBL630313,BAO_0000019,
14366,9680,A,,,22224,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL630314,BAO_0000019,
14367,9680,A,,,22224,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL630315,BAO_0000019,
14368,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630316,BAO_0000019,
14369,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630986,BAO_0000019,
14370,13028,A,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630987,BAO_0000019,
14371,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630988,BAO_0000019,
14372,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630989,BAO_0000019,
14373,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630990,BAO_0000019,
14374,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630991,BAO_0000019,
14375,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630992,BAO_0000019,
14376,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630993,BAO_0000019,
14377,13028,A,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,0,,,1,,U,Autocuration,,,CHEMBL630994,BAO_0000019,
14378,10014,A,,,50597,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630995,BAO_0000218,
14379,9962,A,,,22224,Association constant for compound at 31 degree C was determined,,0,,,1,,U,Autocuration,,,CHEMBL629252,BAO_0000019,
14380,12029,A,,,22224,Calculated antagonist equilibrium dissociation constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL629253,BAO_0000019,
14381,12029,A,,,22224,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,0,,,1,,U,Autocuration,,,CHEMBL629944,BAO_0000019,
14382,10583,A,,3126.0,50512,Dissociation constants vs LTE4 on guinea pig trachea,Trachea,1,,Cavia porcellus,1,10141.0,N,Intermediate,,,CHEMBL629945,BAO_0000218,
14383,568,A,,,22224,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,0,,,1,,U,Autocuration,,,CHEMBL629946,BAO_0000019,
14384,568,A,,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,0,,,1,,U,Autocuration,,,CHEMBL629947,BAO_0000019,
14385,568,A,,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,0,,,1,,U,Autocuration,,,CHEMBL629948,BAO_0000019,
14386,568,A,,,22224,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,0,,,1,,U,Autocuration,,,CHEMBL856024,BAO_0000019,
14387,7493,A,,,22224,Affinity constant KD value was derived from TMP,,0,,,1,,U,Autocuration,,,CHEMBL629949,BAO_0000019,
14388,8371,A,,,22224,Apparent dissociation (binding) rate constant was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL629950,BAO_0000019,
14389,13114,P,,,22224,Dissociation constant (KD) of the compound,,0,,,1,,U,Autocuration,,,CHEMBL630127,BAO_0000100,
14390,15515,P,,,22224,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,0,,,1,,U,Autocuration,,,CHEMBL630128,BAO_0000100,
14391,522,P,,,22224,Dissociation constant from ESR titration experiments,,0,,,1,,U,Autocuration,,,CHEMBL630129,BAO_0000100,
14392,13888,,,,22224,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,0,,,1,,U,Autocuration,,,CHEMBL630130,BAO_0000019,
14393,2616,P,,,22224,Dissociation constant was evaluated.,,0,,,1,,U,Autocuration,,,CHEMBL875234,BAO_0000100,
14394,3798,P,,,22224,Dissociation constant was reported,,0,,,1,,U,Autocuration,,,CHEMBL630131,BAO_0000100,
14395,8731,A,,,50597,Dissociation constant was determined in rat pituitary cells.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630132,BAO_0000218,
14396,11892,A,,,22224,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,0,,,1,,U,Autocuration,,,CHEMBL630133,BAO_0000019,
14397,11892,A,,,22224,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,0,,,1,,U,Autocuration,,,CHEMBL630134,BAO_0000019,
14398,2582,A,,,22224,Equilibrium dissociation constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL630135,BAO_0000019,
14399,11892,A,,,22224,Equilibrium dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL630136,BAO_0000019,
14400,13396,A,,,22224,Kinetic constant KD was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL630137,BAO_0000019,
14401,603,A,,,22224,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,0,,,1,,U,Autocuration,,,CHEMBL630138,BAO_0000019,
14402,15673,A,,,22224,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL630139,BAO_0000019,
14403,10368,A,,,22224,Rate constant for hydrolysis in aqueous acetone.,,0,,,1,,U,Autocuration,,,CHEMBL630140,BAO_0000019,
14404,14228,A,,,22224,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,0,,,1,,U,Autocuration,,,CHEMBL875235,BAO_0000019,
14405,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876439,BAO_0000218,
14406,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630605,BAO_0000218,
14407,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630606,BAO_0000218,
14408,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630607,BAO_0000218,
14409,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630608,BAO_0000218,
14410,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630609,BAO_0000218,
14411,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630610,BAO_0000218,
14412,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630611,BAO_0000218,
14413,11510,A,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629552,BAO_0000218,
14414,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629733,BAO_0000218,
14415,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629734,BAO_0000218,
14416,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629735,BAO_0000218,
14417,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629736,BAO_0000218,
14418,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629737,BAO_0000218,
14419,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629738,BAO_0000218,
14420,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629739,BAO_0000218,
14421,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629740,BAO_0000218,
14422,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629741,BAO_0000218,
14423,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629742,BAO_0000218,
14424,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629743,BAO_0000218,
14425,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629744,BAO_0000218,
14426,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629745,BAO_0000218,
14427,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629746,BAO_0000218,
14428,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629747,BAO_0000218,
14429,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629748,BAO_0000218,
14430,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629749,BAO_0000218,
14431,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629750,BAO_0000218,
14432,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629751,BAO_0000218,
14433,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629752,BAO_0000218,
14434,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629753,BAO_0000218,
14435,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629754,BAO_0000218,
14436,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629755,BAO_0000218,
14437,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629756,BAO_0000218,
14438,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629757,BAO_0000218,
14439,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629758,BAO_0000218,
14440,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629759,BAO_0000218,
14441,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629760,BAO_0000218,
14442,11510,A,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876443,BAO_0000218,
14443,8310,A,,,50588,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629761,BAO_0000218,
14444,8310,A,,,50588,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629762,BAO_0000218,
14445,8310,A,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629763,BAO_0000218,
14446,8310,A,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629764,BAO_0000218,
14447,8310,A,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629765,BAO_0000218,
14448,8310,A,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629766,BAO_0000218,
14449,8310,A,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629767,BAO_0000218,
14450,8310,A,,,50588,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629768,BAO_0000218,
14451,8310,A,,,50594,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629769,BAO_0000218,
14452,8310,A,,,50588,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629770,BAO_0000218,
14453,8310,A,,,50588,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL629771,BAO_0000218,
14454,8310,A,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629772,BAO_0000218,
14455,8310,A,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL629773,BAO_0000218,
14456,8310,A,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625455,BAO_0000218,
14457,8310,A,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625456,BAO_0000218,
14458,8310,A,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL625457,BAO_0000218,
14459,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625458,BAO_0000218,
14460,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625459,BAO_0000218,
14461,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875483,BAO_0000218,
14462,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL634779,BAO_0000218,
14463,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625460,BAO_0000218,
14464,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626117,BAO_0000218,
14465,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626118,BAO_0000218,
14466,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628342,BAO_0000218,
14467,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628343,BAO_0000218,
14468,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628344,BAO_0000218,
14469,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628345,BAO_0000218,
14470,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628346,BAO_0000218,
14471,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628347,BAO_0000218,
14472,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628348,BAO_0000218,
14473,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628349,BAO_0000218,
14474,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875611,BAO_0000218,
14475,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628350,BAO_0000218,
14476,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628351,BAO_0000218,
14477,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628352,BAO_0000218,
14478,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628353,BAO_0000218,
14479,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628354,BAO_0000218,
14480,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626667,BAO_0000218,
14481,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626668,BAO_0000218,
14482,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626669,BAO_0000218,
14483,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626670,BAO_0000218,
14484,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626671,BAO_0000218,
14485,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626672,BAO_0000218,
14486,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626673,BAO_0000218,
14487,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626674,BAO_0000218,
14488,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626675,BAO_0000218,
14489,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626676,BAO_0000218,
14490,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626677,BAO_0000218,
14491,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626678,BAO_0000218,
14492,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626679,BAO_0000218,
14493,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875612,BAO_0000218,
14494,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626680,BAO_0000218,
14495,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626681,BAO_0000218,
14496,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626682,BAO_0000218,
14497,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626683,BAO_0000218,
14498,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626684,BAO_0000218,
14499,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626685,BAO_0000218,
14500,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626686,BAO_0000218,
14501,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626687,BAO_0000218,
14502,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624978,BAO_0000218,
14503,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624979,BAO_0000218,
14504,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624980,BAO_0000218,
14505,12582,A,,1088.0,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL624981,BAO_0000218,
14506,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL624982,BAO_0000218,
14507,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627564,BAO_0000218,
14508,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627565,BAO_0000218,
14509,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,0,,,1,,U,Autocuration,,,CHEMBL627566,BAO_0000218,
14510,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627567,BAO_0000218,
14511,13257,A,,2106.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Spleen,0,,,1,,U,Autocuration,,,CHEMBL627568,BAO_0000218,
14512,13257,A,,2113.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Kidney,0,,,1,,U,Autocuration,,,CHEMBL627569,BAO_0000218,
14513,13257,A,,1255.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Urinary bladder,0,,,1,,U,Autocuration,,,CHEMBL627570,BAO_0000218,
14514,13257,A,,178.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Blood,0,,,1,,U,Autocuration,,,CHEMBL627571,BAO_0000218,
14515,13257,A,,1474.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Bone element,0,,,1,,U,Autocuration,,,CHEMBL627572,BAO_0000218,
14516,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,0,,,1,,U,Autocuration,,,CHEMBL627573,BAO_0000218,
14517,13257,A,,2113.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Kidney,0,,,1,,U,Autocuration,,,CHEMBL627574,BAO_0000218,
14518,13257,A,,2107.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Liver,0,,,1,,U,Autocuration,,,CHEMBL627575,BAO_0000218,
14519,13257,A,,2048.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Lung,0,,,1,,U,Autocuration,,,CHEMBL627576,BAO_0000218,
14520,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627577,BAO_0000218,
14521,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627578,BAO_0000218,
14522,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627579,BAO_0000218,
14523,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627580,BAO_0000218,
14524,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627581,BAO_0000218,
14525,13257,A,,,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,0,,,1,,U,Autocuration,,,CHEMBL627582,BAO_0000218,
14526,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627583,BAO_0000218,
14527,13257,A,,2106.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Spleen,0,,,1,,U,Autocuration,,,CHEMBL627584,BAO_0000218,
14528,13257,A,,2367.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Prostate gland,0,,,1,,U,Autocuration,,,CHEMBL627585,BAO_0000218,
14529,13257,A,,2385.0,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Muscle tissue,0,,,1,,U,Autocuration,,,CHEMBL627586,BAO_0000218,
14530,15413,A,,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627587,BAO_0000218,
14531,15413,A,,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627588,BAO_0000218,
14532,15413,A,,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628250,BAO_0000218,
14533,15413,A,,,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628251,BAO_0000218,
14534,15413,A,,10000000.0,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628252,BAO_0000218,
14535,15413,A,,10000000.0,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628253,BAO_0000218,
14536,15413,A,,1898.0,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628254,BAO_0000218,
14537,15413,A,,1898.0,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL877493,BAO_0000218,
14538,15413,A,,,50597,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628255,BAO_0000218,
14539,15413,A,,,50597,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628256,BAO_0000218,
14540,15413,A,,10000000.0,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628257,BAO_0000218,
14541,15413,A,,1898.0,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628258,BAO_0000218,
14542,15413,A,,,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628259,BAO_0000218,
14543,15413,A,,,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628429,BAO_0000218,
14544,15413,A,,10000000.0,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626862,BAO_0000218,
14545,15413,A,,1898.0,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626863,BAO_0000218,
14546,15413,A,,2037.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625886,BAO_0000218,
14547,15413,A,,2037.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625887,BAO_0000218,
14548,15413,A,,,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625888,BAO_0000218,
14549,15413,A,,,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625889,BAO_0000218,
14550,15413,A,,10000000.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625890,BAO_0000218,
14551,15413,A,,10000000.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625891,BAO_0000218,
14552,15413,A,,1898.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625892,BAO_0000218,
14553,15413,A,,1898.0,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625893,BAO_0000218,
14554,15413,A,,2037.0,50597,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Cerebellum,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625894,BAO_0000218,
14555,15413,A,,,50597,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625895,BAO_0000218,
14556,12404,A,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,0,,,1,,U,Autocuration,,,CHEMBL625896,BAO_0000019,
14557,568,A,,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,0,,,1,,U,Autocuration,,,CHEMBL625897,BAO_0000019,
14558,568,A,,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,0,,,1,,U,Autocuration,,,CHEMBL625898,BAO_0000019,
14559,568,A,,,22224,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,0,,,1,,U,Autocuration,,,CHEMBL625899,BAO_0000019,
14560,12404,A,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,0,,,1,,U,Autocuration,,,CHEMBL626124,BAO_0000019,
14561,7624,A,,,50212,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,1,,Escherichia coli,1,562.0,N,Intermediate,,,CHEMBL628500,BAO_0000218,
14562,7624,A,,,50597,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL857856,BAO_0000218,
14563,7624,A,,,50597,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628501,BAO_0000218,
14564,4643,A,,,22224,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,0,,,1,,U,Autocuration,,,CHEMBL628502,BAO_0000019,
14565,11532,A,,,22224,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,0,,,1,,U,Autocuration,,,CHEMBL628503,BAO_0000019,
14566,11018,A,,,22224,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL628504,BAO_0000019,
14567,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL628505,BAO_0000019,
14568,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,0,,,1,,U,Autocuration,,,CHEMBL874452,BAO_0000019,
14569,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL628506,BAO_0000019,
14570,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL628507,BAO_0000019,
14571,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,0,,,1,,U,Autocuration,,,CHEMBL628508,BAO_0000019,
14572,8949,A,,,22224,Michaelis constant (KM) was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL628509,BAO_0000019,
14573,12404,A,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,0,,,1,,U,Autocuration,,,CHEMBL628510,BAO_0000019,
14574,7625,B,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,0,,,1,,U,Autocuration,,,CHEMBL628511,BAO_0000019,
14575,7625,B,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,0,,,1,,U,Autocuration,,,CHEMBL628512,BAO_0000019,
14576,7625,B,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,0,,,1,,U,Autocuration,,,CHEMBL628513,BAO_0000019,
14577,7625,B,,,22224,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,0,,,1,,U,Autocuration,,,CHEMBL628514,BAO_0000019,
14578,12908,A,,,22224,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,0,,,1,,U,Autocuration,,,CHEMBL628515,BAO_0000019,
14579,10368,A,,,22224,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,0,,,1,,U,Autocuration,,,CHEMBL628516,BAO_0000019,
14580,13108,A,,,22224,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,0,,,1,,U,Autocuration,,,CHEMBL628517,BAO_0000019,
14581,13108,A,,,22224,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,0,,,1,,U,Autocuration,,,CHEMBL628518,BAO_0000019,
14582,15217,A,,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,0,,,1,,U,Autocuration,,,CHEMBL628519,BAO_0000019,
14583,15217,A,,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,0,,,1,,U,Autocuration,,,CHEMBL628520,BAO_0000019,
14584,10933,A,,,22224,Binding constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL628521,BAO_0000019,
14585,2363,A,,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL630443,BAO_0000019,
14586,2363,A,,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL630444,BAO_0000019,
14587,2276,A,,,22224,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,0,,,1,,U,Autocuration,,,CHEMBL857732,BAO_0000019,
14588,14915,P,,,22224,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,0,,,1,,U,Autocuration,,,CHEMBL630445,BAO_0000100,
14589,8847,A,,,22224,Catalytic rate constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL630446,BAO_0000019,
14590,15357,B,,,22224,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,0,,,1,,U,Autocuration,,,CHEMBL630447,BAO_0000019,
14591,2869,A,,,22224,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,0,,,1,,U,Autocuration,,,CHEMBL630448,BAO_0000019,
14592,3484,A,,,22224,Catalytic rate constant against phospholipase A2 was determined,,0,,,1,,U,Autocuration,,,CHEMBL630449,BAO_0000019,
14593,1373,A,,,22224,"Compound was evaluated for catalytic constant, Kcat",,0,,,1,,U,Autocuration,,,CHEMBL630450,BAO_0000019,
14594,8142,A,,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL630451,BAO_0000019,
14595,14131,A,,,22224,Kcat calculated from 0.693/T1/2,,0,,,1,,U,Autocuration,,,CHEMBL630452,BAO_0000019,
14596,17269,A,,,22224,Kcat was determined,,0,,,1,,U,Autocuration,,,CHEMBL630453,BAO_0000019,
14597,3485,A,,,22224,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,0,,,1,,U,Autocuration,,,CHEMBL630454,BAO_0000019,
14598,3485,A,,,22224,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,0,,,1,,U,Autocuration,,,CHEMBL630455,BAO_0000019,
14599,3485,A,,,22224,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,0,,,1,,U,Autocuration,,,CHEMBL631487,BAO_0000019,
14600,5962,A,,,22224,Kcat value was determined,,0,,,1,,U,Autocuration,,,CHEMBL631488,BAO_0000019,
14601,3133,A,,,22224,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL876440,BAO_0000019,
14602,3133,A,,,22224,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL631489,BAO_0000019,
14603,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL857742,BAO_0000019,
14604,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,0,,,1,,U,Autocuration,,,CHEMBL631490,BAO_0000019,
14605,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL631491,BAO_0000019,
14606,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL631492,BAO_0000019,
14607,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,0,,,1,,U,Autocuration,,,CHEMBL631493,BAO_0000019,
14608,4892,A,,,22224,Kinetic parameter for rate of conversion to PABA was determined,,0,,,1,,U,Autocuration,,,CHEMBL631494,BAO_0000019,
14609,3133,A,,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL631495,BAO_0000019,
14610,11488,A,,1988.0,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Feces,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631496,BAO_0000218,
14611,11488,A,,1088.0,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631497,BAO_0000218,
14612,11488,A,,1088.0,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631498,BAO_0000218,
14613,11488,A,,1088.0,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629776,BAO_0000218,
14614,11488,A,,1088.0,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629777,BAO_0000218,
14615,11488,A,,1088.0,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629778,BAO_0000218,
14616,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630456,BAO_0000218,
14617,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630457,BAO_0000218,
14618,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630458,BAO_0000218,
14619,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630459,BAO_0000218,
14620,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630460,BAO_0000218,
14621,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876550,BAO_0000218,
14622,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630461,BAO_0000218,
14623,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630462,BAO_0000218,
14624,11488,A,,,50597,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630463,BAO_0000218,
14625,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630464,BAO_0000218,
14626,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630465,BAO_0000218,
14627,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630466,BAO_0000218,
14628,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630467,BAO_0000218,
14629,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630633,BAO_0000218,
14630,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630634,BAO_0000218,
14631,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630635,BAO_0000218,
14632,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630636,BAO_0000218,
14633,11488,A,,,50597,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630637,BAO_0000218,
14634,7132,A,,1988.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630638,BAO_0000218,
14635,7132,A,,1988.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630639,BAO_0000218,
14636,7132,A,,1988.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630640,BAO_0000218,
14637,7132,A,,1988.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL876551,BAO_0000218,
14638,7132,A,,1088.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630641,BAO_0000218,
14639,7132,A,,1088.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630642,BAO_0000218,
14640,7132,A,,1088.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630643,BAO_0000218,
14641,7132,A,,1088.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630644,BAO_0000218,
14642,7132,A,,1088.0,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL630645,BAO_0000218,
14643,7132,A,,1988.0,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625599,BAO_0000218,
14644,7132,A,,1988.0,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625600,BAO_0000218,
14645,7132,A,,1988.0,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625601,BAO_0000218,
14646,7132,A,,1988.0,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL625602,BAO_0000218,
14647,7132,A,,1088.0,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627470,BAO_0000218,
14648,7132,A,,1088.0,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627471,BAO_0000218,
14649,7132,A,,1088.0,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627472,BAO_0000218,
14650,7132,A,,1088.0,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627473,BAO_0000218,
14651,7132,A,,1088.0,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL627474,BAO_0000218,
14652,13925,A,,178.0,50597,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627475,BAO_0000218,
14653,13925,A,,178.0,50597,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL627476,BAO_0000218,
14654,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627477,BAO_0000218,
14655,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627478,BAO_0000218,
14656,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627479,BAO_0000218,
14657,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627480,BAO_0000218,
14658,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627481,BAO_0000218,
14659,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627482,BAO_0000218,
14660,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL627483,BAO_0000218,
14661,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL875636,BAO_0000218,
14662,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625764,BAO_0000218,
14663,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625765,BAO_0000218,
14664,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625766,BAO_0000218,
14665,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625767,BAO_0000218,
14666,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625768,BAO_0000218,
14667,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625769,BAO_0000218,
14668,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625770,BAO_0000218,
14669,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625771,BAO_0000218,
14670,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625772,BAO_0000218,
14671,12582,A,,1088.0,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,1,,Canis lupus familiaris,1,9615.0,N,Intermediate,,,CHEMBL625773,BAO_0000218,
14672,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625774,BAO_0000218,
14673,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625775,BAO_0000218,
14674,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625776,BAO_0000218,
14675,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625777,BAO_0000218,
14676,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625778,BAO_0000218,
14677,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625779,BAO_0000218,
14678,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625780,BAO_0000218,
14679,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625781,BAO_0000218,
14680,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875637,BAO_0000218,
14681,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626473,BAO_0000218,
14682,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626474,BAO_0000218,
14683,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626475,BAO_0000218,
14684,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626476,BAO_0000218,
14685,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL634397,BAO_0000218,
14686,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL626477,BAO_0000218,
14687,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631069,BAO_0000218,
14688,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631070,BAO_0000218,
14689,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631071,BAO_0000218,
14690,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631072,BAO_0000218,
14691,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631073,BAO_0000218,
14692,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631074,BAO_0000218,
14693,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631075,BAO_0000218,
14694,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631725,BAO_0000218,
14695,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631726,BAO_0000218,
14696,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631727,BAO_0000218,
14697,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631728,BAO_0000218,
14698,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631729,BAO_0000218,
14699,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631730,BAO_0000218,
14700,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631731,BAO_0000218,
14701,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631910,BAO_0000218,
14702,15413,A,,10000000.0,50597,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Hippocampus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631911,BAO_0000218,
14703,15413,A,,1898.0,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631912,BAO_0000218,
14704,15413,A,,1898.0,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Hypothalamus,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631913,BAO_0000218,
14705,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631914,BAO_0000218,
14706,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631915,BAO_0000218,
14707,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875778,BAO_0000218,
14708,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631916,BAO_0000218,
14709,12017,A,,178.0,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631917,BAO_0000218,
14710,12017,A,,178.0,50597,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631918,BAO_0000218,
14711,12017,A,,178.0,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631919,BAO_0000218,
14712,12017,A,,178.0,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631920,BAO_0000218,
14713,12017,A,,178.0,50597,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631921,BAO_0000218,
14714,12017,A,,178.0,50597,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631922,BAO_0000218,
14715,12017,A,,178.0,50597,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631923,BAO_0000218,
14716,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631924,BAO_0000218,
14717,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630234,BAO_0000218,
14718,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630235,BAO_0000218,
14719,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630236,BAO_0000218,
14720,12017,A,,,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630237,BAO_0000218,
14721,12017,A,,,50597,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630238,BAO_0000218,
14722,12017,A,,,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630239,BAO_0000218,
14723,12017,A,,,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630303,BAO_0000218,
14724,12017,A,,,50597,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630304,BAO_0000218,
14725,12017,A,,,50597,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630305,BAO_0000218,
14726,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630306,BAO_0000218,
14727,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630307,BAO_0000218,
14728,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630308,BAO_0000218,
14729,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630309,BAO_0000218,
14730,12017,A,,2113.0,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629309,BAO_0000218,
14731,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629993,BAO_0000218,
14732,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629994,BAO_0000218,
14733,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629995,BAO_0000218,
14734,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631993,BAO_0000218,
14735,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631994,BAO_0000218,
14736,12017,A,,2113.0,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631995,BAO_0000218,
14737,12017,A,,2107.0,50597,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631996,BAO_0000218,
14738,12017,A,,2107.0,50597,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631997,BAO_0000218,
14739,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631998,BAO_0000218,
14740,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631999,BAO_0000218,
14741,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632000,BAO_0000218,
14742,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632001,BAO_0000218,
14743,12017,A,,2107.0,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL874424,BAO_0000218,
14744,12017,A,,2107.0,50597,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632002,BAO_0000218,
14745,12017,A,,2107.0,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632003,BAO_0000218,
14746,3133,A,,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL632004,BAO_0000019,
14747,2742,A,,,22224,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632005,BAO_0000019,
14748,2742,A,,,22224,Compound was tested for amidase rate in the presence of N62C screen enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632006,BAO_0000019,
14749,2742,A,,,22224,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632007,BAO_0000019,
14750,2742,A,,,22224,Compound was tested for amidase rate in the presence of S166C screen enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632008,BAO_0000019,
14751,2742,A,,,22224,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632009,BAO_0000019,
14752,2742,A,,,22224,Compound was tested for esterase rate in the presence of N62C screen enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632010,BAO_0000019,
14753,2742,A,,,22224,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,0,,,1,,U,Autocuration,,,CHEMBL857750,BAO_0000019,
14754,2742,A,,,22224,Compound was tested for esterase rate in the presence of S166C screen enzyme,,0,,,1,,U,Autocuration,,,CHEMBL632011,BAO_0000019,
14755,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL632012,BAO_0000019,
14756,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL632013,BAO_0000019,
14757,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL632014,BAO_0000019,
14758,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL629622,BAO_0000019,
14759,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL629623,BAO_0000019,
14760,2276,A,,,22224,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,0,,,1,,U,Autocuration,,,CHEMBL629624,BAO_0000019,
14761,17269,A,,,22224,Ratio of Kcat to that of Km was determined,,0,,,1,,U,Autocuration,,,CHEMBL629625,BAO_0000019,
14762,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,0,,,1,,U,Autocuration,,,CHEMBL629626,BAO_0000019,
14763,2276,A,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,0,,,1,,U,Autocuration,,,CHEMBL629627,BAO_0000019,
14764,15917,A,,,22224,"Compound was evaluated for constant, Kd",,0,,,1,,U,Autocuration,,,CHEMBL629628,BAO_0000019,
14765,10933,A,,,22224,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,0,,,1,,U,Autocuration,,,CHEMBL629629,BAO_0000019,
14766,10933,A,,,22224,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,0,,,1,,U,Autocuration,,,CHEMBL629630,BAO_0000019,
14767,14293,A,,,22224,Dissociation Constant of compound determined,,0,,,1,,U,Autocuration,,,CHEMBL856030,BAO_0000019,
14768,6698,B,,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,0,,,1,,U,Autocuration,,,CHEMBL629631,BAO_0000019,
14769,6698,B,,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,0,,,1,,U,Autocuration,,,CHEMBL629632,BAO_0000019,
14770,4318,P,,,22224,Dissociation constant of compound with Fructose was determined,,0,,,1,,U,Autocuration,,,CHEMBL629633,BAO_0000100,
14771,4318,P,,,22224,Dissociation constant of compound with Fructose was determined; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL629634,BAO_0000100,
14772,4318,P,,,22224,Dissociation constant of compound with Lactulose was determined,,0,,,1,,U,Autocuration,,,CHEMBL629635,BAO_0000100,
14773,4318,P,,,22224,Dissociation constant of compound with Lactulose was determined; Not determined,,0,,,1,,U,Autocuration,,,CHEMBL629636,BAO_0000100,
14774,14959,P,,,22224,Dissociation constant of the Compound,,0,,,1,,U,Autocuration,,,CHEMBL629637,BAO_0000100,
14775,5913,P,,,22224,Dissociation constant by non-linear regression analysis,,0,,,1,,U,Autocuration,,,CHEMBL629638,BAO_0000100,
14776,14218,P,,,22224,Dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL629639,BAO_0000100,
14777,10689,P,,,22224,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,0,,,1,,U,Autocuration,,,CHEMBL629640,BAO_0000100,
14778,13925,P,,,22224,Dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL629641,BAO_0000100,
14779,16359,P,,,22224,Dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL631344,BAO_0000100,
14780,10944,A,,2385.0,50597,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631345,BAO_0000218,
14781,11080,A,,,22224,The dissociation constant determined by fluorescence displacement assay,,0,,,1,,U,Autocuration,,,CHEMBL631346,BAO_0000019,
14782,17805,A,,,22224,kd value surface plasmon resonance (SPR) method,,0,,,1,,U,Autocuration,,,CHEMBL631524,BAO_0000019,
14783,10944,A,,2385.0,50597,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631525,BAO_0000218,
14784,16645,F,,,22224,First dissociation constant of the binding of compound to V30M TTR,,0,,,1,,U,Autocuration,,,CHEMBL631526,BAO_0000019,
14785,16645,F,,,22224,Second dissociation constant of the binding of compound to V30M TTR,,0,,,1,,U,Autocuration,,,CHEMBL631527,BAO_0000019,
14786,7793,A,,,22224,"Compound was evaluated for equilibrium constant, Ke",,0,,,1,,U,Autocuration,,,CHEMBL631528,BAO_0000019,
14787,12199,A,,1898.0,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Hypothalamus,0,,,1,,U,Autocuration,,,CHEMBL631529,BAO_0000019,
14788,12199,A,,1898.0,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Hypothalamus,0,,,1,,U,Autocuration,,,CHEMBL631530,BAO_0000019,
14789,9680,A,,,22224,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL631531,BAO_0000019,
14790,9680,A,,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL631532,BAO_0000019,
14791,9680,A,,,22224,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL631533,BAO_0000019,
14792,13758,A,,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876552,BAO_0000218,
14793,13758,A,,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631534,BAO_0000218,
14794,13758,A,,,50594,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631535,BAO_0000218,
14795,13758,A,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631536,BAO_0000218,
14796,13758,A,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631537,BAO_0000218,
14797,13758,A,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631538,BAO_0000218,
14798,13758,A,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631539,BAO_0000218,
14799,13758,A,,,50594,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631540,BAO_0000218,
14800,14393,A,,,50597,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625637,BAO_0000218,
14801,14393,A,,,50597,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625638,BAO_0000218,
14802,15078,A,,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625639,BAO_0000218,
14803,13925,A,,955.0,50597,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625640,BAO_0000218,
14804,13925,A,,955.0,50597,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625641,BAO_0000218,
14805,13925,A,,948.0,50597,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625642,BAO_0000218,
14806,13925,A,,948.0,50597,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625643,BAO_0000218,
14807,13925,A,,2113.0,50597,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625644,BAO_0000218,
14808,13925,A,,2113.0,50597,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625645,BAO_0000218,
14809,13925,A,,2107.0,50597,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625646,BAO_0000218,
14810,13925,A,,2107.0,50597,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625647,BAO_0000218,
14811,13925,A,,2048.0,50597,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625648,BAO_0000218,
14812,13925,A,,2048.0,50597,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625649,BAO_0000218,
14813,13925,A,,2385.0,50597,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625650,BAO_0000218,
14814,13925,A,,2385.0,50597,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625651,BAO_0000218,
14815,13925,A,,14.0,50597,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625652,BAO_0000218,
14816,13925,A,,14.0,50597,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625653,BAO_0000218,
14817,13925,A,,2106.0,50597,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625654,BAO_0000218,
14818,13925,A,,2106.0,50597,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625655,BAO_0000218,
14819,9712,A,,178.0,50597,Biodistribution of Compound in rat blood after 15 minutes of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625656,BAO_0000218,
14820,9712,A,,178.0,50597,Biodistribution of Compound in rat blood after 2 minutes of administration,Blood,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625657,BAO_0000218,
14821,9712,A,,955.0,50597,Biodistribution of Compound in rat brain after 15 minutes of administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625658,BAO_0000218,
14822,9712,A,,955.0,50597,Biodistribution of Compound in rat brain after 2 minutes of administration,Brain,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625659,BAO_0000218,
14823,9712,A,,948.0,50597,Biodistribution of Compound in rat heart after 15 minutes of administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625660,BAO_0000218,
14824,9712,A,,948.0,50597,Biodistribution of Compound in rat heart after 2 minutes of administration,Heart,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625661,BAO_0000218,
14825,9712,A,,2107.0,50597,Biodistribution of Compound in rat liver after 15 minutes of administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625662,BAO_0000218,
14826,9712,A,,2107.0,50597,Biodistribution of Compound in rat liver after 2 minutes of administration,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL625663,BAO_0000218,
14827,9712,A,,2048.0,50597,Biodistribution of Compound in rat lung after 15 minutes of administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875621,BAO_0000218,
14828,9712,A,,2048.0,50597,Biodistribution of Compound in rat lung after 2 minutes of administration,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628382,BAO_0000218,
14829,9712,A,,2385.0,50597,Biodistribution of Compound in rat muscle after 15 minutes of administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628383,BAO_0000218,
14830,9712,A,,2385.0,50597,Biodistribution of Compound in rat muscle after 2 minutes of administration,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628384,BAO_0000218,
14831,13925,A,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628385,BAO_0000218,
14832,13925,A,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875753,BAO_0000218,
14833,13925,A,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628386,BAO_0000218,
14834,6941,A,,,50597,Organ distribution in rat blood 2 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628387,BAO_0000218,
14835,6941,A,,,50597,Organ distribution in rat blood 2 hr after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628388,BAO_0000218,
14836,6941,A,,,50597,Organ distribution in rat blood 30 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628389,BAO_0000218,
14837,6941,A,,,50597,Organ distribution in rat blood 30 min after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632756,BAO_0000218,
14838,6941,A,,,50597,Organ distribution in rat brain 2 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628390,BAO_0000218,
14839,6941,A,,,50597,Organ distribution in rat brain 2 hr after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631811,BAO_0000218,
14840,6941,A,,,50597,Organ distribution in rat brain 30 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631812,BAO_0000218,
14841,6941,A,,,50597,Organ distribution in rat heart 2 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631813,BAO_0000218,
14842,6941,A,,,50597,Organ distribution in rat heart 2 hr after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631814,BAO_0000218,
14843,6941,A,,,50597,Organ distribution in rat heart 30 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631815,BAO_0000218,
14844,6941,A,,,50597,Organ distribution in rat kidney 2 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631816,BAO_0000218,
14845,6941,A,,,50597,Organ distribution in rat kidney 2 hr after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875758,BAO_0000218,
14846,6941,A,,,50597,Organ distribution in rat kidney 30 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631817,BAO_0000218,
14847,6941,A,,2107.0,50597,Organ distribution in rat liver 2 minutes after intravenous injection,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631818,BAO_0000218,
14848,6941,A,,2107.0,50597,Organ distribution in rat liver 2 hr after intravenous injection,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631819,BAO_0000218,
14849,6941,A,,2107.0,50597,Organ distribution in rat liver 30 minutes after intravenous injection,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631820,BAO_0000218,
14850,6941,A,,,50597,Organ distribution in rat lung 2 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631821,BAO_0000218,
14851,6941,A,,,50597,Organ distribution in rat lung 2 hr after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631822,BAO_0000218,
14852,6941,A,,,50597,Organ distribution in rat lung 30 minutes after intravenous injection,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631823,BAO_0000218,
14853,6941,A,,2385.0,50597,Organ distribution in rat muscle 2 minutes after intravenous injection,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631824,BAO_0000218,
14854,6941,A,,2385.0,50597,Organ distribution in rat muscle 2 hr after intravenous injection,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631825,BAO_0000218,
14855,6941,A,,2385.0,50597,Organ distribution in rat muscle 30 minutes after intravenous injection,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631826,BAO_0000218,
14856,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631827,BAO_0000218,
14857,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631828,BAO_0000218,
14858,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL631829,BAO_0000218,
14859,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875759,BAO_0000218,
14860,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631830,BAO_0000218,
14861,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631831,BAO_0000218,
14862,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631832,BAO_0000218,
14863,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631833,BAO_0000218,
14864,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631834,BAO_0000218,
14865,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631835,BAO_0000218,
14866,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631836,BAO_0000218,
14867,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631837,BAO_0000218,
14868,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631838,BAO_0000218,
14869,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631839,BAO_0000218,
14870,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631840,BAO_0000218,
14871,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631841,BAO_0000218,
14872,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631842,BAO_0000218,
14873,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631843,BAO_0000218,
14874,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631844,BAO_0000218,
14875,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631845,BAO_0000218,
14876,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631846,BAO_0000218,
14877,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL875760,BAO_0000218,
14878,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL632199,BAO_0000218,
14879,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631847,BAO_0000218,
14880,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631848,BAO_0000218,
14881,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628707,BAO_0000218,
14882,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628708,BAO_0000218,
14883,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628709,BAO_0000218,
14884,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628710,BAO_0000218,
14885,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628711,BAO_0000218,
14886,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628712,BAO_0000218,
14887,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628713,BAO_0000218,
14888,12582,A,,1088.0,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628714,BAO_0000218,
14889,7415,A,,,50597,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL628715,BAO_0000218,
14890,7313,A,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,0,,,1,,U,Autocuration,,,CHEMBL629179,BAO_0000019,
14891,7313,A,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,0,,,1,,U,Autocuration,,,CHEMBL629180,BAO_0000019,
14892,7313,A,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,0,,,1,,U,Autocuration,,,CHEMBL875108,BAO_0000019,
14893,7570,A,,1235.0,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629181,BAO_0000019,
14894,7570,A,,1235.0,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629182,BAO_0000019,
14895,7570,A,,,22224,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629183,BAO_0000019,
14896,7570,A,,,22224,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629184,BAO_0000019,
14897,7570,A,,1235.0,22224,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629185,BAO_0000019,
14898,7570,A,,1235.0,22224,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629186,BAO_0000019,
14899,7570,A,,,22224,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629187,BAO_0000019,
14900,7570,A,,,22224,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629887,BAO_0000019,
14901,7570,A,,,22224,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629888,BAO_0000019,
14902,7570,A,,,22224,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629889,BAO_0000019,
14903,7570,A,,1235.0,22224,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629890,BAO_0000019,
14904,7570,A,,,22224,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629891,BAO_0000019,
14905,7570,A,,,22224,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629892,BAO_0000019,
14906,7570,A,,1235.0,22224,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,0,,,1,,U,Autocuration,,,CHEMBL629893,BAO_0000019,
14907,7570,A,,,22224,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629894,BAO_0000019,
14908,7570,A,,,22224,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,0,,,1,,U,Autocuration,,,CHEMBL629895,BAO_0000019,
14909,14122,A,,,22224,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,0,,Canis lupus familiaris,1,9615.0,U,Autocuration,,,CHEMBL875109,BAO_0000218,
14910,16449,A,,,22224,Absolute bioavailability in male cynomolgus monkeys,,0,,Macaca fascicularis,1,9541.0,U,Autocuration,,,CHEMBL629896,BAO_0000218,
14911,16449,A,,,22224,Absolute bioavailability in maleSprague-Dawley rats,,0,,Rattus norvegicus,1,10116.0,U,Autocuration,,,CHEMBL629897,BAO_0000218,
14912,12017,A,,2107.0,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL629898,BAO_0000218,
14913,12017,A,,2107.0,50597,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630057,BAO_0000218,
14914,12017,A,,2107.0,50597,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630058,BAO_0000218,
14915,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630059,BAO_0000218,
14916,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630060,BAO_0000218,
14917,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630061,BAO_0000218,
14918,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630062,BAO_0000218,
14919,12017,A,,2048.0,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630063,BAO_0000218,
14920,12017,A,,2048.0,50597,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630064,BAO_0000218,
14921,12017,A,,2048.0,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630065,BAO_0000218,
14922,12017,A,,2048.0,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630066,BAO_0000218,
14923,12017,A,,2048.0,50597,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630067,BAO_0000218,
14924,12017,A,,2048.0,50597,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630068,BAO_0000218,
14925,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631113,BAO_0000218,
14926,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631114,BAO_0000218,
14927,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631115,BAO_0000218,
14928,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL631116,BAO_0000218,
14929,12017,A,,2385.0,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630528,BAO_0000218,
14930,12017,A,,2385.0,50597,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630529,BAO_0000218,
14931,12017,A,,2385.0,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630530,BAO_0000218,
14932,12017,A,,2385.0,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630531,BAO_0000218,
14933,12017,A,,2385.0,50597,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630532,BAO_0000218,
14934,12017,A,,2385.0,50597,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630533,BAO_0000218,
14935,15045,A,,178.0,50594,Biodistribution in normal mice blood after 120 hr,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630534,BAO_0000218,
14936,15045,A,,178.0,50594,Biodistribution in normal mice blood after 24 hr,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630535,BAO_0000218,
14937,15045,A,,178.0,50594,Biodistribution in normal mice blood after 4 hr,Blood,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630536,BAO_0000218,
14938,15045,A,,10000001.0,50594,Biodistribution in normal mice bone after 120 hr,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630537,BAO_0000218,
14939,15045,A,,10000001.0,50594,Biodistribution in normal mice bone after 24 hr,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630538,BAO_0000218,
14940,15045,A,,10000001.0,50594,Biodistribution in normal mice bone after 4 hr,Bone,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630539,BAO_0000218,
14941,15045,A,,948.0,50594,Biodistribution in normal mice heart after 120 hr,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630540,BAO_0000218,
14942,15045,A,,948.0,50594,Biodistribution in normal mice heart after 24 hr,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630541,BAO_0000218,
14943,15045,A,,948.0,50594,Biodistribution in normal mice heart after 4 hr,Heart,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630542,BAO_0000218,
14944,15045,A,,2113.0,50594,Biodistribution in normal mice kidney after 120 hr,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630543,BAO_0000218,
14945,15045,A,,2113.0,50594,Biodistribution in normal mice kidney after 24 hr,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630544,BAO_0000218,
14946,15045,A,,2113.0,50594,Biodistribution in normal mice kidney after 4 hr,Kidney,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630545,BAO_0000218,
14947,15045,A,,2107.0,50594,Biodistribution in normal mice liver after 120 hr,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630546,BAO_0000218,
14948,15045,A,,2107.0,50594,Biodistribution in normal mice liver after 24 hr,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630547,BAO_0000218,
14949,15045,A,,2107.0,50594,Biodistribution in normal mice liver after 4 hr,Liver,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630548,BAO_0000218,
14950,15045,A,,2106.0,50594,Biodistribution in normal mice spleen after 120 hr,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630549,BAO_0000218,
14951,15045,A,,2106.0,50594,Biodistribution in normal mice spleen after 24 hr,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL630550,BAO_0000218,
14952,15045,A,,2106.0,50594,Biodistribution in normal mice spleen after 4 hr,Spleen,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL876426,BAO_0000218,
14953,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630551,BAO_0000218,
14954,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630552,BAO_0000218,
14955,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630553,BAO_0000218,
14956,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630554,BAO_0000218,
14957,12017,A,,2106.0,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630555,BAO_0000218,
14958,12017,A,,2106.0,50597,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630556,BAO_0000218,
14959,12017,A,,2106.0,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630557,BAO_0000218,
14960,12017,A,,2106.0,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630558,BAO_0000218,
14961,12017,A,,2106.0,50597,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630559,BAO_0000218,
14962,12017,A,,2106.0,50597,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630560,BAO_0000218,
14963,12017,A,,2046.0,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL876427,BAO_0000218,
14964,14941,A,,,50597,The Kel values in female wistar rats.,,1,,Rattus norvegicus,1,10116.0,N,Intermediate,,,CHEMBL630561,BAO_0000218,
14965,4646,A,,,22224,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL630562,BAO_0000019,
14966,8847,A,,,22224,Hydrolysis rate constant of the compound,,0,,,1,,U,Autocuration,,,CHEMBL630563,BAO_0000019,
14967,11778,P,,,22229,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,0,,,1,,U,Autocuration,,,CHEMBL629673,BAO_0000100,
14968,2363,A,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL629674,BAO_0000019,
14969,2363,A,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,0,,,1,,U,Autocuration,,,CHEMBL629675,BAO_0000019,
14970,2363,A,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,0,,,1,,U,Autocuration,,,CHEMBL629676,BAO_0000019,
14971,2363,A,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,0,,,1,,U,Autocuration,,,CHEMBL629677,BAO_0000019,
14972,8371,A,,,22224,Apparent inactivation rate constant was evaluated,,0,,,1,,U,Autocuration,,,CHEMBL629678,BAO_0000019,
14973,14883,A,,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,0,,,1,,U,Autocuration,,,CHEMBL629679,BAO_0000019,
14974,14883,A,,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,0,,,1,,U,Autocuration,,,CHEMBL629680,BAO_0000019,
14975,4643,A,,,22224,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,0,,,1,,U,Autocuration,,,CHEMBL629681,BAO_0000019,
14976,3519,A,,,22224,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,0,,,1,,U,Autocuration,,,CHEMBL629682,BAO_0000019,
14977,10600,A,,,22224,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,0,,,1,,U,Autocuration,,,CHEMBL629683,BAO_0000019,
14978,8501,F,,,22224,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,0,,,1,,U,Autocuration,,,CHEMBL629684,BAO_0000019,
14979,8505,P,,,22224,Dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL629685,BAO_0000100,
14980,9778,P,,,22224,Dissociation constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL629686,BAO_0000100,
14981,9778,P,,,22224,Dissociation constant at pH 7.4,,0,,,1,,U,Autocuration,,,CHEMBL872932,BAO_0000100,
14982,9778,P,,,22224,Dissociation constant in presence of 1 mM dithiothreitol,,0,,,1,,U,Autocuration,,,CHEMBL629687,BAO_0000100,
14983,13007,A,,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,0,,,1,,U,Autocuration,,,CHEMBL872931,BAO_0000019,
14984,13007,A,,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,0,,,1,,U,Autocuration,,,CHEMBL628151,BAO_0000019,
14985,13007,A,,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,0,,,1,,U,Autocuration,,,CHEMBL628152,BAO_0000019,
14986,13007,A,,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,0,,,1,,U,Autocuration,,,CHEMBL628153,BAO_0000019,
14987,11482,A,,,22224,Kinetic constant for aromatization of androstenedione,,0,,,1,,U,Autocuration,,,CHEMBL628154,BAO_0000019,
14988,11482,A,,,22224,Kinetic constant for aromatization of testosterone,,0,,,1,,U,Autocuration,,,CHEMBL628155,BAO_0000019,
14989,2303,A,,,22224,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,0,,,1,,U,Autocuration,,,CHEMBL628156,BAO_0000019,
14990,11964,A,,,22224,Local inhibition constant was determined,,0,,,1,,U,Autocuration,,,CHEMBL628157,BAO_0000019,
14991,3140,A,,,50347,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,1,,Saccharomyces cerevisiae,1,4932.0,N,Intermediate,,,CHEMBL857533,BAO_0000218,
14992,10650,P,,,22224,Dissociation constant value of the compound,,0,,,1,,U,Autocuration,,,CHEMBL628158,BAO_0000100,
14993,4667,A,,964.0,22224,In vitro permeability through cornea without epithelium,Cornea,0,,,1,,U,Autocuration,,,CHEMBL628159,BAO_0000019,
14994,4667,A,,964.0,22224,In vitro permeability through intact cornea,Cornea,0,,,1,,U,Autocuration,,,CHEMBL875616,BAO_0000019,
14995,9199,A,,964.0,50592,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Cornea,1,,Oryctolagus cuniculus,1,9986.0,N,Intermediate,,,CHEMBL628160,BAO_0000218,
14996,11966,A,,,22224,Rate of enzyme inactivation for the compound was determined,,0,,,1,,U,Autocuration,,,CHEMBL628161,BAO_0000019,
14997,4667,A,,964.0,22224,In vitro permeability through cornea without epithelium,Cornea,0,,,1,,U,Autocuration,,,CHEMBL628162,BAO_0000019,
14998,4667,A,,964.0,22224,In vitro permeability through intact cornea,Cornea,0,,,1,,U,Autocuration,,,CHEMBL628163,BAO_0000019,
14999,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628164,BAO_0000019,
15000,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628165,BAO_0000019,
15001,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628166,BAO_0000019,
15002,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628167,BAO_0000019,
15003,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628168,BAO_0000019,
15004,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628169,BAO_0000019,
15005,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628170,BAO_0000019,
15006,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628171,BAO_0000019,
15007,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL627434,BAO_0000019,
15008,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL627435,BAO_0000019,
15009,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628110,BAO_0000019,
15010,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628111,BAO_0000019,
15011,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628112,BAO_0000019,
15012,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628260,BAO_0000019,
15013,8354,A,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,0,,,1,,U,Autocuration,,,CHEMBL628261,BAO_0000019,
15014,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628262,BAO_0000218,
15015,14439,A,,,50587,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,1,,Homo sapiens,1,9606.0,N,Intermediate,,,CHEMBL628263,BAO_0000218,
15016,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628264,BAO_0000218,
15017,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628265,BAO_0000218,
15018,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628266,BAO_0000218,
15019,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628267,BAO_0000218,
15020,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628268,BAO_0000218,
15021,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628269,BAO_0000218,
15022,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628270,BAO_0000218,
15023,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628271,BAO_0000218,
15024,14439,A,,,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,1,,Mus musculus,1,10090.0,N,Intermediate,,,CHEMBL628272,BAO_0000218,
